<SEC-DOCUMENT>0001159036-16-000133.txt : 20161107
<SEC-HEADER>0001159036-16-000133.hdr.sgml : 20161107
<ACCEPTANCE-DATETIME>20161107160829
ACCESSION NUMBER:		0001159036-16-000133
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20161107
DATE AS OF CHANGE:		20161107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		161978162

	BUSINESS ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>halo3q2016-10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0C65A01FC94E75A06797481E5E91E7D1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number 001-32335</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">___________________________</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Exact name of registrant as specified in its charter</font><font style="font-family:inherit;font-size:10pt;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">___________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">88-0488686</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11388 Sorrento Valley Road, San Diego, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92121</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858) 794-8889</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;in Rule&#160;12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:22%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font><font style="font-family:Wingdings;font-size:10pt;">&#160;&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer  </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was </font><font style="font-family:inherit;font-size:10pt;">129,490,070</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">November&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6CFC4B3DA2B2C65DB88F481E5E9D413F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160; </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:10%;"></td><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s1E74F9B3808E5D0A0B59481E5E9E07BF"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PART&#160;I &#8212; FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s247973265BA7FDF2D0F0481E5E9E766A"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s99D09F38CD41AE6693F8481E5DBA7E53"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; September 30, 2016 and</font></a></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;</font><a style="font-family:inherit;font-size:10pt;" href="#s99D09F38CD41AE6693F8481E5DBA7E53"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s99D09F38CD41AE6693F8481E5DBA7E53">3</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s33BCFC5F78C2262705A9481E5DFEFF26"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; Three and Nine Months</font></a></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;</font><a style="font-family:inherit;font-size:10pt;" href="#s33BCFC5F78C2262705A9481E5DFEFF26"><font style="font-family:inherit;font-size:10pt;">Ended September 30, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s33BCFC5F78C2262705A9481E5DFEFF26">4</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB488508EFA0C1AC21934481E5DF46038"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Loss (Unaudited) &#8211; </font></a></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;Three and Nine Months Ended September 30, 2016 and 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sB488508EFA0C1AC21934481E5DF46038">5</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C7825F7F329BFB6B9D2481E5DAA533B"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; Nine Months Ended</font></a></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;September 30, 2016 and 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s5C7825F7F329BFB6B9D2481E5DAA533B">6</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s4D12715D4553E44A7937481E5EDB51BA"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s4D12715D4553E44A7937481E5EDB51BA">7</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s314C22637885C7D52F17481E6B3AE99D"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s314C22637885C7D52F17481E6B3AE99D">30</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sFAB024D1E6A3D31C9E60481E5FA4AF44"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sFAB024D1E6A3D31C9E60481E5FA4AF44">63</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s3CC104EC89E95A7CC642481E5FA4EFC0"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s3CC104EC89E95A7CC642481E5FA4EFC0">63</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sE5DD2DEF690F752BFC59481E6C3573BC"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PART&#160;II &#8212; OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sAC11ED1FA956B4B1394D481E5FA4DF2F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sAC11ED1FA956B4B1394D481E5FA4DF2F">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8C807C50190CC24D596B481E5FA57313"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8C807C50190CC24D596B481E5FA57313">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sABFC61D70BD4ABD4CF00481E5FA566F6"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sABFC61D70BD4ABD4CF00481E5FA566F6">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s12A58D0085801AD74911481E6CDCD811"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s12A58D0085801AD74911481E6CDCD811">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s292D7AC5243873376E67481E6D0D3DD2"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s292D7AC5243873376E67481E6D0D3DD2">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;5.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sF9A8D4CA9893AD10CD10481E5FA6EA17"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sF9A8D4CA9893AD10CD10481E5FA6EA17">64</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA99F7AF78ADC31644E10481E6D6DE5B8"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA99F7AF78ADC31644E10481E6D6DE5B8">65</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s59D4BEB93F58D9935E6F481E5FA7C644"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s59D4BEB93F58D9935E6F481E5FA7C644">66</a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s1E74F9B3808E5D0A0B59481E5E9E07BF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I &#8212; FINANCIAL INFORMATION</font></div><div><a name="s247973265BA7FDF2D0F0481E5E9E766A"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements</font></div></td></tr></table><div><a name="s99D09F38CD41AE6693F8481E5DBA7E53"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities, available-for-sale</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,410</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,605</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,772</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,304</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,394</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,660</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,803</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; (deficit) equity:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock - $0.001 par value; 200,000 shares authorized; 129,488 and </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;128,152 shares issued and outstanding at September 30, 2016 and </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;December 31, 2015, respectively</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">545,751</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525,628</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(557,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482,658</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s33BCFC5F78C2262705A9481E5DFEFF26"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except per share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,970</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,599</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,747</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment and other income, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,253</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,301</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,637</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing net loss per share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sB488508EFA0C1AC21934481E5DF46038"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized (loss) gain on marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s5C7825F7F329BFB6B9D2481E5DAA533B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,637</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,549</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment-in-kind interest expense on long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of premiums on marketable securities, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,732</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">757</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(260</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152,404</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,360</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from maturities of marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of long-term debt, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock under equity incentive plans, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s4D12715D4553E44A7937481E5EDB51BA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HALOZYME THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div><a name="s3E31F082F7CF109B0C9A481E5D8B031A"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators&#8217; proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant, and it works by temporarily breaking down hyaluronan (or &#8220;HA&#8221;), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (&#8220;Baxalta&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), and Eli Lilly and Company (&#8220;Lilly&#8221;). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (&#8220;PDA&#8221;) (Studies 109-202 and 109-301), in Phase 1b clinical testing for</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">PEGPH20 with </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(eribulin) in first line and second line HER2-negative metastatic breast cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. </font></div><div><a name="s8BAC4A8A9C1D38645FB5481E5D9A2656"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-15&#8221;). Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in the amendments in ASU 2016-15. The amendments are an improvement to U.S. GAAP and are intended to reduce the current and potential future diversity in practice. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2016-09&#8221;). ASU 2016-09 changes certain aspects of accounting for share-based payments to employees and involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Specifically, ASU 2016-09 requires that all income tax effects of share-based awards be recognized as income tax expense or benefit in the reporting period in which they occur. Additionally, ASU 2016-09 amends existing guidance to allow forfeitures of share-based awards to be recognized as they occur. Previous guidance required that share-based compensation expense include an estimate of forfeitures. We have elected to early adopt ASU 2016-09 as of January 1, 2016 and made a policy election to account for forfeitures as they occur. The cumulative effect of adoption was a decrease of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to both additional paid-in capital and accumulated deficit. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires lessees to recognize assets and liabilities for most leases and provide enhanced disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2016-01&#8221;). ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. An entity&#8217;s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of ASU 2016-01. ASU 2016-01 requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement. ASU 2016-01 is effective for interim and annual reporting periods beginning on January 1, 2018. Entities should apply the amendments by means of a cumulative effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of ASU 2016-01. We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued Accounting Standards Update 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2015-17&#8221;). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. For&#160;public business entities, the guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. The guidance may be adopted on either a prospective or retrospective basis. We elected to early adopt ASU 2015-17 on January 1, 2016. There was no impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued Accounting Standards Update No. 2015-11,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2015-11&#8221;).&#160;ASU 2015-11 requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 is not expected to have a material impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued Accounting Standards Update No. 2015-03,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2015-03&#8221;).&#160;ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. The recognition and measurement guidance for debt issuance costs is not affected by ASU 2015-03. We adopted ASU 2015-03 on January 1, 2016. There was no material impact on our consolidated financial statements and related disclosures. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements &#8212; Going Concern </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2014-15&#8221;).&#160;The provisions of ASU 2014-15 provide that, in connection with preparing financial statements for each annual and interim reporting period, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 is effective for the annual reporting period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the effect that the adoption of ASU 2014-15 will have on our financial statement disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASU 2014-09&#8221;). In March, April and May 2016 the FASB issued additional guidance related to Topic 606. These new standards will eliminate transaction-specific and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for our interim and annual reporting periods beginning on January 1, 2018. Entities can transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. We have not yet selected a transition method, and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. Our cash equivalents consist of money market funds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders&#8217; (deficit) equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, restricted cash of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was pledged as collateral for the letters of credit.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major financial instrument type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;transfers between Level 1 and Level 2 of the fair value hierarchy during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;financial instruments that were classified within Level 3 as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to receiving marketing approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, inventories consisted of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant inventory, net, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of bulk rHuPH20 for use in the manufacture of Balxalta&#8217;s and Roche&#8217;s collaboration products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered; (3)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (4)&#160;collectibility is reasonably assured.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (&#8220;GPOs&#8221;), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant. As a result, we recognize </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</font><font style="font-family:inherit;font-size:10pt;">. We allow the wholesalers to return product that is damaged or received in error. In addition, we accept unused product to be returned beginning </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;">&#32;prior to and ending </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">&#32;following product expiration. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution Fees</font><font style="font-family:inherit;font-size:10pt;">. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesalers for distribution services they provide with respect to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant. These fees are generally a fixed percentage of the price of the product purchased by the wholesalers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font><font style="font-family:inherit;font-size:10pt;">. We offer cash discounts to certain wholesalers as an incentive to meet certain payment terms. We estimate prompt payment discounts based on contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discounts and Fees</font><font style="font-family:inherit;font-size:10pt;">. We provide discounts to end-user members of certain GPOs under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals, who are members of the GPOs, with which we do not have contracts. The end-user members purchase products from the wholesalers at a contracted discounted price, and the wholesalers then charge back to us the difference between the current retail price and the price the end-users paid for the product. We also incur GPO administrative service fees for these transactions. In addition, we provide predetermined discounts under certain government programs. Our estimate for these chargebacks and fees takes into consideration contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for product returns and chargebacks are based on amounts owed or to be claimed on the related sales. We believe that our estimated product returns for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. In order to develop a methodology to reliably estimate future returns and provide a basis for recognizing revenue on sales to wholesale distributors, we analyze many factors, including, without limitation: (1) actual </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant product return history, taking into account product expiration dating at the time of shipment, (2) re-order activities of the wholesalers as well as their customers and (3) levels of inventory in the wholesale channel. We have monitored actual return history on an individual product lot basis since product launch. We consider the dating of product at the time of shipment into the distribution channel and changes in the estimated levels of inventory within the distribution channel to estimate our exposure to returned product. We also consider historical chargebacks activity and current contract prices to estimate our exposure to returned product. Based on such data, we believe we have the information needed to reasonably estimate product returns and chargebacks. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer&#8217;s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche&#8217;s Herceptin SC product in August 2013 and MabThera</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;SC product in March 2014 and Baxalta&#8217;s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&#160;the license to our rHuPH20 technology, (ii)&#160;at the collaborator&#8217;s request, research and development services which are reimbursed at contractually determined rates, and (iii)&#160;at the collaborator&#8217;s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators&#8217; ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the market place. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&#8220;VSOE&#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition - Milestone Method </font><font style="font-family:inherit;font-size:10pt;">(&#8220;Milestone Method of Accounting&#8221;). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A milestone is defined as an event (i)&#160;that can only be achieved based in whole or in part on either the entity&#8217;s performance or on the occurrence of a specific outcome resulting from the entity&#8217;s performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to the vendor.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator&#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">&#32;prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 4, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on our collaborative agreements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments in connection with our clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, such revisions to our clinical trial expense accruals have not had a material impact on our consolidated results of operations or financial position.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), and RSUs with performance conditions (&#8220;PRSUs&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. Valuation allowances have been established to reduce our net deferred tax assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, as we believe that it is more likely than not that such assets will not be realized.&#160;The interim tax provision is calculated using the estimated effective tax rate expected to be applicable for the full year. During the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in income tax expense, comprising U.S. federal alternative minimum tax.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">13.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">9.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, respectively, of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i)&#160;research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii)&#160;product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s293BF28B2803C3E912B1481E5D9ACACF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:8%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$153.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;available-for-sale marketable securities in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;other-than-temporary impairments on these marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;because we do not intend to sell these marketable securities prior to maturity and it is not more likely than not that we will be required to sell these marketable securities before the recovery of their amortized cost basis.</font></div><div><a name="s5E48335AA5D87EA2EE00481E5DAA2739"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Collaborative Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Roche Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2006, we and Roche entered into a collaboration and license agreement, under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">thirteen</font><font style="font-family:inherit;font-size:10pt;">&#32;Roche target compounds (the &#8220;Roche Collaboration&#8221;). As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Roche has elected a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;targets, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;of which are exclusive, and in addition retains the option to develop and commercialize rHuPH20 with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;additional targets. In August 2013, Roche received European marketing approval for its collaboration product, Herceptin SC, for the treatment of patients with HER2-positive breast cancer and launched Herceptin SC in the European Union (&#8220;EU&#8221;) in September 2013. In March 2014, Roche received European marketing approval for its collaboration product, MabThera SC, for the treatment of patients with common forms of non-Hodgkin lymphoma (&#8220;NHL&#8221;). In June 2014, Roche launched MabThera SC in the EU.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Roche Collaboration, while we are responsible for the supply of bulk rHuPH20. We are entitled to receive reimbursements for providing research and development services and supplying bulk rHuPH20 to Roche at its request.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Roche Collaboration, Roche pays us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&#8217;s obligation to pay royalties. Roche has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Roche Collaboration </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from Roche, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Election of additional exclusive targets and annual license maintenance fees for the right to </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;designate the remaining targets as exclusive targets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical development milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees, annual license maintenance fees and sales-based milestone payments were deferred and are being amortized over the remaining term of the Roche Collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of Roche deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. For each of the the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of Roche deferred revenues, excluding reimbursements for providing research and development services, as revenues under collaborative agreements. Roche deferred revenues, excluding deferred revenues related to reimbursements for providing research and development services, were </font><font style="font-family:inherit;font-size:10pt;">$36.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Baxalta Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2007, we and Baxalta entered into a collaboration and license agreement, under which Baxalta obtained a worldwide, exclusive license to develop and commercialize HYQVIA, a combination of Baxalta&#8217;s current product GAMMAGARD LIQUID</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and our patented rHuPH20 enzyme (the &#8220;Baxalta Collaboration&#8221;). In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use), a combination of GAMMAGARD LIQUID and rHuPH20 in dual vial units, as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the EU in July 2013. In September 2014, the FDA approved HYQVIA for treatment of adult patients with primary immunodeficiency. In October 2014, Baxalta announced the launch and first shipments of HYQVIA in the U.S. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Baxalta Collaboration is applicable to both kit and formulation combinations. Baxalta assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Baxalta Collaboration, while we are responsible for the supply of bulk rHuPH20. We perform research and development activities and supply bulk rHuPH20 at the request of Baxalta, and are reimbursed by Baxalta under the terms of the Baxalta Collaboration. In addition, Baxalta has certain product development and commercialization obligations in major markets identified in the Baxalta Collaboration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Baxalta Collaboration, Baxalta pays us a royalty consisting of a mid-single digit percent of the net sales of HYQVIA. Unless terminated earlier in accordance with its terms, the Baxalta Collaboration continues in effect until the expiration of Baxalta&#8217;s obligation to pay royalties to us. Baxalta has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Baxalta Collaboration which valid claim covers the product in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from Baxalta, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive target</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the upfront license fee and sales-based milestone payments were deferred and are being recognized over the term of the Baxalta Collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each of the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of Baxalta deferred revenues as revenues under collaborative agreements. For each of the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of Baxalta deferred revenues as revenues under collaborative agreements. Baxalta deferred revenues totaled </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Collaborations</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Lilly proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;targets (the &#8220;Lilly Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Lilly has elected </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;specified exclusive targets and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;specified semi-exclusive target. Lilly has the right to elect up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to Lilly&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Lilly Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Lilly Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#32;following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Lilly may terminate the agreement prior to expiration for any reason in its entirety upon </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;">&#32;prior written notice to us.&#160;Upon any such termination, the license granted to Lilly (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with AbbVie proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;targets (the &#8220;AbbVie Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, AbbVie has elected </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;specified exclusive target, TNF alpha. AbbVie has announced plans to develop rHuPH20 with adalimumab (HUMIRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) which may allow reduced number of induction injections and deliver additional performance benefits. AbbVie has the right to elect up to </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">&#32;additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to AbbVie&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay tiered royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the AbbVie Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the AbbVie Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. AbbVie may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days prior written notice to us.&#160;Upon any such termination, the license granted to AbbVie (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Janssen proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;targets (the &#8220;Janssen Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Janssen has elected </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;specified exclusive target, CD38. Janssen has the right to elect </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;additional targets in the future upon payment of additional fees. In addition, Janssen will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Janssen Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Janssen Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Janssen may terminate the agreement prior to expiration for any reason in its entirety or on a product-by-product basis upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">&#32;prior written notice to us.&#160;Upon any such termination, the license granted to Janssen (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Pfizer proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;targets (the &#8220;Pfizer Collaboration&#8221;). Targets may be selected on an exclusive or non-exclusive basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Pfizer has elected </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;specified exclusive targets. Pfizer has the right to elect </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;additional target in the future upon payment of additional fees. In addition, Pfizer will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Pfizer Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Pfizer Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the date of the first commercial sale of such product in such country. Royalties are subject to adjustment as set forth in the agreement. Pfizer may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">&#32;prior written notice to us.&#160;Upon any such termination, the license granted to Pfizer (in total or with respect to the terminated target, as applicable) will terminate, provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from other collaborators for upfront license fees, license fees for the election of additional targets, maintenance fees and event-based payments since inception of the collaboration agreements are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the Pfizer, Janssen, AbbVie and Lilly arrangements, we identified the deliverables in each arrangement to include the license, research and development services and supply of bulk rHuPH20. We have determined that the license, research and development services and supply of bulk rHuPH20 individually represent separate units of accounting, because each deliverable has standalone value. We determined that the rights to elect additional targets in the future upon the payment of additional license fees are substantive options that are not priced at a significant and incremental discount. Therefore, we determined for each collaboration that the rights to elect additional targets are not deliverables at the inception of the arrangement. The estimated selling prices for the units of accounting we identified were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives. The arrangement consideration was allocated to the deliverables based on the relative selling price method and the nature of the research and development services to be performed for the collaborator. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (non-contingent amount). As such, we excluded from the allocable arrangement consideration the event-based payments, milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fees from Pfizer, the </font><font style="font-family:inherit;font-size:10pt;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fee from Janssen, the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront license fee from AbbVie and the </font><font style="font-family:inherit;font-size:10pt;">$33.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fees from Lilly to the license fee deliverable under each of the arrangements. We determined that the upfront payments were earned upon the granting of the worldwide, exclusive right to our technology to the collaborators in these arrangements. As a result, we recognized the </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fees under the Pfizer Collaboration, the </font><font style="font-family:inherit;font-size:10pt;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fee under the Janssen Collaboration, the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront license fee under the AbbVie Collaboration, and the </font><font style="font-family:inherit;font-size:10pt;">$33.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fees under the Lilly Collaboration as revenues under collaborative agreements in the period when such license fees were earned. We recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;related to event-based payments or milestone payments under these collaborations and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. We </font><font style="font-family:inherit;font-size:10pt;">did not</font><font style="font-family:inherit;font-size:10pt;">&#32;recognize any such revenues for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;">&#32;ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborators are each solely responsible for the development, manufacturing and marketing of any products resulting from their respective collaborations. We are entitled to receive payments for research and development services and supply of bulk rHuPH20 if requested by any collaborator. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We recognize amounts allocated to the sales of bulk rHuPH20 as revenues under collaborative agreements when such bulk rHuPH20 has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We cannot predict the timing of delivery of research and development services and bulk rHuPH20 as they are at the collaborators&#8217; requests. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of our collaboration agreements with Roche and Pfizer, certain future payments meet the definition of a milestone in accordance with the Milestone Method of Accounting. We are entitled to receive additional milestone payments under our collaboration agreements with Roche and Pfizer for the successful development of the elected targets in the aggregate of up to </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon achievement of specified clinical development milestone events and up to </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon achievement of specified regulatory milestone events in connection with specified regulatory filings and receipt of marketing approvals.</font></div><div><a name="s7335B3A7EC3FE7EDEB57481E5DAA8145"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Certain Balance Sheet Items</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,442</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,810</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,048</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,953</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term accrued outsourced research and development is included in other long-term liabilities in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursement for research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,892</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s71582CB4AE35319A31D1481E5DDAB1F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Long-Term Debt, Net</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty-backed Loan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">, through our wholly-owned subsidiary Halozyme Royalty LLC (&#8220;Halozyme Royalty&#8221;), we received a </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loan (the &#8220;Royalty-backed Loan&#8221;) pursuant to a credit agreement (the &#8220;Credit Agreement&#8221;) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the &#8220;Royalty-backed Lenders&#8221;). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (&#8220;Collaboration Agreements&#8221;). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the &#8220;Royalty Payments&#8221;).&#160; The Royalty-backed loan bears interest at a per annum rate of </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">plus the three-month LIBOR rate</font><font style="font-family:inherit;font-size:10pt;">. The three-month LIBOR rate is subject to a floor of </font><font style="font-family:inherit;font-size:10pt;">0.7%</font><font style="font-family:inherit;font-size:10pt;">&#32;and a cap of </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;">.&#160;The interest rate as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">9.61%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement provides that </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Royalty Payments are required to be applied to the Royalty-backed Loan prior to January&#160;1, 2017, </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Royalty Payments are required to be applied to the Royalty-backed Loan between January&#160;1, 2017 and January&#160;1, 2018 and thereafter </font><font style="font-family:inherit;font-size:10pt;">all</font><font style="font-family:inherit;font-size:10pt;">&#32;Royalty Payments must be applied to the Royalty-backed Loan.&#160;However, the amounts available to repay the Royalty-backed Loan are subject to caps of </font><font style="font-family:inherit;font-size:10pt;">$13.75 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per quarter in 2017, </font><font style="font-family:inherit;font-size:10pt;">$18.75 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per quarter in 2018, </font><font style="font-family:inherit;font-size:10pt;">$21.25 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per quarter in 2019 and </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date.&#160;Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The </font><font style="font-family:inherit;font-size:10pt;">final maturity date of the Royalty-backed Loan will be the earlier of (i)&#160;the date when principal and interest is paid in full, (ii)&#160;the termination of Halozyme Royalty&#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&#160;December&#160;31, 2050</font><font style="font-family:inherit;font-size:10pt;">.&#160; Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January&#160;1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to </font><font style="font-family:inherit;font-size:10pt;">105%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we were </font><font style="font-family:inherit;font-size:10pt;">in compliance</font><font style="font-family:inherit;font-size:10pt;">&#32;with all material covenants under the Credit Agreement and there was no material adverse change in our business, operations or financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, accrued interest in the amount of </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was capitalized and added to the principal balance of the Royalty-backed Loan. In addition, we recorded related accrued interest on the debt of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and incurred additional debt issuance costs totaling </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and are being amortized over the estimated term of the debt using the effective interest method. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;">&#32;ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$157.6 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of payment-in-kind interest expense of </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oxford and SVB Loan and Security Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2013</font><font style="font-family:inherit;font-size:10pt;">, we entered into an Amended and Restated Loan and Security Agreement (the &#8220;Original Loan Agreement&#8221;) with Oxford Finance LLC (&#8220;Oxford&#8221;) and Silicon Valley Bank (&#8220;SVB&#8221;) (collectively, the &#8220;Lenders&#8221;), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount of new term loan, bringing the total term loan balance to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. The amended term loan facility was scheduled to mature on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for</font><font style="font-family:inherit;font-size:10pt;">&#32;interest only payments through January 2016</font><font style="font-family:inherit;font-size:10pt;">, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a </font><font style="font-family:inherit;font-size:10pt;">7.55%</font><font style="font-family:inherit;font-size:10pt;">&#32;interest rate on the term loan and a final payment equal to </font><font style="font-family:inherit;font-size:10pt;">8.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the original principal amount, or </font><font style="font-family:inherit;font-size:10pt;">$4.25 million</font><font style="font-family:inherit;font-size:10pt;">, which was due when the term loan became due or upon the prepayment of the facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2016</font><font style="font-family:inherit;font-size:10pt;">, we entered into a new Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;">. Upon entering the loan, we drew </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;and used a portion of the proceeds to pay the outstanding principal and final payment owed on the Original Loan Agreement. The remaining proceeds are to be used for working capital and general business requirements. We have the option to draw the remaining </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the second quarter of 2017 at an annual interest rate equal to the then-</font><font style="font-family:inherit;font-size:10pt;">current prime rate as reported in The Wall Street Journal plus 4.75%</font><font style="font-family:inherit;font-size:10pt;">. The term loan repayment schedule provides for </font><font style="font-family:inherit;font-size:10pt;">interest only payments for the first 18 months</font><font style="font-family:inherit;font-size:10pt;">, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2021</font><font style="font-family:inherit;font-size:10pt;">. The Loan Agreement provides for a final payment equal to </font><font style="font-family:inherit;font-size:10pt;">5.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the initial </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount and, if we exercise our option to draw an additional </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017, </font><font style="font-family:inherit;font-size:10pt;">7.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the second draw. The final payment is due when the term loan becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the term loan in full, subject to a prepayment fee of </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;in the first year and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;in the second year of the term loan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the term loan, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the term loan using the effective interest rate method. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of lender&#8217;s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan.&#160;In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we were </font><font style="font-family:inherit;font-size:10pt;">in compliance</font><font style="font-family:inherit;font-size:10pt;">&#32;with all material covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, including amortization of the debt discount, related to the Oxford and SVB loan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2015, respectively. Accrued interest, which is included in accrued expenses and other long-term liabilities, was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The outstanding term loan balance was </font><font style="font-family:inherit;font-size:10pt;">$54.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s52368C14C8BC07FB8853481E5D9A25E1"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Share-based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,610</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs, RSUs and PRSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have a net operating loss carryforward as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;excess tax benefits for the tax deductions related to share-based awards were recognized in the condensed consolidated statements of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company granted stock options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock during both the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">4.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. We estimated fair value of each stock option granted on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation that we will not be making future dividend payments. The assumptions used in the Black-Scholes model were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.8-66.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.2-67.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.18%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69-1.92%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.34-1.92%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,311</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.8</font></div></td></tr></table></div></div><div><a name="sDA758BEACA060ECB5A2A481E5DC98873"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Stockholders&#8217; (Deficit) Equity</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">383,719</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,626,091</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.74</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.43</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively, for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">215,779</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">134,088</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">82,396</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">52,019</font><font style="font-family:inherit;font-size:10pt;">&#32;RSUs, respectively, to pay for minimum withholding taxes totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. In addition, we issued </font><font style="font-family:inherit;font-size:10pt;">968,652</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">515,695</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in connection with the grants of RSAs during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. Stock options and unvested restricted units totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock were outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="sD862FDD5B636348E9CE8481E5DD9DE14"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="s314C22637885C7D52F17481E6B3AE99D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div></td></tr></table><div><a name="sF9E3E50987214E0F4187481E5FA1DDAE"></a></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">As used in this report, unless the context suggests otherwise, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Halozyme Therapeutics, Inc., its wholly owned subsidiary, Halozyme, Inc. and Halozyme Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. References to &#8220;Notes&#8221; refer to the Notes to Condensed Consolidated Financial Statements included herein (refer to Item 1 of Part I).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and Notes thereto included in Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;opportunity,&#8221; &#8220;project&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this report. Additionally, statements concerning future matters such as the anticipated timing and scope of planned clinical trials, the development or regulatory approval of new products, enhancements of existing products or technologies, timing and success of the launch of new products by us or by our collaborators, third party performance under key collaboration agreements, revenue, expense and cash burn levels, expected repayment of the Royalty-backed Loan and trends and other statements regarding matters that are not historical are forward-looking statements. Such statements reflect management&#8217;s current forecast of certain aspects of our future, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled &#8220;Risks Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators&#8217; proprietary compounds.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex&#174; recombinant, and it works by temporarily breaking down hyaluronan (or HA), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE&#8482; Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), and Eli Lilly and Company (Lilly). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (PDA) (Studies 109-202 and 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(eribulin) in first line and second line HER2-negative metastatic breast cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">third</font><font style="font-family:inherit;font-size:10pt;">&#32;quarter of 2016 and recent highlights include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FDA accepted Genentech&#8217;s (a member of the Roche Group) Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, we announced that PEGPH20 will be included in a pancreatic cancer clinical trial initiative called Precision Promise, an initiative that aims to change the current treatment approach to pancreatic cancer by offering options to patients based on the molecular profile of their tumor. This is being accomplished through the Pancreatic Cancer Action Network leading a collaboration that brings together clinicians, researchers, and drug developers. Pancreatic Cancer Action Network has announced plans to begin enrolling patients at 12 initial consortium sites in Spring 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, after assessing recruitment and the enrollment of increasingly later line patients, we decided to discontinue the PRIMAL study of PEGPH20 with docetaxel in non-small cell lung cancer patients and focus on immuno-oncology therapy in our ongoing phase 1b study of PEGPH20 in combination with KEYTRUDA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we resumed patient enrollment and dosing in our ongoing Phase 1b study evaluating PEGPH20 in combination with KEYTRUDA in relapsed non-small cell lung and gastric cancer patients under a revised clinical protocol. The revised protocol has been submitted to all institutional review boards (IRBs) and is pending feedback from the FDA. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we initiated a phase 1b/2 study with our partner, Eisai, exploring the combination of PEGPH20 and eribulin in first line and second line HER2-negative high-HA metastatic breast cancer.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product and Product Candidates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have one marketed proprietary product, one proprietary product candidate targeting several indications in various stages of development, and two pre-clinical product candidates. The following table summarizes our proprietary product and product candidate as well as products and product candidates under development with our collaborators:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;"><img src="slide1a18.jpg" alt="slide1a18.jpg" style="height:292px;width:684px;"></div><div style="line-height:120%;padding-top:8px;text-align:left;"><img src="slide2a16.jpg" alt="slide2a16.jpg" style="height:338px;width:684px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;"><img src="slide3a13.jpg" alt="slide3a13.jpg" style="height:282px;width:684px;"></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Proprietary Pipeline</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex Recombinant (hyaluronidase human injection)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant is a formulation of rHuPH20 that has received FDA approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant is currently the number one prescribed branded hyaluronidase. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PEGPH20 </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing PEGPH20 in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. &#8216;PEG&#8217; refers to the attachment of polyethylene glycol to rHuPH20, thereby creating PEGPH20. One of the novel properties of PEGPH20 is that it lasts for an extended duration in the bloodstream and, therefore, can be administered systemically to maintain its therapeutic effect to treat disease.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer malignancies, including pancreatic, lung, breast, gastric, colon and prostate cancers can accumulate high levels of HA and therefore we believe that PEGPH20 has the potential to help patients with these types of cancer when used with currently approved cancer therapies. Among solid tumors, PDA has been reported to be associated with the highest frequency of HA accumulation. Approximately 90,000 patients in the United States and the European Union will be diagnosed with PDA in 2016. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pathologic accumulation of HA, along with other matrix components, creates a unique microenvironment for the growth of tumor cells compared to normal cells. We believe that depleting the HA component of the tumor microenvironment with PEGPH20 remodels the tumor microenvironment, resulting in tumor growth inhibition in animal models. Removal of HA from the tumor microenvironment results in expansion of previously constricted blood vessels allowing increased blood flow, potentially increasing the access of activated immune cells and factors in the blood into the tumor microenvironment. If PEGPH20 is administered in conjunction with other anti-cancer therapies, the increase in blood flow may allow anti-cancer therapies to have greater access to the tumor, which may enhance the treatment effect of therapeutic modalities like chemotherapies, monoclonal antibodies and other agents.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pancreatic cancer indications</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study Halo 109-201</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, we presented the final results from Study 109-201, a multi-center, international open label dose escalation Phase 1b clinical study of PEGPH20 in combination with gemcitabine for the treatment of patients with stage IV PDA at the 2015 Gastrointestinal Cancers Symposium (also known as ASCO-GI meeting). This study enrolled 28 patients with previously untreated stage IV PDA. Patients were treated with one of three doses of PEGPH20 (1.0, 1.6 and 3.0 &#181;g/kg twice weekly for four weeks, then weekly thereafter) in combination with gemcitabine 1000 mg/m</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;administered intravenously. In this study, the confirmed overall response rate (complete response + partial response confirmed on a second scan as assessed by an independent radiology review) was 29 percent (7 of 24 patients) for those treated at therapeutic dose levels of PEGPH20 (1.6 and 3.0 &#181;g/kg). Median progression-free survival (PFS) was 154 days (95% CI, 50-166) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median PFS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 219 days, than in the patients with low baseline tumor HA staining (11/17 patients), 108 days. Median overall survival (OS) was 200 days (95% CI, 123-370) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median OS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 395 days, than in the patients with low baseline tumor HA staining (11/17 patients), 174 days. The most common treatment-emergent adverse events (occurring in &#8805; 15% of patients) were peripheral edema, muscle spasms, thrombocytopenia, fatigue, myalgia, anemia, and nausea. Thromboembolic (TE) events were reported in 8 patients (28.6%) and musculoskeletal events were reported in 21 patients (75%) which were generally grade 1/2 in severity.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study Halo 109-202</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2013, we initiated Study 109-202, a Phase 2 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study was designed to enroll patients who would receive gemcitabine and nab-paclitaxel (ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) either with or without PEGPH20. The primary endpoint is to measure the improvement in PFS in patients receiving PEGPH20 plus gemcitabine and ABRAXANE (PAG arm) compared to those who are receiving gemcitabine and ABRAXANE alone (AG arm). In April 2014, after 146 patients had been enrolled, the trial was put on clinical hold by Halozyme and the FDA to assess a question raised by the Data Monitoring Committee regarding a possible difference in the TE events rate between the group of patients treated in the PAG arm versus the group of patients treated in the AG arm. This portion of the study and patients in this portion are now referred to as Stage 1. At the time of the clinical hold all patients remaining in the study continued on gemcitabine and ABRAXANE. In July 2014, the Study 109-202 was reinitiated (Stage 2) under a revised protocol, which excludes patients that are expected to be at a greater risk for TE events. The revised protocol provides for thromboembolism prophylaxis of all patients in both arms of the study with low molecular weight heparin, and adds evaluation of the TE events rate in Stage 2 PEGPH20-treated patients as a co-primary end point. Stage 2 of Study 109-202 enrolled an additional 133 patients, to add to the 146 patients already in the clinical trial, with a 2:1 randomization for the PAG arm compared to the AG arm. We were recently informed by the independent statistician for the data monitoring committee that progression-free survival data are not yet mature for analysis. As a result, we now expect the reporting of data may move from the fourth quarter of 2016 into 2017, depending on when it is mature for analysis.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, our partner, Ventana, received approval for an investigational device exemption (IDE) application from the FDA for our companion diagnostic test to enable patient selection in our Phase 3 Study 301 of PEGPH20 in high-HA patients. Based on the cutpoint for the Ventana diagnostic, we expect approximately 35 to 40 percent of stage IV PDA patients to have high-HA tumors, similar to the previously reported interim results from Stage 1 of Study 202 using the Halozyme prototype assay.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, results from a final analysis of Stage 1 of Study 109-202, based on a February 2016 data cut-off, were presented at the American Society of Clinical Oncology annual conference. The trial included 135 treated patients in Stage 1, of whom a total of 43 patients (22 in the PAG arm and 21 in the AG arm) were determined to have high HA. This final analysis of secondary and exploratory endpoints was conducted using the Ventana companion diagnostic to retrospectively identify high levels of HA. The key results showed in the high-HA patient population:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Median PFS was 9.2 months in the PAG arm versus 6.0 months in the AG arm, hazard ratio (HR) with a 95 percent confidence interval (CI): 0.46 (0.15, 1.40); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Overall response rate of 50 percent, including one complete response in the PAG arm versus 33 percent and all partial responses in the AG arm;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Median duration of response of 8.1 months in the PAG arm versus 3.7 months in the AG arm; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exploratory analysis of median OS was similar between the treatment arms, 11.8 months vs. 10.9 months in the PAG vs. AG arms respectively. Factors potentially having an impact on these results include less aggressive disease among patients in the AG arm and a greater than 40 percent discontinuation rate of PEGPH20 treatment in the PAG arm at the time of the clinical hold, resulting in all patients receiving AG alone in both arms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rate of TE events reduced from 43 percent to 9 percent in the PAG arm and from 25 percent to 6 percent in the AG arm with the introduction of prophylaxis with low molecular weight heparin (enoxaparin) from Stage 1 to Stage 2 of the study. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and the Data Monitoring Committee for Study 109-202 continue to closely monitor the occurrence of TE events in enrolled patients after the revision to the protocol.&#160;The revised protocol includes pre-specified analyses to evaluate the rate of TE events. While the pre-specified TE event rate analysis established in the protocol at the time of the clinical hold in 2014 have been passed, the continuation of Study 202 may be halted again if the FDA determines that imbalances in safety findings, including TE events, occur, or for any other emergent safety concerns.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continue to collect and receive data on Stage 1 and 2 patients including Stage 1 patients who had discontinued treatment and who were in long term follow up at the time of the February 2016 data cut-off.&#160;When the database is considered complete and locked, an updated&#160;analysis and Final Study Report will be generated.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study Halo 109-301</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, we met with the FDA to discuss both the interim efficacy and safety data from Study 109-202, which included the potential risk profile including TE event rate. Based on the feedback from that meeting, we proceeded with a Phase 3 clinical study (Study 109-301) of PEGPH20 in patients with stage IV PDA, using a design allowing for potential marketing application based on either PFS or OS.</font><font style="font-family:Arial;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">The study will enroll patients whose tumors accumulate high levels of&#160;HA measured using the Ventana companion diagnostic test. The FDA provided feedback on the current companion diagnostic approach and confirmed that an approved IDE is required for the Phase 3 study.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of PFS as the basis for marketing approval will be subject to the overall benefit and risk associated with PEGPH20 combined gemcitabine and ABRAXANE therapy, including the:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Magnitude of the PFS treatment effect observed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Toxicity profile;&#160;and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim OS data.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, we received scientific advice/protocol assistance from the European Medicines Agency (EMA) regarding our  Phase 3 study. The EMA agreed to the patient population, and the use of both PFS and OS as co-primary endpoints stating that OS is the preferred endpoint and that ultimate approval would require an overall positive benefit:risk balance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, we dosed the first patient in Study 109-301, a Phase 3 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study will evaluate the effects on PFS and OS of PEGPH20 with gemcitabine and ABRAXANE compared with gemcitabine and ABRAXANE alone in stage IV PDA patients at approximately 200 sites in 20 countries located in North America, Europe, South America and Asia Pacific. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SWOG Study S1313</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, SWOG, a cancer research cooperative group of more than 4,000 researchers in over 500 institutions around the world, initiated a 144 patient Phase 1b/2 randomized clinical trial in some of their study centers, examining PEGPH20 in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) compared to mFOLFIRINOX treatment alone in patients with stage IV PDA (funded by the National Cancer Institute). This study was also placed on clinical hold temporarily at the time of the hold on Study 109-202. In September 2014, the&#160;FDA removed the clinical hold on patient enrollment and dosing of PEGPH20 in this SWOG cooperative study. The study has resumed under a revised protocol, and patient enrollment is continuing. The Phase 2 portion of the study, where up to 172 patients are planned to be enrolled, began in June 2015. As with Study 109-202, the occurrence of TE events will be closely monitored in enrolled patients, and the continuation of this study may be halted again in accordance with event rate rules established in the protocol, or for other safety reasons.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other indications outside of pancreatic cancer</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study HALO 107-201, PRIMAL Study:</font><font style="font-family:inherit;font-size:10pt;">&#32;In December 2014, we initiated a Phase 1b/2 trial, to evaluate PEGPH20 in second line in combination with docetaxel (Taxotere</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in non-small cell lung cancer patients. In August 2016, after assessing recruitment and the enrollment of increasingly later line patients, we discontinued the PRIMAL study.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study HALO 107-101, the immuno-oncology trial:</font><font style="font-family:inherit;font-size:10pt;">&#32;In November 2015, we initiated a Phase 1b study exploring the combination of PEGPH20 and KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, an immuno-oncology agent in relapsed non-small cell lung cancer and gastric cancer. We recently resumed patient enrollment after submitting a revised protocol to all IRBs. We expect to evaluate and identify the dose and safety of PEGPH20 plus KEYTRUDA prior to embarking on dose expansion in high-HA patients in this study. We project that the study will move into the dose expansion phase by the end of 2016.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Halozyme Eisai Clinical Collaboration: </font><font style="font-family:inherit;font-size:10pt;">In July 2016, the first patient was dosed in a Phase 1b/2 study, exploring the combination of PEGPH20 and eribulin in first line and second line HER2-negative high-HA metastatic breast cancer. Halozyme and Eisai will jointly share the costs to conduct this global study.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The&#160;FDA has granted Fast Track designation for our program investigating PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of patients with stage IV PDA to demonstrate an improvement in OS. The Fast Track designation process was developed by the&#160;FDA&#160;to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The&#160;FDA has granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.&#160;The FDA Office of Orphan Products Development&#8217;s mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Similarly, the European Committee for Orphan Medicinal Products of the EMA designated PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, we met with the FDA to discuss both the interim efficacy and safety data from Study 109-202 and to discuss the Phase 3 Study 109-301 as a potential registration study in stage IV PDA patients whose tumors are determined to have high levels of HA accumulation. In June 2015, we received scientific advice/protocol assistance from the EMA regarding our Phase 3 study. In March 2016, our partner, Ventana, received approval for an IDE application from the FDA for our companion diagnostic test to enable patient selection in our Phase 3 Study 301 of PEGPH20 in high-HA patients.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Tumor microenvironment </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">PEG-ADA2:</font><font style="font-family:inherit;font-size:10pt;">&#32;PEGylated adenosine deaminase 2, or PEG-ADA2, is an immune checkpoint inhibitor that targets immuno-suppressive adenosine, which may accumulate to high levels in the tumor microenvironment. We are currently in early pre-clinical development with PEG-ADA2, with the next milestone expected to be final drug candidate selection by the end of 2016. We plan to continue the ongoing studies and characterization of PEG-ADA2 with the goal of determining its suitability as a targeted therapy for clinical study.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">HTI-1511: </font><font style="font-family:inherit;font-size:10pt;">We are in development of a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) to treat solid tumors, including those with drug-resistant mutations. We are in pre-clinical development with a drug candidate selected. Good laboratory practices (GLP) toxicity studies are planned for 2017, and chemistry, manufacturing and controls (CMC) development activities to support a future investigational new drug (IND) filing are underway.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaborations</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Roche Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the Roche Collaboration). Roche initially had the exclusive right to apply rHuPH20 to three pre-defined Roche biologic targets with the option to exclusively develop and commercialize rHuPH20 with ten additional targets. Roche has elected a total of five targets, two of which are exclusive, and retains the option to develop and commercialize rHuPH20 with three additional targets. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, Roche launched a subcutaneous (SC) formulation of Herceptin (trastuzumab) (Herceptin SC) in Europe for the treatment of patients with HER2-positive breast cancer. This formulation utilizes our patented ENHANZE Technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard intravenous form. Roche received European marketing approval for Herceptin SC in August 2013. The European Commission&#8217;s approval was based on data from Roche&#8217;s Phase 3 HannaH study which showed that the subcutaneous formulation of Herceptin was associated with comparable efficacy (pathological complete response, pCR) to Herceptin administered intravenously in women with HER2-positive early breast cancer and resulted in non-inferior trastuzumab plasma levels. Overall, the safety profile in both arms of the HannaH study was consistent with that expected from standard treatment with Herceptin and chemotherapy in this setting. No new safety signals were identified. Breast cancer is the most common cancer among women worldwide. Each year, about 1.7&#160;million new cases of breast cancer are diagnosed worldwide, and over 500,000 women will die of the disease annually. In HER2-positive breast cancer, increased quantities of the human epidermal growth factor receptor 2 (HER2) are present on the surface of the tumor cells. This is known as &#8220;HER2 positivity&#8221; and affects approximately 15% to 20% of women with breast cancer. HER2-positive cancer is reported to be a particularly aggressive form of breast cancer. Directed at the same target, Roche initiated a Phase 1 study of rHuPH20 with PERJETA&#174; (pertuzumab) in patients with early breast cancer in March 2016. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, Roche launched MabThera SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). This formulation utilizes our patented ENHANZE Technology and is administered in approximately five minutes compared to the approximately 2.5 hour infusion time for intravenous MabThera. The European Commission approved MabThera SC in March 2014. The European Commission&#8217;s approval was based primarily on data from Roche&#8217;s Phase 3 pivotal clinical studies, which was published in The Lancet Oncology. NHL is a type of cancer that affects lymphocytes (white blood cells). NHL represents approximately 85% of all lymphomas diagnosed and was responsible for approximately 200,000 annual deaths worldwide in 2012. Lymphomas are a cancer of the lymphatic system (composed of lymph vessels, lymph nodes and organs) which helps to keep the bodily fluid levels balanced and to defend the body against invasion by disease. Lymphoma develops when white blood cells (usually B-lymphocytes) in the lymph fluid become cancerous and begin to multiply and collect in the lymph nodes or lymphatic tissues such as the spleen. Some of these cells are released into the bloodstream and spread to other parts of the body, interfering with the body&#8217;s production of healthy blood cells. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FDA has accepted Genentech&#8217;s (a member of the Roche Group) Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional information about the Phase 3 Herceptin SC and Phase 3 MabThera SC clinical trials can be found at </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.clinicaltrials.gov</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.roche-trials.com</font><font style="font-family:inherit;font-size:10pt;">. Information available on these websites is not incorporated into this report.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Baxalta Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2007, we and Baxalta entered into a collaboration and license agreement under which Baxalta obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA) (the Baxalta Collaboration). GAMMAGARD LIQUID is a current Baxalta product that is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Baxalta announced the launch and first shipments of Baxalta&#8217;s HYQVIA product for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA was approved by the FDA in September 2014 and is the first subcutaneous immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG. The majority of primary immunodeficiency patients today receive intravenous infusions in a doctor&#8217;s office or infusion center, and current subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment. The FDA&#8217;s approval of HYQVIA was a significant milestone for us as it represented the first U.S. approved Biologic License Application (BLA) which utilizes our rHuPH20 platform. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which will be launched in eight European countries to treat primary and certain secondary immunodeficiencies. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pfizer Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics directed to up to six targets in primary care and specialty care indications. Targets may be selected on an exclusive or non-exclusive basis. Pfizer has elected five targets on an exclusive basis. One of the targets is proprotein convertase subtilisin/kexin type 9 (PCSK9) which is the gene that provides instructions for making a protein that helps regulate the amount of cholesterol in the bloodstream. Pfizer initiated dosing of a subcutaneous formulation of rHuPH20 and bococizumab, an investigational PCSK9 inhibitor, in a Phase 1 trial in February 2016. In April 2016, Pfizer completed a Phase 1 study of rHuPH20 with rivipansel, directed to another target to treat vaso-occlusive crisis in individuals with sickle cell disease, demonstrating feasibility of large volume subcutaneous administration with rHuPH20. Pfizer recently announced they have discontinued their development program for bococizumab. The development of the subcutaneous formulation of rHuPH20 with bococizumab has also been discontinued. Pfizer also made a portfolio decision to discontinue development of rHuPH20 with rivipansel.&#160;Pfizer continues to develop a third program with an undisclosed target.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Janssen Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an exclusive basis. In November 2015, Janssen initiated dosing in a Phase 1b clinical trial evaluating subcutaneous delivery of daratumumab, directed at CD38, using ENHANZE Technology, in multiple myeloma.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AbbVie Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. AbbVie has elected TNF alpha as the first target on an exclusive basis. In January 2016, AbbVie initiated dosing in a Phase 1 clinical trial evaluating rHuPH20 with adalimumab (HUMIRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) which may allow a reduced number of induction injections and deliver additional performance benefits.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lilly Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a further discussion of the material terms of our collaboration agreements, refer to Note 4, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">, to our condensed consolidated financial statements. </font></div><div><a name="sE45051F5274C773969B6481E5FA2A7DD"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three Months Ended</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Compared to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three Months Ended</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Product sales, net were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales of bulk rHuPH20:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,694</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Baxalta</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales of </font><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-style:italic;">Hylenex</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total product sales, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,030</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net increased in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2015, due to an increase in the sales of bulk rHuPH20 to Baxalta and Roche. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Royalty revenue was </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase relates primarily to increased sales of Herceptin SC by Roche. We recognize royalties on sales of the collaboration products by the collaborators in the quarter following the quarter in which the corresponding sales occurred. In general, we expect royalty revenue to increase in future periods reflecting expected increases in sales of collaboration products, although there may be periods with flat or declining royalty revenue as sales of products under collaborations vary. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues Under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenues under collaborative agreements were as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.34697855750487%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements for research and development services:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Janssen, Lilly, Baxalta, other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">659</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,463</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments remained flat in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2015.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from reimbursements for research and development services increased in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015 mainly due to an increase in services provided to Roche related to the validation of a new manufacturing facility. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount and timing of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to fluctuate in future periods based on our collaborators&#8217; abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Product Sales</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of product sales were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of in cost of $2.9 million product sales was mainly due to an increase in bulk rHuPH20 sales to collaboration partners. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, clinical trials, preclinical and regulatory activities. Research and development expenses incurred were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PEGPH20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enhanze collaborations and rHuPH20 platform</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,095</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses relating to our PEGPH20 program for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;increased by </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015, primarily due to increased clinical trial activities. We expect these expenses to increase in future periods reflecting expected increases in our PEGPH20 development activities. Research and development expenses relating to our Enhanze collaborations and our rHuPH20 platform for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;increased by </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015, primarily due to an increase in manufacturing expenses related to Roche due to the validation cost of a new manufacturing facility and increased manufacturing for future R&amp;D studies. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Selling, general and administrative (SG&amp;A) expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of $</font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13%</font><font style="font-family:inherit;font-size:10pt;">, was primarily due to an increase in compensation expense in the current period as we increased the number of employees. We expect SG&amp;A expenses to increase moderately in future periods as our operations expand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Interest expense was </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to interest expense incurred on the Royalty-backed Loan we received in January 2016, partially offset by lower average borrowings on the term loan during the quarter. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nine Months Ended</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Compared to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nine Months Ended</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Product sales, net were as follows (in thousands):</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of bulk rHuPH20:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,976</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,587</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baxalta</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total product sales, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net increased in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2015, primarily due to an increase in the sales of bulk rHuPH20 to Baxalta and Roche. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Royalty revenue was </font><font style="font-family:inherit;font-size:10pt;">$36.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase relates primarily to increased sales of Herceptin SC by Roche. We recognize royalties on sales of the collaboration products by the collaborators in the quarter following the quarter in which the corresponding sales occurred. In general, we expect royalty revenue to increase in future periods reflecting expected increases in sales of collaboration products, although there may be periods with flat or declining royalty revenue as sales of products under collaborations vary. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues Under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenues under collaborative agreements were as follows (in thousands): </font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.34697855750487%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:55%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,202</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements for research and development services:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen, Lilly, Baxalta, other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from upfront license fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments decreased in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the same period in 2015, primarily due to the upfront license fees received in connection with the AbbVie Collaboration of $23.0 million that was recognized in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, for which we did not recognize any such revenue in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, offset by licenses fees for the election of additional targets received from Lilly, AbbVie and Pfizer of $16.5 million in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from reimbursements for research and development services increased in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015 mainly due to an increase in services provided to Roche related to the validation of a new manufacturing facility. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to fluctuate in future periods based on our collaborators&#8217; abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Product Sales</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of product sales were </font><font style="font-family:inherit;font-size:10pt;">$25.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cost of product sales was due to a $6.1 million increase in bulk rHuPH20 sales to collaboration partners partially offset by a $1.7 million decrease in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant cost of product sales, due to a decrease in manufacturing costs. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, clinical trials, preclinical and regulatory activities. Research and development expenses incurred were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PEGPH20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enhanze collaborations and rHuPH20 platform</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,154</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,431</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses relating to our PEGPH20 program for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;increased by </font><font style="font-family:inherit;font-size:10pt;">54%</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015, primarily due to increased clinical trial activities. We expect these expenses to increase in future periods reflecting expected increases in our PEGPH20 development activities. Research and development expenses relating to our Enhanze collaborations and our rHuPH20 platform for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;increased by </font><font style="font-family:inherit;font-size:10pt;">162%</font><font style="font-family:inherit;font-size:10pt;">, compared to the same period in 2015, primarily due to an increase in manufacturing expenses related to Roche due to the validation cost of a new manufacturing facility and increased manufacturing for future R&amp;D studies. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;SG&amp;A expenses were </font><font style="font-family:inherit;font-size:10pt;">$33.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$29.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">14%</font><font style="font-family:inherit;font-size:10pt;">, was primarily due to an increase in compensation expense in the current period as we increased the number of employees. We expect SG&amp;A expenses to increase moderately in future periods as our operations expand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Interest expense was </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The increase of </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to interest expense incurred on the Royalty-backed Loan we received in January 2016.</font></div><div><a name="sB0E20C00F40FD00CCAA3481E5FA3BEE8"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and marketable securities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$221.1 million</font><font style="font-family:inherit;font-size:10pt;">. We will continue to have significant cash requirements to support product development activities. The amount and timing of cash requirements will depend on the progress and success of our clinical development programs, regulatory and market acceptance, and the resources we devote to research and other commercialization activities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We currently anticipate a cash and cash equivalents balance of $180 million to $190 million at December&#160;31, 2016, which will depend on the progress of various preclinical and clinical programs, the timing of our manufacturing scale-up and the achievement of various milestones and royalties under our existing collaborative agreements. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may finance future cash needs through any one of the following financing vehicles: (i)&#160;the public offering of securities; (ii)&#160;new collaborative agreements; (iii)&#160;expansions or revisions to existing collaborative relationships; (iv)&#160;private financings; (v)&#160;other equity or debt financings; and/or (vi) monetizing assets. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a &#8220;well known seasoned issuer&#8221;, which allows us to file an automatically effective shelf registration statement on Form S-3 which would allow us, from time to time, to offer and sell equity, debt securities and warrants to purchase any of such securities, either individually or in units. We may, in the future, offer and sell equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital to fund the continued development of our product candidates, the commercialization of our products or for other general corporate purposes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our existing cash, cash equivalents and marketable securities may not be adequate to fund our operations until we become profitable, if ever. We cannot be certain that additional financing will be available when needed or, if available, financing will be obtained on favorable terms. If we are unable to raise sufficient funds, we may need to delay, scale back or eliminate some or all of our research and development programs, delay the launch of our product candidates, if approved, and/or restructure our operations. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders could result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, the issuance of warrants that may ultimately dilute existing stockholders when exercised and covenants that may restrict our ability to operate our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operations was </font><font style="font-family:inherit;font-size:10pt;">$34.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$21.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in utilization of cash in operations was mainly due to an increase in operating expenses for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the corresponding period in the prior year. </font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;">$97.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to net cash provided by investing activities of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This change was primarily due to the $106.0 million increase in purchases of marketable securities for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;using proceeds from financing activities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$150.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This increase was due to net proceeds of $148.0 million from the Royalty-backed Loan, and $55.0 million from the Oxford and SVB Loan and Security Agreement, partially offset by principal and a final payment of $54.3 million on the Oxford and SVB Loan and a $9.5 million decrease in net proceeds from the issuance of common stock under equity incentive plans for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Term Debt</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty-backed Loan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, through our wholly-owned subsidiary Halozyme Royalty, we received a $150 million loan (the Royalty-backed Loan) pursuant to a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (Collaboration Agreements). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the Royalty Payments).&#160; The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">9.61%</font><font style="font-family:inherit;font-size:10pt;">.&#160;The outstanding balance of the Royalty-backed Loan as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$157.6 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of payment-in-kind interest expense of </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement provides that none of the Royalty Payments are required to be applied to the Royalty-backed Loan prior to January&#160;1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January&#160;1, 2017 and January&#160;1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan.&#160;However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date.&#160;Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final maturity date of the Royalty-backed Loan will be the earlier of (i)&#160;the date when principal and interest is paid in full, (ii)&#160;the termination of Halozyme Royalty&#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&#160;December&#160;31, 2050.&#160; Under the terms of the Credit Agreement, at any time after January&#160;1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. </font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Oxford and SVB Loan and Security Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2013, we entered into an Amended and Restated Loan and Security Agreement (the Original Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Loan Agreement provided for an additional $20 million principal amount of new term loan, bringing the total term loan balance to $50 million. The amended term loan facility was scheduled to mature on January&#160;1, 2018.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, we and the Lenders entered into a second amendment to the Original Loan Agreement (the Amendment) amending and restating the loan repayment schedule of the Original Loan Agreement. The amended and restated loan repayment schedule provides for interest only payments in arrears through January 2016, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date. Consistent with the original loan, the amended Original Loan Agreement provided for a 7.55% interest rate on the term loan and a final payment equal to 8.5% of the original principal amount, or $4.25 million, which was due when the term loan became due or upon the prepayment of the facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a new Loan and Security Agreement (the Loan Agreement) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of $70 million. Upon entering the loan, we drew $55 million at an annual interest rate of 8.25% and used a portion the proceeds to pay the outstanding principal and final payment owed on the Original Loan Agreement. The remaining proceeds are to be used for working capital and general business requirements. We have the option to draw the remaining $15 million during the second quarter of 2017 at an annual interest rate equal to the then-current prime rate as reported in The Wall Street Journal plus 4.75%. The term loan repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55 million principal amount and, if we exercise our option to draw an additional $15 million in 2017, 7.25% of the principal amount of the second draw. The final payment is due when the term loan becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the term loan in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the term loan. The outstanding term loan balance was </font><font style="font-family:inherit;font-size:10pt;">$54.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan facility is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc. and any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan.". In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of lender&#8217;s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we did not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Please see our audited consolidated financial statements and notes thereto included in Part II, Item&#160;8 of our Annual Report on Form 10-K for the year ended December&#160;31, 2015 (2015 Form 10-K), which contain our critical accounting policies and other disclosures required by U.S. GAAP. There were no material changes from those policies and disclosures included in our 2015 Form 10-K. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:10pt;">, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related To Our Business</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have generated only limited revenues from product sales to date; we have a history of net losses and negative cash flows, and we may never achieve or maintain profitability.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relative to expenses incurred in our operations, we have generated only limited revenues from product sales, royalties, licensing fees, milestone payments, bulk rHuPH20 supply payments and research reimbursements to date and we may never generate sufficient revenues from future product sales, licensing fees and milestone payments to offset expenses. Even if we ultimately do achieve significant revenues from product sales, royalties, licensing fees, research reimbursements, bulk rHuPH20 supply payments and/or milestone payments, we expect to incur significant operating losses over the next few years. We have never been profitable, and we may never become profitable. Through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have incurred aggregate net losses of </font><font style="font-family:inherit;font-size:10pt;">$558.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approval from the FDA or equivalent health authorities is necessary to manufacture and market pharmaceutical products in the U.S., and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our collaborators attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our collaborators expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our product candidates for failure to collect sufficient clinical or animal safety data and require us or our collaborators to conduct additional clinical or animal safety studies which may cause lengthy delays and increased costs to our programs. For example, the approval of Baxalta&#8217;s HYQVIA Biologic License Application (BLA) was delayed until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, we cannot assure you that they will not arise and have an adverse impact on future development of products which include rHuPH20, future sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant, our ability to enter into collaborations, or be raised by the FDA or other health authorities in connection with testing or approval of products including rHuPH20.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and our collaborators may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns</font><font style="font-family:inherit;font-size:10pt;">&#8221; for additional information relating to the approval of product candidates.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our collaborators must maintain our regulatory approvals. If we or any of our collaborators are unsuccessful in maintaining our regulatory approvals, our ability to generate revenues would be adversely affected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will likely need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will likely need to raise additional capital in the future to continue the development of our product candidates or for other current corporate purposes. Our current cash reserves and expected revenues during the next few years will not be sufficient for us to continue the development of our proprietary product candidates, to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i)&#160;the public offering of securities; (ii)&#160;new collaborative agreements; (iii)&#160;expansions or revisions to existing collaborative relationships; (iv)&#160;private financings; (v)&#160;other equity or debt financings; and/or (vi) monetizing assets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In view of our stage of development, business prospects, the nature of our capital structure and general market conditions, if we are required to raise additional capital in the future, the additional financing may not be available on favorable terms, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of one or more product development programs. If we raise additional capital, a substantial number of additional shares may be issued, and these shares will dilute the ownership interest of our current investors.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of our product candidates or those of our collaborators could be associated with side effects or adverse events.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As with most pharmaceutical products, use of our product candidates or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates or those of our collaborators may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our or our collaborators&#8217; ability to obtain or maintain regulatory approval or market our product candidates. Side effects such as toxicity or other safety issues associated with the use of our product candidates or those of our collaborators could require us or our collaborators to perform additional studies or halt development or commercialization of these product candidates or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical product candidates which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. For example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study 202 as a result of a possible difference in the Thromboembolic (TE) event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by the FDA in June 2014, and we have completed enrollment and resumed dosing of PEGPH20 in Study 202 under a revised clinical protocol. We and the data monitoring committee for Study 202 continue to closely monitor the occurrence of TE events in enrolled patients after the protocol amendments.&#160;While the pre-specified TE event rate analysis established in the protocol at the time of the clinical hold in 2014 has been passed, the continuation of Study 202 may be halted again if the FDA determines that imbalances in safety findings, including TE events, occur.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our contract manufacturers are unable to manufacture and supply to us bulk rHuPH20 or other raw materials in the quantity and quality required by us or our collaborators for use in our products and product candidates, our product development and commercialization efforts could be delayed or stopped and our collaborations could be damaged.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Cook Pharmica LLC (Cook) to produce bulk rHuPH20.&#160;These manufacturers each produce bulk rHuPH20 under cGMP for clinical uses.&#160;Cook currently produces bulk rHuPH20 for use in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant, product candidates and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products.&#160;In addition to supply obligations, Avid and Cook will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We rely on their ability to successfully manufacture these batches according to product specifications. If either Avid or Cook: (i) is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up bulk rHuPH20 production to meet corporate or regulatory authority quality standards; or (iii) fails to manufacture and supply bulk rHuPH20 in the quantity and quality required by us or our collaborators for use in our proprietary and collaboration products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties&#8217; or other third party manufacturers&#8217; business or financial condition could adversely affect their abilities to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by Avid and/or Cook. Any delays, interruptions or other problems regarding the ability of Avid and/or Cook to supply bulk rHuPH20 or the ability of other third party manufacturers, to supply other raw materials or ingredients necessary to produce our products on a timely basis could: (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of proprietary or collaboration product candidates; (ii) delay or prevent the effective commercialization of proprietary or collaboration products; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our collaborators. Such delays would likely damage our relationship with our collaborators, and they would have a material adverse effect on royalties and thus our business and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if&#160;a key collaboration agreement is terminated for any reason, our business could significantly suffer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are dependent on our collaborators to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits from these collaborations. Our collaborators may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions could not be visible to us immediately and could negatively impact the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could delay or suspend our product development activities for some of our product candidates, as well as our commercialization efforts for some or all of our products. Specifically, the termination of a key collaboration agreement by one of our collaborators could materially impact our ability to enter into additional collaboration agreements with new collaborators on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and reevaluate the applications and value of our technology.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Most of our current proprietary and collaboration products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential collaborations, as well as proprietary programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">rHuPH20 is a key technological component of ENHANZE Technology and our most advanced proprietary and collaboration products and product candidates, including the current and future products and product candidates under our Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly collaborations, our PEGPH20 program, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex </font><font style="font-family:inherit;font-size:10pt;">recombinant. If there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for Baxalta&#8217;s HYQVIA product as well as in a former collaborator&#8217;s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">program or the former collaborator&#8217;s program will have a significant impact on our other proprietary and other collaboration product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or our other programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our development or commercialization activities or deter entry into additional collaborations with third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We routinely evaluate, and may modify, our business strategy and our strategic focus to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the third quarter of 2014, we decided to focus our resources on advancing PEGPH20 and expanding utilization of our ENHANZE platform. While we believe these are applications with the greatest potential value, we have reduced the diversification of our programs and increased our dependence on the success of the areas we are pursuing. By focusing on one or a few areas, we increase the potential impact on us if one of those programs or product candidates does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue.  Our decision to focus on one or a few programs may also reduce the value of programs that are no longer within our principal strategic focus, which could impair our ability to pursue collaborations or other strategic alternatives for those programs we are not pursuing.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, we or our collaborators may obtain different results in subsequent trials or studies that fail to show the desired levels of safety and efficacy, or we may not, or our collaborators may not, obtain applicable regulatory approval for a variety of other reasons. Preclinical, nonclinical, and clinical trials for any of our proprietary or collaboration product candidates or development of any collaboration companion diagnostic assays could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates or companion diagnostic assays. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product candidates; for example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study 202 as a result of a possible difference in the TE event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by FDA in June 2014, and we have completed enrollment and resumed dosing of PEGPH20 in Study 202 under a revised clinical protocol;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completion of clinical trials may be delayed for a variety of reasons including the amount of time it may take to identify and enroll patients with high levels of HA in our target population and the ability to procure drug supply required in clinical trial protocols; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory review may not find a product candidate safe or effective enough to merit either continued testing or final approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require that we change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a regulatory agency may approve only a narrow use of our product or may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies (REMS) or conditions to assure safe use programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue regulatory approval for such a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a proprietary or collaboration product candidate or companion diagnostic assay is not approved in a timely fashion or obtained on commercially viable terms, or if development of any product candidate or a companion diagnostic assay is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, and we would become more dependent on the development of other proprietary or collaboration product candidates and/or our ability to successfully acquire other products and technologies. There can be no assurances that any proprietary or collaboration product candidate or companion diagnostic assay will receive regulatory approval in a timely manner, or at all. There can be no assurance that we will be able to gain clarity as to the FDA&#8217;s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit this opportunity will be limited or may not be possible.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that certain proprietary and collaboration products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our third party collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these collaboration products and product candidates and/or damage our collaborations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our development and commercialization collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Baxalta is responsible for producing the GAMMAGARD LIQUID for its product, HYQVIA. If a collaborator, or any applicable third party service provider of a collaborator, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the collaboration product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of collaboration product candidates; and/or (ii) delay or prevent the effective commercialization of collaboration products. Such delays could have a material adverse effect on our business and financial condition. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to manufacture, prepare, fill, finish and package our products and product candidates, and if such third parties should fail to perform, our commercialization and development efforts for our products and product candidates could be delayed or stopped.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on third parties to manufacture, prepare, fill, finish, package, store and ship our products and product candidates on our behalf. If we are unable to locate third parties to perform these functions on terms that are acceptable to us, or if the third parties we identify fail to perform their obligations, the progress of clinical trials could be delayed or even suspended and the commercialization of approved product candidates could be delayed or prevented.&#160;In addition, we are scaling up our manufacturing of PEGPH20 with third party suppliers to support additional clinical trials, including the Phase 3 trial, and ultimately, if approved, potential commercial supply. If our contract manufacturers are unable to successfully manufacture and supply PEGPH20, the progress of our clinical trials could be delayed or halted for a period of time.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to sufficiently develop our sales, marketing and distribution capabilities or enter into successful agreements with third parties to perform these functions, we will not be able to fully commercialize our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be successful in marketing and promoting our approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;">&#32;recombinant, or any other products we develop or acquire in the future. Our sales, marketing and distribution capabilities are very limited. In order to commercialize any products successfully, we must internally develop substantial sales, marketing and distribution capabilities or establish collaborations or other arrangements with third parties to perform these services. We do not have extensive experience in these areas, and we may not be able to establish adequate in-house sales, marketing and distribution capabilities or engage and effectively manage relationships with third parties to perform any or all of such services. To the extent that we enter into co-promotion or other licensing arrangements, our product revenues are likely to be lower than if we directly marketed and sold our products, and any revenues we receive will depend upon the efforts of third parties, whose efforts may not meet our expectations or be successful. These third parties would be largely responsible for the speed and scope of sales and marketing efforts, and may not dedicate the resources necessary to maximize product opportunities. Our ability to cause these third parties to increase the speed and scope of their efforts may also be limited. In addition, sales and marketing efforts could be negatively impacted by the delay or failure to obtain additional supportive clinical trial data for our products. In some cases, third party collaborators are responsible for conducting these additional clinical trials, and our ability to increase the efforts and resources allocated to these trials may be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or our collaborators fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any approved products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our collaborators and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, entirely dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay clinical trials or otherwise inhibit our ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, our collaborators and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with regulatory requirements may result in any of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on our products or manufacturing processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of the products from the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary or mandatory recall;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or termination of any of our ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to permit the import or export of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizure; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">imposition of civil or criminal penalties. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have significant debt and failure by us to fulfill our obligations under the applicable loan agreements may cause the repayment obligations to accelerate.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, our subsidiaries, Halozyme, Inc. (Halozyme) and Halozyme Royalty LLC (Halozyme Royalty) entered into a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders) pursuant to which we borrowed $150 million through Halozyme Royalty (the Royalty-backed Loan). The Royalty-backed Loan will be repaid primarily from a specified percentage of the royalty payments we receive under our collaboration agreements with Roche and Baxalta (the Royalty Payments). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The obligations of Halozyme Royalty under the Credit Agreement to repay the Royalty-backed Loan may be accelerated upon the occurrence of certain events of default under the Credit Agreement, including but not limited to:</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any payment of principal is not made within three days of when such payment is due and payable or otherwise made in accordance with the terms of the Credit Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any representations or warranties made in the Credit Agreement or any other transaction document proves to be incorrect or misleading in any material respect when made;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if there occurs a default in the performance of affirmative and negative covenants set forth in the Credit Agreement or any other transaction document;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the failure by either Baxalta or Roche to pay material amounts owed under our collaboration agreements because of an actual breach or default by us under the collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the voluntary or involuntary commencement of bankruptcy proceedings by either Halozyme or Halozyme Royalty and other insolvency related defaults;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any materially adverse effect on the binding nature of any of the transaction documents or the collaboration agreements with Baxalta and Roche; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme ceases to own, of record and beneficially, 100% of the equity interests in Halozyme Royalty.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement also contains covenants applicable to Halozyme and Halozyme Royalty, including certain visitation, information and audits rights granted to the collateral agent and the lenders and restrictions on the conduct of business, including continued compliance with the Baxalta and Roche collaboration agreements and specified affirmative actions regarding the escrow account established to facilitate payment of Royalty Payments to the Royalty-backed Lenders or other specified parties. The Credit Agreement also contains covenants solely applicable to Halozyme Royalty, including restrictions on incurring indebtedness, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">creating or granting liens, making acquisitions and making specified restricted payments. These covenants could make it more difficult for us to execute our business strategy.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Royalty-backed Loan, Halozyme Royalty granted a first priority lien and security interest (subject only to permitted liens) in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the Royalty Payments. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70 million. Upon entering the loan, we drew $55.0 million and used the proceeds to pay the outstanding principal and final payment owed on our previous loan agreement. We have the option to draw the remaining $15.0 million during the second quarter of 2017. The proceeds are to be used for working capital and general business requirements. The term loan facility is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; and enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary. Complying with these covenants may make it more difficult for us to successfully execute our business strategy. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, or a material impairment in the perfection or priority of lender&#8217;s lien in the collateral or in the value of such collateral. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to make payments on our debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund our research and development programs, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligation, an event of default may occur. In the event of default by us under the Credit Agreement or the Loan Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Credit Agreement or the Loan Agreement which could harm our financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If proprietary or collaboration product candidates are approved for marketing but do not gain market acceptance, our business may suffer and we may not be able to fund future operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assuming that our proprietary or collaboration product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these existing product candidates or any other products which are developed or acquired in the future, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the price of products relative to other therapies for the same or similar treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to fund our sales and marketing efforts and the ability and willingness of our collaborators to fund sales and marketing efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree to which the use of these products is restricted by the approved product label;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness of our sales and marketing efforts and the effectiveness of the sales and marketing efforts of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the introduction of generic competitors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which reimbursement for our products and related treatments will be available from third party payors including government insurance programs (Medicare and Medicaid) and private insurers.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If these products do not gain market acceptance, we may not be able to fund future operations, including the development or acquisition of new product candidates and/or our sales and marketing efforts for our approved products, which would cause our business to suffer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our proprietary and collaboration product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Developing and marketing pharmaceutical products for human use involves significant product liability risks for which we currently have limited insurance coverage.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The testing, marketing and sale of pharmaceutical products involves the risk of product liability claims by consumers and other third parties. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the lack or insufficiency of insurance coverage could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our collaboration product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability claims against us.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success depends on the performance of key management and scientific employees with relevant experience. For example, in order to pursue our current business strategy, we will need to recruit and retain personnel experienced in oncology drug development which is a highly competitive market for talent. We depend substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team. Particularly in view of the small number of employees on our staff to cover our numerous programs and key functions, if we are unable to retain existing personnel or identify or hire additional personnel, we may not be able to research, develop, commercialize or market our products and product candidates as expected or on a timely basis and we may not be able to adequately support current and future alliances with strategic collaborators. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, if we were to lose key management personnel, we would likely lose some portion of our institutional knowledge and technical know-how, potentially causing a substantial delay in one or more of our development programs until adequate replacement personnel could be hired and trained. We currently have a severance policy applicable to all employees and a change in control policy applicable to senior executives.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have key man life insurance policies on the lives of any of our employees.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations, including laboratories, offices and other research facilities, are located in four buildings in San Diego, California. In addition, we have a satellite office in South San Francisco, California. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our collaborators, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors&#8217; insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or our collaborators do not achieve projected development, clinical, regulatory or sales goals in the timeframes we publicly announce or otherwise expect, the commercialization of our products and the development of our product candidates may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we or our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our control. If scientific, regulatory, strategic or other factors cause us to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. For example, the announcement in April 2014 of the temporary halting of our Phase 2 clinical trial for PEGPH20 caused a rapid decline in our stock price. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management&#8217;s attention from our operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future acquisitions could disrupt our business and harm our financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to augment our product pipeline or otherwise strengthen our business, we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may have to issue convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain acquisitions may impact our relationship with existing or potential collaborators who are competitive with the acquired business, products or technologies;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">key personnel of an acquired company may decide not to work for us.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security breaches may disrupt our operations and harm our operating results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our information technology storage and access systems could result in the disruption of our ability to use such systems or disclosure or dissemination of our proprietary and confidential information that is electronically stored, including research or clinical data, resulting in a material adverse impact on our business, operating results and financial condition. Our security and data recovery measures may not be adequate to protect against computer viruses, break-ins, and similar disruptions from unauthorized tampering with our electronic storage systems. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related To Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price is subject to significant volatility.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. As a result, the high and low sales prices of our common stock during the twelve months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$18.65</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.96</font><font style="font-family:inherit;font-size:10pt;">, respectively. We expect our stock price to continue to be subject to significant volatility and, in addition to the other risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the presence of competitive products to those being developed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure (actual or perceived) of our collaborators to devote attention or resources to the development or commercialization of product candidates licensed to such collaborator;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a dispute regarding our failure, or the failure of one of our third party collaborators, to comply with the terms of a collaboration agreement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the termination, for any reason, of any of our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the resignation, or other departure, of members of management or our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general negative conditions in the healthcare industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general negative conditions in the financial markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost associated with obtaining regulatory approval for any of our proprietary or collaboration product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the failure, for any reason, to secure or defend our intellectual property position;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for those products that are not yet approved for commercial sale, the failure or delay of applicable regulatory bodies to approve such products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identification of safety or tolerability issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of clinical trials to meet efficacy endpoints;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspensions or delays in the conduct of clinical trials or securing of regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory action with respect to our and our collaborators&#8217; products and product candidates such as clinical holds, imposition of onerous requirements for approval or product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure, or the failure of our third party collaborators, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure, or the failure of our third party collaborators, to generate product revenues anticipated by investors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product candidate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sale of additional debt and/or equity securities by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to obtain financing on acceptable terms or at all; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a restructuring of our operations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future transactions where we raise capital may negatively affect our stock price.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently a &#8220;Well-Known Seasoned Issuer&#8221; and may file automatic shelf registration statements at any time with the SEC. Sales of substantial amounts of shares of our common stock or other securities under our shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. In the future, we may issue additional options, warrants or other derivative securities convertible into our common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation, as amended, does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation, as amended, does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These provisions may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our board of directors.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Industry</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of product sales, introductions or modifications.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that we change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive. For example, the approval of Baxalta&#8217;s HYQVIA BLA was delayed by the FDA until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, the FDA or other foreign regulatory agency may, at any time, halt our and our collaborators&#8217; development and commercialization activities due to safety concerns. In addition, even if our products are approved, regulatory agencies may also take post-approval action limiting or revoking our ability to sell our products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our products and therefore harm our financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain of these regulations, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers&#8217; and manufacturers&#8217; processes, are in compliance with cGMP and other FDA regulations. If we, or our contract supplier, fail these inspections, we may not be able to commercialize our product in a timely manner without incurring significant additional costs, or at all.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act, false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, any sales of products outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will be able to obtain patent protection for our products and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trademarks to protect the names of our products (e.g. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex </font><font style="font-family:inherit;font-size:10pt;">recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys&#8217; fees and costs, for past infringement if it is ultimately determined that our products infringe a third party&#8217;s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management&#8217;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from &#8220;first to invent&#8221; to &#8220;first to file,&#8221; implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If third party reimbursement and customer contracts are not available, our products may not be accepted in the market.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to earn sufficient returns on our products will depend in part on the extent to which reimbursement for our products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payors are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of reimbursement for the products that we commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If our products are compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures that could cause us to sell our products at lower prices, resulting in less revenue to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of the proprietary or collaboration products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003, could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, the U.S. adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the Healthcare Reform Act). This law substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse and enforcement. These changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional provisions of the Healthcare Reform Act may negatively affect our revenues in the future. For example, the Healthcare Reform Act imposes a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs that we believe will impact our revenues from our products. In addition, as part of the Healthcare Reform Act&#8217;s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program, we will also be required to provide a 50% discount on branded prescription drugs dispensed to beneficiaries under this prescription drug program. We expect that the Healthcare Reform Act and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or successfully commercialize our product candidates or could limit or eliminate our future spending on development projects.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face intense competition and rapid technological change that could result in the development of products by others that are superior to our proprietary and collaboration products under development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary and collaboration products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. The competitors for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex </font><font style="font-family:inherit;font-size:10pt;">recombinant include, but are not limited to, Valeant Pharmaceuticals International, Inc.&#8217;s FDA-approved product, Vitrase</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.&#8217;s product, Amphadase</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, a bovine (bull) hyaluronidase. For our PEGPH20 product candidate, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and collaboration product candidates or that could render our technologies and product candidates obsolete or noncompetitive. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. In addition, many of our competitors have significantly greater experience than we do in undertaking preclinical testing and clinical trials of pharmaceutical product candidates and obtaining FDA and other regulatory approvals of products and therapies for use in healthcare. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="sFAB024D1E6A3D31C9E60481E5FA4AF44"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no material changes in our market risks during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents and marketable securities consisted of investments in U.S. Treasury securities, money market funds, corporate debt obligations and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, based on our current investment portfolio, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.</font></div><div><a name="s3CC104EC89E95A7CC642481E5FA4EFC0"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="sE5DD2DEF690F752BFC59481E6C3573BC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8211; OTHER INFORMATION</font></div><div><a name="sAC11ED1FA956B4B1394D481E5FA4DF2F"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position. </font></div><div><a name="s8C807C50190CC24D596B481E5FA57313"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have provided updated Risk Factors in the section labeled &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The &#8220;Risk Factors&#8221; section provides updated information in certain areas, particularly with respect to the risks and uncertainties regarding the regulatory approval of proprietary and collaboration product candidates.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">We do not believe the updates have materially changed the type or magnitude of risks we face in comparison to the disclosure provided in our most recent Annual Report on Form 10-K.</font></div><div><a name="sABFC61D70BD4ABD4CF00481E5FA566F6"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s12A58D0085801AD74911481E6CDCD811"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Defaults Upon Senior Securities</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="s292D7AC5243873376E67481E6D0D3DD2"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mine Safety Disclosures</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="sF9A8D4CA9893AD10CD10481E5FA6EA17"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Information</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="sA99F7AF78ADC31644E10481E6D6DE5B8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Composite Certificate of Incorporation (1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bylaws, as amended (2)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:13%;"></td><td style="width:83%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed August 7, 2013 (File No. 001-32335).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed December 12, 2011 (File No. 001-32335).</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><a name="s59D4BEB93F58D9935E6F481E5FA7C644"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:24%;"></td><td style="width:23%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc.,</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laurie D. Stelzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laurie D. Stelzer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311q32016.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD86D1C243EDDAC87E64F481E83A413A3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:8%;"></td><td style="width:30%;"></td><td style="width:5%;"></td><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen I. Torley, M.B. Ch.B., M.R.C.P</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312q32016.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF8E92AC04BF6F2C1AFA8481E844AB29B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Laurie D. Stelzer, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:7%;"></td><td style="width:31%;"></td><td style="width:5%;"></td><td style="width:9%;"></td><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laurie D. Stelzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laurie D. Stelzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex32q32016.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1AE784EEA82ED2451856481E84F0DCD3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:6%;"></td><td style="width:32%;"></td><td style="width:5%;"></td><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Laurie D. Stelzer, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:7%;"></td><td style="width:31%;"></td><td style="width:5%;"></td><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laurie D. Stelzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laurie D. Stelzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>halo-20160930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:cc106cfc980e4b838ba773dc6d2f5fe0,x:7a71615a93d64d0d832eb251b637941e-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:halo="http://www.halozyme.com/20160930" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="halo-20160930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_OthercollaboratorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_PublicUtilitiesInventoryAxis_halo_BulkrHuPH20Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_PublicUtilitiesInventoryAxis_halo_HylenexRecombinantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">halo:HylenexRecombinantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PublicUtilitiesInventoryAxis_halo_BulkrHuPH20Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PublicUtilitiesInventoryAxis_halo_HylenexRecombinantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">halo:HylenexRecombinantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:JanssenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerJanssenandAbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:LillyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_LillyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:LillyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_JanssenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:JanssenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerJanssenandAbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_OthercollaboratorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:RocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerJanssenandAbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:PfizerJanssenandAbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:BaxaltaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_halo_ResearchEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_halo_ResearchEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_InlicensetechnologiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:InlicensetechnologiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_InlicensetechnologiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">halo:InlicensetechnologiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2017Member_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2017Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2019QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2019QuarterlyMaximumPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4SD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-12-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2016Member_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2016Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2018QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2018QuarterlyMaximumPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2017QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2017QuarterlyMaximumPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2020QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2020QuarterlyMaximumPaymentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2018andthereafterMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2018andthereafterMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:RoyaltybackedLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Compound">
		<xbrli:measure>halo:Compound</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Segment">
		<xbrli:measure>halo:Segment</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2016Q3YTD" id="Fact-8FCC9EBEB543809A8F67482D4107B229">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q3YTD" id="Fact-12BC8ABA29E0D9C269A8482D40F0F753">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q3YTD" id="Fact-E49218ED7690BD01E563482D41003258">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q3YTD" id="Fact-B419A928C70C06B6A4FB482D41026CD8">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q3YTD" id="Fact-E3342B921F142B45D0B1482D4103E0AD">2016-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q3YTD" id="Fact-461A772C1049A2F0F6CB482D40F89B86">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q3YTD" id="Fact-1FBA800C3C5D32BBE509482D40FCC81F">0001159036</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q3SharesOutstanding" decimals="INF" id="Fact-78DDBDBBCEDBDD837A10482D41086ECF" unitRef="shares">129490070</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2016Q3YTD" id="Fact-EF533D1E2F1E75E75C9E482D40F87304">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2016Q3YTD" id="Fact-8714DE94567613F4C76F482D41095B08">HALOZYME THERAPEUTICS INC.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2016Q3YTD" id="Fact-6B86D6CA334DF5166E75482D4108F4FF">HALO</dei:TradingSymbol>
	<halo:Accountsreceivablefromcollaborators contextRef="FI2015Q4" decimals="-3" id="Fact-03F55A9DA2FA5C8EC53F482D4101091B" unitRef="usd">25939000</halo:Accountsreceivablefromcollaborators>
	<halo:Accountsreceivablefromcollaborators contextRef="FI2016Q3" decimals="-3" id="Fact-CE2A07E45E52B27E3693482D40F0340C" unitRef="usd">5937000</halo:Accountsreceivablefromcollaborators>
	<halo:Accountsreceivablefromproductsales contextRef="FI2015Q4" decimals="-3" id="Fact-ADDBCB39214182BCFDFE482D41003E73" unitRef="usd">2442000</halo:Accountsreceivablefromproductsales>
	<halo:Accountsreceivablefromproductsales contextRef="FI2016Q3" decimals="-3" id="Fact-936FF3678D6F32D63AA8482D41012151" unitRef="usd">1912000</halo:Accountsreceivablefromproductsales>
	<halo:Accountsreceivablefromproductsalestocollaborators contextRef="FI2015Q4" decimals="-3" id="Fact-98770909054ED15C609D482D40F012FF" unitRef="usd">4996000</halo:Accountsreceivablefromproductsalestocollaborators>
	<halo:Accountsreceivablefromproductsalestocollaborators contextRef="FI2016Q3" decimals="-3" id="Fact-4EA174A70AE40BD21479482D4100F0B5" unitRef="usd">10220000</halo:Accountsreceivablefromproductsalestocollaborators>
	<halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-E5C1CF09ECB0C0037839482D41040C1F" unitRef="usd">8617000</halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent>
	<halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-B5ABE8CF8F03A2A2306D482D4105D4BF" unitRef="usd">9947000</halo:AccruedOutsourcedResearchAndDevelopmentExpensesCurrent>
	<halo:AccruedOutsourcedResearchandDevelopmentExpensesLongTerm contextRef="FI2015Q4" decimals="-3" id="Fact-D348B10F66D49868FA93482D41067F8F" unitRef="usd">784000</halo:AccruedOutsourcedResearchandDevelopmentExpensesLongTerm>
	<halo:AccruedOutsourcedResearchandDevelopmentExpensesLongTerm contextRef="FI2016Q3" decimals="-3" id="Fact-629F23EF8938C2D80B35482D4104631E" unitRef="usd">11000</halo:AccruedOutsourcedResearchandDevelopmentExpensesLongTerm>
	<halo:Accruedmanufacturingexpenses contextRef="FI2015Q4" decimals="-3" id="Fact-9937F37373FBCEEA85D1482D41054A20" unitRef="usd">6205000</halo:Accruedmanufacturingexpenses>
	<halo:Accruedmanufacturingexpenses contextRef="FI2016Q3" decimals="-3" id="Fact-0C00576A9D28E2AAE044482D4105057F" unitRef="usd">3706000</halo:Accruedmanufacturingexpenses>
	<halo:AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones contextRef="FI2016Q3" decimals="-5" id="Fact-2E22F0604B7744FFDE8E482D40FCD22C" unitRef="usd">62500000</halo:AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones>
	<halo:Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets contextRef="FI2016Q3" decimals="-5" id="Fact-5D401EFA1126969BBD81482D40FC54B1" unitRef="usd">12000000</halo:Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets>
	<halo:AllowanceforDistributionFeesandDiscounts contextRef="FI2015Q4" decimals="-3" id="Fact-C08E463C483FA1DFBF2F482D4100485B" unitRef="usd">967000</halo:AllowanceforDistributionFeesandDiscounts>
	<halo:AllowanceforDistributionFeesandDiscounts contextRef="FI2016Q3" decimals="-3" id="Fact-D58472EC948E95C447EF482D40FC40B0" unitRef="usd">390000</halo:AllowanceforDistributionFeesandDiscounts>
	<halo:AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-A59CE609696E3EF01C72482D40FCDFE3" unitRef="usd">23000000</halo:AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement>
	<halo:Amountreceivedforsalesbasedpayment contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-3" id="Fact-0E569C81C0DFD7123BE4482D40FC6F43" unitRef="usd">4000000</halo:Amountreceivedforsalesbasedpayment>
	<halo:Amountreceivedforsalesbasedpayment contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-55CC9C1EE0E6D17E3126482D40FCC585" unitRef="usd">15000000</halo:Amountreceivedforsalesbasedpayment>
	<halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-9D29BFDDD4E82455476C482D40FCA470" unitRef="usd">13000000</halo:ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement>
	<halo:DebtInstrumentPrepaymentFeePercent contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-92C7520BD9C0B91A99D0482D4102DFC4" unitRef="number">1.05</halo:DebtInstrumentPrepaymentFeePercent>
	<halo:DebtInstrumentPrepaymentFeePercent contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-09DF30F4F5E1CD92663C482D41039FE9" unitRef="number">0.02</halo:DebtInstrumentPrepaymentFeePercent>
	<halo:DebtInstrumentPrepaymentFeePercent contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-6F902FF1B2BA754407C2482D41080511" unitRef="number">0.01</halo:DebtInstrumentPrepaymentFeePercent>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" id="Fact-8FB6A6ABCC32A5AC4B9F482D40F8BE8D">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" id="Fact-86DB5C04BFCBC3C7AFE2482D40FCC11D">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" id="Fact-7E8226F2A90C0EF8F0ED482D40F8BF4A">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" id="Fact-33A1D7C102FC8E2365CA482D40F4B560">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" id="Fact-2A7836169D06277C88E8482D40FCEBB6">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:DurationOfRoyaltyReceivable contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" id="Fact-C3BBE7D36145B2BF3DE4482D40F8285E">P10Y</halo:DurationOfRoyaltyReceivable>
	<halo:Finalpaymentaspercentofadditionaldraw contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="4" id="Fact-1A6A692F8B9C81E94FE2482D40F46074" unitRef="number">0.0725</halo:Finalpaymentaspercentofadditionaldraw>
	<halo:Finalpaymentaspercentoforiginalprincipal contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-BDB3A26E57E4C2FC1134482D41047C76" unitRef="number">0.085</halo:Finalpaymentaspercentoforiginalprincipal>
	<halo:Finalpaymentaspercentoforiginalprincipal contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="INF" id="Fact-2836C6018850286C6199482D40F893CE" unitRef="number">0.055</halo:Finalpaymentaspercentoforiginalprincipal>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" decimals="-5" id="Fact-D50D7FC1408A1983CB99482D40F856D1" unitRef="usd">23000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-3" id="Fact-E210D4D921796D472785482D40FCA79D" unitRef="usd">10000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" decimals="-3" id="Fact-8144D2B2AA6E262A735A482D40FC08C6" unitRef="usd">15250000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="-5" id="Fact-2F4E8636C802C135987E482D40FC5BF3" unitRef="usd">33000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" decimals="-5" id="Fact-09D340526750FBEA3221482D40F8FB2D" unitRef="usd">12500000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-7673D74FEB3CE8F63F16482D40FC2875" unitRef="usd">20000000</halo:NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement>
	<halo:NumberOfAdditionalTargetOptional contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" decimals="INF" id="Fact-4ECD57177AD47DC9D4BE482D40FC20DF" unitRef="Compound">8</halo:NumberOfAdditionalTargetOptional>
	<halo:NumberOfAdditionalTargetOptional contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" decimals="INF" id="Fact-252E0C93C4E014EDB5EE482D40F8F9FE" unitRef="Compound">4</halo:NumberOfAdditionalTargetOptional>
	<halo:NumberOfAdditionalTargetOptional contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="INF" id="Fact-E5FA400AC70BB3F48003482D40F8C4AE" unitRef="Compound">2</halo:NumberOfAdditionalTargetOptional>
	<halo:NumberOfAdditionalTargetOptional contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" decimals="INF" id="Fact-443988DDE00804DA8FE0482D40F48AC7" unitRef="Compound">1</halo:NumberOfAdditionalTargetOptional>
	<halo:NumberOfAdditionalTargetOptional contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="INF" id="Fact-C5FAFDCF8D6DDA45930F482D40F447DE" unitRef="Compound">3</halo:NumberOfAdditionalTargetOptional>
	<halo:NumberOfTargetsElected contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" decimals="INF" id="Fact-F9CA78243E0B5D49816B482D40FCEFEA" unitRef="Compound">1</halo:NumberOfTargetsElected>
	<halo:NumberOfTargetsElected contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" decimals="INF" id="Fact-FF1E2D65B7C72A646A1B482D40F8DB93" unitRef="Compound">1</halo:NumberOfTargetsElected>
	<halo:NumberOfTargetsElected contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" decimals="INF" id="Fact-99FC70D01515A6D0A43F482D40FC2121" unitRef="Compound">5</halo:NumberOfTargetsElected>
	<halo:NumberOfTargetsElected contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="INF" id="Fact-8989D7CF015768E9E4D1482D40FC656D" unitRef="Compound">5</halo:NumberOfTargetsElected>
	<halo:NumberofProductCompoundCombinationsLicensedtoDevelop contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" decimals="INF" id="Fact-815A3D0D323C461D3821482D40FC5FB6" unitRef="Compound">9</halo:NumberofProductCompoundCombinationsLicensedtoDevelop>
	<halo:NumberofProductCompoundCombinationsLicensedtoDevelop contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" decimals="INF" id="Fact-C4419432C5523D456E2E482D40FC59C8" unitRef="Compound">5</halo:NumberofProductCompoundCombinationsLicensedtoDevelop>
	<halo:NumberofProductCompoundCombinationsLicensedtoDevelop contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="INF" id="Fact-E4389D0E9B50E471E4B9482D40FCE4BC" unitRef="Compound">5</halo:NumberofProductCompoundCombinationsLicensedtoDevelop>
	<halo:NumberofProductCompoundCombinationsLicensedtoDevelop contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" decimals="INF" id="Fact-952166D3651A696E5CEB482D40FC6B27" unitRef="Compound">6</halo:NumberofProductCompoundCombinationsLicensedtoDevelop>
	<halo:NumberofProductCompoundCombinationsLicensedtoDevelop contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="INF" id="Fact-2A71D51D6CE993841188482D40F4EAD1" unitRef="Compound">13</halo:NumberofProductCompoundCombinationsLicensedtoDevelop>
	<halo:Numberoftargetselectedadditionalexclusivetargets contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="INF" id="Fact-1FAE6E28B2B40FCBCFB4482D40F8747D" unitRef="Compound">2</halo:Numberoftargetselectedadditionalexclusivetargets>
	<halo:Numberoftargetselectedadditionalexclusivetargets contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="INF" id="Fact-58A07BC57C2544F4B412482D40F4AA1F" unitRef="Compound">2</halo:Numberoftargetselectedadditionalexclusivetargets>
	<halo:Numberoftargetselectedadditionalsemiexclusivetargets contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="INF" id="Fact-6C588B33F3F3ADA69664482D40F4312C" unitRef="Compound">1</halo:Numberoftargetselectedadditionalsemiexclusivetargets>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-A5FF6A9BA2FFCDD01DAD482D410380FC">P90D</halo:PeriodForTermination>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-5595641AA98CA6B5BB2D482D40F8FC24">P30D</halo:PeriodForTermination>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" id="Fact-D76E6B540254C1AA50D5482D40F4B63F">P90D</halo:PeriodForTermination>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" id="Fact-9E50728DE66ADF1D5E43482D40FC78DD">P90D</halo:PeriodForTermination>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_LillyMember" id="Fact-76B1C0498C1C16DA86EF482D40FC0FC3">P60D</halo:PeriodForTermination>
	<halo:PeriodForTermination contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" id="Fact-A63B18B7421929BD6223482D40F879D5">P30D</halo:PeriodForTermination>
	<halo:Periodtoacceptreturnedunusedproduct contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-1CBFE3E4AC398F6B235F482D410070F5">P12M</halo:Periodtoacceptreturnedunusedproduct>
	<halo:Periodtoacceptreturnedunusedproduct contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-AF476FEB3D4C1914D2F7482D4103D1B7">P6M</halo:Periodtoacceptreturnedunusedproduct>
	<halo:Prepaidresearchanddevelopment contextRef="FI2015Q4" decimals="-3" id="Fact-25E21CFC2DE8BD3CA780482D41044945" unitRef="usd">9225000</halo:Prepaidresearchanddevelopment>
	<halo:Prepaidresearchanddevelopment contextRef="FI2016Q3" decimals="-3" id="Fact-DBDA7FE830A36FB21745482D410684C6" unitRef="usd">8801000</halo:Prepaidresearchanddevelopment>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_AbbVieMember" decimals="-3" id="Fact-C62AC15BB418427A8B06482D40F4292D" unitRef="usd">29000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-3" id="Fact-2C17A3FCEC6323BB1D06482D41027C5D" unitRef="usd">17000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_JanssenMember" decimals="-3" id="Fact-70A2850396C1AAE3A056482D40F42728" unitRef="usd">15250000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_LillyMember" decimals="-3" id="Fact-781B12DC8396480A794D482D40F4D562" unitRef="usd">33000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_OthercollaboratorsMember" decimals="-3" id="Fact-A169FF2C21F8AC4C5673482D40F47DDD" unitRef="usd">93750000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_PfizerMember" decimals="-3" id="Fact-6E5BC5F778CDCBA49261482D40F486A4" unitRef="usd">16500000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-453D019EC834AC2142EF482D40F4E4CD" unitRef="usd">79000000</halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement>
	<halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-3" id="Fact-621658F6827A9EF90620482D410068F2" unitRef="usd">3000000</halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement>
	<halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement contextRef="FI2016Q3_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-3" id="Fact-F14F3EDBD1228A7B76E2482D41016744" unitRef="usd">8000000</halo:RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement>
	<halo:Royaltypaymentstobeappliedtodebtinstrument contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2016Member_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-5B20A37BA619FB89DB5E482D40F45121" unitRef="number">0</halo:Royaltypaymentstobeappliedtodebtinstrument>
	<halo:Royaltypaymentstobeappliedtodebtinstrument contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2017Member_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-F4185502D6583D018A16482D40F82CAE" unitRef="number">0.5</halo:Royaltypaymentstobeappliedtodebtinstrument>
	<halo:Royaltypaymentstobeappliedtodebtinstrument contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2018andthereafterMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-304FD8DC001CA28CA36B482D41079DBA" unitRef="number">1</halo:Royaltypaymentstobeappliedtodebtinstrument>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-3D70B86C1C81C317B9CC482D4104BD0D" unitRef="usd">4499000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-581A0E3BE6A8839EBAD7482D410889D8" unitRef="usd">4641000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableGrossCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-5AC91562B2241D947757482D4100A8B2" unitRef="usd">33377000</us-gaap:AccountsReceivableGrossCurrent>
	<us-gaap:AccountsReceivableGrossCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-11F1F0417291FCA4E390482D41009FFE" unitRef="usd">18069000</us-gaap:AccountsReceivableGrossCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-E87F0FC79BEA73F473C9482D4103CBE8" unitRef="usd">32410000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-E41F0FBAB8525083D4C7482D40F8FC1C" unitRef="usd">17679000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D1163EA39365DFB08DE6482D41068931" unitRef="usd">-699000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9D4A7C73B54C02C1F1E9482D4108083F" unitRef="usd">-505000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-B8C17795E512B81BA959482D410604DB" unitRef="usd">27576000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
	<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="FI2016Q3" decimals="-3" id="Fact-FDB0213DA8F3DD3478EE482D4105B489" unitRef="usd">25744000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-64EA62068D1C331DFB5C482D40FCF2CD" unitRef="usd">26792000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-ED09E981BE1238C183CA482D40F857E5" unitRef="usd">25733000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-B75B9DDB403404169FFC482D40F4CA2C" unitRef="usd">10318000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q3" decimals="-3" id="Fact-2356F2C9044CE8E63911482D40F4EBE2" unitRef="usd">11406000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-0B61F7CDA9B0F169FA00482D410893B2" unitRef="usd">-99000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3" decimals="-3" id="Fact-70F0B8E5D5E1815BA691482D40F0DE34" unitRef="usd">83000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-98C403759DB16896B81F482D41074FEB" unitRef="usd">525628000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q3" decimals="-3" id="Fact-F33FEB0FF7D0D15CAC09482D4105A7F5" unitRef="usd">545751000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-0FCE5BC2DAA4EF63AE60482D40F08454" unitRef="usd">5553000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember" decimals="-3" id="Fact-5BBB0D8305B1371C59E8482D4102E00A" unitRef="usd">2272000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0F3E5BFB676B83803449482D41000542" unitRef="usd">3281000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-5CFD558B5E258E17E416482D4109BA21" unitRef="usd">2269000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-EFB49AE2296F68CE29DD482D4101EB1F" unitRef="usd">3284000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-8CE63A8055E577E26E61482D40F40377" unitRef="usd">15588000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember" decimals="-3" id="Fact-890D622BB6CE6D4E92BA482D410918BD" unitRef="usd">7683000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-283799D84A93C97C4C89482D40F4669C" unitRef="usd">7905000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DC6A670BF1C9C1CCB706482D4108F54C" unitRef="usd">7268000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-ADE4354E394C0EBA0BDE482D4106D025" unitRef="usd">8320000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-69BAB99F565E48CDB5FE482D4104949A" unitRef="usd">6655000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember" decimals="-3" id="Fact-0FB746BF5FF0B4C7BCD6482D41026790" unitRef="usd">2328000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-6F6591EA24D9082C40CB482D4101F7B3" unitRef="usd">4327000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-5F137176CAD4BF3AD397482D40F8E416" unitRef="usd">3045000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-9FD6784AD5604186F13B482D41025077" unitRef="usd">3610000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E417A0F7ED7AEA28DDDA482D4100E1C6" unitRef="usd">18843000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_halo_RSURSAandPRSUawardsMember" decimals="-3" id="Fact-B69830FB692644C1D0F9482D41071DEF" unitRef="usd">6740000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-C89BE47A04B4E4341B27482D40F41C0B" unitRef="usd">12103000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-29F32734289955A82D54482D4108E826" unitRef="usd">8459000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5CF6C8BC23F6DF4399ED482D410406FD" unitRef="usd">10384000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2015Q3YTD" decimals="-3" id="Fact-05AE6136AC2D6651CE68482D4108FF1C" unitRef="usd">885000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FD1172AF28B1D0FD2ECD482D4108D7F0" unitRef="usd">2444000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3QTD" decimals="-5" id="Fact-6857A95B0DF2E7EC7B0AD48A00CD1E98" unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3YTD" decimals="-5" id="Fact-E22DD522F03ABA3B599CD48A2EFB8032" unitRef="shares">9600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3QTD" decimals="-5" id="Fact-620B00EDD0C73A72F66B482D410424BA" unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD" decimals="-5" id="Fact-0C4E179DB3D1B865801E482D41014355" unitRef="shares">9600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-6C8F2B23EA5B9A914491482D40FCD8DE" unitRef="usd">181789000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q3" decimals="-3" id="Fact-E6E0A1FE127807F5DD30482D4103024F" unitRef="usd">282498000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-AEA285A884E84A3407CD482D4104A51E" unitRef="usd">171772000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-5B0E9788966F195E479F482D4109EFF6" unitRef="usd">272605000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-331761F716649683A737482D4101A0BD" unitRef="usd">103642000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-ECCFEE73A9582205D345482D4104C296" unitRef="usd">38595000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-07F18D7743D43814BD47482D40FCCC53" unitRef="usd">65047000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3" decimals="-3" id="Fact-8330ECE3B6E3BA4C55E5482D41061BBC" unitRef="usd">194984000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-7A860D1459D864BA71F1482D4103E2C8" unitRef="usd">129225000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-3BBEA9094AD9A367CCC5482D41051DD4" unitRef="usd">65759000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-455819E1327E37136C75482D4107F40E" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-7B6D22DE9C51AF53CB5C482D40FC1EC5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-1CF387B29858966C4851482D41072FAE" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3" decimals="-3" id="Fact-84BA77144EEB30FE89E4482D4108F722" unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C9A6536728C945F8D995482D40F46DC5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-EE10AA96C016173998D5482D40F42FB9" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3ABC97ADDB68BDB9AA55482D40FCC8C3" unitRef="usd">85000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-28A7003DE401AD68526D482D40F8604B" unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-0DF69488DC3DC83AFB2D482D40F00187" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-894DA57E1A3736C5ACBB482D40FC7AD0" unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3" decimals="-3" id="Fact-B8E641D3B209D78ECE6C482D41031148" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B9663ABFA0957FA45E35482D40FC7715" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-F503FBBE1007D774B0FE482D410536FD" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-89DFA863DE81909BD477482D40FCF65E" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4" decimals="-3" id="Fact-BC7B885A56F5B460E9CA482D41048D4F" unitRef="usd">65047000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-AC0A439C06F60C78C1BC482D40F8EC88" unitRef="usd">2995000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-7D8DBADCD26422735E2C482D41018CD5" unitRef="usd">2995000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-60955C597D6C0C8DF992482D41067295" unitRef="usd">62052000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-94A152829957F4C7A8E9482D40F4AE9E" unitRef="usd">62052000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-747527BCB7AF0E8462F6482D40F8110C" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-19C4E2B3ED24787E4779482D41083B32" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-22A2D065A8307E65EF74482D4104CD05" unitRef="usd">2995000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-C6453CF5D532C66B61E9482D410949AB" unitRef="usd">62052000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3" decimals="-3" id="Fact-7FD7A9D7FB5CC044A486482D41027F16" unitRef="usd">159845000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-857E37012B02EFA9CD07482D40F8CF4D" unitRef="usd">13973000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-A01268C7BBF3EFB516C5482D40FC21B8" unitRef="usd">13973000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-87B7DBC6CFB8950886C8482D4108FCC0" unitRef="usd">51786000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-4EE033633BEECBE88D31482D4104E803" unitRef="usd">51786000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-EF193A3B12CD595B5308482D410444B1" unitRef="usd">94086000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-4723F677A279CCEE15F5482D41069349" unitRef="usd">94086000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D595447D1BBD9E982B69482D40F4B749" unitRef="usd">13973000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-F534686E4D475EB97C3B482D41052873" unitRef="usd">51786000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-FEBD41A085BD3F025FDC482D4107A411" unitRef="usd">94086000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4" decimals="-3" id="Fact-3F87E96FEB3871FDB183482D41098C93" unitRef="usd">65146000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B8CC59D9E34B1E7B4EF8482D40F0B80F" unitRef="usd">2995000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-0C679D1C5F0D8E797196482D40F8FE8A" unitRef="usd">62151000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3" decimals="-3" id="Fact-FE28A05528EDE8B8573E482D40F8B9B6" unitRef="usd">159762000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-6D2C9BA86D0E1AA5D480482D410650ED" unitRef="usd">13973000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-5440943CD8743DEC2B54482D4104A552" unitRef="usd">51785000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-EAA16D7BCB3E25275B9F482D4102ADE6" unitRef="usd">94004000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-98258CF1DCF2352C760B482D40F881B5" unitRef="usd">65047000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-EE8097315C80257355BA482D40FCE7FF" unitRef="usd">159845000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q3" decimals="-5" id="Fact-F0902BD27A27DE100C18482D41084B38" unitRef="usd">153800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear contextRef="FI2016Q3" decimals="INF" id="Fact-AB0836F94302D7803925482D4107A752" unitRef="number">5</us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-0B4A17D991519F44A9B7482D41065C08" unitRef="usd">61389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-3" id="Fact-36B3D763E9E8BD405E20482D410543E8" unitRef="usd">71514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-F1455BC4E262FF4D3635482D410521E6" unitRef="usd">43292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-3" id="Fact-AFC73DCAF38864EEB1EC482D40F4562A" unitRef="usd">61207000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7DCC62F38F87F7BB3623482D41055B03" unitRef="usd">38595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-75DA5A6A56401B16E17A482D4103935F" unitRef="usd">38595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-88ACA35E1A7114444CFB482D40FC4F64" unitRef="usd">35139000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-1FED0D67B0614D938D29482D41082F19" unitRef="usd">35139000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q3YTD" decimals="-3" id="Fact-66D2768239DB8303D3D2482D4106DC21" unitRef="usd">10125000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4B5588C826A7FDAA93A9482D4107C72E" unitRef="usd">17915000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-3157293239A8389542D8482D4105408D" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q3" id="Fact-6D292B9DBDE311E31A18482D4109F83A" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-F0C3BF9841B8013A28ED482D40FC9033" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q3" decimals="INF" id="Fact-2D23BFD1CFB1227A9A5D482D4107F271" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="-3" id="Fact-67B9DB81B6FA1B4A907C482D4101C1A8" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q3" decimals="-3" id="Fact-2FDB490EBB48646BBC93482D41029A57" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="-3" id="Fact-B2CE451E18DF89D7418B482D410396F4" unitRef="shares">128152000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q3" decimals="-3" id="Fact-05BCFC9446CED98C48A9482D40FC65D7" unitRef="shares">129488000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-BAC9D966A185D923471B482D40F492A0" unitRef="shares">128152000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q3" decimals="-3" id="Fact-7395FCEEA51D20BDA4BA482D40F09863" unitRef="shares">129488000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-3EBCA1728ACEF9D7D744482D40F8C3D2" unitRef="usd">128000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q3" decimals="-3" id="Fact-8D0E48FF9E74C9D08AFB482D4104F458" unitRef="usd">129000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-646C0549E77F7D2B59DB482D40F4924E" unitRef="usd">-24420000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E22C91148CC74E5B37A3482D410561B0" unitRef="usd">-36508000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3QTD" decimals="-3" id="Fact-10ABB395527429D02707482D40F0F1AA" unitRef="usd">-29079000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3YTD" decimals="-3" id="Fact-774446A563DBE5693F1F482D4108B387" unitRef="usd">-75455000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q3QTD" decimals="-3" id="Fact-563E2A133ECC3D395B0F482D40F877AD" unitRef="usd">6180000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B7E60F9DD0C267206316482D40FC44F0" unitRef="usd">20818000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q3QTD" decimals="-3" id="Fact-676ED10DB860D0DDC880482D41099AA6" unitRef="usd">9134000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q3YTD" decimals="-3" id="Fact-516EC689D2C32AC4666E482D4101BDB0" unitRef="usd">25204000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3QTD" decimals="-3" id="Fact-CF2432FF0A9EC6539FA7482D4109D478" unitRef="usd">44017000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3YTD" decimals="-3" id="Fact-BB971219D7E4A7B1093A482D40F4506D" unitRef="usd">115747000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-72B0A4CF9700AF20335A482D4105CD7E" unitRef="usd">54596000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3YTD" decimals="-3" id="Fact-ED455A7FBC4312263066482D40FC737B" unitRef="usd">168323000</us-gaap:CostsAndExpenses>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q3" decimals="-5" id="Fact-D13DEB0B5B9808DCFB4A482D4103BA56" unitRef="usd">300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-BB04FABE64781831CF04482D41095FFD" unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-6C9B603D1102F47950DC482D40FCB5F5" unitRef="number">0.007</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentCovenantCompliance contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" id="Fact-71950E8235412B5D3A04482D4104DC0E">in compliance</us-gaap:DebtInstrumentCovenantCompliance>
	<us-gaap:DebtInstrumentCovenantCompliance contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" id="Fact-B83ABEF1F553CFA70C58482D40F0C17F">in compliance</us-gaap:DebtInstrumentCovenantCompliance>
	<us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" id="Fact-54AE6F5B19CE455C61D2482D4101DD7F">plus the three-month LIBOR rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-6" id="Fact-D0F4E313E1E6706BE2CE482D40F83B3D" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-6" id="Fact-FC66803E86A39DE858CA482D4102ECBD" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="-5" id="Fact-AF5DF9A94DB4B37D613C482D4103FDE1" unitRef="usd">70000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-40553AB5AA64B56CE3A2482D40F8FCDC" unitRef="usd">1500000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-32D4544ABF601C4C50C3482D41060FFA" unitRef="usd">700000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
	<us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet contextRef="D2013Q4SD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-6" id="Fact-FEFEDE9777B2B5FEB8B8482D41092D01" unitRef="usd">20000000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-A9CE44E833172C4C5F9F482D410704D5" unitRef="number">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-54A82DE6B6EB55CE733F482D41097AA2" unitRef="number">0.0755</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="INF" id="Fact-79CB2952C95FFF528C4B482D40F48D3F" unitRef="number">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentIssuanceDate1 contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" id="Fact-21B6A3563442665792FE482D41085781">2016-01-26</us-gaap:DebtInstrumentIssuanceDate1>
	<us-gaap:DebtInstrumentIssuanceDate1 contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-F6A556B9247CDB3905C3482D40F8381C">2013-12-27</us-gaap:DebtInstrumentIssuanceDate1>
	<us-gaap:DebtInstrumentIssuanceDate1 contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" id="Fact-2E452A5AFAA2BCF94CA7482D41065F50">2016-06-07</us-gaap:DebtInstrumentIssuanceDate1>
	<us-gaap:DebtInstrumentMaturityDate contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" id="Fact-F594F28834DAA4C0AD8A482D410834C8">2050-12-31</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDate contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-4FC913D5E37F0337DCA6482D40F881B6">2018-01-01</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDate contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" id="Fact-0CC2AF36A5FB028FA82D482D40F033A1">2021-01-01</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" id="Fact-6B2108C758BAF9F6D97D482D4109B342">final maturity date of the Royalty-backed Loan will be the earlier of (i)&#160;the date when principal and interest is paid in full, (ii)&#160;the termination of Halozyme Royalty&#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&#160;December&#160;31, 2050</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentPaymentTerms contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-207BC588C8BCE9F6F54E482D40F8C106"> interest only payments through January 2016</us-gaap:DebtInstrumentPaymentTerms>
	<us-gaap:DebtInstrumentPaymentTerms contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" id="Fact-9589C21A88DE76BACDC5482D4108E2E3">interest only payments for the first 18 months</us-gaap:DebtInstrumentPaymentTerms>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2017QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-4" id="Fact-D8F946CD2CEBC49B19E6482D41044B1E" unitRef="usd">13750000</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2018QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-4" id="Fact-15C1DC732DF8BE8C1F16482D40F0B098" unitRef="usd">18750000</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2019QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-4" id="Fact-F4285E72126E494F7B5D482D410425FA" unitRef="usd">21250000</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="FD2016Q3YTD_us-gaap_DebtInstrumentAxis_halo_A2020QuarterlyMaximumPaymentMember_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-A5C7E95630096C2F58C7482D40F81527" unitRef="usd">22500000</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-4" id="Fact-8E67C12B8AFAB894973E482D41016B3B" unitRef="usd">4250000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-F68CC580B93A7E2FC8C0482D41053D75" unitRef="usd">1600000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-706FA2C657C77D491075482D41002C59" unitRef="usd">3400000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="-5" id="Fact-DBC1E18FD1C84C7F3DF6482D40F41B94" unitRef="usd">15000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
	<us-gaap:DebtInstrumentUnusedBorrowingCapacityDescription contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" id="Fact-9EB28C5A493C2821DCFE482D41042E51">current prime rate as reported in The Wall Street Journal plus 4.75%</us-gaap:DebtInstrumentUnusedBorrowingCapacityDescription>
	<us-gaap:DebtWeightedAverageInterestRate contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="INF" id="Fact-1FF5B2A5D633F6A00784482D4109899E" unitRef="number">0.0961</us-gaap:DebtWeightedAverageInterestRate>
	<us-gaap:DeferredFinanceCostsGross contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-AA8480D3A42456250BB1482D4109AE79" unitRef="usd">400000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4" decimals="-3" id="Fact-91D27D77926C0B9BE3B1482D410283AD" unitRef="usd">53223000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_BaxaltaMember" decimals="-5" id="Fact-881DD1896C86CE4A8F1A482D40F49FD4" unitRef="usd">9000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_InlicensetechnologiesMember" decimals="-3" id="Fact-8FD50BFE3BCDD61145AE482D40F8A481" unitRef="usd">48762000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember" decimals="-3" id="Fact-4F6BE4805F6B427274D6482D40FCBF82" unitRef="usd">39038000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember" decimals="-5" id="Fact-3D22B9897AE1AE88A87E482D40F82348" unitRef="usd">39000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-0FFA5CD9DD9C1172330C482D40FCAED2" unitRef="usd">9724000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember" decimals="-3" id="Fact-950DD83753292F703635482D40F8C60B" unitRef="usd">4461000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3" decimals="-3" id="Fact-3A5F68A8A687594D17D9482D40FCF701" unitRef="usd">50741000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_BaxaltaMember" decimals="-5" id="Fact-40BFA4B0ED4DD49FD003482D40F82E97" unitRef="usd">8400000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_InlicensetechnologiesMember" decimals="-3" id="Fact-5CB92DBF0276CFA33771482D40FCBCE2" unitRef="usd">44942000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember" decimals="-3" id="Fact-4BC4419AB3C2667BAA13482D40F80830" unitRef="usd">36542000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_halo_RocheMember" decimals="-5" id="Fact-FB4A23EA385E8E3C6B2C482D40FCABDF" unitRef="usd">36500000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-B0A70076DD824F2AAA52482D40FCA916" unitRef="usd">8400000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q3_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember" decimals="-3" id="Fact-06449D1A993353D0AFB0482D40FCCCC3" unitRef="usd">5799000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-CE1660FE8BCB1158C7F1482D41029725" unitRef="usd">9304000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-8D3B1A9023367300AF9C482D41016EE7" unitRef="usd">9892000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C2664B87638399C223DD482D41083069" unitRef="usd">43919000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-8DB46FD248E06468C592482D410462D8" unitRef="usd">40849000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-5" id="Fact-4E014141BBBB02674BE1482D40F89236" unitRef="usd">200000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-5" id="Fact-5185895292E5B6480A37D4642F68D2DD" unitRef="usd">900000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-5" id="Fact-8526E8D840131AFCCE4F482D40FC9547" unitRef="usd">600000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-5" id="Fact-CAAC72E7C92182CA7E4ED465E4F6EE4F" unitRef="usd">2500000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-5" id="Fact-174B4AC6C01B873877EA482D40FC618A" unitRef="usd">200000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-5" id="Fact-665A92272B5C73DB249C482D40F4082F" unitRef="usd">800000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_BaxaltaMember" decimals="-5" id="Fact-0A8AFACB272935D18A27482D40FC234D" unitRef="usd">600000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredRevenueRevenueRecognized1 contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" decimals="-5" id="Fact-10D0FF7773B5508BECC1482D40F4DEEE" unitRef="usd">2500000</us-gaap:DeferredRevenueRevenueRecognized1>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2016Q3" decimals="-3" id="Fact-07631C29652C508714CA482D410331DD" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DepreciationAndAmortization contextRef="FD2015Q3QTD" decimals="-5" id="Fact-B4B41306B84667AAC0B7482D40F8386F" unitRef="usd">400000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2015Q3YTD" decimals="-5" id="Fact-6CF1541AA9912486818A482D40F46BE4" unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2016Q3QTD" decimals="-5" id="Fact-223F47F66ABA97A91CB6482D40F41048" unitRef="usd">700000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2016Q3YTD" decimals="-5" id="Fact-89F22A577D50E98004B3482D40F42CA3" unitRef="usd">1800000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B20B957F4B7A8CE1591F482D4105A37A" unitRef="usd">1218000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4B39A6E432B6A52CF738482D41078DAD" unitRef="usd">1766000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-B6918EE5432A15A399AA482D4108987C" unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3YTD" decimals="2" id="Fact-C8CA0827A430F42F0310482D40FC5144" unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-8A4592A72B5F7301038F482D4109F281" unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3YTD" decimals="2" id="Fact-14751200AA7F92F6096B482D4108FF76" unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C495E09BA311934B2B47482D41062BFC" unitRef="usd">8636000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-02BD91C60EEB4B70D60E482D41050E48" unitRef="usd">8201000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-42C9B36F5B8824547B2F482D41033E5D" unitRef="usd">46651000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-0CC43D9B2A65CEDF731A482D4104FAE8" unitRef="usd">10311000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-4EBC26A2818461FA8AB5482D41027B9C" unitRef="usd">9439000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-6EE909EAB00F08BDD83F482D40FC7EA6">P2Y11M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" id="Fact-AA16E2DCE75F25348979482D40FC64F7">P2Y7M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-02EEB6D7E28F695D29AF482D40F86E17">P2Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="FI2015Q4" decimals="-3" id="Fact-841ADB3498C5E2989B50482D41024B6E" unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
	<us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="FI2016Q3" decimals="-3" id="Fact-7D54522692945AC99F28482D41023F0E" unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-499EB655B7721319C18B482D410375B6" unitRef="usd">-24460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DFACE56917C17C7893BD482D40FC9744" unitRef="usd">-36549000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q3QTD" decimals="-3" id="Fact-4B0BEA55150427F66D73482D41062C84" unitRef="usd">-27662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CAC16E786E991E1C04DF482D40FC2322" unitRef="usd">-74053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3QTD" decimals="-3" id="Fact-2D23EC36D4B363E7C162482D410789A1" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q3YTD" decimals="-3" id="Fact-6889658709E3F114D811482D40FC8341" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD" decimals="-3" id="Fact-68DFD5CDC8D74E021019482D41016B6A" unitRef="usd">1284000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-3" id="Fact-8BDEE03463797057177F482D40F8AD8C" unitRef="usd">1584000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A59B845FF3BE7DF39E66482D41078429" unitRef="usd">6011000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D1AD9A12B4CCD631167F482D410600B6" unitRef="usd">-1401000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C1F15325B276188AB2C5482D4106BB28" unitRef="usd">-757000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-100713BF970A7AC565E9482D4104E4E6" unitRef="usd">-14732000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D9453F26F1C179019EE5482D41061794" unitRef="usd">-4600000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7A69F77AE121383A2437482D41066824" unitRef="usd">-2482000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q3YTD" decimals="-3" id="Fact-EDECE8E64E183055916D482D4107B681" unitRef="usd">4695000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E1996CD5112047825038482D4107021E" unitRef="usd">3363000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-80554B427E0EA8870E64482D4106DE45" unitRef="usd">-200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7F89A13425FAA6FD0EB8482D4107A9CB" unitRef="usd">-260000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B0F7F5EBE15A90CB7515482D41082881" unitRef="usd">1000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q3YTD" decimals="-3" id="Fact-16970E209226292C1CC9482D41078557" unitRef="usd">-1085000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-14CC96B2DA9D8D6D543B482D41092393" unitRef="usd">9200000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-0181050F4C08DB2934EC482D40FC8BCA" unitRef="usd">1301000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B93FC1A4963F03773F8B482D41011F38" unitRef="usd">3899000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-88F56F7206C688AF35DA482D41034772" unitRef="usd">5253000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C64FEDAEB8C28A8C14DF482D40FC9E72" unitRef="usd">14378000</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2015Q3QTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-29269369AEEF0099B0D5482D40F8CC9F" unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2015Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-DD96DF4E2E5669F91940482D41088A9F" unitRef="usd">3900000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q3QTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-671EFAF450C7A2162040482D41061326" unitRef="usd">3800000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q3QTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-C7AF31E363151FE5BAB3482D4100FE2E" unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-7AA8104804D1812943F8482D4101668E" unitRef="usd">10200000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-F4DC32D26A9B349667F6482D410149D0" unitRef="usd">4200000</us-gaap:InterestExpenseDebt>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-D7AB80756AABCADC99BA482D4102424D" unitRef="usd">331000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q3" decimals="-3" id="Fact-0F87B5711C0AFE503C5A482D40F0C5F6" unitRef="usd">1654000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2015Q4" decimals="-3" id="Fact-127D769BCBE6F33EE375482D40FCE2DE" unitRef="usd">9489000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2015Q4_us-gaap_PublicUtilitiesInventoryAxis_halo_BulkrHuPH20Member" decimals="-5" id="Fact-A0963D6F2796D23038F10BD5FBEC55F3" unitRef="usd">8100000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2015Q4_us-gaap_PublicUtilitiesInventoryAxis_halo_HylenexRecombinantMember" decimals="-5" id="Fact-8B65DFB1BC25E09B95B3482D4106EF15" unitRef="usd">1400000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q3" decimals="-3" id="Fact-ECB21755A402D312F3AF482D41086FB8" unitRef="usd">12852000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q3_us-gaap_PublicUtilitiesInventoryAxis_halo_BulkrHuPH20Member" decimals="-5" id="Fact-6D69076CDBB1C6AD7795482D40F84BAB" unitRef="usd">9400000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q3_us-gaap_PublicUtilitiesInventoryAxis_halo_HylenexRecombinantMember" decimals="-5" id="Fact-83E4038C0FBA3EB3E3AF482D4103262A" unitRef="usd">3400000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-2854403F45BB980A3E91482D4105CCF1" unitRef="usd">677000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q3" decimals="-3" id="Fact-562395C80E034D57F625482D41082FA1" unitRef="usd">1490000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q4" decimals="-3" id="Fact-9BADC89EC61D96107DF8482D40F01513" unitRef="usd">8481000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q3" decimals="-3" id="Fact-629208F21D8ED9E82F74482D41048380" unitRef="usd">9708000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-6" id="Fact-555680207C00868A8876482D40FCED84" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-6963AAA9014C12FD3D81482D41059CC3" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-2993B5E17A88AB1B85C3482D40FC05BA" unitRef="usd">181789000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q3" decimals="-3" id="Fact-A26C7EE2E9B7231C9A39482D410941AA" unitRef="usd">282498000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F26E61A4A91F546369EE482D40FCD6D0" unitRef="usd">62457000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-EF0B3D553A2614C81867482D4108D65D" unitRef="usd">52660000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2015Q3QTD" decimals="-3" id="Fact-5F7EADC687D4043139BA482D40F89D72" unitRef="usd">2205000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-62B71E8DF1B20C42156B482D40FCB0E7" unitRef="usd">28896000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-B619773A3F6EB956EC31482D41081A88" unitRef="usd">5486000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B8767078E820E3EF5982482D40F42117" unitRef="usd">31023000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LongTermDebt contextRef="FI2015Q4" decimals="-3" id="Fact-85299CC20E3FEB7363A3482D4107F4DB" unitRef="usd">27971000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q3" decimals="-3" id="Fact-EC7777E3E92AE4D3FBDA482D41018214" unitRef="usd">199803000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-79DF535E2625C8648585482D40F8F760" unitRef="usd">21862000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-14C394CF1FC421C40A10482D40FC9397" unitRef="usd">12394000</us-gaap:LongTermDebtCurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DD691971991EDBAE74DE482D4108547B" unitRef="usd">11367000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-96EA8B885BC81FFB480D482D4105BE4E" unitRef="usd">150342000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-70FFF58FD4CB9554C880482D4106728A" unitRef="usd">20644000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-60A3179CB021474D1282482D41067A80" unitRef="usd">-97811000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-8B7C8063AF76A329CC98482D4106EE49" unitRef="usd">-21886000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-EF555EFF32D108CCBF5D482D4106D22F" unitRef="usd">-34616000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-6497F8935BF83B6AA7DB482D410286A6" unitRef="usd">-24460000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-D70027BD9BB54C19A5F0482D410073F0" unitRef="usd">-36549000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-5B8FA9AA4557A2D64225482D41053BD8" unitRef="usd">-28946000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C7C2E4E6160D68FADE17482D40F06089" unitRef="usd">-75637000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2016Q3YTD" decimals="INF" id="Fact-111369B179CD214478FE482D41089E3F" unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-2A23CF92E879AA528DC2482D40F0C457" unitRef="usd">-23237000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-ED885D49140FF1149C76482D40F81AEF" unitRef="usd">-32917000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F663DEC83AB740159AC9482D410238F2" unitRef="usd">-22743000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D5C01E2B5C58B424BB4C482D40FC584C" unitRef="usd">-60635000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B3AD589D388456979992482D4105C9C4" unitRef="usd">4118000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-AE09CC49B9F7E757D73A482D41043685" unitRef="usd">3890000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-140E042F2B118F0B0B90482D410046BE" unitRef="usd">3200000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-259571ACA5840E88BFB7482D41083CB0" unitRef="usd">400000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAssets contextRef="FI2015Q4" decimals="-3" id="Fact-47DABE8BF094D0A8A511482D41061FE9" unitRef="usd">530000</us-gaap:OtherAssets>
	<us-gaap:OtherAssets contextRef="FI2016Q3" decimals="-3" id="Fact-6F4E2329822A2ABCFC78482D4105039A" unitRef="usd">437000</us-gaap:OtherAssets>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-A76D7735A43D0ECA7F86482D41052149" unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-14701A926830308D3194482D4101CC1A" unitRef="usd">41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q3QTD" decimals="-3" id="Fact-9116D2445FB5835693AB482D40F49135" unitRef="usd">-133000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q3YTD" decimals="-3" id="Fact-944C8A9F7986635A4C60482D40F421E9" unitRef="usd">182000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-EFF203B044DD4F5B3157482D41058B2B" unitRef="usd">4443000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-D81938172CA085B26D57482D40FC433F" unitRef="usd">1178000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-5EE6FD80B3631A5C879D482D40F8592C" unitRef="usd">78000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-6E304789E7180F084984482D41039DCF" unitRef="usd">267000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-598F21EBBE92018CD9AD482D41054EE3" unitRef="usd">334000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-089AD822390CD11E4405482D40FCD122" unitRef="usd">960000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-80AF8AF6D639CC8CC8B1482D41038EFF" unitRef="usd">1198000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-9F9FD9E59D0178E187C1482D41042541" unitRef="usd">1810000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-7D0374E4E619E017BDFA482D41083E95" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaidInKindInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3A76D732B8FAB70304CF482D41078216" unitRef="usd">0</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2016Q3YTD" decimals="-3" id="Fact-990B4DA34003F791D68A482D41074031" unitRef="usd">9152000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-FB6AFD2F417B704062F9482D4108FF70" unitRef="usd">700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-ECE358DFBFE60E558E71482D4106DF87" unitRef="usd">800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-0DDC0F6998ABCEDAA130482D410798C0" unitRef="usd">46360000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9BECC5DD2E0E08BE7EE9482D4105C99D" unitRef="usd">152404000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q3YTD" decimals="-3" id="Fact-9E96C4F18BACDE3201FE482D4106313A" unitRef="usd">726000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-858A3AFA26AAB95C7BCE482D41072D25" unitRef="usd">2690000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-C7C2227020D446216A78482D40F01206" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q3" decimals="INF" id="Fact-3D910DD7EDAB13899571482D4105E32E" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4" decimals="-3" id="Fact-07D011FD56A1D51F8A80482D41034BF3" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q3" decimals="-3" id="Fact-41F21323D1E68ED28BA5482D410242FA" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4" decimals="-3" id="Fact-92BA3682B1BDFC4B1CDE482D40FC4513" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q3" decimals="-3" id="Fact-51A2A2F0057074F335EC482D40F87CDF" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-99AACF99296E260E72F1482D40FCEC01" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q3" decimals="-3" id="Fact-F532CB5DD4175142F824482D40FC8DE7" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-94980D8314D5042284EF482D41055E4F" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q3" decimals="-3" id="Fact-2B31EA694EC56359D865482D40FC37DA" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q4" decimals="-3" id="Fact-CD2E7EFC9C5C4B9E3564482D4106F50D" unitRef="usd">10953000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2016Q3" decimals="-3" id="Fact-1C2A2E228FF41684A296482D41058E92" unitRef="usd">11048000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-D9B1476E7BCFACCC282C482D4108C3C7" unitRef="usd">5379000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-2DC30C6D47CD1E08CDCB482D40FC2399" unitRef="usd">6062000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F6C8F9C13059CE60057C482D40F8DC2C" unitRef="usd">5574000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-5581D9EE538FCA0714E8482D41066C19" unitRef="usd">4986000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-3DF58C1699B9906AE962482D40FC7B1A" unitRef="usd">16155000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-F9F3186BE7072E3275FC482D41051C85" unitRef="usd">14960000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="FD2016Q3QTD" decimals="0" id="Fact-EB54FD3311936E916A38482D41072FD3" unitRef="usd">0</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
	<us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="FD2016Q3YTD" decimals="-5" id="Fact-272BC9E0AC018C178ABB482D41040EFC" unitRef="usd">0</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2B0BE116D4DE5AD02308482D410532BD" unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-62098D4D61197A55491B482D41053C22" unitRef="usd">203005000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q3YTD" decimals="-3" id="Fact-97B22258F8782CB07D6C482D41061A8B" unitRef="usd">11367000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2016Q3YTD" decimals="-3" id="Fact-BB9D5D37893B510002E1482D4105F367" unitRef="usd">1622000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-47556813FF1EEDFAB8F8482D41089C49" unitRef="usd">67730000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E7F733A710BBE0A1CBE2482D4107A966" unitRef="usd">57283000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-CB185C25158CE45912CF482D4109BE91" unitRef="usd">12100000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-49F4304F3024E9D95B68482D40F84E12" unitRef="usd">2600000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-2CDA28380E9DD9BE167D482D40F42124" unitRef="usd">14261000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_halo_ResearchEquipmentMember" decimals="-3" id="Fact-6B10C2F40F81B24A33F5482D40F02836" unitRef="usd">9666000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-2098710DB91E9F97CA13482D40F0279A" unitRef="usd">2025000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-29C48B4693899491A341482D40F41329" unitRef="usd">2570000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q3" decimals="-3" id="Fact-9ACF15DBE6FCDE0EEAAC482D40F02FE2" unitRef="usd">15813000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_halo_ResearchEquipmentMember" decimals="-3" id="Fact-FE180BE8B26E0DE54084482D40F49E54" unitRef="usd">10316000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-898C014B2573AF3B5898482D40F4097B" unitRef="usd">2319000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-6F214B23F4D68A0F0D65482D40F4280E" unitRef="usd">3178000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-140DE49B17E3714B5BD7482D410671F9" unitRef="usd">3943000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q3" decimals="-3" id="Fact-ABBA00F7C0BDA049BB89482D40FC778E" unitRef="usd">4407000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RepaymentsOfSecuredDebt contextRef="FD2015Q3YTD" decimals="-3" id="Fact-19C66AEFA9A81D1F6A79482D4105EFE9" unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
	<us-gaap:RepaymentsOfSecuredDebt contextRef="FD2016Q3YTD" decimals="-3" id="Fact-551157959117FE5C8A1B482D4105F3E5" unitRef="usd">54285000</us-gaap:RepaymentsOfSecuredDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-214583B8C89138B7FA98482D41002954" unitRef="usd">27611000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-7FE9E27DC60799EDDBF8482D41008FDB" unitRef="usd">65490000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-70D24D0A3BD5F65A27FB482D40FC1DC0" unitRef="usd">33863000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1AB773E1208D4D872E91482D40FCF645" unitRef="usd">109493000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-289251E77912DFC0D9D5482D41031F6F" unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
	<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-5CC61D7611EB65E3FE99482D41039705" unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-59B61D6A748DF2D3D6E7482D410587FC" unitRef="usd">-482658000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q3" decimals="-3" id="Fact-6E923531EB064DFE16AE482D410372EB" unitRef="usd">-557955000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember" decimals="-5" id="Fact-ADDAA5A0A47160A002E7482D40F46818" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember" decimals="-5" id="Fact-2B1FEFA1F61585013913482D4103FE84" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember" decimals="-5" id="Fact-1DA396DB5FB01DB04BDB482D40F45677" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_PfizerJanssenandAbbVieMember" decimals="-5" id="Fact-D240700CCC8219ECE3C00BE6FF07A4C1" unitRef="usd">6000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-115DB662BF57C5836503482D40F0C446" unitRef="usd">20780000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A6AEA6FE2590633D5F40482D40F8CF04" unitRef="usd">82830000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F3B8C62947647026A989482D40F863DC" unitRef="usd">31853000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3YTD" decimals="-3" id="Fact-8644751E9782259C6B8E482D4102F99D" unitRef="usd">107688000</us-gaap:Revenues>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3QTD" decimals="-3" id="Fact-8E86585EEB21C6ECBEBD482D40FCCD66" unitRef="usd">8274000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C685FADDC4E175D76B02482D41082AFB" unitRef="usd">21431000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-542B3DA524179CCA8931482D4107B394" unitRef="usd">13036000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-F8B73EC802BAE76240B5482D40FC8731" unitRef="usd">36695000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3QTD" decimals="-3" id="Fact-71C8B56DB9903D5B3568482D40F4C291" unitRef="usd">10301000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C56AE9574923CECCD836482D40F027AC" unitRef="usd">32503000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D812965936991BD71DFB482D4109BE84" unitRef="usd">13331000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-994E2173AAC3BEE3421E482D40F4E26F" unitRef="usd">39970000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SecuredDebt contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_halo_RoyaltybackedLoanMember" decimals="-5" id="Fact-7CAA03A239C212B2590C482D4103CC0B" unitRef="usd">157600000</us-gaap:SecuredDebt>
	<us-gaap:SecuredDebt contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-B613D5AE13D97FDE972A482D40F4BE1B" unitRef="usd">54600000</us-gaap:SecuredDebt>
	<us-gaap:SecuredDebt contextRef="FI2016Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorLoansMember" decimals="-5" id="Fact-9C5C95AAF7835D81012C482D4101EC29" unitRef="usd">55000000</us-gaap:SecuredDebt>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-93ADB55C751F46E0EAC7482D40FC600E" unitRef="usd">10226000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-25153C68AD7DDEB9A734482D40F801A9" unitRef="usd">29439000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-0306FD7B8E42AE71D079482D4101E484" unitRef="usd">11599000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-56DF06E5DA5D93A14C26482D4108866E" unitRef="usd">33626000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DE992C42610ECBE42AE6482D41068D87" unitRef="usd">15588000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-3" id="Fact-6C1DF8E0AFC034B8B810482D4108B15D" unitRef="usd">18843000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q3QTD" decimals="3" id="Fact-26A48BAFC988F42CAE58482D4102ED25" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q3YTD" decimals="3" id="Fact-9FD72539F09681C3D6BA482D40F8D7B6" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q3QTD" decimals="3" id="Fact-27FCC4E2CB918D19E066482D4101852B" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q3YTD" decimals="3" id="Fact-4E2D9E7F32591F3F4362482D41028E3F" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2015Q3QTD" decimals="3" id="Fact-1B66FCDB22295CD61C7E482D40F4E40E" unitRef="number">0.669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2015Q3YTD" decimals="3" id="Fact-1D816FF924BB48FC98C5482D40F8252B" unitRef="number">0.670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q3QTD" decimals="3" id="Fact-A3537B3F8795E23EC369482D40F03B0E" unitRef="number">0.707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q3YTD" decimals="3" id="Fact-7D59900CFAFBE69DC10C482D40F4FE70" unitRef="number">0.707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2015Q3QTD" decimals="3" id="Fact-1D2EE93BA4917662BCB5482D4103C781" unitRef="number">0.668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2015Q3YTD" decimals="3" id="Fact-90543A5562B49784B791482D41018878" unitRef="number">0.662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q3QTD" decimals="3" id="Fact-2684B77EE3B7BE05B761482D40F88D85" unitRef="number">0.705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q3YTD" decimals="3" id="Fact-8AC4FC0239C777DE6D82482D40F8D99C" unitRef="number">0.675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q3QTD" decimals="4" id="Fact-CF06F79238C1C4D5FCCD482D40F8F3EB" unitRef="number">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q3YTD" decimals="4" id="Fact-44FAB3BFB66FBB50FD25482D40F8F7C7" unitRef="number">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q3QTD" decimals="4" id="Fact-C604A55BCD888B96A4D1482D40F48AAC" unitRef="number">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q3YTD" decimals="4" id="Fact-EFD3D18C855AB625C9B0482D40F88611" unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q3QTD" decimals="4" id="Fact-DB7CCFB67158A5771EE5482D40F48E18" unitRef="number">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q3YTD" decimals="4" id="Fact-D7315E7B193EB3F4241A482D40F88E75" unitRef="number">0.0134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q3QTD" decimals="4" id="Fact-BF0304715A0441B2A2F9482D4100CCC3" unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q3YTD" decimals="4" id="Fact-EE7EAED25EC36844FC58482D41027F0A" unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D8B0F129B88ED2C03F05482D40F4F008" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q3YTD" decimals="-5" id="Fact-18AF1EFF8ECC30A25651482D4109B62C" unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q3QTD" decimals="-5" id="Fact-29D0484B646DEB07BB19D3369E205FE9" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2FD311671651C57D9142482D40F82385" unitRef="shares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="-5" id="Fact-A78BB32CC85B9A1B6367482D4101B40F" unitRef="shares">9000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q3" decimals="-5" id="Fact-3C51E02F8CC786B1388A482D41023DFB" unitRef="shares">12400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-1B72E83A2E88413F53BB482D4101F638" unitRef="usdPerShare">7.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-126FF0BEDCDC07B37A18482D40FC814B" unitRef="usdPerShare">6.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3QTD" id="Fact-5BD62DE46EDE37A954F9482D40F00D64">P5Y7M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3YTD" id="Fact-8A195C693F28B1331195482D41046F48">P5Y7M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3QTD" id="Fact-960A21530AB9B3794FE2482D41077363">P5Y5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD" id="Fact-7B97A5BB5F424FE915CB482D41077569">P5Y5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-15A37C19B451F046A5C2482D41017DCC" unitRef="shares">52019</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
	<us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-23B41072616A8D7D6030482D4101AAF9" unitRef="shares">82396</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-4439C1577D3382A20A46482D4101ED18" unitRef="shares">515695</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-5CDBD0FE6E36C5F49552482D40F48595" unitRef="shares">134088</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-443FC938F3923C53467E482D40F0EB7B" unitRef="shares">968652</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-8DBBFB3D72A0193511F4482D40F04069" unitRef="shares">215779</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-5048F3ED5EC22761CF14482D4104FD0C" unitRef="shares">1626091</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-B49689CCB98C1F190E0A482D41036D12" unitRef="shares">383719</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-AFA2A1530D6050B899FD482D40F87DAD" unitRef="usd">42999000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q3" decimals="-3" id="Fact-C04C7023B6BC002ABB76482D41041F62" unitRef="usd">-11992000</us-gaap:StockholdersEquity>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3QTD" decimals="-3" id="Fact-025E40A364B07CCFABFE482D410703E4" unitRef="shares">126921000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4D00A5C5F8B7D9F0154A482D40FC5156" unitRef="shares">126127000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3QTD" decimals="-3" id="Fact-937FEFAE7849B37EC15F482D40FC2F46" unitRef="shares">128154000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C70A3F627939BDDB43DD482D40F49299" unitRef="shares">127886000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-28CC98C4BEA794E91CB9482D41048118">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments in connection with our clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, such revisions to our clinical trial expense accruals have not had a material impact on our consolidated results of operations or financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</halo:DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2016Q3YTD" id="Fact-C572A1D3648E7C95AA24482D4107A3DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="FD2016Q3YTD" id="Fact-1FD16045E1EA298CA8ED482D4101DBEF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, filed with the SEC on February 29, 2016. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&amp;#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. All intercompany accounts and transactions have been eliminated. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#8217;s estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-8FAE53305D676E9C2255482D41042816">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Marketable Securities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. Our cash equivalents consist of money market funds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2016Q3YTD" id="Fact-1FF28A64EFC9B5FCBC70482D4100AA1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-944AF5464507EB47279C482D40F4C63B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborative Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Roche Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2006, we and Roche entered into a collaboration and license agreement, under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;thirteen&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Roche target compounds (the &amp;#8220;Roche Collaboration&amp;#8221;). As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Roche has elected a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; targets, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which are exclusive, and in addition retains the option to develop and commercialize rHuPH20 with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional targets. In August 2013, Roche received European marketing approval for its collaboration product, Herceptin SC, for the treatment of patients with HER2-positive breast cancer and launched Herceptin SC in the European Union (&amp;#8220;EU&amp;#8221;) in September 2013. In March 2014, Roche received European marketing approval for its collaboration product, MabThera SC, for the treatment of patients with common forms of non-Hodgkin lymphoma (&amp;#8220;NHL&amp;#8221;). In June 2014, Roche launched MabThera SC in the EU.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Roche assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Roche Collaboration, while we are responsible for the supply of bulk rHuPH20. We are entitled to receive reimbursements for providing research and development services and supplying bulk rHuPH20 to Roche at its request.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Roche Collaboration, Roche pays us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&amp;#8217;s obligation to pay royalties. Roche has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Roche Collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments received from Roche, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Election of additional exclusive targets and annual license maintenance fees for the right to &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;designate the remaining targets as exclusive targets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Clinical development milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regulatory milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Sales-based milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees, annual license maintenance fees and sales-based milestone payments were deferred and are being amortized over the remaining term of the Roche Collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of Roche deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. For each of the the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Roche deferred revenues, excluding reimbursements for providing research and development services, as revenues under collaborative agreements. Roche deferred revenues, excluding deferred revenues related to reimbursements for providing research and development services, were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September 30, 2016 and December 31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Baxalta Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2007, we and Baxalta entered into a collaboration and license agreement, under which Baxalta obtained a worldwide, exclusive license to develop and commercialize HYQVIA, a combination of Baxalta&amp;#8217;s current product GAMMAGARD LIQUID&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#8482;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and our patented rHuPH20 enzyme (the &amp;#8220;Baxalta Collaboration&amp;#8221;). In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use), a combination of GAMMAGARD LIQUID and rHuPH20 in dual vial units, as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the EU in July 2013. In September 2014, the FDA approved HYQVIA for treatment of adult patients with primary immunodeficiency. In October 2014, Baxalta announced the launch and first shipments of HYQVIA in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Baxalta Collaboration is applicable to both kit and formulation combinations. Baxalta assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Baxalta Collaboration, while we are responsible for the supply of bulk rHuPH20. We perform research and development activities and supply bulk rHuPH20 at the request of Baxalta, and are reimbursed by Baxalta under the terms of the Baxalta Collaboration. In addition, Baxalta has certain product development and commercialization obligations in major markets identified in the Baxalta Collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Baxalta Collaboration, Baxalta pays us a royalty consisting of a mid-single digit percent of the net sales of HYQVIA. Unless terminated earlier in accordance with its terms, the Baxalta Collaboration continues in effect until the expiration of Baxalta&amp;#8217;s obligation to pay royalties to us. Baxalta has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Baxalta Collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments received from Baxalta, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront license fee payment for the application of rHuPH20 to the initial exclusive target&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regulatory milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales-based milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the upfront license fee and sales-based milestone payments were deferred and are being recognized over the term of the Baxalta Collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For each of the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Baxalta deferred revenues as revenues under collaborative agreements. For each of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Baxalta deferred revenues as revenues under collaborative agreements. Baxalta deferred revenues totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 30, 2016 and December 31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Lilly proprietary biologics directed at up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; targets (the &amp;#8220;Lilly Collaboration&amp;#8221;). Targets, once selected, will be on an exclusive, global basis. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lilly has elected &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specified exclusive targets and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specified semi-exclusive target. Lilly has the right to elect up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to Lilly&amp;#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Lilly Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Lilly Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Lilly may terminate the agreement prior to expiration for any reason in its entirety upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior written notice to us.&amp;#160;Upon any such termination, the license granted to Lilly (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with AbbVie proprietary biologics directed at up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; targets (the &amp;#8220;AbbVie Collaboration&amp;#8221;). Targets, once selected, will be on an exclusive, global basis. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, AbbVie has elected &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specified exclusive target, TNF alpha. AbbVie has announced plans to develop rHuPH20 with adalimumab (HUMIRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) which may allow reduced number of induction injections and deliver additional performance benefits. AbbVie has the right to elect up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;eight&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to AbbVie&amp;#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay tiered royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the AbbVie Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the AbbVie Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. AbbVie may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days prior written notice to us.&amp;#160;Upon any such termination, the license granted to AbbVie (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Janssen proprietary biologics directed at up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; targets (the &amp;#8220;Janssen Collaboration&amp;#8221;). Targets, once selected, will be on an exclusive, global basis. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Janssen has elected &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specified exclusive target, CD38. Janssen has the right to elect &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional targets in the future upon payment of additional fees. In addition, Janssen will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Janssen Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Janssen Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Janssen may terminate the agreement prior to expiration for any reason in its entirety or on a product-by-product basis upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior written notice to us.&amp;#160;Upon any such termination, the license granted to Janssen (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Pfizer proprietary biologics directed at up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; targets (the &amp;#8220;Pfizer Collaboration&amp;#8221;). Targets may be selected on an exclusive or non-exclusive basis. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Pfizer has elected &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specified exclusive targets. Pfizer has the right to elect &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional target in the future upon payment of additional fees. In addition, Pfizer will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Pfizer Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Pfizer Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the date of the first commercial sale of such product in such country. Royalties are subject to adjustment as set forth in the agreement. Pfizer may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior written notice to us.&amp;#160;Upon any such termination, the license granted to Pfizer (in total or with respect to the terminated target, as applicable) will terminate, provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments received from other collaborators for upfront license fees, license fees for the election of additional targets, maintenance fees and event-based payments since inception of the collaboration agreements are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lilly&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pfizer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of the Pfizer, Janssen, AbbVie and Lilly arrangements, we identified the deliverables in each arrangement to include the license, research and development services and supply of bulk rHuPH20. We have determined that the license, research and development services and supply of bulk rHuPH20 individually represent separate units of accounting, because each deliverable has standalone value. We determined that the rights to elect additional targets in the future upon the payment of additional license fees are substantive options that are not priced at a significant and incremental discount. Therefore, we determined for each collaboration that the rights to elect additional targets are not deliverables at the inception of the arrangement. The estimated selling prices for the units of accounting we identified were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives. The arrangement consideration was allocated to the deliverables based on the relative selling price method and the nature of the research and development services to be performed for the collaborator. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (non-contingent amount). As such, we excluded from the allocable arrangement consideration the event-based payments, milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fees from Pfizer, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fee from Janssen, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront license fee from AbbVie and the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fees from Lilly to the license fee deliverable under each of the arrangements. We determined that the upfront payments were earned upon the granting of the worldwide, exclusive right to our technology to the collaborators in these arrangements. As a result, we recognized the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fees under the Pfizer Collaboration, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fee under the Janssen Collaboration, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront license fee under the AbbVie Collaboration, and the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fees under the Lilly Collaboration as revenues under collaborative agreements in the period when such license fees were earned. We recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue in the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to event-based payments or milestone payments under these collaborations and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;did not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recognize any such revenues for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The collaborators are each solely responsible for the development, manufacturing and marketing of any products resulting from their respective collaborations. We are entitled to receive payments for research and development services and supply of bulk rHuPH20 if requested by any collaborator. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We recognize amounts allocated to the sales of bulk rHuPH20 as revenues under collaborative agreements when such bulk rHuPH20 has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We cannot predict the timing of delivery of research and development services and bulk rHuPH20 as they are at the collaborators&amp;#8217; requests. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the terms of our collaboration agreements with Roche and Pfizer, certain future payments meet the definition of a milestone in accordance with the Milestone Method of Accounting. We are entitled to receive additional milestone payments under our collaboration agreements with Roche and Pfizer for the successful development of the elected targets in the aggregate of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon achievement of specified clinical development milestone events and up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon achievement of specified regulatory milestone events in connection with specified regulatory filings and receipt of marketing approvals.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-0627DB1028242FF4C71A482D40F8ECF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&amp;#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CostOfSalesPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-FA655D8793C48EC2DE5C482D41068B9F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Product Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
	<us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-5751C84CFB5388D9A446482D40F4DA22">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaborative agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;License fees and event-based payments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Roche&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reimbursement for research and development services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,799&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q3YTD" id="Fact-CF1287A573B5933F436A482D41038A2B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSAs, RSUs and PRSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Because we have a net operating loss carryforward as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; excess tax benefits for the tax deductions related to share-based awards were recognized in the condensed consolidated statements of operations for the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company granted stock options to purchase approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock during both the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The exercise price of stock options granted is equal to the closing price of the Company&amp;#8217;s common stock on the date of grant. We estimated fair value of each stock option granted on the date of grant using the Black-Scholes-Merton option pricing model (&amp;#8220;Black-Scholes model&amp;#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation that we will not be making future dividend payments. The assumptions used in the Black-Scholes model were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.5-70.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.8-66.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67.5-70.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.2-67.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00-1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69-1.92%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00-1.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.34-1.92%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrecognized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Recognition Period&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSAs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,439&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-09CA7FEB8A62B7766B57482D4109E35B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2016Q3YTD" id="Fact-79716270001ABDD96D6B482D40F08DE4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes, by major financial instrument type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable &lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;194,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q3YTD" id="Fact-0456C3E0DD4419DCA0D4482D4108F715">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-7E01F7C6D6BABAA12C4B482D40F0C626">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. Valuation allowances have been established to reduce our net deferred tax assets to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as we believe that it is more likely than not that such assets will not be realized.&amp;#160;The interim tax provision is calculated using the estimated effective tax rate expected to be applicable for the full year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-636FC5E585108B3C2AD7482D4103AB9B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to receiving marketing approval from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-8D78D0022D3CBC56C15B482D41088C5F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$153.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available-for-sale marketable securities in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; other-than-temporary impairments on these marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; because we do not intend to sell these marketable securities prior to maturity and it is not more likely than not that we will be required to sell these marketable securities before the recovery of their amortized cost basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:LongTermDebtTextBlock contextRef="FD2016Q3YTD" id="Fact-3D39BBBD9059FBBD0FDA482D40F46F29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-Term Debt, Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Royalty-backed Loan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, through our wholly-owned subsidiary Halozyme Royalty LLC (&amp;#8220;Halozyme Royalty&amp;#8221;), we received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; loan (the &amp;#8220;Royalty-backed Loan&amp;#8221;) pursuant to a credit agreement (the &amp;#8220;Credit Agreement&amp;#8221;) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the &amp;#8220;Royalty-backed Lenders&amp;#8221;). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (&amp;#8220;Collaboration Agreements&amp;#8221;). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the &amp;#8220;Royalty Payments&amp;#8221;).&amp;#160; The Royalty-backed loan bears interest at a per annum rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;plus the three-month LIBOR rate&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The three-month LIBOR rate is subject to a floor of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a cap of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;The interest rate as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.61%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Credit Agreement provides that &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;none&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Royalty Payments are required to be applied to the Royalty-backed Loan prior to January&amp;#160;1, 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Royalty Payments are required to be applied to the Royalty-backed Loan between January&amp;#160;1, 2017 and January&amp;#160;1, 2018 and thereafter &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;all&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Royalty Payments must be applied to the Royalty-backed Loan.&amp;#160;However, the amounts available to repay the Royalty-backed Loan are subject to caps of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.75 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per quarter in 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.75 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per quarter in 2018, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.25 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per quarter in 2019 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date.&amp;#160;Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;final maturity date of the Royalty-backed Loan will be the earlier of (i)&amp;#160;the date when principal and interest is paid in full, (ii)&amp;#160;the termination of Halozyme Royalty&amp;#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&amp;#160;December&amp;#160;31, 2050&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160; Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January&amp;#160;1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;in compliance&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with all material covenants under the Credit Agreement and there was no material adverse change in our business, operations or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, accrued interest in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was capitalized and added to the principal balance of the Royalty-backed Loan. In addition, we recorded related accrued interest on the debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and incurred additional debt issuance costs totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and are being amortized over the estimated term of the debt using the effective interest method. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$157.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inclusive of payment-in-kind interest expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and net of unamortized debt discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Oxford and SVB Loan and Security Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we entered into an Amended and Restated Loan and Security Agreement (the &amp;#8220;Original Loan Agreement&amp;#8221;) with Oxford Finance LLC (&amp;#8220;Oxford&amp;#8221;) and Silicon Valley Bank (&amp;#8220;SVB&amp;#8221;) (collectively, the &amp;#8220;Lenders&amp;#8221;), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount of new term loan, bringing the total term loan balance to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The amended term loan facility was scheduled to mature on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; interest only payments through January 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.55%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; interest rate on the term loan and a final payment equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the original principal amount, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.25 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was due when the term loan became due or upon the prepayment of the facility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we entered into a new Loan and Security Agreement (the &amp;#8220;Loan Agreement&amp;#8221;) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Upon entering the loan, we drew &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$55.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and used a portion of the proceeds to pay the outstanding principal and final payment owed on the Original Loan Agreement. The remaining proceeds are to be used for working capital and general business requirements. We have the option to draw the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the second quarter of 2017 at an annual interest rate equal to the then-&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;current prime rate as reported in The Wall Street Journal plus 4.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The term loan repayment schedule provides for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;interest only payments for the first 18 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;1, 2021&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Loan Agreement provides for a final payment equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$55.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount and, if we exercise our option to draw an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the second draw. The final payment is due when the term loan becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the term loan in full, subject to a prepayment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the first year and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the second year of the term loan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the term loan, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the term loan using the effective interest rate method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The term loan is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of lender&amp;#8217;s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan.&amp;#160;In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;in compliance&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with all material covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense, including amortization of the debt discount, related to the Oxford and SVB loan totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2015, respectively. Accrued interest, which is included in accrued expenses and other long-term liabilities, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The outstanding term loan balance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$54.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of unamortized debt discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
	<us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy contextRef="FD2016Q3YTD" id="Fact-CBB56C779DC147618C50482D4104B71E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&amp;#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders&amp;#8217; (deficit) equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy>
	<us-gaap:NatureOfOperations contextRef="FD2016Q3YTD" id="Fact-81188969F6E438A651DC482D4108643E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Business &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators&amp;#8217; proprietary compounds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant, and it works by temporarily breaking down hyaluronan (or &amp;#8220;HA&amp;#8221;), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#8482;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&amp;#8220;Roche&amp;#8221;), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (&amp;#8220;Baxalta&amp;#8221;), Pfizer Inc. (&amp;#8220;Pfizer&amp;#8221;), Janssen Biotech, Inc. (&amp;#8220;Janssen&amp;#8221;), AbbVie, Inc. (&amp;#8220;AbbVie&amp;#8221;), and Eli Lilly and Company (&amp;#8220;Lilly&amp;#8221;). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with ABRAXANE&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (&amp;#8220;PDA&amp;#8221;) (Studies 109-202 and 109-301), in Phase 1b clinical testing for&lt;/font&gt;&lt;font style="font-family:inherit;font-size:11pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;PEGPH20 with KEYTRUDA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (eribulin) in first line and second line HER2-negative metastatic breast cancer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Except where specifically noted or the context otherwise requires, references to &amp;#8220;Halozyme,&amp;#8221; &amp;#8220;the Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; and &amp;#8220;us&amp;#8221; in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&amp;#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-450C35FC932B273F23DE482D41036FB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update No. 2016-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2016-15&amp;#8221;). Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in the amendments in ASU 2016-15. The amendments are an improvement to U.S. GAAP and are intended to reduce the current and potential future diversity in practice. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 changes certain aspects of accounting for share-based payments to employees and involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Specifically, ASU 2016-09 requires that all income tax effects of share-based awards be recognized as income tax expense or benefit in the reporting period in which they occur. Additionally, ASU 2016-09 amends existing guidance to allow forfeitures of share-based awards to be recognized as they occur. Previous guidance required that share-based compensation expense include an estimate of forfeitures. We have elected to early adopt ASU 2016-09 as of January 1, 2016 and made a policy election to account for forfeitures as they occur. The cumulative effect of adoption was a decrease of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to both additional paid-in capital and accumulated deficit. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 requires lessees to recognize assets and liabilities for most leases and provide enhanced disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-01&amp;#8221;). ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. An entity&amp;#8217;s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of ASU 2016-01. ASU 2016-01 requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement. ASU 2016-01 is effective for interim and annual reporting periods beginning on January 1, 2018. Entities should apply the amendments by means of a cumulative effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of ASU 2016-01. We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued Accounting Standards Update 2015-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2015-17&amp;#8221;). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. For&amp;#160;public business entities, the guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. The guidance may be adopted on either a prospective or retrospective basis. We elected to early adopt ASU 2015-17 on January 1, 2016. There was no impact on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2015-11&amp;#8221;).&amp;#160;ASU 2015-11 requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 is not expected to have a material impact on our consolidated financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#160;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2015-03&amp;#8221;).&amp;#160;ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. The recognition and measurement guidance for debt issuance costs is not affected by ASU 2015-03. We adopted ASU 2015-03 on January 1, 2016. There was no material impact on our consolidated financial statements and related disclosures. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements &amp;#8212; Going Concern &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2014-15&amp;#8221;).&amp;#160;The provisions of ASU 2014-15 provide that, in connection with preparing financial statements for each annual and interim reporting period, an entity&amp;#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 is effective for the annual reporting period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the effect that the adoption of ASU 2014-15 will have on our financial statement disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;). In March, April and May 2016 the FASB issued additional guidance related to Topic 606. These new standards will eliminate transaction-specific and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for our interim and annual reporting periods beginning on January 1, 2018. Entities can transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. We have not yet selected a transition method, and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q3YTD" id="Fact-5BCA44FE565AB3708CFD482D40F0738D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,261&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q3YTD" id="Fact-6B3240E41943E5335893482D4103B96B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_OthercollaboratorsMember" id="Fact-A287508E114886AA0849482D40FC6D70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lilly&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pfizer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock>
	<us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-031527DC7978503384B2482D40FCA056">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Election of additional exclusive targets and annual license maintenance fees for the right to &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;designate the remaining targets as exclusive targets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Clinical development milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regulatory milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Sales-based milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock>
	<us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_halo_RocheMember" id="Fact-D2608001BF73EC2DF09C482D40F45F52">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront license fee payment for the application of rHuPH20 to the initial exclusive target&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regulatory milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales-based milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total payments received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-273C872EFF2661653550482D40F4EF05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the seller&amp;#8217;s price to the buyer is fixed or determinable; and (4)&amp;#160;collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Product Sales,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recombinant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We sell &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (&amp;#8220;GPOs&amp;#8221;), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. As a result, we recognize &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon recognition of revenue from product sales of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Returns&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We allow the wholesalers to return product that is damaged or received in error. In addition, we accept unused product to be returned beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior to and ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following product expiration. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Distribution Fees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesalers for distribution services they provide with respect to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. These fees are generally a fixed percentage of the price of the product purchased by the wholesalers. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We offer cash discounts to certain wholesalers as an incentive to meet certain payment terms. We estimate prompt payment discounts based on contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Discounts and Fees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We provide discounts to end-user members of certain GPOs under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals, who are members of the GPOs, with which we do not have contracts. The end-user members purchase products from the wholesalers at a contracted discounted price, and the wholesalers then charge back to us the difference between the current retail price and the price the end-users paid for the product. We also incur GPO administrative service fees for these transactions. In addition, we provide predetermined discounts under certain government programs. Our estimate for these chargebacks and fees takes into consideration contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allowances for product returns and chargebacks are based on amounts owed or to be claimed on the related sales. We believe that our estimated product returns for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. In order to develop a methodology to reliably estimate future returns and provide a basis for recognizing revenue on sales to wholesale distributors, we analyze many factors, including, without limitation: (1) actual &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant product return history, taking into account product expiration dating at the time of shipment, (2) re-order activities of the wholesalers as well as their customers and (3) levels of inventory in the wholesale channel. We have monitored actual return history on an individual product lot basis since product launch. We consider the dating of product at the time of shipment into the distribution channel and changes in the estimated levels of inventory within the distribution channel to estimate our exposure to returned product. We also consider historical chargebacks activity and current contract prices to estimate our exposure to returned product. Based on such data, we believe we have the information needed to reasonably estimate product returns and chargebacks. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Bulk rHuPH20&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer&amp;#8217;s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche&amp;#8217;s Herceptin SC product in August 2013 and MabThera&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; SC product in March 2014 and Baxalta&amp;#8217;s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues under Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&amp;#160;the license to our rHuPH20 technology, (ii)&amp;#160;at the collaborator&amp;#8217;s request, research and development services which are reimbursed at contractually determined rates, and (iii)&amp;#160;at the collaborator&amp;#8217;s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators&amp;#8217; ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the market place. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition - Milestone Method &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;Milestone Method of Accounting&amp;#8221;). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration is commensurate with either the entity&amp;#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&amp;#8217;s performance to achieve the milestone;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration relates solely to past performance; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A milestone is defined as an event (i)&amp;#160;that can only be achieved based in whole or in part on either the entity&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the entity&amp;#8217;s performance, (ii)&amp;#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&amp;#160;that would result in additional payments being due to the vendor.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator&amp;#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="FD2016Q3YTD" id="Fact-2924D2DA499D120D820D482D40F0AB5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable, net consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from product sales to collaborators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from other product sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from revenues under collaborative agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allowance for distribution fees and discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q3YTD" id="Fact-5990F532E3C9F5C24F27482D40F00D07">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and payroll taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced manufacturing expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less long-term accrued outsourced research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued expenses, current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2016Q3YTD" id="Fact-2B3C99C979172C948214482D40F88306">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSAs, RSUs and PRSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q3YTD" id="Fact-58E07198A8E9960C5812482D4108CDB5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2016Q3YTD" id="Fact-83BE283631C73CA80506482D40F475E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-CEEA1BF71680FBC8A819482D40F45DCF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total prepaid expenses and other assets, current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-F31A567EEB00B7A0C64A482D4102F489">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The assumptions used in the Black-Scholes model were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended &lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.5-70.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.8-66.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67.5-70.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66.2-67.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00-1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69-1.92%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00-1.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.34-1.92%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-C91A3820617285FF8957482D40F8A511">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrecognized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Recognition Period&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSAs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,439&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-44CE5B0C97BBB7D569E7482D40F8AAE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate our business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i)&amp;#160;research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii)&amp;#160;product sales of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q3YTD" id="Fact-97FF8F6F3E7D5D67849F482D4105F309">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We record compensation expense associated with stock options, restricted stock awards (&amp;#8220;RSAs&amp;#8221;), restricted stock units (&amp;#8220;RSUs&amp;#8221;), and RSUs with performance conditions (&amp;#8220;PRSUs&amp;#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q3YTD" id="Fact-02255AD7BAD78195A4C7482D410396AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, filed with the SEC on February 29, 2016. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&amp;#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. All intercompany accounts and transactions have been eliminated. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#8217;s estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update No. 2016-15, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2016-15&amp;#8221;). Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in the amendments in ASU 2016-15. The amendments are an improvement to U.S. GAAP and are intended to reduce the current and potential future diversity in practice. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 changes certain aspects of accounting for share-based payments to employees and involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Specifically, ASU 2016-09 requires that all income tax effects of share-based awards be recognized as income tax expense or benefit in the reporting period in which they occur. Additionally, ASU 2016-09 amends existing guidance to allow forfeitures of share-based awards to be recognized as they occur. Previous guidance required that share-based compensation expense include an estimate of forfeitures. We have elected to early adopt ASU 2016-09 as of January 1, 2016 and made a policy election to account for forfeitures as they occur. The cumulative effect of adoption was a decrease of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to both additional paid-in capital and accumulated deficit. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 requires lessees to recognize assets and liabilities for most leases and provide enhanced disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2016-01&amp;#8221;). ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. An entity&amp;#8217;s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of ASU 2016-01. ASU 2016-01 requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement. ASU 2016-01 is effective for interim and annual reporting periods beginning on January 1, 2018. Entities should apply the amendments by means of a cumulative effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of ASU 2016-01. We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued Accounting Standards Update 2015-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2015-17&amp;#8221;). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. For&amp;#160;public business entities, the guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. The guidance may be adopted on either a prospective or retrospective basis. We elected to early adopt ASU 2015-17 on January 1, 2016. There was no impact on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2015-11&amp;#8221;).&amp;#160;ASU 2015-11 requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 is not expected to have a material impact on our consolidated financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#160;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2015-03&amp;#8221;).&amp;#160;ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. The recognition and measurement guidance for debt issuance costs is not affected by ASU 2015-03. We adopted ASU 2015-03 on January 1, 2016. There was no material impact on our consolidated financial statements and related disclosures. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements &amp;#8212; Going Concern &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;ASU 2014-15&amp;#8221;).&amp;#160;The provisions of ASU 2014-15 provide that, in connection with preparing financial statements for each annual and interim reporting period, an entity&amp;#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 is effective for the annual reporting period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the effect that the adoption of ASU 2014-15 will have on our financial statement disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;). In March, April and May 2016 the FASB issued additional guidance related to Topic 606. These new standards will eliminate transaction-specific and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for our interim and annual reporting periods beginning on January 1, 2018. Entities can transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. We have not yet selected a transition method, and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Marketable Securities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. Our cash equivalents consist of money market funds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&amp;#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders&amp;#8217; (deficit) equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, restricted cash of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was pledged as collateral for the letters of credit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes, by major financial instrument type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale marketable &lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;194,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;103,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; transfers between Level 1 and Level 2 of the fair value hierarchy during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; financial instruments that were classified within Level 3 as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to receiving marketing approval from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inventories consisted of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant inventory, net, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of bulk rHuPH20 for use in the manufacture of Balxalta&amp;#8217;s and Roche&amp;#8217;s collaboration products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;delivery has occurred or services have been rendered; (3)&amp;#160;the seller&amp;#8217;s price to the buyer is fixed or determinable; and (4)&amp;#160;collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Product Sales,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recombinant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We sell &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (&amp;#8220;GPOs&amp;#8221;), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. As a result, we recognize &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon recognition of revenue from product sales of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Returns&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We allow the wholesalers to return product that is damaged or received in error. In addition, we accept unused product to be returned beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior to and ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following product expiration. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Distribution Fees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesalers for distribution services they provide with respect to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. These fees are generally a fixed percentage of the price of the product purchased by the wholesalers. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Prompt Payment Discounts&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We offer cash discounts to certain wholesalers as an incentive to meet certain payment terms. We estimate prompt payment discounts based on contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Discounts and Fees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We provide discounts to end-user members of certain GPOs under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals, who are members of the GPOs, with which we do not have contracts. The end-user members purchase products from the wholesalers at a contracted discounted price, and the wholesalers then charge back to us the difference between the current retail price and the price the end-users paid for the product. We also incur GPO administrative service fees for these transactions. In addition, we provide predetermined discounts under certain government programs. Our estimate for these chargebacks and fees takes into consideration contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allowances for product returns and chargebacks are based on amounts owed or to be claimed on the related sales. We believe that our estimated product returns for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. In order to develop a methodology to reliably estimate future returns and provide a basis for recognizing revenue on sales to wholesale distributors, we analyze many factors, including, without limitation: (1) actual &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant product return history, taking into account product expiration dating at the time of shipment, (2) re-order activities of the wholesalers as well as their customers and (3) levels of inventory in the wholesale channel. We have monitored actual return history on an individual product lot basis since product launch. We consider the dating of product at the time of shipment into the distribution channel and changes in the estimated levels of inventory within the distribution channel to estimate our exposure to returned product. We also consider historical chargebacks activity and current contract prices to estimate our exposure to returned product. Based on such data, we believe we have the information needed to reasonably estimate product returns and chargebacks. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Bulk rHuPH20&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer&amp;#8217;s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche&amp;#8217;s Herceptin SC product in August 2013 and MabThera&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; SC product in March 2014 and Baxalta&amp;#8217;s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues under Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&amp;#160;the license to our rHuPH20 technology, (ii)&amp;#160;at the collaborator&amp;#8217;s request, research and development services which are reimbursed at contractually determined rates, and (iii)&amp;#160;at the collaborator&amp;#8217;s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators&amp;#8217; ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the market place. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition - Milestone Method &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(&amp;#8220;Milestone Method of Accounting&amp;#8221;). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration is commensurate with either the entity&amp;#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&amp;#8217;s performance to achieve the milestone;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration relates solely to past performance; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:60px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A milestone is defined as an event (i)&amp;#160;that can only be achieved based in whole or in part on either the entity&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the entity&amp;#8217;s performance, (ii)&amp;#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&amp;#160;that would result in additional payments being due to the vendor.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator&amp;#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Refer to Note 4, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for further discussion on our collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cost of Product Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments in connection with our clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, such revisions to our clinical trial expense accruals have not had a material impact on our consolidated results of operations or financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We record compensation expense associated with stock options, restricted stock awards (&amp;#8220;RSAs&amp;#8221;), restricted stock units (&amp;#8220;RSUs&amp;#8221;), and RSUs with performance conditions (&amp;#8220;PRSUs&amp;#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. Valuation allowances have been established to reduce our net deferred tax assets to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as we believe that it is more likely than not that such assets will not be realized.&amp;#160;The interim tax provision is calculated using the estimated effective tax rate expected to be applicable for the full year. During the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, in income tax expense, comprising U.S. federal alternative minimum tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the three and nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, respectively, of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We operate our business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i)&amp;#160;research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii)&amp;#160;product sales of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Hylenex&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recombinant. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-DFBD353F80E5C384269F482D4109E40F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; (Deficit) Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September 30, 2016 and 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we issued an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;383,719&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,626,091&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$6.74&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$7.43&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively, for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$12.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September 30, 2016 and 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;215,779&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;134,088&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;82,396&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;52,019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; RSUs, respectively, to pay for minimum withholding taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. In addition, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;968,652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;515,695&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in connection with the grants of RSAs during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 30, 2016 and 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Stock options and unvested restricted units totaling approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;12.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;9.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock were outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September 30, 2016 and December 31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2016Q3YTD" id="Fact-684D4BE0CCEAE87A2058482D40F4375F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Certain Balance Sheet Items&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable, net consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from product sales to collaborators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from other product sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable from revenues under collaborative agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,939&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allowance for distribution fees and discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventories consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work-in-process, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total inventories&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,810&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less long-term portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total prepaid expenses and other assets, current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,261&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;                            &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and payroll taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced manufacturing expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less long-term accrued outsourced research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total accrued expenses, current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term accrued outsourced research and development is included in other long-term liabilities in the condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaborative agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;License fees and event-based payments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Roche&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reimbursement for research and development services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,799&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>halo-20160930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.halozyme.com/20160930" xmlns:halo="http://www.halozyme.com/20160930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CertainBalanceSheetItemsAccountsReceivableDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails">
        <link:definition>2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails">
        <link:definition>2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsDeferredRevenueDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails">
        <link:definition>2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsInventoriesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails">
        <link:definition>2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsNotes" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes">
        <link:definition>2107100 - Disclosure - Certain Balance Sheet Items (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails">
        <link:definition>2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyAndEquipmentDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails">
        <link:definition>2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails">
        <link:definition>2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables">
        <link:definition>2307301 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsCollaborativeAgreementsTables" roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables">
        <link:definition>2304301 - Disclosure - Collaborative Agreements Collaborative Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsCollaborativeAgreementsTablesDetails" roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails">
        <link:definition>2404403 - Disclosure - Collaborative Agreements Collaborative Agreements tables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails">
        <link:definition>2404402 - Disclosure - Collaborative Agreements Collaborative Agreements Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsNotes" roleURI="http://www.halozyme.com/role/CollaborativeAgreementsNotes">
        <link:definition>2104100 - Disclosure - Collaborative Agreements (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.halozyme.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.halozyme.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetLongTermDebtTextualsDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails">
        <link:definition>2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetNotes" roleURI="http://www.halozyme.com/role/LongTermDebtNetNotes">
        <link:definition>2108100 - Disclosure - Long-Term Debt, Net (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.halozyme.com/role/MarketableSecuritiesDetails">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNotes" roleURI="http://www.halozyme.com/role/MarketableSecuritiesNotes">
        <link:definition>2103100 - Disclosure - Marketable Securities (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.halozyme.com/role/MarketableSecuritiesTables">
        <link:definition>2303301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTextualsDetails" roleURI="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails">
        <link:definition>2403403 - Disclosure - Marketable Securities Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBusiness" roleURI="http://www.halozyme.com/role/OrganizationAndBusiness">
        <link:definition>2101100 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDetails" roleURI="http://www.halozyme.com/role/ShareBasedCompensationDetails">
        <link:definition>2409402 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNotes" roleURI="http://www.halozyme.com/role/ShareBasedCompensationNotes">
        <link:definition>2109100 - Disclosure - Share-based Compensation (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationTextualsDetails" roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails">
        <link:definition>2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails">
        <link:definition>2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationValuationDetails" roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails">
        <link:definition>2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.halozyme.com/role/ShareBasedCompensationTables">
        <link:definition>2309301 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitEquity" roleURI="http://www.halozyme.com/role/StockholdersDeficitEquity">
        <link:definition>2110100 - Disclosure - Stockholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitEquityDetails" roleURI="http://www.halozyme.com/role/StockholdersDeficitEquityDetails">
        <link:definition>2410401 - Disclosure - Stockholders' (Deficit) Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies Income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesInventoriesDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails">
        <link:definition>2402409 - Disclosure - Summary of Significant Accounting Policies Net (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2402410 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="halo_A2016Member" name="A2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2017Member" name="A2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2017QuarterlyMaximumPaymentMember" name="A2017QuarterlyMaximumPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2018QuarterlyMaximumPaymentMember" name="A2018QuarterlyMaximumPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2018andthereafterMember" name="A2018andthereafterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2019QuarterlyMaximumPaymentMember" name="A2019QuarterlyMaximumPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_A2020QuarterlyMaximumPaymentMember" name="A2020QuarterlyMaximumPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Accountsreceivablefromcollaborators" name="Accountsreceivablefromcollaborators" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_Accountsreceivablefromproductsales" name="Accountsreceivablefromproductsales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_Accountsreceivablefromproductsalestocollaborators" name="Accountsreceivablefromproductsalestocollaborators" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" name="AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm" name="AccruedOutsourcedResearchandDevelopmentExpensesLongTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="halo_Accruedmanufacturingexpenses" name="Accruedmanufacturingexpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones" name="AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets" name="Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_AllowanceforDistributionFeesandDiscounts" name="AllowanceforDistributionFeesandDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" name="AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_Amountreceivedforsalesbasedpayment" name="Amountreceivedforsalesbasedpayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="halo_BaxaltaMember" name="BaxaltaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_BulkrHuPH20Member" name="BulkrHuPH20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" name="ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="halo_CollaborativeAgreementsAbstract" name="CollaborativeAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_CollaborativeAgreementsDisclosureAbstract" name="CollaborativeAgreementsDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_CollaborativeAgreementsTermsAbstract" name="CollaborativeAgreementsTermsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_CollaborativeAgreementsTextualAbstract" name="CollaborativeAgreementsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_DebtInstrumentPrepaymentFeePercent" name="DebtInstrumentPrepaymentFeePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="halo_DeferredRevenueTextualAbstract" name="DeferredRevenueTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" name="DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_DurationOfRoyaltyReceivable" name="DurationOfRoyaltyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Finalpaymentaspercentofadditionaldraw" name="Finalpaymentaspercentofadditionaldraw" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Finalpaymentaspercentoforiginalprincipal" name="Finalpaymentaspercentoforiginalprincipal" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_HylenexRecombinantMember" name="HylenexRecombinantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_InlicensetechnologiesMember" name="InlicensetechnologiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_JanssenMember" name="JanssenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_LillyMember" name="LillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_NetincomelosspershareTextualsAbstract" name="NetincomelosspershareTextualsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" name="NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_NumberOfAdditionalTargetOptional" name="NumberOfAdditionalTargetOptional" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_NumberOfTargetsElected" name="NumberOfTargetsElected" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_NumberofProductCompoundCombinationsLicensedtoDevelop" name="NumberofProductCompoundCombinationsLicensedtoDevelop" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Numberoftargetselectedadditionalexclusivetargets" name="Numberoftargetselectedadditionalexclusivetargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Numberoftargetselectedadditionalsemiexclusivetargets" name="Numberoftargetselectedadditionalsemiexclusivetargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_OthercollaboratorsMember" name="OthercollaboratorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_PeriodForTermination" name="PeriodForTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Periodtoacceptreturnedunusedproduct" name="Periodtoacceptreturnedunusedproduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_PfizerJanssenandAbbVieMember" name="PfizerJanssenandAbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_PfizerMember" name="PfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Prepaidresearchanddevelopment" name="Prepaidresearchanddevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" name="ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="halo_RSURSAandPRSUawardsMember" name="RSURSAandPRSUawardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" name="RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="halo_ResearchEquipmentMember" name="ResearchEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_RocheMember" name="RocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_RoyaltybackedLoanMember" name="RoyaltybackedLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="halo_Royaltypaymentstobeappliedtodebtinstrument" name="Royaltypaymentstobeappliedtodebtinstrument" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract" name="ScheduleofAssumptionsforFairValueofStockOptionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>halo-20160930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:href="halo-20160930.xsd#CollaborativeAgreementsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:href="halo-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:href="halo-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:href="halo-20160930.xsd#LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:href="halo-20160930.xsd#LongTermDebtNetNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:href="halo-20160930.xsd#MarketableSecuritiesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:href="halo-20160930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:href="halo-20160930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:href="halo-20160930.xsd#ShareBasedCompensationNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:href="halo-20160930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:href="halo-20160930.xsd#StockholdersDeficitEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:href="halo-20160930.xsd#StockholdersDeficitEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_a964a278-7a22-ece3-3868-d4368414d822" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_a964a278-7a22-ece3-3868-d4368414d822" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AllowanceforDistributionFeesandDiscounts" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_f8149a5b-e0a4-fced-4e0e-482d53214247" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_f8149a5b-e0a4-fced-4e0e-482d53214247" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2459ea51-5142-55ca-20ec-74c7ca71f445" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2459ea51-5142-55ca-20ec-74c7ca71f445" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_905ee73c-d176-5287-2ffe-482d53281eba" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2459ea51-5142-55ca-20ec-74c7ca71f445" xlink:to="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_905ee73c-d176-5287-2ffe-482d53281eba" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Accruedmanufacturingexpenses" xlink:label="loc_halo_Accruedmanufacturingexpenses_3f4235a4-2bab-3af6-a046-482d532726d8" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2459ea51-5142-55ca-20ec-74c7ca71f445" xlink:to="loc_halo_Accruedmanufacturingexpenses_3f4235a4-2bab-3af6-a046-482d532726d8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2459ea51-5142-55ca-20ec-74c7ca71f445" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_8eb935ea-63de-339d-c6b8-12474f86bd6c" xlink:type="locator" />
    <loc xlink:href="halo-20160930.xsd#halo_Prepaidresearchanddevelopment" xlink:label="loc_halo_Prepaidresearchanddevelopment_77cfe7e9-c695-3b20-1dd3-482d532b8e4b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_8eb935ea-63de-339d-c6b8-12474f86bd6c" xlink:to="loc_halo_Prepaidresearchanddevelopment_77cfe7e9-c695-3b20-1dd3-482d532b8e4b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f1872ac6-9c1b-bfcf-be43-9e42711f3229" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_8eb935ea-63de-339d-c6b8-12474f86bd6c" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f1872ac6-9c1b-bfcf-be43-9e42711f3229" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_89f93c65-85fd-29e8-1936-9df58443c9af" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_8eb935ea-63de-339d-c6b8-12474f86bd6c" xlink:to="loc_us-gaap_OtherAssets_89f93c65-85fd-29e8-1936-9df58443c9af" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4cde1efa-07a8-ded0-f592-2cecba3dedaf" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4cde1efa-07a8-ded0-f592-2cecba3dedaf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ead76829-c82c-d335-51cd-efe853c4dcb3" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ead76829-c82c-d335-51cd-efe853c4dcb3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f9aa892-872a-217e-f4da-55b8bc195d22" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f9aa892-872a-217e-f4da-55b8bc195d22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4cde1efa-07a8-ded0-f592-2cecba3dedaf" xlink:type="arc" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9a24f45c-1e95-3649-7f52-85ed3c472b12" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9a24f45c-1e95-3649-7f52-85ed3c472b12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_37f1e565-0f5b-d294-1fab-1f43106882e2" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_37f1e565-0f5b-d294-1fab-1f43106882e2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a700ca3-a43b-8976-5354-fe4adf87a5b0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a700ca3-a43b-8976-5354-fe4adf87a5b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_8f89de87-b2e7-9565-1475-be70e859771e" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_8f89de87-b2e7-9565-1475-be70e859771e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_7bdc7fac-6b69-3248-f674-9b4cb03deba1" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_7bdc7fac-6b69-3248-f674-9b4cb03deba1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>halo-20160930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:href="halo-20160930.xsd#CollaborativeAgreementsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:href="halo-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:href="halo-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:href="halo-20160930.xsd#LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:href="halo-20160930.xsd#LongTermDebtNetNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:href="halo-20160930.xsd#MarketableSecuritiesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:href="halo-20160930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:href="halo-20160930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:href="halo-20160930.xsd#ShareBasedCompensationNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:href="halo-20160930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:href="halo-20160930.xsd#StockholdersDeficitEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:href="halo-20160930.xsd#StockholdersDeficitEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_2AC8BC05E3A22568C2DB482D78998E89" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_halo_RocheMember_2AC8BC05E3A22568C2DB482D78998E89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_InlicensetechnologiesMember" xlink:label="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ResearchEquipmentMember" xlink:label="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_OthercollaboratorsMember" xlink:label="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_D2FE34E4CCE922EA98C7482D78B8E26F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_RocheMember_D2FE34E4CCE922EA98C7482D78B8E26F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_909ED58330293E96542C482D78B898E4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_BaxaltaMember_909ED58330293E96542C482D78B898E4" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_LillyMember" xlink:label="loc_halo_LillyMember_D3574CCE30F209EFE9DE482D78B866C3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_LillyMember_D3574CCE30F209EFE9DE482D78B866C3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AbbVieMember" xlink:label="loc_halo_AbbVieMember_956083292AA9BAADFB3D482D78B8472D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_AbbVieMember_956083292AA9BAADFB3D482D78B8472D" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_JanssenMember" xlink:label="loc_halo_JanssenMember_39C9CBB8CB37CE4499A0482D78B8E104" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_JanssenMember_39C9CBB8CB37CE4499A0482D78B8E104" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerMember" xlink:label="loc_halo_PfizerMember_29F5BAA67BC29B7CC22B482D78B86125" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_PfizerMember_29F5BAA67BC29B7CC22B482D78B86125" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_OthercollaboratorsMember" xlink:label="loc_halo_OthercollaboratorsMember_01067060469E349996F1482D78B8E007" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_OthercollaboratorsMember_01067060469E349996F1482D78B8E007" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Amountreceivedforsalesbasedpayment" xlink:label="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_48CB9E5A8C32AE8775FE0BE73C7C028C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_BaxaltaMember_48CB9E5A8C32AE8775FE0BE73C7C028C" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_LillyMember" xlink:label="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AbbVieMember" xlink:label="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_JanssenMember" xlink:label="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerMember" xlink:label="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerJanssenandAbbVieMember" xlink:label="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_472CE539257C5091FFC60BE73C7CD8B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:to="loc_halo_RocheMember_472CE539257C5091FFC60BE73C7CD8B8" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_187E5796A2F2E1BCAE340BE73C7C49D3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:to="loc_halo_BaxaltaMember_187E5796A2F2E1BCAE340BE73C7C49D3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTermsAbstract" xlink:label="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberofProductCompoundCombinationsLicensedtoDevelop" xlink:label="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberOfTargetsElected" xlink:label="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberOfAdditionalTargetOptional" xlink:label="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalsemiexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PeriodForTermination" xlink:label="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones" xlink:label="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets" xlink:label="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:to="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:to="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:to="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:to="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RoyaltybackedLoanMember" xlink:label="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:to="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:to="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:to="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:to="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2016Member" xlink:label="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2017Member" xlink:label="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2018andthereafterMember" xlink:label="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2017QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2018QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2019QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2020QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Royaltypaymentstobeappliedtodebtinstrument" xlink:label="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DebtInstrumentPrepaymentFeePercent" xlink:label="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentoforiginalprincipal" xlink:label="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentofadditionaldraw" xlink:label="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="locator" />
    <definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_62E1BD70AB6A59E1EF86482D78B8B343" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_62E1BD70AB6A59E1EF86482D78B8B343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_EA45B0B0A5A176F124B4482D78B882A9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_EA45B0B0A5A176F124B4482D78B882A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_4BC094F2024660B4F0F4482D78B82177" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_CommercialPaperMember_4BC094F2024660B4F0F4482D78B82177" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RSURSAandPRSUawardsMember" xlink:label="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:to="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:to="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2E5C8F424BBE3B6B9210D480D77371BC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2E5C8F424BBE3B6B9210D480D77371BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:to="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:to="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:to="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:to="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:to="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:to="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_HylenexRecombinantMember" xlink:label="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:to="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BulkrHuPH20Member" xlink:label="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:to="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:to="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:to="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:to="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:to="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NetincomelosspershareTextualsAbstract" xlink:label="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:to="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:to="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:to="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:to="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:to="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PeriodForTermination" xlink:label="loc_halo_PeriodForTermination_1BEF567E991E675C01A6482D7909E3E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="loc_halo_PeriodForTermination_1BEF567E991E675C01A6482D7909E3E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Periodtoacceptreturnedunusedproduct" xlink:label="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:to="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>halo-20160930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:to="lab_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:to="lab_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="arc" />
    <link:label id="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4_terseLabel_en-US" xlink:label="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4_label_en-US" xlink:label="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4_documentation_en-US" xlink:label="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:to="lab_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="arc" />
    <link:label id="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973_terseLabel_en-US" xlink:label="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:label id="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973_label_en-US" xlink:label="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:label id="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973_documentation_en-US" xlink:label="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:to="lab_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="arc" />
    <link:label id="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6_terseLabel_en-US" xlink:label="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6_label_en-US" xlink:label="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6_documentation_en-US" xlink:label="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_OthercollaboratorsMember" xlink:label="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:to="lab_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="arc" />
    <link:label id="lab_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements Disclosure [Abstract]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements Disclosure [Abstract]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsDisclosureAbstract" xlink:label="loc_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:to="lab_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:to="lab_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="arc" />
    <link:label id="lab_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF_verboseLabel_en-US" xlink:label="lab_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:to="lab_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="arc" />
    <link:label id="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16_terseLabel_en-US" xlink:label="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lilly [Member]</link:label>
    <link:label id="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16_label_en-US" xlink:label="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lilly [Member]</link:label>
    <link:label id="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16_documentation_en-US" xlink:label="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lilly [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_LillyMember" xlink:label="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:to="lab_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="arc" />
    <link:label id="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E_terseLabel_en-US" xlink:label="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E_label_en-US" xlink:label="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E_documentation_en-US" xlink:label="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AbbVieMember" xlink:label="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:to="lab_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="arc" />
    <link:label id="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52_terseLabel_en-US" xlink:label="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52_label_en-US" xlink:label="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52_documentation_en-US" xlink:label="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Collaboration [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_JanssenMember" xlink:label="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:to="lab_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="arc" />
    <link:label id="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587_terseLabel_en-US" xlink:label="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587_label_en-US" xlink:label="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587_documentation_en-US" xlink:label="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_PfizerMember" xlink:label="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:to="lab_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="arc" />
    <link:label id="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137_terseLabel_en-US" xlink:label="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer, Janssen and AbbVie</link:label>
    <link:label id="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137_label_en-US" xlink:label="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer, Janssen and AbbVie [Member]</link:label>
    <link:label id="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137_documentation_en-US" xlink:label="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer, Janssen and AbbVie [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_PfizerJanssenandAbbVieMember" xlink:label="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:to="lab_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:type="arc" />
    <link:label id="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements Terms</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements Terms [Abstract]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements Terms [Abstract]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTermsAbstract" xlink:label="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="lab_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="arc" />
    <link:label id="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605_terseLabel_en-US" xlink:label="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product compound combinations licensed to develop</link:label>
    <link:label id="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605_label_en-US" xlink:label="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Product Compound Combinations Licensed to Develop</link:label>
    <link:label id="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605_documentation_en-US" xlink:label="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Product Compound Combinations Licensed to Develop</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_NumberofProductCompoundCombinationsLicensedtoDevelop" xlink:label="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:to="lab_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="arc" />
    <link:label id="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD_terseLabel_en-US" xlink:label="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of targets elected</link:label>
    <link:label id="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD_label_en-US" xlink:label="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Targets Elected</link:label>
    <link:label id="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD_documentation_en-US" xlink:label="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Targets Elected</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_NumberOfTargetsElected" xlink:label="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:to="lab_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="arc" />
    <link:label id="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E_terseLabel_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional exclusive targets</link:label>
    <link:label id="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E_label_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional exclusive targets</link:label>
    <link:label id="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E_documentation_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional exclusive targets</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:to="lab_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="arc" />
    <link:label id="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819_terseLabel_en-US" xlink:label="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional targets, optional</link:label>
    <link:label id="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819_label_en-US" xlink:label="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Additional Target, Optional</link:label>
    <link:label id="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819_documentation_en-US" xlink:label="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Additional Target, Optional</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_NumberOfAdditionalTargetOptional" xlink:label="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:to="lab_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="arc" />
    <link:label id="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021_terseLabel_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional semi-exclusive targets</link:label>
    <link:label id="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021_label_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional semi-exclusive targets</link:label>
    <link:label id="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021_documentation_en-US" xlink:label="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of targets elected, additional semi-exclusive targets</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalsemiexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:to="lab_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="arc" />
    <link:label id="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E_terseLabel_en-US" xlink:label="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of royalty receivable</link:label>
    <link:label id="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E_label_en-US" xlink:label="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Duration of Royalty Receivable</link:label>
    <link:label id="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E_documentation_en-US" xlink:label="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duration of royalty receivable.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:to="lab_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="arc" />
    <link:label id="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3_terseLabel_en-US" xlink:label="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notification period for termination</link:label>
    <link:label id="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3_label_en-US" xlink:label="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period for Termination</link:label>
    <link:label id="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3_documentation_en-US" xlink:label="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for termination.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_PeriodForTermination" xlink:label="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:to="lab_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="arc" />
    <link:label id="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements (Textual)</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements (Textual) [Abstract]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreements.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="lab_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, revenue recognized</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Event-based or Milestone, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="arc" />
    <link:label id="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F_terseLabel_en-US" xlink:label="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional maximum proceeds receivable from collaborators of license and collaborative agreement upon achievement of clinical development milestones for elected targets</link:label>
    <link:label id="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F_label_en-US" xlink:label="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones</link:label>
    <link:label id="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F_documentation_en-US" xlink:label="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones" xlink:label="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:to="lab_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="arc" />
    <link:label id="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7_terseLabel_en-US" xlink:label="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-based payment to be received upon the first commercial sale</link:label>
    <link:label id="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7_label_en-US" xlink:label="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets</link:label>
    <link:label id="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7_documentation_en-US" xlink:label="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets" xlink:label="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:to="lab_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="arc" />
    <link:label id="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B_terseLabel_en-US" xlink:label="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue (Textual) [Abstract]</link:label>
    <link:label id="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B_label_en-US" xlink:label="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue (Textual) [Abstract]</link:label>
    <link:label id="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B_documentation_en-US" xlink:label="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:to="lab_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue relating to upfront payment license fees and annual maintenance fees</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:to="lab_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6_label_en-US" xlink:label="lab_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:to="lab_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:type="arc" />
    <link:label id="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424_terseLabel_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued outsourced research and development</link:label>
    <link:label id="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424_label_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outsourced Research and Development Expenses Current</link:label>
    <link:label id="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424_documentation_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued outsourced research and development expenses current.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:to="lab_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and payroll taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:type="arc" />
    <link:label id="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33_terseLabel_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued outsourced manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33_label_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33_documentation_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Accruedmanufacturingexpenses" xlink:label="loc_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:to="lab_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:type="arc" />
    <link:label id="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF_terseLabel_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term accrued outsourced research and development</link:label>
    <link:label id="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF_label_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outsourced Research and Development Expenses Long-Term</link:label>
    <link:label id="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF_documentation_en-US" xlink:label="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Outsourced Research and Development Expenses Long-Term</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm" xlink:label="loc_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:to="lab_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="lab_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:to="lab_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:to="lab_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues under collaborative agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE_label_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Services Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:to="lab_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE_label_en-US" xlink:label="lab_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:to="lab_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:to="lab_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:to="lab_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:to="lab_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632_label_en-US" xlink:label="lab_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:to="lab_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:to="lab_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:to="lab_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing basic and diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:to="lab_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:to="lab_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:to="lab_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, assets, Level 1 to Level 2 transfers, amount</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Level 3</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0_label_en-US" xlink:label="lab_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:to="lab_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712_label_en-US" xlink:label="lab_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:to="lab_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:type="arc" />
    <link:label id="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4_terseLabel_en-US" xlink:label="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share (Textuals) [Abstract]</link:label>
    <link:label id="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4_label_en-US" xlink:label="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income (loss) per share (Textuals) [Abstract]</link:label>
    <link:label id="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4_documentation_en-US" xlink:label="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net income (loss) per share (Textuals) [Abstract]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_NetincomelosspershareTextualsAbstract" xlink:label="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:to="lab_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares excluded from calculation of diluted net loss, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="arc" />
    <link:label id="lab_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E_label_en-US" xlink:label="lab_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E_documentation_en-US" xlink:label="lab_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_DocumentAndEntityInformationAbstract" xlink:label="loc_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:to="lab_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E_label_en-US" xlink:label="lab_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:to="lab_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:to="lab_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="arc" />
    <link:label id="lab_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2_label_en-US" xlink:label="lab_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:to="lab_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="lab_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA_label_en-US" xlink:label="lab_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:to="lab_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247_label_en-US" xlink:label="lab_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:to="lab_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:to="lab_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A_terseLabel_en-US" xlink:label="lab_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A_label_en-US" xlink:label="lab_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:to="lab_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:to="lab_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D_label_en-US" xlink:label="lab_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:to="lab_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:to="lab_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:to="lab_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:to="lab_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8_label_en-US" xlink:label="lab_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:to="lab_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="arc" />
    <link:label id="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432_terseLabel_en-US" xlink:label="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432_label_en-US" xlink:label="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432_documentation_en-US" xlink:label="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research equipment.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_ResearchEquipmentMember" xlink:label="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:to="lab_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="lab_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:to="lab_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="lab_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="arc" />
    <link:label id="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA_terseLabel_en-US" xlink:label="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty-backed Loan</link:label>
    <link:label id="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA_label_en-US" xlink:label="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty-backed Loan [Member]</link:label>
    <link:label id="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA_documentation_en-US" xlink:label="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty-backed Loan [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_RoyaltybackedLoanMember" xlink:label="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:to="lab_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:to="lab_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:to="lab_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D_label_en-US" xlink:label="lab_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:to="lab_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191_label_en-US" xlink:label="lab_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:to="lab_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B_label_en-US" xlink:label="lab_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:to="lab_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4_label_en-US" xlink:label="lab_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:to="lab_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:to="lab_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="arc" />
    <link:label id="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A_terseLabel_en-US" xlink:label="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 [Member]</link:label>
    <link:label id="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A_label_en-US" xlink:label="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 [Member]</link:label>
    <link:label id="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A_documentation_en-US" xlink:label="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2016Member" xlink:label="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:to="lab_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="arc" />
    <link:label id="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2_terseLabel_en-US" xlink:label="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 [Member]</link:label>
    <link:label id="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2_label_en-US" xlink:label="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 [Member]</link:label>
    <link:label id="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2_documentation_en-US" xlink:label="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2017Member" xlink:label="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:to="lab_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="arc" />
    <link:label id="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F_terseLabel_en-US" xlink:label="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 and thereafter [Member]</link:label>
    <link:label id="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F_label_en-US" xlink:label="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 and thereafter [Member]</link:label>
    <link:label id="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F_documentation_en-US" xlink:label="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 and thereafter [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2018andthereafterMember" xlink:label="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:to="lab_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="arc" />
    <link:label id="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0_terseLabel_en-US" xlink:label="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0_label_en-US" xlink:label="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0_documentation_en-US" xlink:label="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Quarterly Maximum Payment [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2017QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:to="lab_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="arc" />
    <link:label id="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017_terseLabel_en-US" xlink:label="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017_label_en-US" xlink:label="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017_documentation_en-US" xlink:label="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Quarterly Maximum Payment [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2018QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:to="lab_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="arc" />
    <link:label id="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6_terseLabel_en-US" xlink:label="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6_label_en-US" xlink:label="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6_documentation_en-US" xlink:label="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Quarterly Maximum Payment [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2019QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:to="lab_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="arc" />
    <link:label id="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E_terseLabel_en-US" xlink:label="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E_label_en-US" xlink:label="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Quarterly Maximum Payment [Member]</link:label>
    <link:label id="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E_documentation_en-US" xlink:label="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Quarterly Maximum Payment [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_A2020QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:to="lab_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="lab_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Issuance Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:to="lab_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total loan balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="arc" />
    <link:label id="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C_terseLabel_en-US" xlink:label="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments to be applied to debt instrument</link:label>
    <link:label id="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C_label_en-US" xlink:label="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty payments to be applied to debt instrument</link:label>
    <link:label id="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C_documentation_en-US" xlink:label="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty payments to be applied to debt instrument</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Royaltypaymentstobeappliedtodebtinstrument" xlink:label="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:to="lab_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="arc" />
    <link:label id="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee, percent</link:label>
    <link:label id="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C_label_en-US" xlink:label="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percent</link:label>
    <link:label id="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C_documentation_en-US" xlink:label="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee,Percent</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_DebtInstrumentPrepaymentFeePercent" xlink:label="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:to="lab_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant in compliance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:to="lab_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:to="lab_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:to="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:to="lab_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding loan balance</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E_label_en-US" xlink:label="lab_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:to="lab_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, increase</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, interest only period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="arc" />
    <link:label id="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94_terseLabel_en-US" xlink:label="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment as percent of original principal</link:label>
    <link:label id="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94_label_en-US" xlink:label="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final payment as percent of original principal</link:label>
    <link:label id="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94_documentation_en-US" xlink:label="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final payment as percent of original principal</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentoforiginalprincipal" xlink:label="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:to="lab_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="arc" />
    <link:label id="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C_terseLabel_en-US" xlink:label="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment as percent of additional draw</link:label>
    <link:label id="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C_label_en-US" xlink:label="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final payment as percent of additional draw</link:label>
    <link:label id="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C_documentation_en-US" xlink:label="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final payment as percent of additional draw</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentofadditionaldraw" xlink:label="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:to="lab_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:to="lab_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:to="lab_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:to="lab_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:to="lab_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:to="lab_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:to="lab_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:to="lab_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' (deficit) equity (textual)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="lab_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock issued as a result of stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares, restricted stock award, net of forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs surrendered to pay for minimum withholding taxes</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for tax withholding for restricted stock units vested, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:to="lab_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaborative agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:to="lab_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="arc" />
    <link:label id="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2_terseLabel_en-US" xlink:label="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fees and event-based payments</link:label>
    <link:label id="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2_label_en-US" xlink:label="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-license technologies [Member]</link:label>
    <link:label id="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2_documentation_en-US" xlink:label="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-license technologies [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_InlicensetechnologiesMember" xlink:label="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:to="lab_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:to="lab_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:to="lab_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:to="lab_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:type="arc" />
    <link:label id="lab_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements [Abstract]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements [Abstract]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsAbstract" xlink:label="loc_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:to="lab_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:type="arc" />
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E_terseLabel_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</link:label>
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E_label_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement</link:label>
    <link:label id="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E_documentation_en-US" xlink:label="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonrefundable upfront license fee payment received under collaborative agreement.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:to="lab_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="arc" />
    <link:label id="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69_terseLabel_en-US" xlink:label="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Exclusive Targets And Annual License Maintenance Fees</link:label>
    <link:label id="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69_label_en-US" xlink:label="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Received For Additional Exclusive Targets And Annual License Maintenance Fees Under Collaborative Agreement</link:label>
    <link:label id="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69_documentation_en-US" xlink:label="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount received from Roche for additional exclusive targets and annual license maintenance fees.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:to="lab_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="arc" />
    <link:label id="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B_terseLabel_en-US" xlink:label="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical development milestone payments</link:label>
    <link:label id="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B_label_en-US" xlink:label="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Development Milestone Payments Received Under Collaborative Agreement</link:label>
    <link:label id="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B_documentation_en-US" xlink:label="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical development milestone payments received under collaborative agreement.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:to="lab_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="arc" />
    <link:label id="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782_terseLabel_en-US" xlink:label="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments</link:label>
    <link:label id="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782_label_en-US" xlink:label="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments Received Under Collaborative Agreement</link:label>
    <link:label id="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782_documentation_en-US" xlink:label="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments received under collaborative agreement.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:to="lab_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="arc" />
    <link:label id="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52_terseLabel_en-US" xlink:label="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:label id="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52_label_en-US" xlink:label="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount received for sales-based payment</link:label>
    <link:label id="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52_documentation_en-US" xlink:label="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount received for sales-based payment</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Amountreceivedforsalesbasedpayment" xlink:label="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:to="lab_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="arc" />
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A_terseLabel_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Proceeds from Partner of License and Collaborative Agreement</link:label>
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A_label_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Partner of License and Collaborative Agreement</link:label>
    <link:label id="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A_documentation_en-US" xlink:label="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from partner of license and collaborative agreement.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:to="lab_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:to="lab_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:to="lab_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:to="lab_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment-in-kind Interest expense on long-term debt</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:to="lab_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:to="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:to="lab_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="arc" />
    <link:label id="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47_terseLabel_en-US" xlink:label="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hylenex recombinant</link:label>
    <link:label id="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47_label_en-US" xlink:label="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hylenex Recombinant [Member]</link:label>
    <link:label id="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47_documentation_en-US" xlink:label="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hylenex Recombinant [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_HylenexRecombinantMember" xlink:label="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:to="lab_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="arc" />
    <link:label id="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755_verboseLabel_en-US" xlink:label="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">bulk rHuPH20</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755_label_en-US" xlink:label="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bulk rHuPH20 [Member]</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755_documentation_en-US" xlink:label="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">bulk rHuPH20 for use in collaboration products</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_BulkrHuPH20Member" xlink:label="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:to="lab_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:to="lab_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:to="lab_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="arc" />
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823_terseLabel_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823_label_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823_documentation_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_RSURSAandPRSUawardsMember" xlink:label="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:to="lab_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds and Excess Tax Benefit from Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB_label_en-US" xlink:label="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds and Excess Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:to="lab_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:type="arc" />
    <link:label id="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC_terseLabel_en-US" xlink:label="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC_label_en-US" xlink:label="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC_documentation_en-US" xlink:label="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Prepaidresearchanddevelopment" xlink:label="loc_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:to="lab_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699_label_en-US" xlink:label="lab_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:to="lab_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expense and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:to="lab_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:to="lab_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="lab_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:to="lab_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing costs</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:to="lab_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003_label_en-US" xlink:label="lab_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:to="lab_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:to="lab_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:to="lab_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:to="lab_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:to="lab_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:to="lab_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:to="lab_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' (deficit) equity:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="lab_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:to="lab_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock - $0.001 par value; 200,000 shares authorized; 129,488 and 128,152 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:to="lab_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:to="lab_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:type="arc" />
    <link:label id="lab_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36_label_en-US" xlink:label="lab_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions for Fair Value of Stock Options [Abstract]</link:label>
    <link:label id="lab_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36_documentation_en-US" xlink:label="lab_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions for Fair Value of Stock Options [Abstract]</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract" xlink:label="loc_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:to="lab_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities maturities, next twelve months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of available-for-sale securities in unrealized loss position, less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Marketable Securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:to="lab_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period prior to expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:to="lab_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period after expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:to="lab_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:to="lab_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:to="lab_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreements termination notification</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:to="lab_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="arc" />
    <link:label id="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3_terseLabel_en-US" xlink:label="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to accept returned unused product</link:label>
    <link:label id="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3_label_en-US" xlink:label="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period to accept returned unused product</link:label>
    <link:label id="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3_documentation_en-US" xlink:label="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period to accept returned unused product</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Periodtoacceptreturnedunusedproduct" xlink:label="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:to="lab_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:to="lab_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSAs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:to="lab_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="lab_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:type="arc" />
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromproductsalestocollaborators" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:to="lab_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:type="arc" />
    <link:label id="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from other product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromproductsales" xlink:label="loc_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:to="lab_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:type="arc" />
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C_label_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable from collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromcollaborators" xlink:label="loc_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:to="lab_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, gross</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Gross, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:type="arc" />
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80_negatedTerseLabel_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance for distribution fees and discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80_label_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Distribution Fees and Discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80_documentation_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance for Discount and Distribution Fees</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_AllowanceforDistributionFeesandDiscounts" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:to="lab_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adoption and Pending Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:to="lab_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:type="arc" />
    <link:label id="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08_verboseLabel_en-US" xlink:label="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Expenses</link:label>
    <link:label id="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08_label_en-US" xlink:label="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Accounting Policy for Clinical Trial Expenses [Policy Text Block]</link:label>
    <link:label id="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08_documentation_en-US" xlink:label="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for clinical trial expenses.</link:label>
    <link:loc xlink:href="halo-20160930.xsd#halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" xlink:label="loc_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:to="lab_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>halo-20160930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:href="halo-20160930.xsd#CertainBalanceSheetItemsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:href="halo-20160930.xsd#CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:href="halo-20160930.xsd#CollaborativeAgreementsNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:href="halo-20160930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="halo-20160930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:href="halo-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:href="halo-20160930.xsd#LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:href="halo-20160930.xsd#LongTermDebtNetNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:href="halo-20160930.xsd#MarketableSecuritiesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:href="halo-20160930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:href="halo-20160930.xsd#MarketableSecuritiesTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:href="halo-20160930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:href="halo-20160930.xsd#ShareBasedCompensationNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:href="halo-20160930.xsd#ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:href="halo-20160930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:href="halo-20160930.xsd#StockholdersDeficitEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:href="halo-20160930.xsd#StockholdersDeficitEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="halo-20160930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:type="locator" />
    <loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromproductsalestocollaborators" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_A1B21CC09E650D960A1A482D790BCC69" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromproductsales" xlink:label="loc_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_halo_Accountsreceivablefromproductsales_0F5DD767671543144789482D790C62D7" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Accountsreceivablefromcollaborators" xlink:label="loc_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_halo_Accountsreceivablefromcollaborators_D5B3CA34ED8D6FD9B62B482D790CAB6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_7F9E0B0D8B67C8EA1250482D790CF058" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AllowanceforDistributionFeesandDiscounts" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_FF258FCAE312409587ED482D790CBE80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_E16577F2CF4B4B92DAF5482D790BFC9C" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ED4D1B399524801AB7BB482D790C4E06" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_17EC4C6BA9F080200608482D78D863FB" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent_6DC77C3CB04DBD4010FB482D78D82424" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E6671DF10FAF7A59DC5482D78D820E5" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Accruedmanufacturingexpenses" xlink:label="loc_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_halo_Accruedmanufacturingexpenses_6CA3CFAE5F21B1D05E81482D78D85E33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1DE78A7974FD38E8CCA2482D78D86420" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7544A1D1557179CB2F92482D78D8973F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm" xlink:label="loc_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm_F8BC1B16149AC2FCC005482D78D8CDBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_85091724CD995844A57C482D78D875FF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4F74108901D6F0B67587482D78D8D0DB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_E02291297B0BBB9210A9482D789946AE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_E02291297B0BBB9210A9482D789946AE" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_13724F36C54548E1CBCB482D7899E081" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_2AC8BC05E3A22568C2DB482D78998E89" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_halo_RocheMember_2AC8BC05E3A22568C2DB482D78998E89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6B5FA0D8BCB562DEBC5E482D78998657" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_InlicensetechnologiesMember" xlink:label="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_halo_InlicensetechnologiesMember_39EC8F0582F1DD0787DC482D7899B5C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53F6898F53EE2613910B482D789934AE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_12A9712917A65727DC98482D78999596" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A6C46DD993BCB03D87EF482D7899E851" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenue_EDA2FD72E0188E1F634B482D789993CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenueCurrent_FEEC423C55C3DAF513E7482D7899CCC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_41C81BD830DCDBCA3727482D789986EE" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_70FDE5EE959884010658482D78999A6D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A5D83F620B79FB58CF7B0C6007624497" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_116BD28ECD24D18D4E5C0C600762B2FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10030DE880D5D7999A310C600762B32F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_100896BA2D586514A1920C600761E68D" xlink:to="loc_us-gaap_InventoryNet_B99173EC3F4A3A915E5A0C600762D2F6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D1A9C7B4D10E2C90FA59482D7878719A" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C513BE67B37C43BCD60C482D7878DC29" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:type="locator" />
    <loc xlink:href="halo-20160930.xsd#halo_Prepaidresearchanddevelopment" xlink:label="loc_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_halo_Prepaidresearchanddevelopment_480B6CFF7A1D5BD7C96B482D7889C3AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_B323D7B6EC5BF7FB6619482D78897EC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_us-gaap_OtherAssets_5B4C32DFE02CBC8EEA4F482D7889C699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1114456476B5F0F23345482D7889A322" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3D67CFA1C08D143B84F6482D78893F20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_E8E9927CC4959383CBA7482D7889AEFC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9B4FCE613C58C2793007482D78898399" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B4E36BE510B08A23C4482D7878B025" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52090E704EC284623CEF482D787831C3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ResearchEquipmentMember" xlink:label="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_halo_ResearchEquipmentMember_73F44BC5F7929655EAFA482D78782432" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_906E36B2CE6D6A378A51482D7878996B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_A74977280472CB5B16C9482D787826E3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_608317D20B654AD63712482D7878FD98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2756406A63D6230E3326482D78781BD5" xlink:to="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_FB11D11122C55C84DD85482D78780209" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_035DD0F9F4A99DD361A7482D7878B6EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A5EE865AC3B16A0D9E06482D78785768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3E215E0B35E1FE45AEE3482D7878232F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_50E485D3E15050F8705C482D78C8D3DD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_50E485D3E15050F8705C482D78C8D3DD" xlink:to="loc_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract_FADA1DB11C20214ED80B482D78C80D09" xlink:to="loc_us-gaap_DepreciationAndAmortization_D7B6A9607A87B57188ED482D78C8EBF4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0A78D108481AD121CAD0482D78EA8A14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_EE99321283052E4BC692482D78EABEF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_1D5237D5455D7379CA73482D78EAF59E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A77C2AFB5FB9A63DD0C2482D78EA6979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_32CB1E52699EF0B75BDC482D78EA5389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_B1044FAAD12CD112920C482D78EA01A5" xlink:to="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7D9368283E26B07182A0482D78EACFB8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_7ADB3D8A261FA97540FD482D78A917D2" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40C766674FE715F3A9E5482D78A9E33B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_RocheMember_A729AC545BB33FB310C6482D78A914D4" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_BaxaltaMember_AAF6456F4C7E390C959B482D78A97973" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_OthercollaboratorsMember" xlink:label="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A455116E7FA2EC07FC0A482D78A91F0D" xlink:to="loc_halo_OthercollaboratorsMember_233BFFD10B4DF371A73C482D78A9BEC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_4839C0CC733FE4F33E29482D78A98EBE" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_2A4F990BF9740E4A43F9482D78A9BDB9" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock_5BB3DA0D517496FC9E51482D78A90360" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails" xlink:type="extended">
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsAbstract" xlink:label="loc_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsAbstract_0D05E8D967516FC6AD3A482D78B8E4F4" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CBB06864D85FA8353F55482D78B81459" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_D2FE34E4CCE922EA98C7482D78B8E26F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_RocheMember_D2FE34E4CCE922EA98C7482D78B8E26F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_909ED58330293E96542C482D78B898E4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_BaxaltaMember_909ED58330293E96542C482D78B898E4" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_LillyMember" xlink:label="loc_halo_LillyMember_D3574CCE30F209EFE9DE482D78B866C3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_LillyMember_D3574CCE30F209EFE9DE482D78B866C3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AbbVieMember" xlink:label="loc_halo_AbbVieMember_956083292AA9BAADFB3D482D78B8472D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_AbbVieMember_956083292AA9BAADFB3D482D78B8472D" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_JanssenMember" xlink:label="loc_halo_JanssenMember_39C9CBB8CB37CE4499A0482D78B8E104" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_JanssenMember_39C9CBB8CB37CE4499A0482D78B8E104" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerMember" xlink:label="loc_halo_PfizerMember_29F5BAA67BC29B7CC22B482D78B86125" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_PfizerMember_29F5BAA67BC29B7CC22B482D78B86125" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_OthercollaboratorsMember" xlink:label="loc_halo_OthercollaboratorsMember_01067060469E349996F1482D78B8E007" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FE8E20A3D8B488BC54B9482D78B8F8C9" xlink:to="loc_halo_OthercollaboratorsMember_01067060469E349996F1482D78B8E007" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3534559729A022E48FDF482D78B815C4" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement_BBACD871F8BC349845D8482D78B8DF9E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement" xlink:label="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement_89121744FE50CB7875D0482D78B8EB69" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement_73E1E506D766EEF31F2E482D78B82F6B" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement" xlink:label="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement_5FD1F8819B8414638116482D78B8A782" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Amountreceivedforsalesbasedpayment" xlink:label="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_Amountreceivedforsalesbasedpayment_31873BFD227E6469D614482D78B88F52" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement" xlink:label="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_B4684E2C83535B38E276482D78B87501" xlink:to="loc_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement_206F956B8273E48E9A38482D78B86C3A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails" xlink:type="extended">
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsDisclosureAbstract" xlink:label="loc_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsDisclosureAbstract_B0E1EEA8DEBC10FC53100BE73C7C9D41" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E95F6A902FD6FBF2FDE30BE73C7C8FC9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RocheMember" xlink:label="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BaxaltaMember" xlink:label="loc_halo_BaxaltaMember_48CB9E5A8C32AE8775FE0BE73C7C028C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_BaxaltaMember_48CB9E5A8C32AE8775FE0BE73C7C028C" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_LillyMember" xlink:label="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_LillyMember_E1B01EDCBA913C73A6C20BE73C7C4C16" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AbbVieMember" xlink:label="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_AbbVieMember_0830A7746B478E186D220BE73C7C646E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_JanssenMember" xlink:label="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_JanssenMember_1BEDA559ADE48E283D110BE73C7C4E52" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerMember" xlink:label="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_PfizerMember_3A5E8DD18026E6538BB30BE73C7CA587" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PfizerJanssenandAbbVieMember" xlink:label="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6B5672DFB077809AC61F0BE73C7C05F0" xlink:to="loc_halo_PfizerJanssenandAbbVieMember_6BAC8B1FA4E19751C66A0BE73C7CD137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_CF388A92BD6EE41E37140BE73C7CC2CA" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:type="arc" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:to="loc_halo_RocheMember_20846C1AAD69CBD7F0F60BE73C7C11DF" xlink:type="arc" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_97BA9D3D33A2467AEA480BE73C7C43F2" xlink:to="loc_halo_BaxaltaMember_48CB9E5A8C32AE8775FE0BE73C7C028C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_5E61B70E24CC242714CA0BE73C7C5A09" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTermsAbstract" xlink:label="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberofProductCompoundCombinationsLicensedtoDevelop" xlink:label="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberofProductCompoundCombinationsLicensedtoDevelop_129DBFCDBF8CC1B407560BE73C7C1605" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberOfTargetsElected" xlink:label="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberOfTargetsElected_116E89CF8901350D79250BE73C7CCCDD" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_Numberoftargetselectedadditionalexclusivetargets_410ED31CF491D09F7A150BE73C7C9F2E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NumberOfAdditionalTargetOptional" xlink:label="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_NumberOfAdditionalTargetOptional_81A7C92A610681B5AD840BE73C7CE819" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Numberoftargetselectedadditionalsemiexclusivetargets" xlink:label="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_Numberoftargetselectedadditionalsemiexclusivetargets_7613CF8CFCF3E72284790BE73C7CB021" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DurationOfRoyaltyReceivable" xlink:label="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_DurationOfRoyaltyReceivable_C931B5F623DAD3EA01B70BE73C7CE14E" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PeriodForTermination" xlink:label="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTermsAbstract_9A1A052FE83BFF21C8E20BE73C7C9F41" xlink:to="loc_halo_PeriodForTermination_78863FA43B51773A942B0BE73C7CE5C3" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_CollaborativeAgreementsTextualAbstract" xlink:label="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_569EF3A6432EC4AF7B7E0BE73C7CDFB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_A39DF1BD8E2D08C8625B0BE73C7CA58F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones" xlink:label="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones_4CE9208F726B01AFAEE30BE73C7C692F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets" xlink:label="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsTextualAbstract_2D75C3F1F1DE9A0A62DC0BE73C7CF953" xlink:to="loc_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets_89B98CCBDF47F689EC6C0BE73C7CC0F7" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DeferredRevenueTextualAbstract" xlink:label="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABAEBD9D60FEB54E4E3A0BE73C7CF683" xlink:to="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_DeferredRevenueTextualAbstract_2974549435415B2485190BE73C7C673B" xlink:to="loc_us-gaap_DeferredRevenue_41D400D48E4D338453AB0BE73C7CE5CC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CollaborativeAgreementsNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_81D5C69DA8B603F4624E482D7888C1FE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_81D5C69DA8B603F4624E482D7888C1FE" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_08DDC08D8CF5924584DB482D78899930" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ED72D853D8A290AE425482D78A90D0B" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_919EAE202E4E7DA04595482D78A99DCC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31641ECFD40105359B01482D78D8E466" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B58018222EEE2C01BE3E482D78D85A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BC63523BE5327E1234A5482D78D80F43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_364A39A3AE86AB58B2ED482D78D8B84D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9601E26D6C75536A4B48482D78D833BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C77F76B9F187E18301F8482D78D85CE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_CommonStockSharesIssued_D807A888B0B8EEAE76E3482D78D8FC05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_766D34E3AB1E1791A42F482D78D8B5F0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_D87A9F9E2352932834C5482D78D8303E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D92C40A9B19138E4325FD40DF84E774F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D92C40A9B19138E4325FD40DF84E774F" xlink:to="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FB88A2C14D105CE816D0D40DF84ED9E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B4FD8B634A5B1EDDE192D40DF84EAB44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_61DAE6887A5CCAAE2D86D40DF84E4066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_InventoryNet_05F1F97D2B1F03476BD9D40DF84ECC72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_97E18746094C0C6C7782D40DF84FEAD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CD54E77542A61B42405DD40DF84FC450" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0062FC037CC0FE444BB0D40DF84EA5B6" xlink:to="loc_us-gaap_AssetsCurrent_7881DEB1F80298E483A7D40DF84F71F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19521382B95C864C94F6D40DF84F7C50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_87E7C7B34855896BD382D40DF84FB29D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1B4F268402A2155B3050D40DF84F420D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1B4F268402A2155B3050D40DF84F420D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D8038060383443076C5DD40DF84E6BDB" xlink:to="loc_us-gaap_Assets_3CCCC9B401D455F27C52D40DF84F0003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D92C40A9B19138E4325FD40DF84E774F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="loc_us-gaap_AccountsPayableCurrent_00E9C32C7E945DBF2B36D40DF84F623F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C8D35810BA7B713172EFD40DF84F75FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="loc_us-gaap_DeferredRevenueCurrent_DEE5C15D70E838820EB0D40DF84FB5E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="loc_us-gaap_LongTermDebtCurrent_C74CA85A64CE94998874D40DF8505875" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D538118468D14F73084DD40DF84FD6AF" xlink:to="loc_us-gaap_LiabilitiesCurrent_8BD1A680553F5B7BB32ED40DF850B143" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_D7FCCCD48901D162C1F0D40DF85038D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_LongTermDebt_A716C37AF647135CD26CD40DF8509629" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_EDDF17639A87841E9F38D40DF850E63C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6D99BD64AE15FFE3C045D40DF8509FE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_PreferredStockValue_73ED75BAB3DB77AC9EEAD40DF850C437" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_CommonStockValue_55996078DD4D22767324D40DF850C27E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F94508276BC85054E4C9D40DF85079E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2A11CA98BE7CD2B1255ED40DF8502F53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F0029D9F1E32E3097B0BD40DF8508A62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E646136D58445580F293D40DF85013FB" xlink:to="loc_us-gaap_StockholdersEquity_098E565A357ABEAF56C3D40DF8500296" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7EBA5959AA24454218F9D40DF84F7AA9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_855C617B6B594B81BF56D40DF8512DA0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:to="loc_us-gaap_NetIncomeLoss_961F46E8EC1484E45B98482D78A9C3A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58B8BFD839BD74FF4931482D78A94928" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_ShareBasedCompensation_7B5D7937BDDA4E9FA734482D78A985EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_470825CDCAD51A1C98F4482D78A9A637" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_C5B08FAA30F3AA35C4CC482D78A9C079" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_PaidInKindInterest_5DEE62B630E6DB7B8C07482D78A9F0D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D301DE39CD36EAAFA6C0482D78A9F026" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_809884F4818BFEC3B5CD482D78A980AC" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8EF4360908CFD62A9BC6482D78A95AB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5AF6D919E7CB3E777257482D78A9F34B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_BF921384608C67F48FBA482D78A99A82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0D1B48A933C56BD2B1E5482D78A9EBDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_778B96C7483DAFFCC5E7482D78A96E83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_342665FFAB637FB6D732482D78A91933" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67EA077920296E042C40482D78A9193E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_E9484CDA449C59427590482D78A9E672" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_601783339BF72D1B4CF5482D78A99605" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_867D3E946E2063D62CC7482D78A95620" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3E6139309E87A3A80BE3482D78A9FC8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9B2D40458D82CA2C25FD482D78A91344" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_82F7E03383623E2D18BD482D78A98D5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_B8B09A3FC7C5D51F89E1482D78A92BDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_7116BA865AD1F4AA3434482D78A957F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_E55B88C0E7D79CA47F05482D78A95B59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_BE8E1331864FDA88BFD3482D78A9F732" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_C623BC89C7DCF256CA38482D78A92FAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_07ACC28C0C357AE05E2C482D78A9DC7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3EB575E0AF07637D68CE482D78A98C19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C246E27C0BF422A11F84482D78A9A414" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_855711BA11CCB2FE2426482D78A92F5B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:to="loc_us-gaap_NetIncomeLoss_618B73CF287CC7EE1B85D3589376135A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_919E568370FEA8766185D35893758143" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2C569FA3B716C5789E0CD35893763C26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_044F6A07E76CEFA40812D3589376F927" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_D7DB8053AB528F601388D3589376F38B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_FA5DC68BCC555CF1883AD348221D90CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:to="loc_us-gaap_RoyaltyRevenue_D764A3E743835B8F0982D348221DA124" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_858BB88D4DF260E9BFA6D348221DE6EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_237D4F1EB07D94A88571D348221DD69D" xlink:to="loc_us-gaap_Revenues_BC86436684809A25E23AD348221D8EFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:to="loc_us-gaap_CostOfGoodsSold_2768F14A82D6BD21B8E1D348221D1236" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_780C9E9F9A37744E43E3D348221DAF35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9507EE42B978EDCB25FDD348221D5FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_719F0ED3DFE85CD2401BD348221DB90A" xlink:to="loc_us-gaap_CostsAndExpenses_E5E0FA3DB9B6965BE2F8D348221DFA4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_OperatingIncomeLoss_7B7A9CAC5CF4370867D2D348221D0BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F74589B046C796DBF1DAD348221DFB06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_37EBEA636B59DF75DAD8D348221DFC3A" xlink:to="loc_us-gaap_InterestExpense_E1842B9E606FED8A4B46D348221DC632" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_123875675AA7CB95D1B8D348221D0009" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5265DF1F1CEFAA0C8025D348221D6F63" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5265DF1F1CEFAA0C8025D348221D6F63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_NetIncomeLoss_30AFCDEFA4F081022B1ED348221D1A61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_EarningsPerShareBasic_652030864900F3DA9307D348221D8F59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6BF7774E3D6D1B238536D348221D4A40" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6CD5AE7A360FC8F8A7F5D348221D9CE0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="halo-20160930.xsd#halo_DocumentAndEntityInformationAbstract" xlink:label="loc_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_DocumentAndEntityInformationAbstract_48A6C7B990A4FC74BDE0D3A7BBB5C67E" xlink:to="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:to="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_6853892BEF20DAD70C92D3A7BBB6B568" xlink:to="loc_dei_DocumentDomain_69E871BCF881F77A382BD3A7BBB698D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_80612078CD56CB94559ED3A7BBB5306E" xlink:to="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityRegistrantName_954599D61D23300C38B2D3A7BBB683AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_TradingSymbol_1030AB58705CF5C4672CD3A7BBB6E247" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityCentralIndexKey_5A8C3FAAE82362D93010D3A7BBB66FB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentType_12096BBCD57A6A9B93F6D3A7BBB62E9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentPeriodEndDate_8BEE6D4DC660355C504CD3A7BBB65F38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_AmendmentFlag_D309779D684FE08B589FD3A7BBB6385D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentFiscalYearFocus_2177AC6CC3E7B213CC77D3A7BBB67736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_DocumentFiscalPeriodFocus_E12DEC2786AF73A99FFAD3A7BBB66EBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_CurrentFiscalYearEndDate_88CF8D04564DC8267C67D3A7BBB777D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityFilerCategory_22E159F98785B79B92EFD3A7BBB7EFE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_2CC40C7843B92D43C424D3A7BBB62578" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C292C5A0D8C3C7CE5373D3A7BBB7DE42" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D80C325C959696519BD8D3AF67AA6686" xlink:to="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D9BD28D30892AA47FC0BD3AF67AA598A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RoyaltybackedLoanMember" xlink:label="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_halo_RoyaltybackedLoanMember_53490268A1BFFF83F604D3AF67AAFCDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_us-gaap_SecuredDebtMember_80E4EB4BB9C55838B486D3AF67AAB4F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLoansMember" xlink:label="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95016804494E9FA3C9CDD3AF67AAFCE1" xlink:to="loc_us-gaap_SeniorLoansMember_E7C664D4734C5F30B6C3D3AF67AAC29B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FA6AE73C63BD6911D455D3AF67AA628D" xlink:to="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:to="loc_us-gaap_MinimumMember_80830BA487A04AE5DF14D3AF67AAB26B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_CA662D3A67DE242A174ED3AF67AA7191" xlink:to="loc_us-gaap_MaximumMember_876E5C0BDBEDA842042AD3AF67AA1BE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1DAEEA3061BE3A86D224D3AF67AA607D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2016Member" xlink:label="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2016Member_5CA091E9979E418D0FD0D3AF67AA929A" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2017Member" xlink:label="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2017Member_989D3F750F12017E6C60D3AF67AAC0A2" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2018andthereafterMember" xlink:label="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2018andthereafterMember_5DC55242BF03D86168BAD3AF67AA186F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2017QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2017QuarterlyMaximumPaymentMember_A2374847F8974CBE67BCD3AF67AA22F0" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2018QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2018QuarterlyMaximumPaymentMember_DA117E5B30192CE24CCED3AF67AAE017" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2019QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2019QuarterlyMaximumPaymentMember_5B65223058EA6B713AA3D3AF67AA9BC6" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_A2020QuarterlyMaximumPaymentMember" xlink:label="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_963CD67CFEEE4324ADE5D3AF67AA8127" xlink:to="loc_halo_A2020QuarterlyMaximumPaymentMember_C33E3AFEAEE7F2D38F90D3AF67AAE28E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8C484F5EF97E3AC5372FD3AF67AAA249" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_604994461A73CA91B7FED3AF67AA9BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6D2B0759D90CEDF69ED4D3AF67AAE537" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F06A67071059941C808D3AF67AAF074" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_38E833297FBB89903FC5D3AF67AA0C74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8A74E7B394DDECC445ABD3AF67AAEC0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_2EE342BE29BFE33AF465D3AF67AA1C25" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Royaltypaymentstobeappliedtodebtinstrument" xlink:label="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Royaltypaymentstobeappliedtodebtinstrument_1629486F9DA95B5ECD0ED3AF67AA7C2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_EE9E507DC8F5FBFF0816D3AF67AAA377" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_73C23BA59649591BE04CD3AF67AA0E8B" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DebtInstrumentPrepaymentFeePercent" xlink:label="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_DebtInstrumentPrepaymentFeePercent_AC75F304566548EC5614D3AF67AAB60C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_588DAFB8767EB0BD0EB8D3AF67AA4243" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_InterestCostsCapitalized_B014F88236020C1614B7D3AF67AAFE6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_1966B56F7917473D7F49D3AF67AA674D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9BC0F5A60464AEEB96BAD3AF67AAD2B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_81718121DEFCB9845A4CD3AF6AE54267" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_InterestExpenseDebt_10267AE0B26F449C15EED3AF67AA2137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_SecuredDebt_A1FF198E97C4146436BBD3AF67AA2F2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_EE5D865C45F0E34F850AD3AF67AA1D42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_D00A48FF40DAB61B7599D3AF67AAA772" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_87F83FD81C6559799455D3AF67AAC9CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_D76132308C8B454C5173D3AF67AA4DCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_A2DF09EB54097F81F45FD3AF67AA0DE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription_0A66302F9BA813529E4ED3AF67AAC540" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_825A8CAA7C0D3606B240D3AF67AA7E97" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentoforiginalprincipal" xlink:label="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Finalpaymentaspercentoforiginalprincipal_49FAA215874F1D21421DD3AF67AAAE94" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Finalpaymentaspercentofadditionaldraw" xlink:label="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_halo_Finalpaymentaspercentofadditionaldraw_4EC1A8A809007BA64EAFD3AF67AAEB8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="locator" />
    <presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D3D10E1937A80A0B8CD5D3AF67AA6BFD" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2AD8F8747DC3B89D838ED3AF67AA1968" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_37E90B7F770894B130CA482D790DBD75" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_37E90B7F770894B130CA482D790DBD75" xlink:to="loc_us-gaap_LongTermDebtTextBlock_14FA995625422FC72B0F482D790D5812" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_AB8E5D492D7703A4A958482D78B8DEAA" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_0A498965383016D92511482D78B8397F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_62E1BD70AB6A59E1EF86482D78B8B343" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_62E1BD70AB6A59E1EF86482D78B8B343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_EA45B0B0A5A176F124B4482D78B882A9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_EA45B0B0A5A176F124B4482D78B882A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_4BC094F2024660B4F0F4482D78B82177" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_66933E36F0381AA1D82E482D78B820CD" xlink:to="loc_us-gaap_CommercialPaperMember_4BC094F2024660B4F0F4482D78B82177" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8D3EAED0A4B6F67FEE44482D78B82364" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_79FA03A7A478D6B77681482D78B87D57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_141A4BACC9DAF6888BF7482D78B8249B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_A91A6664B616E0288145482D78B8D2E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07DFF8446EF8099B7548482D78B897D2" xlink:to="loc_us-gaap_AvailableForSaleSecurities_388E16E63BD2323AE37C482D78B8EF4D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8CC4E78D21160974E1C3482D78D89ACD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8CC4E78D21160974E1C3482D78D89ACD" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_C7D030B6A93AE7428372482D78D8E1F0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_91D7636017D6C0561BB6482D78F0D723" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_91D7636017D6C0561BB6482D78F0D723" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B2A1C58C76673914FC1B482D78F093C0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_F339D0DFF0C475E19C91D35892DF486F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_5AFCEB8C500020173C8AD35892DF97F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_3560CB14A6D0731A5EC9D35892DFCAAD" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_93633775A20F1B09A896D35892DFF560" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/OrganizationAndBusiness" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86654FA4551C5C73E213482D79061587" xlink:to="loc_us-gaap_NatureOfOperations_C722AACB83D0B2F48D5E482D7906C5FF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_3037D1C558E46FF2B47C482D78B82F14" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_3037D1C558E46FF2B47C482D78B82F14" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07777BE8E844B8A78949482D78B8F717" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DCDED201E686D41870DE482D78B80151" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2E4C53D3FED7CA31ACD8482D78B841ED" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2460D227DAD27F5B13AB482D78B8E4BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_194D007E94C7EC6CD768482D78B8DCD7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_38B45D1982E80FAE619B482D78B8CE3F" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_RSURSAandPRSUawardsMember" xlink:label="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DC2BB8C95FBAA9D071AE482D78B8540F" xlink:to="loc_halo_RSURSAandPRSUawardsMember_4A15A46A93D643EB77DF482D78B84823" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B4EB5EBC4935986763C8482D78B88127" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64520D9925CAD9884DFE482D78B8050D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_95781232318020510BB0482D78B869D8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_BD04BB3AAA58F923063D482D790EC484" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4FB8A0F768CA3938F5D5482D790E462A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_A6BD3605D9521EC8435BD358919ED6BE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation" xlink:label="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_A6BD3605D9521EC8435BD358919ED6BE" xlink:to="loc_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation_2966666088C89E4F17C8D358919EFFAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_A6BD3605D9521EC8435BD358919ED6BE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7DF52DA27F9689341455D358919E6303" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_146480B445363924CC81D480D7729B01" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:to="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D828F0A12AB1D52785B4D480D773B1EE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2E5C8F424BBE3B6B9210D480D77371BC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2E5C8F424BBE3B6B9210D480D77371BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_RestrictedStockMember_D79962F368C358327526D480D774A611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0987B9876A080383A7DCD480D773D5DB" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B6F6BD7DF19E4C9E0828D480D7749603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78B33287B1F6F406EF99D480D773CBF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DCA5AD2EA5D0DD79510ED480D7794207" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9FCF3B3DF7FDE5312A09D480D7793152" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_496CC42A2BB4752C4FADD480D77936B3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails" xlink:type="extended">
    <loc xlink:href="halo-20160930.xsd#halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract" xlink:label="loc_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofAssumptionsforFairValueofStockOptionsAbstract_9ED73BFA6075C20B90AF0C9E5CBB4A36" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B745C1794A4943D6028D0C9E602EFD05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B44ECE4E5305230E130A0C9E602FFB42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:to="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6E4E2022DB02CBCD843E0C9E5D0BA7DF" xlink:to="loc_us-gaap_RangeMember_09884DC87CD21AB0BDE60C9E5D0B47A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A0188656B7ECE30B480C9E5D07626C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_AEFA51D45CD1AA21F07E0C9FD4E180C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D072D52CB834D604C4370C9FD52079F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9E2C8CF9F602EC3290240C9E5DC17C1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_382C6FDBA063BA86DAAC0C9FD54E62A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C068412900B7A5089AE0C9FD57DDD2F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C96282B9EAFDE31AC2E40C9E5D0C5FC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CE47630A843E8A0873A0C9E5F44C387" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_81CBD5F83816768C0A3D482D78FFD8B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_81CBD5F83816768C0A3D482D78FFD8B9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EEE9631B66383D5AA209482D78FFBA14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_81CBD5F83816768C0A3D482D78FFD8B9" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_863598624055F86CBF16482D78FFC19F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_81CBD5F83816768C0A3D482D78FFD8B9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7D9BA712A2C68B344492482D78FFF2E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_81CBD5F83816768C0A3D482D78FFD8B9" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_60CF3949B06AEE03131B482D78FFFF39" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5268D7C1DB0C0D059241D40E4C79747C" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30EA278C01F2C91E301BD40E4C79065E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/StockholdersDeficitEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E3B71A635DCB16DBA095D40E4C79D054" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E3B71A635DCB16DBA095D40E4C79D054" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:to="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_36A17FF09326398B2F28D40E4C79C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FC20A7BD316BAD563B99D40E4C798A1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3CC966601E32906AEBDAD40E4C79B263" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FC6ABA4D389AD341AFEED40E4C79B316" xlink:to="loc_us-gaap_RestrictedStockMember_6B9BCCD1ADC2389675B2D40E4C79D39A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75026DA4EE715DA62090D40E4C794095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55DCA8D47E3B03F95A9ED40E4C79CB75" xlink:to="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F7B738C43C5E0C35CD40E4C79F167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B916F664009779FB8EA2D40E4C792A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_DFB6D2FD741DE560BA97D40E4C7975F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_D73D4A00CE4AA1F4B6C3D40E4C7939F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_FA4B6641D6717B472F81D40E4C79F575" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_C7501815912B6B4B1252D40E4C7944BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A0AD5B122302B480ABCAD40E4C79CCA0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B5A2AE3A13986506DF86D40E4C79ACBD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22158AF675D54A70E0B9482D78892E46" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22158AF675D54A70E0B9482D78892E46" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9B98B3578A669F9C6CC0482D7889B638" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5110952962F6F7CAC294482D78C8DA7E" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CB45482CF924A5E015EF482D78C870C4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9045BC5DBDFE1E31B5FE0C990A5FDD04" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_14AFF4D356DD665E04730C990A5F98F0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_18B47FD5775497FA071E0C990A60A1CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A1BA3857860C44C2ED6D0C990A605359" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_C4B17E32777C619D2DC50C990A60186D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_725CFC44297CEB6120500C990A60E7E0" xlink:to="loc_us-gaap_CommercialPaperMember_7E6BE89CAF2547540E4C0C990A60B356" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C7BC589994D20170AA050C990A60E7DB" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FE0892832D959047B17F0C990A6018C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_523D01C2DD71EF22DDBA0C990A603755" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C42923212CE8DA058F670C990A608043" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4237CA79C266ED9D47E10C990A6031C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_424FE8290533795F36BD0C990A5FEEE6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3F6BC29E82AF7BB68070C990A6154D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2E11234942C213FB2B0E0C990A61FA7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_259E8D87B8665EA6E2CA0C990A61FB0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_EB11F7FAE9A4C9D611200C990A612E3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04EF5A98175E05E7873B0C990A61C742" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_C6E4BA5F0D69A108A4370C990A612ED7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_07D7BA6401FE219A4442D358931EB464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EBC0F40CDCA106778366D358931ECA6C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CD4E0EBF9175B13DED80D358931E11BF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_446A7F826B31B0D456AF0BD624705716" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_446A7F826B31B0D456AF0BD624705716" xlink:to="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5FBC9E08E17818A228BE0BD6247FE9D4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_HylenexRecombinantMember" xlink:label="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:to="loc_halo_HylenexRecombinantMember_57F8E187A9CB511132AE0BD6247F5B47" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_BulkrHuPH20Member" xlink:label="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_782FB4E25666EB1B97A90BD6247F4397" xlink:to="loc_halo_BulkrHuPH20Member_CE8A5EB04488648401670BD6247F9755" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_9D7D10E6D98A5224F3390BD62470E97B" xlink:to="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_F006FF9646C01FF7002A0BD6247F03C5" xlink:to="loc_us-gaap_InventoryNet_178B49211413FB7DF5ED0BD6247F4D71" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2B8899A5CE716584D834D48897076FC9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:to="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_212A269E39F491FBD182D4889707B2F0" xlink:to="loc_dei_EntityDomain_1572B2D77D24AA0AB210D4889707F712" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_6602A6A4C41080FA6E63D48897077656" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_NetincomelosspershareTextualsAbstract" xlink:label="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_6CA5C0FE81759F970853D4889707C7CC" xlink:to="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_NetincomelosspershareTextualsAbstract_124E81A530F3A4FB1EABD4889707AFD4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7C3E00CDFFB0F377D4BBD48897077BA7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_C9ADFF39B6536E18FC21482D79047CF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_EE1023A2764F9993B9F9482D790440AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1B53E03EF428E4F03498482D7904497A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_0CD17B39E98D325675A6482D79049617" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0F8ACD265AF960E132E2482D790473EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5592C64B1F6DE9C195E1482D79045EB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_CB3DEAADAF45171CCFB9482D7904F09B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_431685D93583E3DB348E482D7904F742" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_F72442922B34F1D11DA7482D79049554" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8677088834FB8296F38B482D790509F8" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock" xlink:label="loc_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock_B37B854A9C11558D1352482D7905FC08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C0B39C8B86A91BD91DD1482D7905FB8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_90911525A5C6B9E7696F482D7905CD4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3B41153B1DDCCF87DD20482D79055DBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DA7B7C0795ADD627D789482D79046490" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1A3987F8244074D3F69E482D79057CFE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrentAbstract" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract_74274C1914A31CFE7EA2482D78D80611" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_859AF6ADB8895B1F5317482D78D8DEB4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_40B4A99DC640C7DE7442482D79099B62" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E1AFFCC2F4D7AACAE393482D7909C9A8" xlink:to="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:to="loc_us-gaap_MinimumMember_8FE19542189D0469AC69482D79098F75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_986992CD3032A7F8155B482D7909D741" xlink:to="loc_us-gaap_MaximumMember_B40A6A76650B5ADF0835482D79097657" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_74A2FB83900696482C3B482D7909C9F2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_37EB66090982E661A0B3482D790972F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5879BA7E02CD6A78CF77482D790995EB" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_PeriodForTermination" xlink:label="loc_halo_PeriodForTermination_1BEF567E991E675C01A6482D7909E3E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="loc_halo_PeriodForTermination_1BEF567E991E675C01A6482D7909E3E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9F8BBC14FF401EC83376482D79096202" xlink:to="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:type="arc" />
    <loc xlink:href="halo-20160930.xsd#halo_Periodtoacceptreturnedunusedproduct" xlink:label="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_514D0F09D6C48798BA2C482D79090997" xlink:to="loc_halo_Periodtoacceptreturnedunusedproduct_F4FFEA8D570D7CD4BA6C482D790921D3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4EC966E2DB07866995E0482D78A9053C" xlink:to="loc_us-gaap_NumberOfOperatingSegments_D8F3406E7B7A01B346F3482D78A93F10" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_52231C329B0DC77BDB7F482D78893639" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_52231C329B0DC77BDB7F482D78893639" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_85BBD6CBC73D4DB81088482D7889F9F8" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>slide1a18.jpg
<TEXT>
begin 644 slide1a18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" .T"*@# 2(  A$! Q$!_\0
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M_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BO[$_U4R;_H%I_P#@,?\
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MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
M094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1
MJ^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-
M_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&
M5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9
MJ*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\
MD:C_ (?#?M'?]%(D_P#!'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_
M  9+_,^F?^'PW[1W_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53
M)O\ H%I_^ Q_R#_7+/O^@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[
M1W_12)/_  1Z;_\ (U?,U%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\
MA\-^T=_T4B3_ ,$>F_\ R-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_
M . Q_P @_P!<L^_Z#*G_ (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\
M12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_
MT4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P"
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MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
M094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1
MJ^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-
M_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&
M5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9
MJ*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\
MD:C_ (?#?M'?]%(D_P#!'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_
M  9+_,^F?^'PW[1W_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53
M)O\ H%I_^ Q_R#_7+/O^@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[
M1W_12)/_  1Z;_\ (U?,U%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\
MA\-^T=_T4B3_ ,$>F_\ R-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_
M . Q_P @_P!<L^_Z#*G_ (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\
M12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_
MT4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P"
MQ_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P
M1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=
M_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_U
MRS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\ D:C_ (?#?M'?]%(D_P#!
M'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_  9+_,^F?^'PW[1W_12)
M/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53)O\ H%I_^ Q_R#_7+/O^
M@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[1W_12)/_  1Z;_\ (U?,
MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
M094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1
MJ^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-
M_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&
M5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9
MJ*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\
MD:C_ (?#?M'?]%(D_P#!'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_
M  9+_,^F?^'PW[1W_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53
M)O\ H%I_^ Q_R#_7+/O^@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[
M1W_12)/_  1Z;_\ (U?,U%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\
MA\-^T=_T4B3_ ,$>F_\ R-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_
M . Q_P @_P!<L^_Z#*G_ (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\
M12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_
MT4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P"
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MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
M094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1
MJ^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-
M_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&
M5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9
MJ*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\
MD:C_ (?#?M'?]%(D_P#!'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_
M  9+_,^F?^'PW[1W_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53
M)O\ H%I_^ Q_R#_7+/O^@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[
M1W_12)/_  1Z;_\ (U?,U%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\
MA\-^T=_T4B3_ ,$>F_\ R-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_
M . Q_P @_P!<L^_Z#*G_ (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\
M12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_
MT4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P"
MQ_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P
M1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=
M_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_U
MRS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\ D:C_ (?#?M'?]%(D_P#!
M'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_  9+_,^F?^'PW[1W_12)
M/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53)O\ H%I_^ Q_R#_7+/O^
M@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[1W_12)/_  1Z;_\ (U?,
MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
M094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1
MJ^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?3/\ P^&_:._Z*1)_X(]-
M_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\ 0+3_ / 8_P"0?ZY9]_T&
M5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;]H[_ **1)_X(]-_^1J^9
MJ*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\ #X;]H[_HI$G_ ((]-_\
MD:C_ (?#?M'?]%(D_P#!'IO_ ,C5\S44?ZJ9-_T"T_\ P&/^0?ZY9]_T&5/_
M  9+_,^F?^'PW[1W_12)/_!'IO\ \C4?\/AOVCO^BD2?^"/3?_D:OF:BC_53
M)O\ H%I_^ Q_R#_7+/O^@RI_X,E_F?3/_#X;]H[_ **1)_X(]-_^1J/^'PW[
M1W_12)/_  1Z;_\ (U?,U%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\
MA\-^T=_T4B3_ ,$>F_\ R-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_
M . Q_P @_P!<L^_Z#*G_ (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\
M12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_
MT4B3_P $>F__ "-1_P /AOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P"
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MU%'^JF3?] M/_P !C_D'^N6??]!E3_P9+_,^F?\ A\-^T=_T4B3_ ,$>F_\
MR-1_P^&_:._Z*1)_X(]-_P#D:OF:BC_53)O^@6G_ . Q_P @_P!<L^_Z#*G_
M (,E_F?3/_#X;]H[_HI$G_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JI
MDW_0+3_\!C_D'^N6??\ 094_\&2_S/IG_A\-^T=_T4B3_P $>F__ "-1_P /
MAOVCO^BD2?\ @CTW_P"1J^9J*/\ 53)O^@6G_P" Q_R#_7+/O^@RI_X,E_F?
M3/\ P^&_:._Z*1)_X(]-_P#D:C_A\-^T=_T4B3_P1Z;_ /(U?,U%'^JF3?\
M0+3_ / 8_P"0?ZY9]_T&5/\ P9+_ #/IG_A\-^T=_P!%(D_\$>F__(U'_#X;
M]H[_ **1)_X(]-_^1J^9J*/]5,F_Z!:?_@,?\@_URS[_ *#*G_@R7^9],_\
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MG_@CTW_Y&H_X?#?M'?\ 12)/_!'IO_R-7S-11_JIDW_0+3_\!C_D'^N6??\
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MIO\ \DT?ZUY-_P!!5/\ \"C_ )C_ -3<^_Z ZG_@N7^1\S45],_\.>?VCO\
MHF\G_@\TW_Y)H_X<\_M'?]$WD_\ !YIO_P DT?ZUY-_T%4__  */^8?ZFY]_
MT!U/_!<O\CYFHKZ9_P"'//[1W_1-Y/\ P>:;_P#)-'_#GG]H[_HF\G_@\TW_
M .2:/]:\F_Z"J?\ X%'_ ##_ %-S[_H#J?\ @N7^1\S45],_\.>?VCO^B;R?
M^#S3?_DFC_ASS^T=_P!$WD_\'FF__)-'^M>3?]!5/_P*/^8?ZFY]_P! =3_P
M7+_(^9J*^F?^'//[1W_1-Y/_  >:;_\ )-'_  YY_:._Z)O)_P"#S3?_ ))H
M_P!:\F_Z"J?_ (%'_,/]3<^_Z ZG_@N7^1\S45],_P##GG]H[_HF\G_@\TW_
M .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\ \"C_ )A_J;GW_0'4_P#!
M<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UK
MR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .>?VCO^B;R?\ @\TW_P"2
M:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P# H_YA_J;GW_0'4_\ !<O\
MCYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)O)_X/--_^2:/]:\F_P"@
MJG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\ HF\G_@\TW_Y)H_X<\_M'
M?]$WD_\ !YIO_P DT?ZUY-_T%4__  */^8?ZFY]_T!U/_!<O\CYFHKZ9_P"'
M//[1W_1-Y/\ P>:;_P#)-'_#GG]H[_HF\G_@\TW_ .2:/]:\F_Z"J?\ X%'_
M ##_ %-S[_H#J?\ @N7^1\S45],_\.>?VCO^B;R?^#S3?_DFC_ASS^T=_P!$
MWD_\'FF__)-'^M>3?]!5/_P*/^8?ZFY]_P! =3_P7+_(^9J*^F?^'//[1W_1
M-Y/_  >:;_\ )-'_  YY_:._Z)O)_P"#S3?_ ))H_P!:\F_Z"J?_ (%'_,/]
M3<^_Z ZG_@N7^1\S45],_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!Y
MIO\ \DT?ZUY-_P!!5/\ \"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_
M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
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M_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\
M\"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?V
MCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .
M>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P#
MH_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)
MO)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\
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M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
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M_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\
M\"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?V
MCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .
M>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P#
MH_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)
MO)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\
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M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
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M_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\
M\"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?V
MCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .
M>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P#
MH_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)
MO)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\
MHF\G_@\TW_Y)H_X<\_M'?]$WD_\ !YIO_P DT?ZUY-_T%4__  */^8?ZFY]_
MT!U/_!<O\CYFHKZ9_P"'//[1W_1-Y/\ P>:;_P#)-'_#GG]H[_HF\G_@\TW_
M .2:/]:\F_Z"J?\ X%'_ ##_ %-S[_H#J?\ @N7^1\S45],_\.>?VCO^B;R?
M^#S3?_DFC_ASS^T=_P!$WD_\'FF__)-'^M>3?]!5/_P*/^8?ZFY]_P! =3_P
M7+_(^9J*^F?^'//[1W_1-Y/_  >:;_\ )-'_  YY_:._Z)O)_P"#S3?_ ))H
M_P!:\F_Z"J?_ (%'_,/]3<^_Z ZG_@N7^1\S45],_P##GG]H[_HF\G_@\TW_
M .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\ \"C_ )A_J;GW_0'4_P#!
M<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UK
MR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .>?VCO^B;R?\ @\TW_P"2
M:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P# H_YA_J;GW_0'4_\ !<O\
MCYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)O)_X/--_^2:/]:\F_P"@
MJG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\ HF\G_@\TW_Y)H_X<\_M'
M?]$WD_\ !YIO_P DT?ZUY-_T%4__  */^8?ZFY]_T!U/_!<O\CYFHKZ9_P"'
M//[1W_1-Y/\ P>:;_P#)-'_#GG]H[_HF\G_@\TW_ .2:/]:\F_Z"J?\ X%'_
M ##_ %-S[_H#J?\ @N7^1\S45],_\.>?VCO^B;R?^#S3?_DFC_ASS^T=_P!$
MWD_\'FF__)-'^M>3?]!5/_P*/^8?ZFY]_P! =3_P7+_(^9J*^F?^'//[1W_1
M-Y/_  >:;_\ )-'_  YY_:._Z)O)_P"#S3?_ ))H_P!:\F_Z"J?_ (%'_,/]
M3<^_Z ZG_@N7^1\S45],_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!Y
MIO\ \DT?ZUY-_P!!5/\ \"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_
M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
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M_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\
M\"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?V
MCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .
M>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P#
MH_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)
MO)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\
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M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
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M_P##GG]H[_HF\G_@\TW_ .2:/^'//[1W_1-Y/_!YIO\ \DT?ZUY-_P!!5/\
M\"C_ )A_J;GW_0'4_P#!<O\ (^9J*^F?^'//[1W_ $3>3_P>:;_\DT?\.>?V
MCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\ H#J?^"Y?Y'S-17TS_P .
M>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'FF_\ R31_K7DW_053_P#
MH_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_\'FF_P#R31_PYY_:._Z)
MO)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@N7^1\S45],_\.>?VCO\
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M $3>3_P>:;_\DT?\.>?VCO\ HF\G_@\TW_Y)H_UKR;_H*I_^!1_S#_4W/O\
MH#J?^"Y?Y'S-17TS_P .>?VCO^B;R?\ @\TW_P"2:/\ ASS^T=_T3>3_ ,'F
MF_\ R31_K7DW_053_P# H_YA_J;GW_0'4_\ !<O\CYFHKZ9_X<\_M'?]$WD_
M\'FF_P#R31_PYY_:._Z)O)_X/--_^2:/]:\F_P"@JG_X%'_,/]3<^_Z ZG_@
MN7^1\S45],_\.>?VCO\ HF\G_@\TW_Y)H_X<\_M'?]$WD_\ !YIO_P DT?ZU
MY-_T%4__  */^8?ZFY]_T!U/_!<O\CYFHKZ9_P"'//[1W_1-Y/\ P>:;_P#)
M-%'^M>3?]!5/_P "C_F+_4W/O^@.I_X+E_D?NO1117\=G]YA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !11FC- !11FB@ HHS1F@ HHHH **** "BBB@ HHHH **** "BC.:*
M "BC-% !1110 4444 %%%% !1110 444QKB-#\TB#ZF@3DEN/HJ/[5'_ ,](
M_P#OH4HN8R?]8G_?5/E9/M(]T/HHS12+"BBB@ HHHH **** "BBB@ HHHH *
M**,T %%%&: "BBB@ HHHH **** "BBB@ HHHH ***,T %%&:* "BBB@ HHHH
M **** "BBB@ HHW#/6B@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !110>E $>-RXZUR/QE^-/AO]G[X;ZAXL\6:
ME_9.@:68Q<70MY9_*,DB1(-D:L[9=T' /6NN_A]ZKWUE#J-JT,\,=Q&_WHW0
M,K?@:JFXJ:]HKKK;^G^1CB%4=-JB[2Z7U5_-75_O7J?- _X+(_LX_P#10I.F
M/^0!J?\ \CTO_#Y/]G''_)0I/_!!J7_R/7T-<>"=%$;?\2G3?ND_\>R?X5\P
M_P#!*#PYI,WP&\4:?<6-E->:+XTUBRN!+"C/&RSAL'T^5EKZ:E1RB>&GB'"I
M[KCISQZW_N>1\=B,1GU+&4L+[6E^\4G?DE]FW_3SK?\  ]>_9T_;5^&G[6%[
MJEOX!\2?V]-HJQR7B'3[JU,(D+!#^^C3=NV-TS]VO6,X7L*^2_V4K>WE_P""
MEW[2+:?'"MG9VWA^W;R0JHLGV1\CY>^0WXAJ^LAN7;SNZ\UY><86CAJ_+1OR
MN,96>K]Z*=M$N_8]OA_'XC%X5U,1;F4IQT32?+)QO9M]NY-10**\L]P****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_4/&4GD0Z='?2;+:,O,B22OS]V.-GDQU;9CGI7=LVXXKQ?\ ;[_:"UK]EO\
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MCSPO=VT4E?7T./\ ^'2VF8_Y+;^T%_X5B_\ QBC_ (=+:9_T6S]H+_PK%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML]YJ&N(/LK2* H*6W*[55555=G"A1MQ7U+I^FV^FVRP6\4<,,8552-0JHHZ
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH)P*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU=>NW0^3S++:6%E+&4L4\.I:R^'E;[VDG9^F_5,\=^'_ .SI\3OVO?C/H7Q
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M#_B(*^$/_0K_ !&_\ +/_P"2J/\ B(*^$/\ T*_Q&_\  "S_ /DJC_4W._\
MH%G]P?\ $0.'O^@N'WGW?CWHQ[U\(?\ $05\(?\ H5_B-_X 6?\ \E4?\1!7
MPA_Z%?XC?^ %G_\ )5'^IN=_] L_N#_B('#W_07#[S[OQ[T8]Z^$/^(@KX0_
M]"O\1O\ P L__DJC_B(*^$/_ $*_Q&_\ +/_ .2J/]3<[_Z!9_<'_$0.'O\
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M?^A7^(W_ ( 6?_R51_Q$%?"'_H5_B-_X 6?_ ,E4?ZFYW_T"S^X/^(@</?\
M07#[S[OQ[T8]Z^$/^(@KX0_]"O\ $;_P L__ )*H_P"(@KX0_P#0K_$;_P
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M'WGW?CWHQ[U\(?\ $05\(?\ H5_B-_X 6?\ \E4?\1!7PA_Z%?XC?^ %G_\
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M$/\ T*_Q&_\  "S_ /DJC_4W._\ H%G]P?\ $0.'O^@N'WGW?CWHQ[U\(?\
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M %-SO_H%G]P?\1 X>_Z"X?>?=^/>C'O7PA_Q$%?"'_H5_B-_X 6?_P E4?\
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M1!7PA_Z%?XC?^ %G_P#)5'_$05\(?^A7^(W_ ( 6?_R51_J;G?\ T"S^X/\
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M^IN=_P#0+/[@_P"(@</?]!</O/N_'O1CWKX0_P"(@KX0_P#0K_$;_P  +/\
M^2J/^(@KX0_]"O\ $;_P L__ )*H_P!3<[_Z!9_<'_$0.'O^@N'WGW?CWHQ[
MU\(?\1!7PA_Z%?XC?^ %G_\ )5'_ !$%?"'_ *%?XC?^ %G_ /)5'^IN=_\
M0+/[@_XB!P]_T%P^\^[\>]&/>OA#_B(*^$/_ $*_Q&_\ +/_ .2J/^(@KX0_
M]"O\1O\ P L__DJC_4W._P#H%G]P?\1 X>_Z"X?>?=^/>C'O7PA_Q$%?"'_H
M5_B-_P" %G_\E4?\1!7PA_Z%?XC?^ %G_P#)5'^IN=_] L_N#_B('#W_ $%P
M^\^[\>]&/>OA#_B(*^$/_0K_ !&_\ +/_P"2J/\ B(*^$/\ T*_Q&_\  "S_
M /DJC_4W._\ H%G]P?\ $0.'O^@N'WGW?CWHQ[U\(?\ $05\(?\ H5_B-_X
M6?\ \E4?\1!7PA_Z%?XC?^ %G_\ )5'^IN=_] L_N#_B('#W_07#[S[OQ[T8
M]Z^$/^(@KX0_]"O\1O\ P L__DJC_B(*^$/_ $*_Q&_\ +/_ .2J/]3<[_Z!
M9_<'_$0.'O\ H+A]Y]WX]Z,>]?"'_$05\(?^A7^(W_@!9_\ R51_Q$%?"'_H
M5_B-_P" %G_\E4?ZFYW_ - L_N#_ (B!P]_T%P^\^[\<T+C-?%/PS_X+C_"W
MXK_$OP]X9L?#GC^"^\1ZG;:7;2W%G:+#%)-*L2,Y6Y)"[G&<!FQ_#7VJDGF#
M/\+#(KR<PRO%X&2IXRFX-]&>YE.=X',H.I@*JFEO8DHHH/-<!ZPW=E:&P5^[
MGZT'BN?^(OBV;P-X*U#5+?2=4UJ>QC\R+3]/C$MS>-T"(&*KN)[LP4=213A!
MRDDNI%2:C%RELC.^,/QC\,? 7P#?>)O%>J6>C:/IZ;I+B8_>;LBK]YW;H%7)
M:OECPU\+/%W_  4U\1VOBGQ_9WWA'X*6LRW.B>$V8Q7GB0#!2YO2IXB/#+&/
M;']]_'-7U?XU?&/]H1?&WQ2^ ?C'Q5I.B2[_  SX7@O8H=+TH_\ /68,#]HF
MZ?,V%Z_+C:%^A4_;V^, ^[^R_P"-<#IC5X?_ (BOMX93B,!37U9QE5E]KVD/
M=OTC[V_>73IW/S2IG6&S*JUC(SA1B](>SG>?G*T?A[1Z]>Q]3Z)HUCX<TJVL
M=/M;>QLK2-88+>",1QPHHVJJJO"@ =!5UFQSQ7CO[,7[0GC7XV7^K0^*OA7K
MGPYCL%C>WEO[U+A;TL6W!=JC&W _[ZKV+%?'8JC4HU'3J_%ZI_BKH_0L#B:5
M>BJE#X?--?@TF2#I10**P.P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >D_L;?\G?\ PI_['#2?_2R&OZ(U.(D^E?SN?L;?\G?_  I_['#2?_2R&OZ(
MU_U2?2OYY\8O]_H?X7^;/Z@\"/\ D7XG_&OR)****_(3]X&_RKB_CI\4YO@M
M\+]3\26_AWQ!XKFTXQ8TK0[4W5_=;Y4C_=Q#[VW?O;T5&/:NT(S]:CDV_,6/
MW?4=*JG)1FG)77;N98B,I4W&+L^_;S/DM?\ @J+JV.?V=OV@#_W*S_XTT?\
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MBL3K"BBB@ HHHH **** "BBB@ HHW49H **** "BBB@ HHHH **** "BBB@
MHHHS0 44@<-T(I<T %%&:,T %%%% !1110 4444 %%%% !11NHW4 %%&:,T
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M)4PN85Z*E.5/EIM<\G+5N=[-M]E<FHH'2BO!/JPHHHH **** "BBB@ HHHH
M**** "BBB@",=*^8?^"RG_*./XA?[VF?^G*UKZ>'2OF'_@LI_P HX_B%_O:9
M_P"G*UKVN&O^1MAO^OD/_2D?.\7?\B3%_P#7N?\ Z2S\,:***_LH_@DZ+X9_
M"WQ%\8O&$'A_POI5UK6L72N\5I;A2\BH"Q/_  $ FNY\2?L'?&?PC#-+??#'
MQDL<(W2/#ILEP /7,8:O4O\ @BZ /^"A'A4-]T6E]_Z2R5][^*?VN/C9HO\
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M1)@23W3)O>-I -PM[<9X'WB.S2%AZ'^O$JF68?$T*/-6KMQC"_5:-W[(\_\
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MKTWQFJOU&>$7N8AM2ONK?\$\C_45T(YC3QCM/#).-MG?]+:GY\_"7]F'Q_\
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ME+G^\1_>-8W_  21_9\\(?!/]G77OVC/'EM',-/6Y;2#)$LOV2WA;8\L:_\
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MP]\1]3\0?%?QG;VMUH/@F7R;&*Z"R6YN5B\V6:0-U\I&1E_VGS_ M1_M"_\
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M>%JS]G4J^RES*TD^Z[H^5F_X)J?'8 ?\6Q\2C_@$?_Q5<3I_[,?C_6OBU<>
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /2?V-O^3O_A3_ -CAI/\
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MW^!OA&;PSIVJ0S6=S>26,-C!;0RC$GV>&,G+N&;+OM*]=K$Y7X=^#7QA\0?
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M*XO]H7_@L_X;T+X8S^#?@;X&@\,6-PCPF]N]/M[>&V#@AO)M(]R,QS]Y^/\
M8:OC']FK]I7Q3^RA\5[/Q?X4NHX;ZW!CN+>49M[^%BN^&0+U1MJ_[2L%8;2*
MUS#!YIG^5U(UZ/L9J2E33=V[=)=OZ[:XY;C,HX<S>E+#U_;PE%QJ22LM?Y>]
MOZ>NG*^/_ &K_"[QGJ?AW7K"?3-9T>X>UN[:4;61U_\ 0E_NLORLOS5]N?\
M!!CX(:UK?[1&J>/FM;B#PWH&ES6'VLY6.>YF:/$:_P!_:BN6_NY3^\M>G/\
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M]E7[SC^*OMSQ/_P6/_9]\;ZY/J6K_!O4-6U*X"B6[O-'TZ:9]JA1EVD+-M4
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M_MV?M$Z;^U7^T_XB\=:18W^GV&L):K%!>A!-'Y=M%$=VQF7[R'^*OI[]E?\
MX+,VOPN_9;_X0'QQH^O:YJ.GVDVG6%_9^6P>U,>(DE+R*VY-VW(_@5?XOO>-
MG'!>/^H8:O@X>_RTXU8=[6L_56L?09!Q]EZS+%T,?/\ =J525&?;F;NO1IW]
M?D? 1/RBO7_V!EQ^VI\*\=3XDM/_ $8*\@^\:[?]FKXGVOP5^/O@_P 7:A;W
M%U9>'-6M[^:&WV^:Z(X)"[F5=W^]7Z_FU&=3+ZU*G'WI1?\ Z2?A^48BG2S*
MC6J.T5--_>?J9_P4N_X*F^*OV*_C/8>#_#_AS0M4^WZ%#JHO+^23Y'>>XBV;
M$(R (0>HZU^6G[0W[1?BS]J#XDW'BKQAJ O]4F00QHB;(+2%68B*-/X47)_$
MDG<S,U>F_P#!2C]K_1?VUOCMIGBS0]-U32[2QT.'2WBOP@E+I/<2$C8S#;MF
M'Y&OGKH*^5X+X7H8' 0JU:/)B)1=WU_KT/L>.N,,1F68U*4*[EAU)<JZ?UZG
M]"OQ$_:,TOX,>/\ X9^'=7*1V_C^2;3K:Y=]HANDB1X4/_73+)_O%*_+_P#X
M+@:S\0H_VI5TGQ-?R7'@^.V6]\,111>5;K$Z[9<_WIE=6#$MG:4^ZK;:H?\
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M,8;"WDV$]L[<5TW_  4]^.'B_P")?_!/C3_'GPNU9K?PCKT"-KR11*UX;*X
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MXO\ @I1;_LAV?BS2?&%CKGBCP_XDCB>*W@=)FMIEW(_RRNJ['0@'_KFM4?\
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MESX6U:QMY)IM-U"&-.6=[=U5?^!;:H#'&:_:[]M?_@IBW['O[1?A;P*W@?\
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M];=BO]2L#1R>&88S%<E2HFX+E;3MTYEU9\!T445^@'YJ%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z3^QM_P G?_"G_L<-
M)_\ 2R&OZ(U_U2?2OYW/V-O^3O\ X4_]CAI/_I9#7]$:_P"J3Z5_//C%_O\
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MR7XW?4D KY+_ &A/CIX^^._[1EQ\&?A+J</AYM(MEN/%'B5XBS:>&V_NH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBNDXPHHHH **** "BBB@ HHHH ,T444 %%%% !1110 4444 %%%% !1110
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MZ'#$+G2'TZ[!EBEV^=;^=Y?E-Y3_ #J=^W ?NU9/_!.+_@J18?L[^#)OAO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110!Z3^QM_P G?_"G_L<-)_\
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M!T?X=ZQ)\-M'O$E>V_M"WMY/$#HWWY&\W<D?]Q?O?Q-\VU4YSN-#PUHFL?\
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M HHHH **** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !1110 4444
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M ^G1OI%X+Z"^NO.M$W1([PA5WO$K1?=7B0_6OCO_ (( \?M9>*-O_0JS9_\
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MWS;ONJS5[W_P79^,FG^-/VFO!?A.QFCN+CP=:,]\RG*PS73QGRV_V@D4;?\
M;1:NM1PV%XHA2RQ))PE[11^'R;7>_P#6IG1K8O%\)5*N;-MQJ0]DY?%_>2;U
M:M_6A[S_ ,%I_P!K/XA?LMS_  ND\!^))O#YU@:DUYY=M#.)_*^R>7D2HPX\
MQ_SJG_P39_;>G_X*(>$?%WPI^+5AIVM:A_99N/M"6XA74[0N(Y/,1?E25'>,
MAD"_>4X5ERW'_P#!PCH5]K3_  >6SL[J\:./5PWDQ-(5)^PXZ5F?\$//V5O%
M/P\\>^)_BAXJTN\\.Z)!HSZ;9G4HFM6NF>6.628*^/W2+#C>WRG?QT;'R5'!
M9:N#X8J2BJZ;Y6M)WYW;7=GVU;'YK+C>>#@Y/#M1YXN[A;V:OILO\_4\Y_X)
M@_#.7X*_\%8[OPC-(9F\.R:MIZRD?ZY8U=5?_@2A6_X%7F'_  5V/_&Q+XD_
M]=[+_P!(+:O7OV(?C-8?$S_@M/?>(K&2-M-\3:CJZV4GW?.B\B1HV_X$L0;_
M (%7F_\ P5]\"ZQ%_P %&O%T:Z;?22>(FT^;2U6!F;4%:T@B_=*/O_O4=./X
MD:OL<OK27$<9XGW9RPT;^O,KGPN8T:;X6E#!^]&.+=O3E=CZ<_X+/?\ )A'P
M?_Z_K/\ ]-TM;_P'O]%_X)?_ /!+BS^(D.EVU]XT\:6UO>[Y5_X^KBZ!>UB=
MN&\J*)LE 1R),8+5B?\ !;V!O#?[%OPET>\/DZA;W]NCPGK^ZL71_P#OEF7\
MZVO'7@&;_@H;_P $>_!]OX-VZAXD\(P6;_80X$DEW90M;3PG/W6*,[*#URG]
MZOC:/O9-@Z5=VH3KRY^UKNU_+<^[Q$7'/<;4H*^(AAX^S[WY5>R[GPOXF_X*
M:?';Q+XJDUF3XCZ]:S-)YD<%HRPVL7/"B$+L95_VE;_:W5V7[1'_  5E\=?M
M(?L]Z-X+UK2]%35+*]2\O-;2!&ENFB96A:.)AMADW9WLGWONJJJS*?F#4_#^
MH:%KDVF7VGWEGJ5O+Y,MI/"T<\;_ -PHPW*W^S7HWQ%_8N^)?PF^#FD^//$7
MA74M+\.ZO*T<4LR;9;?[NQIH_O1J_.POMSC_ &EW?K53)\@A5H.4(*2?N;*[
M\NY^*TL\XDG3KQ52I*#7[R]W9>?;UT/TQ_X(U_M2>/OVC_AG\0;SQMXBNM>N
M-'N8$LI)(8H_(#1.64;$7N!]ZOR]^._[5'C[]IR?3&\=^(KGQ$^BK*+)I8(H
M_L_F[-^/+1?O;$^]_=K]!/\ @W[ /P?^*V?^?RW_ /1,E?ESFOG^%\NPM//\
MPY*:7(Z?+HM+Q=[=K]3ZGC'-,94X9RWVE5OG4[ZO6TE:_>W2Y]+?\$H?V:]+
M_:<_:^TS3]=M8[K0?#MI)K=];/\ <NA$Z)'$?53+)&S#^)59:]\_X*?_ /!4
M[QIX?^,VK_#OX<ZE_P (OH_AF3['?7]JH^UWMP%^=%?_ )91(?E^7:VY&^;;
M\M>7_P#!$;XOZ?\ ##]M".PU*9+>/QAI4VD6TC':OVGS8I(U_'RV0?[3BLC_
M (*P_LB^)O@/^T_XH\32:==W'A/QAJ,FK66IHA:%99COEA=E^XZR%]H;[RX(
M_BVYXVCA\3Q8Z.9J\8T_W:ELW?7U>_\ 2-,#7Q.$X,]ME3:G*HU4<?B2MHK[
MI?Y^8O[-?_!8+XN? OQ0CZYK5WX\T&3BYT[590TI_P!J*?:SHWM\R_[/\5>
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MG7JQHTU>4C]*/^"6.CV/[%G_  3^\;_&[Q!:[Y]<5[FWB9_+:>"W+16\8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >D_L;?\G?\ PI_['#2?_2R&OZ(U_P!4GTK^=S]C;_D[_P"%/_8X:3_Z
M60U_1&O^J3Z5_//C%_O]#_"_S9_4'@1_R+\3_C7Y$E%%%?D)^\$>-X[\]J^7
M_P#@LFW_ !KD^(&.[:;_ .G*UKZA[5E>)_"FF^.="FTW6-/LM5TVX*^=:W<"
MS0R[6#+N1P0<, WU45U9?BOJV*IXFU^22?W.YYV;8%XS!5<(G9SBXW]4T5=!
M\#:/_9%I_P 2O3?]2G_+LG]WZ5;_ .$$T<_\PG3!_P!NJ?X5JQJL:*JC"KP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6/I+]NS_ (*-:Q^VWH'A?1Y/#MKX4T7PT\DJ6=M>&=+EV4(C-\B[=B!@ O\
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 9XKU7]CC]I.']DSXWV/CEO#D/B>[
MTNWFCM+>6Z-L(991L\W=L;=B-G7;_P!--W\->5D?+G]*4#802*YL7A:6*H3P
MU=7A+1G9@L75PN(CB:#M*+NO5>IZ1^UC^TEJG[6GQTU?QQJUJEC)J7EQ0623
M-,EG"B*B(&PN[HS?=^\S5M?L/_MD:M^Q+\7IO%.FZ;'K$-U8RV%W82W!A2=&
M97#;@K;6#H#]W^\O\5>.'UI!QS7)/)\%/!_V>X?N[6MY'9#/<=''?VDJG[V]
M[^?Y'T%X/_;J3P+^W7/\;M-\'6MN]U<W-X^B+?GRS-<6[Q2OYNS=\SN\GW?O
M-MH\9_M_ZYXA_;HC^.6FZ3#H^I1W%M*=-%T98IHXH$MY(B^U3ME0$'Y?EW_[
M-?/H/-!YKG_U;R]R]I[/7D]GU^#M_6ITQXHS)0]G&I9>T]KLOXG?;\-O(]^_
M;&_;<@_:R^-WA_QU_P (;:>&]8TA(H[GRK\SKJ(BEWQY^1=I7YAN^;*X_NU]
M0?\ $0]K 15;X5Z8VW@9UQ__ (Q7YQ,<\TH.'YKAQ7!N4XBE3H5:5XT](^\]
M+_,]#!\=9WA:]7$4*UI5-9Z1U:^1]:_'_P#X*E-^T)\?_AKXXU;X>V$<?PYG
MENHM-75&=+V5BCQ,7\KY=DD2-]UMVVO-?VZ_VU=8_;A^*=AXBU+3(M#MM-L%
ML;2PBN6N$B^<N[[F5=S,3_=^ZJ^E>*#KR.*.JC+5V87AG+L-4ISH4[.FFEJ]
M$W=[LXL;Q9FF+A4IXBK=5&I3T6K2LMET2VV/0/V6_P!H74_V6?CIH/CC285O
M+C197WVKRE$O(G1D>)F[;E9N=ORMM;M6Q^VC^T_%^U_\;IO' \,P>&+Z\M(;
M>^AANS<+=2Q!D$N2B[6V;$_X M>3XY QFAA@GC%=DLIPCQBQZA^\4;7\NQP_
MVSC/J+R]S_=-\UM-]K]QM%%%>D>2%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >D_L
M;?\ )W_PI_['#2?_ $LAK^B-?]4GTK^=S]C;_D[_ .%/_8X:3_Z60U_1&O\
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M1110 4449Q0 4444 %%%% !1110 4444 %%%% !1110 444'I0 T_*:^7O\
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MCU_T#/#/_@W7_P")H_X<<_'K_H&>&?\ P;K_ /$T?ZZY)_T$P^\/^(?\1?\
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M<_'K_H&>&?\ P;K_ /$T?\..?CU_T#/#/_@W7_XFC_77)/\ H)A]X?\ $/\
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M0_XB_P"@6?W'R#17U]_PXY^/7_0,\,_^#=?_ (FC_AQS\>O^@9X9_P#!NO\
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MZ!GAG_P;K_\ $T?ZZY)_T%0^\/\ B'_$7_0+/[CY!HKZ^_X<<_'K_H&>&?\
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M $"S^X^0:*^OO^''/QZ_Z!GAG_P;K_\ $T?\..?CU_T#/#/_ (-U_P#B:/\
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M0^\/^(?\1?\ 0+/[CY!HKZ^_X<<_'K_H&>&?_!NO_P 31_PXY^/7_0,\,_\
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M0_XB_P"@6?W'R#17U]_PXY^/7_0,\,_^#=?_ (FC_AQS\>O^@9X9_P#!NO\
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MZ!GAG_P;K_\ $T?ZZY)_T%0^\/\ B'_$7_0+/[CY!HKZ^_X<<_'K_H&>&?\
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MXY^/7_0,\,_^#=?_ (FC_77)/^@J'WA_Q#_B+_H%G]Q\@T5]??\ #CGX]?\
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M&Y*VC[>2/4]WTHW'VKRW_A:OQ*_Z)3_Y<EM_\31_PM3XE?\ 1*3_ .%);?\
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M4G_PI+;_ .)H^IS[K_P*/^8?7J?:7_@,O\CU+<?:C<?:O+?^%J?$K_HE)_\
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M .)H_P"%J_$K_HE)_P#"DMO_ (FCZG/NO_ H_P"8?7J?:7_@,O\ (]27K_\
M6H)YKC_AGXX\0>++[4(->\+MX9FM5B>(?VC%>>>'W_W!\NW9WZ[J[!AD_P#U
MZQE%J5F=,)J:NO\ (=1114EA1110 4444 %%%% !1110 4444 %%%% !BBBB
M@ HHHH **** "BC-&: "BBB@ HHHS0 4449H **,T9H **,T9H **,T9H **
M** "BC-% !111F@ HHS1F@ HHS1F@ HHS10 4444 %%%&: "BC-% !11FC-
M!11FB@ HHHS0 4444 %%&:,T %%%% !11FC- !11FC- !1110 4444 %%&:,
MT %%%% !11FC- !11FC- !11FB@ HHS10 4449H **,YHS0 449HH **,T4
M%%&:,T %%&:* "BC-% !11G-&<4 %%%% !11FC- !11FB@ HHS10 4449H *
M*,T9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HQ110 4444 %%%% &8W_(Y)_P!>3?\ H:UIUF-_R.2?]>3?^AK6G0 4444
M%%%% !1110 4444 %%%% !67XH_U5C_U^P_^A5J5E^*/]58_]?L/_H5 &I11
M10 4444 %%%% !1110 4444 %%%% !5?5/\ D&W/_7)_Y58JOJG_ "#;G_KD
M_P#*@"/0/^0)8_\ 7NG_ *"*N53T#_D"6/\ U[I_Z"*N4 %%%% !1110 444
M4 %%%% !1110 4444 9?AS_CYU7_ *_6_P#1:5J5E^'/^/G5?^OUO_1:5J4
M%%%% !1110 4444 %%%% !1110 4444 9GA+_D#-_P!?-Q_Z/>M.LSPE_P @
M9O\ KYN/_1[UIT %%%% !1110 4444 %%%% !1110 4444 9EE_R-VH?]>UO
M_P"A2UIUF6?_ "-VH?\ 7M;_ /H4M:= !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%!Z4 -/(S45S<QVMNTDCJD<:Y9F. !ZU*.*^7_^"P?Q
M.U#X8?L#>,9M,DDM[K6/(TDRIU2*:55F'_ HMZ?\#KJP.%EBL33P\=Y-+[SA
MS+'1PF%J8F6T$W]QX+^TG_P6_P!0NOB3)X/^!?@__A-K^%VB74I[>:ZCO'7[
M_P!GMH"LCJO]]F7_ '=OS'B]"_X+._&WX$^*K./XR?"IK/1[Y\*1I5UI%YM[
MF)IV:.7;G[OR_P"\*]V_X(?_ +/V@?#_ /8]TOQK#:P2^(?&L]S-=WF SI#%
M</#'"I_A3]UO(_O.V>@Q]0_'WX'^'_VB_A1K'A+Q)9Q7>FZM T>2@:2V?!V3
M1D_=D1OF5NQ%?6XG&91A,4\!]6YH1?+*=WS:;L^'PN!SO&X19E]:Y927-&"2
MY;/5)C_@?\<_#?[1'PPTWQ=X4U!-2T?4H]T;XP\;#AXW7^!U;*LI[BOB;X$?
M\%I+[Q'^V5=?#SQOH^@Z/X?EU>ZT6TU.U:19(9TF:.$S;W9=C[=I(QM9U/W<
MXXK_ (-^/&NIZ)XQ^*/@*XG^T:;9K#J,2(VZ&&=':"5D_P!]?*_[]"ODK3?V
M8-7_ &H/C]\<+/P_YLVM>%VU/7;6T0;FO_*U!$>(?[>R1RO]Y@H[UZ>7\-X&
MGB\7AL6_=BH\LNW-LSR<RXLS&>#P6*P:]^3?-'OR[H_9G]N7X_:E^R]^RQXJ
M\=Z/:V>H:CH*6[P6]WN\B3S+F*([MI#?=D)Z]A61_P $\_VGM7_:_P#V8]-\
M;:Y8:=INHWEW<V[PV0?R0L4I0$;R3SCUKX<G_;G/[5G_  1Y^(V@:_>&7QSX
M-M;"WO3(W[S4K;[=;"*Z_P!H_P #_P"TN3]\5Z1^PG\1[WX2?\$2?$WB'3)'
MAU32[369+25?O0S&20(__ 68'\*\NIP]['+Y0J1_>^V4+^37Y=3VJ/$[K9E&
MK3E^Y=!SM_>3U^:V-K]LS_@M/9_"7XA77@3X7^'4\<>*K>X-E+<N7:SBN=VW
MR8XHOWEPX;Y6"L@ST9N=OD-Q_P %<OVGOA$(]=\>?!V.W\,NRF1I] U#2U4,
MQ"JL\C,J,W^VK=1_P+L/^#?OX Z&_P ,_$WQ*NK6WN_$4^JOHUK<.%=K.W2&
M*1]G]TR--\WLB_C^BVJ:3:ZWIUQ9WEO#=6MTABEAF0/'*A&TJP/!4CM3QV)R
MO+:[P,<,JG+I*3>K?6W8C+<'F^:T%F+Q3I\VL()*R72_<\C_ &*OVW/"G[<'
MPVFU[PY#?6-UILBP:EI]XO[RRE*Y W#Y70\[6'IR%;*CYW_;9_X+.6OP<^(L
M_@'X6Z GC?Q=;S&SN)Y-[VEO=9V^0D<7[RX=6^5MI55;Y=Q;<%]X^/>CZ-^Q
M9^Q%\0)OA]I-EX;CT;1[V\L8K&':L-U(K;9?]HJ[ \]E Z"OE3_@WZ^ VAR?
M#CQ5\2KRUAO?$LNK-HUK-)MD>R@2&*5]G]UG:;YOXMJ+ZG/-@<+ERIULSG3;
MIQ=H0;ZON_+^KG3F.,S-U</E$*B56:;G-+9+LN[_ *MTXY_^"P?[1_P:U"VU
M7XD_"6&U\-W$JJ1/HE]I#-G^&.:4LN[&?O*:_0#]DO\ :S\*_MB?"ZW\4>%;
MES'N\F]LY\+=:?/@$Q2*#U[@CAEKO?&7@W2?B%X8U#1=:T^UU/2=2A:"ZM;B
M,/',C=58=Z_+C_@E9!<?LV_\%2OB+\,=,NI[CP]*-1L=ADW9%K-OMY7Q_&J;
MT_[:FKE#!9I@ZM2C2]E4IKFT^&4?\S.,\?D^.HT:]9U:55VUW4NGR9])>#/^
M"C7BGQ%_P5"O/@=)HNAQ^';:XN8DOE$OVQA'9&X7^/9]X;?N]*^S!\JG^M?E
M;\+/E_X.&-4_Z_K[_P!-+U^@'[:GQ*O_ (0?LG_$+Q)I<C0ZEI.A7,MG*@RT
M,QC(1_\ @+%6_"N7/,LI4\1AJ.'5N>G!_.1W</YM5GA<5B,0[^SJ5/NC;0^8
M?VV/^"SMK\&OB+/X!^%WA^/QQXPMYC9W%Q)O>SM[G.WR$BB_>7#JWRMM955O
MEW%MP7QMO^"PG[1WP9U*WU;XD_"6&U\-W$BJ1/HE]I#-N_ACFE9EW8S]Y378
M?\&_?P&T.3X<>*OB7>6L-YXDFU9]&MII-LCV,"0Q2OL_NL[3<_Q;47U.?T-\
M8^"])^(7A:^T;6M/MM4TK4H6M[JVN(P\4Z-P593UKT<9B,JRW$/ _5O:*.DI
M-ZM]>7L>5@<+G.:X;^T?K7LW+6$$E9+I?N<%^R=^UEX3_;%^%MMXH\*W4C1A
MO)O+.?"W6G38R8I5!Z]PPX9:\Y_;_P#^"E?A7]AG3K:SEMV\1>,M2B\RST>&
M;RO+BR1YT[X;RTR"!\I9MIP.&*_'7_!*^&X_9J_X*D_$;X8Z7=3W'AZ0:C8A
M&DW9%K-OMY7Q_&J;T_[:M6=^S#X#TW]M/_@LK\0+_P 91KJNG^&+S4;^&SNP
M#',+2X2SMHW0]0BLC;?NY3YO]K2/#V#I8VK5JW="$.>W5I[(S_UHQM? 4J5%
M)8BI-TV^B:W9K)_P5@_:P\2Z;_PD>D?"6W;PVP#PRQ^%M2N+5D;Y@QE67YEV
MX^92J_=]:^D/^">7_!6G3?VQ?%[>#=?\.W'AOQI'$\\:V^^XLKQ$Y?YL;H67
M^[)Q_M;OEKZ&^.G[37@']F#1]/O/''B"U\.V>H2F"U>6&202N%W%1L5NU>)>
M"OV\OV4_#_Q'U37=#\2>&;'Q-XJ:**^O;;2[F.?4&4X0.PBYY;\>]<=6I1QF
M&E[+ M?RRA?\=-3MHT<1@,7#VV8I_P \)V_#73^O0P?V_O\ @HIXU_8:_:$\
M)65[X=T74?AQXBV/)J"I-]NA5'5;E!\^QG165UX^;>J^IKT_]N+]N/2_V4OV
M6QX]TMK'6;K6OL\7A^%W/DZ@\PWA^/FV"+<_'H!WJ3_@HW^RA#^U[^R]K6@0
M0I)X@T]?[2T-SU6[B4E4SV65=T9]GSVK\H/V6_#?C7_@H'\6_A?\(M>N+F3P
MK\/4F,ZD,KVEBLV^?S&_OM^ZMT_N_(/[U=F3Y5@<=A(8F7N^QO[3S6Z?Z''G
MF<9CEV-J86G>?M[>R\GLU\M_N/US_8,^-/C/]HK]G;2O&OC;2=)T2\\0.]Q8
MVE@DJK]CX$4C[V;YI,%QCC8R=\UZIXRUN3PYX-U34(XTDDL;26X1&/RL40L
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MPKX%T'Q$N@7!CMP+:[GNI46!97=EB?\ A!8_*O1:XS_@@F-W[3OQ:[?Z&O\
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M"NCO_78^C_V_/^"F?A7]AC3(-/FM9/$7C+4H_/M-(BD\D)%N(\Z:3:VQ,A@
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MDJ&*KNF^;W867).'2S[]SZFHH'2BOA3]*"BBB@ HHHH **** "BBB@ HHHH
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M%:0A&$E_,EO_ , XY<&^UP&(PE=J\ZDJD&NC>W_!/@7_ (-XSC]G[Q__ -C
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M /@MG^S!XJL?&GA7X\>"X)IKSPBL,>I_9T\R6Q^SS-/;W>W^)59F#G^$"/\
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MQUX.M/C%X-BFM_%W@>-);]K0%9I[.-MXF!7^.W;Y\_W W]Q:^MO%O[+/P_\
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M#_@UX8^'WPQ7P;I&CVMCX76&:W73HP?)6.4LTB8)Z,7?_OJL_P""G[.7@?\
M9UL;ZV\$^'-/\.PZFZRW4=HI43,H(4G)[9/YUX%/-*-/!8C"03_>-6]$^I]-
M4RBO5S##8V;7[N+3]6NA^9O_  4V^)>G_!O_ (*^>"?%6L+<MIGAZWTJ^N1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F-_P CDG_7DW_H:UIU
MF-_R.2?]>3?^AK6G0 4444 %%%% !1110 4444 %%%% !67XH_U5C_U^P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^0,W_7S<?^CWK3H **** "BBB@ HHHH **** "BBB@ HHHH S+/_ )&[4/\
MKVM__0I:TZS+/_D;M0_Z]K?_ -"EK3H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<1^S?\&M+_X*_P#_  63^-WQ2^)UM'XC^&_[+>O-\/O 'AB^03Z:FJP_\?\
M?R1-\CR"6-67<&SYD6?]0E?K!0!\H_L%?\%F_@3_ ,%$/$%YX;\&^(-2T'Q]
MIN_[9X-\4V1TK7K;9]_]RS,LFW^+RG?;_%MK:_X*1_\ !3?P9_P3#\">$=>\
M8>&/B!XM_P"$V\01^&=)T[P?IT-_J%Q>R1O(B"*6:+=NV;5",S,S*NVND^-G
M_!/'X-_M"_'[P-\5/%G@72=0^(/P[ODO]&UR/?;W2.@.Q9FC9?/C1L.J2[E5
MAQU8-\?_ /!Q5XKTKP#XI_8GUS7M3L-&T/1?VB?#=_J&H7]REM:6%O$[R23R
MR.0J1HBEF=B%502: -Z;_@Y2^"OA1;6X\=?#?]I#X7:3.JM-JGBOX=W%O9V.
M64?O6B>5N"X^XK?RS]9_%']M/P+\-_V.-<^/%O?2^+OA[H?AV7Q2MWX?:*Z?
M4;*.)I2;?>Z(S%5^ZSKSP<5XQ^U#_P %FOV./ OP5\22^*/C9\)?&NBW&G3Q
M76A:+K=GK\^L1,A5K46]N\F\OG;M;:OS?,57<U?$G['WP@\8_!G_ (-)?BU8
M^,-+U+PZVK^%/%.M:+I%^'$^F:9<>;);H5?Y@K_/*N?O+.&_BH _6O\ 9[^-
M6E_M)? CP3\1=!M]0M-%\?:!8>)-/AOD2.ZBM[RW2XB254=U618Y%#*K,N[.
M&;K7"_M*?MV^$?V5_CS\&_A]X@TWQ)>:U\<-7N=$T&;3[>&2UM9H$CD=KEGE
M1D3;(,;%=CS\M?(__!./_@MI^RC\)_\ @GG\!_"_B+XY>!]*\0^&_AYX?TG4
M[&XFD6:SNH--MXIHG^3[R.C*?]VO(?VYO^"AGP5_;>_X*F_L&VOPF^(WAWQU
M<>'?'>I2ZE'IKNS6:2VT"QE]RC[Q1_\ OF@#]#/V\/\ @HG\-_\ @G;\/]-U
MSQ]=:M=7WB*[_L[PYX<T*Q-_KGB:[^7_ $:RMP1O?YT^9F5%WJ"P++GY[^''
M_!?WP:WQ?\,^#_B[\&_CQ^SQ_P )Q=+9^'=;^('AG^S])U"X<_);/<*Y\J5L
MK\K+M7^-E[^U:Q_P3V@\8?\ !432OVD]>\3?VPOA7P1)X2\,^&9-,VQ:'<2W
M#2SZDEQYIW2R1N\./*7Y&^\VU:\7_P"#EOQ-X5TS_@D/\1-&\06-OK&M>+Y[
M'1/">F&,27E_K,MW%]G%JF&9I442RX7YBD;K_%0!]0_MF?MJ_#S]@;X%7WQ$
M^)FM?V+X?LY4M84CC,]WJ5T^[RK6VA7YI97VMA1_"K,VU59A\E>#/^#A_P &
MZ=XO\/Q?%KX)_'SX!^$?%]REIHWC#QSX:^QZ)*\FWRDN)E=OL[-D\ME55=S,
MJY*\'X[^'&K?&W_@K[^QC\(?B4R:RGP7^$<OQ%U:SE=IH+[75\K3DN)/X7:*
M>+S48_Q;O[V&_0+]K;]F_0?VO_V:O&_PS\3V=M?:/XRTBXTQUF3<L#NA\J8>
MCQ2;)%8?,K("* /1XI5GB5D965AD$=#3Z^*O^#>3XV:M\=_^".OP5U;7)VN-
M8TS3KKP_<M(V]\:??7%E%N/=O)MXJZ7]N?\ ;G\7?L5_M7_L_P!GJ&G^')O@
MM\5M=D\&Z]JTUO.-2T+6)T+:8RRB3RO(GD#(V^/Y=C-O_AH ^L**\)_X*1?M
MHZ=_P3X_8F^(7Q:U%(+F;PKI;-I=E+G;J6I2L(K2W.#NVR3O$&V_,J;V_AK2
M_8%_:ZT?]O']CGX>_%K152&V\::1'>7%LCEA8W:DQ75OG_IE.DL>>^S- '2?
MM0?&B;]G+]GGQEX\A\.:YXND\):3<:HNBZ/%YM]J1B0MY42_WFQ[_0]*R_V-
M/VCYOVN?V7/!?Q)F\*Z]X&D\8:>M^VB:S'LO-/\ G9</PN5;;O5L+N1E; SB
MOEOP%_P5#^('Q@\*_MH?$+PWH_@]OA;^S_;:GI?@:]GM+E[GQ'K&F:?+/?/<
M.LP1[-9U1$\I49E<_/E:](^#WQ]^/'[6W_!,CX4_$KX9_P#"I=(^*OCS0],U
MN_C\36>H/X>A2>'?.D4=O-YZMN9=FZ1N^<T =]_P3_\ VYO#_P#P4._9XC^)
M'A?2=:T72Y-6OM)%MJ?E>?YEK.T#G]V[+M9ER.:K_P#!//\ ;JTG_@H=\"+W
MQWHV@ZAX>M;'Q#J/A]K6\F261GLYO*:3<GR[6ZBO@/\ X-=X?V@A^ROH[W%W
M\&S\$?\ A)/$(O(8K74O^$J^V_:I=Q24R?9?)\_'5-WE_P"U7E/_  1)_:B^
M/7C;]G3Q7\&_V;?"/A--<\.^.]>U+Q7XZ\=?:/[ T);F\=K>SMX;=O-O+R1$
M9SMVQQ+LW;M_R@'[F45^=_P0_;K_ &BOV4/V[_ OP'_:DM? 'B72_B]!<_\
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M\]O=PNH=)8W6^P\;*0RLO#*16=_SJ/\ _= /_<;4'_!.S_@OK^R%\&_^"?\
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M75K-?6O@[1+W7)K:)@LDZ6UN\S(I;HS*A'/]ZOA'5]<_X*??#?PU)XVN-/\
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MI7RC'$GR[PQ9E- 'UQ1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO[ /PBF\;_%CQ9I_A305?R+?S5:2YU";&1!;PH&DED]E7Y1EFVJI:OCC2O\
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M\CDG_7DW_H:UIUF-_P CDG_7DW_H:UIT %%%% !1110 4444 %%%% !1110
M5E^*/]58_P#7[#_Z%6I67XH_U5C_ -?L/_H5 &I1110 4444 %%%% !1110
M4444 %%%% !5?5/^0;<_]<G_ )58JOJG_(-N?^N3_P J (] _P"0)8_]>Z?^
M@BKE4] _Y EC_P!>Z?\ H(JY0 4444 %%%% !1110 4444 %%%% !1110!E^
M'/\ CYU7_K];_P!%I6I67X<_X^=5_P"OUO\ T6E:E !1110 4444 %%%% !1
M110 4444 %%%% &9X2_Y S?]?-Q_Z/>M.LSPE_R!F_Z^;C_T>]:= !1110 4
M444 %%%% !1110 4444 %%%% &99_P#(W:A_U[6__H4M:=9EG_R-VH?]>UO_
M .A2UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+W
M_!:K_E$?^T=_V(&K_P#I.]?4->:_M=_LZ67[7?[,/C[X7ZCJ5UI%CX^T.ZT.
MXO;9%DEM4GC*,Z*WREESWH ^6O\ @F#_ ,$V/V=?%O\ P3K_ &>?$FJ? +X*
MZGXBU3X<^'-3N]5N_ ^F37MS=2:9;2//),T.]Y6=B[.3N9B6SFOMWP]X>L?"
M>B6NEZ58V>F:=8Q+#;VMI L,$"+T1$4;5 ]!7)_LR?!"T_9C_9O^'WPWL;ZX
MU2S^'OAO3O#=M>3JJ3745G:Q6ZRNH^4,RQAB!ZUWU 'Y;?\ !O?\$O!?Q*^'
MW[5-]XB\(^&/$%Y#^T=XMMTN-2TJ&ZF6)8K!@@:1"VW<S''^T:_1OP?\!O _
MP\UC^T=!\&^%=#U#88_M.GZ3;VLVP]5WHBMMK\^=-_X-ZO$_@#QSXZU3X>_M
M>?'3X;Z;X\\4ZAXMO=(T!XK6S6]O'W2-A6^9MJQIN;G;&M>X?L2_\$R_B'^R
MA\:U\5^)OVJOC7\8--^PS6?]@>*+H26&]]N)MNX_.FTX_P!XT ?./["/Q+LO
M^"9?_!8_]H3X#_$.>S\/Z-^T7XE;XF_#C59G\JSU:XNV?[98[VX6?S-J(G&Y
MH&4?ZR)6_2SXL?#VW^+7PJ\3>%;K4-8TFV\4:5=:5+>Z3=&TU"S2>%XC+;S#
M_52H'W(_\+ &O,?V[_\ @GA\)_\ @H_\($\'?%;PY_;-G92M<Z;?6\K6VI:-
M<%=OG6LZ_,C=,J=R-M7>K;:^3[#_ ((P_M*?#C3(]!\ _P#!0'XN:-X.MV\N
M"R\0>%[/Q#J4-O@ 1K?23(ZLJ[@K*NU?EVJNV@#Y1_X+)?\ !/W3OV-?A_X)
M\%_"#X]?M1>(/V@OBUXBM-$\'Z!?_$ZZN4:)I5^TWDT2(K+ B?(79E56EW<J
MC5]&?\%[?A?IL^G?L'>"_$4%KXJTF7X]^%-$U2+58%O(=8@8-#,MPDNX2K*N
M[>K[MVXYS7T+^PM_P1T\!_L;?%+4/BCKWB'Q9\8_C9JRO'=>/?&5U]JU""-@
M5:&T3[EK%M)7"Y;:S+NV?*/0?VX/V!M(_;>\2?!G4M6\0:EH<GP8^(&F_$"R
M2TA21=1GLG+);R;ONQMW*_-0!J>!?^"<7[//PN\2V^L>&?@/\&?#FL6;+)!?
MZ7X*TVSN82IW K+'"K*00#P>U<5_P6J_Y1'_ +1W_8@:O_Z3O7U#7FO[7?[.
MEE^UW^S#X^^%^HZE=:18^/M#NM#N+VV19);5)XRC.BM\I9<]Z /G+_@F)^PS
M\$_%O_!-7]GG5M4^#GPMU/5-4^&GAN\N[R[\*6$\]U.^E6SO+([1;G=F8EF;
MEB<UX%_P4[_9R^'WP)_X*B_L S>"/ G@[P;+J7CW54NVT/1;;3C=!+6VV!S"
MB[MNYMH;U-?HM^S)\$+3]F/]F_X??#>QOKC5+/X>^&].\-VUY.JI-=16=K%;
MK*ZCY0S+&&('K7GG[5_[ ^D?M8?M&_ KXB:AK^I:3>_ O7+K7+"TMH4>+4WG
MCCC*2LWS*%\O^'^]0!VW[5_[5G@?]B;X"^(/B3\1M:BT/PMX=@\VYF?YI9W/
M"0PI_P M)7;:JHOWF-?$G[ O[+GQ _X*(?M)Z3^U]^T=H\VBV>EAW^#?PUN_
MFC\'V3[635;M.C:A*H5AN'R?*W#+$L7;?\%2O^"+5]_P5)^*OA?6M<^.7C;P
M;H/@B2*\T+0-'TZW-I9WJG+7KEVS+/GY59ON+\JJ-SL_'_\ #C/XR?\ 1_W[
M4'_@>O\ \70!H_M,ZG'\#?\ @XL_9[\6:PRVNC_%;X8:S\/;&Y<[8VO[:\74
M5A9ON[G5U5!_$S8K[5_:2^..C?LR? 'QE\0_$$\=OHO@O1KG6;IG?;N2"-GV
M#_:8@*H_B9@*\A_:&_X)D^%?VO/V+/"_PA^)?B+Q3XDU+PC;V,VG^-TN_L_B
M*UU6TBV)JT4WS;+EFW,W56WM7S_'_P $-O'WQKNM%T7]HC]J_P")'QR^%>@W
M$-U%X*ET:UT2VU8PL'B34[B%VEO4#C)W[6/R_,-M ':?\&X?PEU3X._\$9?@
MM9ZW!);ZIK=E>>(90Z[6:._O[BZ@;&/XH)86_&O8O^"GW[&,/[?/[#/Q!^&.
MY;?5M8T\W&@W>?+;3]5MV6>RG5_O)MGC0,5(.QG7O7NNDZ3:Z-IEO9V=M!:6
M=I$L,-O#&$C@11M5%4?*JJ.,"KM 'XL?L_?M7ZC_ ,%Z_P!H/]EWX;ZO9W::
M7\"=/_X6%\9[2X@:-9/$UA*]A96+J<?>N8Y;GR_F5HI]I^:-JS/C%^U1KG_!
M";XD?M2_ ?P[9WLG_"W43QO\!;:UC+&/5-8N$L+NPB_AW6URZ3)%N_U=NS?>
MEK]3OV9?V$? 7[)?Q5^,'C#PAI[6FL?&GQ&OB777('RS"$)L3 ^X93<3_-D^
M9=R_P[54_:,_83\ _M1?';X._$3Q5IHN/$7P3UFXUC0Y-HP[RV[1['_V5E6W
MN%])+9/>@#P6_P#V-=-_8!_X( _$'X4V/DRW/A?X0^(!JMU&3C4-1ETNZEO+
MC/4A[AY2N[HNU?X:]%_X(J_\HC_V<?\ L0-(_P#2=*]K_:)^#MO^T)^S_P".
M/ -Y>3Z;9^./#]_X?GNX5#2VJ7=N\#2*K<%E5\X/I67^R)^SI9?LB?LP^ ?A
M?IVI76KV/@'0[70[>]N46.6Z2",(KNJ_*&;':@#XY_X-@/\ E%C:_P#8[>(_
M_3C+67_P:[^&K?0_V!?'5Y'#%%+K7Q6\1W4[J.9F66* ,?\ @,0'_ :^JO\
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M"C'[,NM_#'QU!,-/U(I<V&HVV%O-#OH\^3>6[-]V5&)_WE9T/RLU>=_M2_\
M!,[4/VQ/V =!^ ?C?XN>+KZSAGL1XA\0Q6<46H^*K2T?>L%QSM5G986>1?F9
MHLX^8T ? _\ P3._8"_:J_:LM/%O[7GAW]I.W^ ?B3]I:];69=&;X:Z?XIGA
MTF*21=.B6ZO)59(O(V;410&C$3,6.-K?VP?V:/C]_P $F_VK/AO^VQ\2/CPO
MQZTWP_>VO@?QZUO\/[3PO-8>&[R5D,[BSE9;A8IY49=R[O,\A=Q7[O[,>%_#
M>G^"O#6GZ/I-G;Z?I>DVL5G9VL";(K:&-%1$1?X555  ]JYK]I#X"^'/VH_@
M/XN^'/BZU^V>&_&>E3Z3?I_$$E0KO0_PR(<.K?PLJGM0!+\4_CMX5^#'P3UO
MXB^(M:L;'P9X?TJ36KS5!*'A-HB>9O0K]_<N-H7[Q90N<U^*L_['/QV_;^^$
M_B7_ (*):/=:YH/QQL=9M_%'P?\ "KNS10>$M/\ .5=.DB7[[WL4LK[5_P!=
MVPMT]?H!\2_^"-=O\9?V!OA3^SEXL^+'B[5O /P]O++^U_+M(K>Z\7Z?9RYM
M-.N74_NX8T")N3YCY,3?>7G[0T72+3PWH]K86%K#9Z?90I;VUO!&(XK>)!M1
M$5>%55"@*.E 'DO[ O[:/A;_ (*!_LF^#_BOX1DV:?XFM0UU9,X:72;Q/DN+
M23_;BE#+_M+M8?*RU^:?Q ^%'Q1_X+9_\%=_&7CWX3_%JV^$/A#]D.Y/@WPM
MXBE\*6_BB+4M=E63^TY8K:XE6 ,GRIYOS?+';,HW-N7[F_9]_P""85G^R;XY
M^/5]\-/'VO>%=!^.$LVK1Z!%:1/9^$-9EA\N34;'IM9F.\Q-\O[N)?NHHKN/
M^"<_["/A7_@G!^RIH/PK\)W=WJMII<MQ>7NJWJ*MYK%W/*TDMQ-MZORJ>RQH
MO\- 'Y\?\%%O^",?[8?[0'[/\FJ:W^V*GQ6U_P"&-S_PF?A31$^$>E:#=3:M
M9H[P+!>6LWFQ2-RJ\,K,4W#^)?N+]B;]MC3?^"AO_!-#1?BMIXMX;KQ)X9G7
M5[.(_+IVI11/%=V^&^8*LZ/MW?>0HW\5?3=?,_[(_P#P3;T+]C#5_C9;^%?$
M6J#P?\9-?F\2)X<>W1;7PU>W$3)=FV*_P2_(=C+M7RD5: /!_P#@V=\-Z?XQ
M_P""!?P=TG5K*TU/2]4MO$-G>6=S$LL%U"^O:FKQ.C?*RLK%2K#G-?)_[:^B
M^*O^"!7PE^,WPYCAUCQ-^Q[\=/#.O:=X4D^>ZN?A?X@O+"Y5+!F^\UC<2O\
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M_!0*S\.7^N7GB/PCX]\#SM<^%?&WA:_;3]>\.RL5W^3,.&1MOS(ZLOIM;YJ
M/>?%7BS3?!'AK4-:UC4+/2M)TFVDO+V\NYU@M[2&-2SR2.WRHBJI)9C@8K\L
M/^"&_B;0?&G_  2*_:CUCPJGE^%]6\>^.[S1U*[2ME+:QO ,?P_NRE>P7O\
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M_B,O<#(^ZL<2&5C_  I$U?MSX[\*1^.?!&L:+-(\$>L64UD\J#+1K*C(2/\
MOJO*?V&/V*]%_8@_8Q\)_!.SU&X\6:#X5L;C3_M.I6Z*U_'-/+*XEC7Y-O[X
MKM[J* .V_9W^*'A'XV? [PEXL\ WUEJ'@O7-+AN='FLW5H?L^Q0B87[K)C8R
M?PLK*>16Y?\ CO0])\7:;X?O-:TJUU[6HII]/TR:[CCO+V.+:97BB)WNJ;EW
M%5^7<,U\+I_P0RU#X"ZOJ_\ PS1^T3\5/V>_#NMW!NY_"MI%;Z_X?M)G.97M
M;:[&Z!GVKG:_;^[A:[K]C/\ X(T^$?V:/CV_QB\;^.O'GQT^,QM#86OBOQK>
M+.VBV[!@T5C;J-ENK!F_O,H9U5E5W5@#RO\ X)':'$G_  5R_P""A^I?*TUQ
MXL\-6I.WYE1+"Z;K]7_\=KRC]N_]GW5?B=_P<C^!+?4/BGXX^#\7C/X-RZ=X
M,\0^&_L\4]U?VNH2RW6F(]Q#*FXP.\[;=K8*+N^;:?OO]E_]A32?V8?VE?CE
M\2K'7=0U2]^.6KV.KW]G<0HD6F/:V[P*D17EE97S\W2IOV\?^"?7P]_X*'?"
MJW\+^/+;4K>[TBZ&I^']?TBZ:RUCPS?K]RZM+A?N2+QP=RMM7<K;5P >)G_@
MDA\2U&3^VY^U!C_K\TG_ .0Z\9_9]_9%\%^'?^"3'[8-G^SK\7/$_P :KOXG
M1>*GNM3NHXI);CQ%]@D@N8H?)AB5VG;9\Z*RLS*R,RD5W7B/_@BG\3OBMI;>
M%_B'^VK\>O%/PWF AN-"MHK+2[W4;?\ C@N;^)/-E1_NMN7E2P[U]H_L[_L\
M^#?V4_@SX?\ A[\/_#]GX9\'^&K?[-I^G6V66%=Q9F+,69W9V9V=BS,S,S$L
M: /#/^"(/Q)\)_%#_@D_\!;OP;):MIVE^#=/T:]A@V[K34+6W2"\C<#[LGVA
M)6.[YFW!OXJ^>_\ @Z>^(GA7PS_P3FT?0=<EM_\ A(/%'CS0T\.6Y<>:T\%R
MLL\JC[VU;82HS=FF0?Q#/HOQ*_X(EQ>&?C/XH\>_L[_&SXB?LWZUXVG-YX@T
MO0(K?4O#NJ7;-E[MM.N!L2=L_>1E7T5=S;N,^(/_  ;I>%/C[X(U2Z^*GQ=^
M(_Q3^*VJ3V31^./$!BF?0H+>[BN7MM-L1B"SBE:+:^W<VUG ;:S*0#T#_@Y"
M_P"4)GQ\_P"P59?^G*SK@/\ @O'_ ,JWGC[_ +%3PU_Z<=,KZY_;\_9 TW]O
MK]D3QI\(=8UB^\/Z;XVMH;6>_LXTEGMA'<13Y57^5N8@/QK#_;3_ &"-'_;1
M_8$UKX!:IKVI:+H^M:;I^FR:K:0I)<1K9SV\RLJ-\N6-N!C_ &C0!\I?\'"4
MJ^$?@%^RYXXUV.XG^&G@#XU^%M;\:QK$TD-OIR^:OVB;'_+)&8)M/WFG05^C
M^A:W9^)]'LM2TZ\MM0TZ_@2ZM;NVE66&YB=0R21NORLK*00PX(-8/Q%^#WAO
MXM_"/5/!'BO1[/Q)X9US3VTO4=/O5\R*\@9 C*P_JO(/(YKX?T;_ ((@^.?@
M1H4GAGX$?M<_&CX5?#[S&^R>%[JWM/$%MH\+9+064UP!+;IN9BOS,5SGEOFH
M ^\HO'NAS>.9O#,>LZ2WB*WLTU&;2UO$:^BM7=HTG:'=O6)G4J'*[<J1VK<K
MY5_8'_X)/^ ?V$/%_B3QPNN>,/B5\6/&P6/7O'?C&^_M#6;R)=NVW1MH6&#Y
M5^11N.U S-L3;]54 ?EK_P $X_B/9?\ !//_ (*]?M)?LZ^.IH?#\7QO\52_
M%?X=74LGEV>M+?,RW5K&6_Y;JZ!%3^+[/+C^#=^I5?//_!0?_@F/\)/^"F?P
MTL_#OQ/T6XN+C1Y6N=%US3;C['J^A3MMR]M/M;;NVKN1U>-MJDH2JD?,>A_\
M$;?VFOA[%'I'AG_@H-\6[7PC'&84M-6\*6FL:G''C:BB^EG\S<HQ\VSM_#0!
M]R^+/VF/A_X#^-?AGX<ZUXPT'2_'GC2WN+K0]!N+Q$OM4C@&Z5HH^K;5#?[V
MQ\9V-M^(/V*]7L_AK_P<)_MB:#XL*6_BSXB:!X2U[P=-<Q^6VI:/:V#V]TEO
MN^\L<^Q6V9W-"['[E>S?L'?\$>/AG^PW\0]4^(C:IXR^*7Q?\0Q>3J?CWQOJ
M3:IK,B%54QQ,0%AC^7'RKOVX5G9173?M\_\ !,SX?_\ !0*U\.:AKMUXD\'^
M/_ \[77A;QOX6OSI^O>'Y20S>5, 5:-MOS(ZLO)V[6^:@#Z U[7K+PSHMYJ6
MH7EMI^FZ=#)=75U<2B*"VC12SN[M\JJJJ2S'@8K\F_\ @B]XHT/QS_P1<_:T
MUKPO'Y/AG6/&/C^]TB/;M\NSELD>%<?]<V6O<I?^"*'C+XV7$6D_'S]JSXP?
M&3X<6\JR/X.6WM?#MGJP!_U6HRVG[V[AX7Y-R?,N[=7K_P"RI_P2]\*_LE?L
MI?%3X1^']8O%\/\ Q.UG7=5)2TB@&BIJD2Q&WMXT^7RX%4!/I0!Q_P#P;Q:#
M'X;_ ."+WP!MX84A630);IE7HS2WEQ*6^K,^[\:X3]KV0V__  <8?LA[/E:X
M\#^+HY/]I1;[@/\ OJOK?]B7]EC3_P!B7]E'P+\*-+U6\US3_ NFKIL%]=QK
M'/=*K,VYE7Y0?F[5SOQ5_84TGXJ?MY_"OX\W&N:A:ZM\*])U32+72HX4:WOD
MOX]CN[GYE9.HVT ?)W[#?B+3_A;_ ,'"O[97AOQE<K;^,?B+I/A;6_!DEW^[
M_M72+:QDCN([7=][RI616"9W-!(?X&K])9[A+>-I'946,99F.%4>M?.G[?'_
M  3$^'/_  4#M_#VH>))/$7A7QWX)E:Y\*^-?#&H-INN^'9F*G=#,OWEW*/D
M=67TVM\U?/OC'_@B-\4/CIH\WACXH?MJ?'3Q=\.;J,V]UH.GV=AHL^I6^ &A
MN;N)"TR,!AMR?,"W]Z@"3_@XU23]H7_@A7\5=3^'NI6OBC29(-,U>2?1;A+R
M'4;"WU.VEN&CECW*R(L9E9AQMA:I/@C_ ,$S_$GQ5^#GA7Q)X+_;A_:0N_".
MN:3:WVC36=UI"P-:/$K1;%6SVJNPJ-O\.-M?8_P5_9B\ _L[? '2_A;X/\+:
M5H_@/2;!M-AT<1>;;R0N&\Q9=^6E:3<Y=GW,[.Q8DDU\=V7_  0YU[X$WFI6
M7[/'[3?Q;^!7@?5;U[UO!]O!:ZYI.F^9\TJV*W2[[4,WS?>;#$T <WI?_!/3
MP+\/O^"F_P #I?B!^UE\6OB%\:/"MOJ.O^#O#?B&2QEDFLFB\B\9C#:*R12)
MD?,Z[_)?;NV/B[_P2.T.)/\ @KE_P4/U+Y6FN/%GAJU)V_,J)873=?J__CM>
M]?L'_P#!*GP+^P[XU\0>.6USQA\3/BWXNB^S:YX[\7ZB;[5KV'<'^SQ]$@@#
M*OR1K_ FYFV+MZK]E_\ 84TG]F']I7XY?$JQUW4-4O?CEJ]CJ]_9W$*)%ICV
MMN\"I$5Y965\_-TH ]ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH S&_Y')/^O)O_ $-:TZS&_P"1R3_KR;_T
M-:TZ "BBB@ HHHH **** "BBB@ HHHH *R_%'^JL?^OV'_T*M2LOQ1_JK'_K
M]A_]"H U**** "BBB@ HHHH **** "BBB@ HHHH *KZI_P @VY_ZY/\ RJQ5
M?5/^0;<_]<G_ )4 1Z!_R!+'_KW3_P!!%7*IZ!_R!+'_ *]T_P#015R@ HHH
MH **** "BBB@ HHHH **,T9H **** ,OPY_Q\ZK_ -?K?^BTK4K*\.R*+K5/
MF7_C]/?_ *9I6KF@2DGL%%%% PHHHH **** "BBB@ HHHH **** ,SPE_P @
M9O\ KYN/_1[UIUF>$O\ D#-_U\W'_H]ZTZ "BBB@ HHHH **** "BBB@ HHH
MH **** ,RS_Y&[4/^O:W_P#0I:TZS+/_ )&[4/\ KVM__0I:TZ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK%\5>/=#\"V]O+
MKFLZ5HT=U*(8&OKM+99I#T1=Y&YN1\OO6K!<)<1K(C*ZR#*LIRK#UH EHHK$
MA^(&@S^*V\/QZUI$FNQQ^=)IR7D372)_>,6=^WWQ0!MT45B>+?'FA^!;>&;7
M-9TG18;B3RHGOKM+=9'/ 52Y&6Y''O0!MT5\/?\ !7W]HKQE\#OB7^R#;^#?
M$VH:'9^._C=HGA_7$LW7R]6TV<2>;;OQ\T;87I7W#0 445BZ/X_T+Q%KEYI>
MG:YI-]J6G_\ 'S:6]Y'+-;?[Z*=R_C0!M445F^)?%6F^"M(FU'6-0L=+T^W&
M9;J\N$@AB^KN0HH TJ*S/"_BS2_&^D1ZAHNI:?JVGS?ZNYLKA+B&3Z.A*FM.
M@ HK'_X3K1?^$J_L'^UM+_MSR?/_ +.^V)]K\O\ O^5G?M]\5)XH\7Z7X%TB
M34=:U/3]'TZ'_675[<I;PQ_5W(44 :E%5=.U.WUBPBNK2XANK>X7?%+%('CD
M7U4KU%&JZM:Z)827=Y<06=K"NYY9I!'&GU)Z4 6J*R?"?C?1O'FEK?Z'JVEZ
MU8L<+<6%TEQ$?^!H2*\+_:>_9M^,'Q8_:P^#?B_P/\9+GP+X!\#WDTWB[PM'
M8><GBR)F3:C/G^ZKI\WW-V]?FH ^BJ*^)_\ @M_^TSXZ_9=^ WPIU;P%X@NO
M#>H>(/BWX<\/7\\,44IN+"YEE$T!\Q& 5PJ_,,-QUK[8H **P]=^(&A>%]7L
M[#5-<TC3;_4#BUMKJ\CAENO]Q&.6Z'I6Y0 45\0_!G]H3QKXA_X+U?&;X9WG
MB+4;CP+X?^&>CZOI^BNP^S6MW+<*LDRC'WF6OL32_B!H.M>(KS2;'7-)O-6T
M_P#X^K*&\CDN+;_?C!W+_P "H VJ*\__ &F_A]XK^*O[/GC3P[X&\62>!/&&
MM:/<6>C^($@$[:3<NC!)MG?:W_ EZCYA6?\ L;_"SQM\$?V9/!OA/XC>.)_B
M5XUT.P^SZKXEF@\A]5EWLP<KDGY5*IN;YFV;CR: /4**Q_%GCG1/ .G+>:YK
M&F:+:R.(Q-?W*6T;.>B[G(&ZM&WNH[ZWCEB=)(Y%#HZG<K ]"#0!/1574=3M
M]'L);J[N(;6WMUWRRRR!(XU]6+=!6=X,^(GA_P")&G->>'=<T?7;1#L:?3KV
M.ZC5O3<A(H VZ*\5_;6_:!\<?LS?#O3_ !7X/^&\GQ*TW3[[S/%-I;ZW;:;>
MZ;I:QNTMU;+<,L4\J-L;RFD3<N[YLXKXD_X(_?\ !5GQG^U]KVI>&_!NBZ]\
M6])B^(>O3^(_%^MZI#ID7A+0)+R?^R[>*%_W]S/Y"V[;$CV(K$%]^Y5 /U%H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.?V:?V5_ /['GPX?PG
M\-_#=OX3\-->S:@-.MIY9((YIFW2L@D=M@9N=JX7VKT:BB@ HHHH **** "B
MBB@ KE/C1\&O"_[0OPPUCP7XTT6S\1>%_$$'V?4=-NU+074>X-M;'^T%/X5U
M=% &?X>T"S\*Z!8Z7IUO'9Z?IMNEK:V\?"PQ1J%1%_V0H K0HHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#S7X/_ +)WP]^ 'Q"\=^+/"/AF
M'2?$GQ.U%-5\4:@)YIY]7N$W[&<R.VU4\U]J)M5=QPM>E444 %%%% !1110
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M\E,^)W_@;!_\:KT,%A<'4BWB*W(_\+?ZGDYAC,;2DEA:'M%_B2_1GW=YJ_\
M/1?SH\U/^>B_G7PG_P .&?!O_13/B=_X&P?_ !JC_APSX-_Z*9\3O_ V#_XU
M7?\ V?E?_04__!;_ ,SS_P"TLX_Z U_X,7^1]V>:G_/1?SH\U/\ GHOYU\)_
M\.&?!O\ T4SXG?\ @;!_\:H_X<,^#?\ HIGQ._\  V#_ .-4?V?E?_04_P#P
M6_\ ,/[2SC_H$7_@Q?Y'W9YJ?\]%_.CS4_YZ+^=?"?\ PX9\&_\ 13/B=_X&
MP?\ QJC_ (<,^#?^BF?$[_P-@_\ C5']GY7_ -!3_P#!;_S#^TLX_P"@1?\
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MS4_YZ+^='FK_ ,]%_.OA/_APSX-_Z*9\3O\ P-@_^-4?\.&?!O\ T4SXG?\
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MN5_H?F?A_FF.6;PIPDY1G?F7RW/U@HH%%?@I_204444 %%%% !1110 4444
M%%%% &9X2_Y S?\ 7S<?^CWK3K,\)?\ (&;_ *^;C_T>]:= !1110 4444 %
M%%% !1110 4444 %%%% &99_\C=J'_7M;_\ H4M:=9EG_P C=J'_ %[6_P#Z
M%+6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Z_\
M!5']M23_ ()Z?L"_$CXM6NGPZIJGAFQBBTFSF?\ =W%_<SQ6ML& ^9D669'9
M5Y*HW*]:^BJ^:?\ @KE^Q7??\%!O^">7Q+^%6DW5O9:_KUE#=:+<3<)'?VMQ
M%=6ZLW\"O)"(V?\ A61CSTH ^:OV7O\ @W@^'7Q"\$Q^./VM(=1^/GQX\80+
M=^(M8UO5+J.VTEI$_P"/"SAAD2-(H,[5;;]X%D\M=J+\V?MH?\$[]0_X)R_M
M^_L;Z!\//$WB"Y_9Y\1_&'3+S3_".L:A+J/_  ANL1;UV6,\I,BVL\$KGRG=
MF\R!FRVZOKK]C3_@OA\*?%OPUB\/_M":_IOP#^.'A-4T_P 7>%O%['2BMTH
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M]9UY(%MDU9(+*Z6.]9%^5&E@6*5E_A9VKY7^!7[4G[)G_!5#XE>*?C7^V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#,;_D<D_Z\F_]#6M.LQO^1R3_ *\F_P#0UK3H **** "BBB@
MHHHH **** "BBB@ K+\4?ZJQ_P"OV'_T*M2LOQ1_JK'_ *_8?_0J -2BBB@
MHHHH **** "C%%% !BC%%% !BC%%% !BJ^J?\@VY_P"N3?RJQ5?5/^0;<_\
M7)_Y4 1Z!_R!+'_KW3_T$5<Q5/0/^0)8_P#7NG_H(JY0 8HQ110 8HQ110 8
MHQ110 4444 %%%!H 1AD5SGQ$^'.A_%?PC>Z#XBTNUUC2-23RKBTNHA)'*/Z
M,#@AARK $<@5T0X^E)GWIQDXOFCN34IQG'EFKH^'-._X(2_!+4?&-YJ'F^,H
M[6WNR%TQ=2C^RXVJV,^3YNWYO^>E?8'PT^&.@_!_P;8^'O#.DV>BZ/IR;(+6
MUC")'W)_VF+<ECEF))/-:'A[_CYU3_K]/_HM*TUP#_\ 7KMQ>:XS%I0Q%1R2
M[L\W Y+@<')SPM*,&^R'T445PGJ!1110 4444 %%%% !1110 4444 9GA+_D
M#-_U\W'_ */>M.LSPE_R!F_Z^;C_ -'O6G0 4444 %%%% !1110 4444 %%%
M% !1110!F6?_ "-VH?\ 7M;_ /H4M:=9EG_R-VH?]>UO_P"A2UIT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$_]GCP#\;FA
M/C3P/X/\7&W_ -5_;6C6^H>7_N^:C8K=MO"&E65A8VL.F:?#:Z7M^Q0I;HJ6
M>!@>6N,)@?W:UJ* *3Z/:3:K'>R6L#WL*&-+@QCS%0]5#=<5:EC6>)E=596&
M"#T-/HH JZ9I=MHUE';6=O!:V\7"111A$7Z 5R_Q/_9[\ _&[R?^$T\#^#_%
MWV?B+^VM&M]0\OZ>:C8KLJ* ,FV\':39V%C9PZ7IL-II95K*%+5%CL\=/+7&
MU,?[-:U%% 'R/_P41\.?M/\ @CXE>"_BE^SWJ>G^,-(\,I);>+?A5JLD%G#X
MLM6;(EL[MTS!>)EL;I%1MJ==K1R^.Q?\%7/C9<V]SIO@W]@'XUV7Q%U(^6HU
M3[#IN@^>QX>;4]VUD&[<257/(ROWJ_1JB@#Y1_X).?L2>*_V0_A)XPUSXG:M
MINN?&+XQ^)[GQKXUN=/S]AMKN?:$LK;=\WD01@(N?XB^/EVU](^._AMX=^*F
MAMIGB?P_HOB+39/O6FJ645Y W_ ) RUNT4 <[\/?A3X7^$NA_P!F^%/#>@^&
M=-W;OLFDZ?%9P9QC[D2JO2M:\TBUO[F":XM+>XEM6WPO)$K-"W]Y2?NGZ5<H
MH 9+&L\3*ZJRL,$'H:@TS2[;1K*.VL[>"UMXN$BBC"(OT JU10!3_LBU_M?[
M=]EM_MWE>3]H\H>;Y>=VS?\ >VYYQTJGXP\#:+\0]%?3?$&CZ7KFG2G,EKJ%
MJES"_P!4<%:V** .1^&/P&\#_!&WF@\%^#?"?A&"Z^:>/1-)M[!9O]X1(N?Q
MKH+K1K2_O+>YGM;>6XLR3#+)$&>'=P=K=5S[5>HH IZCHUKJ\:+>6MO=I&ZR
MHLT8D"NO0C=_%[U<HHH X+QY^S)\-?BEXCM]9\4?#[P1XBUBU*O!?:IH5K=W
M,)7D%971F7H._:NO.B6<M[;W)M;9I[12D,GE#?"IX(1OX1]*O44 4DT>TAU6
M2]CM8$O9D$;W C'F,@Z*6ZXKCO"7[,'PU^'_ (MN->T'X>^!]$URZ?S)M1T_
M0;6VNIGY.YI40.6Y/.?XJ[ZB@"O=V4=Y;20S1I-#,I1T<;E<-U!'I5=] L)-
M&_L]K.S.G[/+^S&%?(V#ML^[BM"B@"*"%+>)8T146,8557"J/2H%TBU&IM?"
MTMQ>2)Y;3B)?-9/0MUV^U7** ,WQ+X5TSQKI$NG:QINGZKI]QQ+;7END\,GU
M1P5-8?PT^!7@GX+02P^#?!_A;PE#<']ZFC:5;V"R<Y^81(N>:ZZB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBTK4QFLOPY_Q\ZK_ -?K?^BTK4H **** "BBB@ HHHH **** "BBB@ HHHH
MS/"7_(&;_KYN/_1[UIUF>$O^0,W_ %\W'_H]ZTZ "BBB@ HHHH **** "BBB
M@ HHHH **** ,RS_ .1NU#_KVM__ $*6M.LRS_Y&[4/^O:W_ /0I:TZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@#,L_\ D;M0_P"O:W_]"EK3K,L_^1NU#_KVM_\
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M[^T!^S[X%'A'_A(_^%Z^*W\,_;?[4^Q_V'M1'\_R_)?S_O\ W-T?3[U>=?\
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MF0.DB-N5U/((;N*\'_:7_;B_X9X_;!^ ?PI_X1?^V/\ A>%UK%N-4_M+[/\
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M444 %%%% !1110!SW@?_ )"/B3_L+'_T1!70USW@?_D(^)/^PL?_ $1!70T
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M-5ELM)M3=:A>)!YDK16\*_ZV9PFU$_B9@*]$_P"(AGP+_P!&^_M@?^&KN/\
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MB?X2>'[F+5/%'@37-4\=^(X;=_,_L2RBLU: S[?N-*T;;0W^Q_?7=T/[<O\
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M_$C7-8\?:U::#H7A;2O&>J:AJ^MSSS*FZ*V:[7=%'D,[M\JX4?,[(K 'K/\
MP7A_X* ?%;]B7QY^S!<_"(3^(;KQYXMNM*E\-VY@\KQ;))#$EE:M*ZML1IYD
M^9&5MK?>KF_CO^QY^W3\(_@3K7QHL?VN)-<^*'AO39/$-_X%7PE:Q^$+M8$\
MV73;<9WJ B.BS,OF2,JY\IG9UW/^"L_@>Q\-_MO?\$ZO#]HLRZ?H_P 1)X+9
M97:5PEO90;-S-RS?(OS'FOOK]H3_ )('XX_[ %__ .D[T ?G-^R_\:OVB/\
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M*+=E2%]T$+0_,OW7W?>%3?L-?\K"_P"W-_V / W_ *:ZQ_\ @VN\>Z/\+O\
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M:G\8?L.7VOZ#XP^-$,\.I^'_ (OWFBQQV6G^%Y(6EFU*[L$.V6\B;R88HO\
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MKM%9>&/$4LKWVYU^98[/9<Q-)G=YD\C_ '8Z_;;]FKX"^'_V6/@#X-^''A>
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MOCK4?BOHGPWTC3-<\/>)=3V-JUC;70Q_9]](O^ME7Y&5V^9ERWW654"3YO\
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M_:Y3]F_]G2XT/1?%VFZ5'KGC?QQJUI]NM?!=I*P\F&*W^[+>2KAU1_EVL/\
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MI^QRRS2>:L1;:S[5^\-NY&5C\=6/_*H?XG_Z^;O_ -2^@#]H?"W_ "+>G_\
M7M'_ .@+6A6?X6_Y%O3_ /KVC_\ 0%K0H("BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,QO^1R3_KR;_T-:TZS&_Y')/\ KR;_ -#6M.@
MHHHH **** "BBB@ HHHH **** "N?^(?_'OI'_86M?\ T.N@S7/_ !#_ ./?
M2/\ L+6O_H= '04444 %%%% !1110 4444 %%%% !1110 53\0?\@*^_Z]W_
M /035RJ?B#_D!7W_ %[O_P"@F@"OX)_Y$K1_^O*#_P! 6M2LOP3_ ,B5H_\
MUY0?^@+6I0 4444 %%%% !1110 4444 %%%% !1110!SW@?_ )"/B3_L+'_T
M1!70USW@?_D(^)/^PL?_ $1!70T %%%% !1110 4444 %%%% !1110 4444
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M\.>(-4NOB=\2H?!LJS^'=%\;>*Y]8T?0I4;*/#:E53Y!\JK)O7VW?-7WA10
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M+??M/V_[)O\ P2R^,GB5KH0ZKJ6@3^'-&7&99K_4!]DA\I?XF5I3+C^[$QZ
MUW'_  2\_9FD_8Y_X)X_![X:W5O]EU/PQX8M(M4B_P">=_*GGW?_ ),2RUZU
MX\^&/AOXJ6%K9^)_#NA^([/3[N._M8-4L(KR.WN4SLG19%8+(N3M<?,-QKHJ
M "BBB@ HHHH **** "BBB@ KA_CO^SWX)_:B^%^I>"_B'X7T?QAX5U88NM-U
M.V6:)V'W77/*.IY5UPRGY@0:[BB@#\WS_P &OO[.^EK=6.@>)OCKX2\+WLOF
MR>&]'\=W$>E8^Z4V.KR%64LOS.S89OFKZX_8S_8#^$?_  3Y^'4GA?X0^!])
M\'Z;<NLE]+"7GO=2==VU[BYE+2RL-S;=[$+N*KM%>T44 >8?'7]D;P+^TCX\
M^'?B;Q;I=QJ&L?"O6_\ A(?#DL=W+ MG>;-F]E1@L@V_POE:]/HHH \M_9?_
M &1O _['VA^*]-\!Z;<:7:^-/$U[XPU5);R6X\[4KS9]HD!D8[%;RT^1?E7M
M7D7[5G_!&?X"_M=?%-?'FL>'M6\*_$<(8V\6>#M8N?#^KS?=^:62W8+,R[%P
M\JNPV@9KZOHH ^2/V1_^"*7[/_[&_P 5?^%@:'X<U;Q1\1%3RX?%'B_6;C7=
M3M1_TQ:=BD3<M\Z(K_.PW;3MKW_X^?L\>"?VI/A5JG@GXA>&-'\7>%=84I=:
M;J, FB?^ZZ_Q)(OWED0JZGYE*FNXHH ^!-,_X-N_V9HY[.UU"U^)?B+PGIKQ
MO9^$M7\=:E=:#;LC*5Q;F7YE^1/E9BN%'%?9>N_ _P *Z[\%-0^'/]C6>G^"
M]1T:;0)-*TY!9P0V,L+0-#$L6WRE\MF5=FW;VKL** ."^!W[.OA/]G?X#:!\
M,O"^E^3X-\,Z:ND6.GW4K70^R@;?+=I2QD!4\[LYS7R=XO\ ^#=K]FO6?%6J
M:AX?T_X@?#NQUZZ:[U70O!_B^_T?1M09OO*UI&_EI'N .R+8J[5VX'%?=U%
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M  'X1M)M/\,^&;5;+3K>6=YWBB!)P7<EFZGK7:44 >;^,?V6_!OCK]HGP?\
M%34]/N)O&G@.SN]/T:[6ZE2.WANDV3*T2GRWW#NR\5Z1110!XK^VA^P3\,OV
M^? =GH/Q&T%KYM*G^U:5J=G.UKJ>CS\?O;>X3YD/RKE3E&VKN5L"O._V2?\
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M?P3_ ,B5H_\ UY0?^@+6I67X)_Y$K1_^O*#_ - 6M2@ HHHH **** "BBB@
MHHHH **** "BBB@#GO __(1\2?\ 86/_ *(@KH:Y[P/_ ,A'Q)_V%C_Z(@KH
M: "BBB@ HHHH **** "BBB@ HHHH **** .>^&?_ "+,G_81O_\ TLFKH:Y[
MX9_\BS)_V$;_ /\ 2R:NAH **** "BBB@ HHHH **** "BBB@ HHHH S+/\
MY&[4/^O:W_\ 0I:TZS+/_D;M0_Z]K?\ ]"EK3H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0I&N-3\/P)IB^(=*8I'=Z=?)$%2XB>+YDWJ662*+:RKN!^[?^">W_)@WP/\
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M .?K^Y?Y!_JCE/\ SY7WO_,^#O\ APYX,_Z*9\4/_ R#_P"-4?\ #ASP8?\
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MU<JGX@_Y 5]_U[O_ .@F@"OX)_Y$K1_^O*#_ - 6M2LOP3_R)6C_ /7E!_Z
MM:E !1110 4444 %%%% !1110 4444 %%%% '/>!_P#D(^)/^PL?_1$%=#7/
M>!_^0CXD_P"PL?\ T1!70T %%%% !1110 4444 %%%% !1110 4444 <]\,_
M^19D_P"PC?\ _I9-70USWPS_ .19D_["-_\ ^EDU=#0 4444 %%%% !1110
M4444 %%%% !1110!F6?_ "-VH?\ 7M;_ /H4M:=9EG_R-VH?]>UO_P"A2UIT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M50+T 'I0!X[^W]^Q;X9_X*$?LE>,?A-XL4PV/BBT*VU\D?F2Z3>HP>WNX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S&_Y')/^O)O_0UK
M3K,;_D<D_P"O)O\ T-:TZ "BBB@ HHHH **** "BBB@ HHHH *Y_XA_\>^D?
M]A:U_P#0ZZ"N?^(?_'OI'_86M?\ T.@#H**** "BBB@ HHHH **** "BBB@
MHHHH *I^(/\ D!7W_7N__H)JY5/Q!_R K[_KW?\ ]!- %?P3_P B5H__ %Y0
M?^@+6I67X)_Y$K1_^O*#_P! 6M2@ HHHH **** "BBB@ HHHH **** "BBB@
M#GO _P#R$?$G_86/_HB"NAKGO __ "$?$G_86/\ Z(@KH: "BBB@ HHHH **
M** "BBB@ HHHH **** .>^&?_(LR?]A&_P#_ $LFKH:Y[X9_\BS)_P!A&_\
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MP_\ %+]D'5O@EX6^P37)\1S^/[+6D\Y-NRW^SQ6Z-\^6^;=QMH K_P#!3?\
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MQAHN@^ M"TZQUVT\16L4&LV\6GP)%=Q(T+%4E0!PI/"O7!_M(?MK?%/]K/\
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M#^WM_P $XO WCCQI<?:?'EJ]WH7BAQ#%;LVH6=P\+NT<05$:1%CE*JJJOFX
MQ7UU7YL?\&Z<B^$F_;%\"_+_ ,4E^T/XF\I?[L,OD(G_  '_ $=C_P "K])Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@_\0O&-Y#J/BCQAX9MM3U.YBMT@2:9Q\S!$ 5?H!7T!7Y6_"C]NS5OV /\
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MNV1W:/Y95\I_XJ /O.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'W_!%^3QW\)O%$UC;R:IX>NM#U/0-0>".ZM)+F)HQ%)"RLT4D>WA6^937;?
MW]B[2?V"?!&L_M2_'#X@?$;Q]\5] \(:AK?C"^O=<G;2[1?(^TW-K8Z<K+!'
M%$$>*!-O?^\R[0#[NHK\1_V<?AY\/?\ @K)\/X?C1^U]^U-::9<>-F>^\/\
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M'P__ ,%&?@$_C/1]!\2>#]6T?4YM!\1^'==M7M[[0=3@VB:U<D*LFW<,,O\
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M44 %%%% !1110 4444 %%%% &8W_ ".2?]>3?^AK6G68W_(Y)_UY-_Z&M:=
M!1110 4444 %%%% !1110 4444 %<_\ $/\ X]](_P"PM:_^AUT&<5SWQ".;
M?2/^PM:_^AT =#11FB@ HHHH **** "BBB@ HHHH **** "J?B#_ ) 5]_U[
MO_Z":N53\0?\@*^_Z]W_ /030!7\$_\ (E:/_P!>4'_H"UJ5E^"?^1*T?_KR
M@_\ 0%K4H **** "BBB@ HHHH **** "BBB@ HHHH Y[P/\ \A'Q)_V%C_Z(
M@KH:Y[P/_P A'Q)_V%C_ .B(*Z&@ HHHH **** "BBB@ HHHH **** "BBB@
M#GOAG_R+,G_81O\ _P!+)JZ&N>^&?_(LR?\ 81O_ /TLFKH: "BBB@ HHHH
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MM=O1?ZE+! J/?W AB@$LI'WY/*@ACW-SMB0?PBDUOPAI7B35]'OK_3[.\O-
MNGO--N)H1)+83/#+ TD3'[C-%-*F1_#(R]Z /GC]KWX,Z#^SK_P1U^+'@'PO
M;?8_#O@WX0:UHVG0_P 2P0://$F[^\Q"Y9OXF)/>F_\ !%7_ )1'_LX_]B!I
M'_I.E?17C/PEI?C[PCJGA_7+&VU31=<LY;#4+*Y0207EO*C)+$ZGAD9&92/0
MU!\._AYH7PG\"Z3X8\,Z3I^@^']!M4L=/TVQA$-M90(-J1(B\*JKVH ^#?\
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MB5D675+*:W>*SU7RT^>.-V=7V,O\!VM*A5VZ#X-_\$2/V3?@#XJ@UKPS\!_
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M_ -AX#N+J&]N-$BT:!;2[N('5XIYEV_O959$(>3<WRCF@#Y0_P""RMDNH?\
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M5)R-NZOKK.148W XC!U?8XF'+(K+LTPN.I>VPD^:(X4445RGH!1110 4444
M%%%% !1110 53\0?\@*^_P"O=_\ T$U<JGX@_P"0%??]>[_^@F@"OX)_Y$K1
M_P#KR@_] 6M2LOP3_P B5H__ %Y0?^@+6I0 4444 %%%% !1110 4444 %%%
M% !1110!SW@?_D(^)/\ L+'_ -$05T-<]X'_ .0CXD_["Q_]$05T- !1110
M4444 %%%% !1110 4444 %%%% '/?#/_ )%F3_L(W_\ Z635T-<]\,_^19D_
M["-__P"EDU=#0 4444 %%%% !1110 4444 %%%% !1110!F6?_(W:A_U[6__
M *%+6G699_\ (W:A_P!>UO\ ^A2UIT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %!HHH \=_:R\;_$/X>^$&U+X8
M^%[/Q=XJ5$C33;F3RXVB:5=[YWI]W_>KYM'[6?[:@_YH#X;_ / Y?_DNOMYN
M?%Z?]>;?^AK6FR\5Z>#S"E1ARSH1GYN_Z-'C8[*ZU>IST\1.GY*UOQ3/@_\
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MY 5]_P!>[_\ H)H K^"?^1*T?_KR@_\ 0%K4K+\$_P#(E:/_ ->4'_H"UJ4
M%%%% !1110 4444 %%%% !1110 4444 <]X'_P"0CXD_["Q_]$05T-<]X'_Y
M"/B3_L+'_P!$05T- !1110 4444 %%%% !1110 4444 %%%% '/?#/\ Y%F3
M_L(W_P#Z635T-<]\,_\ D69/^PC?_P#I9-70T %%%% !1110 4444 %%%% !
M1110 4444 9EG_R-VH?]>UO_ .A2UIUF6?\ R-VH?]>UO_Z%+6G0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 9C?\CDG_7DW_H:UIUF-_R.2?\ 7DW_ *&M:= !1110 4444 %%%% !1110
M 4444 %<_P#$,9M])_["UK_Z'705S_Q#_P"/?2/^PM:_^AT = %QVHHHH **
M** "BBB@ HHHH **** "BBB@ JGX@_Y 5]_U[O\ ^@FKE4_$'_("OO\ KW?_
M -!- %?P3_R)6C_]>4'_ * M:E9?@G_D2M'_ .O*#_T!:U* "BBB@ HHHH *
M*** "BBB@ HHHH **** .>\#_P#(1\2?]A8_^B(*Z&N>\#_\A'Q)_P!A8_\
MHB"NAH **** "BBB@ HHHH **** "BBB@ HHHH Y[X9_\BS)_P!A&_\ _2R:
MNAKGOAG_ ,BS)_V$;_\ ]+)JZ&@ HHHH **** "BBB@ HHHH **** "BBB@#
M,L_^1NU#_KVM_P#T*6M.LRS_ .1NU#_KVM__ $*6M.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!A&_\ _2R:NAH **** "BBB@ HHHH **** "BBB@ HHHH S+/_ )&[4/\
MKVM__0I:TZS+/_D;M0_Z]K?_ -"EK3H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9_\ (W:A_P!>UO\ ^A2UIT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!;JR(ZLK,JR.^"I^Y7F.E?\ !+[]KB?2[>2\_;^\>0WC1(TR1_#W2'1'V_,
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M\WGNR/+Q;JYFG9EC96^]*Q#.X^5555 /I&BBOR/M[?\ :I_;[_X*H_M7^ ?
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M7N^7=C&:UJ "BORY_;!U/]H[]J+_ (+5ZO\  GX4_M(:K\"_#.A_"JU\9O\
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M)7I6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+W_!:K_E$?\
MM'?]B!J__I.]?4-?+W_!:K_E$?\ M'?]B!J__I.] 'Q)^P+XI_X*86_["GP3
MB\!>&?V/KCP/'X"T-?#LNLRZY_:,FG?V=!]E:Y\N<)YYBV;]BA=V['%<)^TE
MK/[76K?\%5/V&U_:;TGX%Z781^.K_P#L _#U]0:5Y/L\7G?:/M<C_+M\K;L_
MVLU^F_\ P2=_Y19?LT_]DJ\+_P#IHM:^7_\ @LK_ ,I0/^">/_8_ZQ_Z2VM
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M_P"$M\;:A\)_%=BN-5\,^+]'O+._TV554O&2L31N0<A0K;CM^Z.E>)?MB_\
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M#_\ TEH 3]AK_E87_;F_[ '@;_TUU\M?LN?\$]V_X*"_\%?/VR=,\>:]JC?
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M"\*[)&8A<R%5Z\FN _9F_9A^(?P__P""=/[9'QJ^+VDCPS\3OVC-(U[Q1?\
MAO>))/#6GQ:7<Q:?82O_ !2I$69ON[?,52JLK"@#@[#]KGQM^RU_P;A?LQ:;
M\,)H;7XH_&*W\/\ PV\)7KMQIE]J/F#[5MVMN9(XI-O'RNR'YMNUOH?X&_\
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M_P""I'BK]CCP3)]E^"_[8WB+3/BEKYM9MDN@6EJ\KZ]$FWE/M4MK"ZLVU/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% '/>!_^0CXD_["Q_\ 1$%=#7/>!_\
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M &V RWXUI44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %4_$'_("OO^O=_P#T$U<JGX@_Y 5]_P!>[_\ H)H K^"?^1*T?_KR@_\
M0%K4K+\$_P#(E:/_ ->4'_H"UJ4 %%%% !1110 4444 %%%% !1110 4444
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MAS\0O"]W9WFC^)M!MKA?LQ^2WF$:I-;D?PM%*KQ,O\+1D5ZW0!\]_P#!-_\
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M*J'HWS;0K$?.7_!6W_E*?_P3W_[';Q!_Z;HJ\L_X. M-^)GQ/_X*)_L0^ ?
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MV)AX%^("_8_B[\ M2E^'?C&QDE$EPL]C^ZMYW/\ %YD2!?,RRO)%*P8URO\
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M["Q_]$05T-<]X'_Y"/B3_L+'_P!$05T- !1110 4444 %%%% !1110 4444
M%%%% '/?#/\ Y%F3_L(W_P#Z635T-<]\,_\ D69/^PC?_P#I9-70T %%%% !
M1110 4444 %%%% !1110 4444 9EG_R-VH?]>UO_ .A2UIUF6?\ R-VH?]>U
MO_Z%+6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<
MV\=W T<B+)'(-KJR[@P]#4U% 'Y<W/\ P2<_:/\ ^";?Q5\3^)OV)?B%X-D^
M'OB>YEU*[^$?Q!CN'T6QN7QN>PFB;<F>R[HOE55=Y=J[>GUVX_X*;_M!6/\
MPCJ:;^SC\![2ZA$=]XHM;R\UW4K?.[<]G;MNAW]/EF7_ ('7Z/T4 ?._[ ?_
M  3V\/\ ["G[-UY\/_\ A(/$GQ"N?$5]=ZOXHUKQ+<O=3^(;ZZ_X^97C=F1$
MDZ;%^K%V9G;Y@^'?[ _[5O\ P2^U/6O#_P"S!XD^&'Q%^!^HWLVIZ7X)^(UU
M>VFH>#WED+O:Z?=VZLKVVYBVV7;M]&8O(_Z3T4 ? 'P4_P""<'QJ_:/_ &M?
M"OQP_:X\7>"-6O/AS*+GP-\._ XNF\-:'=LO_(0N'NAYEQ>+GY>-J-&K*^/E
M'J/Q._8>\6>,_P#@KS\,/C_:ZAX>C\'^"_ FI^%[VSEGF75)+FYG:2-XT$1B
M,0!^8M*K?[)KZNHH YSXK>&;CQM\,O$6BVCPQW6L:9<V,+2L517EB9 S8!XR
MWI7Y2?M^_LA^)/V#_P#@TN\6?"7Q=>Z'J7B/P9I%A;WMSI$TLMC(S^)+>=?*
M>2.)V&V4?>1?FW5^OU?('_!2/_@DMIO_  4OU[1K?Q5\6_BOX=\!Q1VL&O>"
M=$U)(-#\1QV]P]PC31E"RR^8Z[GW'Y88OE5D5P =K^U5^Q7X?_X*#_\ !/Z3
MX5^(+V^T>WU[1K&6RU6R/^D:/>P"*:VNH^1EHY40[=R[EW+N7=7S'8:%_P %
M1/!WA!/ L&H?LM^))(+?[%!\0;^34XKXI\JK=36BIY;7&TEMJQF/<G\7\7Z/
M6=G'IMI#;P1K%#;H$1%&%50,!15B@#YK_P""7G_!/VS_ ."<?[-,GA&7Q%?^
M-?%WB36+KQ1XP\37BLL^OZO=;?/N,,S,J[8T11N)^3<?F9J^0?@U^S/XND\=
M>.OC#_P3M^.7PZD\'^-O$5S-XM^'7CC3;UO#EIKJLOVF6/RD6\L9F^7=!Y:[
ME9?FV>4J?JE7QG\<O^"+O@7QO\<]<^*'PS\>?%#]GWXA>)]SZ]J'P_U9+.Q\
M12D_ZV^LI8Y()9!N=MRJC,SEV+-\U 'PS_P6J_9G^/\ XQ_X)X>/O&_[7'Q:
M^'YM=!MDA\'_  Z^&-G=VFDZMKUQ+Y%I+-/=?Z7=R1^8SK;JNWY"Y^5&S^BO
MB+_@GQX9_:B_X)?^&O@'\3K&X-FO@[2=(N9;9E6\TF]M;6%4NK=V4JLT4L>Y
M6V[6P5965F4^??!G_@B;X8T3XV>'OB-\8/B=\5/VB_%OA"5;C0!XXU))M'T&
MX7;BYMK")%B6?<,[WW895;[RAJ^WJ /SM\%>"?\ @H]^S3X:A\"Z1J7[.7QK
MTK35^QZ-XR\4W.J:5JWV=!M1]3MX5999, +NB=F;[S,S;FKG?V=?^",/Q@\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** .>^&?_ "+,G_81O_\ TLFKH:Y[X9_\BS)_V$;_ /\
M2R:NAH **** "BBB@ HHHH **** "BBB@ HHHH S+/\ Y&[4/^O:W_\ 0I:T
MZS+/_D;M0_Z]K?\ ]"EK3H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,QO^1R3_ *\F_P#0UK3K+:0?\)6B
M[!G[(QW\[OOKQ6I0 4444 %%%% !1110 4444 %%%% !7/\ Q#_X]](_["UK
M_P"AUT%<_P#$/_CWTC_L+6O_ *'0!T%%%% !1110 4444 %%%% !1110 444
M4 %4_$'_ " K[_KW?_T$U<JGX@_Y 5]_U[O_ .@F@"OX)_Y$K1_^O*#_ - 6
MM2LOP3_R)6C_ /7E!_Z M:E !1110 4444 %%%% !1110 4444 %%%% '/>!
M_P#D(^)/^PL?_1$%=#7/>!_^0CXD_P"PL?\ T1!70T %%%% !1110 4444 %
M%%% !1110 4444 <]\,_^19D_P"PC?\ _I9-70USWPS_ .19D_["-_\ ^EDU
M=#0 4444 %%%% !1110 4444 %%%% !1110!F6?_ "-VH?\ 7M;_ /H4M:=9
MEG_R-VH?]>UO_P"A2UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%5X[J.:Z>)9$:2-0SH#\R[NF1^!H L4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !114%M>17)D6.2.3R7V/M;.T^A]Z )Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH S&_Y')/^O)O_0UK3K,;_D<D_P"O)O\ T-:TZ "B
MBB@ HHHH **** "BBB@ HHHH *Y_XA_\>^D?]A:U_P#0ZZ"N?^(?_'OI'_86
MM?\ T.@#H**** "BBB@ HHHH **** "BBB@ HHHH *I^(/\ D!7W_7N__H)J
MY5/Q!_R K[_KW?\ ]!- %?P3_P B5H__ %Y0?^@+6I67X)_Y$K1_^O*#_P!
M6M2@ HHHH **** "BBB@ HHHH **** "BBB@#GO _P#R$?$G_86/_HB"NAKG
MO __ "$?$G_86/\ Z(@KH: "BBB@ HHHH **** "BBB@ HHHH **** .>^&?
M_(LR?]A&_P#_ $LFKH:Y[X9_\BS)_P!A&_\ _2R:NAH **** "BBB@ HHHH
M**** "BBB@ HHHH S+/_ )&[4/\ KVM__0I:TZS+/_D;M0_Z]K?_ -"EK3H
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MY^PG\%=<\,_M[:YX-\-ZSX#T*^TK08_A=I]XNB6DNG0/#:+,UTK2K%&RQ[V
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MK%'_ +*86OL_X _M#>"_VI/AK:^,/A_XBT_Q5X8O)IK>#4;)BT,KQ2-%(H)
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M,Q;=NYKY/_X-LM:OK;_@GSKG@F>]NKZP^$_Q&\1>#-(EN'\R;[%;76^)&/\
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M:+^R[_P<F?"6\\$Z?:^'H_CQ\.M<M/%MG8Q""VU2>P;[3#>.B_*T_P JIO\
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M86E@\%>*O#T5CKGA3]UY4C6#[%66VVM\K1?P^6[1I\E8/[#7_*PO^W-_V /
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M.:^*_P#@C]^T/JW[*'_!'']I"XDN;SQ%I_[+_BOQOHWAN.^E:662QTJ$75M
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M",^F66FWFHW!GNO[/_L>\:RB=S]YHK5H8O\ MEVZ4 ?;WBS_ (+*?LQ^"H?
MDEY\8_"\C?$YE/AF"SCN+Z?50T[6Z.L4,;ND;3(\:O(JJS*0"<5B_P#!+S]E
M7X)_LW>+_C]??!WQIX@\7WWB?X@7;>-4U+4_MBZ)K467FLD_=IMV?:/F+;W;
M<NZ1MHQ\Y_\ !J=^R+X3^'/_  2H\'_$1M'L;KQG\2+R]O\ 4-4N8%FNHX;6
M_EM;6W1V&Y(HUMED5%^4.[-7=?\ !$O6X?#FO?MSZA<"0V^G_M&^*[B7RUW-
ML2&U8[1W;B@#ZE_:Q_X*!?!?]AO2K.Y^+/Q(\,>!_P"T%9[2"^N"UU=JO#-%
M;H&E=0?XE0BJ7[(W_!1_X%_MYQ72_"7XF>&?&ES81">ZLK:9H;Z"(G;YCVTJ
MI,J;L+N*;<\5\7_\$$_V6]!_:U^$EU^V5\7-)TOQQ\7_ (WZK?WUG<:I +R'
MPGIEO>2VUM8V*2;A$J_9RV]?GVLJ]FSN?\%YOV+O#7PS_9HU#]I_X7Z;IGP_
M^.7P'D@\2:9X@TBV2U;5+:.=5N+&\";5N('C=_E?<>-OW7=6 /O#Q]^T-X+^
M%WQ+\&>#_$'B+3M)\3_$2:ZM_#>FSLRSZQ);QK+,L7'.R-E9O]ZNXK\Q/VV/
MB2OQJ_X*-?\ !+_QE';M;P^+)?$>LB/!_<_:="LYPG/^_P#^.U^G= '!_!K]
MI/P)^T/X!N_%7@KQ1I/B#P[87EQ87.H6TO[F&>W;;,C%L8V-]ZO%_@K_ ,%H
M/V6_VA?C4OPZ\'?&SP7K7C"2Y-G;6:RRPQZC,"1LMII$6&X8X^7RG?=_#NKX
M\_X) ? K5/VGO^"$'QT^'.AZC_9.L>.-?\<Z%973.4C@FN'EB0NP!;R]S -@
M9VEJW?\ @G9\=_@3\0O"OPJ_93^/GP5T/X6_'3X3VUBND>&/%&AQ-9:Q>62+
MC4M'N]K1S>:8S*?GWLQ?_7J&D(!^I5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9C?\CDG_7DW_H:UIUF-_P C
MDG_7DW_H:UIYH **** "BBB@ HHHH **** "BBB@ KG_ (A_\>^D?]A:U_\
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M: "BBB@ HHHH **** "BBB@ HHHH **** ,RS_Y&[4/^O:W_ /0I:TZS+/\
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MH;@^$]-6/4+R-,?VA?2EI;NX]</.\C+G[J[5_AKW2B@#Y(_X+4_L0ZE^W/\
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MTM0U7X?^#=(\-WES:?#NX^SW$UG90V[O%NPVQFC)&X X-?=W[!7[:VH?MQ^
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MT31/NVO_ ,M&9B%V\K^K]% 'Y??!^Y^*7_!7C_@IO\*_C%K'PI\;?"']G_\
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M&?%S16TKPUJ&ERS^(MGG+)<ZYJ\,.];"")8A$BRL-OF.S-\VZOVHHH ^#/\
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M HHHH **** "BBB@ HHHH **** ,RS_Y&[4/^O:W_P#0I:TZS+/_ )&[4/\
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MMQ_P30\/^!/@UJO[4WP'TG2_AG\>O@9"_BZ+5]$M4L8]=LK8;[V"\C0!)_\
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MJT8Z(DHH!R**S.@*Y_XA_P#'OI'_ &%K7_T.N@KG_B'_ ,>^D?\ 86M?_0Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9C?\ (Y)_UY-_Z&M:=9C?\CDG_7DW_H:UIT %%%% !1110 4444 %%%%
M!1110 5S_P 0_P#CWTC_ +"UK_Z'705S_P 0_P#CWTC_ +"UK_Z'0!T%%%%
M!1110 4444 %%%% !1110 4444 %4_$'_("OO^O=_P#T$U<JGX@_Y 5]_P!>
M[_\ H)H K^"?^1*T?_KR@_\ 0%K4K+\$_P#(E:/_ ->4'_H"UJ4 %%%% !11
M10 4444 %%%% !1110 4444 <]X'_P"0CXD_["Q_]$05T-<]X'_Y"/B3_L+'
M_P!$05T- !1110 4444 %%%% !1110 4444 %%%% '/?#/\ Y%F3_L(W_P#Z
M635T-<]\,_\ D69/^PC?_P#I9-70T %%%% !1110 4444 %%%% !1110 444
M4 9EG_R-VH?]>UO_ .A2UIUF6?\ R-VH?]>UO_Z%+6G0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9C?\CD
MG_7DW_H:UIUF-_R.2?\ 7DW_ *&M:= !1110 4444 %%%% !1110 4444 %<
M_P#$/_CWTC_L+6O_ *'705S_ ,0_^/?2/^PM:_\ H= '04444 %%%% !1110
M 4444 %%%% !1110 53\0?\ ("OO^O=__035RJ?B#_D!7W_7N_\ Z": *_@G
M_D2M'_Z\H/\ T!:U*R_!/_(E:/\ ]>4'_H"UJ4 %%%% !1110 4444 %%%%
M!1110 4444 <]X'_ .0CXD_["Q_]$05T-<]X'_Y"/B3_ +"Q_P#1$%=#0 44
M44 %%%% !1110 4444 %%%% !1110!SWPS_Y%F3_ +"-_P#^EDU=#7/?#/\
MY%F3_L(W_P#Z635T- !1110 4444 %%%% !1110 4444 %%%% &99_\ (W:A
M_P!>UO\ ^A2UIUF6?_(W:A_U[6__ *%+6G0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 9C?\CDG_ %Y-_P"AK6G68W_(Y)_UY-_Z
M&M:= !1110 4444 %%%% !1110 4444 %<_\0_\ CWTC_L+6O_H==!7/_$/_
M (]](_["UK_Z'0!T%%%% !1110 4444 %%%% !1110 4444 %4_$'_("OO\
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M^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\
MB*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_Y
MXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^
M$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_
M (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?
M^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC
M_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C
M_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[
M7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(
MH_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"V
MX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2
M^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\
MB*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@
MMN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^
M$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_
M (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_
MX+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O
M_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C
M_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J
M?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#
M+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"V
MX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GC
MJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH
M R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@
MMN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_Y
MXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U*
M* ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_
MX+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?
M^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM
M2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J
M?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[
M7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(
MK4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GC
MJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2
M^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\
MB*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_Y
MXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^
M$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_
M (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?
M^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC
M_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C
M_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[
M7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(
MH_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"V
MX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2
M^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\
MB*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@
MMN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^
M$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_
M (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_
MX+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O
M_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C
M_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J
M?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#
M+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"V
MX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC_A+[7_GC
MJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C_P"(K4HH
M YQM?@_X25)_(U/R?LS)N_L^XZ[P?[E7_P#A+[7_ )XZI_X+;C_XBM2B@#+_
M .$OM?\ GCJG_@MN/_B*/^$OM?\ GCJG_@MN/_B*U** ,O\ X2^U_P">.J?^
M"VX_^(H_X2^U_P">.J?^"VX_^(K4HH R_P#A+[7_ )XZI_X+;C_XBC_A+[7_
M )XZI_X+;C_XBM2B@#+_ .$OM?\ GCJG_@MN/_B*/^$OM?\ GCJG_@MN/_B*
MU** ,O\ X2^U_P">.J?^"VX_^(H_X2^U_P">.J?^"VX_^(K4HH R_P#A+[7_
M )XZI_X+;C_XBL7QAJZ:G#IZV]MJ3F'4;>:3_B7SC:BOEC]RNNHH R_^$OM?
M^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[7_GCJG_@MN/_ (BC
M_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(H_X2^U_YXZI_X+;C
M_P"(K4HH R_^$OM?^>.J?^"VX_\ B*/^$OM?^>.J?^"VX_\ B*U** ,O_A+[
M7_GCJG_@MN/_ (BC_A+[7_GCJG_@MN/_ (BM2B@#+_X2^U_YXZI_X+;C_P"(
MH_X2^U_YXZI_X+;C_P"(K4HH R_^$OM?^>.J?^"VX_\ B*JZSXCM[S2+J..'
M4]\D+H!_9UQU*_[E;U% '-^%=?ATWPOIMM-!J:S6]K%&Z_V?<-M*HH(^Y6A_
MPE]K_P \=4_\%MQ_\16I10!E_P#"7VO_ #QU3_P6W'_Q%'_"7VO_ #QU3_P6
MW'_Q%:E% &7_ ,)?:_\ /'5/_!;<?_$4?\)?:_\ /'5/_!;<?_$5J44 9?\
MPE]K_P \=4_\%MQ_\11_PE]K_P \=4_\%MQ_\16I10!E_P#"7VO_ #QU3_P6
MW'_Q%'_"7VO_ #QU3_P6W'_Q%:E% &7_ ,)?:_\ /'5/_!;<?_$4?\)?:_\
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M+N7']GS-\KW$KJ?E3^ZPK:_X2^U_YXZI_P""VX_^(K4HH R_^$OM?^>.J?\
M@MN/_B*/^$OM?^>.J?\ @MN/_B*U** ,O_A+[7_GCJG_ (+;C_XBC_A+[7_G
MCJG_ (+;C_XBM2B@#+_X2^U_YXZI_P""VX_^(H_X2^U_YXZI_P""VX_^(K4H
MH R_^$OM?^>.J?\ @MN/_B*/^$OM?^>.J?\ @MN/_B*U** ,O_A+[7_GCJG_
M (+;C_XBC_A+[7_GCJG_ (+;C_XBM2B@#+_X2^U_YXZI_P""VX_^(H_X2^U_
MYXZI_P""VX_^(K4HH Q=%O/[0\0WUPD=TL+00HIEMWBW,K2YQO4?WEK:HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>slide2a16.jpg
<TEXT>
begin 644 slide2a16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 1*"*@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P 1&XD_Z"I'W%_P_P"_C1_T ?AS_P" %Y_\E4?\/^_C1_T ?AS_ . %Y_\
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MG_05(^XO^'_?QH_Z /PY_P# "\_^2J/^'_?QH_Z /PY_\ +S_P"2J^':*/\
M4+(?^@9?>P_XB-Q'_P!!4C[B_P"'_?QH_P"@#\.?_ "\_P#DJC_A_P!_&C_H
M _#G_P  +S_Y*KX=HH_U"R'_ *!E][#_ (B-Q)_T%2/N+_A_W\:/^@#\.?\
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M>P_XB-Q)_P!!4C[B_P"'_?QH_P"@#\.?_ "\_P#DJC_A_P!_&C_H _#G_P
M+S_Y*KX=HH_U"R'_ *!E][#_ (B-Q)_T%2/N+_A_W\:/^@#\.?\ P O/_DJC
M_A_W\:/^@#\.?_ "\_\ DJOAVBC_ %"R'_H&7WL?_$1N)/\ H*D?<7_#_OXT
M?] 'X<_^ %Y_\E4?\/\ OXT?] 'X<_\ @!>?_)5?#M%'^H60_P#0,OO8O^(C
M<1_]!4C[B_X?]_&C_H _#G_P O/_ )*H_P"'_?QH_P"@#\.?_ "\_P#DJOAV
MBC_4+(?^@9?>P_XB-Q)_T%2/N+_A_P!_&C_H _#G_P  +S_Y*H_X?]_&C_H
M_#G_ , +S_Y*KX=HH_U"R'_H&7WL?_$1N)/^@J1]Q?\ #_OXT?\ 0!^'/_@!
M>?\ R51_P_[^-'_0!^'/_@!>?_)5?#M%'^H.0_\ 0,OO8O\ B(W$G_05(^XO
M^'_?QH_Z /PY_P# "\_^2J/^'_?QH_Z /PY_\ +S_P"2J^':*/\ 4'(?^@9?
M>P_XB-Q'_P!!4C[B_P"'_?QH_P"@#\.?_ "\_P#DJC_A_P!_&C_H _#G_P
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M[#_B(W$?_05(^XO^'_?QH_Z /PY_\ +S_P"2J/\ A_W\:/\ H _#G_P O/\
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MV+_B(W$?_05(^XO^'_?QH_Z /PY_\ +S_P"2J/\ A_W\:/\ H _#G_P O/\
MY*KX=HH_U"R'_H&7WL/^(C<1_P#05(^XO^'_ '\:/^@#\.?_   O/_DJC_A_
MW\:/^@#\.?\ P O/_DJOAVBC_4+(?^@9?>P_XB-Q'_T%2/N+_A_W\:/^@#\.
M?_ "\_\ DJC_ (?]_&C_ * /PY_\ +S_ .2J^':*/]0LA_Z!E][#_B(W$?\
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MQ?\ #_OXT?\ 0!^'/_@!>?\ R51_P_[^-'_0!^'/_@!>?_)5?#M%'^H60_\
M0,OO8O\ B(W$?_05(^XO^'_?QH_Z /PY_P# "\_^2J/^'_?QH_Z /PY_\ +S
M_P"2J^':*/\ 4'(?^@9?>Q_\1&XD_P"@J1]Q?\/^_C1_T ?AS_X 7G_R51_P
M_P"_C1_T ?AS_P" %Y_\E5\.T4?ZA9#_ - R^]B_XB-Q'_T%2/N+_A_W\:/^
M@#\.?_ "\_\ DJC_ (?]_&C_ * /PY_\ +S_ .2J^':*/]0LA_Z!E]['_P 1
M&XD_Z"I'W%_P_P"_C1_T ?AS_P" %Y_\E4?\/^_C1_T ?AS_ . %Y_\ )5?#
MM%'^H60_] R^]B_XB-Q'_P!!4C[B_P"'_?QH_P"@#\.?_ "\_P#DJC_A_P!_
M&C_H _#G_P  +S_Y*KX=HH_U"R'_ *!E][#_ (B-Q'_T%2/N+_A_W\:/^@#\
M.?\ P O/_DJC_A_W\:/^@#\.?_ "\_\ DJOAVBC_ %"R'_H&7WL?_$1N)/\
MH*D?<7_#_OXT?] 'X<_^ %Y_\E4?\/\ OXT?] 'X<_\ @!>?_)5?#M%'^H.0
M_P#0,OO8O^(C<1_]!4C[B_X?]_&C_H _#G_P O/_ )*H_P"'_?QH_P"@#\.?
M_ "\_P#DJOAVBC_4+(/^@9?>Q_\ $1N)/^@J1]Q?\/\ OXT?] 'X<_\ @!>?
M_)5'_#_OXT?] 'X<_P#@!>?_ "57P[11_J%D/_0,OO8O^(C<2?\ 05(^XO\
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M\:/^@#\.?_ "\_\ DJOAVBC_ %"R'_H&7WL/^(C<1_\ 05(^XO\ A_W\:/\
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M?_ "\_\ DJOAVBC_ %"R'_H&7WL/^(C<1_\ 05(^XO\ A_W\:/\ H _#G_P
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M][#_ (B-Q'_T%2/N+_A_W\:/^@#\.?\ P O/_DJC_A_W\:/^@#\.?_ "\_\
MDJOAVBC_ %"R'_H&7WL/^(C<1_\ 05(^XO\ A_W\:/\ H _#G_P O/\ Y*H_
MX?\ ?QH_Z /PY_\  "\_^2J^':*/]0LA_P"@9?>P_P"(C<1_]!4C[B_X?]_&
MC_H _#G_ , +S_Y*H_X?]_&C_H _#G_P O/_ )*KX=HH_P!0LA_Z!E][#_B(
MW$?_ $%2/N+_ (?]_&C_ * /PY_\ +S_ .2J/^'_ '\:/^@#\.?_   O/_DJ
MOAVBC_4+(?\ H&7WL/\ B(W$?_05(^XO^'_?QH_Z /PY_P# "\_^2J/^'_?Q
MH_Z /PY_\ +S_P"2J^':*/\ 4+(?^@9?>P_XB-Q'_P!!4C[B_P"'_?QH_P"@
M#\.?_ "\_P#DJC_A_P!_&C_H _#G_P  +S_Y*KX=HH_U"R'_ *!E][#_ (B-
MQ'_T%2/N+_A_W\:/^@#\.?\ P O/_DJC_A_W\:/^@#\.?_ "\_\ DJOAVBC_
M %"R'_H&7WL/^(C<1_\ 05(^XO\ A_W\:/\ H _#G_P O/\ Y*H_X?\ ?QH_
MZ /PY_\  "\_^2J^':*/]0LA_P"@9?>P_P"(C<1_]!4C[B_X?]_&C_H _#G_
M , +S_Y*H_X?]_&C_H _#G_P O/_ )*KX=HH_P!0LA_Z!E][#_B(W$?_ $%2
M/N+_ (?]_&C_ * /PY_\ +S_ .2J/^'_ '\:/^@#\.?_   O/_DJOAVBC_4+
M(?\ H&7WL/\ B(W$?_05(^XO^'_?QH_Z /PY_P# "\_^2J/^'_?QH_Z /PY_
M\ +S_P"2J^':*/\ 4+(?^@9?>P_XB-Q'_P!!4C[B_P"'_?QH_P"@#\.?_ "\
M_P#DJC_A_P!_&C_H _#G_P  +S_Y*KX=HH_U"R'_ *!E][#_ (B-Q'_T%2/N
M+_A_W\:/^@#\.?\ P O/_DJC_A_W\:/^@#\.?_ "\_\ DJOAVBC_ %"R'_H&
M7WL/^(C<1_\ 05(^XO\ A_W\:/\ H _#G_P O/\ Y*H_X?\ ?QH_Z /PY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU\ZCK7JX3,\-B:E6E0GS.F[2\F>/C,IQ6%ITZU>-E45X^:%).<TE?1?[0O\
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MUYJ&*U]%@\92Q-&->@^:$MF?+XS!U\)7E0Q$;3CNF-HHHKJ.,**** "BBB@
MHHHH **** "BBB@ HHHH **** "G=1]ZC_5MZU]K?L\?\$4_%'[0WP9\/^-+
M'QMH-A;^(+1;N.UFLY&DA#$C:2/I7DYMGF"RR"JXV?(I:'N9+P_C\UJNC@(<
M\DK]-OF?%.[,6/2C*EO:OL+]K'_@CWXD_9-^!NL>.=0\8Z+JUKH[VZ26D%M)
M'))YL\<0P2<?*S[OPKA_VEO^"=VL_LT?LU>$?B5?>(=-U.Q\72VD4-E! \<D
M'GVDMP,L3AMHC*_C7#@^*\JQ*A[&M?GERQWU:UMMYG=C.#<XPKJ*O1:Y%S2U
M6B;M??NCYSIS-N5>>E>Y?L,_L-ZM^W#XKUW2M)URQT.30K1+MWN8'F60.^S
MQ]*X[PS^SW?>)_VGXOAC'?V\-]-X@;P^+TQMY:NLS0^9M^]C<N:]!YU@_:U<
M.Y^_27-+R1YO]AXYT:5?V?N57:#TU>UCSW.&]:4,N[E?PS7Z%#_@WK\9$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _33_@W/_P!?\8/]W1O_
M &^K].T^[7YB?\&Y_P#K_C!_NZ-_[?5^G:?=K^4/$7_DHL3_ -N_^D1/[3\)
M_P#DEL-_V]_Z7(6BBBOBC]%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH :/NU^.O_!?O_D\W0?^Q/M?_2R^K]BA]VOQU_X+]_\
M)YN@_P#8GVO_ *67U?H7AC_R/J?I+\C\K\8_^2<G_BC^9\-T445_41_'9^KG
M_!'GP?J?Q#_X)J?$;0=&N4L]6UK4M5L;.XD<QI;S2V$"(Y906 #,#D GZUZ;
M^QU\)/&?[ 7[/_Q U3XW?$"U\0:/&B7%M#_:$][#8PQHZLJ/.J-NF9D01*NW
M<BXRSFO(/^"6&OWWA/\ X)/_ !<U33;J2QU"PGUFYMKB)MLEO(FFPE'![,"
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M$=*.82_=JE%4I2VNDK^5_P"NQ\2I8W&<+5GEJ?M76;JQA\5GMIO;^NC/!_\
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MGBWPAXN7Q!IOB;7K'6UD$OVZ.]E$SE6R-QS\W_ O[U?ISX]\40_\%'O^"/\
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MI>WZ]3YW_::&0X-9U=55B(N'/\?L]+[ZVO\ ITL=)_P7X_Y/+T'_ +$ZU_\
M2R^KV'XGG/\ P;Y::/\ ITL,_P#@VCK!_P""WW[*'C[XJ?'WPKXJ\*^%=<\3
M:=<:%'I4ATNT>[>WFBN9I/G1%+(K"<?,WR_*?2NO_;!\,W7[.W_!$K0O!/BC
MR['Q!=)IMF+4R!F6X^UK=/%\OWBB(^=O]TUY>'QE"KEF4X>E-2G&K&\>JLW<
M];$8*O1S;.L34@XPE1E:5M-4K:^8W_@GO+I?[%W_  2F\1?&*.P@O/$&M)<W
MP:5=ID9)VM+6%F^]Y7F+O_[:M7YL_%7XY^+OCCXOGU[Q=X@U36M2N)?-\V>=
MML+=A$GW8U7^%4556OT=_P""96O:!^V5_P $[/$_P'U+4(]/UK28[F%%^]((
M)YFN(+E5R-ZI<-@K_LH&QO&?B#XG_P#!.[XT?"KQO)H=W\/?$FJ2+)Y<-WI-
MA+?6=R/F 9)(U(VL!G:VUE'WE6OHN&<1@:&;8]YBTJ_.[<W_ #[Z6OY?H?+\
M5T<=7R;+O[+4GA_9J_)_S\^U>W6^U_,%_P""A?Q9'[/^H?#>;Q9>7GA_4FV/
M-<%I;V.#!#VPG8[O)?(R/[HVJRJ2I^J/^"!7C?6->^-GC&ROM7U2]L[;0(UA
M@N+IY8H<3J%VJ3M7Y>/E]*\/\0?\$D_BEX-_9BUKXC:]#I^BMHZBX?1+F95N
MVM%7][,6W;$9>-L1^9EW?=;:K>O?\&^C!/V@/'!^]MT!,?\ ?]:TXFGE%7(<
M9/+.1ZKFY5]J\?ZN9\(QSK#\1X*GF;FKK3FO\-G_ %8^=OVD?C7KGA']N[Q=
MJ<^H:CJUGX4^(=YJ5KI]W>.]ONMM0E9$",2JKM&WY5^ZU?H/^U9\&W_X*3_"
M/PC\8/@KXPN[7Q7X5B+V%J+OR"TF5>2W?G_1[I&QR?E;@$[2KK^=?QP^&.J_
M&G_@H+X]\*Z"+5M6USQSJMI:BYG2WB#->3=7<[?_ &9ONJK,RK7T-\%_V:?V
MCO\ @G#^U/HUIX7T;5/%>AZX]LFHMID$DVCW\3;?,21L?N7B8OME?8>,_=9E
M;BSG"X;ZMA*]"K"GB*=.ZC*UIQLKI^;_ ,_5=F08S%/%XW#XFC.IAJE3E<H7
MYH2N^5KT_P O1_'WQZ\:^-/'_P 6=:U#X@W&IW'BSSVAU 7\?E36[IQY6S:N
MQ5Z*BJJK7'XX_G7Z!_\ !P%\/M!\/?&;P/KMA#;PZ]K^GW":J(P%:58&A$,C
M^K8=TW'^&-1V6OS[QBOT'A?,88_*Z6*IPY$U\/:VFGEIH?G/%V5U,NS>M@ZE
M3G:>_>^NOGKKYA1117O'S(4444 %%%% !1110 4444 %%%% !1110 4444 %
M?:?_  1&\;ZU=?MIZ9I4VK:G-I<.C7>RS>Z=H(\*NW:F=JU\6 9-?8'_  0^
MX_;QT_\ [ U[_P"@K7R_&<8RR7$N7\C_ "/L. JDHY_A5%_;7YG-_P#!5_QQ
MKDG[<GQ*T>36-4;25O+?;8FZ?[-_QZP-]S.W[WS5^@/[1G[&^N?MM_\ !/3X
M3>%] U+2])O=.@TK5'DO]_ELB:?)&5&P$[LS _@:_.C_ (*N?\I!OB5_U^6W
M_I'!7VI_P4@^)OB3X4_\$P?@UJ'A;Q#KOAN^GFTBWEN=+OI;.9XSI5PQ0M$0
M2NY5;'W=RKZ5^<YU0KO#Y1#!M0F[6=NO+'5GZAD6(H?6\[GCTYTXWNKZVYWL
MSO/^"8?_  3;\5?L.^.?%&K>(M<T'5H=:L([6)-/,Q:-ED+Y.]1QS7Y__"3+
M?\%;K#W^)<W_ *<)*^G/^"%WQQ\;?%CXJ^.K7Q1XP\5>);>UTF&6*/5=6N+V
M.)S*02@E=MIP!TKYC^$__*6VQ _Z*9-_Z<)*O+Z>,I8_,X8^:G5]DM4K+9F6
M:5L!5RW*9Y=3<*?MG9-W?Q*^I^AO[?G_  3U^('[5GQHT[Q%X7^([>$-/L]&
MBT][/S;A=\J33NTG[M@/F61!Z_)7YD?MY_LU^(OV6?C39^&_%'BC_A+M2N-(
MBU!+XM*VV-Y98Q%^\9F^5HF;_@5?:_\ P5X^ OQM^)_[3&CZA\.M*\87VAQ>
M'+>WEDTJ[>&!;A;B[+*P5U^;8\?X,*_//X^?#OQ[\-/&L-A\1+76K/79+1)H
MDU28S3?9R[J"K%F^7<K_ /CU=/A]&K]7IOZU!QY7[BBN=?/<YO$N='ZU4BL+
M4C+G7[QM\C]%L?L;_P %(_V2OB9^U-I/@M?AOXIL_"]SH-Q/->2S:E<V+.'6
M+84,$;EF4H?O8ZU\^_\ !:WQ+;>"/V//AG\/]>UN'7O'<%W:75S,?]=<BWM9
M89KHKU4/*XQG[V6Z[37TA^VI^UY+^R?\9O@S/>W0A\+>*+R]TK60YPD2L+?R
MYS_UR<Y)[(TGK7P+_P %M/V7IOA-^T5'X]L1<3:#X_'G22$LZVUZ@"R)GLKK
ML=?<R8^5:^1X(P]2MC<%3Q<N6FN>5/3633=XM_CZ'W'B#B:5'+\=/!Q<JC4(
M5+O2*:332\]O4\2_X)]?L\K^T[^UIX1\,S6_G:2MU_:&K K\HM(/G<-_LOA8
MOK*M?KM8_MCZ'XU_;B\1_ >>.TGMK?P]'(7DY\^[.YY[;'\2_9Y8F_X!*.U?
M+?\ P1%^&ND?!#X"^._C9XLD73=/FC>UBNY8V;R+&UR]PZA06;?+A=HRQ:W
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MYQAHRCA\1./.VW9[M[OU-OXB?$;7/BOXSU#Q%XDU*\UK6M3E\ZYNK@[GD/\
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MCA >5E7Y?E'\-?.XH-=68Y;A<=2]CBX*:[,Y,MS7%Y?6]O@ZCA/NCZT^*?\
MP6<^+_Q@^&^N>%]6MO!XTWQ%8S:;<M;Z=-'+Y4J-&^QO.;#;6_NUXO\ LO\
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M%_;'^.LG[2/[3GC+QDS,]KJVH.+/(Z6D7[J ?]^D3_@6ZOT@^"GCWQ9\./\
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M^2BQ/_;O_I,3^T_"?_DEL-_V]_Z7(6BBBOBC]%"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :/NU^.O_!?O_D\W0?\ L3[7_P!+
M+ZOV*'W:_'7_ (+]_P#)YN@_]B?:_P#I9?5^A>&/_(^I^DOR/ROQC_Y)R?\
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M*S!=OI'_  38_9Z_X:6_;$\)Z)/;^=I.F3_VQJ@*[HQ;6[*^QO\ 9>3RH_\
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MR(.%?,6QF_B#G/W5V]U\</AM8_#'_@NCX:73X5AM=<UNQUAHTZ+),A\T_P#
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M/ON(HF^5$W':KD\>E?2?[(GP:TG]H/\ X(S>'?".O:U_PC^DZQ!,+C4 47R
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M4*+MW;L_>KA_V1OVW/''[%WBN;4/"=U!+8WV/[0TN]4R6E[CHQ4$%77YL.K
M_P"\ORUY"!C'O1]W-:4N'L!#"2P'LU[.6MM]7ZF=3B;,JF-68.J_:QM9K3;3
MH?IE:_\ !PM9MI\<UU\)0VK1QE=T>MJ$/T9H-P#>G/XU\K_MI_\ !3/X@?MH
M0KIFI-;^'O"L3"1='T]CMF<=#<.?FD8-T7Y57Y6V[OFKYSI5QWKS<OX(R7!5
MOK%&C:<?-NWI=L]3,^/\\S"@\-B:[<7NDDK^MDKGTW^T1_P4EOOC7^RGX?\
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M "2V&_[>_P#2Y"T445\4?HH4444 %%%% !1110 4444 %%%% !1110 4444
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M6+^"*3YMTWM>S/O?_@DU/):?\$M/C1-$\D<T5[K#HZG# C2;;!!_"MR1H?\
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M1110 49HHH **** "BBB@ HHHH *,T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Z:?\&Z'^O^,'^[HW_M]7Z=
MI]VOS$_X-S_]?\8/]W1O_;ZOT[3[M?RAXB_\E%B?^W?_ $F)_:?A/_R2V&_[
M>_\ 2Y"T445\4?HH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #1]VOQU_X+]_\ )YN@_P#8GVO_ *67U?L4/NU^.O\ P7[/_&9N
M@_\ 8GVO_I9?5^A>&/\ R/J?I+\C\K\8_P#DG)_XH_F?#=%%%?U$?QV%%%%
M!1110 49HHH **** "BBB@ HHHH *,T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 &:,T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %&:** "C-%% !1110 49HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /TT_X-T/\ 7_&#_=T;_P!OJ_3M/NU^8G_!N@?W_P 8/]W1O_;ZOT[4
M_+7\H>(O_)18G_MW_P!)B?VGX3_\DOAO^WO_ $N0M%%%?%'Z*%%%% !1110
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M?B*/]>,]_P"@B7X?Y!_Q#CAS_H%C^/\ F?G_ /\ $/=\-_\ H=/'7_?=K_\
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M +[M?_C-?H  ?:C'N*/]>,]_Z")?A_D'_$..'/\ H%C^/^9^?_\ Q#W?#?\
MZ'3QU_WW:_\ QFC_ (A[OAO_ -#IXZ_[[M?_ (S7Z 8/M1CW%+_7C/?^@B7X
M?Y!_Q#CAS_H%C^/^9^?_ /Q#W?#?_H=/'7_?=K_\9H_XA[OAO_T.GCK_ +[M
M?_C-?H  3Z4 'VI_Z\9[_P!!$OP_R#_B''#G_0+'\?\ ,_/_ /XA[OAO_P!#
MIXZ_[[M?_C-'_$/=\-_^AT\=?]]VO_QFOT P1Z48/M1_KQGO_01+\/\ (/\
MB''#G_0+'\?\S\__ /B'N^&__0Z>.O\ ONU_^,T?\0]WPW_Z'3QU_P!]VO\
M\9K] /Q%&,=Q1_KQGO\ T$2_#_(/^(<<.?\ 0+'\?\S\_P#_ (A[OAO_ -#I
MXZ_[[M?_ (S1_P 0]WPW_P"AT\=?]]VO_P 9K] /Q%&/<4O]>,]_Z")?A_D'
M_$..'/\ H%C^/^9^?_\ Q#W?#?\ Z'3QU_WW:_\ QFC_ (A[OAO_ -#IXZ_[
M[M?_ (S7Z 8]Q0 3Z4_]>,]_Z")?A_D'_$..'/\ H%C^/^9^?_\ Q#W?#?\
MZ'3QU_WW:_\ QFC_ (A[OAO_ -#IXZ_[[M?_ (S7Z  'VHQ[BC_7C/?^@B7X
M?Y!_Q#CAS_H%C^/^9^?_ /Q#W?#?_H=/'7_?=K_\9H_XA[OAO_T.GCK_ +[M
M?_C-?H!@^U'XBC_7C/?^@B7X?Y!_Q#CAS_H%C^/^9^?_ /Q#W?#?_H=/'7_?
M=K_\9H_XA[OAO_T.GCK_ +[M?_C-?H!@^U&#[4?Z\9[_ -!$OP_R#_B''#G_
M $"Q_'_,_/\ _P"(>[X;_P#0Z>.O^^[7_P",T?\ $/=\-_\ H=/'7_?=K_\
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M:_\ QFOT P?:C!]J?^O&>_\ 01+\/\@_XAQPY_T"Q_'_ #/S_P#^(>[X;_\
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M/Q%'^O&>_P#01+\/\@_XAQPY_P! L?Q_S/S_ /\ B'N^&_\ T.GCK_ONU_\
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M?_H=/'7_ 'W:_P#QFOT _$4?B*/]>,]_Z")?A_D'_$..'/\ H%C^/^9^?_\
MQ#W?#?\ Z'3QU_WW:_\ QFC_ (A[OAO_ -#IXZ_[[M?_ (S7Z ?B*/Q%'^O&
M>_\ 01+\/\@_XAQPY_T"Q_'_ #/S_P#^(>[X;_\ 0Z>.O^^[7_XS1_Q#W?#?
M_H=/'7_?=K_\9K] /Q%'XBC_ %XSW_H(E^'^0?\ $..'/^@6/X_YGY__ /$/
M=\-_^AT\=?\ ?=K_ /&:/^(>[X;_ /0Z>.O^^[7_ .,U^@'XBC\11_KQGO\
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M *'3QU_WW:__ !FC_B'N^&__ $.GCK_ONU_^,U^@'XBC\11_KQGO_01+\/\
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MN^&__0Z>.O\ ONU_^,U^@'XBC\11_KQGO_01+\/\@_XAQPY_T"Q_'_,_/_\
MXA[OAO\ ]#IXZ_[[M?\ XS1_Q#W?#?\ Z'3QU_WW:_\ QFOT _$4?B*/]>,]
M_P"@B7X?Y!_Q#CAS_H%C^/\ F?G_ /\ $/=\-_\ H=/'7_?=K_\ &:/^(>[X
M;_\ 0Z>.O^^[7_XS7Z ?B*/Q%'^O&>_]!$OP_P @_P"(<<.?] L?Q_S/S_\
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MCV\N;Y6^,'B8"UN/*'_$FTKIL1O^?;_:JY_PI7QU_P!%B\4_^";2O_D:N]T
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M;_G%'UR?9?\ @,?\@^HT^\O_  *7^9Y?_P *5\=?]%B\4_\ @FTK_P"1J/\
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M<4;?\XH^N3[+_P !C_D'U&GWE_X%+_,\O_X4KXZ_Z+%XI_\ !-I7_P C4?\
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M&W_.*-O^<4?7)]E_X#'_ "#ZC3[R_P# I?YGE_\ PI7QU_T6+Q3_ .";2O\
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M_P XHV_YQ1]<GV7_ (#'_(/J-/O+_P "E_F>7_\ "E?'7_18O%/_ ()M*_\
MD:C_ (4KXZ_Z+%XI_P#!-I7_ ,C5ZAM_SBC;_G%'UR?9?^ Q_P @^HT^\O\
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M:EC*L*<J,X*I?E;V=C[Z#[![XX%)N+$<?7/:OQBN=3_: _::_P""@'Q.\#^
M_BEXMTVXT?Q#K%S;6]SXGO;>RM[:"^9!$B(650JLBJFW;M%>X_L"?M=_&3X/
M_MRR? 7XQ:I+XADO/,AAN)Y%N);.9;?[3&Z3K\TD4L0^[)\RLP^[AEI5^$ZU
M.BZD:L924.=Q^URBPO&]&KB%1G1G&+GR*?3F['Z7CG_/6HVF5)#N91^-?%__
M  55_P""DM]^R5%IG@OP/#'=_$/Q%%YRNT'G+IENQ:-)%3[KS.X(1&R/E8LI
MX5OG/1_^":7[6WQPTB/Q3XB^)\NBZQ>#[5%8:AXAO5N(&8]&6%#%#\NWA-V,
MX(&-M<V#X=Y\/'%XNJJ4)?#?=_+MYG5CN*.3$2PF"HRK3A\5ME\^_D?J]@':
M0?\ Z]&[:?;UK\M?V9O^"@?Q:_8F_:*M?A/^T)/>7VCWCI##JM](LT^GJ[,(
M[D7/_+>W9OO,[%EVM]WRRA]E_P""['Q4\3_"C]G?PA?>%/$FO>&;J[\0B&:?
M2M0FLI98_LL[;&:)@S+N56Q_LT5.&<1'&T\(Y*U3X9K6+*I\6X:> JXV,7>G
M\4'HTS[E4[Q03M'85^1_@;]GS]M6Q^$6@^/O"_Q&UCQ%8ZIIL&N6EF/$DUW=
MF*>%) CQW:^6[A7^YN9=P.,\9^D/^"5W_!2O6?VHM5U3X>_$2&.U\?:#$\R3
MBW^S_P!HQQMLD#Q\!)T8C<% !&?E7:U7C.&:E*A+$4*L*D8?%RO5?(C+N+:6
M(KQPV(I2I2G\/-L_1GW 2I./QHP ">E?FI^VI\</&WA7_@L/\-/#>E^,/%&F
M^';^ZT07.E6NJSQ6-R)+IE</"K^6=R\-N7YJ]Y_X++_$+Q#\,OV*;W5?#6MZ
MQX=U2/5;*,7FF7DEG.JLYW+OC(;!Z5S?V%5]KAZ/,KUTFO*YU+B:E[+%5>1_
MN&T_.Q]9!M_*\T?+CFOF;]@OXWG1/^";'A/QWXWUS4+Y=/TF[O\ 4M1OKB2Z
MN)$BGGRS.Y+N=J@ 'YONBOBH?M#?M'_\%9/B;K&G_#&^G\">"-,?:6BOGL8X
M$.XI]IN8@99)7Q]R/*K_ '?O,VF%X?JUJM6,I*$*;M*;VWL1C.*J-&C1E"+G
M4JI.,%OM<_6[S ?ND$>U!;/7%?E'XQ_8+_:V_9,TIO%7@_XE:AXJ^P 7,^GV
M&JW-Q(Q'S.?LUP/+N!_L\LW]VO:/&VA_M*?MT_L4^ ]4T>>3X6^-%U![F^,&
MLW6D_P!I6?E,(YBL0,B;V8-Y3_W=W0A:TK</T8\DJ>)A*$G;FVMZHQP_$]:7
M/"KA9QJ15[;W]'L?>3RC;\NTGN,TX'CI^M?AG^SA9_M*?M1?&37O!/AKXO>,
M(]:\.Q3SW;7OC#4(X,13)"VQE+9^=Q_#]VOVB^"WAW6/"/P>\+Z7XAO6U#7M
M-TBTMM2NFF:<W%RD*+*^]OF?<X8[FY.<UCGN1_V9)4Y58S;Z1Z'1P[Q&\U4I
MQHR@EU?7R.N'2B@45X)],%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** ,O0/^0KK?_7ZO_I/!6I67H'_ "%=;_Z_5_\ 2>"M2@ HHHH
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M?[+5WYAFU-U<)CX65*,M8+I+J_U7_!/+RW):WL<;E\[RKN.DW?6/17_!_P#
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MQ_P2X_X)R:S^Q[/XB\6>.-4M-7\<>)T$,OV:>2>.TAW^;)NE<*TLKO@LQ7^
M8)R6/YP>/_B)\0OA1^W9\<O$OPVOKO3=3T?6];N+ZX@CBD>&R_M/9(=KAMR[
MS%NVKN5?F^ZK5^\_E[5/<XK\OOV(O@)KEU_P5<^-4GB3P?K2^$]>;Q);FXOM
M,DCL;Z&;45^579=KAT+?=/S+7!P_GCG7Q6.QEI/D6CV>JTL=O$W#T:='!X#
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M (++_LT6/QU_9!U37-T4.M?#U)-:LIV'WH57_2(<_P!UT4'_ 'HTKQ3_ ()
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MQ5&OB\+F&9JG*$*BBH)[NW6Q]+?L.#?^Q9\(SMZ>#=(_$_8H:_/B2WM_#O\
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M5V<8U(SS'FB[^['_ -).'@6G*&6<LU;WY?F.HHHKY<^R"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,OP__P A#6/^OW_VC%6I67X?_P"0AK'_ %^_^T8JU* "BBB@ HHHH **
M** "BBB@ HHHH *R_%W_ "+\O^^G_H:UJ5E^+O\ D7Y?]]/_ $-: -2BBB@
MHHHH **** "BBB@ HHHH **** "LOQ=_R+\O^^G_ *&M:E9?B[_D7Y?]]/\
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M\J=10+E0$9% &!110, ,4444 ($"] !^% 4+T I:* LA-HSG SZXI2,T44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#+\/_\ (0UC_K]_]HQ5J5E^'_\
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M@FT_ZX)_Z#5NJFB_\@FT_P"N"?\ H-6Z "BBB@ HHHH **** "BBB@ HHHH
M**** ,O0/^0KK?\ U^K_ .D\%:E9>@?\A76_^OU?_2>"M2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK?$30O!_B6^\,R:WI5Y9K;7,]K+L<J'(894H^/[KK0!]\45\W?LG?MI_$/\
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M /X32XTGQ-X<TJ:TCUW5;+P5K7@?5/"0NV9+:XN]&U9I9Y=/=T=?MT4^U&#
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MQC<M 'N5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%> _'K_@
MHS\.?V<_VQ?A)\$?$=\\/B[XQ)>-I."ODVQ@4>4)B3\OVB3?%%_>D0K7OU !
M1110 45\F_L]?\%(]8_:6\'_ +3UQX>^&=Q<^(/V>_%NM^$--TBWUD3R^,;K
M3X-\>QFA06[3OA-G[S;N^\U>F?L#?'OQS^TW^R=X0\;?$KX<:E\)?&FMQ3MJ
M/A>_=VGT[9<2Q(S;T21?-C1)=CJK+YFWYL;F /9J*** "BBB@ HHHH ****
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MU;JIHO\ R";3_K@G_H-6Z "BBB@ HHHH **** "BBB@ HHHH **** ,O0/\
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M^+F\6VWAAX(M2D_LF]T];=Y@[1#_ $J&+?D1O]S=MQSC(K-_X)6?#K_A4_\
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M_P ,L?\ !L@EPI^RS_\ "H+V_@/W=MQJ=M+/&?\ OY=K7TU_P2N^'7_"J/\
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MN5_X)K:<C_\ !8_]O.Z;_60WWA*)>.SV%TQ_] 6O,_\ @IW^SGH_CW_@M?\
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MBO\ M"^!_@3<Z#%XS\5:!X7D\4:BFDZ0NIWL=L=0NG^[%'N/S-_B/6@#P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<NI"[%NSCCS%CB=67^%D=3\RL*\]_8<_:@\(_"K_ (.7OVSOAUX@OK73M?\
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M5:E9?A__ )"&L?\ 7[_[1BK4H **** "BBB@ HHHH **** "BBB@ K+\7?\
M(OR_[Z?^AK6I67XN_P"1?E_WT_\ 0UH U**** "BBB@ HHHH **** "BBB@
MHHHH *R_%W_(OR_[Z?\ H:UJ5E^+O^1?E_WT_P#0UH U**** "BBB@ HHHH
M**** "BBB@ HHHH **** ,SPE_R!F_Z^;C_T>]:=9GA+_D#-_P!?-Q_Z/>M.
M@ HHHH **** "BBB@ HHHH **** "JFM?\@F[_ZX/_Z#5NJFM?\ ()N_^N#_
M /H- !HO_()M/^N"?^@U;JIHO_()M/\ K@G_ *#5N@ HHHH **** "BBB@ H
MHHH **** "BBB@#+T#_D*ZW_ -?J_P#I/!6I67H'_(5UO_K]7_TG@K4H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G_9T_8_\ "?[+
M_BWXD:UX=DUBXU#XI>)9O%.M27UPLVVZE_@BVHNV)?X5;=M]:]8HH XO]H'X
M*Z3^TA\$?%7@'7IM0M]#\7Z9/I%^]C*L5SY$R%'".RLJDJ67[IZU;^#7PLTO
MX%_"/POX)T))H]#\'Z3::+IPF??*+>VA2&+>V!N;:BY/K74T4 >3:M^Q]X3U
MO]L?2_CC<R:O)XRT7PN_A*TB^T+]@BM7N&G=_+V;O.+.5W;L;?X>]>LT44 ?
MGS8?\&XGP8T22[;3_'WQZTN.^NI+R:*R\9"VB>61MSOM2$#<QKO?"/\ P1.^
M&/A/X ?$SX;R^+_BYK>@?%2"PM]5DU;Q-]LNK5+.=IT%L[Q;8M['#_*VY57I
M7V310!^?MG_P;I_"/3[6.WM_B9^T/##"BI'&GCEE6-5X"J/)X6OI3X2?L*^%
M_@Y^R1K/P;L=<\::IX;UZRU"QNM1U753>:N4O$=)"+AD^\JO\GR_+M7K7MU%
M '!_LX? #0?V5?@7X7^'?A9;S_A'O"-@FGV7VJ023M&O=RJ@,Q))9@HZUI?&
M3X2^'OCS\+=>\&^*]+AUGPYXFLI-/U"SE'RSQ.NT\]59?O!A\RLH8<@5U5%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYV^?<_.1\VQ'VYXH _16OB__ (+R?M<>//V,?^"=&N>)/A?K2Z!\1]8U[2-
M\.W[VEO=^1<7-]$'_=3H\3[H%F7YD;&[=U7->9_#+_@@7X8_:3\.6_C#]LG7
M/%'QX^*VO0+<:E;7'B"]T[0/#3N@S9:=:6<L4:Q1;F7?_$V9,*S5\I_\%"?V
M _$7['_[87[)/P-\%^+/$6N_LY_$GXMZ1K]KX9UV_EU2X\(W>DONN+:TGEW2
M+8SVUT7\IV?;);,VY=S;@#]OK"&2"RACFE:XD1%5Y64*TAQRV!QS[5:KX$_;
M_P#C)\2?VLOVX-$_9%^$'BW5/AK!_P (Y_PF/Q-\<::%_M+2=)>4P6]AIY;[
MEU<2=9?O1HRLN[#+5+5?^#9_]F&'15O/#]G\1/"?Q%M3YUG\0=/\;:FWB.WN
ML#%QYDDS0LVY0<>5MZXV[C0!^A%%?DW_ ,$!T^+GB[]KS]MC7OBAK=OXD^(7
MAO5]&^'Z:EMD@L;ZXTFTN+5KI8_X/M*I:SOM7[TC':N=M>'_ /!,_P#X)Y_!
M7_@IO\,?%%Q\5/&_Q)T/]O30-5OI?%VL3^(KW3_$WA&[2\?[.UI9&40&S2/R
M<;(V5=VU6B^15 /W4HK\Z_\ @LI^WWJ_[,]W\(_V>?"/Q2\._#+QG\7EECU7
MXC^++^UM8_".C6L86XOR\K11&\G.4B^[\ZOMVML9? W_ ."='_!+G7?#TDWB
M3]HSP;XL^(-Q$WF_$#5/CY%)XB:9AS/N6\6V\S[WWH"O/(:@#]D**_/?_@A!
M^V#JGQBL_C3\&]:^)FE_&IO@'XBM=.T7Q_9:E%J#>)=$O8I)K%YIXBR2SQB&
M6)W5FW,F#EE9F^T/VD_B6OP6_9S\?^,6?RQX3\.:AK)?T^SVLDN?_'* /FO_
M ((B_M4^/OVSOV8?&WQ \=:__P )!#JGQ)\06_A=A96]JMEHD$ZP6UN/)1-X
M1DE^>3=(V[YF;BOLROQ7_P""$?\ P1FTW]J+_@FK\-?$'[1&K>(O&'@Z]L[J
MY\(> (-6NM,T72[2>]GG:[NTM94-W=7,CM+NE9E6)HDQ\NU?=OV)OA4G_!-#
M_@L_J?[-_P /=8UZ3X'^.OA8?'VF^%]2U*?4D\(ZE!J7V-EM'F=Y$MI8]S,&
M)W/MY^2@#],J*_/G]IW5;SXE_P#!Q-^S+X5ANK@67PW^'7B;QM<VZ.5C?[=_
MQ+$9U^ZV&0;<]"*]6_X+D?%F3X)_\$C?V@->AN&M9F\(W6EQ2JY1XWO=MDI5
MNS;K@8H ^L**_(O_ (+5Z5XE^#?_  ;T?!KX4Z%/>MXL\82^"? -JHG:.>\O
M%BBEV%\[MSR6G//K7L&M?\&Y'PC^._@^;6/CAX@\??%'XU:I"9[CQW+XDO;&
M32;YOFWZ=9P2):V\$38\J(Q,JJB"@#]%**_%'_@DA^S1XZ_X+<?LUVU]^U%X
M^\2>,/A'\+;RZ\#Z/X8T[4KO2X_'%Q:M\^KZM<12+/<,J210HN]?F@=V^9G\
MSVS]E3]G[2_^"6'_  6JT7X&_"/4->L?@O\ %CX=7OB6;P=>ZI<:C:^'M3L[
MA4%U:M<.\D:RI\K;F.YCRS;8U0 _4*BOS#T'P;XF_P""\_[0GQ(F\0>,O%G@
M_P#93^%OB.X\&Z;X<\.WS:==_$74[3Y;V[O;F(^:MFDA58HE;]Y][Y&1MSOV
MH/\ @B[X'_X)W?![Q-\<OV1V\0?"'XE?#/2IO$,FG0:_?:AHOC&VLXC+-IVH
M6UU++YJRQ1NJLK(RR,K[MWS4 ?IU17XV? ?Q7JG[-?\ P9WZSXBOK^\.MZ_X
M&UF62^FN'\]I-6U&XMX'WD[MWEW,(7Z+7JG[#O\ P0N\,_M"?L;?#?4/VL+K
MQ#\7/%4GA73+>RT.XUN_T[1?!]BEG$EO90VUK-$KSI'_ *VXDW2/+O.[^)@#
M]/Z*_.O_ () 6^L_LO\ [<?[4'[+L/B?7/%7PV^$[^'];\%?VO=O>7F@VVJ6
MCRS:>TSDLT4;*GE*W10S?QU^BE 'SS\*?@M\=/#G_!0+XD>-/$WQ4TW6O@=K
MVCVMIX6\$QZ:L=SHEVBP^9,\VS)&Y;C^-M_V@9V^4HKZ&KX!_P""(FLWGQ4^
M)W[9/Q"NKJXN;?7/CIK&@Z=NE9U^QZ9%!!$R>BMO;I_=-?)__!'']A[5O^"H
MOA/XR_$#XO>,?%%]\#?%OQ7\1ZWH?@G3-6N=-BUZZEF1);R\N;=TGEMT5%AB
MMPZQJT<K;?F^8 _:ZOGO]ICX*?'/X@?M3?!GQ'\.OBEI?@WX;^$[ZXF\<^'K
MC3!/-XGA?8$1'VG'RB1?O)L+[_G8*J_&<7[+VA_\$>?^"M_[.?AOX&W6L>&_
MA7^T9_PD&C>*/ LNJ7%]ID-S8V2W5OJ%HD[NT4N]E5V!^XI48W\>D76L77Q5
M_P"#FRSTV.ZN&T;X6_ A[R6 2MY2ZA>ZMY?*_=S]G=?RH _0BBOR1_;@_;7\
M-_MS_P#!0OQI^S]XF_:.T#]G;X%?!V*WA\7W2>,;+PYKWQ U6=&=M/M[B=U>
M.S@7Y)]BMN;<K?>1DX+XQ_L._P#!/OX2_#O4?%7[,_[37PW^"OQL\/0/J>A>
M(M*^-D5Y_:5[$C,D%Y#=7TL<L,K95U55_P!:WWERC '[5T5^?N@?\%G)K;_@
MA?X7_:DN?#\>L>,?$>DPZ?9:#99\K4O$+WC::(E[K$UXCN5SN6-64;F'./\
M#[_@@7X>_:9\-P^+/VRO$WB[X\?$W7H$GU&Q?Q#>:5X<\.N<-]ET^TL9856.
M+E=[$^8VY]JLU 'Z-5\:?\%J?VI/'W[,?P"^&<?PQU[_ (1OQE\2_BEX>\#V
M-X+&WO&Q>S.TJ".XCD3+1Q.N=NY<\<UC?LA?\$C]<_X)V?M3:5?_  7^*6O:
M=\ +[3[B'Q!\-_$=S<:Q#;W?S&WN-,E=\V_S-\^[=N5.?,W+Y7S3_P %E_\
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MOQ*_X),^!V^#MQ]K\<?M?#3_  ?X*M4E_?Q?VF%6[+'Y=IAB=X6?_EG+*F:
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M^C>"],U:/26\/:@GA>)M%6U21D?R;[3(]B).OE?*\L6XKDJS+M:@#[8HHHH
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M8^&;K7M&M_$>J0275CI4U]$E]>11_?EBA)WNB_Q,JX%?G+_P<&_!;P=\ /\
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MX8_"+XA_LR?$34@WCC]E767\/&ZNWV-J7AR13/I.H?-]V-K;**O\$<46?O4
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M_?-?$?\ P_T^"/\ SY^./_!5%_\ 'J/^'^GP1_Y\_''_ (*HO_CU'^KN9_\
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MIT+_ (+C_ BPL6CDOO$V[SIGXTA_NM*S#OZ$5>_X?J_ 3_G^\3?^"A_\:?\
MJ_F7_/B7W!_K-E7_ $$1^]'V1AJ,-7QO_P /U?@)_P _WB;_ ,%#_P"-'_#]
M7X"?\_WB;_P4/_C1_J_F7_/B7W,/]9LJ_P"@B/WH^R,-1AJ^-_\ A^K\!/\
MG^\3?^"A_P#&C_A^K\!/^?[Q-_X*'_QH_P!7\R_Y\2^YA_K-E7_01'[T?9&&
MHPU?&_\ P_5^ G_/]XF_\%#_ .-'_#]7X"?\_P!XF_\ !0_^-'^K^9?\^)?<
MP_UFRK_H(C]Z/LC#48:OC?\ X?J_ 3_G^\3?^"A_\:/^'ZOP$_Y_O$W_ (*'
M_P :/]7\R_Y\2^YA_K-E7_01'[T?9&&HPU?&_P#P_5^ G_/]XF_\%#_XT?\
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M?<P_UFRK_H(C]Z/LC#4?,*^-_P#A^K\!/^?[Q-_X*'_QH_X?J_ 3_G^\3?\
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M &@ZZ6'Q[[-OX5]F?M1?$_\ X4?^S+\1?&GF>3_PB/AG4];W'^'[-:RS9_\
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M55RORKRSHK;WQ@^+7_!*_P""_P +IO%M[X?_ &.=;LS;-<6NGZ!X:T#5M3U
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M*DT ?&G_  ;I?#'_ (51_P $7O@38O&5N-4TBXUR5B/FF-]>W%TK'U^29/P
MKEO A_X6E_P<S^/-2V^;;_"OX$Z?H&/O"&ZO]6^V;_9C#E?]VOO+PWX:T_P7
MX?L])T?3[/2]+TR%+6RLK*!8+>UB1=J1QH@"HBJ  JC JKI?P[\/Z'XNU3Q%
M8Z#I%GXAUQ(HM2U."RBCO=02)=L2S3 ;Y B_*NXG;VH _,?_ ().?M7>"O\
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M#OC'0IFWR:=K>FPZA:R-@C+12JR$_,W;O7.? G]CGX2_LPRW4GPX^%_P_P#
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MQSR;7><+M?Y4*LNY@VT9/C'Q;8?%7_@YE^$>CA?.B^%/P5U;Q5G^&WEO[_\
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M'2=',>/NFWLXHB/_ !ROC_X%RGXJ?\'*_P ==:V^8OPI^#^A>#@V.(6O[O\
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M^'9\2>%_'NK?#R)HM U+Q'HVEG4H/"=O!;A8KJ^2/,OENRJFZ.-OXOXMBO\
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M3\.:E=07$Z8#3V,UO#*LL$F4=/FSM<8,BCS&^>/B/^U!\3OVZ?\ @M?^Q?\
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M&3_"C_A!M%_Z ^F_^ R?X5K44>VG_,'U>E_*ON,G_A!M%_Z ^F_^ R?X4?\
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M_H#Z;_X#)_A6M11[:?\ ,'U>E_*ON,G_ (0;1?\ H#Z;_P" R?X4?\(-HO\
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ME'UFK_,P^JT?Y%]QRG_"C/!?_0H^&O\ P60?_$4?\*,\%_\ 0H^&O_!9!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHKQ']NS]O7X>_\ !.WX)GQQ\1+V^CM;
MJ\33=)TS3K9KK4]>OI S16EI"/OROM/WF51C+,M 'MU%?G?=?\%;?VGO#FB1
M^+M;_8 ^)5E\.%C^U3WMIXWTV\\1PVP!9G_L546?S  ?W3,K5ZQ_P3U_X*Z^
M _\ @I1\<OBAX9^'EG-=>'_AWINA:C#KSW/_ "%#J=O+*\+6Y16MY;9X7BD1
MF;YU;[N* /</V>?VK/ /[5MMXPF\ ZZ=>C\ ^*+WP9KS?8;BU^PZM9^6;BV_
M?1IOV>8GSINC;=\K-7I%?BI_P3$_X*6:?^RIKW[4/PS\(^!?$WQD^-GB[]I#
MQMJNC^"?#[)#(MDOV)#>WMW)^ZL[7S%9/-?.Y@0%;#8^I]8_X+/^/OV6]<TN
MX_:F_9C\6? GP/K%Q':#QIIGB>T\9:+I<TFT(+Y[2-'ME9FV;BC?-C&5^90#
M]!**^?\ ]O[]OSPW^P-^S=#\0;[2=4\:7&N:E9:%X8T/0]LMUXEU.\8BVMH&
M^[\^TOOY^5&VAFVJW!_LB_\ !0?XO?%?XZV/P]^,G[+OCOX)ZMK6FRZII>JP
MZU:^*=!FCB"F2*XO;5$6UG^=0J2+\S<?W=P!]>45\E_MX_\ !5[PW^QU\4M!
M^&/AGP?XK^,7QL\50B\TOP-X6B#W26FYE-W=S-^[M8,JWSONZ9V[=S#R"X_X
M+@^/?V:M=TF;]J?]EKQQ\ /!.N7264?C&V\16GBW1]/D?_5_;GM$5K=6^[T9
MMW\/WMH!^B=%?+G_  4M_P""H7A+_@FQ\%_AS\0->LEU_P )>//&NF>%I=2M
M;X)!I=K=P7%PVI95)/.BCBMV;8G+AN&KS;0?^"L_Q1;X$?$WXQ>)/V7_ !-X
M)^#_ (/\'W7B[PWK.M>++*/5O%:1!62&33(T>6Q:2/<^Z5FVJH^]NH ^[**_
M.3PU_P %W/%/[3FG:+'^S+^S9XL^/FI?V18ZAXFN8_$UGH&@>';NYM8[AM-&
MIW*&*XNH-^R1$5=K#'WLJOIG[*?_  5XC^)_[15K\%?C1\*_%G[//QCU:*6X
MT71-<NHM1TWQ+%&I:7^S]2@'D7#1[6W+\O\ L[OF50#Z/_:+_:9\#?LE?#1_
M&'Q$\06_AGPY'=V]BU[-%+*GG3R+%$F(T9OF=@O2N3_;D_X* _"__@G)\)].
M\:?%K7YO#OA_5=8@T*UGBL9KQY+F5)9%&R)6;:L<,KL?1/[Q53\!_P#!T_\
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M&9=>L+F.[6P\3V&D1V%C)9RO]O$MR=DT?W?DC^9M^10!Z=\%_P!I7P/^T/\
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MVVD,C74MM+(H6*9BBLK;L+C;7TO\:O$5EX1^#GBS5M0TV/6M/TO1[R\NM/E
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MVBPU&Q?=',N2"K*V&1U8,K(X#(RLK!64BNSGA2XB:-T5UD&&5ERK#TK\XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSA_:PTFQ\<?\
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M.2OC+<?"'7/A'I/BGP7\.]&M="?Q]:7M\D>CSI%)<M9I;_ZM_MCRJ[?W9/\
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MQ!X@3<ME$UO_ ,\H/D?<WRLLLZ8^85]OT44 ?$W_  4Y_86\=_$_]I/X"_M
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M*ZW_ -?J_P#I/!6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]"T]KJ023M;VL*01;V 7+[$7)P.:ZVBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH **** "BBB@ HHHH **** "BBB@#,\)?\@9O^OFX_]'O6G69X2_Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OS\_X*V_'[XI?%#]IOX2_LD_!
M7Q3<?#WQ1\6;2\U_Q7XSM@&NO#?AZU#+)]F7[RSSR!D21=I5E4!EWL\?Z!U^
M;O\ P5LA\3?L1_MU_!_]LK1_"^L>,O!/@W1+WP-\2-/T>!I=1T_1;AVGCU%%
M'WXH)RSN&Q]U>55F= #0N?\ @V-_9AM]%CNM&M_B7H/Q(MX_,@^(EIXXU+_A
M(H[K#8NMS3&#S-QS\L*K\M>1?\$.- ^)W@S_ (+!?MG>'_C!KEKXH\>^'=*\
M)Z7<Z[;P>1_;EK%:RI97DB [5EEM/L[R ?\ +1GK[&UC_@MM^R;I'P>;QT?V
M@/A?<:-]F-RMO;ZY#)JD@"[O*6Q4_:O.Y'[KRO,Y^[7QY_P0\_:(\3?M6?\
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MYN30!]:4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY!-I_P!<$_\ 0:MT %%%% !1110 4444 %%%% !1110 4444 9>@?\A76_\
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M%%9_^!9KSS_@HOX:_:$O?A1H^N?LW^)-%L?&WA;58M0O/#>LVMLVG>-K!?\
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M "BBB@#+T#_D*ZW_ -?J_P#I/!6I67H'_(5UO_K]7_TG@K4H **** "BBB@
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M^1ZEN/M1N/M7EO\ PM3XE?\ 1*3_ .%);?\ Q-'_  M3XE?]$I/_ (4EM_\
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M*3_X4EM_\31]3GW7_@4?\P^O4^TO_ 9?Y'J6X^U&X^U>6_\ "U/B5_T2D_\
MA26W_P 31_PM3XE?]$I/_A26W_Q-'U.?=?\ @4?\P^O4^TO_  &7^1ZEN/M1
MN/M7EO\ PM3XE?\ 1*3_ .%);?\ Q-'_  M3XE?]$I/_ (4EM_\ $T?4Y]U_
MX%'_ ##Z]3[2_P# 9?Y'J6X^U&X^U>6_\+4^)7_1*3_X4EM_\31_PM3XE?\
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M1_PM3XE?]$I/_A26W_Q-'U.?=?\ @4?\P^O4^TO_  &7^1ZEN/M1N/M7EO\
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M_P"!1_S#Z]3[2_\  9?Y'J6X^U&X^U>6_P#"U/B5_P!$I/\ X4EM_P#$T?\
M"U/B5_T2D_\ A26W_P 31]3GW7_@4?\ ,/KU/M+_ ,!E_D>I;C[4;C[5Y;_P
MM3XE?]$I/_A26W_Q-'_"U/B5_P!$I/\ X4EM_P#$T?4Y]U_X%'_,/KU/M+_P
M&7^1ZEN/M1N/M7EO_"U/B5_T2D_^%);?_$T?\+4^)7_1*3_X4EM_\31]3GW7
M_@4?\P^O4^TO_ 9?Y'J6X^U&X^U>6_\ "U/B5_T2D_\ A26W_P 31_PM3XE?
M]$I/_A26W_Q-'U.?=?\ @4?\P^O4^TO_  &7^1ZEN/M1N/M7EO\ PM3XE?\
M1*3_ .%);?\ Q-'_  M3XE?]$I/_ (4EM_\ $T?4Y]U_X%'_ ##Z]3[2_P#
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M?_$T?4Y]U_X%'_,/KU/M+_P&7^1ZEN/M1N/M7EO_  M3XE?]$I/_ (4EM_\
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M4^)7_1*3_P"%);?_ !-'_"U/B5_T2D_^%);?_$T?4Y]U_P"!1_S#Z]3[2_\
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M $2D_P#A26W_ ,31_P +4^)7_1*3_P"%);?_ !-'U.?=?^!1_P P^O4^TO\
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M_P#"U/B5_P!$I/\ X4EM_P#$T?\ "U/B5_T2D_\ A26W_P 31]3GW7_@4?\
M,/KU/M+_ ,!E_D>I;C[4;C[5Y;_PM3XE?]$I/_A26W_Q-'_"U/B5_P!$I/\
MX4EM_P#$T?4Y]U_X%'_,/KU/M+_P&7^1ZEN/M1N/M7EO_"U/B5_T2D_^%);?
M_$T?\+4^)7_1*3_X4EM_\31]3GW7_@4?\P^O4^TO_ 9?Y'J6X^U&X^U>6_\
M"U/B5_T2D_\ A26W_P 31_PM3XE?]$I/_A26W_Q-'U.?=?\ @4?\P^O4^TO_
M  &7^1ZEN/M1N/M7EO\ PM3XE?\ 1*3_ .%);?\ Q-'_  M3XE?]$I/_ (4E
MM_\ $T?4Y]U_X%'_ ##Z]3[2_P# 9?Y'H&AHT=]JFX8W7>X>_P"ZBK2W'VKR
M>+XQ?$>6_FMQ\*?FA5';_BI;7^+=_L_[-3?\+4^)7_1*3_X4EM_\33^IU.Z_
M\"C_ )A]>I]I?^ R_P CU+<?:C<?:O+?^%J?$K_HE)_\*2V_^)H_X6I\2O\
MHE)_\*2V_P#B:7U.?=?^!1_S#Z]3[2_\!E_D>I;C[4;C[5Y;_P +4^)7_1*3
M_P"%);?_ !-'_"U/B5_T2D_^%);?_$T?4Y]U_P"!1_S#Z]3[2_\  9?Y'J6X
M^U&X^U>6_P#"U/B5_P!$I/\ X4EM_P#$T?\ "U/B5_T2D_\ A26W_P 31]3G
MW7_@4?\ ,/KU/M+_ ,!E_D>I;C[4;C[5Y;_PM3XE?]$I/_A26W_Q-'_"U/B5
M_P!$I/\ X4EM_P#$T?4Y]U_X%'_,/KU/M+_P&7^1ZEN/M1N/M7EO_"U/B5_T
M2D_^%);?_$T?\+4^)7_1*3_X4EM_\31]3GW7_@4?\P^O4^TO_ 9?Y'J6X^U9
MOBM&ET.15!8[TX'?YUKS_P#X6I\2O^B4G_PI+;_XFH;[XP?$BRLYIG^%/RPH
MSM_Q4EMV&?[M/ZG4[K_P*/\ F'UZGVE_X#+_ "/6-Q]J-Q]J\K3XL_$EXU8?
M"GAAG_D9+;_XFG?\+4^)7_1*3_X4EM_\32^IS[K_ ,"C_F'UZGVE_P" R_R/
M4MQ]J-Q]J\M_X6I\2O\ HE)_\*2V_P#B:/\ A:GQ*_Z)2?\ PI+;_P")H^IS
M[K_P*/\ F'UZGVE_X#+_ "/4MQ]J-Q]J\M_X6I\2O^B4G_PI+;_XFC_A:GQ*
M_P"B4G_PI+;_ .)H^IS[K_P*/^8?7J?:7_@,O\CU+<?:C<?:O+?^%J?$K_HE
M)_\ "DMO_B:/^%J?$K_HE)_\*2V_^)H^IS[K_P "C_F'UZGVE_X#+_(]2W'V
MHW'VKRW_ (6I\2O^B4G_ ,*2V_\ B:/^%J?$K_HE)_\ "DMO_B:/J<^Z_P#
MH_YA]>I]I?\ @,O\CU+<?:C<?:O+?^%J?$K_ *)2?_"DMO\ XFC_ (6I\2O^
MB4G_ ,*2V_\ B:/J<^Z_\"C_ )A]>I]I?^ R_P CU+<?:LWQ6C2Z'(J@L=Z<
M#O\ .M>?_P#"U/B5_P!$I/\ X4EM_P#$U#??&#XD65G-,_PI^6%&=O\ BI+;
ML,_W:?U.IW7_ (%'_,/KU/M+_P !E_D>L;C[4;C[5Y6GQ9^)+QJP^%/##/\
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M%);?_$T?4Y]U_P"!1_S#Z]3[2_\  9?Y'J6X^U&X^U>6_P#"U/B5_P!$I/\
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M .)H^IS[K_P*/^8?7J?:7_@,O\CU+<?:JNL%CI-T!U\E\?E7F_\ PM3XE?\
M1*3_ .%);?\ Q-'_  M3XE?]$I/_ (4EM_\ $T?4Y]U_X%'_ ##Z]3[2_P#
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MBBC- !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#+L?^1IU+_KC!_P"U*U*R['_D:=2_ZXP?^U*U* "BBB@ HHHH
M **** "BBB@ HHHH *S_ !3_ ,BWJ'_7M)_Z U:%9_BG_D6]0_Z]I/\ T!J
M+5C_ ,></^XO\JFJ&Q_X\X?]Q?Y5-0 4444 %%%% !1110 4444 %%%% !6?
MXI_Y%O4/^O:3_P! :M"L_P 4_P#(MZA_U[2?^@-0!:L?^/.'_<7^535#8_\
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M\3F6(QN/S1Y9A:GLH02<Y+=WV2['QOX=_P""S?QG_9Y\7V=C\</A?);Z==,
M)(=/FTN[9,+N>/S6:*;;_=7;\S;=RU^A?A?]H7PGXH^!L'Q(AU1;?P?<:<VJ
MF^ND:%8K=5+,S!AN&W!X_+-:GQ0^$/AGXU>$I=#\6:'INO:3,RR-:WL(D0NI
MRI'HR^HYKXJ_X+W>.[KP)^R=X9\+:5_H.FZ]J\<%Q'"NR-H+>)I%APO1?,\I
ML?\ 3,5G#ZGFV)HT*%+V4Y/WK/2WDNY=3Z]DN%K8C$5O:TXKW;K6_F^W]>O
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M&'P>.P7]H8:G[.4)*,X]'?9K_(G"XK'9;CGEN*J^TA.#E"3W5MTS<_X)L_\
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M4TMY_.^S.1N1T?:NZ-USM;:.59?X:\D_X*!?\%=]&_92\42>"O">DIXN\=#
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MW]7Q6(=/5<BLN2:ZK_$_ZZ'V[1117P)^FA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 9=C_ ,C3J7_7&#_VI6I678_\C3J7_7&#
M_P!J5J4 %%%% !1110 4444 %%%% !1110 5G^*?^1;U#_KVD_\ 0&K0K/\
M%/\ R+>H?]>TG_H#4 6K'_CSA_W%_E4U0V/_ !YP_P"XO\JFH **** "BBB@
M HHHH **** "BBB@ K/\4_\ (MZA_P!>TG_H#5H5G^*?^1;U#_KVD_\ 0&H
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M['A_^)K# YQET,#/"8B$VYRYG:R]%Z?J=./X?S2>80QN'J07)&RNF[=WZO\
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M +ZKGPF:1I8"M@VM:G+_ .2NYTX[)Y5\SH8^^E-2T]58[-@!$WIBOQN_8W^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &78_\C3J7_7&#_VI6I678_\ (TZE_P!<8/\ VI6I0 4444 %%%% !111
M0 4444 %%%% !6?XI_Y%O4/^O:3_ - :M"L_Q3_R+>H?]>TG_H#4 6K'_CSA
M_P!Q?Y5-4-C_ ,></^XO\JFH **** "BBB@ HHHH **** "BBB@ K/\ %/\
MR+>H?]>TG_H#5H5G^*?^1;U#_KVD_P#0&H M6/\ QYP_[B_RJ:H;'_CSA_W%
M_E4U !1110 4444 %%%% !1110 4444 %%%% &78_P#(TZE_UQ@_]J5J5EV/
M_(TZE_UQ@_\ :E:E !1110 4444 %%%% !1110 4444 %%%% &7X/_Y%FS_W
M/ZUJ5E^#_P#D6;/_ '/ZUJ4 %%%% !1110 4444 %%%% !1110 4444 9EG_
M ,C=J'_7M;_^A2UIUF6?_(W:A_U[6_\ Z%+6G0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 '2BBB@ HHHH **** #%&*** "BBB
M@ HHHH *.E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 &**** "BBB@ HZ444 &**** #K1BBB@
MHHHH ,4444 %%%% !1110 4=:** "BBB@ HHHH *.E%% !1110 4444 %%%%
M !1BBB@ HQ110 4444 %%%% !1110 4444 %%%% !1UHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;M0_Z]K?_P!"EK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^?O^"AG_!0WP/_ ,$T/@C8^/O'UCXDU+2=2UF'0X(-"MH9[IKB6*:5
M?EFFB7:$MWS\V>G%?0-?C+_P>&?$?^S_ (,_!/PBLG_(8UK4=7=/^O6&&($_
M^!A_6@J)[C\)?^#I_P#9>^)?BFUTW4/^%B>"X[J58Q>Z]HL'V6/=MVEVM;B=
ME7GKM^7'.*_1G0=>LO$^B6>IZ=>6VH:;J,$=U:W5O*)8+F-U#(Z.O#*RL"I7
M@YK^;_\ X*1?M-?L9^.O^"?W@7X>_!OP7I.H?%[3(-*M9_$FD>$O['D+Q0(E
MT]Q,T44MT\K#HRON9M^X-][]6/V:?VA8?^"1W_!$'X;^(OC:NI6NI>&]#B@7
M22!_:-Q<7$LLMIIZ(Y^65(F165O]6L+Y^X: E$^^**_#F'_@L3_P4)_:F\+7
MGQ(^$?P-L;/X9QR2R6/V?09=1ENH0W]^657NF7:5+6T2KNW?+\M?;W_!%[_@
ML=9?\%2/A_KUAKFBVGA3XE>#/*.KZ;;.[6MY"Y*K=6X?YU7>K(R,6*-L^8[Q
M0'*?=%%?EC_P4O\ ^"_'BCX4_M+7'P'_ &;/ *_$SXG:?<&TU.ZELYM0MK>8
M)N>VM[>W=9)98_XW9E2)D965L-M\9\,?\%BOV]/V4_B[X7M_CE\!+CQ%X=\8
M7D=E;66F:$\-],[+N\NTEMWDC,^T[O)E4LVQE^3YF4#E/UJ_:Z_:.TW]D/\
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M'A_[3'?^(+RV:\6Y\I@CSVZ^;'%%;J_RK+.S++YB;0O&X#E/V HK\</V3O\
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M[PJ7!9+3;!\\UTR_PJWRG*[6Q(T0!]P5XS^WO^V#IO[ _P"R5XL^+&L:/?\
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MC25^*WP)^.'P6\&^(KN*TT_Q;XHT,1:5"\O^K^UNK?Z/NRO]_'S;MJJS!O\
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M!_\ @KO)YG_!*WXYMJ,<<,C>";\O'&YD59?*^4!L+N&_'.!74_\ !,I+A/\
M@G)\ UNL_:/^%<^']^>O_(-M^O\ M4"Z'N=%%% @HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M+L?^1IU+_KC!_P"U*U*R['_D:=2_ZXP?^U*U* "BBB@ HHHH **** "BBB@
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MWQEHWC;PCH_PKTK0[?\ LZ\>_BBM[6TBA58X<9W"1%4)Y6-X9=NW=Q7Y8?\
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M_P!7Y?\ K$V_<^[_ +7S4 ?3WA;_ )%O3_\ KVC_ /0%KXY_X.#/!FK>-_\
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M.N_%6STJSU&QF\O[+:+80>1&8L+OW,O+;F/M0!\[_L._\IO_ -N;_KU\"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,NQ_Y&G4O^N,'_M2M2LNQ_Y&G4O^N,'_ +4K4H ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,NQ
M_P"1IU+_ *XP?^U*U*R['_D:=2_ZXP?^U*U* "BBB@ HHHH **** "BBB@ H
MHHH *S_%/_(MZA_U[2?^@-6A6?XI_P"1;U#_ *]I/_0&H M6/_'G#_N+_*IJ
MAL?^/.'_ '%_E4U !1110 4444 %%%% !1110 4444 %9_BG_D6]0_Z]I/\
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M)K=M]MM_!'@JP^V7UK;?\_%V^=EO%_O;FY#;=OS5YSX!_P""\&F^$_BQX?\
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M>T2[U3PGKVD^7+>++$[P?8[M3]FG\UHW1?G5MRMQM^:OSU_93_;_ /&FF?\
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M^Z7^0?VUCO\ H#G]\?\ ,^\MW^T*S_%+?\4WJ'S?\NTG_H!KX=_X=H_M$_\
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M_HZCQ-_X#W'_ ,D4?V3A/^@N'W2_R#^VL=_T!S^^/^9]Y;O]H4;O]H5\&_\
M#M']HG_HZCQ-_P" ]Q_\D4?\.T?VB?\ HZCQ-_X#W'_R11_9.$_Z"X?=+_(/
M[:QW_0'/[X_YGWEN_P!H4;O]H5\&_P##M']HG_HZCQ-_X#W'_P D4?\ #M']
MHG_HZCQ-_P" ]Q_\D4?V3A/^@N'W2_R#^VL=_P! <_OC_F?>6[_:%9_BEO\
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M8[_H#G]\?\S[RW?[0HW?[0KX-_X=H_M$_P#1U'B;_P ![C_Y(H_X=H_M$_\
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MY_PP?^U=_P!')_\ DM)_A0\HPW_05#_R;_(7]N8S_H"J??'_ .2/O"BO@_\
MX8/_ &KO^CD__):3_"C_ (8/_:N_Z.3_ /):3_"E_9.&_P"@J'W2_P @_MS&
M?] 53[X__)'WA17P?_PP?^U=_P!')_\ DM)_A1_PP?\ M7?]')_^2TG^%']D
MX;_H*A]TO\@_MS&?] 53[X__ "1]X45\'_\ #!_[5W_1R?\ Y+2?X4?\,'_M
M7?\ 1R?_ )+2?X4?V3AO^@J'W2_R#^W,9_T!5/OC_P#)'WA17P?_ ,,'_M7?
M]')_^2TG^%'_  P?^U=_T<G_ .2TG^%']DX;_H*A]TO\@_MS&?\ 0%4^^/\
M\D?>%%?!_P#PP?\ M7?]')_^2TG^%'_#!_[5W_1R?_DM)_A1_9.&_P"@J'W2
M_P @_MS&?] 53[X__)'WA17P?_PP?^U=_P!')_\ DM)_A1_PP?\ M7?]')_^
M2TG^%']DX;_H*A]TO\@_MS&?] 53[X__ "1]O>$?^1:L_P#<_K6E7P+HG["W
M[55SI4#P_M(>7$R_*OV:3Y?TJU_PP?\ M7?]')_^2TG^%-Y3A?\ H*A_Y-_D
M']NXS_H"J??'_P"2/O"BO@__ (8/_:N_Z.3_ /):3_"C_A@_]J[_ *.3_P#)
M:3_"E_9.&_Z"H?=+_(/[<QG_ $!5/OC_ /)'WA17P?\ \,'_ +5W_1R?_DM)
M_A1_PP?^U=_T<G_Y+2?X4?V3AO\ H*A]TO\ (/[<QG_0%4^^/_R1]X45\'_\
M,'_M7?\ 1R?_ )+2?X4?\,'_ +5W_1R?_DM)_A1_9.&_Z"H?=+_(/[<QG_0%
M4^^/_P D?>%%?!__  P?^U=_T<G_ .2TG^%'_#!_[5W_ $<G_P"2TG^%']DX
M;_H*A]TO\@_MS&?] 53[X_\ R1]X4#K7P?\ \,'_ +5W_1R?_DM)_A1_PP=^
MU=_T<G_Y+2?X4?V3AO\ H*A_Y-_D']N8S_H"J??'_P"2/O!237GO[3'Q^TG]
MF#X*>(/&NMG=9Z+;^8D"MB2\F)VQ0KQP7<JN>@SD\ U\H_\ #"'[5Z_\W)G\
M+:3_  KQ'_@H!^Q7^T-X8_9GU;6O%_Q<E^(7A_1YH;FZTN*"164;MIFZ?,L>
M_=_N_-_#79E^0X.MBJ<*F)@TY+1<VOX'!FG$6/I82I4IX2:DD]7RV7GHSYO^
M.'_!4[XT?&;Q[=:Q#XRU7PK;3?)!8:)</9P0(O0?*=SMUY=F^\?]VOLK_@D]
M_P %8/$?QD^(=G\-/B5=6^H7]]$_]D:T4\N>>5?F^SS!5V-F/.U_E;*;6W,^
M1^5=>W_\$W/ 6J?$+]N/X:6VDI,9+'7+;4[AT'^KM[=UED+?[.Q"O_ J_7,]
MX=RUY94BJ:CR)VE;:Q^+</\ $V:+-:<G4<G.233>]WV_+L?T&T4*,***_GH_
MIX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\D_P#@LQ^RAX5_
M;:_X+@_LA?#;QI)K,?AO7O#'BI[IM*OWL;K,%JTZ;)4^9?GB7/\ >7(K];*^
M/_VCOV(/&GQ8_P""O'[./QQTN31%\&_"G0_$&G:TDUT\=\TE]:20PF&/85==
MSKNRRX]Z /'_ /B%H_9?_P"?SXP?^%Q=5R/_  ;\_"JQ_9>NOVW/!_@^WU#4
M+'P/\5M0L-'@O;@W%S<+!:*L2/*?F=FV@9K]3J^2O^";7[%GC+]D_P",O[3F
MO^*)-&DL/B]\3+OQ?H8L;EY9%LY455$RLB[)./NKN_WJ /S^_P"""&D?MF-^
MP%I_CWX4V/[*^M6/Q6UW5O$NLZUXRU37H_$>K:B;V:"9[W[-;-%N#0D*JLWR
MX;JS5ZU_P4._84_;T_X**_ VU\&>*(?V._#=SI.LV6OZ)X@T?6O$::IH=];2
MADGMW>S959EW)T^Z_KBO1D_8,_:,_P""<_QK\9:[^R?>?#OQ=\)?B%J=QX@U
M+X9>,[B?35T#4YF5I9=)NH494BEV_P"JDVI'\NU6^\K+G]B3]J'_ (*-_%'P
MI>?M1ZM\/?AW\(?!>L6VOQ?#KP+<W%[<^)KVW?? =1OGVX@23#;(OE;'*JP6
M0 '%?MC?#7_A8G_!Q=^Q%#XM@L;Z_P!#\%:[J]U'$#);F^@MYV1T+*IVI/MD
M1MH^:-?E6NP_X.,XE\:_#K]FOX<Z]-):_#;XG_'#P]H'C-]YCBN[$M+*+21E
M(PDC)NW?PF!6_AKVCXT?L6^,?'__  5\^"_QRL)-'7P9X!\'ZSH.J+-<.M\U
MQ=9\KRH]FUD]6W+7IW[>7[$G@[_@H/\ LS:]\,?&L=U'I^K!)[+4;3 O-%O8
MCNM[VW<_=EC;_OI693\K-0!ZUHND6GAO1[6PL+6&ST^RA2WMK>",1Q6\2#:B
M(J\*JJ% 4=*R8/A5X9MOB5<>,H_#NAQ>,+NQ32Y]:2QB749K1'+I;M<;?,,2
MLQ;9NV[C7P?X2A_X*-?LK^#%\%VFE_ ?]H*ST>(VFB^+]3UB]T/6+J%,")]3
MMV#1R3[>&\J3YN&9V;<S>M?\$_?V6?VB/"/Q6\6?%3]HSXN6GB3Q1XKLH].L
MO WA-KB'P;X6@1]ZM"DW[R6X/0RNN[:S*6E^5E /@W_@F!:_M:>//VEOVNOB
ME\+=+_9SU36]<^,&K^&=<N_B'J&LQ:Y8)IQ1+:PC^R0.BVD4$J*G.YL'/W%K
MWC]M3]EK]O7]NG]E[QA\*O&VA_L3_P#"/>+;%K:6XBU;Q(9[&4$/%=0F2T95
MEBD574E?O+7>?'K_ ()]?&O]G+]L#Q-\>/V4?$'@F&\^)+0O\0/AYXQ\Z'0_
M$%Q$A1-0MI[=6DM[SGYN-KLS,S'[K<?\5_V6?VTO^"G>E+X!^-=Y\,?@/\$[
M]T_X2;3O!6I7&L>(_$]NKJ[67VEU6*W@?9AG7YMK;2LBEEH \I_X+D_!#Q1X
M5_X(2?!'X<_%WQ#I=YXDT_Q7X2\.>)=;LKF6>UF**]O+="65(G;*+O9G13N+
M5^L/PY^'FB_"/X>Z)X5\-Z;:Z/X?\.V,.F:;8VZ[8;.WB01QQ*/[JJH%?G1_
MP<Q_"G1;K_@F9X!\#QV\EKX=F^(_AC0U@AD.Z"T+R0;%8[C\L?&6S75>&/ O
M[>/[%.F1_#_P5;_"G]H;P)I:^1X:\2^+M<N='\2V-LN-D.I[$:.Z:-3L66+#
M.L>Y]K-MH Q_V]_#&F_"'_@O#^QCXS\'P0V/CCXE#Q+X9\4PVA$,FOZ/;:<D
MJ/<[?]9]G;YUW?\ /-!_ N-+_@JA_P IC/\ @G?_ -C!XP_]--O79?L&?\$X
M/B-H'[4&L?M'?M*^+M!\;_&[5M/.C:)IF@Q2KX<\!:<S9>WT\3?O&>3C?*P5
MOFD7+[V=NJ_;9_8L\8_M!?\ !0+]D_XFZ%+HT?AWX*ZKX@O?$"W5R\=Q(E]8
MQ00?9T5&$C;T;=N9=H_O4 >2_P#!33_E.+_P3G_Z^OB#_P"F:TKD?VT/@_HG
MQ?\ ^#F3]EW^W;*WU"W\+_#O5M?MH9DWQ_:H9YUADV_WHY'61?[K(K=J^A_V
MQOV+/&7QX_X*4?LD_%C1)=%7PO\ !";Q7+XA6YN7CNI!J>GP6UO]G148/\\9
MW;F7:/6D^)_[%7C+QC_P6+^%OQXM9=%_X0GP?X U/PS?QR7#K?&ZN)BZ%(MF
MUDP>6W#Z4 >Y?M:^$M/\?_LJ_$K0]5MX[S3-6\+:G9W4++E9(I+2567_ +Y-
M?'O_  2 ^!^E_M6?\$,?V>=-\1W>KVE_IFC1WVBZWIEP(-4\.W=O/<16]U:2
MLK!)(X_DVLK1O&SQ2(\3O&WW'\6?#5QXS^%WB32+0Q"\U;2KJRA\PX3?+$R+
MD^F6KQ;_ ()._LN>)OV+?^"=WPL^%OC"33)/$O@W2GLK]]/F:>U9VN)9/D=E
M5F7:Z_PB@#DI_P!@GXH>(?A=:?#75/BM\.;3X=V-PEQ;2>'OA/;Z9XFM9(KC
M[3#=PW+WL^F0WWGJLK7$6E(!(SO#';OL:/Z+^#/P8\-_L_?#G3?"/A33VTW1
M=+$C11M/)<2S2R2-+-/--(S233RRN\LDLK-)))([LS,Q-==10!1U;3+;7M+N
M;.^M[>\L;R)X;BWF021SHPVLCJW#*RD@JW!K\A?VT?@;KG_!N;\2E_:+^ UQ
M>-^SKXDURWM_B9\*WD,ECIAN76)=1TW=_J&W%%V_PNT2?-$1'%]F?\%0OV$_
MB-^TAJWP[^)7P1\?+X%^,OP?OIKW04U66:3P_KD$Z>7<65["F<+(GR^:J%@&
M9>ZLGR]\;?V0/VV/^"N]OHOPQ_:(T7X6_!?X'VFJ6VI>*HO"FJ/J>K^+EMW5
MTMX69W6")W&X,VUD*JQ\S;M8 W_^"P/C?2O@Q_P4A_8'_:"U&XA7X>Z7X@UC
MPUJ>JW*D65@=8L(XK29V_P"68_US[F^5?*W=FK]/ VX97D5Y/^UK^QKX _;3
M_9BU[X1^.-)-UX/UVT2U\FU?R9K%HBK036[[3LDB9$93AE^7#*REE/PI\./@
M=_P49_X)S:$O@SP+K7PH_:D^&^E@1:%-XMNIM'\4:?;KM5+=Y=ZQ.JKG#222
MMQ]Y%"I0!^HM%?F7\0/V;/V\O^"F&BMX-^+FO?#;]FKX1ZL@@\0V'@>[EU?Q
M5KENRYDM?M3[H(8G^XS(RM]X,LL;;6_1+X9?#RQ^$GP[T'PQI<FHS:;X>L(-
M-M7O[V6\NFBBC$:&6:5FDE?:O+LQ8T =%7YM_P#!JM>?VO\ \$G;/4IMWV_5
M/&>O7=]O/[SSFO&SO_VMH6OTDK\V?^#:F-? ?P'_ &@?AE<L(=4^&?QN\1Z5
M+:XPT,!,#1/_ +K,LN#_ +- &MXZ_P"5I3P/_P!FZW?_ *?9:Y/X5?#G3O%'
M_!UY\4-?O;>.XNO"_P %[%[ LF[[/-/<6T32J?X6\HRI_NRM7T-XF_8K\8ZO
M_P %K?#?[044FBCP)I/PFF\$SQM</_:!OGU-[I6$6S;Y7EM][?NW?PT?##]B
MKQEX._X+%_%+X\74NB_\(3XP\ :9X9L(X[AVOA=6\P=R\6S:J8'#;C]* /%/
M^"L_AC3_ (X?\%8_V&?ACXXCAN?ACK&I^)_$-QIMVP>QUO5M/T^*2RBFC;Y6
M\MGRJMG?Y[I_%7Z/XV\#@5\X_P#!2K_@GII/_!1#X)Z;HW_"0:EX%\<>$=5B
M\0^#?&&EK_Q,/#.IQ?=E3E6:-E^5TW+N^5N&16'@NB>*O^"EWA_PW;^$;KP?
M^S#KFM1HML/'KZYJ,-FP^9?M$VGK$LC2XVLRIM3=T7;]T XK]DOX/>$?@[_P
M<_?M"+X3MK6S_P"$F^%-CK^LV]L-L<.HSW]OYQ*_PO*J),W]YI6;^*HO$FF?
M'/\ X(5?$'XG>,O#?@V+XU_LH^+O$M]XZUC3='=8/%7PZDNF$MY+#$YV7=FI
MW-L5MRJNYFB57=^N_P""=?\ P22^(W[&7_!3SXB?&?Q=X\'Q)A^(O@>&QUG7
M[Z3R;_4-=:\BEF9+1$\NWLTBB2.)%=MB(JU2^*/P\_X*.:CX*\8?"F.\_9[\
M::-XN-]I]I\2;PW6F7VEZ?=%QNFTU$:,SQ1.414\Q?E3>9/F9@#Z%_;$^,?A
MO]H3_@C[\7?'7@_4H]8\,>+/A'KFJZ9>(&436\ND7#H2K?,K<_,K#<K J?F%
M>"_!O2I-<_X-7ELX5W37G[.%_ GU;09U'\Z]ZLOV!F^$7_!)'5OV<?!M]'J%
MY!\-=0\&Z=?7W[B.\NY["6'SY=H;RU>>4N<;MH;^+%=-^P7^S'?_  %_X)Y_
M#'X0^.(=+U'4/#?@VT\-ZU%;2M-9W!2V$4RJS!2R-R/NB@#G?^",NIQZI_P2
M9_9QDCZ+\.]%AZY^9+.)#_X\M?/GQOMFO/\ @Z)^"WE[2;3X):I+*,\JAO[A
M ?\ OHUSWP/_ &6OVX/^"6.@W'PM^"MM\(_CC\%=/GN9?"'_  E>IW&DZ_X:
MAEE,HLYW7]W-$C.^UEW,W_3)=L:^M?\ !.#_ ()Y_%'P'^T[XX_:2_:.\4>'
M?$7QL\>:5%X>L]+\.++_ &)X+T9)%E^PVIE_>,6D5&9O[RM\SL[.P!J?\%EO
MVW/$W[.OPCT'X8_"-?MW[07QZO6\,>![1'_>:;N7_2M5?^Y%:Q-OWGY5<HQ#
M*KUC^-_V"?#_ .P/_P $&?C!\(?"?^F/8_"OQ,VI:E(G[_7=3GTJY:XO9>K,
MTDI^4,3MC")]U%KY]N_V._V[M%_X*9>/OVC--\)?LZ>)=2U>R_X1SPC:^)?$
M6HR_\(?HJ.Q$%N(8459Y?E:63GYFE"X5V6OL+]DF;]JGXE:[XDT;]I;P=\"]
M.\$7^CR6\">#-1U"ZN;J=V5'BF6X^7RFB:7[OS9Q0!>_X(RZG'JG_!)G]G&2
M/HOP[T6'KGYDLXD/_CRU\^?&^V:\_P"#HGX+>7M)M/@EJDLHSRJ&_N$!_P"^
MC7/? _\ 9:_;@_X)8Z#<?"WX*VWPC^./P5T^>YE\(?\ "5ZG<:3K_AJ&64RB
MSG=?W<T2,[[67<S?],EVQKZU_P $X/\ @GG\4? ?[3OCC]I+]H[Q1X=\1?&S
MQYI47AZSTOPXLO\ 8G@O1DD67[#:F7]XQ:149F_O*WS.SL[ 'C?[.'P4T?QQ
M_P '4/[1GC+4M/M[Z_\ !/P^T*/3)9D#_89KRUM4:5,_=?RHI4W+_#+(.]:G
M_!V!X$M?B!_P2TL[*XA\RX;Q[H:6LJ+NEMY)99("R?[6R5Q_P*O?O@#^Q=XR
M^&7_  5J_: ^-^HR:*W@WXE^'?#^E:0D5P[7R36,.R;S8]FU5S]W#-N]J/\
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M])$BJWV8Q*JK##$VW:S;B_S'Y5H VOV,O!WB?_@BW_P4U^&O[*&E^+M4\=?
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M?@;:6_AW5OAO^SS\;4LR+9/%%CKTNBS7B<8FN892B^9_>$,2CT#?>;=^#W[
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MN60G<,_,K;67YHU/]KSQ9^V1_P &Q?QPU3X@M;M\1/!>@:[X+\431,66\O\
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M,_9%_P""*'B?P_\ "/P7H'@?3Y?&FB:E%IVAV"6T$EZUW OF^4HVL[>5&O\
MP!:^D/V>_P#@B5\"_!7PP_XNE\/_  ?\9_B=XDC%WXR\9>,=+AUK4]:U&1/W
MTL<MPC-;Q!FVQI#L5$1/XEW4 ?7^E:K:ZYI=O>V-S;WEG=QK-#<0N'BF1AN5
MU8<,K#N/6N=^+OQW\#_L^>&%UKQ]XR\*>"-&9_+%]X@U>WTVVW_W?-F=5W?C
M7P=_P0\T=OV6?VB/VN_V:K+5KZ\\!?!'Q9IFJ>%H[Z<RMHUAK-G)>?8U8_\
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M>.M#^)GA:TUOPWK6E>(-&U!/,M=0TV[CNK6X3^\DL;%6'^Z:YWXQ_M._#?\
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M6;AV_P ^K^9X&#X5RO"XCZW0HI3_ *V6R^1)1117C'T 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A
MO[>/[#'A_P#;^^%.A^$/$FK:UHUCH/B;3O%$4VF^5YLD]G(72-O,1EV,3SQF
MO<J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY[_ &?/V ](_9M_
M;1^,_P 7M!U_4HX?C=_9]SK'AUH$^Q6][:1F(7<3_>#RAW9Q_$SY_A%?0E%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EV/_(TZE_UQ@_\
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M'M]#U[0-7\-ZA<?;Y;5!;_:;22WAECDAEV!U^9?O'&Y%\QOTV\'_ /(LV?\
MN?UJQ=Z3:ZC/;R7-K;W$EJ_F0/)&K-"_]Y<_=/N* /SQ_P""3,?BO]L3]O3X
MY?M;:SX-U_P)X)\::5IG@OX?V6NP&VU/4=,M"TD][)"?N)+-L9/JP^;;N;2_
MX)1Z3=6'_!4+]OZXGM;B&"\\9^'V@DDB94F"Z=+DH?XOPK]"** /SW_X.B]'
MN]=_X(F?%JUL;6XN[B2ZT/9%!$TCMC6;,G"K7IG_  7DT^XU?_@C[\?K>U@F
MN+B;PM*J10H9'<^;'P%'6OKRB@#\F_\ @N?H%]JG_!LII-C:V-Y<7O\ 8'@U
M3;PPM)+\LMCGY5YXK] _V_K1YOV#/C7!;QM(TG@+78XXT7<S,=/G  %>PT4
M?F_^S-^Q./V[O^#:CP'\%]2F;1+SQ9\.+*WMY[B)O]!O8'2XMG=,9VK/#$S?
MQ;=V*S_V=/\ @OIX$_9D^&&G?#W]K^+Q)\#?C)X)LHM-U>+4]!O;[3O$30Q;
M?M]C<VD4T<L<JIOQN^\S*GF8W5^F%5;[3K?48_+FABF17610Z!@KJVX-SW!Y
MH ^(OV/O^"C'Q$_X*/?M;6.J_"GPCJ'A_P#9>\,Z?=IJOBSQ7HDMI=>.M0?"
MVZ:3$[H\<$6"[3NK;MSHR*VUJR/VQ_\ @M-^S+\)_'GQ&^#/[2WA_P 2>$['
M3QY-O;^*_!\^IZ1XZLVB!\ZS,"31R)OWI^\V?,O9MRI]_55N=/AOC'YT,<WD
MN)$WH&\MQT8>AH ^%_\ @W8^&?BOX5_\$[OL^O:3XE\,^&]6\6ZOJW@/0?$&
M[^TM#\-3SJUC;S*QW*W^MDY_AE!^Z17WE110!F6?_(W:A_U[6_\ Z%+6G699
M_P#(W:A_U[6__H4M:= !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!EV/_(TZE_UQ@_\ :E:E9=C_ ,C3J7_7
M&#_VI6I0 4444 %%%% !1110 4444 %%%% !6?XI_P"1;U#_ *]I/_0&K0K/
M\4_\BWJ'_7M)_P"@-0!:L?\ CSA_W%_E4U0V/_'G#_N+_*IJ "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 9=C_R-.I?]<8/_:E:E9=C_P C
M3J7_ %Q@_P#:E:E !1110 4444 %%%% !1110 4444 %9_BG_D6]0_Z]I/\
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MED=W7;\\C-Q0!T'[(5Y'J/[)OPON()%EAN/"6E2(Z'*LILXB"*^.?@O#]O\
M^#FCXS7$++)'I_P3T>UN"O\ RSD?4%D53[[5S7(_!7]C7]O[_@GQ\/H?A1\%
M_'G[//Q,^%NC%[7PM?\ Q(@U6VUW0+1G9D@E^R?NY8XE;8OWF^[A411'7T)_
MP3'_ ."<VO?L<:I\0_B#\3/'3?%#XY?&2]M[[Q;XA2U^S6<<5NC);65I%_!!
M$KLH^[N^7Y55%50#RC]J#_E9*_9?_P"R:>)__9JZO_@I%^PC\4]3_:$TG]I;
M]G;Q)H>E?%[PSX7E\*:MX?\ $2,VB^--$\]KG[)(Z?/!.DK,Z2K]YMBLR*N:
M[_XO?L->(OB'_P %6/A#\?;75M%M_#GP\\)ZMH%[I\WF_;IY;S=L>/">7L7/
M.YE:N8_;A^%_[8VA_&?4/&WP!^(7PJUCPCJ.BI87O@3XA:=<16FGRQ%]UW:7
M5D/.:1U<[EE;;\O\7R*@!Q_A;_@HC;_MX_\ !,[]IC3]8\):I\.?BC\,?">N
MZ!XV\(:A,L[Z/=_V7<,CQ3)\LUO*H9HY5^]M;^':S?/'Q,\2:_X1_P"#.2SO
M/#<DD>IO\+M,M7:-S&PM)KNWBN_F'_3L\WUZ5]+_ ++/_!+[QUX!_9D_:*N/
MB)XS\/\ B?X[?M.6%T/$>JZ?;/;Z'ISG3I;*QM+<%?-:VMDD/SLN]E/W>/F]
MJ_8J_8O7X%_\$Y? WP(\?1Z'XKM]%\)KX6UV.)'DT_5(FB:*9,.%9HW5F'S*
M.M '9?L<> _!_P ,_P!DWX;:'\/8;&'P3I_AJQ715M%"Q36QA1TEX^\T@;>S
M]69RQR3FOB+_ (+_ /P_\)W/QW_85\57,-BOCBQ_:)\+Z3I\V%^TR6$MSYMR
MG]YHQ+#:G_99A_?H^$/[ _[97_!-.RN/ W[.OQ!^$7Q-^#,<_F:!HOQ7;48M
M8\*Q.W-O#<V2[9H$/S?-M^7Y51?XN<^)O_!$3XY?M1?M$?!OXZ?&'XP>&?$?
MQ4^'_P 1] \0OHVE6]U8^$_#>@V5PUQ=V&F1,KRRW,\J6S>=/L9O*VL<!: .
M3_X*@^%/C+\7/^#B'X(Z/\,]6^'.EZSX0^%=[XA\)_\ "=6]U>:2;][VY@OF
MBB@^;[5]G6%@W\*P;OO!=OOW_"O/^"FG_11?V/\ _P $&M?_ !5>P?\ !2/_
M ()T0?MRZ'X0U[PYXLU'X9_&#X7W[ZMX'\9Z?!'/+I%PZ;)89HG^6:UF4*LD
M7\6T=5W*WA>M_#O_ (*;>/=$_P"$1N?'W[*/@NSDC6"Z\;Z'INKW>M*C;098
M;.X7[,)P%9F#;4^<;=N* .J_X(E_L)_$G]AGPO\ &"T\?>+/AUXBM?'/C6?Q
M):67@R6Z_LS0[N7<M];I%,O[E?,1/W89MNU@<5]T5X;^P'^PKX5_X)[?L^V_
M@7PS=:EK%U<7L^L:_K^I2>9J7B;5;AMUQ?7+_P 4CG:/]E41<MMS7N5 'YW_
M /!'3_E(K_P4 _[*7I__ *1/7-_\$FOA9H]Q_P %J?\ @H!XVFM89_$%GK^A
M:+:W++^\M;:6T>69%/\ ==XH=W_7!:^C_P!A3]AOQ!^RU^U)^TQXZUC5M%U#
M3_C9XLMM?TJWLS)Y]C%%;M$4GWH%WDG^!F6D_8L_88\0_LQ_MD?M.?$?5-6T
M6^TGXXZ_IFKZ5;6GF_:+%+6U>!UN-R*NYF?(V%J /%/^#I)([+_@C7X\UR-(
M_P"TO"^M:!JFFSX^>TN%U:UC$B-U#;)'7([,U>8?\'%'A[Q_\4OVR?V'? _A
M"]\(6$.L>,M6U*V/BR.>?09M:LX+633UNX8OF?[UPB#G<TI7[N[/UY_P6._8
M;\0_\%&_^">?C?X/^%]7T?0]<\43:=);WVJ&7[+%]FO[>Z??Y2,WS+"RC"_>
M(KK/^"@_[!7A7_@HC\ 6\%>([[5- U#3=0M]<\.>(]+(34?#6JV[;K>\MV/\
M2Y*L/XE=@"IVLH!\\_\ "O/^"FG_ $47]C__ ,$&M?\ Q55?^"5?[!?QP_9Q
M_;A^.WQ.^*GC3X1:M)\5;:P;6=$\"F]A@M=5A5=ES);W _=/+ [LS;LLS[L?
M-5:+P!_P4X\,>&H_!]GXZ_9.\0QQPFW3QUJ>FZO;:RZ#*^=)9Q*;3[2<JP"K
MY7RL&4U[S_P3D_X)W6?["OAGQ5JFL>*=2^)7Q:^).HKK'CCQOJ<"076N72KM
MCCCB7B&UB4LL4()5-S8_NJ ?0EC_ ,C3J7_7&#_VI7Y[?L+)'I7_  <5_MS1
MRR;9]6\/^";V"-AM\R./2DB=A_> ;:,_[5?H38_\C3J7_7&#_P!J5\6_\% /
M^":?Q*\<_M1:+^T?^S9X\T?X=_'#1]'_ .$=U.TUZU:?P_XQTP2>:MO>!%:1
M&5MN)%5F^1/N%%90#H?^"_UY':?\$;/V@FFD6%&\,.@+'&6::)57_@3%5_X%
M7L_[ -G)8_L(_!.WFC>&:'P%H<<B.,,K+I\ (-?#/Q+_ .">/[8G_!4K4]!\
M*_M5>*_@YX(^!^EWMOJ6L^%?AH+^2\\8S0%9$BN)KK/E0>8,_(_;[K,J2K]U
M?MA?#?XA^-/V2O&7AGX+>(-)\!_$*\TDV?AK5+N#-II<OR@?*J/L78"BLJ-L
MR&VMMVT >HWEY#I\2O+)'&K.J LP4%V;:H^I8@?C7YJ?\%>/^";NI? _4/$7
M[9'[,^I?\*W^-W@"QN-<\2VEK%_Q*OB!IL*-/=P7EL/E>=D1FWXW2,O/S^7+
M'[!\7?\ @F=XP_;6_P""8W@OX6?&[XB2R?&CPN+368?'OAY&B?3=>M69H+R(
M;8O,55;8WRQE^7'EOM9? ?B9^Q]_P4B_:V^$5Q\$/B1\2?V>_#OP[UJ Z/XF
M\;^'K._D\2:[IC?)*HMW5;82SQ[E=56%=K,-W]X ^[OV"/VK[']N7]C?X=?%
MG3[!M+A\<:-'J$MBTF_[%<<I/"'_ (E25'56XW* <+]VO9*^<?'7[(7BCX+_
M /!-BX^#/[./B&U\">)O#OAA-#\(ZOJ@\];21 H\V9MC_O'7?ND$;;7DWA>-
MM=U^QAX-^)'P\_9:\#Z'\7_$VG>,OB7IFEI!X@UFPB\NWOK@$\K\B;L+M7?L
M7>REMJ[L4 >J4444 %%%% !1110!E^#_ /D6;/\ W/ZUJ5E^#_\ D6;/_<_K
M6I0 4444 %%%% !1110 4444 %%%% !1110!F6?_ "-VH?\ 7M;_ /H4M:=9
MEG_R-VH?]>UO_P"A2UIT %%&<44 %%%% !1110 4444 %%%% !1110 4444
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M_#>\NTM9?%]IKMIXHM-)#MM26^CM4#VZ;_ES\WWEV[F95H _1BBOG7_@H?\
M\%$O"W_!/3]BW4OC;J5C-XMT&U?3TM+?3+J('4A>3Q1(\<K?)LV2>;N_B5:X
M?]DK_@I=XW_;/^-VD_\ ")_L]>-K'X$ZQ!<36?Q0UW5(=-CU!$BW0S6^F.GV
MF2"<E=DK%/E;=MZK0!]A45\#>+_^"V6H?%GXD>(/"W[+OP'\:_M,-X5NCI^J
M>(=/U:UT#PO%>#[UO%J=UNCE=?XBB[>59696W5R?Q._X.*-'_9O^'/B*/XO?
M!/XA_#'XN:&+*>T\!ZE<V\C>)K>YNHK?S]-U!/W%TL32CS%&UEPWRG:VT ^U
M/C]^U7X;_9\OM*TFZM=>\3^,/$0<Z)X5\.V#:AK&K;"%9UC&(X(%=XD>[NG@
MM8FEC\V>/<M<EI?[=]OH&NV%I\2_AC\2_@Q:ZQ<Q66G:MXJ32KK2KJYD8(D,
MEWI5]>Q6C,[(B?;&@6621$B:1SMKY._X*#:%#XK^ 7[9MWJFEZ1J_BS_ (2G
MPIH$5KJ$O[F;15719[2U=FC;;:R7-UJ#-M1QYDL_#,NU;OP@_9BT#X<?MYGP
MKXN^"OP7^"GA7Q?\)O$"ZEH7P\E6\\/^+K1+W3H[A]6F:PTWRY+9)E6!?LTV
MY+RZ/GQ;=DH!^D5<C\9?C/X3_9Y^&NK>,/'7B+1_"?A?0XO/OM4U.X6WMK<9
MVC+-W9B%51\S,RJ,DBO/_P#@G'XAUKQ;^P;\(]2UZYU"]U2\\+V4DEU?ILNK
MQ/*7RIY1_P ])(MCM_M-7QU_P<GV4&C^!/V;_%GC/39=;^!W@WXM:5>_$:R,
M+SVXL6RD<]S$JE7@1BZLK#:S2HG\= 'U?^QY_P %2?V??V^-=U+2?A'\4?#_
M (RUC28VGNM/B6:UO%B5MC2B&X2.1X@Q4;U4K\R\_,*^@G=8D+,VU5Y)-?+7
MC/\ X)N?!S]H?]HGX-_M >%9O^$:\2> 2;[2-:\%R6EO;^)M/GA"K;73K$ZW
M%JT9^7:5;9(^UANKYC_;?UOQ?_P5]_X*)ZU^R+X4\3:SX*^"/PKTVVU7XPZS
MH\WDWVNS72;[;1(9,,JQM&=SY^5L2[E/E*K@'T'\;?\ @O/^R!^S[XNN-%\2
M?'CP7_:5I+Y,\6E?:-9\B3.TH[644JJ5;[P8_+@[L8KU;]E;_@H=\$/VW[68
M_"?XH>$?&EQ:)YMQ:6-X!?6Z?=WO;/ME1<_Q,F*C_9S_ ."=/P+_ &3O!UMH
M/P_^%?@GP[96J[3)'I<4UU<-A5+S7#AI97*A?F=V:O*_VA/^"(GP%^-WQA\(
M_$?1O#LWPK^(?@_6+;5(/$/@-QH-U?I%(&EMKCR0JR)+'F-GV^: ?E<+E6 /
ML*BBO+?VTOVEM-_8Z_9,^(GQ1U;RVL_ VA76K+"[;?M4T:'R8!_M2R[(U_VG
M% &=\'_VW/ GQX_:9^)7PK\+W&J:IXC^$?V1/$MQ'9L-.LYKE/,BMQ<?=>;:
MK[D7[I1@>17L=?G/_P $T;5?^"8/_!%#6/CE\1+2]UCQQXJTO4/C#XYE&$OM
M8OKU6NTB);[C^4UO%M/RJ^]L<M70?LK?\%FO%W[=GB+P%>_"']FWQYXB^&OB
M22T@\0>.M3UBWT?3-!>1 ;I;=)4:34/LK[XG:(*K21,%8C:S 'TA^R=^WU\*
M/VW]1\<6OPR\5+XDN/ASK+Z#X@06<]M]CNE++@>:B[T8H^UTW*VP\UU'AG]I
M?P/XR^/'B;X8:;X@M[SQUX+L[74-:TJ."7S-/@N1NMW=RGE_..@5BU>#_L*?
MM:^%?CQ^P;KWQW^#WP6^P?\ "4:CJVHQ>'M)BL+&^\77MO=2VKW#RKLB::>2
M%OGE;=_>:OBC_@E1^UM\4OB1_P %8?VI/'7_  SGXVFM_B%XP\.^#M<N_P"W
M=-\KX??V79_99DN/WG[UE642LL&[[NW[U '['T5X-^UU^W9I/[)/Q3^"G@^Z
MT+4M>U3XV>+4\+6 M)4C_L_Y-\MU+N^]'&N,A>?FKU_XA>,K3X<^ M;\0:A\
MMCH-A/J-QSC]W%&TC_\ CJF@#:HKXIU;_@L;I^A_\$P_!G[54WPR\63>!_$,
M\,FM6%M<13:AX;TV2ZDMO[0= -LT:[4=E3YMLJ_PJS+['^UM^W]\./V/?V.]
M0^.'B#6+?4/",>GPWFDFPE$TOB)[A UI;VG_ #T>?<NW^$+EVPJLP -W]L3]
MLKX>?L'_  2OOB+\4->_X1WPC87,%I+=K:3W;^;*X1$6.%'=B3_=7@!C7?\
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MUX+?5M)USPW<#3_$_A?6[0V>M>%[WYO]'N86Z?<?:RY5MK?Q*RCYR_X-X/\
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MBK7/&6CV6FRZ%IFC1I=7WBN[O1E+6UA^4JR+EG=V"JJ_WF56 /LJBOAGP/\
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MO2:A)X_M]*/V\7\C27D4+32M:I.6^;SEMC"KAOF5E93\P- 'TA1110 4444
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MY[XKT)EPO-?F5:E*E-TYK5:'ZSAJ\*U*-6F[J2NOF244#I14&P4444 %%%%
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M[K/C\:KIWB#2[)%Q%;W(LPT4R1*JHKJ3(V.<+A5HZ-_P1P^,?Q(_X*-_ /\
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MG-_P<VZK)XE_8$\&_"V&:2%OCG\4?#?@65D/S)'+=-=%OINM$_,5^C-?FO\
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MFB^,KSP[XFL?C%\6/$/CJ&WMXWEA&G:FENBVMPDJ -)MA<.J[DPWWFH U_\
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M>*/AK\._AC(K?VCHOPZGO9-0\5,HRMO<W=Q_J;-FQO6+YY%5E.W=N7M_@O\
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MHUA\.ULI?)O(]=:Y79+$Z_,FV#[0NX?WU7*LRM0(;_P3O3_AN+_@H/\ &?\
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MGI/Q(_X.'/V<VU>WCO(_#O@+5-9M8Y4W+]IBEG6)_P#>1GWK_=9%-=Q\ _\
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M#_[/?Q*_L?Q79V^C7FBZQ]E$GV6\BGN)I/D+JKJ564;6PK*RY7H#0![C\%_
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M295"]59971EZ;97K]QJ^3_V/_P#@G*OPB^$/[0'@CXBR:%XK\/\ QL^(NO\
MBM[2W\TQKI^II BV\N]5*S+Y1Y3H=K!LT$GT#\$/ /ACX5?![PQX=\%6]C:>
M$]'TV"VTB.SQY'V4(-C*5^5MR_-N_B)SWKX@_P""QG@'PR?VV/V*/%$D5K'X
MR7XIVNDP2!<3W&GMB652?XD258O]TSG^\V;7PL_92_;&_8$\+GP+\(/%WPG^
M+'PQTV3R_#T/Q$EO[77M#MOX;7SK5?*FBC^ZI;:W3:J+\BXOB#_@D9\8OC?^
MTW\'_CA\4OB=X?\ $'Q'\$^+;35K_3-/2XMO#FB:3 =S66EPLK.\LDFUWGGV
MLV%7Y=OS 'Z/5X_^W/\ M::-^PU^RGXR^*FNP27UCX3LQ+'9Q-Y;WUQ*Z06\
M ;^'?-(B[L':"6[5[!7B_P#P4 _8^TO]O3]D/QE\*M6OIM)B\46T8M]0B3S&
ML+J&5)X)=O\ $JRQ(67*[EW+N&[- 'Y\ZI_P1Y^.G[1>B6W[4'B[QM:1_M86
M]Q:>(?"_A^:SA;PYH-O!OEAT9T=6^;:_^MW?NY?XF;=*WNGPJ_X+[_#/6/!'
MA[2O&6@^,-#^-ESKT7A35_AMI^DRWVM6.H;E$TB1+]^U52SJ_P!YE7:%9QMK
M/\/^$_\ @I#!X$A\#_VY^S?:S6-NMD?'MR=1N=0ND4LJW"VVSR?M.T*S;XO+
M;=_WSS5Q_P $%/$'PGGT+XK?#;XR>(+G]J+2]5;5-4\:^)Y)9[#Q0DH6.:RN
M+52_E6WEC:BKN95W*6^XT05ZGZ7T5C^#9-8G\*:>WB"'3;;7&MT^WQZ?,\UJ
MDVWY_*=T1V3=G;N536Q02%%%% !1110!\Q_MA_\ !/;1/VTOB19ZAJWBOQ9X
M>DT2Q6W2+2+A(TF5W=LON1N>*\I'_!!SP:?^:F?$[_P-@_\ C5?;MD=WBC4?
M^N,/_M2M$G Z8^IKUL-GV.H4U2HU+)>2/"Q7#>78BJZU:G>3\V?"/_#ASP9_
MT4SXG_\ @;!_\:H_X<.>#/\ HIGQ0_\  R#_ .-5]X[0:-@KH_UGS/\ Y^O[
ME_D8?ZHY3_SY7WO_ #/@[_APYX,_Z*9\4/\ P,@_^-4?\.'/!G_13/BA_P"!
MD'_QJOO'8*-@H_UGS/\ Y^O[E_D'^J.4_P#/E?>_\SX._P"'#G@S_HIGQ0_\
M#(/_ (U1_P .'/!G_13/BA_X&0?_ !JOO'8*-@H_UGS/_GZ_N7^0?ZHY3_SY
M7WO_ #/@[_APYX,_Z*9\4/\ P,@_^-4?\.'/!G_13/BA_P"!D'_QJOO'8*-@
MH_UGS/\ Y^O[E_D'^J.4_P#/E?>_\SX._P"'#G@S_HIGQ0_\#(/_ (U1_P .
M'/!G_13/BA_X&0?_ !JOO'8*-@H_UGS/_GZ_N7^0?ZHY3_SY7WO_ #/@[_AP
MYX,_Z*9\4/\ P,@_^-57U?\ X(4^#=/TFZF'Q+^)S-#$\@!O8,' S_SRK[YV
M"J'BE<>&]0_Z]I/_ $!J/]9\S_Y^O[E_D'^J.4_\^5][_P SX;A_X(0>#7A5
MO^%F_% ;@#_Q^P?_ !JG?\.'/!G_ $4SXH?^!D'_ ,:K[LL5_P!#A_W%_E4N
MP4?ZSYG_ ,_7]R_R#_5'*?\ GROO?^9\'?\ #ASP9_T4SXH?^!D'_P :H_X<
M.>#/^BF?%#_P,@_^-5]X[!1L%'^L^9_\_7]R_P @_P!4<I_Y\K[W_F?!W_#A
MSP9_T4SXH?\ @9!_\:H_X<.>#/\ HIGQ0_\  R#_ .-5]X[!1L%'^L^9_P#/
MU_<O\@_U1RG_ )\K[W_F?!W_  X<\&?]%,^*'_@9!_\ &J/^'#G@S_HIGQ0_
M\#(/_C5?>.P4;!1_K/F?_/U_<O\ (/\ 5'*?^?*^]_YGP=_PX<\&?]%,^*'_
M (&0?_&J/^'#G@S_ **9\4/_  ,@_P#C5?>.P4;!1_K/F?\ S]?W+_(/]4<I
M_P"?*^]_YGP=_P .'/!G_13/BA_X&0?_ !JC_APYX,_Z*9\4/_ R#_XU7WCL
M%&P4?ZSYG_S]?W+_ "#_ %1RG_GROO?^9\'?\.'/!G_13/BA_P"!D'_QJJ^K
M_P#!"GP;I^DW4P^)?Q.9H8GD -[!@X&?^>5??.P50\4KCPWJ'_7M)_Z U'^L
M^9_\_7]R_P @_P!4<I_Y\K[W_F?#</\ P0@\&O"K?\+-^* W '_C]@_^-4[_
M (<.>#/^BF?%#_P,@_\ C5?=EBO^AP_[B_RJ78*/]9\S_P"?K^Y?Y!_JCE/_
M #Y7WO\ S/@[_APYX,_Z*9\4/_ R#_XU1_PX<\&?]%,^*'_@9!_\:K[QV"C8
M*/\ 6?,_^?K^Y?Y!_JCE/_/E?>_\SX._X<.>#/\ HIGQ0_\  R#_ .-4?\.'
M/!G_ $4SXH?^!D'_ ,:K[QV"C8*/]9\S_P"?K^Y?Y!_JCE/_ #Y7WO\ S/@[
M_APYX,_Z*9\4/_ R#_XU1_PX<\&?]%,^*'_@9!_\:K[QV"C8*/\ 6?,_^?K^
MY?Y!_JCE/_/E?>_\SX._X<.>#/\ HIGQ0_\  R#_ .-4?\.'/!G_ $4SXH?^
M!D'_ ,:K[QV"C8*/]9\S_P"?K^Y?Y!_JCE/_ #Y7WO\ S/@[_APYX,_Z*9\4
M/_ R#_XU1_PX<\&'_FIGQ/\ _ R#_P"-5]X[!1L%'^L^9_\ /U_<O\@_U1RG
M_GROO?\ F?!Q_P""$WANR_>V'Q6^)UG=K]R;[9$VWU^ZBMT_VJ7_ (<AM_T7
M/XF_^!'_ -E7WAMHVT?ZT9G_ ,_/PC_D'^J.5?\ /O\ \FE_F? 5K_P11:36
M;JW_ .%X?$M3"D3;OM'+9W?[?M5S_AR*W_1=/B;_ .!'_P!E7V]9#_BJ-2_Z
MXP?^SUIX]J/]:,S_ .?GX1_R#_5'*O\ GW^,O\SX._X<BM_T73XF_P#@1_\
M94?\.16_Z+I\3?\ P(_^RK[QQ[48]J/]:,S_ .?GX1_R#_5'*O\ GW^,O\SX
M._X<BM_T73XF_P#@1_\ 94?\.16_Z+I\3?\ P(_^RK[QQ[48]J/]:,S_ .?G
MX1_R#_5'*O\ GW^,O\SX._X<BM_T73XF_P#@1_\ 94?\.16_Z+I\3?\ P(_^
MRK[QQ[48]J/]:,S_ .?GX1_R#_5'*O\ GW^,O\SX._X<BM_T73XF_P#@1_\
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M_P!E7WCCVHQ[4?ZT9G_S\_"/^0?ZHY5_S[_&7^9\'?\ #D5O^BZ?$W_P(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?(7[<?\
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M_P!I>#/A-<>#X_"NF_8;>+^RUO\ 3+B>[_>I&LLOF2QHW[UWVXPNT5YK<?\
M!LM^SWH6FKJG@[6/B]X+^)UK&3;?$*Q\;7[Z]Y^!B67>_D/\R[F58TW;F'R\
M;?,_^#?^P^)>B?\ !2O]O/3?C!J-AKGQ$TF]\%:;JFJ65NL$.L+;V6HP6][Y
M:\(T]LD,S*/NM*W"_=H _2C]H[PWXV\7? 'QEI?PX\16'A7Q]J6CW-MX>UB]
MM?M-OIM\T3+!,Z%6!59-IY5Q_L/]UL+]B3P1\4OAS^RQX+T/XV>+-(\=?%#3
M[1X]?US2[?R+2^D\UVCV+L3.V(QH7V)O9"VU=VVH/V_YY+7]@[XV30N\<D7@
M+771T.&5AI\Y!!K\^_$?B"^'_!H3'J*WMY_:'_"I+=_M/GMYV_>G._[VZ@#]
M9**_*G]AS_@CMHO_  49_8]^&OQ(_:[U#Q-\3-4\2>&M.NM!\(Q:_?Z7X=\(
MZ9]EC^R)%#:S1R/=20;'GFE=F9WV[?DW-V'_  2RL_$7[#?_  4R^-'[(\GB
MK7?%GPUTWPQ8_$+X?KK-Z]Y>>'K&:<6UQ8><YW-$LSC8O94W?>=J /TFK\@/
M@G^T5^WS^WSXY_:"N?AG\2O@?X9\%_"_XE:_X&MK/Q!X>FDO'BLY 4.^)'!_
M=21KN9MVY6K]?Z_"C_@G1^TQ^U)\&_'/[86E_!#]FO2_C)X3O/CSXLN-0UNX
M\=:?H)L+LR(KVXAN'5WVQ+$^]>/WF/X: /T'_8J^%_[<7A;XW:;>?'+XG?!'
MQ3\.UM)EN-/\-:-<6NI-*8_W+*[Q*NU7QN^;I5C]E3]M#QQ\7?\ @KS^U7\&
MM9N--D\$_".Q\+W'A^**T$=S&]_IJ7-QYDO\?[QCM_NU!^Q3^UA^V!\5_C7I
MVB_&+]E'2_A/X'EM)I+CQ';_ !$TW6GAE5,Q1_9H':0[VXW?PUY=^P%_RL6?
MM^?]@GP)_P"F2*@#Z:_X*L?M&^)OV1_^"=OQ:^)7@^6TA\3^#]#>_P!/DNH!
M/"LJNB_,A^\/F/%>@?LD_$75/C!^RG\,_%VLM"^K^*O"FE:O?-$GEQM<7%G%
M+(57^%=SMQ7@O_!??_E#?^T)_P!BK)_Z-BKU_P#X)[?\F#? _P#[$#0?_3=!
M0![#17AO_!1G]L6S_P""?G[$_P 1?C#J&G_VHO@G2_M%M9[]BWEW++';VT3-
M_"C3S1*QZJI.,]*^+?@!_P $&-/_ &SOAQ9_$K]M;Q'XP^+GQ5\96Z:E-HZZ
M_=Z5H?@Y)45HK*TM[5XE5XL_,?N-)N^5OF=P#]1**_#?_@H%^QU\1O\ @G1^
MUK^Q[X.\,?$CQAXL_9W\3_'GPK<Z=IGB+49+[4?".IQ7:H;**Z8[I+&X@FD=
M8GW;&MO]IF?UK_@L,WQ5\5?\%Q/V8?!?PC\4-X.\0^./!NMZ3-K31F?^P[-B
M[W=[%$S"-KB.V27RM_\ RT*4 ?K=17YC_M'_ /!NA\(_"?P.\3>,OAGK'Q*\
M/_M":'ILVJ:1\2KOQKJEUK5UJ$,9E4W6Z;R&25UP^R)?O<>E>@?![_@KE<:-
M_P $"=&_:P\86D>L:UI_@_[3>P1[;>/5-6CN3IRCCB-9;Q1G;]U7X7^&@#[X
MKXP_X*]?M5>/_P!ES7OV68? FO?V''\1OCMX:\&>(O\ 0K:Y_M'2;QIA<6W[
MZ-_+W[%^>+;(N.&%>&? /_@@]I_[;7PUL_B1^VMXB\7?%SXI>-+5-2ET9-=O
M-)T+P='*FZ*RM+:U>)5>)6^9C\K2;OE;YG?YT_X*(?L->./^"?\ ^U7^QIX1
M\/\ C[Q1XT_9YUSX_P#A2^TG2O%%Z=1U'P7JT-T$6UM[EOF>SG@FF=4;.QK?
M_:9G /W-HHK\]?\ @J?\??B=\>?VQ?AO^QS\'?%%W\/=7\?:'<>+_'?C*S"M
M?:%X<CE>WV6GS;EGGF1TWC:R?N]K?,Q4 ^]K'_D:=2_ZXP?^U*U*_,^Y_P"#
M9?X(:-:7\W@?QE\9/ GQ.MH8);3Q]:^,+N?5OM2EF2692ZQ2KN4,458^X5E^
M]77?\$Y?BOXB_P""C7[+/QG_ &>_VD(?[2^(?PKUR7P+XUO=(N6L(_$-NW[V
MVOXG@*-$TL:MG9M^YNVKNV* =Y_P31_:Z\=?M(?M-_M8>&_%NIP7^C_"GXB_
M\(_X<BCLXH6L[/R-^QF10TC;OXGRU5O^";/[5?C[X]?MF_M?>$_%FO?VMH'P
MM\;V>C^&+7[%;P?V9:R6K2/'OCC5Y<L,[I6=O]JOB;_@C-_P27^"\O[?'[2F
MJ-IGB47GP)^+-O;^$C_PDE]BW6!%G3[0OF8N?G5?];NW=*H?LM?LO^-_VW?^
M"O'[;7P[D\:>(/ _P3L?&EEK'C)/#=V]CJ_BBX>WDBM--^UJ=T5JRI<//L^9
MMJ)E=VY0#]MZ*_'G_@H!^P'X/_X(2Z+X&_:2_9IG\0?#_3_#?BW3--\?^&6U
M^_U'2_%NDWEPL$IE2ZFD_?JSIM;.%W;AM9%S]!?\%ZOV_P#7?V5_ GPO^%O@
MKQIH/PQ\:?'S7GT1?&NMW<-K8^#M*@$37^H&65U1)46>%4W?WV*LKA* /T$H
MK\7H_P#@FG_P3%N]"2^U3]J'PQJWQ,_UTOQ$F^/%K_PD<ESALW.[[5Y ?+?\
M\C]U>OS9]C_X)#?MWZQ\1[']H#]G?Q+\4M#^.&H_!2Q%UX;^(^DZG#?KXLT*
MZMV,)FEAD=6NK=L1ROO+;F53N9&D< _3ZBOQ"_X-[_\ @F3I?_!0+_@GO\/O
MB)^T#K7BCQWHOAW4KJ#P!X<_MR[L]*T>&UU"5Y+J6*)T^T7,MY]H5FEWKY4<
M:_[*_M[0 45^;O[8'C3XD?\ !2W_ (*0Z[^RKX$\=^(OA;\+?A3HEAK7Q3\1
M>'+G[+KVJW%\OFVFD6T_WH(W@^=Y%^\"ZL-J[7M^(/\ @V7_ &=]!TF34/AC
M??$_X2?$:-6EM/&FA>,M2DU)+H?-'-*LTS1R!6QE55-R[AN5CNH _1>BOCOX
ML?M)>/O^"5?_  2.U[XA?&[Q!H_Q2\?_  XT79/J.FVC:?!KUY)<+;6*R!F^
M\SRVZRNJK_&RI_#7SW\ O^""VG_MI?#S3?BA^V/XN\>?%'XJ^,;:/5I](BUV
MXTG0_!_F('BM+.WMG3:T 8*S;MK.I..K, ?IIX/_ .19L_\ <_K6I7Y6_ ^V
M\=?\$6?VY_A+\*Y/''B;XB?LU_M"75SH_AV'Q'="\U7P'KRC>ENEPWS2VL_"
MJG\+,QQN1FG]*_9#UBZN/^#AK]KRSDNKB2SM_!GA%HH&E9HHRUKR0OW1F@#]
M"**^0_\ @O)J%QI'_!'WX_7%K/-;W$/A:5DEA<QNA\V/D,.E?)G_  7$\>ZU
MX$_X-[?A/KVDS7#:O9OX*NHMLC[KB18HFV-M(9E9@,\\YH _6^BOSO\ #_\
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MX^:9^SK\%?AGH=OK/C_5'\56GAW5/&%_=(DMOI-M<32@^0L$T<DFU>\BLO\
MJFH _6ZBOQ.^(G[!'[!GP<\+W'B;]EO]K;X=_ ?XO:/#]ITC6-.^--K>6>I7
M"9=(-0AN+QUE@D/R,J[5^;++(NZ-O4_BQ_P4P^)W[;G_  ;2^*OC-\/8=2T?
MXG)IR:5XD?PX0USI_P!FOXH-6NK,J6VJUIYTRLK;HDDW!MR!J /U>HK\W?\
M@F;_ ,$R_P!F2WU+P%\</V5OBEX[M-*A+/KXTSQ=+J-KXR,D7S0ZO;7&_P N
MX5RC,JI$R[?NJVUE_2*@#,L_^1NU#_KVM_\ T*6M.LRS_P"1NU#_ *]K?_T*
M6M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH I:YJJZ%HUY>LDDBV<+SE5&YGVJ
M3@?E7YZ?\&Y7P_@\<?LO>*/V@]>$>I?$?XZ>*=3U35=38!I8K>*ZDBCM$/\
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M)O %\FGZQ<V=O*UBDTBEE6*YV>3-T8?NG;&W^Z5+>O4 %%%% !1110 4444
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M^.?[,/P]T/X>_%WX"ZE!X[L)-)25?[8M+/+W=G*NX[T: N^W&6\K9]UVJ/\
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M2^+(]!T>/Q1<68TV76%LHUU"2U#^8+=I\>88O,^;9NV[N: -ZOQU_P""0?\
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M VW-3^,_!>C_ !%\,W>B>(-'TW7-'U!/*NM/U"V2ZM;I,YVO$X*LN0/O+VH
M^ ?VF_VK_P#@G=^S3\*+CQ$NC_LU>.M3GA_XDOASPAH^BZUJ_B"X?Y88;>&V
M1V_>OA!(VV,;OF:O7/A=^U;X/_8;_P"">/@OXD?&3X?^&_V<;/Q!-:?VOX>T
M&P:>QT.[OI0D1N/L]NGE-L\MI2Z;8FRA=V56;U+X3_\ !/'X"_ +QB/$G@?X
M)_"?PGX@C=I8=2T?PG86=W;EEVGRY8XPR+C^%2!R?6O5/%/A73?&N@7FD:UI
M]CJVDZE$8+RRO;=)[>ZB88*.C@JZG^ZU 'Y%_%.^^!OPX_X*]?LX^(OV-_%_
MA63QW\5O$+V_Q)\/^ M2BOM"UCPWY32W%]>PV[/;PRQX+HV$:1F9_O+NK]B*
M\M^!'[%?P@_9<U?4M0^&OPM^'O@&^UE=E[<^'O#UKILURF[=L=XD5F0-R$^Z
MOH*]2H S+/\ Y&[4/^O:W_\ 0I:TZS+/_D;M0_Z]K?\ ]"EK3H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)T#SE$G]DK=66^XN$4_=E=88D5Q\RJ)5_C->[^"OV+?B!^S3_P %H_$/Q6\
MZ79W'P9^.WAQ(OB! MW%!)I6O66_[+?I"S*TBRQ_(WEAOFGE=NQKXQ^ WPQ^
M/6F?\%B_VVOBE^S]J'A_6/$'A7Q3I&EZYX%\1SM;:9XPL)K%I%V7(_X][R!X
MOW3M\FV60-\NY7 /UP_:1_9U\&_M:_!3Q#\._B!H5KXB\)^)K4VM[97"9SW5
MT;JDJ-AT=?F5E5AR*_)KX)?$37?&7_!J;\=-#UW5;OQ OPYL/$W@S2M8GD\Q
MM3TZQN#';.#_ '$C*Q+_ +,*U]"_$[XZ_MX_ML>#;KX=^&?V>])_9C3Q 'T[
M6O'GB'QU9:]+HL)7$QL+:R"O)-MR(YF^3<P^[]]=3]N[]D#PM^P5_P &[/Q6
M^$O@V.1=$\(?#Z]MEGE7]]?S-EY[J3_;EE=Y&Q\J[\#Y0!0!Z_\ \$8?V6O!
MW[)G_!-;X1Z/X0L+2'^W/#&G^(-7U"%5:76;^\MH[B>X=_O/NDD8)N^[&$0?
M*HKY\_X. _AOI7P5O_@;^TQX7M_[)^,'P_\ B+HNAVM_9'RKKQ!IEY,\5QI4
MO_/5'1WQN^ZK2@8WM7'_ +!_B/\ ;"_X)\?L;_#'2/#?PMTW]J;X3ZCX6TS4
M_#UQ9^)[?0/%'AB&YM8I_L%PEPK174$3N4B:+YECV[MJJ%7T;P;^R%^T!_P4
MA_:O\ _$[]I_PSX;^%/PV^#^J?V[X2^%FFZTFNW.H:RJ_N=1U*\AQ _D9_=)
M'WW!E"LWF@'$ZQ\&]%^*O_!VM::CK%C;WUQX#^!2>(=-\X;A;W?]I-9B51_>
M6.\DQ_=^]]X"NF_X+5^%Q^T]^WM^Q7^SSXDDN/\ A5WQ(\3:WX@\3V3/Y=KK
MS:-9)=6]E+_$T;,SADZ-YB?Q*K+[%X7_ &1_'&E?\%V/$_QRETVW_P"%=ZI\
M'+?P=;Z@+N-I6U)=52Y:+R=WF!?*7._;MKI?^"HW_!/:;]O7X0:$WA?Q1-\/
M_BU\.-9B\3> _%D<7F?V1J"8!25?XX)4^1UY'"-M?9L8 ]_\,:%9Z)?7.FV-
MG;V>G6=G;VT-K#$$AAC42*$5!\JJ!QM6OSU_X)__  ]L?V/?^"['[27P?\#P
M_P!F_#/QEX/TSXE'1+4 :?H.K2SK:S+%'C;#YZEI-B_+M1%^ZB*NAX>_;/\
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M?AW]B[PWX-\67""$^)]?^*.FZAX?TUF)47/D6X6YF3Y6/E+\ZY7.[^( \_\
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M?A#\8]/\<:;;Z9=>-?B]X@\7:2(;N*X^T:==_9_)E)C8[6;RG^1OF&.:^TJ
M/S$_:@U&W^$'_!T1^SYXE\12+!H_Q$^%.H^#M$N+D^7#'J4%U=7+(CGY3(Z3
M1IM^]F91_$M?IW7S1_P5#_X)RZ#_ ,%+/V<%\)7VK7OA'Q9X?U"/7?"'BBQ7
M_3/#NJ0_ZJ9.0Q3LZAEW#!#*RJR_,'@/]K[_ (*$?LBZ9;>$_B9^S-HW[17]
MFAX8_''@GQ?::7)JB @(\UE+%N$IR-S".)<-D+\K9 /TVK\W_P#@XFZ?L9?]
MG*>$_P#VYK-\3^'_ -NW_@I_K%AH.OZ+:?L7?"..^BN-6N=+\2IK/CC68HI
MWD6\]OMBM5D*\LRJR_\ 35-R/Z!_P7&_9'^+'[1OPH^ ]Q\'_#-KXZ\3?"?X
MJZ/XWGT_4M8ATX7EO80W+8::4@;GD,:G:K'YRV/EH ^\J_-__G:^_P"[:_\
MW8*ZK0/VO_V]+O7[*'4OV._ ECI\UQ''=7"?%BSE:"-F =PGE?-M7)VUQ/[9
MOP$_:9^%O_!9RU_:)^"_PAT#XIZ#)\)XO L]OJ/BZUT/R;AM3ENG?Y]SMM58
MOX=IWGYOEH _2RBODG]DW]H_]K;XD?&BSTOXN?LW^%/AKX)DMYWN-<T_X@6^
MLSPRJF8D%NB*S;V^7/\ #7UM0!^5_P#P0Q/_ !H*^('_ %]>./\ T==5V'_!
MK%^SCX;^"_\ P2$\ ^)-+TVWC\1?$F2\UG7=1$8\^]=+RYM[=&?&[RXH(D55
M^Z&:1A]]JZS_ ():_L,_$C]F+_@DWXM^%/C#1[73?&NK7'BB2VLXK^&>-EOI
M9VM_WJ,R+N5U[_+GFO7/^"/W[-_BS]D?_@FM\)?AOXZL8=-\6^$](>TU*VAN
M4N8X7:XEDPLJ%E;Y77[K4 ?/?[56BV?P[_X.0OV4]>TFVCL]4^(G@CQ7H6O3
MQ#:U_:V=K]JMUD_O;)><G^ZO]T5^CE?''[4G[(WCKXH?\%?/V6_BYH^G6\_@
M?X8:1XIM/$-XUW%'):R7UCY-L%B9M[[G[JK;>]?8] &99_\ (W:A_P!>UO\
M^A2UIUF6?_(W:A_U[6__ *%+6G0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/;86_P#9B/+I&AG[9!Y>E)<GY99XHH]TC+\K.SLOR\U^D]%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9=C_ ,C3J7_7&#_VI6I678_\
MC3J7_7&#_P!J5J4 %%%% !1110 4455U.^73=,N+EEW"WB:4@?Q;1F@"U17Y
M9_!7_@XW\:_M&?#>P\7^ _V*?VA?%WA?56E%IJNE117-K<-&[1/L=4VG;(CJ
M?1E-?47[!'_!0CQQ^V-X[US2?%?[-OQ<^"=KI-@MY!J/BVW$5OJ#F14\B+Y1
M^\PQ;Z"@#ZJHKY__ &'_ -OG2/VWO$GQFTW2?#^I:')\&/B!J7P_O7NYDD74
M9[)PKW$>W[L;=@WS4?\ !2/]OG2/^";W[.D?Q%UO0-2\26,FN6.ABSLIDBEW
MW4NQ7W/\NU: /H"L_P 4_P#(MZA_U[2?^@-6A6?XI_Y%O4/^O:3_ - :@"U8
M_P#'G#_N+_*IJAL?^/.'_<7^534 %%%% !17SGXL_;T_X1;_ (*<^$?V</\
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ME/[;/[,=O^V;^R=\0/A7<:M/H$'CS1I]'?48K<7#V8E&/,$;,N['IN%>K44
M<;\ /A4GP,^!7@OP1#>2:A'X-T*QT)+MXO+:Z6UMT@60ID[=VS=MR>M=E110
M 45\Y_M8?M<_$CX"_M._!3P7X0^!OBKXD>%OB1JDMEXE\5:?<%+3P5"K0JL\
MX$;C;M>20^8T081;4+NVU?HR@#+L?^1IU+_KC!_[4K4K+L?^1IU+_KC!_P"U
M*U* "BBB@ HHHH **** "BBB@ HHHH **** ,OP?_P BS9_[G]:U*X/QU\25
M^#W[//B#Q=):M?1^%=$O-7-LC[&N%MXI)=@.#C<$QG;WKG?V%?VJK?\ ;?\
MV1/ 7Q8M=%G\.V_CO2UU./39;D7$EF&9EV&557=]WKM% 'KU%%% !1110 45
M\Z?LT?MYG]HK]N']HOX,#PK_ &.?@#+X?C_M?^TOM']N_P!JV4MUGR?)3[/Y
M7E;/OR;]V?EZ5]%T %%%% !1110 4444 9EG_P C=J'_ %[6_P#Z%+6G699_
M\C=J'_7M;_\ H4M:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!EV/_ "-.I?\ 7&#_ -J5J5EV/_(TZE_U
MQ@_]J5J4 %%%% !1110 5G>+/^16U+_KUE_] -:-9WBS_D5M2_Z]9?\ T T
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MO1_X*V_\I3_^">__ &.WB#_TW15[5_P4"_X)E>!?V]M8T/7/^$B\0_#KXQ>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNWY0JK\M?H[6?XI_Y%O4/^O:3_T!J /.?V.?V0O '["_[/NA?#GX9Z##X?\
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MM<+]@^P)="Z!6+9N\WS%'S;\;?X:^%/VY_B7^SC^U-^V;J_P@_:X\#_\*/\
M&'A5Q-\+_B6?$DNFKXDL'^8RVFJK%"EO*C-M>TG:1%=VVEFYK]3:Y+XL?!'P
M7\?O"O\ 8?COPCX9\::*7\W^S]=TJ#4;4O@C=Y4R,N[:3_#WH _(K]H#X<?L
M0_L/^$[SQG9_%#Q!^U%\;)+2:P^''A_5_'9\=ZH-6F1H[;[):0EDB/FE&\]X
MSLV_)\^U6_0[_@D-^ROK/[%'_!-CX0?#/Q$L,7B#PYH8.J11E66WN[B62ZFB
MRORG9),R;A][;FNP^!'_  3_ /@7^R]K[:O\._@_\-_!>L2!E;4-'\.6MK>;
M6ZIYR)Y@3C[N[;7LE 'COQ[_ &+?!_[2'QV^$OQ"\02ZTNN?!?4[O5?#Z6EP
ML<#37,*PR^>C(2Z[5& I7%>4_M@_\$A/!O[4?QS;XI:+\0OC%\&OB3=:<FE:
MCK_P\\3-I4VM6T?^JBNXV1TE5!G;@*W3KM7'UQ10!\^_L#_L"> _^">7@?6?
M"/@4:Y?'5;M=9UO7-<O?MVL>(;^4OYEU=W&U=\K;1]U57VY-?059=C_R-.I?
M]<8/_:E:E 'QA^T-_P $1?AK\7OCOJWQ2\#^,?BG\ _B)X@4_P!MZO\ #37Q
MHZ>('W,WFWMN8WBF?<S,S;59F.YF9OFKD]8_X-U?@5X\^%'C#0?'FN?%7XD^
M*O'D5M;:KX[\4^)/[2\3+;P745TEK;S/%Y5O!YL2Y6.(%E^5BWR[?ONB@#D_
MC'\'?"_[07PTUCP;XX\/Z7XH\*^((?LVH:9J%N)K>Y3*L,J>ZLJLK#YE959<
M$"OB-/\ @WW\,^$M('AWP/\ M)?M;?#OX?\ SQCPIH/Q$9-.LH?X8+8RPO)#
M$,[2N]MR\'N:_0BB@#QG]BO]@_X9_L ?"9_"/PUT+^R[:\N7OM3U"ZF:ZU/6
M[IVR]S=W+_O)I6S_ !?*OW5"KQ7G/[87_!('X5?M>_%ZT^)'V[QU\+_BK9P_
M9?\ A-OA[KC:#KEQ#M"B*:159)E4*G^L1FVHJYV_+7U910!\+_"3_@@_\/=#
M^+^A>.OBC\2OC9^T/KWAF<7>CV_Q*\3?VII.E7"[MD\-FL:1API_CWKN&[:&
MKZV^.'P,\(_M+?"S6/!'CSP[I?BKPGX@@^S7^FZA#YT%PN593ZJRL RNN&5E
M5E*D UV5% 'YYQ_\&]?AC3_#:^$]-_:4_:ZTGX:K";5/!MI\1=NEPV^-@M4W
M6YD6U\O<OD[MISU]?L#]E7]DCX=_L2_!K3_ 'PO\+V'A/PKIC%X[2UW,TTK!
M5>::1RSRRMM7<\C,QVCT%>F44 ?C/_P2<_X)D_#7]NS]G;XI:YKTWB[P=X^\
M+?'#Q?%H?C;P9K+Z+XBTE&F@+11W**=T>[YMDJNJL690-QKZX^$?_!"KX=Z'
M\6_#_CKXJ?$#XQ?M%>)/"<AN-%'Q*\1?VIINCSY4K/;V:QI$KC:/O[_F^;[P
M7;]@^!_AUX?^&EA=6OAS0=%\/VM]=R7US%IEE%:QW%Q)_K)G5  TC8&YS\S;
M:WZ .,\0> ;'XK?!+5?"^I_:/[-\2:5<Z5>&%_+E$$Z/%)L;!PVUVV\5F?LJ
M?LU>'?V.?V>/"?PO\(MJ4OAOP78+IVGMJ$PFN6B5F;YW555F^;^Z*[+P?_R+
M-G_N?UK4H ^+?CM_P1&^'7Q*^.&N_$CX?>.?B[^S]XV\58EUZ]^&?B+^QK?Q
M!/ND;SKVV,;Q2ON=F9@%9F.X_,68])^QK_P1^^%/[&WQ<O\ XD1W_CKXH?%7
M4(/LK^-_B%KS:[KT-OLV>5%*RHD2[=RY1%8JQ7=M^6OJZB@#S#]K#]D;X=_M
MO?!F_P# 'Q/\+Z?XL\+ZBWF-;W0*R6LJ@JL\,JX>&5=QP\;!L,P^Z6KY*A_X
M-]_"NI:?%X;\2?M%?M9>,/AG&@BD\$ZO\0G;2KR'_GVF,4*2O;;>/+WKC'WJ
M_02B@#Y__9$_X)M?"S]AGXM?$;Q9\-]*N/#[?$Z#1K;4-*BD1=,L8]+M9+:U
M2VB5 8_W<CE]S-N8YXK'_9>_X)=?#S]DO]L+XP_&SPWJ7C"Y\6?&RX6XUFVU
M'4EFL+0[VE86Z! R[I&9OG>38/E38ORU],44 %%%% !1110 4444 9EG_P C
M=J'_ %[6_P#Z%+6G699_\C=J'_7M;_\ H4M:= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EV/_ "-.I?\
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M_P#P[(^$?_/I\0/_  Y'B3_Y.H_X=D?"/_GT^('_ (<CQ)_\G5] 44 ?/_\
MP[(^$?\ SZ?$#_PY'B3_ .3J/^'9'PC_ .?3X@?^'(\2?_)U?0%% 'S_ /\
M#LCX1_\ /I\0/_#D>)/_ ).H_P"'9'PC_P"?3X@?^'(\2?\ R=7T!10!\_\
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M/_DZC_AV1\(_^?3X@?\ AR/$G_R=7T!10!\__P##LCX1_P#/I\0/_#D>)/\
MY.H_X=D?"/\ Y]/B!_X<CQ)_\G5] 44 ?/\ _P .R/A'_P ^GQ _\.1XD_\
MDZC_ (=D?"/_ )]/B!_X<CQ)_P#)U?0%% 'S_P#\.R/A'_SZ?$#_ ,.1XD_^
M3J/^'9'PC_Y]/B!_X<CQ)_\ )U?0%% 'S_\ \.R/A'_SZ?$#_P .1XD_^3J/
M^'9'PC_Y]/B!_P"'(\2?_)U?0%% 'S__ ,.R/A'_ ,^GQ _\.1XD_P#DZC_A
MV1\(_P#GT^('_AR/$G_R=7T!10!\_P#_  [(^$?_ #Z?$#_PY'B3_P"3J/\
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M?0%% 'S_ /\ #LCX1_\ /I\0/_#D>)/_ ).H_P"'9'PC_P"?3X@?^'(\2?\
MR=7T!10!\_\ _#LCX1_\^GQ _P##D>)/_DZC_AV1\(_^?3X@?^'(\2?_ "=7
MT!10!\__ /#LCX1_\^GQ _\ #D>)/_DZC_AV1\(_^?3X@?\ AR/$G_R=7T!1
M0!\__P##LCX1_P#/I\0/_#D>)/\ Y.H_X=D?"/\ Y]/B!_X<CQ)_\G5] 44
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MY'B3_P"3J/\ AV1\(_\ GT^('_AR/$G_ ,G5] 44 ?/_ /P[(^$?_/I\0/\
MPY'B3_Y.H_X=D?"/_GT^('_AR/$G_P G5] 44 ?/_P#P[(^$?_/I\0/_  Y'
MB3_Y.H_X=D?"/_GT^('_ (<CQ)_\G5] 44 ?/_\ P[(^$?\ SZ?$#_PY'B3_
M .3J/^'9'PC_ .?3X@?^'(\2?_)U?0%% 'S_ /\ #LCX1_\ /I\0/_#D>)/_
M ).H_P"'9'PC_P"?3X@?^'(\2?\ R=7T!10!\_\ _#LCX1_\^GQ _P##D>)/
M_DZC_AV1\(_^?3X@?^'(\2?_ "=7T!10!\__ /#LCX1_\^GQ _\ #D>)/_DZ
MC_AV1\(_^?3X@?\ AR/$G_R=7T!10!\__P##LCX1_P#/I\0/_#D>)/\ Y.H_
MX=D?"/\ Y]/B!_X<CQ)_\G5] 44 ?/\ _P .R/A'_P ^GQ _\.1XD_\ DZC_
M (=D?"/_ )]/B!_X<CQ)_P#)U?0%% 'S_P#\.R/A'_SZ?$#_ ,.1XD_^3J/^
M'9'PC_Y]/B!_X<CQ)_\ )U?0%% 'S_\ \.R/A'_SZ?$#_P .1XD_^3J/^'9'
MPC_Y]/B!_P"'(\2?_)U?0%% 'S__ ,.R/A'_ ,^GQ _\.1XD_P#DZC_AV1\(
M_P#GT^('_AR/$G_R=7T!10!\_P#_  [(^$?_ #Z?$#_PY'B3_P"3J/\ AV1\
M(_\ GT^('_AR/$G_ ,G5] 44 ?/_ /P[(^$?_/I\0/\ PY'B3_Y.H_X=D?"/
M_GT^('_AR/$G_P G5] 44 ?/_P#P[(^$?_/I\0/_  Y'B3_Y.H_X=D?"/_GT
M^('_ (<CQ)_\G5] 44 ?/_\ P[(^$?\ SZ?$#_PY'B3_ .3J/^'9'PC_ .?3
MX@?^'(\2?_)U?0%% 'S_ /\ #LCX1_\ /I\0/_#D>)/_ ).H_P"'9'PC_P"?
M3X@?^'(\2?\ R=7T!10!\_\ _#LCX1_\^GQ _P##D>)/_DZC_AV1\(_^?3X@
M?^'(\2?_ "=7T!10!\__ /#LCX1_\^GQ _\ #D>)/_DZC_AV1\(_^?3X@?\
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M5] 44 ?/_P#P[(^$?_/I\0/_  Y'B3_Y.H_X=D?"/_GT^('_ (<CQ)_\G5]
M44 ?/_\ P[(^$?\ SZ?$#_PY'B3_ .3J/^'9'PC_ .?3X@?^'(\2?_)U?0%%
M 'S_ /\ #LCX1_\ /I\0/_#D>)/_ ).H_P"'9'PC_P"?3X@?^'(\2?\ R=7T
M!10!\_\ _#LCX1_\^GQ _P##D>)/_DZC_AV1\(_^?3X@?^'(\2?_ "=7T!10
M!\__ /#LCX1_\^GQ _\ #D>)/_DZC_AV1\(_^?3X@?\ AR/$G_R=7T!10!\_
M_P##LCX1_P#/I\0/_#D>)/\ Y.H_X=D?"/\ Y]/B!_X<CQ)_\G5] 44 ?/\
M_P .R/A'_P ^GQ _\.1XD_\ DZC_ (=D?"/_ )]/B!_X<CQ)_P#)U?0%% 'S
M_P#\.R/A'_SZ?$#_ ,.1XD_^3J/^'9'PC_Y]/B!_X<CQ)_\ )U?0%% 'S_\
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M/_#D>)/_ ).KZ HH ^?_ /AV1\(_^?3X@?\ AR/$G_R=1_P[(^$?_/I\0/\
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M%_YJ/XC]/^OZI/\ AV1\(_\ GT^('_AR/$G_ ,G5[U8_\></^XO\JFH ^?\
M_AV1\(_^?3X@?^'(\2?_ "=1_P .R/A'_P ^GQ _\.1XD_\ DZOH"B@#Y_\
M^'9'PC_Y]/B!_P"'(\2?_)U'_#LCX1_\^GQ _P##D>)/_DZOH"B@#Y__ .'9
M'PC_ .?3X@?^'(\2?_)U'_#LCX1_\^GQ _\ #D>)/_DZOH"B@#Y__P"'9'PC
M_P"?3X@?^'(\2?\ R=1_P[(^$?\ SZ?$#_PY'B3_ .3J^@** /G_ /X=D?"/
M_GT^('_AR/$G_P G4?\ #LCX1_\ /I\0/_#D>)/_ ).KZ HH ^?_ /AV1\(_
M^?3X@?\ AR/$G_R=5/Q#_P $S?A)%H-\RVGC[<MNY'_%QO$9_A/_ $_5]&5G
M^*?^1;U#_KVD_P#0&H \+M/^"9'PC:SB/V7X@?<7_FH_B/T_Z_JD_P"'9'PC
M_P"?3X@?^'(\2?\ R=7O5C_QYP_[B_RJ:@#Y_P#^'9'PC_Y]/B!_X<CQ)_\
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M?_/I\0/_  Y'B3_Y.H_X=D?"/_GT^('_ (<CQ)_\G5] 44 ?/_\ P[(^$?\
MSZ?$#_PY'B3_ .3J/^'9'PC_ .?3X@?^'(\2?_)U?0%% 'S_ /\ #LCX1_\
M/I\0/_#D>)/_ ).H_P"'9'PC_P"?3X@?^'(\2?\ R=7T!10!\_\ _#LCX1_\
M^GQ _P##D>)/_DZC_AV1\(_^?3X@?^'(\2?_ "=7T!10!\__ /#LCX1_\^GQ
M _\ #D>)/_DZC_AV1\(_^?3X@?\ AR/$G_R=7T!10!\__P##LCX1_P#/I\0/
M_#D>)/\ Y.H_X=D?"/\ Y]/B!_X<CQ)_\G5] 44 ?-WA7_@F;\))_#]J[6OC
M[<R]OB-XC7O_ -?U:/\ P[(^$?\ SZ?$#_PY'B3_ .3J]L\'_P#(LV?^Y_6M
M2@#Y_P#^'9'PC_Y]/B!_X<CQ)_\ )U'_  [(^$?_ #Z?$#_PY'B3_P"3J^@*
M* /G_P#X=D?"/_GT^('_ (<CQ)_\G4?\.R/A'_SZ?$#_ ,.1XD_^3J^@** /
MG_\ X=D?"/\ Y]/B!_X<CQ)_\G4?\.R/A'_SZ?$#_P .1XD_^3J^@** /G__
M (=D?"/_ )]/B!_X<CQ)_P#)U'_#LCX1_P#/I\0/_#D>)/\ Y.KZ HH ^?\
M_AV1\(_^?3X@?^'(\2?_ "=1_P .R/A'_P ^GQ _\.1XD_\ DZOH"B@#Y_\
M^'9'PC_Y]/B!_P"'(\2?_)U'_#LCX1_\^GQ _P##D>)/_DZOH"B@#S?X'_ ;
MPW\ I]4TGPW%K$=C<"&Z<:EKM]JTF]MZG]Y=S2N%PB_*&V]?4UZ1699_\C=J
M'_7M;_\ H4M:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7+^-?C%X1^&EU;V_B3Q5X;\/3W2%X8]3U*&T:91QE0[+N%=17\Z?_  >A
M:&OB;]M?]GO3GD,:ZAH-Q;,R]5#WZKG]: /Z$O"'CS0_B'IOVWP_K6DZY99V
M^?I]XES%GTW(2.QK:K^6']I[]CKQ=_P;G_\ !5WX,V'P7^+&I>-M6\7R65W)
MHZ0_8[NYA>]^S_V?>0I(R3Q7"[@C?*V[=M5619&_IV^*OQ5\._!'X>:QXN\7
M:YIWAOPOX>M3>:CJ=_.(;>SB7JS,WY8ZL6 ')H ZBBORG_XC#_V2?^%ICP_]
MG^*?]C>?Y!\2_P!@1?V<%W8\WR_M'VOR\<_ZC?\ [%?0G[(7_!>;X"_MR_M=
M:M\&?AM=>)M=\0:7:W=ZNIK8Q+I%_#;E SP3><696WKMW(OOMH ^U**^+?V2
M?^"Z?P3_ &O_ -K[6O@3IUMXW\&?$[0_M*2Z/XKTR+3Y)I[5\7%O$5F?=*B[
MGV=T1V7(4TWQ;_P78^">@?\ !02W_9GT>U\<>-OB=)J$6E2Q^'=,BN[&TN&4
M/*DLS3)M\A-S3G;MBV.&^9&4 'VI17S#_P %'O\ @KA\$_\ @EIX0T^_^*7B
M"XCU;6=QTO0-)A%WJ^HHIPSI#N55C']^5D3=\N[=Q7RM\+?^#N?]DWXC^!/$
MFL7TGQ!\)WWAVV6Z31]7TFW6\UA#($(M&BN'B>1=P8H\B-MW;0VUJ /T3^.?
MQ]\$_LT_#ZX\6?$'Q5H?@WPU:RI!+J>KWB6MK%)(P5%+OQEFX%9NE?M7_"_5
MO@MI_P 2(/B%X-_X0'5N++Q'+J\$6F77SM'A+AW$;?.CK][JIK\J_P#@NS^W
M=X*_X*._\&Z'B#XI?#Z'7(/#.J>*]/L8DU>U2VNM\%^$?<B.ZXW#CYJ^'_VV
M_P!M/P?X._X-D_V=?@3=1ZT?&WC*T_X2;3Y([=6L5M;?6K]'5Y-^X/N'"[3]
M: /Z8O!?C;1OB/X9L];\/:MINO:/J">9::AIUTEU:W29V[DD0E67(/W3VK8K
M\M_^#8'_ (*)?#OXW_\ !.?2?AKITFK:;K7P$T* >*KS4X8K;3HTN)[R5)(Y
MMYRBI"Y9G5-M5_B__P '>O[)GPM^*]QX:L_^%D>-+.RN&MY=?T+1[=]+R."T
M9FN8I94S_$L>T_>7<,4 ?JA17P3\&_\ @XX_9I_:&_:X\'_!WP+JWBCQ1KWC
M@0G3-2L],4:7NDMS/Y<KR2++%(BJRNC1;E88K[VH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#+L?^1IU+_KC!_P"U*U*R['_D:=2_ZXP?^U*U* "B
MBB@ HHHH **** "BBB@ HHHH *S_ !3_ ,BWJ'_7M)_Z U:%9_BG_D6]0_Z]
MI/\ T!J +5C_ ,></^XO\JFJ&Q_X\X?]Q?Y5-0 4444 %%%% !1110 4444
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M^GRMX;T_P39647@[5I(OM4NC7-G%Y44SC*^;OC,J2\@L)7;[V* .7_X)R_\
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M 4444 %%%% !6?XI_P"1;U#_ *]I/_0&K0K/\4_\BWJ'_7M)_P"@-0!:L?\
MCSA_W%_E4U0V/_'G#_N+_*IJ "BBB@ HHHH **** "BBB@ HHHH *S_%/_(M
MZA_U[2?^@-6A6?XI_P"1;U#_ *]I/_0&H M6/_'G#_N+_*IJAL?^/.'_ '%_
ME4U !1110 4444 %%%% !1110 4444 %%%% &78_\C3J7_7&#_VI6I678_\
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MGX0\*R3IYMO;:AJDRRNMU/%EXK>VMKB7!B:58(I4E;)_9]_X*>Z;\2+K3?\
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M-N=+2_,BFZ7"-O9-GW/EW9^\* /I.BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***_-_1?^"]'C+XD>(/'D?P]_9%^,WQ&T
M7P!XGU'PI?:OHEW:20RW=E)LE5$_UF[:4;;MSB1: /T@HKXS_8F_X+1>"OVL
M?V@I_@_XD\"?$SX)_&"/3SJ=MX4\=Z3]@GU:V4;GEM'#%954!ST5F6-V4%4;
M;]F4 %%?..I?M4_%2R_X*3:;\(X?@CKD_P )[SPT^KS?$I;S_0;>\&<6K)LV
M[MRJFSS/,)DW[=BLU?1U !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &78_P#(TZE_UQ@_
M]J5J5EV1_P"*IU+_ *XP?^U*U,T %%%% !1110 4444 %%%% !1110 5G^*?
M^1;U#_KVD_\ 0&K0K/\ %/\ R+>H?]>TG_H#4 6K'_CSA_W%_E4U0V/_ !YP
M_P"XO\JFH **** "BBB@ HHHH **** "BBB@ K/\4_\ (MZA_P!>TG_H#5H5
MG^*?^1;U#_KVD_\ 0&H M6/_ !YP_P"XO\JFJ&Q_X\X?]Q?Y5-0 4444 %%%
M% !1110 4444 %%%% !1110!EV/_ "-.I?\ 7&#_ -J5J5EV/_(TZE_UQ@_]
MJ5J4 %%%% !1110 4444 %%%% !1110 4444 9?@_P#Y%FS_ -S^M:E9?@__
M )%FS_W/ZUJ4 %%%% !1110 4444 %%%% !1110 449HS0!F6?\ R-VH?]>U
MO_Z%+6G699G_ (J[4/\ KVM__0I:TZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "ORS_ ."HWQQ\'_LX_P#!??\ 8U\8>/?$VC^$?"^E
M^%_%BW>JZI=+;6MNTMD\2;W;Y1ND=%'^TPK]3*_+O_@I?\(O"OQT_P"#@;]C
M7PSXV\+^'_&/AK4/"WBYKK2-;TR'4;&X,=E+(A>&961MKJK+E?E95- 'U%_P
M^N_9'_Z.,^#_ /X4EM_\57SO_P &_GQ$T/XL?&;]MCQ-X9UC3]>\/:[\:KV^
MT[4;*42VUY!) C)*CKPRLO.:^JO^'3O[+/\ T;3^S_\ ^&\TC_Y'KY:_X('>
M!M%^&WQO_;=T'P[H^E>']"T?XV7MI8:=IEHEK:6,*0HJ1111A41%7[JJN%H
MXC]H#Q/:_P#!!'_@IC>?%>X6YLOV7?VG+ET\81V\+RQ>#O%4:,\=ZJ*/ECNE
M#[E7^)I3]V*):[+_ ((P?"3Q!^V3\;?&W[='Q0TV>SUKXG1MHOPPT>[&YO"_
MA*)SY3J/X9;IMSEE^\K.Z_+<%:[+_@YNTVWO/^"'WQR,T,,OD0Z3+'O0-Y;_
M -LV/S#T;D\^]?9GP3TRVT;X.>$[.RMXK6TM='LX88(D$:0HL"*J*HX"J.U
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M4 >TZ7%<1:9;I<.LERL:B5U&%9\?,?SJU110!^=_[0'_ "LP_ '_ +)!KO\
MZ5-6?^TO_P K.G[-?_9*M?\ _0[BM#]H#_E9A^ /_9(-=_\ 2IJS_P!I?_E9
MT_9K_P"R5:__ .AW% &M_P %(_\ @L_XA_8*_;_\&_!_3OA[_P + _X3WP8V
MI:#I>FK*NKZQKKWKVMM9++GR8;=E0O)*Z-Y:H[?-PIXKXY_\%#_VW/\ @GEH
MEG\5/V@/A?\  O7/@?\ ;[:'Q#%\/+_4I-?\&VL\@B$\QN/W5QY;.BMY2[6;
M&&16W+K_ +0/@^V\4?\ !T?\!;RXCCDF\/\ P;U;4+9F'^K=KJ[M\K_M;+A_
M^^J]F_X+\@/_ ,$;/VA,C/\ Q2SG_P BQ4 >4O\ MX_M;?MX+K'BS]D7P3\&
M;/X0Z3>RV6E>)OB==:BL_CQH'V2S:=;VFWRK7S$=%>=AYGW@R?,J]U^RI_P5
M5USX[_L2_&[Q+XD\&V_@SXV_L^VNK6GC'PI/(\UE;:A9VLMQ"\3AMSVLZIE3
MNW<2 ,P"R-[M_P $Z?"]OX)_8 ^!VD6T,<$.G> ="MU1.@VZ=;KU[_6OSW^'
M'R_M(_\ !8#;_P!"_IG_ *C.H4 ;?[*?_!5S]K;_ (*H_ G2/$'[./PS^$&@
MQZ780)XF\5?$.?4H=&OM79%>XL-*M[?=.ZP;D5IY6V;MRCHK-=^'_P#P7I^)
M-MJ7B+X&^+O@FLO[96DZ[#H&G>"]'OG70M>BGA>X765NY,^1810(SR;F=MK1
M?-\[>5[]_P &_/A"V\#?\$:?V?[.UCCCBN/#?]HL$'WGN;B6X<_4O*QKR'X&
M>$[>]_X.DOC9K$D,3W&G_!?2X(I&^\GFWEMNP/\ =AQG_&@"'6O^"AW[77[
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MF=;A(@3_ , B1?\ @- '0_LZ?\%#_CI\$OVW/#'[/_[67ACX=V.M_$RPFN?
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M@N^M9AH7P7TM?B9\8+22#RH6\2V<KV-E8/&WW?\ 24EN/*;<K03[>JM7[24
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M/,5(F6,L/E5UPNI_P=(:;%K'_!)S5+.<;X+KQAX>@E']Y6U")37Z*XV\#@4
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M^"/_ #Y^./\ P51?_'J/^'^GP1_Y\_''_@JB_P#CU'^KN9_\^9?<'^M64_\
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M^:^(_P#A_I\$?^?/QQ_X*HO_ (]1_P /]/@C_P ^?CC_ ,%47_QZC_5W,_\
MGS+[@_UJRG_G_'[S[<_[YH_[YKXC_P"'^GP1_P"?/QQ_X*HO_CU'_#_3X(_\
M^?CC_P %47_QZC_5W,_^?,ON#_6K*?\ G_'[S[<_[YH_[YKXC_X?Z?!'_GS\
M<?\ @JB_^/4?\/\ 3X(_\^?CC_P51?\ QZC_ %=S/_GS+[@_UJRG_G_'[S[<
M_P"^:/\ OFOB/_A_I\$?^?/QQ_X*HO\ X]1_P_T^"/\ SY^./_!5%_\ 'J/]
M7<S_ .?,ON#_ %JRG_G_ !^\^W/^^:/^^:^(_P#A_I\$?^?/QQ_X*HO_ (]1
M_P /]/@C_P ^?CC_ ,%47_QZC_5W,_\ GS+[@_UJRG_G_'[S[<_[YJAXH_Y%
MO4/^O:3_ - -?&7_  _T^"/_ #Y^./\ P51?_'JJZO\ \%Z/@CJ&DW4*V?C?
M=-"Z#.EQ=2,?\]J:X=S/_GS+[@_UJRG_ )_Q^\^X;+_CSAZ?<'\JE_[YKX?M
M_P#@O?\ !&*&-/L?CCY0!_R#(O\ X]4G_#_3X(_\^?CC_P %47_QZE_J[F?_
M #YE]P?ZU93_ ,_X_>?;G_?-'_?-?$?_  _T^"/_ #Y^./\ P51?_'J/^'^G
MP1_Y\_''_@JB_P#CU'^KN9_\^9?<'^M64_\ /^/WGVY_WS1_WS7Q'_P_T^"/
M_/GXX_\ !5%_\>H_X?Z?!'_GS\<?^"J+_P"/4?ZNYG_SYE]P?ZU93_S_ (_>
M?;G_ 'S1_P!\U\1_\/\ 3X(_\^?CC_P51?\ QZC_ (?Z?!'_ )\_''_@JB_^
M/4?ZNYG_ ,^9?<'^M64_\_X_>?;G_?-'_?-?$?\ P_T^"/\ SY^./_!5%_\
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M98IR6&YAN57;<SJS-NKE]9_X)3?M;?'#1[CP_P#%/]O3Q;>>$[AFM[NT\&^
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M!_CSX@ZG>76E>%?#=_H T6&#RY'>Y??'>PW:N'MYX) KH55OF7^[E3YK??\
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M/BA\!]"O;>YG\,Q^$+?3-4\4PV[K);6NIZ@LK/+$K(F_:NZ;;N.UMK+^C%%
M#418D"JNU5X %.HHH **** "BBB@ HHHH **** "BBB@ HHHH \7\2_L/>#?
M%W[;WAGX_P!U)K@\=>$O#=QX5L8X[E%T]K2>5Y'+Q;-S2;I&^;>/]VIO$'[%
MO@_Q'^VSH/Q\N)-:_P"$X\.>&)O"-FB7*K8_8I9S.Y>+9N,F\_>WXQVKV*B@
M#SG]JO\ 9J\._MC?L\>+/A?XN;4HO#?C2P;3M0;3YA#<K$S*WR.RLJM\O]TU
MTGPR\ 6/PI^&V@>%],^T-IOAO3;?2K,SOYDI@@B6*/>V!EMJ+GCK7144 ?/N
MD?\ !./X>Z%XR_:$UR.;Q%]M_:6M(;/Q=OO$9(TBLI;%/LB[/W1\J9_O;_FQ
M]*]"_9?_ &=M!_9(_9^\(_#/PJVH2^'?!.FQ:5ISW\HEN6ACZ;W55#-_P$5Z
M!10!X[X7_8K\'^#?VS_%?QXL9-:;QQXR\/6WAJ^CDN4:Q6UMW#QE(]FY9-R\
MMN/TH_;E_8N\'_\ !0+]GC4OACXZDUF+PWJEW:7LS:5<K;W.^VG2>+#LCC&]
M%S\O2O8J* /$?VY?^"?WPQ_X*)_"B'PG\3=%FU"VTV[74=)U&RN'L]2T6Z7I
M-;7"?-&WMRK?+N5L"OFWPW_P;P_"W4_&>@ZI\3OBM^T=^T!IGAFY6]TWP]\3
M/';:UHMO,OW9/LZPQ;O3:S%&7Y65A7Z 44 >6_MA?LH^%_VX/V:/%7PI\:2:
MI#X7\8016U\^FSK!=!$FCF7RW9&5?FB7^$\5WWA#PS;^"_">EZ/9^9]CTFTB
MLH-YW/LC147)_O8%:E% 'COA?]BOP?X-_;/\5_'BQDUIO''C+P];>&KZ.2Y1
MK%;6W</&4CV;EDW+RVX_2N+_ &V?^"57PG_;L\4Z'XH\1P^)/"GQ"\+C9I'C
M;P?JSZ+XBT^/YOW2W,7WD^9L!U;;N;;MW-GZ6HH ^)_@=_P0M^%/PT^+V@^/
M/''B_P",OQ^\5>$V\S0KKXK^+W\1IHLN[<)8(2B1!U;E2RMM;YAA@K5[M^U=
M^Q;X/_;%OOAG<>+I-9CD^$_C;3O'^B?V?<+"K:C8ES")MR-OB^=MR#:3_>%>
MQ44 >4?M@?L8?#;]NSX-W7@7XI>%[/Q1X?N)!/$)"T5QI\Z@A+BWF3$D,J[F
M^="ORLRG*LRGY6_XAXOAIX@$.F>-OC-^U-\3? \$L4@\%^*_B7<7GAYEB^Y&
MT"1HY3V\ROT HH XJ[\._P#"C_@;<:;\-_!^D32>%]'DB\.>&8)TTBQG>*)O
ML]F)%1UMT9E5-^QE7=G::_)W18?V%O\ @H/XQU;QOX^UC4OV-?VCHY9+;QSH
MB>.6\%:U!=H=S[S+Y4%XK*"_VA(MSJY9]K?=_9>O,?CA^QS\)/VFYHIOB-\+
M_A_X\GA3RHI?$'AZTU*6%.2 CRHS+U/W3W- 'X^^._@5^S+\<_BQ\,?V=?V/
MXH_B/XBUKQ]I/C+XK>/X=0N-=-CHFF2M*PNM5D9E:2638L443>7N3[H9U9OV
M>^/GQIT']G'X)^+O'WB>X^R^'?!>DW.L:C+_ !+!!$TKA1W8A<*O\3$"G_"'
MX$>"?V?/"QT/P!X,\*^!]%WF7^S_  _I5OIEIO/5O+A15W>^*U?&_@71/B;X
M9N]#\1Z/IGB#1=04+=:?J5HEU:W"@A@LD3@JWS 'Y@>E 'PS_P &]G[--UX#
M_95\2?&[Q+H=GHOC_P#:@\1W7Q%U:W@A6-;&RNI9);"U4*H^18I6F'&[==MF
MOT JGIVFV^CZ?!:VMO%:VMJ@BAAB0)'"BC 50. H'05<H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O'?V0/V+/!_[$?AOQIIG@N76I+?QWXNU#QOJ
M?]H7*SLM_>^7YRQ;47;%^Z7:OS$?WC7L5% !7COP$_8M\'_LW_';XM?$+P_+
MK3:Y\:-3M-5\0)=W"R0+-;0M#%Y"*@*+M8Y#%LU[%10!X]<?L7>#[K]NN#]H
M9I-8_P"$\M_!/_" )']H7^S_ .SOMK7V?*V;O.\UC\^_;MXV]Z3P/^Q5X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8['X=X5I1B]^7J?)Y'X=Y?EV*6+4G.2VOT'44"BOBS] "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\3_X*+_M21_L3?L,?%+XJGRFN/!?A^YO
M;%)>8YKTCR[1&_V6N'B7_@5>V5^<?_!T'=-KO_!.CP[X%\QX[?XJ?$SPWX3N
M-IQO22Y:XQ_WU;*?^ T ;'AOXR?&+]C[_@WHF^*'B+Q9J'BKXS:7\/9/&%QJ
M>O1BX:.[N4^U) Z?*NV!)4BV_P#3+WKZT_8J^*&K?'+]C?X3>-->>WDUSQAX
M-TC6]1:&+RHFN;FRAGE*I_"N]VXKQG_@N):QV?\ P1X_:$AA58X8?!%ZB*HV
MA0$& *^1?V(?VW?V]/#7[&'PATWPK^Q#HGB;PSI_@K1K72-8;XL:1:-JUFEA
M"L%R87?=&98PC[&^9=VTT ?67[?7[8OC3]GO]N;]DOP%X;N-/C\/_&'Q)JVE
M^(TN+42RR0V]I'+$(F_Y9MO8\U]?5^*WQN_:%_:1^-__  5E_8?C^//[/6G_
M  /M-.\7:P^CSVWC.Q\0_P!JN^GKYR%;=F\K8%0Y;[WF>U?46KZM=#_@Z1TN
MQ^U7'V/_ (9F:?[/YC>3O_X2:5=^S[N[;QF@#]!Z*\?_ &_YY+7]@[XV30N\
M<D7@+771T.&5AI\Y!!K\R_B1XDU"/_@S8MM26^O!J/\ P@6FO]J\]O.W?VO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\)_\&_/[1OCG]I[]BWQ3X@\?>)M2\5:S9_$37M*AN[UE
M9X[6"6,11+M'W54G%?=E?F__ ,&OG_*/WQI_V57Q+_Z.BH ^V/$?[7?PI\%_
M#:;QGK'Q,^'^E>$+>Z:PEUR[\0VD.G1W*G!@:X:3R_-!XV;MU;'P@^.O@K]H
M/P<OB+P'XP\,^-M :0Q+J6A:G#J5IO4 E/-B9EW#<ORYS\U?CM_P;L?\$R/
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MAO\ 4IRJ[=[WDJM<E^OS>9W.,9K=_P""?G_!-SP[_P $W8?'&B^!?%7C"[\
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M\>>4E1\?+0!^C\4JSQ*R,K*PR".AI]%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9=C_ ,C3J7_7&#_VI6I678_\C3J7
M_7&#_P!J5J4 %>!_\%,?VU]+_P""=_[$'Q ^+&HF"2?PWIKC2K69OEU#4I?W
M5I;_ -[:T[INV_=0.W\->^5^6?[>V@6?_!7+_@L-X#_9EN8%U;X/_L_VB_$+
MXEQ!CY&HZG*FS3M-D(_Z9RJ[+_%'/..J4 ?-.O\ ["'AOPO_ ,$/M-\8VOQ(
M\(R?M:Z#KW_"_9=5;6[-]2F\0$K=363#?N9OLP5/*7Y6N80W\6*_7S_@G_\
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M[!GQ#\ ?MK?"_2/[5\0^ [2X\#^,-.7<JZUH]_E;(S;5.5M]0:)AW+3I_=H
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M-JWQ,^'?CW2_&7AFX30_#]IJD5QJU]J+1;K,):*?/AEBN?)9F>-?(9=S[=M
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M\0>+OA=)X$@^*'@%]?NS?:CX?M6O4L+G3_M#'<\'G[F16^ZJ?WF9F^KO^"9
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M_BY\0OB9HEUX2\+^&/!NKPZYJ-]?7\+6T6^*W9VB5#-O;S-I;9L7+LJUP/\
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M1GZE5,LC*.BEW_O&C5]'M=:ACCO+6WO(X9H[A%FB$@CDC<.C@'HRLJLK?PD
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M,T<_V?XK\'>.M6@\/W^CZA&-LL:)=NADBSRK+SM*[E5LJ/%9?C99_P#!:?\
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M)[+PEXAOK22T3Q=+]CE^VWELCA7:U5O)B1V7:S12,&/W5_33XB_L'? _XO\
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MURTK,5&SRP59ANVU\J_\&]GQ5\6?'']L[]N3Q=XV\*ZEX'\0>(/&&B7;Z!J
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M 4=37P3XE\/Z@_@;_@CR%L;PG3;71Q=X@;_1?^*<LU^?CY/FXYK]A** ./\
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M^534 %4M6TFUUG3+BSO+:"[L[N)H9K>:,/'.C#:R,I^5E8<8-7:* /G[0O\
M@EA^S3X4\>Q>*-+_ &?_ (.6&O0NLT5Y;^#["-[>56#+*@6+:C[ESO7#=>>3
M7T#110!YE^T'^QW\)_VK;2SM_B=\-O _CY-/W"S;7M#M]0DL\G+>4\J,T>[
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M3TU&P>9%62,'*O%(JDA98W5T==S;61AFN<\:_MO^#? W[9O@OX"M'KFI>/\
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M]ICPWX#\)^&?!7AVW^'7AR6+2M!TN'3;.)W*L[+#"BHK,W);'-?IQ0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>&)-\BPP1-*^%[MM4\5^*7_!7C]JWXZ?&W1_AM\8]#_8[^,GPZ\;?LX>(/\
MA,+;Q'J<UK+:+I<:;K^SG$+[_(EC1"^-WRQL.C-7ZC>-/C7H?[7_ /P3&\2>
M//!TOV[1OB!\.;_4--^;,@$^GRMY3[>CHQ*,O9E84 >B_LP_M&>&_P!KGX ^
M%?B5X/DO)O#/C"R6_P!.>[@,$S1$D?.A^Z?E-8'Q%_;2\#_"_P#:S^'?P7U:
MXU)/''Q/LM0O]#ABM&>VDBLHFEG\R7^!MJMM_O5XO_P;^W:7O_!&K]GV2/.U
M?#*QG/JL\JG_ ,>%>4?MJ6SW'_!Q]^Q6T:Y6'PGXQ>3V'V"5?_0B* /:_P!L
MK_@L1\+?V,OC+;_#F]T;XE?$3QZU@-6O= \!>&Y=<O-'LF;"W%R%*K$AY;&X
MMM7.W#+NW=$_X*G_  K\<?L<Q?'+P>WB[QUX-:[73I;3P[X>NM0UBVN=X1X9
M;)5\U'B9AOW+\J_-RI5C\X?M.>$?C+_P3._X*'_$O]ICP'\-;SXW_"WXR:9I
M$'CS0]$9?^$J\,RZ7;_98KJQB;_CZ@:+YFA7YF=B3L5=U?9G[&7[4GP[_;)_
M9]T7XA_"W4(-0\)>(&FFCV6_V::WN/-9KB*:/JDZRE]^>K-NRV[<0#\U_P#@
MVP_;T\+I\+_$?PU?PM\3%U3Q-\1_%&M0:H?"ET-%M(<-=;+B\QY4,VR$KY;-
MG>R+U:OI+0/^#A7X"_$CPIX.O_ MA\4OB5J/C,/-#HGA/PI-J.J:7;K>R6?V
MB]C#!;:-IHWV[WW,J[@O2N-_X-T?^4?GQ8_[*KXN_P#1ZUR__!HM\&M)^'O_
M  2'T?Q-9V,,.K?$#Q#J>HZC=",>;=""X:SB4M]XHBVYPO16=_[S4 ?9/[;G
M_!2KX/\ _!/7P[I-U\3/$C6.K>()5@T?P_I]NVH:UK#[L8M[2+=(ZJ6P7^XI
MVKNW,H/CGP%_X+Z?!+XQ?&#1_ ?B/1_BK\&_$GB:X%GH47Q'\*RZ%#K4[/M2
M*&;<\>]_EVK(R;MRJ/F.VO-_^"6WP[TO]IS_ (*B_M;_ !S\<6ZZQX\^'/CR
M;X9>$H[_ />-X7TBSAQOMD^[%]J\UFW_ 'F_>_-^]?=]N?M>_LH^#?VV/V?/
M$OPW\>:7;ZGH'B*T>$M)&K2V$VT^5=0LWW)XF.]''W66@#XG_P""HW[8O@O]
MO;_@W1^,7Q2^'L^H7/A/Q%H<L=G)?6IM9V,&J1V\FY&Z?/$]=E\2] _9UUIO
MV'V^,GA>37/B!)]AC^&=VBW!73]2CLK6=FD,3JA3=%"X\U77=$IQ7PS\ [?[
M+_P92^*(MRR>7IFLIOC;<KX\32\J?[M?17[:_P#R6O\ X)9_]C!%_P"F:VH
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M$G[,=N\?_!I7^T5(R_)<:EXF>,_WE_M%%S_WTIKZO\?_ +2W_!1WXU?#6Z\
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MO\7M'C=/^%=:9X4\164-PDGV6XALXHV:*1=R^9%*@='&?F16KYW^!%W^W?\
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M** "BBB@ HHHH **** "L_Q3_P BWJ'_ %[2?^@-6A6?XI_Y%O4/^O:3_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/G/4_P!@&S\3_P#!2[3_ -H_Q!XGNM8N/"_A)_"OA7PZ]DL=MX?:>3=<WJR[
M]SSRJSQ9VK^[?;\VT5]&444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6'X_\ #UYXH\!ZUI>FZK<:'J&I6$]K:ZE @>73Y71@
MDR \%D8A@/\ 9K<HH ^*/^"=/_!)OQ+^Q5^T[X^^+'C;XY^(_C3XL\?:-::+
M<W6L:-'8S0Q6S[HSO25]WR_+C K[7HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS4>W7\J_'_,/JLO^?C_#_(\K_M[XT?\ 0N?#?_PH+W_Y#H_M[XT?]"Y\-_\
MPH+W_P"0Z]4^:CYJ/;K^5?C_ )A]5E_S\?X?Y'E?]O?&C_H7/AO_ .%!>_\
MR'1_;WQH_P"A<^&__A07O_R'7JGS4?-1[=?RK\?\P^JR_P"?C_#_ "/*_P"W
MOC1_T+GPW_\ "@O?_D.C^WOC1_T+GPW_ /"@O?\ Y#KU3YJ/FH]NOY5^/^8?
M59?\_'^'^1Y7_;WQH_Z%SX;_ /A07O\ \AT?V]\:/^A<^&__ (4%[_\ (=>J
M?-1\U'MU_*OQ_P P^JR_Y^/\/\CRO^WOC1_T+GPW_P#"@O?_ )#H_M[XT?\
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M+GPW_P#"@O?_ )#KU3YJ/FH]NOY5^/\ F'U67_/Q_A_D>5_V]\:/^A<^&_\
MX4%[_P#(=']O?&C_ *%SX;_^%!>__(=>J?-1\U'MU_*OQ_S#ZK+_ )^/\/\
M(\K_ +>^-'_0N?#?_P *"]_^0Z/[>^-'_0N?#?\ \*"]_P#D.O5/FH^:CVZ_
ME7X_YA]5E_S\?X?Y'E?]O?&C_H7/AO\ ^%!>_P#R'1_;WQH_Z%SX;_\ A07O
M_P AUZI\U'S4>W7\J_'_ ##ZK+_GX_P_R/*_[>^-'_0N?#?_ ,*"]_\ D.C^
MWOC1_P!"Y\-__"@O?_D.O5/FH^:CVZ_E7X_YA]5E_P _'^'^1Y7_ &]\:/\
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M%SX;_P#A07O_ ,AT?V]\:/\ H7/AO_X4%[_\AUZI\U'S4>W7\J_'_,/JLO\
MGX_P_P CRO\ M[XT?]"Y\-__  H+W_Y#H_M[XT?]"Y\-_P#PH+W_ .0Z]4^:
MCYJ/;K^5?C_F'U67_/Q_A_D>5_V]\:/^A<^&_P#X4%[_ /(=']O?&C_H7/AO
M_P"%!>__ "'7JGS4?-1[=?RK\?\ ,/JLO^?C_#_(\K_M[XT?]"Y\-_\ PH+W
M_P"0Z/[>^-'_ $+GPW_\*"]_^0Z]4^:CYJ/;K^5?C_F'U67_ #\?X?Y'E?\
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MP^JR_P"?C_#_ "/*_P"WOC1_T+GPW_\ "@O?_D.C^WOC1_T+GPW_ /"@O?\
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MU_*OQ_S#ZK+_ )^/\/\ (\K_ +>^-'_0N?#?_P *"]_^0Z/[>^-'_0N?#?\
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MOQ_S#ZK+_GX_P_R/*_[>^-'_ $+GPW_\*"]_^0Z/[>^-'_0N?#?_ ,*"]_\
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MS4>W7\J_'_,/JLO^?C_#_(\K_M[XT?\ 0N?#?_PH+W_Y#H_M[XT?]"Y\-_\
MPH+W_P"0Z]4^:CYJ/;K^5?C_ )A]5E_S\?X?Y'E?]O?&C_H7/AO_ .%!>_\
MR'1_;WQH_P"A<^&__A07O_R'7JGS4?-1[=?RK\?\P^JR_P"?C_#_ "/*_P"W
MOC1_T+GPW_\ "@O?_D.C^WOC1_T+GPW_ /"@O?\ Y#KU3YJ/FH]NOY5^/^8?
M59?\_'^'^1Y7_;WQH_Z%SX;_ /A07O\ \AT?V]\:/^A<^&__ (4%[_\ (=>J
M?-1\U'MU_*OQ_P P^JR_Y^/\/\CRO^WOC1_T+GPW_P#"@O?_ )#H_M[XT?\
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M+GPW_P#"@O?_ )#KU3YJ/FH]NOY5^/\ F'U67_/Q_A_D>5_V]\:/^A<^&_\
MX4%[_P#(=']O?&C_ *%SX;_^%!>__(=>J?-1\U'MU_*OQ_S#ZK+_ )^/\/\
M(\K_ +>^-'_0N?#?_P *"]_^0Z/[>^-'_0N?#?\ \*"]_P#D.O5/FH^:CVZ_
ME7X_YA]5E_S\?X?Y'E?]O?&C_H7/AO\ ^%!>_P#R'1_;WQH_Z%SX;_\ A07O
M_P AUZI\U'S4>W7\J_'_ ##ZK+_GX_P_R/*_[>^-'_0N?#?_ ,*"]_\ D.C^
MWOC1_P!"Y\-__"@O?_D.O5/FH^:CVZ_E7X_YA]5E_P _'^'^1Y7_ &]\:/\
MH7/AO_X4%[_\AT?V]\:/^A<^&_\ X4%[_P#(=>J?-1\U'MU_*OQ_S#ZK+_GX
M_P /\CRO^WOC1_T+GPW_ /"@O?\ Y#H_M[XT?]"Y\-__  H+W_Y#KU3YJ/FH
M]NOY5^/^8?59?\_'^'^1Y7_;WQH_Z%SX;_\ A07O_P AT?V]\:/^A<^&_P#X
M4%[_ /(=>J?-1\U'MU_*OQ_S#ZK+_GX_P_R/(H+[XSP:G<7'_"/?#<_:$1,?
MV]>\;=W_ $Y^]6?[>^-'_0N?#?\ \*"]_P#D.O5/FH^:CZPOY5^/^8?59?\
M/Q_A_D>5_P!O?&C_ *%SX;_^%!>__(=']O?&C_H7/AO_ .%!>_\ R'7JGS4?
M-1[=?RK\?\P^JR_Y^/\ #_(\K_M[XT?]"Y\-_P#PH+W_ .0Z/[>^-'_0N?#?
M_P *"]_^0Z]4^:CYJ/;K^5?C_F'U67_/Q_A_D>5_V]\:/^A<^&__ (4%[_\
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M<4U<FG5SRES.]K'33ARJU[A11106%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .=^(^H:]I?@;5KCPSI]CJGB"&V=M/M;RY-O;W$V/E5W
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M3R/K7P7X]T/XBZ.VH:#K&EZU9QR&%Y["Z2XB5P%)0LA(W ,#CW%<QXM_:O\
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M/YKH>IE>8+%TG);IV=G=7\GU1\+_ !QT3QQ^T#_P4\U3X<Z3\4O&G@/0M/\
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MK?X6>,O$"Z3I/Q'\"ZEJ4C"..TM->M99I&)QA55]Q.?2O1MV5[?7->%^-_\
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M_2--T'3XI&@""!OD:1C&=S,OS8W8!-:?[?/[ OA7P_\  /Q=XT^%^EV/P_\
M%GA_0[UY6T.W6SM=6L?);[5:30(/+</%OVG;N#A3NJOJ.%C66$J5&I7LW;1/
MMW^?X">98QT/KE.FG"UTK^\UW[>=OQ/L/1=;L_$>EV]]I]Y;:A97<8EAGMI1
M+#,IZ,KKPR^XKE/B#^T=\/\ X3ZG#8^*/''A/PW?7 W16^IZM;VLLB^JH[@X
M]Z^8KC]H/4_V:/\ @CAX-\2:&JMX@;POI=AI>X!E6YN%CB5\'KL#%\=RHKO/
MV>/^"97PY^''@R&3QEX=TGXB>-=45;K7-<\16R:I->7;<NR><'V+N)QCYB,;
MBQYK*I@*5*,IUI.W,XJV[MN_+H:QS*OB)1IX>*ORJ3OLK[+S>Y[L/B?X9_LK
M3=2_X2#0_L&M3I:6%S]OB\F^F?.R*)]V)';!PJY)VFNA!";BQ'N:_.S]N;]C
M[3?V<OBY\%]8\#-+H7@WQ!\3=&.J>'(G+6,>HB1O)NX4/^J)B\]'"X5OW?R_
M+7?_ /!6K]H*/PS?_#WX6W'B'4/">@^/KJ:;Q/J^GPRSW5OID"KO@1(D>3,Y
M8KN5>-AS\I:M8Y/"K.DL/*ZG?IJK;Z=_3<PEGDZ,*SQ,.5T[+?1WVU[>NQ]%
MW?[8'PHM?$W]CS?$SP''J@?RC:/KUJLP?.-FW?G=S]WK7I%NRS1AHV5E894C
MH:^ ]+\;?L)Z7X'30%\.Z-):+%Y7GS>!]5EOFXQDW+6IGW?[6_-:G_!+/XTV
M5A\:_'?PI\+ZUK'B;X;:7;)K7A*^U*WNH9]/A9D2>R/VB-'*I)(NW/HQ_B^6
ML1E/+2E4IQDN7^:-KKR_R%A<[;KPI5'%\W\LKV?FNWG^!]UD\5\??%+Q!XX_
M;-_:W\3?"WPIXOUKX?\ @+X;06S>)=5T:01:IJ=Y<IYD<$$W_+)%3.6'1D((
M(9:^P'X/XU1L- L=)O;JXM;.TMKB]??<21Q+&T[?WG(^\?<UYF%KJBY2M=VT
M\GW^[_,];'866(48<UHWU\UVOZVO]Q\/_'#P-XV_X)?PZ9\2/#_Q'\<^._A_
M;WUO9^*- \5W_P#:+QV\TOE_:+:7:/+979?E 7+,,L5^6ONR)UEA5EY5AD$&
MOBS]JKQ;)_P4)^.EO\!_"):Y\&^&-0AU#XBZW%S!$L3[DTV-_P"*9G7YMOW6
M3_8=:^U43:FW;P!ZUVYE*]*FZW\1WOZ:6OY[_*QY^4I*M55'^$K)>NO-;RV\
MKW,OQ+XSTKP99PW.KZGI^EV\\JP12W=PD*22M]V-2Y&6;L.O%<UXU_:6^'?P
MV\1QZ/XA\=>$-#U:8+LLK_6+>WN&W?=PCN&Y^E?-O_!;^2^B_90\/OI3^5JB
M^,M.-HWR_+-MFV'YOE^]CK7H/@[_ ()D_"/2_AG)I/B'PGI?C#6=2BWZMX@U
M6W\_5-0N7'[VX^T-F2-F8EL(R[:F."P\</#$UI/WFU9>5M?Q*K8_%2Q53"X>
M"]Q)W;[WTT]#W'Q5XYT7P3X=FUC6M8TO2-)M5\R6^O;I(+>)?5I'(4#\:S/A
MG\;?!OQEM;B;PCXJ\/\ B>&U;9.VEZA%>>0QZ!O+9MI^M?"/_!.O]FE?CSKG
MBSP_\1KZ?QIX$^!NOWOA?POHNH(LEJ\JSN7N+A/^6S)'L1!(NU5=@%KN?C]\
M%/#'['O[;_P-\6_#[2K/PD/&>KS>&=;T_38Q;65_#*@V%H4 0%6.[( RRIZ5
MU3RFA"M+"^T;G9M::;7MWV^YG)3SC$SHQQ?LTJ;:3UUWM?MH_O6OD?;LMS';
MP-)(RI&BY9F;  ]:\_TO]J_X7^(O%:Z#8_$;P/>:U*XCCL8-<MI)Y)&SA%17
MRS<=!S^=> ?M=P:E^UK^V1X<^ L>JW>F>"K/0F\6^+OL5PT,VJ0^=Y$=DS+T
M1F(9E/WE?/!1:]/UC_@F[\"]9\$MH,GPQ\)06OE>4MS;6"0WJ#U%RO[[=_M%
M\UQK"X>G"+KR?-+71;+SO^7XG=]>Q5:I)8:*M%VNV]7Y67X_@>P67B[2]4UZ
M]TFUU+3[C5--"-=V<=PC3VH<90N@.Y-PZ9'-?)_B_P#:PT.V_P""FOAFTC^(
MVFP^"E\%79O8!KZ+I?VQ;HA?,7S/*\\+_>^;:*YO_@FQ\.=<^$G[=GQ_\,^(
M-:N_$5UHMIHEM:ZC=-NGNK,12?9O,;^*18?*1F_B9&I_C;]F7X;'_@JSX4T'
M_A7W@G^P[[P)>7]QIYT.U^RSW O"/.>/9M+X_C(S7I4L#0H8B=.;YE[/F37G
M&_\ PQYE;,,3B<-2JP7*_:6:?E*W3\3[*T_XA:!JFM6FGVNMZ3<7]]9+J-O;
MQW<;RW%LW"W"(IRT1_OCY:U[JY2RMWDD=(XXUW.[':J@=237R$=$M?#O_!9C
MP[86-I;V-A8_"$6]K;V\8BBMXTU*10B(ORA57:%5?NCVKZD^*W'PP\1?]@RY
M_P#135X];"JFZ:3^))_>>YA<<ZD:DFO@;7W$$GQ8\+IX1M]?/B+0_P"PKA_+
MAU W\0M97W%=JR[MC'<K#KU6H8OC7X/D^(J^$5\4>'6\5,ID71QJ4/V\J%W$
M^3NWXV\YV].:_-/XA220_P#! +P%):LPNEUA#&1][?\ VG<[?_'J^\/@3^RA
MX$_98\&QZQ'H^FW7B:QLI)M5\37-LLNK:C*R[[F5[E_WC>8P+$;MM=V*RNEA
MX.3FV^>4$O\ #;7\3S<'FU?$U8QC%*/)&;=_YKZ?@>A_$/XN>%?A)IB7GBKQ
M)H/AJSE;:D^J7\5I&[>@:1@"?:H?AK\;/!_QDLI;GPGXI\/>)(8-HE?3-0BN
MA#GH'V,=I]C7YN?LY?'[X%?'?Q3KGQ4^/^H7&O>+M:OIH](T*^T#4M3TSPYI
MR.RPP(B6[P2,WWF;YO\ @+&3=8_:D^*O[/\ X5MK7Q_\ [Z;PC\4O#%Q'-9V
MVD^&-3TZQUN$.OG6LT?V98=K)N_N[BNTM_=['P^U/V$E/F[\ONW]>WG^!QKB
M:]/ZQ%PY.W-[UO3OY?*]S]12N!6?XB\1:?X1T>XU'5+ZTTW3[5=\US=3+##"
M.F6=CM7\ZSOA7XX3XF_#/P[XDC@DM8_$&F6VI)$YRT0FB638?<;L5X]_P5/_
M .4?WQ-_[!B?^CHZ\'#X?VF(C0EI=I?B?1XK%>RPLL1'6R;_  N>H^/_ (^>
M!_A3I]I=>*/&'A?P_;WZ[[9]1U2"V6Z'7,>]AO\ ^ YK4\"_$CP_\4-%_M+P
MWKFDZ]I^[:+K3KN.ZASC.-Z$CH0?Q%?,W[&W[ /A/5OA!H/B_P")^CZ;\1?'
M7B;3+:YO+K7;5+V&QA,8:&TMX9 4BCB0JORK\S!F_NJO)?M:_!?2_P#@GKXD
MT3XX?#&WB\+Z3;ZM:Z?XR\.V9:#2]3L9G\KS1"OR1RQLZ[=JX^8-V;?Z$<#A
MIU?JM&;<]EIHWVWOZ/\ !'E?VEC(48XNM32ANU?5+OVTZK\6?96I>--'TK7;
M;2[K5M.M]3O(WFAM);I(YYT3EW1"=S*O<CI6?X ^,GA+XLO?KX7\4:!XB;2Y
M!%>#2]0BO/LCG.T/Y;-M8[3P?[I]*^,?^"@?PI7X[_\ !2KX&^$YKR[L=,US
M1]034_LTQB>XLT5Y9K?*D,%E1&B;;_#(U>Q?M6:_X?\ ^">?[&_C#7?AWX7\
M/^']080VUC!IUA';K/>2ND$<KJB_O&0-O^;.[9CO4O+8<M&,&W.ILNBU:U''
M-ZG/6G**5.E>[ZO1/1?,]>^(7[0_@'X27<=OXJ\;>%?#EU)C;%J>K6]K(0>A
MVNX.*Z3PWXKTSQGI,>I:/J.GZII]P,Q75G<)/#)]&0D'\*^=?V>_^"9GP_\
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MIB5CNK*X2XA<J<'#H2.#2>)_&>D^";*.YUK4].TFWFD6"*6\N4@1Y&^Z@9R
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ME.]3=Z^ZWWM:_P K_P"1Q?V5BXT'A*=5*GLM/>2[7O;YVV/E+PY^SHW[5/\
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M1A0HK[5T#6;?Q)H=IJ%G)YUG?PI/#)M*^8CJ&5L'D<'O41\#:+G_ )!.E_\
M@*G^%:2QB"/:JA57@#TIXVM1JSYZ:E=[W:?Y)!EV%Q%"'LZKC9;<J:M][9\E
M_P#!89-OP+\"^@^(&C#_ ,>EKZV',?X5!?:=!J$:K<0QS*IW .@8*?7FK1Z5
M%3$\U"%&WPW_ !M_D:4L'R8BI6O\=OPO_F?)7_!*D?/^T!_V5S6__:--_P""
MDH_XOS^S/_V/\6/?Y17U99:?#8F3[/#%")GWOL4+N8]2?4T7&GP7DD330Q32
M6[;XV= Q0^H]*Z/[0OBGB+?+Y6.7^R_]C6$YNVOSN?)W[8N@^(OV;/VJ?#G[
M06@Z/J'B+P[;Z*_AGQCIUA!YEU!8^:TZ7B+U?8^-W]U8Q_"S,O3WO_!6#X#V
M_A,:G9^.+?5IY$5K?3;*TN)+^Z=L[(DAV!M['C#!>>N*^DF /^[6#IWPU\.Z
M3XA;5;7P_H]OJ3##7D=G&DS=?XP-W<_G1'&8><(K$0;<=+IVNNST?WDRP&)I
M5)/"U$HRU::O9]UJON[GQO\ \$X?&'BGXC_MT?'W7/&&B/X9UC5K+0[H:3(V
MZ6PMS#)Y$<G_ $T\GR]P_O%LJOW:[KQN"/\ @L5X)_[)S>_^EAKZCM]-M[>Z
MDG6*)9IL!Y%0*SXZ9/>G'38&O5N6AB,ZKL678-X7TSZ5I4S-3K2K1C:\.6W;
MW;$X?)Y0P\:,IW:GSW[^]<^2/VV]9NOV7_VM/A_\<KC2=0U/P7:Z1<^%O$\U
ME#YTNDP22B6"X9!\Q3S"=V/3'WF56D^/W_!5#X4ZC\)[_2_ >N'QYXR\36SZ
M=H>C:7:S//<W,P*)OR@\M0S MN^; .%8\5];/;K)&RLNY6&"*PO#7PN\,^$-
M3DO-)\.Z+IEY<<27%K8QPR2=/O,J@GH/RJ:6-PW+#V\&Y0[.R?773\N@JV78
MI3J?5II1J:NZNT[6=M5^/4^$OVM?@7>?LY?\$BO /@O4O*;4-)U?2Q?(C>9&
M)Y;III4#=U5Y"N?:OT$O+&+5=.EM[B-7@N(VCE1NC*PP13[ZPM]1A\NXABGC
MSG;(@9<_C5A3D5CB<PE6BE):\TI?^!6_R.G!Y9"A-N+T<8QM_AO_ )GPQ^RW
M\?M-_P"";EK<?!;XN27?A_2=*OKF7PCXGN+=Y-/URQEF:4(TB!MDR-*=RM\H
MW*./EW=E\1/^"D]E\3O$=AX+_9^AM_B%XTU"ZA$]Z;*9M%T*VWKYEQ<R?)N7
M;D (W4_>SM5OJG5]"L_$&GM:7UG:WUO(,-%/$)(V^JM5?PWX.TGP7I_V72--
MT_2[;M%9VR0(/P0"NB6.P\Y.M4IMS?G[K?>UK_*YRT\KQ-."H4JB5-;:>\EV
MO>WSM_F7[42"W3S"K2;?F*C S["O _\ @JAQ_P $_?B9_P!@U?\ T=%7T$!M
M_"O$_P#@HIX!UGXH_L6^/M \/V$^J:QJ>GB.UM81F29O-0X'X URY?*,<73D
M_P"9?F=V:0E+!58QWY7^1Y#^RQ_P42T'X7?##P_X.^-<C?#SQ=H>EVT<$NH1
MO]AU^T$2K'=P3*&1MRXW+NW*V?\ :"\[\?/C+#_P4Z\<:'\*OABMQK/P_LM5
MM]2\:>*OL[QV$<4#>8MC&74>9([!?N_['WEWE?K3P=\.K#6/@WX9TCQ%HMC?
M_9-,MHI;6_MDG6-UA56&U@1D<BNJTK2+70K".UL[2WL[>%<+%!&J(H]E6NYX
M_#TZTJ]*G:IK;71/NE:_IJ>7#+<74P\</6JWIZ7T]YKLW>WJ[?<?*OQP3_C;
MK\#01G;X:U@C_OU)7JW[=?[.TO[4G[+?BKP;9W"6NJWL4=QIT[#A+F"59H@3
M_"K,@0GLKL:]8?38)KR.X:*-IXUVI(5&Y0?0U9SG\JXY9A+GI3AHZ:_)M_J>
MA#+8<E:G/55&_P 4E^A\G_!+_@J/X-MO#"Z+\7KH_"_XD:&JV^L:3J]O)"DK
MJ/\ CX@?;M>&3[R\\>Z[6;E;[XB2?\%+_P!IKP+_ ,(=9WC?!WX7:Q'XCO?$
MEQ:O##K>JP?\>]O;"0!F$;.VYL=V^[\GF?8/BCP#H?C6&)-:T?2]66%MT8O+
M1)U1NN1N!Q6E!;QV4"QPQQQQQC"JHVJH]A71]=PT6ZE&G:;\]%?LK?==Z>9S
M_P!FXJI%4<153A&W2S=N[O;ULM?(^4_VK_!_BK]GO]JK1/CWX6T#4/%VD#1F
M\-^,-'TZ+?J'V/S1+'=VZ9_>,C ;E_NH.Q9ENK_P5_\ @KJUEY>@ZMXB\3>(
MI@R6_A_3_#][)J-S,/\ EDJM&$W9.W[^W_:XKJ?VIO#'Q@\->/\ 0/''PMO(
M?$%II4#VVM^"K^Z6W@UJ+=D26\K+B*X7)Y9@ORK_ +2OR5]^W/X^E:6WT?\
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MIXRA.,5B(MN.FCM=>>C^\ZY9=B*<YRPTTE-WLU>S[K5?=W/-?V<?B]X\\4_
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MZ)6OZW;^X^(_!7Q)M_\ @F5\?O'FB^.[:]L_A7\1-?G\2Z#XFBM'GM=/N[@
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MOQ>NC\+_ (D:&%M]8TG5[>2%)74?\?$#[=KPR?>7GCW7:S<I??$1_P#@I?\
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M"]33+#QI862Z;)IMXP^2.\A7]VJNPX9>!RV< JLG[;W[6?Q,^#W[7GPW\"^
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M\?-L) )7/J*NUY)[P4444 %%%% !1110 4444 &**** "BBB@ HHHH ****
M"BBB@ HHHH *,444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %!&:**  #%%%% !1110 48HHH **** "BBB@ HH
MHH **** "BBB@ HHHH *.E%% !1110 4$9HHH **** "BBB@ HHHH *-H':B
MB@ HHHH **** "CK110 8S1110 8HQ110 =:*** "BBB@ HHHH **** "BBB
M@ Q1BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !11
M10 4444 %%%% !1110 4444 %'2BB@ HHHH ,4444 %%%% !1110 4444 &*
M*** "BBB@ HQ110 8HQ110 4444 %%%% !1110 4444 &**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^GW(U/\ @H?\1- ^''[&'Q%F\0W5O#;:EH5YIEO%*X5KNXGA>..)!U+,Q[=
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MMM?-)'$?\$_-/ATS]B'X3QPKM5O"^GRD?[3P([?JQKRKX=$R?\%D/B,O\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #K1110 4444 %%
M%% !1110 8HHHH **** #%%%% !1110 4444 %%%% !1BBB@ Q1110 4444
M&**** "BBB@ ZT444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** #%%%% !1110 4=:** ,3QWX&TKXD^$=0T+7+*+4=)U2%K>[M
M92?+N$;JK8_A-6?#'AJR\':!8Z3IEK#8Z;IMNEK:V\2[8X(D4*B*/[JJ *T$
MZ4/THYI?!?0CDC?GMJ.HHHH+"C%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>slide3a13.jpg
<TEXT>
begin 644 slide3a13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" .4"*H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,
MXHS0 449HH ***,T %%%% !1110 4444 %%%% !1110 4449H ***,T %%%%
M !1110 4444 %%%% !111F@ HHS1F@ HHHH **** "BBB@ HHHH **** "BC
M-% !111F@ HHS10 4444 %%%% !1110 4444 %%&:* "BBC- !11FB@ HHHH
M **** "BBB@ HHHH ***,YH **,T9H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHH/2@"-V#+@?-33\F30!G/3ZUR'QR
M^"'A[]HGX::CX/\ %5K)?:#JQB-U D[P-)Y<J2I\Z$,N'1>AJJ:BYJ-1V77K
M^&GYF-:4U3<J2O+HGIKZV=O6S]#KFGCQ_K$7_@5*MS%U$B<_[0YKY/E_X(J?
ML^I&Q'A74LJ"?^0W>8_]&5X7_P $]O\ @F+\(/CY\%=2U;Q3H-W>ZI9>(M1T
MW?%JMQ$JQ0SE47:DFW[M?14\KRR="==8B5HM+^&NM_[_ )'R=;.LYIXF&%>%
MIWFFU^]?2U_^7?F?I)'.K-PP;UP>E <,N>E?$_\ P3[^"?AW]G;]O3X^^$?"
MMK)9:'I-CH1A@>X>=D,L#ROEW9FY9R?QK[:/!KR\UP,,)6]G3ES)J,D[6^))
M[7??N>UDN95,=AO;58\DE*46D[ZQDX[V7;L244 YHKSSV HHHH **** "BBB
M@ HHHH Y#XT>-]6^&_PTU+6M#\.7GBW5+% \&DVLHBFO2752JLP., EO^ U\
M[#]OOXP ?\FP^-/_  ;P?_$5]:-RG%-9 T9^[R,5Z&!Q6'I1:K454?=N2_)H
M\?,,#BJTE/#XATUV2B_GJF?%_P /?^"I7Q ^*=A>7?A_]G7Q7JMOIUY+IUR\
M&L1$0W$6-\9_=]1N%>E_LH_MNZQ^T%\7O$G@OQ#\.]4\ ZSX<L8+^2&]ODN&
M=)6(3A5&WCFN&_X)K>-M)\"^(?C-X#U2^M=,\1:'X^U2_-E<R>7))9S[9(;A
M W5&52>,X7!.-PS)^REXFL?B_P#\%'_CAXJ\/W,>H:#INFZ5H;:A!S!<7*!V
MD1''#["K*<?J"M?38["8-K$1IX;DC"*E&5Y]7&V[MJF?&Y9CL=?"SJ8ISE.;
M4H6AT4K[)/1H^P!Q10.E%?$GZ4%%%% !1110 4444 1D9'\J^;_BU^S[^T)X
MH^(NK:AX5^/5CX7\/W4@:RTM_"-G>-9IM7Y?-<;G^;<<MZU](%,KC% ..G\Z
MZL'C)8:;G%)_XHJ7YIGGX_+:>,@H5)25OY92C^,6F?GW\5[7]J#X5?M#_#+P
M#)^T%:WLGQ*.HB.]7P?IZ"P^QPI*<IY?S[MX7[RXIW[72?M._LA_!R;QI>?'
MZU\006M[;6K6<?@_3[=G\V54SO\ +;IG^[7K_P#P42\*>)O#'BGX6_%WPMH%
MYXJNOA7JER^H:7:)ONI[&[A$4[Q+_$RA5X _BSP%->0?'S]IS_AYO#X9^%?P
M_P#!OB^.QOM9L[_Q)J^K::;6WTBTADWNN<G,IV_=R-V,#=N./OLOQ$L1'#XC
MV5/V2O[5^SAI:3WTT]VUN_34_+\SPL,-/$X7VU55FU[%>TJ:WBK6][7W^:]]
MNNA^@D#;X$8]2H-.IL*>7$J_W0!3J_-WN?KT+\JN%%%%!04444 %%%% !111
M0 W[AKQ_XS_MX_"?]GKQI_PC_C'QA::'K'D+<_9I;>=V\M]VULHC+_"W?M7K
MV,>_Z8K"U_X9^'?%=Y]JU30='U"ZV[/.N;..5R!VRPKHPLL.I_[2FX_W6D_Q
M3_(X<='%.G_L;BI?WDVOP:_,\3_X>R_L^9_Y*-I__@%=?_&J!_P5E_9\!_Y*
M-I__ (!7?_QJN _X*<?"SPWX8\._".^M="T>PM[;XFZ&;YX;*-%-N3,K*^%^
MY\PX;BNZ_;\^&G@[PS^Q1\2[Z'P]H%G-#X>N5CFCL84=)&C*IA@O!W$5]-1P
M.45%0<8U/WDK?%'35+^3S/CJN9YY2EB%*5+]TK_#+71O^?R/>O!WBC3_ !QX
M5TW6M*N%O-,U:UBO+2X4$+-#(H='&>>5(/-:HY_E7G'[(5O+I_[*WPWAF4QS
M1^%]-1U/\+"UB!%>C@X-?*UZ:IU90CLFS[;!UG5H0J3W:3'CBBBBLSI"BBB@
M HHHH **** (U/IT^E.;_/%)\P/_ ->O&/VI+'XZWFJ:6?A'>?#NWLEB?^T!
MXF%T9&?*[/*\E3QC=G=[5MAZ/MIJ',H^;V.7&8CV%)U.5R\EJSV=MV*0<&OA
M_P",_P 0?VP_@5\*]=\8:OJ'P-N-+\/VDE[<QVD6H23,B#)5590"WU(JUX3\
M6?MC^,?AMI_BBUU#X$+IVI:='J<221:BLPB>,2 $!=N=I]<9[U[*X?DZ:JJM
M3LW;=[_<?.OBR"J.E]7J\R7-;EZ=]S[7Q@TBGCCM7C?[ GQPUK]I']DOPCXT
M\1+9KK&M)<M<+:1-'"/+N9HEVAF8CY4'5J]D3Y1BO&Q6'GAZTJ%3>+:?JM#Z
M+ XJ&*P\,33VFDUZ-7)****Q.H**** "BBB@ H-%!Z4 ?+OQO_:F^+7[,7Q3
MU:]USX;3>-/A3)(CVFJ^&F\W4M+CV+O^T6[?? 8.VY<*JXW/7J'[//[77P]_
M:?T1KSP7XFT_56C4//:9\J\M<_\ /2%\2*/]HC:>Q->F,K'.[GCH:_-GX2?L
MA_#WXX>*?C]XK\3:W>^!]<\+_$G5/L7BFQU7^S9M+3*-RY/E[-S-][GYFPR[
MJ^FP-' XW#S]K'V<X)>]'6]W;6/ZI_)GQ&98G,<MQ4/83]K"HY>[/2UE?22Z
M=E)/U1^E!("_YYH[>X_2OSG_ &4_V[OB\GQLF\"Z&K?M'>#]/D6W;Q18V;:3
M-:>HDFE @=E49&6^?M*U?HN#M'3YNM>;FV3U<OJ*G5:=]5;]4[-?-(]G(L^H
MYK1=2BG'E=G?OY-7B_5-DM% .117EGO!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ,(('2F!^*>.E<5\;_#_C#Q%\+]2LO
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M_M@?M2_LU?"C4?&?B?P'\+8M$TMH5G:"_N)'/FRI$F!YG]YQ7W-!)YL8/3<
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MV04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^R;6 $[BDMPF))-W\>/F;_GHRU]H^"/AUH?PS\.6^D^'M)T_1-+M5VQ6ME
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M)_9Q\8>,-)^,GQTNM2\.:7->P0W?BK?#*ZK\H<"(,5]@16A\-_\ @F[#XP^
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M^E>)G%2G4QU:=+X7.5O2[L?39!3J4\LP\*JM)0C>^][*]R2B@45YY[ 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^/4>EWUOXJE^R^'/&FEQ^3:7\_ 6"YCP!'*Q( VA1N8#:PRX^N-^4^M?,O\
MP5X\-V.L_L&^,KZ\D$-UH+6FHV$ZG;);7*7,00H?X68,4_X&:]Z^%FMW/B;X
M;^'M2O%VW5]IUO/./1VC4G]37-F,:=?"T\=3BHMMQDEHKI)W2Z73U6UUYGH9
M34K8?&U<MJS<U%*46]79MJS?6S6C>MGKL=(.E% HKPSZ8**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJE:I&M[6J[<\TM.MHQW5EKI=M-W>Y,****\(^J"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX4W3<;7BU:W:W1KT;1*.E%%%<![ 4444 %%%% !1110 4444 %%%% !1110
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M_P"(Y9%_S[J?='_Y(_=;\J/RK\*?^'P?[1O_ $4B3_P1Z;_\C4?\/@_VC/\
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M_P"!2_\ D0_XCED7_/NI]T?_ )(_=;\J/RK\*?\ A\'^T;_T4B3_ ,$>F_\
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M"'.?YZ?_ (%+_P"1#_B.61?\^ZGW1_\ DC]UORH_*OPI_P"'P?[1O_12)/\
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M\^ZGW1_^2/W6_*C\J_"G_A\'^T9_T4B3_P $>F__ "-1_P /@_VC?^BD2?\
M@CTW_P"1J/\ B$.<_P ]/_P*7_R(?\1RR+_GW4^Z/_R1^ZWY4?E7X4_\/@_V
MC/\ HI$G_@CTW_Y&H_X?!_M&?]%(D_\ !'IO_P C4?\ $(<Y_GI_^!2_^1#_
M (CED7_/NI]T?_DC]UORH_*OPI_X?!_M&_\ 12)/_!'IO_R-1_P^#_:,_P"B
MD2?^"/3?_D:C_B$.<_ST_P#P*7_R(?\ $<LB_P"?=3[H_P#R1^ZWY4?E7X4_
M\/@_VC?^BD2?^"/3?_D:C_A\'^T;_P!%(D_\$>F__(U'_$(<Y_GI_P#@4O\
MY$/^(Y9%_P ^ZGW1_P#DC]UORH_*OPI_X?!_M&?]%(D_\$>F_P#R-1_P^#_:
M,_Z*1)_X(]-_^1J/^(0YS_/3_P# I?\ R(?\1RR+_GW4^Z/_ ,D?NM^5'Y5^
M%/\ P^#_ &C/^BD2?^"/3?\ Y&H_X?!_M&_]%(D_\$>F_P#R-1_Q"'.?YZ?_
M (%+_P"1#_B.61?\^ZGW1_\ DC]UORH_*OPI_P"'P?[1G_12)/\ P1Z;_P#(
MU'_#X/\ :,_Z*1)_X(]-_P#D:C_B$.<_ST__  *7_P B'_$<LB_Y]U/NC_\
M)'[K?E1^5?A3_P /@_VC/^BD2?\ @CTW_P"1J/\ A\'^T;_T4B3_ ,$>F_\
MR-1_Q"'.?YZ?_@4O_D0_XCED7_/NI]T?_DC]UORH_*OPI_X?!_M&?]%(D_\
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M_P# I?\ R(?\1RR+_GW4^Z/_ ,D?NM^5'Y5^%/\ P^#_ &C/^BD2?^"/3?\
MY&H_X?!_M&?]%(D_\$>F_P#R-1_Q"'.?YZ?_ (%+_P"1#_B.61?\^ZGW1_\
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M_P"(Y9%_S[J?='_Y(_=;\J/RK\*?^'P?[1O_ $4B3_P1Z;_\C4?\/@_VC/\
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M_P"!2_\ D0_XCED7_/NI]T?_ )(_=;\J/RK\*?\ A\'^T9_T4B3_ ,$>F_\
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M (?!_M&?]%(D_P#!'IO_ ,C4?\/@_P!HS_HI$G_@CTW_ .1J/^(0YS_/3_\
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M (?!_M&?]%(D_P#!'IO_ ,C4?\/@_P!HS_HI$G_@CTW_ .1J/^(0YS_/3_\
M I?_ "(?\1RR+_GW4^Z/_P D?NM^5'Y5^%/_  ^#_:,_Z*1)_P""/3?_ )&H
M_P"'P?[1G_12)/\ P1Z;_P#(U'_$(<Y_GI_^!2_^1#_B.61?\^ZGW1_^2/W6
M_*C\J_"G_A\'^T9_T4B3_P $>F__ "-1_P /@_VC/^BD2?\ @CTW_P"1J/\
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M_@4O_D0_XCED7_/NI]T?_DC]UORH_*OPI_X?!_M&?]%(D_\ !'IO_P C4?\
M#X/]HS_HI$G_ ((]-_\ D:C_ (A#G/\ /3_\"E_\B'_$<LB_Y]U/NC_\D?NM
M^5'Y5^%/_#X/]HS_ **1)_X(]-_^1J/^'P?[1G_12)/_  1Z;_\ (U'_ !"'
M.?YZ?_@4O_D0_P"(Y9%_S[J?='_Y(_=;\J/RK\*?^'P?[1G_ $4B3_P1Z;_\
MC4?\/@_VC/\ HI$G_@CTW_Y&H_XA#G/\]/\ \"E_\B'_ !'+(O\ GW4^Z/\
M\D?NM^5'Y5^%/_#X/]HS_HI$G_@CTW_Y&H_X?!_M&?\ 12)/_!'IO_R-1_Q"
M'.?YZ?\ X%+_ .1#_B.61?\ /NI]T?\ Y(_=;\J/RK\*?^'P?[1G_12)/_!'
MIO\ \C4?\/@_VC/^BD2?^"/3?_D:C_B$.<_ST_\ P*7_ ,B'_$<LB_Y]U/NC
M_P#)'[K?E1^5?A3_ ,/@_P!HS_HI$G_@CTW_ .1J/^'P?[1G_12)/_!'IO\
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MY^F\/YY0SC 4\PPR:A.]K[Z-KHWV[DE%%!Z5YI[1&<(OS?2N9^+?BCPOX/\
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MQ1^%/Q"O-23X;ZMX-U*:U2,WPT-X&9%8ML\SROHV,^]>F%]Q]?QKC_AI\!/
M_P ')[J3PCX/\,^&6O@HN7TK3(+,W 7.T/Y:C=C)QGUKL"FP\?RKQ<1.G*HW
M3O;SW/J,#3K0HJ-:W-_=V_$D'%% HKG.P**** "BBB@ HHHH **** "BBB@
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M_9.\1:A^UM=_"#2O+U#7HM9FT>&;&R.58V;-P?1!$AE([ &OT%UWX+?LM_\
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M2&+/;?*Z+G_:KT'.:^6/^"QFE_;_ -B/5+B:-YM.T_5]-NM21!EFMA=1J_\
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M;A6^F]?K77>%?!FG>!]&CT_2[..TMU8N0OS,[MRSNQ^9W9N6=LLS$D\UL!<
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M[*.JLEO?\#T,HQ>,>/K87&\C<8P=XIK=ST=V]K:>I/1117B'TP4444 %%%%
M!1110 4444 %%%% !1110 T?=K\=?^"_?_)YN@_]B?:_^EE]7[%#[M?CK_P7
M[_Y/-T'_ +$^U_\ 2R^K]"\,?^1]3])?D?E?C'_R3D_\4?S/ANBBBOZB/X[/
MUD_X(S1:#<_\$Y_'R^+-H\+-JVIC5=S.J_9/L5OYW*?./DW?=^;T[5S^O?\
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MG)6LO3?^M9KX&7#_  ]5RW,)KV]><&H)WY%%WN[::[?T[?8G_!Q&=VC?"/\
MW]4_E:5Y=_P0'\0:G:_M8^(],ADN#I>H>&Y9[N$,?*+Q7%N(Y&']Y?,D4?\
M75J^TOVYOV9_AG^W?:>%(]9^)5CH*>%S<L@LKVV=IO.$60V\\;?+'3^]7E5K
MXW_9_P#^"1?PA\2OX)\16_C/Q]K47EQQOJ$=[>3R*&\M)/)VK;VZL2QX4MS]
M]@M?*9=G$*G#2R*C3E.O)M6Y797E>[?EO^9]IFF2SI\5OB*O6A##Q2=^=7=H
M)62WU>AY3^S=IUCHO_!>;Q%;V/E_9WU35Y !QF5[6220?]]EZ\&_X+!,3_P4
M7^(^>/FT[_TVVE<I^R'^U&_PA_;=\/?%#Q--/=[]7N+K69T3+.+M)4GEV+U*
M^<7VK_=K]%OVBO\ @F5X _X* ?%6W^+FD_$H6NC:U#%_:2V$<5W'>+$@3,<V
M\>2VQ44AE?!7IUKZ3%5H9#G-'$8^_L_JZI\UF_?3O;0^5P>'EQ%D5;"9=R^T
M^LNIRW2]QJU]>USS_P#X*_L6_P"":OP;]K[2\?\ @KN*N?MO:C>>%?\ @B?\
M-[;P]YB:;J&G:%#J3PC:&A:V$C,^W^],$S[M7F?_  6G_:L\'^--&\(_"7P3
M>VNJV/@^87&H7%M)YD%O+%$88K=77Y78(TF_'W<JOWMRKJ_\$W/V[?A_XX_9
M]F^ OQFDM+?298WL]-OKU]EG<V[MO$,LG_+&1'Y1]P'RC!5D7=XF'RK&4LGP
MN8>R<E3JNHX=>1O>WRN>YB<VP-7/<9EOME&56C&FI].=+:_9[?@?G1VHQQ7Z
M@:K_ ,&_7A?7=:&H:#\6+J'P[-B6.&73(KN0Q^TZRHAX_B\NO)?^"C?PU_9K
M_9^^"&E^!? LS:W\1=+N/-;4[.Z2XE(8CS/MLBC8<JOR1)M9& ;Y59M_Z%A>
M/,NQN(I8;!QG4E+>T7[GF[V/S3'>'>:8##5,7CI0IPCM>:]_RC:_XV/:/^#>
M@X^&?Q-_["%K_P"BI*_+'/%?IM_P0,\>:+X/^&_Q(75-7TO39)[^T\M;FZCA
M9P(I.FYOFK\X?A_X)U#XD^.='\.Z7&)M2UV\AL;92>#)*ZH/^ [C7'P^_8Y]
MFE6I[L?W?_I+/0XF_?\ #N44:/O2_>Z?]O(QR<5);QK+.BR-LB8C<_\ =6O7
MOVX_V8=/_9#^.MUX+LO%$7BIK:UBN)I5MO(DLW<;EAD&XKOV;6X/W77[O2O'
MP@*9W?A7W&%Q=/&8:->@[PG&Z_IGY]C,'5P6*=#$*TH.SZZ_(_4S_@OQ>WFB
M? KX9:3I<;0^&IKZ;S5A.V$21PH+=..,;'FQ_NU^69.56OU _9,_:]^%_P"W
MI^RY:_!?XS7EOIOB"Q@BM;2]NIUM_MOEC;#<03-PERJ\,I^_D\,KLH:G_!OQ
MX;L==_M&^^+5U_PC,;>8\(TJ*.X\G_KY,I0?7RMO^S7Y7PWQ#A>'L/+*\V4H
M3A*5G9M3N[W5C]?XJX9Q?$^+AF^3N-2G*,4US).FTK---KU/S%@B261?,;9&
MS+N;^ZM?J3_P7O-UX>_9V^&>EZ2OD>%SJ#(ZQ'$0:.W MUXX(V&7'^Z*^;/^
M"GNE?L]>#;?PQX8^$*+=>(O#Z&VU2_L)_.LIX_F;]])_RVN-Y^^G"AF5ONJJ
M?0'['G[8_P ,_P!MW]EV'X(_&J^M]-UJRMX[2RO[N80"]2(8AFBN'X2Z0#:V
M[[_^UO=5Z<\QE7$/!9_"A+V5*4N:#6MGISV\K7.;AW T<+]?X;JXB'M:T8\D
MT_=NM>6_G>Q^8H&[ K]4OV6KJX\7?\$+?&D?B3,UE9:3K2:<\YW92+>\.-W]
MV887_=6JNC_\$!O!6@^(FU;6_BA?W7A6$B9[=;**UD:,<_-<F1EVX[JBUP/_
M  4Y_;Y\%6'P5M?@3\'WLY?#=K'#;:C?63[K6."(J4MH7_Y:[BJL\F2I^[N8
MLVW+.LZH<25L/@LIC*3C-3E.S2@EZ]3HR/A_$<+4,5CLYE&//3E",.9-S;]+
MZ':?\$S?^40OQH_[CG_IKAK\OR:_4S_@D#/X:\5_\$^/'7@_7O$6FZ'_ ,)%
MJNHV#/-=1QS)'-96\?F!'//4_E7S[^W1_P $Y?A[^RY\$#XG\,_$=O%6H_;X
M;3['YML?D?=EL(2W&!^='#N;4,'G6-PM?F4JM3W='^9EQ+DM?'9%@,9AW%QH
MTGS:J^_;<]T_X*7C/_!(7X,GWT(?^4N:OS#(]Z_9;Q'\&O /[8__  3_ /A5
MX+USQ[IOAO\ LO2M(OW:&]MS,LD=AY?ED.W'^L/Y5\D:C_P3Q\"_#3]NSX:^
M$['QM9^)/"]Y'_;>LW=W<VZQ)%;RDF$E"%_>[%3U^>L>">(,-@L)7PE92YU*
MI/X7LE??;H;\><,XO,,7A\90<?9N%.%^9;O3;?J?2_ASX->+/V4O^"0?_".^
M$?#>K:MX\\:6>ZZ@T^U>2:WFOA^\=PH^4Q6^(]W]]%]:K?&#X.^*OVH_^"/]
MI:^+/#VJZ3\0/ -F+N.&_MVCN)9+(,A<!AEO-MMWU=O:N=_;]_X++>(O@'\?
M)_"7PWL_!NM:3I-I!]MO+Z*6Z\RY==Y6-H9T7:$:(=SNW_W:L_\ !/O_ (+#
M:[^T=\;I/!_Q*M?!>BZ;J-A,]C=644UN#<)M8QR&:5UVF/S#_#\R@=Z^1CEN
M>1PZSAT%\?M>:_O6[6[6Z'VLLUX>EB7D?UAV]G[#EM[E^]^]^I\E_P#!&LEO
M^"B/@7/>/4/_ $@N*_2?6?B)^S?X%_;OO&U6XTS3?C;=-!:?:+V&[Y,ELB0K
M%(P^SHS1.B?*0S;BO4U\.?LH?#[1?V:?^"S$.DQ:II8\-V-SJ4]A>?:D^S_9
M9K&:2%?,SC<JN$/^TIKZF^._["_P9^-'[45W\6O$GQ0MH566TO)M.BU2TAM\
M6L<2+ND8E@A\L%L8ZGD=:]+C"IA\3FL:]:4XTYT%;D6[;=HOR[H\[@:GB<)D
MTL/0C3G4IXAW4VK**BDY+7==&CY,_:G_ &>O$OPU_P""KG@V?Q_JEOX@L_'7
MBK3;^'45M_(BN;?[7%']F9.=OE*%3&YODV'=DFNV_P"#A#5M6?XK_#VQD:1=
M#CTF>:U7/R&=I0)3C^\$$7_?5>=_\%@_VS]!_:-^/WAZ'P-??;-+\!PND6K6
M[86XNW=7=H6_B1/*BVO_ !-NV_+M9OI/X>?'SX0_\%=?V>].\%?$?4+?PS\1
MM+V/$WFI;RF?&WS[1W^5T?\ CA^]QT^5'KU/]MPD<NSG%TFXTXN,TH_!?12M
MZ;[6/'Y<!C9YID6!K+FJ34XR;TFUJXWZZ[=S\H_X:_5+]IRZN/%W_!"+P[J7
MB8^=K$.GZ1-:2S,6D=OM4<:/EN2S6[-_WT:C\%?\$+_AS\(-<;Q%\1/B,=7\
M,:8PN)+::!-)MV4=IIC,WR^NW9]:\-_X*S_\%"M%_:).F_#OX?%3X'\-S"6>
M\B7RXM2G1&1!$G_/")2<?WF.=NU59O0QV;4>(\QPD,KBW&E-3G.S25NFO<\W
M+\FK\+Y5C:N;RC&5:#IPIIIMM_:TOHOZZ7^JO^":WAGP?XQ_X)0Z;I/CU8W\
M*:C=WEKJ"R3R6ZL'U%U12\;*R?.R<@K^597_  4$^*/A#_@F;^RY)\-?AQX-
MNM+_ .%A6]VEO=+(\MI 718IY7ED=Y'GV%,*?8Y^7:?-/A-XZT:V_P""$.O:
M.^K:;'J[17I%HURBW!_XF!(^3=N^[BMSP_X_T'_@IW_P3)D\/^(M<TNU^)G@
MT;+::^O(X9;B\A3]S*2[#<MQ$=CM]W>SG^$5\C++IPS*>-Q7-+#K$-3CK;RE
M;UW^X^VCFE*644L!A'".)>&BXSLK_P!Z-^EUMYZGQ'_P3W_9[_X:9_:V\(^&
MYK?SM)CNO[0U7<OR_9(/G<-_OX6+ZRK7Z5?M<_$;XK:/_P %#_AC<>%_!7BS
M5/ O@X>3JEU:6$KVUS]M&RX.5&'\J(1LO^V&6O#O^"-$?A7]FWX)_$7XM^*M
M0TZUU#RY+2UMI9T6\6VMD\R8(A;+&67"A<9)A7UK@I?^"_GQC,C%?#WPY5=W
M"FPO"2/K]JKWL_H9CG&<U/J5%3IT8N'O.RO):M>=M/D?-\-XG*\DR.E]?KNG
M4K353W%=VB_=3\KZEG_@O#^ST? '[0^D^/+.';8>-K3R[HH/E6\MP$+'^[NB
M,/\ O&-ZU?\ @WV _P"%_P#CK_L )_Z/6O3/C%\:])_X*6_\$L=2U?6;OP[I
MOQ \-SR7_P!ABG$:K<VK,2(8Y'+L);5S@9;YY,9.VO(?^""_BS2_!WQU\;3:
MIJ6GZ='+H2(C75PD*D^>G +-1]8Q-3A'$8#$Q?M*#Y'\FK?A^0G0PM/C;"YC
MA9+V6(7M%\T[W\[Z_,^=?CU_RD(\:?\ 91;[_P!.;U]C?\'#JQOKOP?61MD;
M0ZIN?^Z,V=?&?QRU*"Y_;W\87D<T+6LGC^]F6975D*G478.#]W;M^;=7UK_P
M7_\ &FD^,=3^%)TK5M-U06T&J>:+2Y2;R]QL\9VDXZ-_WS7K5:$WFF4JW_+N
M7_I"/$P]>DLFSG7>K#_TMG=?\%[6NO#_ .SM\,]+TE?L_A@Z@R2+$<1!HX +
M=>."-AEQ_NBORR)RG7IVQ7Z=?L>_MD?#/]MS]EV#X(_&J\M]-UJRMX[2RO[J
M<6XO4B&(9HKA^$ND"[6W??\ ]K>ZK>TC_@@/X+T+Q VK:U\4+Z[\+0$3/;"R
MBM9#&.?FN3(R[<=U1:X^'>(</P]AY99FL91G&3L^5OG3>ZL>EQ-PUB>)\33S
M?)YQE3E&*:YDG3:5FFG^A:_9;NY_%_\ P0M\9Q^),S6=CI.M+IKSG=F.+>\.
M-W]V8$+_ +JU7_X)3>)K[P;_ ,$K/BQK&EW+V>I:7<:S=VMPGWH94TZ%T<>X
M(!KS_P#X*=_M[>"-/^#%K\"O@[):S>&[6.&UU*^LGW6J0Q%2EM"__+7<54O)
MDJ?NY8LVW=_X)R>-]'T7_@D]\8-/O-4TVUU"X_MORK::Y1)I,Z9$!A&;)R>*
M^?QV7XF64U,95IN,:]=2C#LK]5YGT6!S3"T\ZI82E54I8?#N#FMG)+H_([/X
MOZ!IO_!8?]@:R\7:':V\?Q0\&H^^TA^^;E%!FM?]R90KQY_BV#</GK*_X+3P
M-;?L&_"&.16CDCU"R#*PP5;[!+\IKX\_X)M?MH7'[&7[0-OJ-U),?">O;+'7
MK==Q_=Y^2X _B>)F8_[K..]?9W_!>3XE>'_'?[-_@M='US2=4;_A(EFQ:7D4
MS;/LL_/RMTY6NR63XK+>(,)@DN:ASN</*ZUC\G^9Q1SK!9KPWC<>WRXEQC"I
MYV>DOFM_0_*VOT[_ .#=DXTSXM9^[YFEY_*[K\Q*_27_ ((">-](\':1\5?[
M5U;3=-^T/I@B^UW*0^80+O.-Q&>H_.ONO$B,IY!6C'^Y_P"E(_//"NM&GQ)1
MG-VTG_Z2SM-*_;&_9%_81AU_5_A9I\FK>+-4MS"\%D+Z62;YMRHT]UE8HV=5
MW;,GA3M;:*\1_P"",/C&\^)O_!1KQ-XBU+RO[0U[2=2U*Y\M=JB6:Z@D?;_L
M[B:^'M7?.L797D>>_P#Z%7UU_P $0/$6G^$OVSKJZU*^L]/M_P#A&[I/-N9E
MB3/G0<99NM>1F7"U# 9)BJU.4ZE6I#64G=Z=#V\KXPKYGG^"HSC"G2ISTC%6
M6N[/T9U?X/\ P5^"GB'QI\>='\+R:OXJ\/M?3:K=V-Q/=723(K+<JD,DOE))
MMW9VA?E)[-S^?G[)GQ^7]L/_ (+&>&_&NN6<5G#J5W<O963E9%@6"PG6W7..
M77:&W=W^[7LO[*_[:&G_  V_X*5_%SP/K6J6;^#?'VMW$UI/-,GV2&\5>#G.
MT++&-A;^)HXJ^1_VJ/ TG["W[;/]H>!]0L+C3K"_CU_PY/;SBXB2%GR('*MT
M1E>(JS;F4*W\=?-<-9/4C+$8+$\SK5:/[N;;MRM?#Y69]7Q9GU"<,-CL)RJA
M2K_O())>]%_%YW7Y]3O?^"X^IZI>?MT7=OJ#2?8K/1K-=-4ME1"P8NP';]Z9
M/^^:^0;*_FTR[@N+::2WN+=UEBEC8K)&ZG<&5OX65J_6K7#\#_\ @M!\,M%E
MN=:7PA\2-'B\OR%E1;ZU8_?CV/C[3;[OF4CD;O\ EFS,M9_PJ_X)&?"?]C/7
M[?QY\3OB!;Z[8Z%,+FUCOX4TRQ$J'=&60R.TS+A=J!N6_A.<5[&3\:83+,KC
MEN+I25>FN7DY7[WITU/#SO@7&YKFT\UP-6$L/4ES^TYU:*?=;Z?U8S_^"WT3
M:O\ L2?"O5-:CC3Q-_:ELDP;[Z^;8RM.!_P-(_Q K-_X*8<_\$A_@R?^P$/_
M "ES5\R_\%1_V](OVT_BO9PZ%'/;^#/"XDATWS04>^D?;YERZ?P@[ %5OF50
M?NLS*OWIXD^"_P /_P!L7]@+X4^#-<\?:=X<_LW2M(OW:"\@,RR1V'E^60[<
M?ZP_E7S\L+5RG"Y=5QL6K5)3:M?E3L[?\ ^CAC*.=8W-*. E%WIQ@FW;G:TO
MJ? O_!'CQ%J6A_\ !0CP3#ILEP(]42\M+R)&*K-;_9)9#O\ 51(B/_O(M>Y?
MM?6%CI?_  70\%RV_EK)>:GHLMUVS-\B+_P+RU2O7OA=X$_9I_X)1VNK^,$\
M9+XJ\5O9M!;QOJ%O>:@0WS>5;P0JNW>P7+OPO]Y5+5^<^N_M5ZSXV_; M_B]
MK$8DU-/$%MK;6\+X41V\B-';J?01Q(GS=A\U?18?VF=YIB,PPD)1I^QE33:M
MS2>OW(^:Q$J>091ALLQE2,ZOMU4:B[\D4K:^;/HS_@OUN_X;+T'=_P!"?:X_
M\"[ZO8_B=_RKY:;Q_P N=AS_ -Q:.O1?VD_V-OA[_P %;HO"_P 1/"?Q$33W
MLK%;.=X+=+O,.\R"*2(R(T,JEY/O?WNG%>1?\%2OCGX#^ _['FA_L\^"=5CU
MN]MQ:PWY2<2FRMX&67=,R<>=+*$.P=%+-\OR[OG\MQD<70R[*:49>VHU5*:Y
M7HHMWN?29E@98&OFF=5YQ]C7IM4W=/F<K6L=+\';R\\)_P#! 34KSPWN_M&;
M3]0^U20#:^U]2ECG8[>?E@W?\!45^5Q&#7W3_P $G?\ @H7X<^">A:I\*_B7
MY2^"?$4KO:WMRGFVUF\HV303CM XQ\WW59FW?*2R^N>+O^"$?@+XJ:M_;WP]
M^*#:;X;U!FF@A%FFK1JK<[8YUF3*#^'=N;_:-?19;FU'AS'XNCF<7%59N<)V
M;33Z:=CYC-,EK<49;@JV42C*5&FJ<Z=TFFNNK6C/RZ[U^@'_  ;Z-M^/_CK_
M + "?^CUJ_\ MB?LZ_LR_L=?LOZIX-.H2>*OB?>$36MU;7"2ZG#<JK*IDV_)
M!;\G=&W+[OXF567G_P#@@SXOTOP=\=/&TVK:A8Z=')H2(C74Z0JS>>G +-79
MQ!G$,UX<Q-:A2E&.B5XVYM5JO(X.&<CGDO%&$H8JK"4MW9WY-'H_,^7OVO+R
M;3_VR?BC<0R26]Q;^--5>.2-MK1LM]*RLK?PM7Z%_LP?M>_#O_@J3\'H_A/\
M8K6UM_&RQA;6XRL)OY%7Y;JU?'[JX_O1]#S@,I9%^#_BKJ?A&[_X*!^,;KQ>
MM]?>"[CQQJ3Z@VG3!97MFO9?GC?:<K@JWR_>7Y59=VZOT(O/^"2_PB^-7CSP
MG\2OAGXRC\-^%;)K:ZEMM)*W4%QY&"KQ3&3=!)\HWL=YW D@-N->;Q17P,,!
MA*>,4Z=2,$X5(K:5EIIKKV/4X0P^85,QQ<\$X5*<IM5*4G\46W[VNFG?\#\[
M_P!MO]CO7/V*_C-/X8U64W]A=)]JTO4E38E_ 3C.W^&16^5E_A_W65J\?QA?
M]ZON#_@N%^TSX7^.OQE\+Z!X8OK/6/\ A#+:YCO;^UD62!IIWA_<AU^_L$0W
M8)56<K]Y6 ^':_0.%,9B<5E=&OC%:HUK_G\UJ?G/&&!P>#SBMA\ [TT].OR^
M3T^04445] ?+A1110 4444 %%%% !1110 4444 %%%% !1110 9^6OL#_@AV
M-W[>6G_]@:]_]!6OD _=%?6?_!%KQ#8^%_VX;"ZU&^L]/MUT>[!EN9EB3)5<
M#+-7S?&$92R7$QC_ "/\CZK@><8Y_A92_P"?B_,Y'_@JYQ_P4'^)6?\ G\M_
M_2."OTN^+>L_!KP[^P+\*)?C=:"^\+M9Z6EFGDW$N+S^SY"IQ!\W^J$W^SS]
M*_,G_@J)K-KK_P"WI\1+RQNH+RUFO(&2:"0.DG^BP+P1\IKZL_X*C^.-%\0?
M\$P_@W8V&J:;=WUK=Z09H(+E)98<:5<@Y16R,,0*_/<ZP$\10RC#W:O:[6C7
MNQZ]#]-R/,X83$YWB4HSM>REJG[[Z=3Z,_X)Z^*?V:]>\8^)%^!MA]BU5+.-
MM2S;7L6Z'=\@_?\ R_>_NU^;_P )FV_\%;;'V^)<W_IPDKV/_@@EXPTGPA\7
M?'TFJZCI^GQS:1;JCW4Z0*[>:>%W-S7BGPHUNT@_X*JV>H275K'8K\1YIS</
M(HB*?;I&W[_N[=O>JP>5SP689G0C*<U[):R=V]'U%F.<0Q^6Y5B)1A3?MG[L
M%9+WET/T6_;[^,'[-/@;XR:?9_&/PQ_;7BA]&BFMYAICW)6S,TRHFY2/^6BS
M';[U^9'[>GC7X5^._C/9WOP?TG^QO"T>DPQ3P?93;;KI992[;6)_Y9M%\W^S
M7Z4_MM_L._"W]M[XMV/B[5/BI::#<6>DQZ2(+2[M9(V1)II-^6;[V9BO_ :_
M-;]O7]FGP[^RI\:+3PWX7\3'Q9IMQI$.H/>YC;;*\LL9C_=DCY5B5O\ @5<_
MA_\ 48JG"-6K[;E=X/FY/EI8V\3(YA*4ZLZ5+V'/&TU;VC]=;_@?L[^T;^SE
M\+/VF]6\,Z'\1--M]9OK=;B[TBU>_N+5F"^4)R/)=-^W='PV?YU^=W_!:+]K
M>U\1ZGI_P/T'P[=:#I'@&[CDN6N(Q$LSI"4@2W16_P!0(I-P8_>RORC;\WLW
M_!7;]J6/X2>-?@AXT\'ZQIVJ:AX8U2\N)(;:\219(RD*R1/L)(#IO3_@1KS?
M_@L1X5\&_M#_  G\(_'#P;JVFW%XUI;V^J6JW$7VE[27YH7>/=N#Q2/L9?O?
MO!_<KP^"\OEA\7@L1C>9TY\_)O:%1-K;S7XGTW'F:4\5@\=AL X0JP4'-I*]
M2G9/?R?X+S/+?^")_P"SI_PN/]KR'Q!>V_G:/X M_P"TI"5S&UW)N2V4^X.^
M1?\ KC7V;X(^(GQ5F_X*Q:Y>W?@KQ=#\,[^P;PQ#>26$B6:"WW2QW6<;6#3F
M95?^Y.OI7F/[%WQ'T+_@GS_P2^UKQRM]H=[XX\2;M3AT][E))&ED*PV<3(C*
MYC"XE8<-AY.5[>.C_@OS\9@P/_"/_#?*_P#4/O/_ )*KTLXP>:9WF6)K82BI
MTXITES.UK:MKSOU/%R/,,GR#*\)A\97<*LFJSY%>]]$GY6Z'F?\ P5E_9Z_X
M9_\ VS_$0MK?RM'\5?\ $_L,#Y5\]F\Y!_=Q.)#M_NE:^_OV7K/X=W__  1Q
M\+P_%=E'@%[4?VF6DN$'_(3/D_- 1*/WWE]/QXS7CO\ P5%\1^&_VSOV#_ G
MQ5TV_P!'C\2:&D-Q=V$=TAN(XKG9%<P[,[VV3*G_  %7-1^*_'6BO_P0$BT=
M=6TYM5^SVH^QBZ3[1_R&XS]S.[&WGITJ\=5KYCD^ P]92A4A7C3FUNFKJ]^]
MK._<,OI8;*\\S+%4>6=.>'E4@GLT[.S7:]U;L9/[6/\ P4.^#/PN_9/U;X0_
M +3Y)+/7XI;.YNE@N(K6VAERL[%[C]]-*Z_)N/&UMV[Y55O4/^"1.I^']"_X
M)C>.KWQ9;BZ\+V=YJTNJPE#)YUF+2-IDV_Q93<-M?DP/F-?JC_P2>/AGQQ_P
M3>\9^"=<\2:;H9\37FJ::[RW<4<T4=Q:QQ&15=N=N3C/'RUW\9<.X?+,F5*@
MY2<JJ<Y-WD_.YY? _%&*S;/O:UU"/+2E&$$K0796/,_CK\?_ -C/6_@IXLLO
M"/@K['XIO-)NHM)N/[&EC\JZ:)EB;<S?+A]O-=Y^PN@/_!$OXKMW%EKV/_ 2
MN!^.W_!)/X5_"SX*>*O$NF?%XZMJ.@Z3=:A;67FVC?:9(HF=8_E;=\S*%XK5
M_P""._QY\#^+?@'XV^!/C;5(=)?Q5+<_8GEF6'[=#=0+!)%$YX\U=NX _,=_
M&[;7#F%/"U,F=7+IU:BIU(2ES\S:2[72T/0RVIBZ>>JCFE.E2E4I3A#DLDV]
MKV;U/+O^"%Q_XSF7_L 7G_H4->:_\%0<_P##??Q,_P"PDG_HB*OT(_9L_8,^
M'?\ P2QU_6OB5XL^)$=[LLGLK5[FV6SCMXG96("!W>:4[% V<\M\ISQ^6_[4
M7QE_X:"_:$\7>-%MVM8?$.HR7$,+G+)!]V(-_M;%7=7T&0XZ&:9]6S#"INE[
M)0YK-:WOU/F>),!/*>'*&5XQI5G5<^5-.RM;6Q^@O_!9_C]@OX0?]?MG_P"F
MZ6N2_P"#>==WQ(^)G_8+L_\ T9-6Q_P6$\=:/XD_88^$]GI^K:;?75M>V9DA
MMKE)'3%A*.0K;ASBN3_X(%>,-+\'?$/XC2:IJFGZ<LVFVBHUS<I"LA\R3[NY
MN:\&G1G_ *EUX<NO,_\ TM'TE:O3_P!>\-/F]WE7_IMG'_\ !/33K/4?^"PT
MOVMH]UOKFNRVZL!\TBK=8_X$%W'\*YW_ (+4ZWJVI?M_>)K?4O.^Q:=9V,.F
M!R2GV=K9';9_L^<\WW?XMU>2ZM\8-2^#'[9FK>-/#MQ&U]HGBJ[OK9PV8IE^
MT2;D)7JCQLRM_LLU?I%XO\)? O\ X+.^!M&U2VU]O"_Q"TRV,30K)%_:-J#\
MS0RQ-_KX0V65D]>&7++7L9E4EE6;X?-\1!RHNER-I7Y'>]SP\KHQSG)L3D>&
MFHUU6]HDW;G5K67FM_N/R'SB@=:_4GP7_P $6_A7^S5J0\5?%?XE0ZWH.FL)
M!;7$":/:2L.=LI::1I%_V$92WOTKX-_;2UGX:^)/VB->O/A39W=CX0GEW1I*
MGEP-+_&UO'MW10,?NHWS+_=5=JK]=D_%N$S7%.A@HRE!1^/E:7IKU^1\7GG!
MF-RC"JMCY0C)NW)S)R]=+JWS/*****^J/C0HHHH **** "BBB@ HHHH !Q1C
MBG;?W>?>NL^ /@^R^(GQU\$>']261].U[7['3[H1OY<C12W"(^&[-M)KGQ%:
M-"E*O/X8G1AL/*M5C1AO)V.3V[1G%)CUK]9_B=_P30_9+^$/B+3M!\5>(+SP
MWK&N1;[-+S7FA+KG9N4N-@^;CFOC'_@I?_P3^_X87\?Z.NF:G=:QX5\31R/I
MTUVJ_:H)(BOFQ2,H"L=KH5957=EOE^6OD<HX\R_,*\</3C.+GM=6YK;V/ML\
M\.\SRS#RQ-64)J+2ERN[C?:ZZ'S.0-M(&^;-?J3X4_X)O_LT^"_V7O OCOXB
M:AJ.A+XCTK3Y9;F;5I(H9+J>V69E  XW8=L>U?./[?WPD_9O\ ?"32[KX-^)
M5UKQ%)K$<-U%_:;W++:&&9G?:0/XQ$-W^U1E_'6#QM=4*%.I\7+S<NGWE9EX
M>X[ X9XFO5I[7Y>;WK/RL?(C'<<T C'2OU#T+_@G/^S?^R+\(?#,_P >M0DN
M/$GBA0GFS7MY#!#.4!>.)+7'R)N4%Y<CC/R[MH^4?^"F'[*_P\_9@^)FEP_#
MWQ=;ZW8ZU:+>OI9G^TS:8C -$WG(,-%(K93=\^.?F!!&F5\;8',,5]5HPGK>
MTN7W7R[V?^=C'-N L?EV#6+KSAI:\%+WX\VUU_E<^:R!MI-WS9K]2?"G_!-_
M]FGP7^R]X%\=_$34-1T)?$>E:?++<S:M)%#)=3VRS,H '&[#MCVKYQ_;^^$G
M[-_@#X2:7=?!OQ*NM>(I-8CANHO[3>Y9;0PS,[[2!_&(AN_VJSR_CG"8W$1P
M]"G4^+EYN73[S3,O#['8##/%5ZM/X>;EYO>L_*Q\A]:=_$-U>C?LB_ >;]IG
M]H[PEX+A#>3J]\/MCH<&*U3YYW!_O")'V_[6VOL/_@J9_P $L?!_[,7P$LO&
MG@&WU:./3=02WU=+F[:X40R_*D@W#C;+L7_MK[5ZF/XHP6$S"EEU9_O*FWZ7
M]>AY66\(X_'996S7#K]W2W[^=O1:L_/3&*<JENE)NXK]:_B7_P $QOV5/@5I
M.D7'C;5=0\.KK'R6KWNMR1)*X4,1NQ@8R.M3Q!Q1ALI=.%:$I2J7MR*^UK_F
M7PWPCB\ZA5G0G&$:=KN3LM;V_(_)0C;2#K7V)_P4M_X)L:1^R7X8T/QMX'UR
MYU[P1X@F2V4W$B3R02/&TL3I)$ LL3QJ^#CY<+R=V:S?^"=G_!,+5/VSX[CQ
M)KFH7'AOP#ITK0/=Q(/M6I.H^=(-Z[%5>\K;E#?*JM\VV8<79;++?[4=2U/;
M^]S?RV[CEP7FRS3^R%"]7_R6W\U]K?UN?)^,K29^7ISZU^G]W\(?^"?_ (-U
M)?#>H:M:7FK*S6[7HU?5)4WCY2S30M]G7GOPM>+_ /!0K_@F)X7_ &??A1;_
M !,^'?C2UUCP;>2QHEI>744DDGFGY3;3)A;A?]C&Y55FW-@X\[ \=8*OB(8>
MK3J4W/X>>-HR]-ST\P\/<;A<-/$TZU.JJ>LU3G=Q]5H?$X.*,U]N']A'P(O_
M  2,'QD^SZA_PFAAW^;]L;R,_P!I_9O]7C_GGV]:\@_X)K?L]>'?VH?VJM+\
M'^*HKJ;1[RRNYW2WF:!\I&2/F^M>G2XFP<\+B<5'FMAY-2]8;V/)K<(XRGBL
M-@Y6YL0HRAKTEM?0\"HQFO9/V_/@KH?[.O[7?C#P;X=CGCT;0Y+46R3R>:Z[
M[6"5LGO\SM7*_LR> [#XI?M$^!O#>JQRR:9KVO6>GW:QOY;M'+,B/AOX3M)K
MTJ>9TJF!68+X''G^5KGDU,IK4\>\ME\:GR>5[V.'R"H'YFDXSZU^KGQ@_P""
M>W['_P"S_K]OI/C3Q#?>']4N[=;N&WN=:E61XF8H'&%Z;D*_\!KX%_:!^$7A
MO7?VO=0\&_!CS_$^A:A<6=KH(AG,[W3O!$T@WMC[LID^9OE51_=6O!R7C+"9
ME*7LH3C%)OFDK1LO[Q])GW ^,RE15:I"<Y/EY(2O.[\K7_I'C@&33@O.*_3O
MPM_P2Y^ G['OP_T_5_V@O%45_JVH+M-L+^:UM%?&YE@2'%Q)M[N6QT^5<\VW
M_P""<_[,'[:G@R\/P/\ $RZ+KUA#YH2&^N;C;NZ&XMKIO."-]W*[<>^-M<$_
M$;+E+G4*CI[>TY?<^_\ X!Z</"W-'#E=2FJMK^SY_P!Y]VWXGY<K@O\ -28X
MKJ/C1\'/$'P!^)>L>$?$]E]BUC19O*G3=E)%QE'0]T=64@_W6K[;_9&_X)%^
M'8/@[#\3/CQKTGAK09HEO(M+^T"S$4+8V&YE<;E9^,1)M;YE^;<VQ??S3B;
M9?AH8JK+F53X>75R]#YK)^%,QS'%SPE&/*X?'S:*-N_8_/PL=NVE8AB-JU^H
M&D? 3]@OXUZHWA?PYK<.DZY<,L45TNKZC;O([=!&]X3!(S?W0&YKY-_;F_8+
M_P"&+_CCH/A__A(+/Q#HWB)UFM6W"*_@B\U4831J3C[WRN/E?:WW=I \_*^-
M,'C*_P!7E3G2J;Q4XVNO(]/-N \9@L/]:A5IUJ:?*W3E=)OOL?.(P>M-K[2_
MX*[_ +#O@3]C?_A7?_"$V^I6_P#PDJZ@;TW=VUQN\G[+LQNZ?ZYZN?L^?L)>
M ?B/_P $QO%WQ4U2WU)_%FCV^IRVTD=XR0AH%/E93H:TCQA@I8"EF*OR5)<B
MTUO=KOY&53@C'QS&ME;:]I2ASO72UD]-.S/B)AM.*4-SR,U]F?\ !+3_ ()]
M^$_VF/#'BCX@?$2^N(?!?A25[=[:"9H1.Z1+/,\LB_,L:(Z'"<G=]X;?F[[]
MIO\ 9#_99\=_LS>(/B!\)?&EKX?D\.MY026\N9HKFXPS);M#<9N%>3!V%>."
MVU@IQCB.-L%1Q[P').332<DKI-[)O_@&V%X!S"MERS+GA&+3<5*5I-+=I=OF
M?GG1117V1\+L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX?\ [:WQ&T?5_%6K>((;WP_9+"++3KR&*.2%I&93(K1N_+*XRK+G:?2OS_\
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M&_X*>>$_ _B"..6^T'Q3%:3_ +O]W<IG<DJJ?X'0HZY_A9:M_P#!'RUU"?\
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ME*B^;EJ1<Y:OXDV?,Y3Q-C:?!=:I'EYJ<U37NKX6OZU/J/\ 8X^*N@?LV?\
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MXKFBU_R\B^M^K^>][?!M%%%?LY^$A1110 4444 %%%% !1110 4444 %%%%
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MS7\C\S_C!XVM_B1\6_%7B*SM7L[7Q!J]WJ4%N^W=;I/,[JGR_+\JMMK]A?\
M@E-^SOH7P&_8[\*R^(;?38]>^(DYU+;=JA:0RQEX(4S_ -.\8?9V8R5^8OP4
M^%\/[;7[=D&F:?8R6&C^,/$EQJ4UNN%^Q6#2O<2+\O"L(LJO\.[;7Z7?\%(/
M@G\:OB7\2_A>WPIT*UFT/P!=)K>6U""UCEO$=5CBV,ZG"1*PZ;2L["O4X^QD
M:D<-DJFJ-X\\FWM:.D6_-_D>3X;9>Z4L5GLJ3KN+Y(I*]W)^\TO)?F?F/^WU
M^SZW[,7[6'B_PK##Y.EK>?;M+^7Y?L<W[V-5_O;,[/\ >1J\9!Q7ZD?\%[OV
M?I->^'/@_P")UO8M!>Z.5TC5UX9DAE^>'<PXVI+O3CJTXK\N=_R;:^XX+S?^
MT<HI5I/WU[LO6/\ GO\ ,_/>/<C>5YU6H17N2?-'T>OX;?(;1117UA\6%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5/INH
MW&DZA;WEG<36MU:RK-#-$[))"ZG<KJR_,K*W\5044-7T947R^]$V?&7Q"U[X
MA7D,_B#7-8UZXMTV12ZA>RW3QIG=M!<MM6K7B'XL>*O%GA^'2=4\4>(=4TNW
MV&*RNM2FFMX]B[4VHS;5VK\JUSG:BN?ZI1]WW8^[L='UNKK[[][?S.TTW]H[
MXA:/I\%G9^//&=K:VL2PPP1:W=1I"BC:$"J^U55?X:H^+?C'XN^(>FI9^(/%
M/B37+..59DM]0U*:YB5U5E#@.S+NVEES_M-7,@XH)S4QR_#1E[2,(\W^$N69
M8F4>2527+ZL[3X??M#^/?A/I4MAX7\;>*O#MC-N9K?3M4FMXBS?Q;$<+N_VO
MO5S/B3Q)?>+M;N-2U6_O-4U*\??<W=W.T\\S>KNQW,W^]5'-.5MAHIX.A"I*
MM&G&,I?:%4QV(G35&I.3BME?0[+3?VCOB%H^GV]G9^//&=I:VL2P001:W=1I
M"BC:$55?:JJO\-5=>^./C3Q<EJFK^,/%6J+8W"7=LEWJUQ,MO,F[9*FY_E=<
MMM9?FYKE0V*"=QJ?[/PRES1IQOZ%2S/%N/LW4E;U9M^-/B+XB^(MQ;R>(=?U
MK79+566!M1O9;IH5;[P4NS8K$HS0#BNBE1A"/)3CRQ.:I6G.7M)RO(Z#QE\5
MO%/Q"@MX?$'B3Q!KT-JV^&/4-0FNEA9OXE#LVVCQ?\5/$WQ!M[>'Q!XD\0:Y
M#:-NACU#4);A86;KM#L=O_ :Y\&BLXX2C'EY81]TUEC*\K\TW[V^NYT4GQ8\
M5OX0_P"$?;Q-XB;0?+\K^S?[2F^Q[,[MOE;MFW=\WW:P()WMY8Y(V:.2-MRN
MAVLK?WA3**JE1I04E&/Q&=3$5)-.4K\IZ;:_MG?%RPT;^SX/B=X]BL\X"+KU
MR"H]%;?N5?\ 96O/=8UB\\1:E-?:A=75_>7#;Y;BXE:661O4LWS-53K0.:RP
M^7X:A)SHTXQYNT3HQ&98K$14:]24K=VV;X^*'B8^#/\ A'?^$DU__A'=N/[+
M_M"7['MW[_\ 4[MGW_F^[][YJI>&/%^K>"M8CU#1=4U+1[Z-6C6YLKE[>55;
MJN]"K5FGK3FVXXS5K#TE&4>7XC'ZU5O&7,[QV\B[XB\2ZEXNUJ?4M6U"^U34
M+K'G75Y,\\\VU55=SLS,WRJH_P" U#I6K76@:I;7MA<7%E>6<JS0W%O*8Y87
M5MRNC#YE96_B6JP&:*U]G'DY.7W3/VTN;VE_>-CQ?X[U[X@ZA'>:_K6JZW=0
MQ>2DVH7DMU)&FYFV*7+,J[F/'^U6.3F@#-'0TZ-.,(\D%RQ"K4E.7-4=V=/\
M./C1XP^$%W)-X5\4:_X;DF_UO]FZA+:B;_?V%=W_  *K'Q)_: \=?&-$C\6>
M,?$WB**-MR0ZAJ,UQ#&V-NX(3M7_ ("M<A17-_9^&]K[?V<>?ORZ_>=7]I8I
M4OJ_M9<G:[M]P9K1\+>+]6\#ZS'J6BZGJ&CZA;_ZJZLKA[>>/Z.C*RUG4 XK
MIJ4X5(\D]3EIU)TY<T':1Z1XE_;"^*WB_2?L&I_$KQQ>V7E^6\$FM7!21?\
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M>=_!K-O:7Y[?BE]_J3L_4[*BC-&:]$HKWNG0:E#Y=Q;PW$><[9$#K^M6***
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M([5WYX;^5)$NU<<<"C;P>:52HYS<F7A<.J-)4T[V_%]7\WJ24445F=(5YO\
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M7OB=^U)JGQ3MY6TO7+C6%U2R*'<UGY17[.I/\6Q$1?\ :VU^A6B_MC_L[_\
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MWP_^(O[&'BKX)_&;Q%::3I\$1@TJZO<_-;2?.BHV/]9;S#>N>@:,#[AK\\^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!W3.>MAZ=:/+45_ZW3Z/S1YROQSB\$;K7QS%'X;N(Q\M^VYM+NA_>6?&V/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJO\ \DUZEM%&T4?7\3_S\E][#^R\%_SZC_X"CRW_ (8X\"?\\?%'_A6:K_\
M)-'_  QQX$_YX^*/_"LU7_Y)KU+:#1M%'U_$_P#/R7WL/[+P7_/J/_@*/+?^
M&./ G_/'Q1_X5FJ__)-'_#''@3_GCXH_\*S5?_DFO4M@HVBCZ_B?^?DOO8?V
M7@O^?4?_  %'EO\ PQQX$_YX^*/_  K-5_\ DFC_ (8X\"?\\?%'_A6:K_\
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M]2V"C8*/K^)_Y^2^]A_9>"_Y]1_\!1Y;_P ,<>!/^>/BC_PK-5_^2:/^&./
MG_/'Q1_X5FJ__)->I;11M%'U_$_\_)?>P_LO!?\ /J/_ ("CRW_ACCP)_P \
M?%'_ (5FJ_\ R31_PQQX$_YX^*/_  K-5_\ DFO4MHHVBC^T,3_S\E][#^R\
M%_SZC_X"CRW_ (8X\"?\\?%'_A6:K_\ )-'_  QQX$_YX^*/_"LU7_Y)KU+8
M*-HH^OXG_GY+[V']EX+_ )]1_P# 4>6_\,<>!/\ GCXH_P#"LU7_ .2:/^&.
M/ G_ #Q\4?\ A6:K_P#)->I;11M%'U_$_P#/R7WL/[+P7_/J/_@*/+?^&./
MG_/'Q1_X5FJ__)-'_#''@3_GCXH_\*S5?_DFO4MHHV"CZ_B?^?DOO8?V7@O^
M?4?_  %'EO\ PQQX$_YX^*/_  K-5_\ DFC_ (8X\"?\\?%'_A6:K_\ )->I
M;!1M%'U_$_\ /R7WL/[+P7_/J/\ X"CRW_ACCP)_SQ\4?^%9JO\ \DT?\,<>
M!/\ GCXH_P#"LU7_ .2:]2V"C:*/K^)_Y^2^]A_9>"_Y]1_\!1Y;_P ,<>!/
M^>/BC_PK-5_^2:/^&./ G_/'Q1_X5FJ__)->I;11M%'U_$_\_)?>P_LO!?\
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M%9JO_P DUZCM6EV@4?7\3_S\E][#^R\%_P ^H_\ @*/+?^&./ G_ #Q\4?\
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MK_\ )->I;!1L%'U_$_\ /R7WL/[+P7_/J/\ X"CRW_ACCP)_SQ\4?^%9JO\
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MX$_YX^*/_"LU7_Y)KU+8*-@H^OXG_GY+[V']EX+_ )]1_P# 4>6_\,<>!/\
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M%'U_$_\ /R7WL/[+P7_/J/\ X"CRW_ACCP)_SQ\4?^%9JO\ \DT?\,<>!/\
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MK_\ )-'_  QQX$_YX^*/_"LU7_Y)KU+8*-@H^OXG_GY+[V']EX+_ )]1_P#
M4>6_\,<>!/\ GCXH_P#"LU7_ .2:/^&./ G_ #Q\4?\ A6:K_P#)->I;!1L%
M'U_$_P#/R7WL/[+P7_/J/_@*/+?^&./ G_/'Q1_X5FJ__)-'_#''@3_GCXH_
M\*S5?_DFO4M@HV"CZ_B?^?DOO8?V7@O^?4?_  %'EO\ PQQX$_YX^*/_  K-
M5_\ DFC_ (8X\"?\\?%'_A6:K_\ )->I;!1L%'U_$_\ /R7WL/[+P7_/J/\
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MKN(_G?WL?U##?R+[D>7?\,=^!?\ GEXI_P#"MU7_ .2:/^&._ O_ #R\4_\
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M .TE"<-@@X]ZT-6UBTT+2KB^OKFWL[.TB::>XFD"1P(HW,[,>%"@9R:^"?\
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MQ]2/+-Q/O*-3GIQGW$896LKQ/XPTOP/I$VHZUJ>GZ3I]N,RW-Y<)!#$/=W(
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MWE=?E*^]?#W_  7JU:#7/V'/#=Y:S1S6UYXGLYXI$.Y9$:TNF!'L5_G7N_\
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M]O2E*4%*2LQ:***1H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<%? G_!/K_@D3X=_;*_9XMO&FI>+M;T>ZN+ZXM&M[:WB=,1,%4Y/UK[+\4?
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M /COX ^$_#NBZEX?=6N[.Q6VTN".6"99K><(-BLQ8NK'KA$KJ/\ @KC^Q_\
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M$;X<_P#!5#QE\4-5T>U@\&ZM<ZI+;7:WT+NZSM^[_=AMZY^E>H?\%2OV#/\
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M^#@G3CK/Q_\ AC9K)Y;76FRP;]N[;NN%&:\3_8S_ &/?"T'_  4,D^%/Q?\
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M^,7[.%[8_#/P)X/T#QI8W,-Y8/IVGVVFM=;3LDA>1%7Y#&[G:6QN1/2OL/\
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M?&W_ (*._#/XA^'=(MKKPKX=_L?[?<O?0Q/']GU"6>7",=QVHRGY1\W2MO\
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M,FM?YH[??T.K%4<?B<@I4:M)^TA.*:L^CW]+=3VO_@K+S_P3N^)#?WK*W_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** #I1BBB@ Q1110 8HHHH
M*,8HHH **** "BBB@ HQ110 4444 &**** "C%%% !1110 4444 %%%% !11
M10 4444 %&,444 %%%% !BBBB@ HQBBB@ HHHH ,8HHHH *,444 %%%% !11
M10 4444 '6BBB@ ZT8HHH **** "BBB@ HHHH ,4444 %%%% !1BBB@ HHHH
M **** "BBB@ HZT44 %&*** "BBB@ Q1110 4444 %%%% !1110 4=*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@#+\-_P"LU+_K]?\ ]!6M2LOPW_K-2_Z_7_\
M05K4H **** "BBB@ HHHH **** "BBB@ HHHH S&_P"1R3_KR;_T-:TZS&_Y
M')/^O)O_ $-:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#/U.>.*^TU9(\M)<,L9Q]UO*E.?R#?G6A67K
M_P#R%=$_Z_6_])YZU* "BBB@ HHHH **** "BBB@ HHHH *R_%W_ "+\O^^G
M_H:UJ5E^+O\ D7Y?]]/_ $-: -2BBB@ HHHH **** "BBB@ HHHH **** "L
MOQ9_R"X_^OZT_P#2B*M2LOQ9_P @N/\ Z_K3_P!*(J -2BBB@ HHHH ****
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M#<<&H?BA\9?"/P/\._VUXT\5>'?"&C^9Y7VW6M2AL+4/@G;YDK*N["GC/\-
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M5 U?XH6?QLU#5/$&K>#((_\ A7<>LPRV]O8[HT345MU??Y#,/E?9M\R5SO\
MFVU]#^-_'>A?#+PO=:WXCUK2O#^BV"[[G4-2NTM;6V7.,O+(0J\G^(T ;=%>
M3_!K]N+X.?M$^*KC0_ ?Q4^'_C#6K52\ECI&N6UW/L'5U1'+,O'WERM>;_\
M!0SX[:7XL_X)?_'+Q5\/?&6GZG_9GA;5T@U?P[JR3_8[J&)@P2:%_DE1NN&W
M*U 'U!17D/[!FL7GB7]AKX,ZAJ5U<:A?:AX%T2YNKFYD::6XE?3X&=W=N69F
M))8]<UTGQY^.O@_X ^ )=8\;>,/#/@G3;MC96U]KFK0:;!+<M&[I$DDKJ&E9
M8W8*IW;48_PT =U17P3_ ,&_W[9VC_';_@GM\--#\3?%C2_&7Q>\K5KC5=.U
M/Q0FI>)/*75;SRGFBDD:YVB P[6=?]68^V*^O/C1^TA\/OV;M(M[_P"(/CCP
MGX)L[K>()=<U6#3UN&7&X1^:Z[VY'RKD\T =U17F/@_]LOX2?$+X7:GXXT3X
MG> =2\':'_R$M:AUVU:QTSYMH^T2[]L7/]\K72:G\9?".BZKX9L;[Q7X;LKW
MQF2N@6\^I0QR:X50.?LBELS_ "%6_=[OE8&@#JJ*X'X5?M-_#KXY^(M:TGP3
MX]\'^+]3\..(]5M=&U>WOI=/9LX\U8G;9\RLOS?Q*PZJ:P_BK^W7\%?@5XQ3
MP[XT^+7PZ\*Z](0/[/U3Q#:VMS'NZ%T=PR+_ +38% 'K5%<:OQ^\#-)X9C/C
M3PGO\;,\?AU/[7M]VO,B[G%I\_\ I!5>3Y6[%=!XA\2:?X/T2ZU35K^STO3K
M&)IKBZNYE@@@0=7=V.U5]S0!I45XO\,_^"BGP%^,GC2/PWX5^,GPT\0:]</Y
M<%C9>(K6::Z;.,1*K_O3_N;J]&^)GQ,\.?!OP5>>)/%WB#0_"WA[33&;O5-7
MOHK&SM=[K$F^:5E1-TCHB[C\S,J]30!T5%?GA_P1B_;T\,?%'5/CAX?\2_&C
M0?$7B35/C7XCB\':9J?BZ*\OKK1PELUJNGQ/,SO9\3&/R1Y?#[?XJ^N_&W[:
MOP?^&WQ0C\%^(OBE\/=#\73;=FBW_B"UM[[+8* Q.X96;<-H/WNU 'JE%>1_
MMW^#5^(G[$WQ=T-FFC;4O!NK112Q'$D,GV278ZG^\K[6'TKSC_@BW\0[KXH?
M\$K_ ('ZI?327%TOAF*P:1V+,WV5WM5R3WQ"* /J.BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL/XA>/-(^%G@/6
MO%'B"^@TO0?#MA-J>HWLV?+M+:!&EEE;'\*HK-^%?EY\);O]I[_@O.MYX_TG
MXH^*/V6OV8;B\E@\*6OAA/)\8^,8(I63[?+=Y5K-'(.U49E^4KL==LS@'ZOT
M5^9OBC_@B+\;/V=;";Q#^SG^V;\?(O%EDK7":/\ $S6D\3:%J\O=)4,2+#OP
MH\WRI67;_P!\^Y?\$G/^"E.I?MP^&?&7@WXB>&X_ /QZ^#^H+H_CKPTA/DI*
MV[RKVUW$[K:?8Q7YFV_WF5DD< ^P**X*Z_:>^&UE:>+KB;XA>"(H/A_*L'B>
M1]=M5C\-RD95+T[_ /16(YQ+MKG_ -GC]NSX+_M9:G>6/PQ^*?@+QUJ&GIYM
MU9Z)KEO>7,$?'[QHD?>$R<;BN,T >NT45X'XS_X*C?LV_#OQT_AG7OCY\']'
MUZ%S%/97?BZPBDMG7JDNZ7]TW^R^#0![Y16;X?\ $-AXNT.SU32[ZTU+3=0B
M6:VN[699H+B-AD.CJ=K*1T*US'QN_:0^'O[-7AR'6/B+XZ\(^ ]+F8I%=^(-
M7M]-AF8=51IG4,W(^5>>10!W-%>=? ;]J_X8_M2Z9<7OPU^(G@GQ];6BJUP^
M@:U;ZA]D+;MOF")V*$[3PV/NFODO_@I;\1O$7A/_ (*R?L%:+I.OZUINC^)=
M;\6)JMA:WTL-MJ:Q:7;M&)XE.V4(S%AO#;6- 'WS16/XO\9Z/\._#-YK6O:M
MINAZ-IZ>;=7VH726UO:ITW/(Y"JONQKS'X1_\%"?@-^T)XS;PWX%^-'PM\7Z
M^TC1)INC^*+*\NIBJ[CLBCE9G7:#\R@CY30![-117C_QO_;\^!_[,WBRWT'X
MA_&#X:^"=<N-FS3];\26EC=;7^ZYCDD#*G^VP"^] 'L%%<&O[3GPWFTSPK?#
MX@^!VL?'5XNG^&[C^W;7R?$%R<X@LWW[;B7@_)%N;BM/P[\8/"/C'X@>(/">
MD^*O#>J>*O"?D-KFC6>IPS:AHRSIYD!N;=6,D/F)\R>8J[EY% '4T5C^+_&&
ME?#WPOJ6N:[JEAHNBZ/:O>W^H:A<I;VMC @+R2RRN0J(J@LS,VU56D\&>-='
M^)'A33]?\.ZMINO:'K%NEY8:CIUTEU:7T#C*2Q2H61XV4@JRG!S0!LT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117P#_P<2?$WQS\-?V0?AW#
MX!\=>)OAWK'BSXI:#X;FU?0KMK:\AMKO[2DH#*>1]UMOJ@H ^_J*_)']L#X#
M?M0?\$=_@'J7Q[\+_M8>,?C'H/P]>&[\0^"_B)9Q3V^N63S) Z1789I(95WJ
M5V]6'7^!_P!)=/\ VH?!MG^S;HGQ9\2^(-'\$^"=8TBQUA]2\0ZA!IMIIT5X
ML1A$TTK+&C,TT:?,W+LJCK0!Z317F]Q^UK\*[?XYV?PRD^)'@;_A8VHQ-/:^
M%_[<MO[7F18O.)6VW^9_JLO]WE%9ONJ357]H3]LOX2_LF0V;?%#XE>!_ 7]I
M?\><>NZS;V,MT!]YHTD=6<+ZJ.* /4J*X/X%?M+_  [_ &H_";:Y\-_'7A3Q
MUH\<GE27>@ZI!?Q0O_<<Q,VQO]EL-7;7-Q':0-)(ZQQQC<[,VT*/4T 345X1
MHW_!3S]G'Q)\1[?PA8?'CX17WB>ZD\F'3K;Q;92S2R_\\EVR?-)_L?>]J]/T
M/XN>%/%'Q"USPCI_B?P[J'BSPND$NLZ):ZG#+J.DI.GF0M<6ZMYD2R+\R%U7
M<O(S0!U%%>0^*/V\O@CX%^,2_#O6/B]\--)\>2.D2^'[SQ):0:D9'QLB\AI-
MXD;<NU,;FSP*\3_X+E?M=Z#^S)_P3L^*D ^)VD_#WXB:QX6O9/"<:^(H](UJ
M]N$"C-B/-2=Y%9EYB^8;A0!]E45\X_\ !,C]K+P7^T]^R7\/4\/_ !,\+?$/
MQ5HO@_1#XH33_$5OJVHV-W+9)O-]LD>2.9Y4FW>;\S,C_P 0:O>/&/B[2_A[
MX0U3Q!KE];Z7HVAV<VH7]Y.=L5I;Q(TDDKGLJHK,?I0!K45^2WPG^('[3G_!
M?C6-5\8>#?B/XA_9>_96@O9K#P]=Z%;^7XP\<B)VC>Z%QE6M(MV[YD;"LNS;
M*RM(OH&I_P#!!KXB_"?26U;X-_ML_M2:'XTM]\\;>,?$:>)-%O)MO'G6311J
MREOXF\W;N^ZV.0#]*:*^:?\ @F;\6?V@?B'\*/$&C_M'> ;#PGX\\%ZN^CC6
MM*N$?2?&4*HK)J%K'N\R)6##<&55W=-K;XHO4/CU^UE\+_V5]+MKSXE?$3P3
MX M[S<;9_$&MV^GM=;?O"(2NID89'"YH ]&HKR?PQ^W%\&?&GP9OOB-I?Q9^
M'-YX!T=D74/$2>([0:7I[,ZQJL]P7\N)B[*NUV5MS*.XKK?&'QH\'_#Q_#JZ
M_P"+O#6AMXPOXM+T(:AJ<%M_;5W*,Q6]KO<>=*X^ZD>YF["@#JZ*\1^)W_!1
MWX _!?XF?\(9XN^-'PO\->+ P1]*U+Q-:6MU"S?=61'D'ELW8/BO9K&\BU*V
MBN+>2.:&9 Z2(=RNIY!#=Q0!8HKS_P".G[4_PS_9<T2#4OB5\0O!G@.QN-RP
M2^(-8M]/6Y9>JQ^:Z[V_V5R:K_ 7]KSX5_M56%U<?#/XD>"/'T5CC[5_PC^M
M6^H-:[NGFK$[,G_ L4 >D454U'48-*L9KJZFAM[>V1I9997"1QH!DLS'HH'>
MO"/#G_!5/]FGQAX_C\+Z7\?/A%J'B"XE^S164'BNRD>:3^XG[S:[?[*\T ?0
M5%9/BWQ5I?@'PQJ.N:YJFGZ+HNBVLM_J&H7]PEO:V-M$A>6:65R%CC2,,S.Q
MVJJDFO/=;_;B^#'AS7_!>G7WQ;^&MKJ'Q&2WF\+6\GB6T63Q%'<<6[VB^9^^
M25L*CIN5V957+,* /6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U__D*Z)_U^
MM_Z3SUJ5EZ^?^)KHG_7ZW_I//6I0 4444 %%%% !1110 4444 %%%% $9.#6
M=XN.-"E_WT_]#6K\LRQ(7/RJHR37Y5_MP?\ !<C7W\;ZGX9^%-OIEMH^FSM;
MG7+J,74M^Z,/WD*?<1-P.-P8L-K?+]VO6R?)<7F=5TL*MMWT1X6><18+*:2J
MXM[[);L_5=&S_P#JI,Y;M7Y2_L9?\%UO$H\?:;H/Q:M].O\ 1]2F2V.M6D(M
MIM/9FQYLJ#Y'CZ9VA65<M\WW3^JUO.MS&)$*M'(NX,.011G&1XO+*BI8I6OL
M^C'D7$.#S:DZF$EMNGNBQ1117DGN!1110 4444 %%%% !1110 5E^+/^07'_
M -?UI_Z415J5E^+/^07'_P!?UI_Z414 :E%%% !1110 4444 %%%% !1110
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M22)Y)KED</(SG;N=EVMMWMS/_!$R\\4?\$Z?^"SWQ-_91_X2.X\3>![V.[>
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MQ_P<6:CK#:=J']CM^S\+);_[,_V8S?V_$_E>9C;YFWYMN[.V@#(^'UC#H_\
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M3O\ @YE\):MXY_X)(>,=/T33=1UC4)-=T%TMK&V>YG8+JEN6(1 6X'- $/\
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M!\(ZIJ7PW\"75OX7U#4M+AOK[P\D<:*OV6XE5I8FVQI\RL"VT9KYC_X*0_\
M!6#X+?\ !0']AWQE\%_$/P:^)TW[16OV=QIF@?#?4/!MS-K&BZW\T,-Y#=^5
MY"Q12[7:5)%9H]R[?F9:^H/V\OA1XV\+_P#!O+XN\$^)&O/$WQ"TGX16^CZL
M]ONNYM1U&*QBBN&&W+2LTJN=W\76@#U3_@E1^S=\.O@A^Q?\+]9\&> ?!/@_
M6/%W@?0;K7+_ $70[73[C69!81OONI8D5IVW2R-N<L=TCG^(UQW_  <$76M6
MG_!&C]H"30#(M\/#>R7:2I^S-<0K=?A]G,U>V_L#Z?<:3^PM\%[.Z@FMKNU\
M":'#/%*A1X773X%92I^ZP;/%=Y\5/AAH7QI^&FO^#_$^GV^J^'?%&GSZ7J=E
M+]RZMYD*2H?]Y6- 'E__  33TG0="_X)W_ NV\,)''X?7P#HDE@4 421M80O
MO.WC<V=S'NS&O<J_'_\ 9\_:@^+7_!O/97'P=^./@7QU\3/V<=%NKB3P/\4/
M#=J=3FT73V.^*PU&%579L^;YBR[>5021A=GL&K_\'1O[+_B#28K7X9S?$GXO
M^-+Z-FL?"GA?P9J$FI7$O.U/WT2)UVY9"^-W1NE 'WA\>_BM:_ CX&>-/&]Y
M'YUIX-T*^UV>/./,2UMWG89_W4-?G7_P1R_X)Q^%?VM_@_9?M6_M%Z/I/Q?^
M+OQLC.O0)XELTU'3/">G/*[6EE86\V^.-5BV-NQN7<JKMVLS_3G[$<WQT_:O
M_9L\<2?M,>#_  WX%A^(DMW;:/X1TV1IM0T71)X/*\F^GW%'N&5F;Y47;GY@
MI/EQ_(?['7[<&J?\$,O!#?L\_M3:+XHT_P"'_@F2X3P#\5=*T2ZU31];T;S7
M=(KP6J2R6]Q KJFS:WR[0>%624 X'_@Y+_X))> /@A^P#\0OC#\$-&L_A7J%
MG!8V'C/1/#5NMCI'B[27U"WVI-:1XB66"Y,,RRHJMM1U;=\NWM/^#BOP_P")
MO&'P#_8JT7P9KDWAGQ=K7Q;\/:;HNK1 -)IE[-:O%#<#/\22.K?\!KS'_@N'
M_P %#/&'_!4;_@G?X^T+]FGP'XPU[X0::ME>^+?'&I:+=Z='K:"_@%O8:/;R
M(L]U(TNR65]BK'%$RM]\5]-?\%<O >J>++S]@/['H^I:@NC_ !O\+7M[Y%J\
MPL8HXV)EEVCY%5L?,WRK0![]\./^"-/[,OP[^"7_  @O_"F_ OB*SGM6@U+5
M-=TB#4-8UF1Q^]N;B]=//>=V+/O5EVL?DV87;\W_ /!%'XX3_LS?\$^?VD_#
M^N7VH:[X>_9*^(WC'PQI+7$YDG;1])C6YBBWMSQNE1?[J[5^Z,5^FE?G+_P1
MP^"DGBO0_P!N[POXLTC5+'1O''[0?C:!EN+=K=KZQNEBB,L1=?F1E9MKKN6@
M#F/^"1?_  3C\(_MD?!W2?VJOVD-#T?XP?&#XS0G7+<^)+1=0TOPKICN6LK*
MQM)=T2(D>Q]^W>K/@-]YF]^^*W_!$;X'^*_C/X)^)'@'1?\ A1OQ \$ZPFIQ
M:U\/;6UT=]3BROG6EW"L1@GBE PV^,MUYVLRM\S_ +''[:NO_P#!#OP(O[/O
M[47AWQ9#\/\ P,\\'@+XK:+H=SJVD:QHWGL8HKY+999+6YB5T39M;Y<+_"LD
MOI_AS_@N+>?MD?&+PCX4_9.^%/BKXL:3?:M$/$OC77M.O/#WA?1=-#*TKI<3
M1>8\[(Q*)Y>[Y>$D^[0!XS_P<"_M4:#XE_;/^"O[,_CS4O%^E_!K7-.E\<?$
MB'PO8WM]J6OV,4LL5GIY2T1I5MY+BW?S6']Y6RK(NZCXS^,__!,WQS\(9/ ]
MW^S_ 'UOH9M3:QR6/P2U:SU"WRNWS8[R*S6Y67_IKOWLW)+=:^B/^"K'P(^)
M'PH_:?\ A-^UK\'_  I=_$/Q%\*K2]\/>+O!]IM6]\0>'+K<\C6G\3W,$FYT
MB^;>SKA?E*OEZK_P<K_L\3^'5M_#.F_%KQ9\19H$:W\ 6/@34DUYIY.$@??$
M(%;=E=RRL/E;;N^7(!\T_L5_M$^)/'G_  1:_;F^%^K7GC3Q%X7^$'@[Q-8^
M!O$7B?2[K3]0U3P]<:/?&RBE2XC1VD@\ET8G[H9%^ZJU[Y_P;W?\$[?AWX(_
MX)W?!_XG>)/"^B>,/BCXGTJTUS_A)]<LH[[4M-A1/+T^WM)I0[V\-O:)#&BQ
M%5^4M_%76>+;O]H+XK?\$4/VE-6^.FBZ7I/CKQEX'\7W>B^$-'M_-N?#NGRZ
M9<K9Z?-(C-]JN<8RRJK?.JE=P:O;/^"1?AR?PE_P2X_9ZTZ[L[G3;RS^'NB1
MW%K<(R2PR_8HMX=6Y5MQ/!Z4 ?1U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0:** /'
M_P!L;QO\0OA_\-+'4OAGX9M/%GBJ/4T2'3;F0)')&T<H=L[T^ZO/WJ^:Q^UG
M^VH/^: ^&_\ P.7_ .2Z^WM>.=3T7_K];_TGFK39>*]+!YA2H0Y:E&,_-W_1
MH\?'976KU.>GB)T_)6M^*9\'_P##6?[:W_1 /#?_ ('+_P#)='_#6?[:W_1
M/#?_ ('+_P#)=?>6W_.*-O\ G%=G]L8?_H%I_P#DW_R1Q_V%B?\ H+J?^2__
M ")\&_\ #6?[:W_1 /#?_@<O_P ET?\ #6?[:W_1 /#?_@<O_P EU]Y;?\XH
MV_YQ1_;&'_Z!:?\ Y-_\D']A8G_H+J?^2_\ R)\&_P##6?[:W_1 /#?_ ('+
M_P#)='_#6?[:W_1 /#?_ ('+_P#)=?>6W_.*-O\ G%']L8?_ *!:?_DW_P D
M']A8G_H+J?\ DO\ \B?!O_#6?[:W_1 /#?\ X'+_ /)='_#6?[:W_1 /#?\
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M110 4444 %%%% !1110!E^&_]9J7_7Z__H*UJ5E^&_\ 6:E_U^O_ .@K6I0
M4444 %%%% !1110 4444 %%%% !1110!F-_R.2?]>3?^AK6G68W_ ".2?]>3
M?^AK6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445R
M?Q)^-'@[X-VUK-XQ\6>&?"L-\[);R:QJ<-BMPR\E4,KKN(R.E '645P/@?\
M:@^&OQ,UA-.\-_$+P-X@U"1MJVVF:[:W<S'#'&R-V;^%OR-=1XN\8:3X#\/7
M6L:YJFGZ+I-DF^XO;ZX2VMK9<XW/(Y"J,D<M0!K45Y5_PW/\$?\ HL/PK_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#SO]J7X"0_M1?L_>+/ -QKWB#PO_PDU@]K%K&AWLEGJ.DS<-'<
M0RHRD,DBHV,[6VE6RK,*^,?AS\3?^"@/[''@ZW\$ZU\%? W[4\&AB.RTWQEI
MGQ A\*:CJ5LH4)+?6][%)F?;]]D;YF5OOD[F_1*B@#X%_9\_8V^/'[5'[:7A
M+X_?M/1>#_"-M\+X+M?A[\-_#-ZVI1Z3=7:>5/?ZA>,JK/<>4-B+'^[7Y6'E
ML&5_>O\ @ISX*^*OQ2_89\?^$?@O'I__  L+QAI_]A65U>7OV.'3H;EA%<W'
MF_>5T@:79M^;?LKZ HH \S_8]_9CT']C']ESP+\*_#*[='\#Z/#I<4FP*UTZ
MC][<.!_'+*7E;_:D:O3*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O7_^0KHG
M_7ZW_I//6I67K_\ R%=$_P"OUO\ TGGK4H **** "BBB@ HHHH **** "BBB
M@ Q67XN_Y%^7_?3_ -#6M2LOQ=_R+\O^^G_H:T :F**** "BBB@ HHHH ***
M* "BBB@ HHHH *R_%G_(+C_Z_K3_ -*(JU*R_%G_ ""X_P#K^M/_ $HBH U*
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,OPC_P B_%_OO_Z&U:E9?A'_
M )%^+_??_P!#:M2@ HHHH **** "BBB@ HHHH **** "BBB@#+\-_P"LU+_K
M]?\ ]!6M2LOPW_K-2_Z_7_\ 05K4H **** "BBB@ HHHH **** "BBB@ HHH
MH S&_P"1R3_KR;_T-:TZS&_Y')/^O)O_ $-:TZ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OSE_X+@_#/0?C'^U#^QGX5\4:7:ZUX?U
M[X@W%I?V%PNZ*ZB:"+*-[5^C5?FM_P %Z?AC-\:/V@OV/?"=OXD\1>#Y]>\?
M75I'K6A736NI::6@B_>V\H^Y(O9J"HG>_M1?\$+_ -E'6/@1XGF7X?:'\/)M
M-TVXO8?$NE7,UG/HKQ(T@N=V_:RIMW%75EV[OK7S[>?'7Q=^T?\ \&INN>*O
M'%Q=7WB&7PU/8O?7+,TVH1VNK?9H9W9OF9VCB3<[?,S!F[U[?)_P0/\ #_CN
MR_L[XE?M#_M2?%+PX\J//X?U_P =R2:7?!>0L\6S<WS8/RNAXKK?^"RGP^T7
MX4?\$6_BSX;\-Z79Z+H.@^&8+&PL;5-D%I EQ J(J_W5% &?^S)_P1N_9>\8
M?LV?#W5M3^"O@N\U+5/#.FW=U<20/OFEDM8G=V^?[S,2:]FN_P!E/X=_LC?L
M@_$[0/AKX3TGP=HNH:-J>H7%IIZ,J2W#631M*=Q/S;$1?^ U\S?LX?\ !#+X
M0^-?V=_ >M77B?XSQW6L>'-/O9DM_'5[#$KRVT;L$0-M5=Q^5?X:^@_#G['W
MA?\ 8L_8Q^*'AOPKJ'BS4K#4M+U/4Y9/$&L2ZK<+*UAY6U7E^8)MB7Y?7=ZT
M$GR-_P $:O\ @E-^SO\ '_\ X)D?"GQ9XR^$WA7Q#XDUS3[E[[4;F)_/N66]
MN4!9E<?PJ!^%:/[$WPYTC]@7_@MMXP^ OPIU#4)/A7XH^'R^,M1\-27KW=OX
M3U5;I8AY6\ED62%D9@Q9F\^+)VJFWX.^&7[.GQ4^ O\ P3Q^ /QPL_CI^T-8
M_ W6'EM_'>C>$/%EU93^$+=[V>!+RSC4M%Y&X NC1[M[?>^?<G['_P#!.K]@
M7X._LD^#KCQ5\,;C4O%M]\1;>'4;WQIK&I_VIJ?B&%QYL<C7&%4HV_?^[50S
M-ELD"@L^G*^ _P#@EM_RE*_;S_[&7PY_Z175??E? ?\ P2V_Y2E?MY_]C+X<
M_P#2*ZH(/(_V&_V$/A#^U_\ M\?MGWOQ-\ Z#XTNM#^(B06$NH1LS6J212LX
M7:P^\P'_ 'S7VI\&_P#@EC^SU^SY\2M+\9>"_A/X3\.>)]%9VLM2M876>W,D
M31/MRW\2.Z_\"KX-_9+_ ."=G@?]MO\ ;^_;(OO%FK>/--ET'XAK;6X\/^(K
MC28W5XW8[UB;YV^7JU?9'[/?_!(/X9?LS_&/1?''A_Q!\5K[5]!:5[>#5_&-
MY?6;[XGB;?"[;7^5VQN_BP>U 'QW_P %M?\ @F;\!?@-\'_A'JG@_P"%WA?P
M_J'B#XMZ#HVHS6L3JUY93_:&FA?+?=?8N[Z5^B7[-7["'PA_9 U75;WX8^ =
M!\&W6N11P7\NGHRM=(C,R*VYC]TL?SKYC_X.$_\ D@OP*_[+AX9_E=U]]1T#
MZ'Q7_P %O?VD-:^&O[+VG_"WP')))\5/V@-33P3X:@B?;)"DY5;RZ)_ACCA?
M87_@:=&[5B_\$-?BWX@\._"3QA^SG\0+A9/B)^S=JW_".3/N;_B9:0^9-.ND
M#<^68?D7^ZB19^]7ROJG[3OQ>_:8_P""LWB7X\?#/X!ZM\>_A]\&Q>> /!KV
MWB:WT6QL[Y57[=?H\L;^<\BR2HK*NWRY(OF.%JO\4_VJ_C-\ /\ @I9\/?VF
M/B/^SCJOP*\$ZM%#\/O'NH2>*;76K74+6YE_T>ZE\B)&C:W94;>RG<L")N7Y
M=P4?HQ\>K&'Q'^WY\"M,UZ.&30+33/$6MZ2LP'EMX@@2SBMV7<W,J6-UJ;(-
MK?+YK?+LK\X_V5/@5_PA7PJ_9S^(DGP?^$/@N*X^,*0/\3O#5WY_C?4O/UF_
MMA;W</V"WQ;W+.MK*WV^XVQ/N\I_NI^L7[07[/\ H'[2_P /X='U:XU*PN+"
M[CU;1=;TFX6#4]!OHPWE7MI,58)*JNZ_,K(Z.\;H\3NC>$3_ +!/Q0\0_"ZT
M^&NJ?%;X<VGP[L;A+BVD\/?">WTSQ-:R17'VF&[AN7O9],AOO/596N(M*0"1
MG>&.W?8T80=;^P=:6^@>-?C]HNBK'#X1T?XF7*Z-'%\L,,L^G:?>:BD2X"JO
M]I7%\S;?^6CR^E?1E<C\&?@QX;_9^^'.F^$?"FGMINBZ6)&BC:>2XEFEDD:6
M:>::1FDFGEE=Y9)96:2221W9F9B:VO%VH2:5X5U.ZA61YK6TEEC"#+,RHQ&/
M>@#\^?\ @A7=Q_M*?&S]K3]I.Z5I+CXC_$N;PMHTKCYUT3188[:T(_N[]YW
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M(?MW?$R;3[*[^(5C\8M7\/P74D2M-IFGM<32GRF_@\^1FWX^]Y"T >Q>'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% &7X1_Y%^+_??_T-JU*R_"/_ "+\7^^__H;5J4 %%%%
M!1110 4444 %%%% !1110 4444 9?AO_ %FI?]?K_P#H*UJ5E^&_]9J7_7Z_
M_H*UJ4 %%%% !1110 4444 %%%% !1110 4444 9C?\ (Y)_UY-_Z&M:=9C?
M\CDG_7DW_H:UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &7K_ /R%=$_Z_6_])YZU*R]?_P"0KHG_ %^M
M_P"D\]:E !1110 4444 %%%% !1110 4444 %9?B[_D7Y?\ ?3_T-:U*R_%W
M_(OR_P"^G_H:T :E%%% !1110 4444 %%%% !1110 4444 %9?BS_D%Q_P#7
M]:?^E$5:E9?BS_D%Q_\ 7]:?^E$5 &I1110 4444 %%%% !1110 4444 %%%
M% !1110!E^$?^1?B_P!]_P#T-JU*R_"/_(OQ?[[_ /H;5J4 %%%% !1110 4
M444 %%%% !1110 4444 9?AO_6:E_P!?K_\ H*UJ5E^&_P#6:E_U^O\ ^@K6
MI0 4444 %%%% !1110 4444 %%%% !1110!F-_R.2?\ 7DW_ *&M:=9C?\CD
MG_7DW_H:UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 9?AO_6:E_U^O_Z"M:E9?AO_ %FI?]?K_P#H*UJ4 %%%% !1110
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M#\&1Z3+X@TW4M,M(EU.W:>WV7%Y% ^45U;.USM^;[U 'U!1110 4444 %%?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7XY>%]*T8^-?%#VD4<&M6][;I/;I"ZS,S,%BC\S=%%N:->7VAJX?XT?\%YO
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MM[2VV_;&BW7#?=D;[.K-\K2LO\/S5]M?\%Q_^"IOQ#^%'Q^\'_LO_ _7]/\
M"/B;7+6#^W/%6JWX@?3$G^6%%NYF_<[8E:66=MTFUX]AW;MWA_\ P0$_;K_9
M'_X)V_LZZIJWCSXIQVWQ9\?W7VC6U_X1O6;IM,MHF9;>T$J6KQLWS/*Y1OF:
M55^;8K5Q_P#P7[_9\T'X:?\ !6'PA\9/B7H>O>(O@7\5+6Q^WS:5-)#.OD6J
M6\L2'C9*L:0W"HVWS/F7^_M!_:+7Q6^%7[0O[#WPVO/BMX)_;^\-_$SQ-X?3
M^TM6\,GQQ]N6\1/FE\J&ZN)8[QE7/R/$C,JML^;:K?17[4W_  55\2?M=?\
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MOW/V[X9ZIC_EXVQ+N_\ '$_]!K[R"X__ %4XFC^WO^G%/_P /]68],35_P#
MV?!>?V]S_P!$S_\ (5?&?_!4CX1?']-2T'QS\9K+19(3#_8UM=:0RM;PD,\H
M1P/NR-O?:?XMGM7[> ;AS]:Y_P"(7P[T/XK>$KW0?$>EV.M:-J"A+FTNXA+%
M)R&'RG^(, P/564$8-=V5\5O"XB-?V$$NMHV=O(\O..#/KN%E1^L5&^EY75_
M-6/YIZ^SO^"&GPCUCQG^VO8^*+.&X71O!MG<RZA.J_NBT\$L$43'U9G9PO\
MTR;^[7V?K/\ P04^".I^*3J,-QXVT^T9]_\ 9EOJ<?V51_=R\32[?^VF:^IO
M@A\ ?"/[./@J'P[X-T.ST/2XV#LD"_/</M"[Y'/S2/A1\S$MP*^NX@X^PN)P
M4\-A(MN:M[W2^Y\7PSX;XS#9A#%8R22@[Z:W:V.YHHHK\E/VX*R_%W_(OR_[
MZ?\ H:UJ5E^+O^1?E_WT_P#0UH U**** "BBB@ HHHH **** "BBB@ HHHH
M*R_%G_(+C_Z_K3_THBK4K+\6?\@N/_K^M/\ THBH U**** "BBB@ HHHH **
M** "BBB@ HHHH **** ,OPC_ ,B_%_OO_P"AM6I67X1_Y%^+_??_ -#:M2@
MHHHH **** "BBB@ HHHH **** "BBB@#+\-_ZS4O^OU__05K4K+\-_ZS4O\
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MI^5*^K:** ./^$_P*\)? Z#7X_".@V'A^/Q5K=QXBU9;12OV[4+C9YUR_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#+U_P#Y"NB?]?K?^D\]:E9>O_\ (5T3_K];_P!)YZU* "BBB@ HHHH *,44
M4 %%%% !1110 5E^+O\ D7Y?]]/_ $-:U*R_%W_(OR_[Z?\ H:T :E%%% !1
M110 4444 %%%% !1110 4444 %9?BS_D%Q_]?UI_Z415J5E^+/\ D%Q_]?UI
M_P"E$5 &I1110 4444 %%%% !1110 4444 %%%% !1110!E^$?\ D7XO]]__
M $-JU*R_"/\ R+\7^^__ *&U:E !1110 4444 %%%% !1110 4444 %%%% &
M7X;_ -9J7_7Z_P#Z"M:E9?AO_6:E_P!?K_\ H*UJ4 %%%% !1110 4444 %%
M%% !1110 4444 9C?\CDG_7DW_H:UIUF-_R.2?\ 7DW_ *&M:= !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!EZ__P A71/^OUO_ $GGK4K+UJ-7U'2"7VLMVQ _O?N9>/\ /I6I0 4444 %
M%%% !1110 4444 %%%% !67XN_Y%^7_?3_T-:U*S_$=HUYH\D<?WF=.O^^IH
M T**** "BBB@ HHHH **** "BBB@ HHHH *R_%G_ ""X_P#K^M/_ $HBK4K%
M\;W:V>C0NV?FU"RCX_VKJ)1_.@#:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH R_"/_(OQ?[[_P#H;5J5B^ [M;[PU!*JL 7E7G_9E=:VJ "BBB@ HHHH
M **** "BBB@ HHHH **** ,OPW_K-2_Z_7_]!6M2L7PE>+>3ZP K#R=0>,Y_
MW$_QK:H **** "BBB@ HHHH **** "BBB@ HHHH S&_Y')/^O)O_ $-:TZS&
M_P"1R3_KR;_T-:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** .=\!_\?6O_ /86E_\ 0(ZZ*N=\!_\ 'UK_ /V%I?\
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M ?9GP.U#QCK/PA\/W/Q"T_2-)\;3V2/K-GI4K2V-M<_QI$S$ED^IKL*^/_\
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MXN\;:QK&LZU>6/BI-^IW3W$]K"JMLM][?-MC4[5^E?H)_P $\?\ DP'X'?\
M9/M!_P#3;;T >R45Q?[0OQNT7]FSX'^+/'WB1Y4T/P?I5QJUWY2[I)$B0OL1
M?XG;&U1_>(KX/_9^_9,^.'_!47X=Z?\ %WXR_&[XI?";0?&D":EX9\"?#;6/
M[%32=/?+V[W=QL=KB:1"DOS+\N5^[_JT /TDKX\_X*:_M8?%+X3_ !A^!?PB
M^#\WA;2_&7QNU74X5UG7K66\M]+M=/MHYYF6&,_,Q64?,WRKMZ?-N7S'PWX[
M^+O_  2D_:O^'/@?XA?$;7OC)\"?C'K2^&M%\1^(@)O$/A76I1_HUK<7"_\
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MWVB+</O+GUH _1*BOS_^%G["7Q._;^^&.C_$OXU?&[XQ> ]3\4V46IZ-X/\
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MMX?TRRO;MY;'POXJL54QI"&^6%+R#:H1?FEG=F_AH ^]**^+?^"XW[5_BSX
M?LGZ;X)^%]]-9?&;XZZ_:> O!<EO(4GL;BZ=?M%Z&7YD6"#?^]7_ %<DD35]
M6_";P1<?#3X6^&_#MYK6J>)+K0=,M["?5=3G,UYJ<D42HUQ,Y^])(REV/]YJ
M .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N _:E^-$?[.'[-
M/Q ^(4EO'=KX)\.ZAKBV\C[%N&MK=YEBW?[;(%_X%7?U\:_\%]_&EQX-_P""
M3?Q6CLMS:EXBBL=!M(Q]Z9[R_MX&3_OV[_E0!])?LY_';P_^T]\"_"?Q"\+3
M_:- \8:;#J=H6^_&)!\T;_W9$;<C+_"R,*ZZ^O8M-M)+BXDC@@MU+RR.P6.-
M0,DL3T%?G[_P3#TR;_@G+^U_XX_9(U2ZN)O">IVW_">?"^ZN)"WF6DIVZAIX
M8_Q03AG5?O,OFNWWJ[3_ (+4?&'Q!>_![PK\ OA_=_9_B1^T9JW_  BMHZ[F
M?3=)V[]3O6 _Y9QP?(W^S*Q'W: /9/\ @G_^VWH7[?OP0O\ QYX=A$>D0>(]
M3T:U;=\UQ#;7!2&<C^%I8?*DV_P[\5[I7YZ_\$(?A]I_[,/B;]J#X&Z9)<?V
M7\-_B6;K34GD\R6.ROK*#[.I;_=M_P#OK=7H'_!.#XR>*OB1^V9^UYHWB#Q!
MJVKZ3X/\;V=CHEI=W+2Q:5 UJS-%"I^XK-\VT4 ?95?,'[>'[7'BK]G#X^?L
MX^&O#T>DMIWQ5\;_ /".ZT;RV:65;;RM_P"Y9778^?XFW?[M<E_P7F^,GBSX
M#?\ !-[Q-XD\%^(-6\+Z_:ZOH\,6H:;<M;W$:2ZC!&ZAUYVLK%6_V6-<_P#\
M%</^3O\ ]B7_ +*G_P"V] 'JG[>O[8GBC]EKXK_L]Z%X?L=!O+/XL>/[;PIJ
M[:A!+)+!;2HS%[<I*@64;>KAU_V:VOVN-0_:#LOC#\(5^#=CX+N_!LVN%?B#
M)K+[;F'3]T7S6_S#YMGVC[NYMXB^7;NKXI_X+0?L@7&N?M@_LYZU_P +:^,=
MHOQ"^*=EIR:=;Z[#'9>%?W&/M&EI]GS;S_)G>[2?,6XKU;]K7_A+_P!CCXD_
ML<^ M#^)_P 2?$5CKGQ)EL-;U+7]76XU+7K616E\B[>-(EEC5GVJ-GRJJT ?
M?U%?G/\ \%A?VC_C5\&OV[_V6?#/P7OY)-8\=CQ)ISZ/<W3II5Y,UM;10W=Y
M$O\ K8[/SGN=O_3(^M=-;_\ !&CQGK=G+KWB#]K[]IB;XE72[GU72?$":;H\
M,N.4BTQ4:-8-WS>5O_A'S#F@#[RKY?\ ^"5?[7'BO]L[X!^*/$OBZ/28]1T;
MQOK'AZ!;"W:&+[+:RA(MP9V^?:?F/Z5RW_!,_P#:P^)7B'XF_$3X!?';^S[S
MXN?"G[/=1ZYI\ AM?%NCSC]Q?JB\+)NX=5557>JXW*]>-?\ !)[]H?1?V3/^
M"6WQP^)'B R-I/@WQ_XKU.6)#^\G99DV0K_M22%$7_:<4 ?I=17Y@_ S]E#Q
M]_P41^&NE_%+X^_M,?$7P/>>,K9=5T?P1\/?$L7A_3_#5K.NZ!)>':XG6,H^
MZ1=R,64EN:Z3X*_&SX@?\$Y_VV/ /P=\=?%6\^-WPE^,336'A+Q)J\Z77B#P
M[JL2*PL[V9/]?'/G:CM\VX_PJC[@KE/T:KQ?]O?]L'2_V#?V8=9^*&M6K7VE
M^'[W3H;JWC;][)#<7]M;2LG]YTCE=PO\6RO:*^#O^"]6AVWQ9^#_ ,$?A3=+
M)-9_%CXOZ!H.HP)(8VDL-TLMP<K\WRJB=*"3[A\->(+'Q=X=L=4TNZM[[3=4
MMTN[2YA??'<0NH='4]U92#GWK(^+_P 4]%^!WPM\1>,O$EVNGZ#X6T^;5-0N
M"?\ 5PQ(7?']YMJ\+_$<"OC[_@CIX]U;X*M\0/V5?&E[-=^*/@)?K%H%U<'Y
M]:\,W)\S3[A?[WE*WE,%^6/]TG6LK_@K3>7?[9/Q^^%/[(>@74T=GXVN1XO^
M)$MN[+)8^&K*566)B/N_:;E513_"R)V:@#ZG_8D_:5A_;#_90\!_$ZWL5TU?
M&6E)?O:!_,%I)EE>/=WVNK+^%>K5\%_\$#[=]3_X)C3?#FXO;VWN/A_XE\1^
M"Y[BUG,-U;LE]-+N1QRCJMRNT_P[5KJO^"/O[07B_P 6>"/B%\'?BAK5YKWQ
M8^ WB2;0=5U"]<M<ZUI\[//IVHO[2P[E7^+;$I;YFH ^RJ*^*-2^-'B[]IO_
M (+'VO@/PGXBU?3/AK^S[X>_M/QJFGW+1P:YK6HC%G87&S[Z11+YV/[RRJPK
MS[XY_'#X@_\ !0_]N3QS\%O ?Q6NO@M\)_@_';VGC'Q-HT\=MKWB'4YU9FLK
M.9SNMXXE#!I8_F61&SN5DH _1BOE_P#X*O\ [77BK]BK]F#3?&'@^/29-6NO
M%>DZ,ZZC T\7D75QY<ORJZ_-MZ'=7S+\:OV1/'W_  3\\ ZI\4/@'^TU\1/'
M%]X/MCJVJ>"/B%XFB\0Z;XFMH$9KB*+:J/#</&I(:,;F;Y05^7;/_P %:/VC
MM&_:\_X) _#3XEZ LT.E^,?%OAC4(H)?]9:NUYB2!C_$T<@=&(X.SY: /TSH
MKXX_X*6_M:_$3PO\3?AS\ _@C)I]K\7/BX;B7^V;Z#S[;PAI, _TC461OE=^
MJQJVY69&X+;5;C+[_@C-\0M*T$ZQH/[9'[2D7Q,CB5EU/4=>6ZT.:5?F"OIC
M+M\C=N^3S6V[V^]0!]]45\>_\$^_VVO&/[17P7^*7A7XDV-IH/QI^"MW<:#X
MI33P4M+M_*>2UO[?^['.B,?]Y&9=JLH'Q]_P2G^%?QX_X*T?L=^']>^*GQP^
M*7@OX?Z']ITK3/\ A$M;^QZ[XPN!<RM->WUZZ.[1)O%ND73]P6^7;N<*Y3]@
MZ*_)&P\>_M-?LL?MIZA^QKX<^)6K>.C\0-/M/$GA7XA^*V74-7\%Z*6N4U"2
M;(_TJ=6MV2!9/EWE#\JMM7H_VU_V6/B1_P $G?A;-^T=X _: ^-7Q$NO!-Y9
M3^+/#7C[Q'_:>F^)K&6X2WE5$5$6&1?.78V&V*K;?F^\!RGZET5\4?\ !1#]
MMOX@VWB;X4?!O]GY;!/BI\;HI-0M=:U.W$EKX6T:*+?-?NC?*9=I^165ERC+
MM+%%;"F_X(Q^,M'TN'7-%_:^_::C^)5K'^ZU;4O$27NCR2[>$?3&3RVM]_S>
M4SM]X_,>*"3[THK\X?\ @D=^T?\ &[XK_P#!0G]I3P?\:M0DCUCP!9:!I_\
M95I<.VD13+%*CW]I$W^J6\5(KC;_ --?PK]'J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U__ )"NB?\
M7ZW_ *3SUJ5EZ_\ \A71/^OUO_2>>M2@ HHHH **** "BBB@ HHHH **** "
MJ^H?\>K?4?SJQFJ>K7,=K8222ND4:<LSMM51GJ:%KL#=M66@WK2ALURGA;XT
M>#_'.KS6&B^*/#NK7UMQ+;66I0W$L?\ O(C%EKJU'R\54Z<HNTU8SIU835X.
MXM%%%2:!1110 4444 %%%% !1110 5SWQ-_Y%RV_["NF_P#I=!70USWQ-_Y%
MRV_["NF_^ET% '0T444 %%%% !1110 4444 %%%% !1110 4444 <_\ "_\
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M)'_A7:/F9E6OLR[_ &A_ 5A\*V\=3^-/"L?@M8OM']NG58/[-V8SN\_=Y?\
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M_#[X[?%J/3KS1_"/QH^*>K^*/"]I<Q>4\EB[A5N-O;S&W*W^U$V/EVUW$?\
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MKXP\56UO::MJT:G[1?0P#;"CG/W47I0!\@Z7_P K*VI?]FYK_P"I'%2^#/\
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M'1=!T_3?$_CQK1O$&HQ*?/U8VL316_FG//EQNRK_ +U 'S%^UO\ LX_LV_\
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M4DF9/H@KZ2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /#?^"D/[(EI^WK^PU\3?A'=316K^,]&>WLKB92T5K>Q.L]I*^.=J7,4
M+GV6OD__ ((]?\%7M#'PUTO]G;X_:A8?"O\ :(^$-I'X<U31]?E6QCUV"U18
MH+VTF<^5-YL2HS"-OF.YT7RRK5^D5>%_MB?\$W_@=^W]I=K;_%[X;^'_ !H]
MC&8K6]F5[74+6/D[([N!TG1-S$[5<+DYH V?VF?VX?A+^QS\.;KQ9\2?B!X7
M\*Z/;P>>AN[U//O/EW!;>%29)W9?NI$K,U?%W_!'[P1XK_;0_;<^+'[;WC'P
M_JGA/0_'VD6_@WX7:1J:;+Q?#D+I*][*G\'VF6*.5/\ ?EV[HVC9O4/@;_P;
ML_L:_L^^-;;Q!H/P1T.\U6SF\VW?7-1OM:AA.[<N(;N:6+Y>S%-W ^:OMF*-
M8(E5%5548 '04 ?GA_P1UB7_ (>+_P#!0!MJ[F^).GJ3W_X\G_QIW_!TBVW_
M (([^-".&_X2#P__ .G6VK[:^&O[/?@OX0^,_&'B+PSX=T_1=:\?WR:EXAO+
M=2LFJW*)L667G[P7BF_'[]GGP7^U'\-;GP?\0/#NG^*O#%Y-#<3Z=>JS0RO%
M(LL;$ C[KJK?A0!\._\ !;1]1_9<_:C_ &6OVKY-)O-8\"? S6]6TSQNMK$;
MB;3--UJVBLO[06/^[ V=Q7YCOC'2ON+X?_M#> _BG\*;?QSX<\8^&M<\&W42
MS)K5IJ,4EB$(#9:4':O5<ACE<\XKK=1TZ#5;&:UNH8;BWN4:*6*5 \<B$8*L
MIZJ1VKXP\=?\&Z7[%OQ$\;/K^H_ 7PW'J$D[7#)I^HZAIUFSDY/^C6]PD&W_
M &=FWVH ];_9B_X*#?"/]OSQ9\3/"OPWUV\\46W@"Y32-9U>TLYETJ>6:-LI
M:7F/*F*[6#;&]&&Y65C\D?\ !OM\<M!_9<^#MY^QG\0-1TWPO\9O@?KFI6 T
MR]E%NWBBQN[V:^MM0LMV/.C=;D#:OS !&8#>M?H-\&?@AX/_ &=_A[I_A/P+
MX8T/PAX:TM2+73=(L8[2VAW<L=B #<S?,S?>9N37GG[87_!.'X'_ +?FFV,'
MQ@^&^@^-I-,1XK2ZN%D@O;5&^9DBN8729%)YVA\9H ^:/^"_7[6WAU/V3->_
M9U\+76G^+/CE\=EA\(^'/"-I.LMXOVJ5%EN[A5S]G@BB\Q_-DVKN4?PAF7B?
MVS/A?_PH_P#X*'?\$N?!:W#7R^#_ /A(M$^T%BS3?9]"LX=^3\QW;,U]<?L>
M_P#!*[]GW]@'4;J]^$?POT#PCJ5Y!]EFU!7FOM0:/.=GVFX>24*>Z[L-M7/0
M5ZAX^_9Y\%_%'XE^#/&'B#P[IVK>)_AW-=7'AO4IU9I]'DN(UBF:+GC?&JJW
M^[0!^?\ X=^*FA_\$Q_^"[7QFN/B==V?AGP3^UQIN@ZCX1\47\PAT^/4])M6
MM+C39[A_EBD?SO-7<VW#1*/F?;7VM^UQ^W1\+?V&_@9J/Q"^(OBW2M$T&UMC
M<6J&X1KK6&V[DAM(MVZ>5_X57UR=JY8=5\?/V=O _P"U#\-;_P '_$3PKH?C
M+POJ!5Y].U2U6>(NOW7&[[KK_"ZX9?6OG?X#_P#!!C]D;]FCXEV?B_P?\$O#
M=GXBTZZ^V6EU>W=[J:V<P^Z\4=U-+&C+U7:HVGE<&@#XC\*?\$SOB=\??^#;
M;XD:&="FTOXH_%KQ!=_%[3_#;?,UN\M_%>PV"HP51)+;6ZA4*KMDG7<JMNK[
MP_8A_P""OWP3_;-^"NF^(8?'7A;PKXD@@6/Q#X8US4XM/U3P_>H-MQ;S0S%'
MVI)N4/MVMC->V_M,2?$2T^ OBF?X3Q^%[CXD6UB\WA^#Q'%+)I=U<K\PAG\J
M6)PK@,F]77:S*QW*I4_E-\1?VU/V%?BM<1ZI^W!\ [?X-_'2Q1+/Q#;Z_P"
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M%%=QRRW4R+_JHD5/O/MZ^BMMZ3_@KA_R=_\ L2_]E3_]MZ]I_91_X)<? /\
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M/P[X9T4.MEIUHI6"V#RM*X7/K([M_P "H ^-_$%FMS_P<M:(Y+!H/V>&<?\
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M &>?^BE:;_X!7?\ \:H_X>U_L\_]%*TW_P  KO\ ^-5U7_#O+X'?]$I\"_\
M@GA_^)H_X=Y? W_HE/@7_P $\/\ \377S9)VJ_?#_(X^7/\ O2^Z7^9RO_#V
MO]GG_HI6F_\ @%=__&J/^'M?[//_ $4K3?\ P"N__C5=5_P[R^!O_1*? O\
MX)X?_B:/^'>7P-_Z)3X%_P#!/#_\31?).U7[X?Y!RY_WI?=+_,Y7_A[7^SS_
M -%*TW_P"N__ (U1_P /:_V>?^BE:;_X!7?_ ,:KJO\ AWE\#?\ HE/@7_P3
MP_\ Q-'_  [R^!O_ $2GP+_X)X?_ (FB^2=JOWP_R#ES_O2^Z7^9RO\ P]K_
M &>?^BE:;_X!7?\ \:H_X>U_L\_]%*TW_P  KO\ ^-5U7_#O+X&_]$I\"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!EZ_\ \A71/^OUO_2>>M2LO7_^0KHG_7ZW_I//6I0 4444 %%%
M% !1110 4444 %%%% !6?K^FV^JZ3-:W5O#=6\XV2Q2QB1)%)Y#!NHK0JOJ'
M_'JWU'\Z$[.Z!I/1G%^#/V9_AW\.]>_M30? G@W1=2_Y^[#1+:VG_P"^T0-7
M=%<?_6I5Y%+UJI5)S=YNYG3H4Z2M35@HHHJ30**** "BBB@ HHHH **** "N
M>^)O_(N6W_85TW_TN@KH:Y[XF_\ (N6W_85TW_TN@H Z&BBB@ HHHH ****
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M%"HGTE_PJ3PG_P *W_X0S_A&?#__  B/V7[%_8G]G1?V?]G_ .>7D;?+\O\
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M&_L+^'97'V.&^\5:R\;?=:6#3HI8F_WE:)L?[U:?_!P7_P FA> O^RI^&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH R]?\ ^0KHG_7ZW_I//6I67K__ "%=$_Z_6_\ 2>>M
M2@ HHHH **** "BBB@ HHHH **** "J^H?\ 'JWU'\ZL57U#_CU;ZC^= %BB
MBB@ HHHH **** "BBB@ HHHH **** "N>^)O_(N6W_85TW_TN@KH:Y[XF_\
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MM7DEBLHKNUE.1(\2/(J^4\OW4;Y@GW?O+]+Z;)=26$+74<,=TR S)%(9(U?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"1R3_KR;_T-:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^VQXF_:L\(>-/"GQ(T6S\/\ Q=^#NL_\(WXOMK)]]E=S;2T5[;^D4ZJS!?\
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M7K_Q+X\^#?CS6/!>J:GJ$C27FH)!+YD4\K-U_P!:T:_[,- 'VM1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-W;D-M_>K92E.?\ >VUPO_!&+P+!\//^"5OP)L(1M6X\)VNJ-QM^>\!NW_\
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M_5_ ,FL>#=%ETC0]4VC4+;3-X6V>X1?]7+*J^:R-]SS=O;-!6IZM_P $%/\
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MN+>S\1:YJ6M76BSRMA!?VNO275NI?^!7DA$3/_"LC-7UE^R3_P %[?@KX[\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#?BAJJ^(/#VO7*6,>JW(5;O3)G^6-F=57?$SX5M_S#=D-\NUOUL!Z8K^;7X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX(-_!_0?@!\8?VO?!OA=8X_#OAWXGO::=#&Q9;2%8FQ!N;YCY6?+Y_N5F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &7K_\ R%=$_P"OUO\ TGGK4K+U_P#Y"NB?]?K?^D\]:E !1110 444
M4 %%%% !1110 4444 %<_P#%#_D2[G_KK;_^CTKH*Y_XH?\ (EW/_76W_P#1
MZ4 =!1110 4444 %%%% !1110 4444 %%%% !7/?$W_D7+;_ +"NF_\ I=!7
M0USWQ-_Y%RV_["NF_P#I=!0!T-%%% !1110 4444 %%%% !1110 4444 %%%
M% '/_"__ )$NV_ZZW'_H]ZZ"N?\ A?\ \B7;?]=;C_T>]=!0 4444 %%%% !
M1110 4444 %%%% !1110!SO@/_CZU_\ ["TO_H$==%7.^ _^/K7_ /L+2_\
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MM;=NVMM?Y=GZ#>&O#MCX-\.6&D:7:6^GZ9I=M%9V=K GEQ6\,:JB(B_PJJ@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 9>O_P#(5T3_ *_6_P#2
M>>M2LO7_ /D*Z)_U^M_Z3SUJ4 %%%% !1110 4444 %%%% !1110 5S_ ,4/
M^1+N?^NMO_Z/2N@KG_BA_P B7<_]=;?_ -'I0!T%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9>O_ /(5T3_K];_TGGK4K+U__D*Z)_U^M_Z3SUJ9H **** "BBB@ HHS1F@
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M]>3?^AK6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV3_BQXB^+/Q(L=(TR/Q59V=MJ?BWQ"D%NKO:LRQ)-=2!=S88[5;YMK5\U?\
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MLUK:ZAJT27,T3?=E6+._R_\ ;V[?>O"_^#AG_E#G\:/^O73/_3M8UI?L+_\
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MPW1206[;]0OXMP7_ %LC_(_]VZE0_<KU?_@O5^T%XT^$_P"RGX/\!_#G6/\
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M)\)_#O@WP7IMOHWA/PSI\6G:390.\D=O;1KA%#NS,W'\3,6;J2:ZZ@ HHHH
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M0#]OC_H>/AG_ -^(_P#Y$H_X0#]OC_H>/AG_ -^(_P#Y$KK_ +!7_032_P#
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M6_%FH^"_%FG^%[S4?$C6^L7.CW$6GW"O)\C)<,GEMN_AVM\U?MA10.Y^ O\
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MXBU2RCN]$\QUC4WUK,ES"F]OE3S&B\O<>%$A[4"B?2-?"_\ P1^^'_B#P/\
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M[4'P \2>!_\ A(?$'A"YUNWV6FMZ)=O:WVEW"LKQ31NC*WRR!=R;AO7<O\5
MCY)\$?\ !8#QU\$_#UOX7^/'[-_QVM?B)I$0@O+WP9X9&O:'KSI\OVBUN(G5
M5\UAN\H_<W*NXUX+\:/B7\7/VE_^"NW['WC+QIX%OOA=X+FUO6K;P?X9UET.
MOS1Q60EN]0O(TRMNSK]G18&9F7RF_O;F^C/"/C+]NS]G;PQ9^%+[X=_"_P".
MYTO%K;^+8/%C:#=ZA /E26[MYHF'G[<;_+9EW?WOO5O_ ++?[&7Q9\??M86?
MQ^_:-U;PK)XP\.Z7/I'@SPEX7\V32_"<%PN+B=II?FFNI5RC-]W;GYB-JQA9
M@?MN_#+Q[^R'^W-I/[5/PW\(ZO\ $30[OPZWA+XD>%M) ?59;%)1+;ZC91G_
M %LT385D^\R(JC:K,Z'BK_@NWX+\2:9+I7PJ^&_QB^)7Q%N"L%GX<B\(WFG>
M1._W/M=Q.BQP1?WG^;:%/UK[NHH(/)_V--(^*FE?L[>'O^%T:MI.K?$B\22\
MU;^S+5(+6R:1RZ6J;/E?RD(CW_Q,I;YNM?//_!%OP/KWP[\-?M.?VUH.M:5)
MJGQ\\5:G817EF]L^H6LB6?E3P^;M#QOM;:_W6QUK[>HH _+G]MW_ (*<^!_V
MJ?V3?''P=\:? /XL#XP>(+2ZTK2_ M]X5EO)4U,[XK>[M[Q$:!HXG*2B=&Z#
MY=W?ZJTP^(/V0_\ @D4%\=WRWGBCX<_"Q_[7N'E\P/=6NEG>F_\ Y:'>FS=U
M?[W5J^G*^6/^"OGP&^(W[5/['MS\+_AQ91S3^/-7L--U^_EOHK;^Q]($ZRW4
MZ[S^\;$:IL56+*[T 4?^"%7PUN/A-_P24^".DW221R7&AOJ^U_O!;ZZGOE_\
M=N!7UK6;X3\,V/@CPOINBZ7;QVNFZ/:Q65I GW888D"(@^B@"M*@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OS=_X.0/V*?B!\?/V<?"/Q2^"<.K?\+L^$.JL-(;2$W:A=:?J:K8
MWD$7'WL212[C]U(I?[U?I%10!XC_ ,$\/V.=)_8$_8L^'OPETGRI%\'Z4D%[
M=1+M6^OGS+=W'_;2X>1QGHK*O:N$_P""OO[#NN?MW_LDIH_@W5H]#^)7@37[
M+QQX'O92!#'K5@SM;K*?X4=7D3=_"75OFV[3]4T4 ?G'\/\ _@X6\*_#KP=:
MZ#^T5\,?BU\)OC!I_P#H6J>'X/!][J-GJ5VO&_3KB%72:"5MNS<W\>-SK^\;
MQGPKXK^/O[77_!>;]F/XP>,/A3XG^'OPC71_%-KX4TS4+&7^U-*MCILRF\U?
M:K164]X[Q*D#2;E6!5^]\S_L%10!^>__  2R^&_B/PA_P53_ &^M7U;P_KVE
M:1XE\3>&I=(OKRQEM[;4T2RNU=K>5E"RA2P!*%MN5K0\9_#GQ#<?\')_@WQ6
MN@ZTWA>W^ ESILFLK92FPCNFUN1Q;F;;Y8EV?-LW;MO-??%% 'YQ_M8^$?B1
M_P $SO\ @HKXH_:@\!^ _$GQ6^%?Q?TC3],^*7A[PY$+G7M'N=.3R++5;2WR
M#<(L#%'B'*YD8LJG*GQ$_P"#@31_BUX8D\-_LU_"?XN?%?XNZP#9:;IEWX3N
MM(TO1;IEXEU.YN B111?>;:WS;=N] WF+^CE% 'P!\.O^".VI>&_^"'GB[]F
M_4M>M]0^(7Q T;4-1US6Y6/V>?Q%>/\ :FD9E7<8$N!''NV[FCBW;<G;7F_[
M.W_!?30/V6_@EX>^'/[1_P +_C%\./C!X*TN'1+_ $R'PK<:G:^(9[=$@6XT
M^XAW1RI/M#+N8*K,5#NNV1OU'HH _/?_ ())_#WXC_'G]KKX[?M7?$CP3K?P
MQM_BK#IGA[P3X6UI/(U>ST6P1O\ 2+N+_EF\\A1]C?,NU_O(R,WG7[:?_!8?
MX;_%/X%_$KX,_&#]G'XS1_$/4UO]$TGP!>^$7U7_ (26?<\=I<6=W KP-G,4
MOFHVZ)MWE-+M5F_4VB@#YR_X)-?!;QQ^SQ_P3=^#7@GXC7$TOC+PWX9M[344
MFD\V2SZM%:ENY@B*0\<?NN]?1M%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M')/^O)O_ $-:TZS&_P"1R3_KR;_T-:TZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U_\ Y"NB?]?K?^D\
M]:E9>O\ _(5T3_K];_TGGK4H **** "BBB@ HHHH **** "BBB@ KG_BA_R)
M=S_UUM__ $>E=!7/_%#_ )$NY_ZZV_\ Z/2@#H**** "BBB@ HHHH **** "
MBBB@ HHHH *Y[XF_\BY;?]A73?\ TN@KH:Y[XF_\BY;?]A73?_2Z"@#H:***
M "BBB@ HHHH **** "BBB@ HHHH **** .?^%_\ R)=M_P!=;C_T>]=!7/\
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M6?\ GWTO_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\
MQ% &I167YFL_\^^E_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_
M]_W_ /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO
M_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167
MYFL_\^^E_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_]_W_ /B*
M/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\ O_\
M$4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167YFL_\^^E
M_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_]_W_ /B*/,UG_GWT
MO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\ O_\ $4 :E%9?
MF:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167YFL_\^^E_P#?]_\
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M^^E_]_W_ /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\
MGWTO_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &
MI167YFL_\^^E_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_]_W_
M /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\
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M45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\ O_\ $4 :E%9?F:S_ ,^^E_\
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M6?\ GWTO_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\
MQ% &I167YFL_\^^E_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_
M]_W_ /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO
M_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167
MYFL_\^^E_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_]_W_ /B*
M/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\ O_\
M$4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167YFL_\^^E
M_P#?]_\ XBCS-9_Y]]+_ ._[_P#Q% &I167YFL_\^^E_]_W_ /B*/,UG_GWT
MO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\ GWTO_O\ O_\ $4 :E%9?
MF:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% &I167YFL_\^^E_P#?]_\
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M^^E_]_W_ /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\
MGWTO_O\ O_\ $4 :E%9?F:S_ ,^^E_\ ?]__ (BCS-9_Y]]+_P"_[_\ Q% !
MK_\ R%=$_P"OUO\ TGGK4K!O[76+V[L9/*TQ?L<YE_U[\_(Z?W/]NK7F:S_S
M[Z7_ -_W_P#B* -2BLOS-9_Y]]+_ ._[_P#Q%'F:S_S[Z7_W_?\ ^(H U**R
M_,UG_GWTO_O^_P#\11YFL_\ /OI?_?\ ?_XB@#4HK+\S6?\ GWTO_O\ O_\
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M%9_B;2=8\0:=';[-.B\N[MKG/GO_ ,LITEQ]S^+9C\: .DHK+\S6?^??2_\
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M^^E_]_W_ /B*/,UG_GWTO_O^_P#\10!J45E^9K/_ #[Z7_W_ '_^(H\S6?\
MGWTO_O\ O_\ $4 4? ?_ !]:_P#]A:7_ - CKHJYO0](UC1I=0;R]-?[==-=
M?Z]_EW*JX^Y_LUH>9K/_ #[Z7_W_ '_^(H U**R_,UG_ )]]+_[_ +__ !%'
MF:S_ ,^^E_\ ?]__ (B@#4HK+\S6?^??2_\ O^__ ,11YFL_\^^E_P#?]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !11FB@ HHW"@-N'% !110&S0 449HH **,T9H **,T$
MXH **,T9H ***,T %%%% !111F@ HHS10 44!LFB@ HHS1G% !11F@-NZ4 %
M%&:,T %%%&: "B@,#WHS0 449HH **,T9H ***,YH ***"<4 %%&:* "BC-%
M !11N&:"V#0%PHHHS0 449Q10 45#]JC\_R_,C\S&[;N^;'KBILT!OL%%%%
M!1110 449HH **,T4 %%%&: "BC-% !11FC- !11NP:A>ZCCFCC+H)),E5)Y
M;'7% 71-111F@ HHHS0 4444 %%&:,T %%&:,T %%&:* "BBB@ HHS1F@ HH
MS1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 8.#07VGZ"DW9/X5X;_ ,%#OVEW_98_9?U[
MQ!8MGQ!J 72M#B W/-?395-J_P 10!Y-O\7E$5KAL/*M5C2AN]#GQ>*AAZ,J
M\]HJY\S^.O\ @H#X@T[_ (*'0>(K=KK_ (4?X:U)/AUJMYYG^B?VA/NE>X_[
M9RQHK/V1/^FM?H4AR![U^6/@_P"-_P +[#_@GM-\&=2\&?%J;4-8L7GU'4O^
M$7DDW:J["7[5DON8),$VYY*(JFOKW_@EO^TW<?M)?LJZ7_;$DW_"7>$'_L'7
M8YU99S-"-J2.&^;<\>QF_P!O>O\ #7TF=X#EHJK2I\JI^YZKI+YN]_D?*\/Y
MIS8AT:E3F=1<WH^L?DK6^9RG[,?_ ">)^U]_UVT?_P!-\U=-_P $?_\ E'-\
M-?\ KC>_^E]Q7,_LQ_\ )XO[7W_7;1__ $WS5TW_  1__P"4<WPV_P"N-[_Z
M7W%9YHE]7GZTO_39IE+?UJ'I5_\ 3B/;OB]\7/#OP,^']]XH\5ZG'H^@Z;Y8
MNKMT=UC\R1(DX0%N7=%X'\5?&O\ P2[_ &R_A_>^+_B5X9N/%D,VN>,_B7K&
MI:!;/',S7MG*D+1NAV;55MC\$K]T\5]U:AI\.I6<D5Q%'/%(/F1U#*?P-?)O
M_!++0[,VOQTF%K;^=;_%SQ!'$WE#,:@6^ I["N# NC]3J^T3YM.OW=#NS%XA
M8^BZ35M>GW]?N/2O$W_!1;X*^#_!^GZ]J'C_ $JWTW5KB2ULR(IGEG>*3RY,
M0JADVJ_RE]NWWKT7XC_&CPK\'O!K>(O%&O:?X>T5=G^E7TODJ2W10&Y+'^[C
M=7R!_P $3O@CHMG\&_$_C:ZL;>\U[5_$-[81W$R"1K6TB?B&//W%+O*QV_>W
M+N^[70>!/AWIW[9'_!0/XDZ_XVACUC0_@Y-:Z%X9T:Z3S+6&XEA$MQ=21-P\
MFX85CQMV_P!Q6KJQ&6X6%>I"+?+3W>FNJ227J]_G;H887-,94P]*;2YJNRUT
MT;;;OV6WROU/7O@__P %$_@K\>O%O]@^%_'VDWVL,_EQ6LT<UG)<MZ1><B>:
M?]S=7H?PJ^+_ (=^-WAJ36/"^J1ZMIT5U+9/-'&Z!)HCM="' /RFN=_:$_9;
M\'_M&> 9]#U[1[3/E8L;^&%8[S295'[N>WD'S1O&V&&./EP>.*^3/V'_ (E:
MI^S;_P $H?B!XDCD^V:]X9OM<,4K+YJR7:R%$=AW7S=K-_LYK".#PU:BZF'N
MI7BK.SWOULOR-I8[%X?$*GBK.-I.ZNMK=+OOWU\CZ?\ CI^W=\)/V:]7_L[Q
MGXXTO2-45%<V:))=W4:M]TM%"CR+GW6O O\ @H5^T!X,_:%_98\*:MX+\2:;
MXDT^/QYHJRO:2[FMW\X_+(A&]&_V6"FO4O\ @GQ^RCX?^"7P4TC7I[>+6/&G
MC&UCUG7==N@)[J\N+A!*ZB1OF$8+D #K]X_,S&O$?^"L'[*GAWPX/!?Q&\-V
M,.@ZI_PEFF6.M162K!!J\+W */,B\-*CJNUOO;7;.<+MZ\NIX*.-C3BW=/?2
MS^6Z\M6<695L?+ 2K22LUMK=+UO9^>B]3[GU[Q%9>%=#N-2U*]MM.L;.(S7%
MQ<RB*&!1U9W;"JH]2:\'L_\ @JU^S[=^*/[%3XF:.MYG9YCV]REKG./^/AH_
M)Q[[\5Y%_P %2?'4GBOX\_"7X9WWA_Q9XH\(WAN/$GB#1O#MMY][K"6_$$.W
M>@,7F$M("W3:?O!:ZC4?VEO#.K^ ?^$7N?V6?C)-X=2+R5TT^"K+[-$F NT)
M]HVCC'W?2N>CEM)4HU*R;YM=&E97MUW_  ]3HK9O5=:=*BTE#35-W=K]+6WW
MU]#ZRL-3M]7T^&ZM;B*\M;J-9(IHG#QRH1N#*1P5(Z&O(]9_X*$_!GPK\+=,
M\97_ (^TF#P_K0F_L^8I*TUYY3M')Y< 3SG"NI7A.U>5_P#!+M?$W@Y/B)X1
MNO"?CKPOX!TO4(KWP;%XHLFAN[>VG\PS6F=[AEBD4;?F+8DR:X?_ ((;?LZZ
M'!^R_9^/]0L[?5->U:\N;6RN;H>:VFV<4[+Y$.[_ %:M+YTC!?O-)S0\MP]*
M-6=63:@XVM;7F3?G9Z>?4<<VQ->5&%"*3FI7O?3E:7E=:^5]&?6'PH_:H^'O
MQQ\!7WB;POXLT;5-"TQ6>^NA-Y(L% W,9EDVM$-H+?.%X&:Y/X=?\%&_@G\6
M_B2GA'P_\0-(U#7IW\J" QS0QW3_ -V*5T6*5CV",V:^:OCU^RYH'B/_ (*L
M>'/"=I'_ &3X1\=>'$UGQ9H]D/)M==>RGE:(2HOR[2Z0[A_$JMW9FKV/_@J'
M\&O#-Q^P[XLOH]'L+*^\'V::CHMW:0BWGTR:*160PNF&3N,+_>JOJ.#=2G3O
M+]Y:VWNWTUTUU[6T(698_P!G4J-1_=7OO[UM=-=-.]]3Z6U/5K;1--GO+RXA
MM;2U0RS33.$CA11DLQ/ 4#DFO"8O^"IO[/\ +XM30Q\3="^V2':)"LPM/QN-
MGD#\7KR/]HJXN_VNOB!^S[\)M<O+B#PQXRT9_%?BJ.W=H6U58+>-XK?>/X&E
M)+KZ;3\I"U]9)\#_  >W@ >%3X7\/GPWY7D?V7]@B^R;,8QY>W;^E<OU7#T(
M1>)NW+M965[=4[[;:>IV1QF*Q4I+"\J4>K3=W9/HU;??7T(] ^-_A7Q?\0-0
M\*Z;K%K>:]I=G#J%S:1!CY=O,,Q2;\;&5@?X6->?^)?^"C'P6\(>$=/U[4?B
M!I=OINJW$EK:-Y,\DL[Q2>7)MA5#)M5_E+[=OO7A7[#?P*M?V<O^"D?QD\+Z
M7<7,VAV_AZPGTN*>4RM8V\KEQ;J6).Q&+JO^R%J+_@B?\$-'M/@_XF\;75C;
MWFN:QX@O;".XF02M:VD3\0QY^XI=Y6.W[VX;ONUVULMPE*,ZCDVDH6V5^=-^
M=OQ."CFV-K3ITE%)R<[[NW(TNZO^!W7[)]P+[_@IC^U!*N[;)#X6=<@J<'3#
MC@U[KK7[1W@W0?B_I_@&;7+=O&&J1^?!I5O')<3B/^^_EJWEKWW/M&.?>O@C
MXH_M/>(_@?\ \%,_C=X0\'+I%GXN^*%SX<TO3=9U>98M.T9DTP$RR9^^_P"\
M'EQ_Q-V;[C?9W[*'['N@_LOZ/?7,=Y=>)/&/B!OM&O\ B746\R^U:;J<DYV1
M@_=0' [[FRQ>:8.-.,*]=VYH0Y4NONK5^7XO\2<GQU2K*>&H+X:D^9OI[S=E
MW;^Y?@3?&O\ ;K^$O[.OB^UT'QEXVTO1=9NE61;5TEFDC#?=:3RT;RE/J^T5
MZ9X5\6Z;XW\.V>KZ/J%GJFEZA$)[:[M)EF@G1NC(Z\,*^,+[7K7]@[]J+XG:
MU\2O"MQJ/P]^+%_#=6_C*"R^VQ:=E%C-C?(H+1Q*WW6P5;*_>^;R_K?X.>'_
M  GX:^&FDV_@:UT>T\*R1?:-/32D1;-DE/F;TV?+ABQ;(]:X,9@Z=&G&=.[O
M;72STU]&MK?D>GE^.K5ZTH5+*U]-;K73U36MU;YG42RA$;.<**^*O^">?[2/
M@7]F_P#8(T?5/&_B;3?#EK/K6L+!]I?]Y<$7\^1%&,O)M_V0:^UGXC;V%?!G
M_!'']E?PW-\.+KXG:Q#_ &UXBN-6O[+2FNCYT>B6T5U)E8$;_5.\OFNS#GYN
M-N6W:X&-+ZE6E6O9.&W7XON,LREB/KU&.'2NU+?I\.OGZ:'TQ\!OVYOA/^TM
MJ7V+P3XTTO6=05&E^Q,LEK=%%^\PAF1)& ]0M>L2W*6T322,J(@RS,V% ]:^
M<?\ @I!^S7H_Q-^!VM>-;55T?QU\/;&77]!URVVQ75K+:H9A&7_BC;;MPWRC
M=FO%_P!NG]I+6/BQ^Q-\%+.WM-<>3XT3:>NNVV@P9O[BT\A9[NWMD9AEG/R@
M,=K+E6^5C11R^GB90=!M)NSOK;KY7T\D36S:MA%..*2;2NK:7UMMK;7S>Y[M
MXD_X*I? #POXN;1;KXE:2UXK^67M[>XN;8-Z?:(XVB_\?KV_PEXSTGX@^&K7
M5]#U*QU?2]0B\VWN[*=9H)T/\2NO!KY2\'?M%^%O ?P]A\+Z3^RQ\9K/P[#'
MY1LE\'6C1.J@\L&N?G/)Y.6.3US6/_P3XBUGP/\ M1>-])\/_#KXA> _A'XB
MTX:S:6/B/3/LL.EZHKI'+%;[7=525&+[=W&S"JJK5ULOH>SE*FFG'NT[_=L_
MO]3+#YI7]I&-5J2GV4E;[]UYZ>AU_P#P2A;/@KXP+M_YJIKIS^,->F?'#]NW
MX2_LXZT=,\9>.-)TG4E56:R0275Q&&^Z7BA1V3/^THKYF_9M^+EY\!/V)_VF
M/%^G!6U#1?'WB*:SW)O59R84B8C^)0[ _05[;^P5^R7X;^#'P.T36+JPM=8\
M:>*K*/5M>UN\07%Y?W%POFN#*V6V+O*@#@XSU9B=,;0HJK4KU[VYK)+KIKKK
M:VG3J9Y=BL0Z-+#8>W-:[;V2O9:*U[^JV/5_@Q^T%X-_:$\.R:MX+\1Z7XDT
M^&012O9S;F@?&=KK]Y&Q_"P!HUSX]^#_  S\1I_".H:]8V'B"UT=O$$UO<$Q
MB'3Q(8FN&D(V*@<$?,PKYF_;%^&.E?LD?M ?"_XP>"+.W\/WFO>*K3PIXILK
M*,16VLV=X67S'C7AI8F3<I5=S,P)^[7-?M*_ VQ_:%_X+(^#]#UO=-X?@^'B
M7^IV&\K%JD46H7)2WE ^_%Y_DN4;Y6\JLZ.6X>I)3YFJ;BWYIQW7G^'R-J^;
M8FDO9N*=124?)J6S\OQVZGO'@O\ X*7_  .\?_$&/POH_P 1-'NM8N)UMH(F
MCFBAN)&;:J1S.BQ.S'@!7.<C&:]X=\#<3P!U]*\3_;B^"7AOX@?L:^-M#O-+
MLX[/2=%N+[3A#"L?]GSV\+20O%M'R;60?=_ARO0XKPOXN?M%^+8?^"2O@/5+
M'5+B#QAX\LM)\._VNSGS(9+G;')<%_X79%?Y\C:S[NU94\#2Q'*\/=7ERZZ_
M/1(VGF5;#2G'%6=H\RLK;=+-ORUO]Q[A\3/^"D?P/^$/C%M U[XB:+;ZM#+]
MGFAMQ+>?9Y!G*2M"CK&R[?F#E=O>NLTS]JWX<Z^WA5-/\6Z3J \<3RVNB-:.
M;A-0EB4-(BL@*J54\A\5'^SS^RSX(_9C^'-KX=\+Z+9V\*VZPW-V\*-=:DV/
MFDG?&79B2>>!G:H50%KY2_:)_9?\/_!'_@I)\!?$GA6(:/:^+]9O3J&DVQ\N
MS^U16H'VF*$?*C.C[7(P#L7^)FW:X?"X&O-TH.46E)WTULF]K:?>S+$8S,</
M3C6J*+3:32OI=I;WUW[(^]]VVOA7_@J5^UYX'\-?%'X5>%_^$J6SUSP7\2-$
MUCQ!:JDRFRL C2O(Y";77RY$;:I)^;I7W4H)%?)/_!471[237OV?YS;6_G3?
M%W08Y6,2[I$S,,,>X]JPR?V7UI>U5UKMZ>C.G/O:_4Y>R=GIOZ^J/HCX/_&[
MPM\?? T'B;PCJ\.M:)<.\4=U'&\:ED.UQAP&X/M7F/BK_@I[\!?"'BTZ+>_$
MS0?MR.T;^0LUQ!&0<$--&C1+SZM7&_\ !2S4+^_\*?#GX3Z'<MH%O\6/$T6C
MZI=68$4B6"J9+A4(^ZS_ "K_ +0W+_%7N'@;]FKP%\,OA['X7T;PGH-GH*Q>
M4]F;))(YAC!,FX'S&;NSY8YR:?L<+"FJM:_O7LDULNK=OT)CBL75FZ%&UX6Y
MFT]WK9*_Z]3JO"/B[2_'7AJSUC1=0M-6TN^B6:VN[2=9H9T;HR.O#"M0G:N<
M=J^._P!GCPI;_LC?\%$O$'PM\.LT/P_\<>&?^$OL-+R6BT:^2X\B5(5S\L4B
M@N?]K8HX6OL53NXKDQF'5*:Y7=-77HSMP.*E7IOG5I)M/U7]7/@/]JS]NGX:
MZ5_P42^#-T?&<$.G?#^;Q)I_BG$=QLT^X:U$"(XV?.?-5A\N[E:[7X__ !$T
M?XF?MR_LA^)M$OH[[0]63Q+=6MTJLB2Q-I\.'^8 C\:O?M2>'[$_\%-/V8T^
MPVC+>)XH:=3"N)3_ &<#EN/FY]:X_P#X*?\ PD@^+G[6_P"S#X0^T7.G:?J]
MWKEK=BRD:!GM/*LVGA5DP5$D2O&<?PN:^DPZP\ZF'C9Q_=SN]]/WGDOZT\SY
M+$/%1AB974K58:6MK^[ZW?\ P^OD>V7_ /P5 ^ NF>.F\.3?$O05U-9/*9U$
MS6:MG'-R$\C_ ,?KWB*9+F'S$965AD,#D,*XG6_V?/"&L_!J\\ MX=TNW\)W
M5FUDVFP6R1P(A&,HH&%8=0PY5@#7RC^RM^T+KOPJ_P""/&L>)FO)+_5O!-MJ
MNG:;<7.9&_<W#Q6V_P!53*+M_NH!7B_4Z->GS8:Z?,HZ_P!Z]GLK;;:^I[WU
M_$8>IRXNS7(Y:)JW+:ZU;OOOIZ'T%\=/^"@OP=_9RUYM)\8>.M-TW5(\>99P
MQ37MQ!NZ;T@1V3_@0%=A\%/VBO!/[1?AV35/!/B73/$5G"=DIM)/WENQZ+(A
MPZ-[, :^,/V'_B=I'[.GP6TW_C'_ ..&O>+-:A%_KOB+_A&[>YEUJYF!=W$S
MW.]X_G(7=MR.2-S-2:CKNH2?MB_#_P >?#+X&_%OP'=7FI1Z5XP^W:!%9Z;J
MNF3E4:640S/^]@;:ZMM'W?F/"UV3RNA>5*%TU?WFU9V\MU?IJSAIYWB/=K3L
MXRM[J4KJ_GL[==$?1>C_  C^&=I_P4)U;Q1!KNK-\5;GPPAN=)-R_P!E33]Z
M1"<)LV_>1%V[]N?FV;OFK;\;_MV?"7X=:-KE]KGC;2["#PWJ;Z/J"R)*TL=X
MB[FA2-4WRL!S^[5J\S\._P#*9O7LC_FED7'_ '$5KS__ ()]_!32?$_[<G[1
M7C35+6.^U#1?%D]AIIF4.MD97=YG13PKL%A7>/FVJ1WJ98.G*+J5Y-J,(O[[
M*WIJ5''5HR5+#12<ZDEUZ:WWW_K0^U? WC;3?B1X0TW7M'N/M>DZO;)>6<_E
MNGG0NNY'VN PW*<\BN<\=?M&^!_AAXQ.@^(?$FGZ/JBZ5)KC1W;&)$LHVV/,
MSD;%4-QRV:[:*);=0L:A548P!P*^'/VK/@_IGQP_X*[?";2=<MUO='M?"DVI
M75H_S17?DW$SQI(O1T\T1L5;Y6VUP9?AZ5:I)5&U%)OST1ZF98NMAZ,732<V
MTO+5V/J?X$?M,^"?VE?"5_KW@K7H]:TC3;I[.XNA;36Z1RHJLP_>(N[Y6!R.
M,,*\Z\2?\%4_@!X8\7'1;KXE:2UZK^67MX+BXME;_KXCC:+_ ,?KSW_@KMXT
MO/#WPH\$^ =%L]::U^(OB&'3M3MM @5K^ZT^-=\T$"952[@(NUF"LH93\I-2
M^$/VB_"_@'P!;^%M'_98^,MIH,,8B-B/!MHT3J,\LK7/SDY/+98Y/7-=M/+Z
M#I*NXR:E>RNE9+JVUKKY'G5LUQ"K/#QDDX6N^5N[?1)/33NV?5O@_P 9:3\0
M?#EGK&AZC8ZQI>H1^;;WEG.LT$Z?WE=?E->5^//^"A7P8^&'Q/;P?KGQ T33
M?$$;^5/;OO,=H_\ <EF"F*)N>CNIKQ#_ ()[P:QX)_:F\<:/X?\ AS\0O ?P
MA\1Z>-9L['Q'IGV6+2]45TCEBM]KNJI*C%]N[C9A555KGO@UKGAO]B?4/%?P
MG^.'A6"WT'QIX@O+RP\87=FMUH_B**XD9D2[DQB*=0VW:_R@>BX=JCE=%5)1
M=YV2:2M?7?OJNJ7Y!+.*TJ5.:2A=M-N]KK;MI+HW^9]E_$'XU>%?AAI>BZAK
MVM6MC:>(M0M]+TR?:TJ7=S/GR44H#]_!P?N^]>=_%+_@H_\ !+X+>,V\.^)/
MB#I-KK,+^5/;Q1377V9^ZRF%'6-O]ERIKQ__ (*X_#^.[_9N^%7A?PLT/A]+
MCQ[HNF:5)8@1)8;HYXX6BVXV[,JR[?[M?27P4_9I\%_ +X?V_ASP[H.GVMBD
M(CN)&@1Y[\_Q/.Y&Z5V/)9NIKG6'PE/#QK5N9MMZ*RVMK>S^XZ?K>-JXJ5"C
MRI12U=WOTM=??^9O?#CXI>'_ (P>%+?7/"^M:?KVDWG^JNK*=98CZC(Z,.X/
M(JI\6_C?X2^ ?A9M<\9>(M,\/Z:IV":\F">8_P#<0?>=O]E037S)_P (%8?L
M9_\ !2CP7:>#8?[*\*_'2TU--5T6!?\ 1;>_LH5G6ZBC'";E;:VWY?F?/\.W
MS'Q-\5;3XD?\%'?'^O\ BSX8_$'XH:3\,S;Z#X9T_0](BU"RTJ;;YEQ<3)+,
MB^>TGW&VGY?]Q&K:GE5.<N>+?L^7FZ7WM;M>_7Y^1C6SJK3I\DDE4Y^3K;:]
M^]K=.^GF?4WP<_X*-_!/X]^+$T/POX_TF\U:>3RX+:XBFLI+E_[L0G1/,;V3
M->X;LG%?"_[3OQ.\-_M/?#B^T+6?V;?CK#>>5C3-3B\)VJ7>ES*O[J6*1;G<
MNQL';T(XP>E3_$K]H7XH>#O^"4VBW>N6^I>&_BGK\MOX3EN+R,PW-M)+=&W^
MU-N^Z[P+OW\;7<-VQ14RN$^7V.G,[6;3WZW73OH*CG4Z?.J_O63=TFMNEG?7
MMKK\CW/XN?\ !1CX*? GQ')HOB;X@Z-::M;OY4]I;K)?2V[YQME6!'V-[-BN
MZ^#?[0?@K]H'06U3P7XFTCQ%:1G;*UG.&>!NRR)]]&_V6 -<_P#LW?LD>"?V
M8?AS9Z'X=T2Q61852^U":%6O-2DV[7EF<\LSG/'W5W84!>*=X>_8\\!^$_CR
MOQ(T71VT/Q')926-S_9TS6MKJ",5YGA3"2LN/E+>QY*J5XZWU&SC3YK]'I9_
M+I][.^@\Q;4ZG+RO=:W7SZ_<CY5_:I_;I^&NE_\ !1/X,W3>-((=-^'\_B33
M_%&(I]EA.UJ($1P$^<^:K+\N[E:]H\1:!\'?CI^U-\'/B(WBC4YO%EUIEU-X
M0MK:>2.UU:V2-WD=D,?&U92WWD+?=.X#;7-_M4>'=/;_ (*:_LQQ_8;3;>)X
MH:X7R5Q*?[.!RW'S<^M6OVA+>.T_X*A?LWQPQK'&FE^(@JJ-JK_H@[5[4HTI
M0HJE>+]E)[K9<^FW5_A]YX,95H5*SJVDO:P6SW?)KOT7XZ^1]">%_C+X:\8_
M$3Q%X4TW5(9_$7A,P?VK8F-TEM1,N^)OF RK+SN7(]ZM?$WXDZ'\'_!&I>)/
M$6I0:/HFDQ^;=W4V=D*[@H)QR?F(&!US7S-^V9'_ ,,L?M5_#WX[VH\G0]1<
M>#O&I5?E%E.V;:Z?_KE,J[F^]M"+3_VW96_:E_:/^'/P'M&:71V<>,?&@4_+
M_9UL^+>W?U6>?Y2/O+M1J\NGE\)RIS3]QJ[?:WQ?\#U1ZU7-*E.%2$E^\3LE
MWO\ #_P?1GU)X;\1VOBSP_9:K8RM-8:E EU;2-&T9DC=59&VL R_*1PPS7B_
MQ._X*8? WX->+I=!U_XAZ5;ZK;2^1-#:P3WWD/W#M#&ZH5_BW'Y>^*Q_^"JO
MQ=UGX,?L7:]-X;>XAUO7)K?0K2:V4^;";APCE-OW7V;PK=F*UYO^S_\ %[PK
M^SG\*;7PKX?_ &9_CDMK' L5U._A&T,VJ28&^29OM/SLS#//RC@+A0HJL+E]
M.5'ZQ43:D[))I;=;OU[&>-S2K"O]7I-)I7;:;WZ)+T[_ 'GUI\,?BOX;^-'A
M*'7_  GKVF>(-'N"52ZL9UFCW#JA(Z,.ZGD5TV:^#?V<Y]4\-?M\Z?JW@/X1
M_$_X>^ _'%G<6_BVTUG1%LM.BNXT>6VO(UCD=49F7RFZ+^\Z99C7VUXY\3)X
M*\&:MK,RF2/2;*:\91_&(T9\?^.UQXS!1I5%&F[J6OGZ.W4[LNQTJU%SJJSB
M[/>WJK]/^&.-^._[7GPU_9H6'_A./%^D^'[B=/-BMI6:6XD3=MWK"@:1EW=P
MN*D^!/[6/PZ_:5M[F3P+XNTGQ%)9JK7$,+LEQ"I^Z7B<*Z@^I6O"?^"9'P(T
MWQI\*+?XU>+K.S\1?$;XE3S:M=:E=1+*UC"TC+%;V^[/EQK&J_*OKM^ZJ@5?
M^"F_P9TKX0?#A/CQX,L[3P[\0/AU=VUZMU:1+ -8MI+B.*:UN0NW?&RR'K\W
MRX[UW_4\(ZWU--^TO:^G+?M;>U]+W\['G_VAC?8?76E[.U[:WY=[WVO;6UO*
MY].:'\8/#GB/XFZYX.M-4CF\3>&X(+C4;#8Z/!'.NZ)_F&UU//*$[>AP:UO%
M?C'2_ ^F+>ZO?6]A:27,%FLLS[5::>5(8D^K2.BC_>KY;_:UU*/X&_M"?"GX
M_67G0Z->>7X2\6,5V_\ $NO2'MIY?[JPW!#-_$=RBN5_X*0Z)K_[:GQIT?X%
M^$-0DL?^$?TB?QCKEW&VU8[A4:/3K<L#\I:4[F5OX75Q]RHHY;&I4A[UHM7;
M[6W_ .!ZHTK9S*E2J>[>:=DN]]OUOZ,^X<;>1SZUYE>_M??#FP^'GBCQ9-XH
MM5\.>#-3.C:Q?^3,8K2[$B1&+(3YSODC7*;A\XKP^7_@H'<S?\$T?^%A!&7Q
M\T'_  C?]G[ MQ_;^[[/L\OCGS/WVS^Y7&?MG?L_Q_LQ?\$3M>\'[O/O]/M]
M,GU*<G<US>2ZK:RW$A;O^\9L>P%/#Y6O:1I5W9RJ*'XZOY75B<5G$O92JX;5
M1IN>O>WNKYV=_0^BOC7_ ,%!/@[^SQK\6D^+O'6FZ7JL@5FM(XIKJ> -\R^:
MD*.T61S\^VO1?AM\3M!^+_@ZR\0>%]7LM<T;4%+07EI*)(GVDJP]F5@RE3RK
M*0>17"_L?_LY:+\!/@EI-I;VL5UK>J6D=WKFJS+OO-7O)5#RRS2-\SY<G 8_
M*-HKR']C?1(O@]^WS\?O VA_Z+X6V:7K]MIRY6"RN;F)C.8E^Z@=B.%_N(/X
M:B>$P\XU%0O>GK=[/5+:VF_=FE/&8JG.E+$)<M32RO=.S>]]=NR/>OCI^T[X
M!_9IT>"]\=>*-+\.PW&[R4N'+37&.NR- 7?'^RIK!^ W[=GPD_:7U,Z?X*\;
M:;J^H[6<64B2VEU(J_>*PS(DC >H6OC/]G#XVVGC#]H#XC?%;Q5\'_BA\3-;
MO->N=)T"^TK0X=0T_1-.MSY20P^;,FR5OF\S:O?[WSOGI/VR_&\/[1OA WV@
M_L_?'3P[\3M'E6^\.^(X_#-O;SVEU&0R^9(EP6,38PRLK=<A=R\=CRBC&:H3
MOS=[JR?IO9=7?Y'G_P!O5YQ=>G;DZ1M*[7KLF^BL_4^V/'_QL\+_  N\0Z#I
M.OZS:Z7?>)I)HM-CF#;;EHD\R3YL;5VISEB!7'^ ?VZ?A+\3]+\57VA^-M*O
M-/\ !*J^M7I66*TLU;=@^<Z"-P=IP48YQQ7RW^WIX9O?VE-=_9'TWQAI]UI%
MYXLOR-?T\AK>6$O;VS7=O_>7_EHGT)KW;]O?]E_4/BU^RL_AWP/H^EM=:'?V
M.IVNA;$M;358K64,;)L;5567.WH-P7[N=PP67X6,*2JR=Y^EE:5OGMY'1+,L
M9.=9T8IJGLK.[O%.WEOYWVL=E\"?VXOA3^TUK$VE^"?&FEZQJEN&+6FV2WN'
M5>K)'*B,ZC^\H(KUEFV_-7SE^S7\?/A7^U'XZLY&\*P>&/BKX(MGA?1M:TQ+
M?6-#1E$;^4Q7F(YQN0_=89"[MM?1P&#TKS\=0C2J<BBUY/\ S5KH];+<1*O2
MYY24O-:?@[V9(#D4445R'H!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS,6&3QTW-Q7_  2<^'&O?"C]A/P?H7B32+_0]:LY;]I[*]A,4T.^]G==P/\
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MUZI^T3\-=-F\+ZC'H_CKP;JT/B#PW>2C,*W<.<1R\?ZN12RM]1U7*GSS0_\
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M' ;^+J?K [L'O2"/<V[C\JVIXN*IJE5CS);=+?\  .:O@).JZM"?*WOI=/\
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M+]W%($PM&*Q3KJ,;6459?>W^H\#@OJ_-)N[F[M[=$MO1$M% X%%<IWA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 '6BBB@ HHHH **** "BBB@
MHHHH **** #%%%% !1110 48HHH **** "C&:** "BBB@ Q1110 8HQ110 4
M444 %%%% !1110 8HHHH **** #I1110 4444 %%%% !1110 4444 &****
M"BBB@ HHHH ,4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** #%%%%
M !1110 =:*** "C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803436864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Nov. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,490,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803932144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,207<span></span>
</td>
<td class="nump">$ 43,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">159,845<span></span>
</td>
<td class="nump">65,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,679<span></span>
</td>
<td class="nump">32,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">12,852<span></span>
</td>
<td class="nump">9,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid manufacturing costs</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">16,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">6,062<span></span>
</td>
<td class="nump">5,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">272,605<span></span>
</td>
<td class="nump">171,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,407<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">282,498<span></span>
</td>
<td class="nump">181,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,641<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">25,733<span></span>
</td>
<td class="nump">26,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">9,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">12,394<span></span>
</td>
<td class="nump">21,862<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">52,660<span></span>
</td>
<td class="nump">62,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">40,849<span></span>
</td>
<td class="nump">43,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">199,803<span></span>
</td>
<td class="nump">27,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 200,000 shares authorized; 129,488 and 128,152 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">545,751<span></span>
</td>
<td class="nump">525,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(557,955)<span></span>
</td>
<td class="num">(482,658)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(11,992)<span></span>
</td>
<td class="nump">42,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">$ 282,498<span></span>
</td>
<td class="nump">$ 181,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803485600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">129,488<span></span>
</td>
<td class="nump">128,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">129,488<span></span>
</td>
<td class="nump">128,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803621376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 13,331<span></span>
</td>
<td class="nump">$ 10,301<span></span>
</td>
<td class="nump">$ 39,970<span></span>
</td>
<td class="nump">$ 32,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties</a></td>
<td class="nump">13,036<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
<td class="nump">36,695<span></span>
</td>
<td class="nump">21,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenues under collaborative agreements</a></td>
<td class="nump">5,486<span></span>
</td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">31,023<span></span>
</td>
<td class="nump">28,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">31,853<span></span>
</td>
<td class="nump">20,780<span></span>
</td>
<td class="nump">107,688<span></span>
</td>
<td class="nump">82,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of product sales</a></td>
<td class="nump">9,134<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
<td class="nump">25,204<span></span>
</td>
<td class="nump">20,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">33,863<span></span>
</td>
<td class="nump">27,611<span></span>
</td>
<td class="nump">109,493<span></span>
</td>
<td class="nump">65,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">11,599<span></span>
</td>
<td class="nump">10,226<span></span>
</td>
<td class="nump">33,626<span></span>
</td>
<td class="nump">29,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">54,596<span></span>
</td>
<td class="nump">44,017<span></span>
</td>
<td class="nump">168,323<span></span>
</td>
<td class="nump">115,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(22,743)<span></span>
</td>
<td class="num">(23,237)<span></span>
</td>
<td class="num">(60,635)<span></span>
</td>
<td class="num">(32,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,253)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
<td class="num">(14,378)<span></span>
</td>
<td class="num">(3,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(27,662)<span></span>
</td>
<td class="num">(24,460)<span></span>
</td>
<td class="num">(74,053)<span></span>
</td>
<td class="num">(36,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,946)<span></span>
</td>
<td class="num">$ (24,460)<span></span>
</td>
<td class="num">$ (75,637)<span></span>
</td>
<td class="num">$ (36,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic and diluted net loss per share</a></td>
<td class="nump">128,154<span></span>
</td>
<td class="nump">126,921<span></span>
</td>
<td class="nump">127,886<span></span>
</td>
<td class="nump">126,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792315680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,946)<span></span>
</td>
<td class="num">$ (24,460)<span></span>
</td>
<td class="num">$ (75,637)<span></span>
</td>
<td class="num">$ (36,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (29,079)<span></span>
</td>
<td class="num">$ (24,420)<span></span>
</td>
<td class="num">$ (75,455)<span></span>
</td>
<td class="num">$ (36,508)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792418752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,637)<span></span>
</td>
<td class="num">$ (36,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">18,843<span></span>
</td>
<td class="nump">15,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Non-cash interest expense</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payment-in-kind Interest expense on long-term debt</a></td>
<td class="nump">9,152<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on marketable securities, net</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">14,732<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(3,363)<span></span>
</td>
<td class="num">(4,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,401)<span></span>
</td>
<td class="nump">6,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(4,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(34,616)<span></span>
</td>
<td class="num">(21,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(152,404)<span></span>
</td>
<td class="num">(46,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">57,283<span></span>
</td>
<td class="nump">67,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,690)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(97,811)<span></span>
</td>
<td class="nump">20,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of long-term debt, net</a></td>
<td class="nump">203,005<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(54,285)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans, net</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">11,367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">150,342<span></span>
</td>
<td class="nump">11,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">17,915<span></span>
</td>
<td class="nump">10,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">43,292<span></span>
</td>
<td class="nump">61,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 61,207<span></span>
</td>
<td class="nump">$ 71,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6581620208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators&#8217; proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant, and it works by temporarily breaking down hyaluronan (or &#8220;HA&#8221;), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;"> Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (&#8220;Baxalta&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), and Eli Lilly and Company (&#8220;Lilly&#8221;). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (&#8220;PDA&#8221;) (Studies 109-202 and 109-301), in Phase 1b clinical testing for</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">PEGPH20 with KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (eribulin) in first line and second line HER2-negative metastatic breast cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794371168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-15&#8221;). Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in the amendments in ASU 2016-15. The amendments are an improvement to U.S. GAAP and are intended to reduce the current and potential future diversity in practice. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-09&#8221;). ASU 2016-09 changes certain aspects of accounting for share-based payments to employees and involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Specifically, ASU 2016-09 requires that all income tax effects of share-based awards be recognized as income tax expense or benefit in the reporting period in which they occur. Additionally, ASU 2016-09 amends existing guidance to allow forfeitures of share-based awards to be recognized as they occur. Previous guidance required that share-based compensation expense include an estimate of forfeitures. We have elected to early adopt ASU 2016-09 as of January 1, 2016 and made a policy election to account for forfeitures as they occur. The cumulative effect of adoption was a decrease of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to both additional paid-in capital and accumulated deficit. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires lessees to recognize assets and liabilities for most leases and provide enhanced disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-01&#8221;). ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. An entity&#8217;s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of ASU 2016-01. ASU 2016-01 requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement. ASU 2016-01 is effective for interim and annual reporting periods beginning on January 1, 2018. Entities should apply the amendments by means of a cumulative effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of ASU 2016-01. We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued Accounting Standards Update 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2015-17&#8221;). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. For&#160;public business entities, the guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. The guidance may be adopted on either a prospective or retrospective basis. We elected to early adopt ASU 2015-17 on January 1, 2016. There was no impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued Accounting Standards Update No. 2015-11,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2015-11&#8221;).&#160;ASU 2015-11 requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 is not expected to have a material impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued Accounting Standards Update No. 2015-03,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2015-03&#8221;).&#160;ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. The recognition and measurement guidance for debt issuance costs is not affected by ASU 2015-03. We adopted ASU 2015-03 on January 1, 2016. There was no material impact on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements &#8212; Going Concern </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2014-15&#8221;).&#160;The provisions of ASU 2014-15 provide that, in connection with preparing financial statements for each annual and interim reporting period, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 is effective for the annual reporting period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the effect that the adoption of ASU 2014-15 will have on our financial statement disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2014-09&#8221;). In March, April and May 2016 the FASB issued additional guidance related to Topic 606. These new standards will eliminate transaction-specific and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for our interim and annual reporting periods beginning on January 1, 2018. Entities can transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. We have not yet selected a transition method, and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. Our cash equivalents consist of money market funds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders&#8217; (deficit) equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, restricted cash of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> was pledged as collateral for the letters of credit.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major financial instrument type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> financial instruments that were classified within Level 3 as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to receiving marketing approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, inventories consisted of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant inventory, net, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of bulk rHuPH20 for use in the manufacture of Balxalta&#8217;s and Roche&#8217;s collaboration products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered; (3)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (4)&#160;collectibility is reasonably assured.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (&#8220;GPOs&#8221;), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. As a result, we recognize </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</font><font style="font-family:inherit;font-size:10pt;">. We allow the wholesalers to return product that is damaged or received in error. In addition, we accept unused product to be returned beginning </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> prior to and ending </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;"> following product expiration. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution Fees</font><font style="font-family:inherit;font-size:10pt;">. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesalers for distribution services they provide with respect to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. These fees are generally a fixed percentage of the price of the product purchased by the wholesalers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font><font style="font-family:inherit;font-size:10pt;">. We offer cash discounts to certain wholesalers as an incentive to meet certain payment terms. We estimate prompt payment discounts based on contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discounts and Fees</font><font style="font-family:inherit;font-size:10pt;">. We provide discounts to end-user members of certain GPOs under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals, who are members of the GPOs, with which we do not have contracts. The end-user members purchase products from the wholesalers at a contracted discounted price, and the wholesalers then charge back to us the difference between the current retail price and the price the end-users paid for the product. We also incur GPO administrative service fees for these transactions. In addition, we provide predetermined discounts under certain government programs. Our estimate for these chargebacks and fees takes into consideration contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for product returns and chargebacks are based on amounts owed or to be claimed on the related sales. We believe that our estimated product returns for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. In order to develop a methodology to reliably estimate future returns and provide a basis for recognizing revenue on sales to wholesale distributors, we analyze many factors, including, without limitation: (1) actual </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product return history, taking into account product expiration dating at the time of shipment, (2) re-order activities of the wholesalers as well as their customers and (3) levels of inventory in the wholesale channel. We have monitored actual return history on an individual product lot basis since product launch. We consider the dating of product at the time of shipment into the distribution channel and changes in the estimated levels of inventory within the distribution channel to estimate our exposure to returned product. We also consider historical chargebacks activity and current contract prices to estimate our exposure to returned product. Based on such data, we believe we have the information needed to reasonably estimate product returns and chargebacks. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer&#8217;s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche&#8217;s Herceptin SC product in August 2013 and MabThera</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> SC product in March 2014 and Baxalta&#8217;s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&#160;the license to our rHuPH20 technology, (ii)&#160;at the collaborator&#8217;s request, research and development services which are reimbursed at contractually determined rates, and (iii)&#160;at the collaborator&#8217;s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators&#8217; ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the market place. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&#8220;VSOE&#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition - Milestone Method </font><font style="font-family:inherit;font-size:10pt;">(&#8220;Milestone Method of Accounting&#8221;). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A milestone is defined as an event (i)&#160;that can only be achieved based in whole or in part on either the entity&#8217;s performance or on the occurrence of a specific outcome resulting from the entity&#8217;s performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to the vendor.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator&#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 4, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on our collaborative agreements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments in connection with our clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, such revisions to our clinical trial expense accruals have not had a material impact on our consolidated results of operations or financial position.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), and RSUs with performance conditions (&#8220;PRSUs&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</font></div><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. Valuation allowances have been established to reduce our net deferred tax assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, as we believe that it is more likely than not that such assets will not be realized.&#160;The interim tax provision is calculated using the estimated effective tax rate expected to be applicable for the full year. During the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in income tax expense, comprising U.S. federal alternative minimum tax.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">13.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">9.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i)&#160;research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii)&#160;product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790678800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable securities disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$153.8 million</font><font style="font-family:inherit;font-size:10pt;"> of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale marketable securities in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on these marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> because we do not intend to sell these marketable securities prior to maturity and it is not more likely than not that we will be required to sell these marketable securities before the recovery of their amortized cost basis.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790702640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Roche Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2006, we and Roche entered into a collaboration and license agreement, under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">thirteen</font><font style="font-family:inherit;font-size:10pt;"> Roche target compounds (the &#8220;Roche Collaboration&#8221;). As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Roche has elected a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> targets, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of which are exclusive, and in addition retains the option to develop and commercialize rHuPH20 with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> additional targets. In August 2013, Roche received European marketing approval for its collaboration product, Herceptin SC, for the treatment of patients with HER2-positive breast cancer and launched Herceptin SC in the European Union (&#8220;EU&#8221;) in September 2013. In March 2014, Roche received European marketing approval for its collaboration product, MabThera SC, for the treatment of patients with common forms of non-Hodgkin lymphoma (&#8220;NHL&#8221;). In June 2014, Roche launched MabThera SC in the EU.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Roche Collaboration, while we are responsible for the supply of bulk rHuPH20. We are entitled to receive reimbursements for providing research and development services and supplying bulk rHuPH20 to Roche at its request.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Roche Collaboration, Roche pays us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche&#8217;s obligation to pay royalties. Roche has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Roche Collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from Roche, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Election of additional exclusive targets and annual license maintenance fees for the right to </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;designate the remaining targets as exclusive targets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical development milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees, annual license maintenance fees and sales-based milestone payments were deferred and are being amortized over the remaining term of the Roche Collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of Roche deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. For each of the the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> of Roche deferred revenues, excluding reimbursements for providing research and development services, as revenues under collaborative agreements. Roche deferred revenues, excluding deferred revenues related to reimbursements for providing research and development services, were </font><font style="font-family:inherit;font-size:10pt;">$36.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Baxalta Collaboration</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2007, we and Baxalta entered into a collaboration and license agreement, under which Baxalta obtained a worldwide, exclusive license to develop and commercialize HYQVIA, a combination of Baxalta&#8217;s current product GAMMAGARD LIQUID</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;"> and our patented rHuPH20 enzyme (the &#8220;Baxalta Collaboration&#8221;). In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use), a combination of GAMMAGARD LIQUID and rHuPH20 in dual vial units, as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the EU in July 2013. In September 2014, the FDA approved HYQVIA for treatment of adult patients with primary immunodeficiency. In October 2014, Baxalta announced the launch and first shipments of HYQVIA in the U.S. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Baxalta Collaboration is applicable to both kit and formulation combinations. Baxalta assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Baxalta Collaboration, while we are responsible for the supply of bulk rHuPH20. We perform research and development activities and supply bulk rHuPH20 at the request of Baxalta, and are reimbursed by Baxalta under the terms of the Baxalta Collaboration. In addition, Baxalta has certain product development and commercialization obligations in major markets identified in the Baxalta Collaboration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Baxalta Collaboration, Baxalta pays us a royalty consisting of a mid-single digit percent of the net sales of HYQVIA. Unless terminated earlier in accordance with its terms, the Baxalta Collaboration continues in effect until the expiration of Baxalta&#8217;s obligation to pay royalties to us. Baxalta has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Baxalta Collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from Baxalta, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive target</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the upfront license fee and sales-based milestone payments were deferred and are being recognized over the term of the Baxalta Collaboration. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each of the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of Baxalta deferred revenues as revenues under collaborative agreements. For each of the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of Baxalta deferred revenues as revenues under collaborative agreements. Baxalta deferred revenues totaled </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Collaborations</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Lilly proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> targets (the &#8220;Lilly Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Lilly has elected </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> specified exclusive targets and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> specified semi-exclusive target. Lilly has the right to elect up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to Lilly&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Lilly Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Lilly Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Lilly may terminate the agreement prior to expiration for any reason in its entirety upon </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us.&#160;Upon any such termination, the license granted to Lilly (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with AbbVie proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> targets (the &#8220;AbbVie Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, AbbVie has elected </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> specified exclusive target, TNF alpha. AbbVie has announced plans to develop rHuPH20 with adalimumab (HUMIRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) which may allow reduced number of induction injections and deliver additional performance benefits. AbbVie has the right to elect up to </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to AbbVie&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay tiered royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the AbbVie Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the AbbVie Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. AbbVie may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days prior written notice to us.&#160;Upon any such termination, the license granted to AbbVie (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Janssen proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> targets (the &#8220;Janssen Collaboration&#8221;). Targets, once selected, will be on an exclusive, global basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Janssen has elected </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> specified exclusive target, CD38. Janssen has the right to elect </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> additional targets in the future upon payment of additional fees. In addition, Janssen will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Janssen Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Janssen Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Janssen may terminate the agreement prior to expiration for any reason in its entirety or on a product-by-product basis upon </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us.&#160;Upon any such termination, the license granted to Janssen (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Pfizer proprietary biologics directed at up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> targets (the &#8220;Pfizer Collaboration&#8221;). Targets may be selected on an exclusive or non-exclusive basis. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Pfizer has elected </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> specified exclusive targets. Pfizer has the right to elect </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> additional target in the future upon payment of additional fees. In addition, Pfizer will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Pfizer Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Pfizer Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years following the date of the first commercial sale of such product in such country. Royalties are subject to adjustment as set forth in the agreement. Pfizer may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us.&#160;Upon any such termination, the license granted to Pfizer (in total or with respect to the terminated target, as applicable) will terminate, provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments received from other collaborators for upfront license fees, license fees for the election of additional targets, maintenance fees and event-based payments since inception of the collaboration agreements are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the Pfizer, Janssen, AbbVie and Lilly arrangements, we identified the deliverables in each arrangement to include the license, research and development services and supply of bulk rHuPH20. We have determined that the license, research and development services and supply of bulk rHuPH20 individually represent separate units of accounting, because each deliverable has standalone value. We determined that the rights to elect additional targets in the future upon the payment of additional license fees are substantive options that are not priced at a significant and incremental discount. Therefore, we determined for each collaboration that the rights to elect additional targets are not deliverables at the inception of the arrangement. The estimated selling prices for the units of accounting we identified were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives. The arrangement consideration was allocated to the deliverables based on the relative selling price method and the nature of the research and development services to be performed for the collaborator. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (non-contingent amount). As such, we excluded from the allocable arrangement consideration the event-based payments, milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> license fees from Pfizer, the </font><font style="font-family:inherit;font-size:10pt;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;"> license fee from Janssen, the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront license fee from AbbVie and the </font><font style="font-family:inherit;font-size:10pt;">$33.0 million</font><font style="font-family:inherit;font-size:10pt;"> license fees from Lilly to the license fee deliverable under each of the arrangements. We determined that the upfront payments were earned upon the granting of the worldwide, exclusive right to our technology to the collaborators in these arrangements. As a result, we recognized the </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> license fees under the Pfizer Collaboration, the </font><font style="font-family:inherit;font-size:10pt;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;"> license fee under the Janssen Collaboration, the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront license fee under the AbbVie Collaboration, and the </font><font style="font-family:inherit;font-size:10pt;">$33.0 million</font><font style="font-family:inherit;font-size:10pt;"> license fees under the Lilly Collaboration as revenues under collaborative agreements in the period when such license fees were earned. We recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue in the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> related to event-based payments or milestone payments under these collaborations and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. We </font><font style="font-family:inherit;font-size:10pt;">did not</font><font style="font-family:inherit;font-size:10pt;"> recognize any such revenues for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborators are each solely responsible for the development, manufacturing and marketing of any products resulting from their respective collaborations. We are entitled to receive payments for research and development services and supply of bulk rHuPH20 if requested by any collaborator. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We recognize amounts allocated to the sales of bulk rHuPH20 as revenues under collaborative agreements when such bulk rHuPH20 has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We cannot predict the timing of delivery of research and development services and bulk rHuPH20 as they are at the collaborators&#8217; requests. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of our collaboration agreements with Roche and Pfizer, certain future payments meet the definition of a milestone in accordance with the Milestone Method of Accounting. We are entitled to receive additional milestone payments under our collaboration agreements with Roche and Pfizer for the successful development of the elected targets in the aggregate of up to </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;"> upon achievement of specified clinical development milestone events and up to </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon achievement of specified regulatory milestone events in connection with specified regulatory filings and receipt of marketing approvals.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6609778192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certain Balance Sheet Items</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,442</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,178</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;">                            </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term accrued outsourced research and development is included in other long-term liabilities in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursement for research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,892</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790658032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Debt, Net</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty-backed Loan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">January 2016</font><font style="font-family:inherit;font-size:10pt;">, through our wholly-owned subsidiary Halozyme Royalty LLC (&#8220;Halozyme Royalty&#8221;), we received a </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;"> loan (the &#8220;Royalty-backed Loan&#8221;) pursuant to a credit agreement (the &#8220;Credit Agreement&#8221;) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the &#8220;Royalty-backed Lenders&#8221;). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (&#8220;Collaboration Agreements&#8221;). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the &#8220;Royalty Payments&#8221;).&#160; The Royalty-backed loan bears interest at a per annum rate of </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">plus the three-month LIBOR rate</font><font style="font-family:inherit;font-size:10pt;">. The three-month LIBOR rate is subject to a floor of </font><font style="font-family:inherit;font-size:10pt;">0.7%</font><font style="font-family:inherit;font-size:10pt;"> and a cap of </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;">.&#160;The interest rate as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">9.61%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement provides that </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;"> of the Royalty Payments are required to be applied to the Royalty-backed Loan prior to January&#160;1, 2017, </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the Royalty Payments are required to be applied to the Royalty-backed Loan between January&#160;1, 2017 and January&#160;1, 2018 and thereafter </font><font style="font-family:inherit;font-size:10pt;">all</font><font style="font-family:inherit;font-size:10pt;"> Royalty Payments must be applied to the Royalty-backed Loan.&#160;However, the amounts available to repay the Royalty-backed Loan are subject to caps of </font><font style="font-family:inherit;font-size:10pt;">$13.75 million</font><font style="font-family:inherit;font-size:10pt;"> per quarter in 2017, </font><font style="font-family:inherit;font-size:10pt;">$18.75 million</font><font style="font-family:inherit;font-size:10pt;"> per quarter in 2018, </font><font style="font-family:inherit;font-size:10pt;">$21.25 million</font><font style="font-family:inherit;font-size:10pt;"> per quarter in 2019 and </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;"> per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date.&#160;Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The </font><font style="font-family:inherit;font-size:10pt;">final maturity date of the Royalty-backed Loan will be the earlier of (i)&#160;the date when principal and interest is paid in full, (ii)&#160;the termination of Halozyme Royalty&#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&#160;December&#160;31, 2050</font><font style="font-family:inherit;font-size:10pt;">.&#160; Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January&#160;1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to </font><font style="font-family:inherit;font-size:10pt;">105%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we were </font><font style="font-family:inherit;font-size:10pt;">in compliance</font><font style="font-family:inherit;font-size:10pt;"> with all material covenants under the Credit Agreement and there was no material adverse change in our business, operations or financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, accrued interest in the amount of </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;"> was capitalized and added to the principal balance of the Royalty-backed Loan. In addition, we recorded related accrued interest on the debt of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and incurred additional debt issuance costs totaling </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and are being amortized over the estimated term of the debt using the effective interest method. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$157.6 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of payment-in-kind interest expense of </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;"> and net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oxford and SVB Loan and Security Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2013</font><font style="font-family:inherit;font-size:10pt;">, we entered into an Amended and Restated Loan and Security Agreement (the &#8220;Original Loan Agreement&#8221;) with Oxford Finance LLC (&#8220;Oxford&#8221;) and Silicon Valley Bank (&#8220;SVB&#8221;) (collectively, the &#8220;Lenders&#8221;), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount of new term loan, bringing the total term loan balance to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. The amended term loan facility was scheduled to mature on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for</font><font style="font-family:inherit;font-size:10pt;"> interest only payments through January 2016</font><font style="font-family:inherit;font-size:10pt;">, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a </font><font style="font-family:inherit;font-size:10pt;">7.55%</font><font style="font-family:inherit;font-size:10pt;"> interest rate on the term loan and a final payment equal to </font><font style="font-family:inherit;font-size:10pt;">8.5%</font><font style="font-family:inherit;font-size:10pt;"> of the original principal amount, or </font><font style="font-family:inherit;font-size:10pt;">$4.25 million</font><font style="font-family:inherit;font-size:10pt;">, which was due when the term loan became due or upon the prepayment of the facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2016</font><font style="font-family:inherit;font-size:10pt;">, we entered into a new Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;">. Upon entering the loan, we drew </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;"> at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.25%</font><font style="font-family:inherit;font-size:10pt;"> and used a portion of the proceeds to pay the outstanding principal and final payment owed on the Original Loan Agreement. The remaining proceeds are to be used for working capital and general business requirements. We have the option to draw the remaining </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> during the second quarter of 2017 at an annual interest rate equal to the then-</font><font style="font-family:inherit;font-size:10pt;">current prime rate as reported in The Wall Street Journal plus 4.75%</font><font style="font-family:inherit;font-size:10pt;">. The term loan repayment schedule provides for </font><font style="font-family:inherit;font-size:10pt;">interest only payments for the first 18 months</font><font style="font-family:inherit;font-size:10pt;">, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2021</font><font style="font-family:inherit;font-size:10pt;">. The Loan Agreement provides for a final payment equal to </font><font style="font-family:inherit;font-size:10pt;">5.50%</font><font style="font-family:inherit;font-size:10pt;"> of the initial </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount and, if we exercise our option to draw an additional </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> in 2017, </font><font style="font-family:inherit;font-size:10pt;">7.25%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the second draw. The final payment is due when the term loan becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the term loan in full, subject to a prepayment fee of </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> in the first year and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> in the second year of the term loan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the term loan, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the term loan using the effective interest rate method. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of lender&#8217;s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan.&#160;In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we were </font><font style="font-family:inherit;font-size:10pt;">in compliance</font><font style="font-family:inherit;font-size:10pt;"> with all material covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, including amortization of the debt discount, related to the Oxford and SVB loan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively. Accrued interest, which is included in accrued expenses and other long-term liabilities, was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The outstanding term loan balance was </font><font style="font-family:inherit;font-size:10pt;">$54.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of unamortized debt discount of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790668864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs, RSUs and PRSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have a net operating loss carryforward as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> excess tax benefits for the tax deductions related to share-based awards were recognized in the condensed consolidated statements of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company granted stock options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock during both the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">4.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. We estimated fair value of each stock option granted on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation that we will not be making future dividend payments. The assumptions used in the Black-Scholes model were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.8-66.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.2-67.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.18%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69-1.92%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.34-1.92%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.8</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790640448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' (Deficit) Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; (Deficit) Equity</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">383,719</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,626,091</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.74</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.43</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively, for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">215,779</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">134,088</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">82,396</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">52,019</font><font style="font-family:inherit;font-size:10pt;"> RSUs, respectively, to pay for minimum withholding taxes totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. In addition, we issued </font><font style="font-family:inherit;font-size:10pt;">968,652</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">515,695</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in connection with the grants of RSAs during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. Stock options and unvested restricted units totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2016 and December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794483792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803427136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.&#8217;s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption and Pending Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-15&#8221;). Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in the amendments in ASU 2016-15. The amendments are an improvement to U.S. GAAP and are intended to reduce the current and potential future diversity in practice. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-09&#8221;). ASU 2016-09 changes certain aspects of accounting for share-based payments to employees and involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Specifically, ASU 2016-09 requires that all income tax effects of share-based awards be recognized as income tax expense or benefit in the reporting period in which they occur. Additionally, ASU 2016-09 amends existing guidance to allow forfeitures of share-based awards to be recognized as they occur. Previous guidance required that share-based compensation expense include an estimate of forfeitures. We have elected to early adopt ASU 2016-09 as of January 1, 2016 and made a policy election to account for forfeitures as they occur. The cumulative effect of adoption was a decrease of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to both additional paid-in capital and accumulated deficit. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires lessees to recognize assets and liabilities for most leases and provide enhanced disclosures. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-01&#8221;). ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through net income. An entity&#8217;s equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of ASU 2016-01. ASU 2016-01 requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement. ASU 2016-01 is effective for interim and annual reporting periods beginning on January 1, 2018. Entities should apply the amendments by means of a cumulative effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of ASU 2016-01. We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued Accounting Standards Update 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2015-17&#8221;). ASU 2015-17 requires companies to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. For&#160;public business entities, the guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all companies in any interim or annual period. The guidance may be adopted on either a prospective or retrospective basis. We elected to early adopt ASU 2015-17 on January 1, 2016. There was no impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued Accounting Standards Update No. 2015-11,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2015-11&#8221;).&#160;ASU 2015-11 requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU 2015-11 is not expected to have a material impact on our consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued Accounting Standards Update No. 2015-03,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2015-03&#8221;).&#160;ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. The recognition and measurement guidance for debt issuance costs is not affected by ASU 2015-03. We adopted ASU 2015-03 on January 1, 2016. There was no material impact on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements &#8212; Going Concern </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2014-15&#8221;).&#160;The provisions of ASU 2014-15 provide that, in connection with preparing financial statements for each annual and interim reporting period, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 is effective for the annual reporting period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the effect that the adoption of ASU 2014-15 will have on our financial statement disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2014-09&#8221;). In March, April and May 2016 the FASB issued additional guidance related to Topic 606. These new standards will eliminate transaction-specific and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for our interim and annual reporting periods beginning on January 1, 2018. Entities can transition to the standard either retrospectively or as a cumulative effect adjustment as of the date of adoption. We have not yet selected a transition method, and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. Our cash equivalents consist of money market funds.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders&#8217; (deficit) equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or market. Cost is determined on a first-in, first-out basis. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to receiving marketing approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered; (3)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (4)&#160;collectibility is reasonably assured.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (&#8220;GPOs&#8221;), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. As a result, we recognize </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns</font><font style="font-family:inherit;font-size:10pt;">. We allow the wholesalers to return product that is damaged or received in error. In addition, we accept unused product to be returned beginning </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> prior to and ending </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;"> following product expiration. Our estimates for expected returns of expired products are based primarily on an ongoing analysis of historical return patterns.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution Fees</font><font style="font-family:inherit;font-size:10pt;">. The distribution fees, based on contractually determined rates, arise from contractual agreements we have with certain wholesalers for distribution services they provide with respect to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. These fees are generally a fixed percentage of the price of the product purchased by the wholesalers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Payment Discounts</font><font style="font-family:inherit;font-size:10pt;">. We offer cash discounts to certain wholesalers as an incentive to meet certain payment terms. We estimate prompt payment discounts based on contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.&#160;&#160;&#160;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discounts and Fees</font><font style="font-family:inherit;font-size:10pt;">. We provide discounts to end-user members of certain GPOs under collective purchasing contracts between us and the GPOs. We also provide discounts to certain hospitals, who are members of the GPOs, with which we do not have contracts. The end-user members purchase products from the wholesalers at a contracted discounted price, and the wholesalers then charge back to us the difference between the current retail price and the price the end-users paid for the product. We also incur GPO administrative service fees for these transactions. In addition, we provide predetermined discounts under certain government programs. Our estimate for these chargebacks and fees takes into consideration contractual terms, historical utilization rates, as available, and our expectations regarding future utilization rates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for product returns and chargebacks are based on amounts owed or to be claimed on the related sales. We believe that our estimated product returns for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant requires a high degree of judgment and is subject to change based on our experience and certain quantitative and qualitative factors. In order to develop a methodology to reliably estimate future returns and provide a basis for recognizing revenue on sales to wholesale distributors, we analyze many factors, including, without limitation: (1) actual </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product return history, taking into account product expiration dating at the time of shipment, (2) re-order activities of the wholesalers as well as their customers and (3) levels of inventory in the wholesale channel. We have monitored actual return history on an individual product lot basis since product launch. We consider the dating of product at the time of shipment into the distribution channel and changes in the estimated levels of inventory within the distribution channel to estimate our exposure to returned product. We also consider historical chargebacks activity and current contract prices to estimate our exposure to returned product. Based on such data, we believe we have the information needed to reasonably estimate product returns and chargebacks. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer&#8217;s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche&#8217;s Herceptin SC product in August 2013 and MabThera</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> SC product in March 2014 and Baxalta&#8217;s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i)&#160;the license to our rHuPH20 technology, (ii)&#160;at the collaborator&#8217;s request, research and development services which are reimbursed at contractually determined rates, and (iii)&#160;at the collaborator&#8217;s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators&#8217; ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the market place. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (&#8220;VSOE&#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition - Milestone Method </font><font style="font-family:inherit;font-size:10pt;">(&#8220;Milestone Method of Accounting&#8221;). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A milestone is defined as an event (i)&#160;that can only be achieved based in whole or in part on either the entity&#8217;s performance or on the occurrence of a specific outcome resulting from the entity&#8217;s performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to the vendor.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator&#8217;s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments in connection with our clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Historically, such revisions to our clinical trial expense accruals have not had a material impact on our consolidated results of operations or financial position.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), and RSUs with performance conditions (&#8220;PRSUs&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. Valuation allowances have been established to reduce our net deferred tax assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, as we believe that it is more likely than not that such assets will not be realized.&#160;The interim tax provision is calculated using the estimated effective tax rate expected to be applicable for the full year.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i)&#160;research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii)&#160;product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. Our chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6601857152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair value, assets measured on recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major financial instrument type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794462160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale marketable securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790846640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements Collaborative Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock', window );">Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Election of additional exclusive targets and annual license maintenance fees for the right to </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;designate the remaining targets as exclusive targets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical development milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock', window );">Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive target</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember', window );">Other collaborators [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock', window );">Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68059916&amp;loc=d3e50766-111635<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 25<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68059916&amp;loc=SL6750900-111635<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803439376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,442</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,178</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Summary of Deferred Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursement for research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,892</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629180720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs, RSUs and PRSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The assumptions used in the Black-Scholes model were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.8-66.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.5-70.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.2-67.0%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.18%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69-1.92%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00-1.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.34-1.92%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.8</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6585011984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6627187936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract', window );"><strong>Restricted Cash and Investments, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6804040496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">$ 159,845<span></span>
</td>
<td class="nump">$ 65,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">194,984<span></span>
</td>
<td class="nump">103,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value, assets, Level 1 to Level 2 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">129,225<span></span>
</td>
<td class="nump">38,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">65,759<span></span>
</td>
<td class="nump">65,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">35,139<span></span>
</td>
<td class="nump">38,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">35,139<span></span>
</td>
<td class="nump">38,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">51,786<span></span>
</td>
<td class="nump">62,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">51,786<span></span>
</td>
<td class="nump">62,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">94,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">94,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">13,973<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets Measured on Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value disclosure</a></td>
<td class="nump">$ 13,973<span></span>
</td>
<td class="nump">$ 2,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792856704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 12,852<span></span>
</td>
<td class="nump">$ 9,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=halo_HylenexRecombinantMember', window );">Hylenex recombinant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=halo_BulkrHuPH20Member', window );">bulk rHuPH20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=halo_HylenexRecombinantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=halo_HylenexRecombinantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=halo_BulkrHuPH20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=halo_BulkrHuPH20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803755168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Revenue recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Period prior to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Collaborative agreements termination notification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Periodtoacceptreturnedunusedproduct', window );">Period to accept returned unused product</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Period after expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Collaborative agreements termination notification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Periodtoacceptreturnedunusedproduct', window );">Period to accept returned unused product</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Periodtoacceptreturnedunusedproduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period to accept returned unused product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Periodtoacceptreturnedunusedproduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792470080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Income tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,284<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792637664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Net (Loss) Income Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NetincomelosspershareTextualsAbstract', window );"><strong>Net loss per share (Textuals) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from calculation of diluted net loss, amount</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NetincomelosspershareTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) per share (Textuals) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NetincomelosspershareTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790676832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803744912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">$ 159,762<span></span>
</td>
<td class="nump">$ 65,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated fair value</a></td>
<td class="nump">159,845<span></span>
</td>
<td class="nump">65,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">51,785<span></span>
</td>
<td class="nump">62,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated fair value</a></td>
<td class="nump">51,786<span></span>
</td>
<td class="nump">62,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">94,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated fair value</a></td>
<td class="nump">94,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">13,973<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 13,973<span></span>
</td>
<td class="nump">$ 2,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6787040368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities Textuals (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities maturities, next twelve months</a></td>
<td class="nump">$ 153.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear', window );">Number of available-for-sale securities in unrealized loss position, less than one year</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other than Temporary Impairment Losses, Marketable Securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6805399648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements Collaborative Agreements Textuals (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>Compound</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTextualAbstract', window );"><strong>Collaborative Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones', window );">Additional maximum proceeds receivable from collaborators of license and collaborative agreement upon achievement of clinical development milestones for elected targets | $</a></td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets', window );">Sales-based payment to be received upon the first commercial sale | $</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue relating to upfront payment license fees and annual maintenance fees | $</a></td>
<td class="nump">50,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue relating to upfront payment license fees and annual maintenance fees | $</a></td>
<td class="nump">36,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_BaxaltaMember', window );">Baxalta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRevenueTextualAbstract', window );"><strong>Deferred Revenue (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue relating to upfront payment license fees and annual maintenance fees | $</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop', window );">Number of product compound combinations licensed to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfTargetsElected', window );">Number of targets elected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Numberoftargetselectedadditionalexclusivetargets', window );">Number of targets elected, additional exclusive targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfAdditionalTargetOptional', window );">Number of additional targets, optional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTextualAbstract', window );"><strong>Collaborative Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue, revenue recognized | $</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember', window );">Baxalta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTextualAbstract', window );"><strong>Collaborative Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue, revenue recognized | $</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_LillyMember', window );">Lilly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop', window );">Number of product compound combinations licensed to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Numberoftargetselectedadditionalexclusivetargets', window );">Number of targets elected, additional exclusive targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfAdditionalTargetOptional', window );">Number of additional targets, optional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Numberoftargetselectedadditionalsemiexclusivetargets', window );">Number of targets elected, additional semi-exclusive targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_AbbVieMember', window );">AbbVie [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop', window );">Number of product compound combinations licensed to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfTargetsElected', window );">Number of targets elected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfAdditionalTargetOptional', window );">Number of additional targets, optional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_JanssenMember', window );">Janssen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop', window );">Number of product compound combinations licensed to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfTargetsElected', window );">Number of targets elected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfAdditionalTargetOptional', window );">Number of additional targets, optional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTermsAbstract', window );"><strong>Collaborative Agreements Terms</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop', window );">Number of product compound combinations licensed to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfTargetsElected', window );">Number of targets elected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NumberOfAdditionalTargetOptional', window );">Number of additional targets, optional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DurationOfRoyaltyReceivable', window );">Duration of royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PeriodForTermination', window );">Notification period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_PfizerJanssenandAbbVieMember', window );">Pfizer, Janssen and AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_CollaborativeAgreementsTextualAbstract', window );"><strong>Collaborative Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue Recognition, Event-based or Milestone, Revenue Recognized | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_CollaborativeAgreementsTermsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements Terms [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_CollaborativeAgreementsTermsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_CollaborativeAgreementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_CollaborativeAgreementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRevenueTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredRevenueTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DurationOfRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of royalty receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DurationOfRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfAdditionalTargetOptional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Additional Target, Optional</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NumberOfAdditionalTargetOptional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberOfTargetsElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Targets Elected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NumberOfTargetsElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NumberofProductCompoundCombinationsLicensedtoDevelop">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Compound Combinations Licensed to Develop</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NumberofProductCompoundCombinationsLicensedtoDevelop</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Numberoftargetselectedadditionalexclusivetargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets elected, additional exclusive targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Numberoftargetselectedadditionalexclusivetargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Numberoftargetselectedadditionalsemiexclusivetargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets elected, additional semi-exclusive targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Numberoftargetselectedadditionalsemiexclusivetargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=halo_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_LillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_LillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_PfizerJanssenandAbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_PfizerJanssenandAbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6803605120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative Agreements Collaborative Agreements tables (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement', window );">Additional Exclusive Targets And Annual License Maintenance Fees</a></td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement', window );">Clinical development milestone payments</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement', window );">Regulatory milestone payments</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Amountreceivedforsalesbasedpayment', window );">Sales-based milestone payments</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember', window );">Baxalta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement', window );">Regulatory milestone payments</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Amountreceivedforsalesbasedpayment', window );">Sales-based milestone payments</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_LillyMember', window );">Lilly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_AbbVieMember', window );">AbbVie [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_JanssenMember', window );">Janssen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement', window );">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember', window );">Other collaborators [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement', window );">Total Proceeds from Partner of License and Collaborative Agreement</a></td>
<td class="nump">$ 93,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received from Roche for additional exclusive targets and annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Amountreceivedforsalesbasedpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for sales-based payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Amountreceivedforsalesbasedpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical development milestone payments received under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront license fee payment received under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from partner of license and collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payments received under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_LillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_LillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793223248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts Receivable, Net, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsalestocollaborators', window );">Accounts receivable from product sales to collaborators</a></td>
<td class="nump">$ 10,220<span></span>
</td>
<td class="nump">$ 4,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsales', window );">Accounts receivable from other product sales</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">2,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromcollaborators', window );">Accounts receivable from revenues under collaborative agreements</a></td>
<td class="nump">5,937<span></span>
</td>
<td class="nump">25,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, gross</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="nump">33,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AllowanceforDistributionFeesandDiscounts', window );">Allowance for distribution fees and discounts</a></td>
<td class="num">(390)<span></span>
</td>
<td class="num">(967)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 17,679<span></span>
</td>
<td class="nump">$ 32,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromcollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromcollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsalestocollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales to collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsalestocollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllowanceforDistributionFeesandDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for Discount and Distribution Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AllowanceforDistributionFeesandDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790629408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, Raw Materials</a></td>
<td class="nump">$ 1,490<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Inventory, Work in Process</a></td>
<td class="nump">9,708<span></span>
</td>
<td class="nump">8,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 12,852<span></span>
</td>
<td class="nump">$ 9,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790596640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Prepaidresearchanddevelopment', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 8,801<span></span>
</td>
<td class="nump">$ 9,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expense and other assets</a></td>
<td class="nump">11,048<span></span>
</td>
<td class="nump">10,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less long-term portion</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expense and other assets, current</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 5,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Prepaidresearchanddevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Prepaidresearchanddevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792211632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 15,813<span></span>
</td>
<td class="nump">$ 14,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(11,406)<span></span>
</td>
<td class="num">(10,318)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,407<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10,316<span></span>
</td>
<td class="nump">9,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">2,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="nump">$ 2,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6786365008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationAbstract', window );"><strong>Depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790838912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Summary of Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent', window );">Accrued outsourced research and development</a></td>
<td class="nump">$ 9,947<span></span>
</td>
<td class="nump">$ 8,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and payroll taxes</a></td>
<td class="nump">8,201<span></span>
</td>
<td class="nump">8,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accruedmanufacturingexpenses', window );">Accrued outsourced manufacturing expenses</a></td>
<td class="nump">3,706<span></span>
</td>
<td class="nump">6,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,890<span></span>
</td>
<td class="nump">4,118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">25,744<span></span>
</td>
<td class="nump">27,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm', window );">Long-term accrued outsourced research and development</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">$ 25,733<span></span>
</td>
<td class="nump">$ 26,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourced research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Outsourced Research and Development Expenses Long-Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accruedmanufacturingexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accruedmanufacturingexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793334624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">$ 50,741<span></span>
</td>
<td class="nump">$ 53,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Less current portion</a></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">9,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">40,849<span></span>
</td>
<td class="nump">43,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">36,542<span></span>
</td>
<td class="nump">39,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_CollaborativeArrangementMember', window );">Other collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">9,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_InlicensetechnologiesMember', window );">License fees and event-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">44,942<span></span>
</td>
<td class="nump">48,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">$ 5,799<span></span>
</td>
<td class="nump">$ 4,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=halo_InlicensetechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=halo_InlicensetechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806644112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net Long-Term Debt Textuals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">plus the three-month LIBOR rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt Instrument, Maturity Date, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">final maturity date of the Royalty-backed Loan will be the earlier of (i)&#160;the date when principal and interest is paid in full, (ii)&#160;the termination of Halozyme Royalty&#8217;s right to receive royalties under the Collaboration Agreements, and (iii)&#160;December&#160;31, 2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt instrument, covenant in compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">in compliance<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lender Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Royaltypaymentstobeappliedtodebtinstrument', window );">Royalty payments to be applied to debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Royaltypaymentstobeappliedtodebtinstrument', window );">Royalty payments to be applied to debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2018 and thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Royaltypaymentstobeappliedtodebtinstrument', window );">Royalty payments to be applied to debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2017 Quarterly Maximum Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2018 Quarterly Maximum Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2019 Quarterly Maximum Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | 2020 Quarterly Maximum Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember', window );">Royalty-backed Loan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 27,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Term loan, increase</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> interest only payments through January 2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Finalpaymentaspercentoforiginalprincipal', window );">Final payment as percent of original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued interest, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  07,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt instrument, covenant in compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">in compliance<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">interest only payments for the first 18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt Instrument, Unused Borrowing Capacity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription', window );">Debt Instrument, Unused Borrowing Capacity, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">current prime rate as reported in The Wall Street Journal plus 4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Finalpaymentaspercentoforiginalprincipal', window );">Final payment as percent of original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Finalpaymentaspercentofadditionaldraw', window );">Final payment as percent of additional draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee,Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Finalpaymentaspercentofadditionaldraw">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final payment as percent of additional draw</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Finalpaymentaspercentofadditionaldraw</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Finalpaymentaspercentoforiginalprincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final payment as percent of original principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Finalpaymentaspercentoforiginalprincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Royaltypaymentstobeappliedtodebtinstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payments to be applied to debt instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Royaltypaymentstobeappliedtodebtinstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of unused borrowing capacity under the debt instrument and conditions under which the commitment can be withdrawn by the lender.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Allowance for Funds Used during Construction<br> -URI http://asc.fasb.org/extlink&amp;oid=6504829<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2018andthereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2018andthereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2017QuarterlyMaximumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2017QuarterlyMaximumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2018QuarterlyMaximumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2018QuarterlyMaximumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2019QuarterlyMaximumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2019QuarterlyMaximumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2020QuarterlyMaximumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2020QuarterlyMaximumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790912512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 6,655<span></span>
</td>
<td class="nump">$ 5,553<span></span>
</td>
<td class="nump">$ 18,843<span></span>
</td>
<td class="nump">$ 15,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
<td class="nump">7,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSU, RSA, and PRSU awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">2,328<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">6,740<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">8,459<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 3,284<span></span>
</td>
<td class="nump">$ 10,384<span></span>
</td>
<td class="nump">$ 8,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790655152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Share-based compensation textuals (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation', window );">Proceeds and Excess Tax Benefit from Share-based Compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Grants in Period, Gross</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793468464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Share-based compensation, valuation (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Fair Value Assumptions, Expected Volatility Rate, Minimum</a></td>
<td class="nump">70.50%<span></span>
</td>
<td class="nump">66.80%<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
<td class="nump">66.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions, Expected Volatility Rate, Maximum</a></td>
<td class="nump">70.70%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 5 months<span></span>
</td>
<td class="text">5 years 7 months<span></span>
</td>
<td class="text">5 years 5 months<span></span>
</td>
<td class="text">5 years 7 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Fair Value Assumptions, Risk Free Interest Rate, Minimum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions, Risk Free Interest Rate, Maximum</a></td>
<td class="nump">1.18%<span></span>
</td>
<td class="nump">1.92%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">1.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793662192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Share-based compensation, unrecognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 46,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 11 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 10,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 7 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 9,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793474128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options and restricted stock units</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises</a></td>
<td class="nump">383,719<span></span>
</td>
<td class="nump">1,626,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price</a></td>
<td class="nump">$ 6.74<span></span>
</td>
<td class="nump">$ 7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issued during period, shares, restricted stock award, net of forfeitures</a></td>
<td class="nump">215,779<span></span>
</td>
<td class="nump">134,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of RSUs surrendered to pay for minimum withholding taxes</a></td>
<td class="nump">82,396<span></span>
</td>
<td class="nump">52,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issued during period, shares, restricted stock award, net of forfeitures</a></td>
<td class="nump">968,652<span></span>
</td>
<td class="nump">515,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC^AY%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0
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M'N,4.3M=4[F"I.S[<?*0BV?0)H_TLG_1P\\Q!0=[L3;0A,O5G')MPO'.CG;
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M'WB9FG[@_>TYN0L?WO?>O=T%I_]*PC]02P,$%     @ +(%G24KTQ5T^ 0
M:0,  !$   !D;V-0<F]P<R]C;W)E+GAM;,V334_#, R&_PKJO4NS24-$70^
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MS:.E:<9 +\_+]L-NHNC&S<NT6RH$O;.FE,;+DM&=MUJ5M"HENQ5:F$(R '$
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M2Y<QYJ,F66B>/U"E.DV:<I(JQUKK=]3VT;RWHBVZ.O*^#GW['5!+ P04
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M(F!ME2,ZXY^(G;N!!P<JY*ZK-]P3I0++;' E?X-6GH;W@."34-VU[#-S/IA
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M4-&3U%NL];<#P!XD:Z_C;)BI^3]02P,$%     @ +(%G2</"/1'_ P  *1(
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M<3N_R9A/^N;R\6+F]G9H\R]02P,$%     @ +(%G2=>F![*= 0  L0,  !@
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M[V+<)6.@>/?8C--ZSOX#4$L#!!0    ( "R!9TF,8/B1R@$  . $   9
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MV?T",A>0I8 $XT'(V_Q*#2T+)2>D!^K^7;*W<.5(+#.RWK0/??<A>RY)_J7
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MNPQJN37];6[O.W=&<0.C#N<CU^7<M_H#4$L#!!0    ( "R!9TD,XY9(%P(
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MTW@W#UR@>'.;;L.(S?\"4$L#!!0    ( "R!9TF/\3(9*@(  /0&   9
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M[75FFSLQ)JG*BE[4A]>H(^@^Z.A)ZBY6?6YW93N0;+R=,?>#KOH'4$L#!!0
M   ( "R!9TFU1TAO:@(  !D)   9    >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;)66VXZ;,!"&7P7Q (M/G"*"U$U5M1>55GO17CN)$] "IK:3;-^^MB%9
M[-*&W 1L_OGY9N*Q*2Y<O,F*,16\MTTGUV&E5+^*(KFK6$OE$^]9IY\<N&BI
MTD-QC&0O&-W;H+:)$ !)U-*Z"\O"SKV(LN GU=0=>Q&!/+4M%;^?6<,OZQ"&
MUXG7^E@I,Q&5172+V]<MZV3-NT"PPSK\!%<;F!J)5?RHV45.[@,#O^7\S0R^
M[=<A, RL83ME+*B^G-F&-8UQTF_^-9I^O-,$3N^O[E]LNAI_2R7;\.9GO5>5
MI@5AL&<'>FK4*[]\96,.L3'<\4;:WV!WDHJWUY P:.G[<*T[>[T,3S(PALT'
MH#$ W0(@^6\ '@.P%Q -9#:OSU31LA#\$LB>FG\;KK1<&!/M'.ADI!W:<@VS
MYQ*3N(C.QLC1/ \:9#5H3K%Q%!\FD0:8I4 >!;+QV,9#@.\;8,\ 6P,RII&X
MD-V0QJ!)K28&*8%SJHVCP@@M@"$>#'%@TEF809-839[E:);%$6% [J/$'DH\
M02%XEB2>O(2 C.2S*(X*YS"_SY)X+,F$!>;POD'J&:2/KI+,,\@6K))LDBA.
M8C+_SSBJ'.#L/DSNP>0.S (#"/S>!8\6!/[5_G!!24;1D&U& )@MB:/*4[1@
MM4)_'X#(P5FPR*"_$T#\<%'\_H5D25&FS4E(_H^%XLJR-$$+@/PNAM,VQC%8
M8.$W'TP>+HO??C!=4I9TNG^F^?QNXJ@(2?S-()H<8CT]LN]4'.M.!ENN]'EH
MC\(#YXII+_"DBU/I[Y3;H&$'96Y3?2^&DWL8*-Y?/T1N7T/E'U!+ P04
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M&A,P&!B4P  &EKQ4$..N-V)1(Q8D0)=R/]S4 >.&<6/B]H^"K2[ @G0<HN,
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M639YRSK^U@[,39ZM3P>[_+7IOG8CMAK>EAD.FO+P^?+/Z0VDY?]02P,$%
M  @ +(%G2>842]'% @  Z@H  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULE9;?;ILP%,9?!?$ !1ML2$20FC_3=C&IZL5V[29.@@HXPT[3O?UL0ZCM
MN@NY"=CYG<_G?+%.3G%AW2L_4BJ"]Z9N^2(\"G&:1Q'?'FE#^ ,[T59^LV==
M0X1<=H>(GSI*=CJHJ2,8QSAJ2-6&9:'WGKJR8&=15RU]Z@)^;AK2_5W2FET6
M(0BO&\_5X2C41E06T1BWJQK:\HJU04?WB_ 1S#< *T03ORIZX<9[H))_8>Q5
M+7[L%F&L<J UW0HE0>3CC:YH72LE>?*?0?3C3!5HOE_5O^ER9?HOA-,5JW]7
M.W&4V<9AL*-[<J[%,[M\IT,-2 EN6<WU9[ ]<\&::T@8-.2]?U:M?E[Z;_)X
M"/,'P"$ C@'C.?Z 9 A(/@+2_P:D0T Z]00T!"#GA*BO73NW)H*41<<N 3\1
M=9_ 7.*=$I'*@;2+ZZ7^0?K=MS*%21&]*2&+6?8,U S.?,C:1,!(1#(!;Q;0
MSF()C7#H.V!E$CCWYG!39/.%R)=I)HY9B8Y/!K/2VP*I(Y!J@7000':2;>]%
MSV1]DAAYH94)(802'[0V(9#GJ9?:6!1"^01?D%,6LLK"MP6P(X#O-39S!+()
MQO8,[ID$9EYC32B!.? ::T( @MAOK$EELQC=KBIWJLJMJK+; C-'8':OKR!V
M^T,\P=D!ZDN%TC:OM38%,^CUUJ)PEL9>;RTJPWDRH;1/K0]8I4VX]P"Z$O!N
M@]V> I(I!B?FM8Q3?U.P* CQS&^P2>4I\E(;B\K@E&X)W&X'['8WFR#A=A:
M[C;8[2T 3S$8&UTPP<![ZU8V!?/4;[!)R>;@QS86EB<P=FJ+C#_RAG8'/4+Q
M8,O.K>@=&7?',>T1JD' V5^"^0IX]M=JK-.#PX=\69S(@?XDW:%J>?#"A!P_
M].2Q9TQ0F7;\(&T^RL%S7-1T+]1KIOSO1[%^(=CI.EF.XVWY#U!+ P04
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M$=X3,GZ(OSO&I:J&(7%VH[]/(]29ULYN3$"Q7F]X=FS#K%9PB_A0UIIWCJS
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M(2G/NJ0\P_0W4([2);M2 D8HXF&K(L3G"[.AAKX<#HE@%FW&%@5Y&ZA8JN8
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MT4NLM$55"QE-(;[$.6K(1)TRL*80_+FEZCCOMQ7(#Z;G^AL9[C 83L8HQ0T
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MM5AM:A'HN"Q4D&@$*#&IB+%8-"QM(L3K3D'UCFCON4Z[EP:QL=C;\S9_[^
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M.OJ!L#PP_H 7\L4+X'<@V:0] ?QX;-8H%]#PQERQ$5RE[DQCOZ-O"1"-XE'
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MT\G)P1G5BYR>3LX/X/\NX)]G]M/# _A[^MOH$A&NKKL;CN*-4&<?12>@@9V
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MK* AQ-R-36A4ON6"9S)T[#WI15LWS.LCA8S<)<F,#CXDV!K3R6*''GU_=^:
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MF!B @$912X[RMK#9]*SN#&<': 9=5QF*AR36"+]P91;<&P^_EW9KV2#RFBH
M[KE-LN6'!N':/% ;^@LGG$[ Y.A3^HU\]HO#@^/,/2RM=*QZ0WDLR*RHAMA9
MA: 9@PY>-'H IOI):=:_4#LB<AD!XSJ+/6?S78T=IV5W\+QRDR&;+$H4;9".
M&[X3^!0UC+6D"W9X06X^D<:(+R6@@:U)30T/]0L=E>8:=DZKLL7+1F741%#O
M/G9U3H1&Z2*<-J%A+JA:PKJYQQ'1@6PS?5&&9P[DT58X]3BT]N=E54E7.CH^
M4WOK/&K('!&(3Q1R1: F7DX"PI=C=U-O0AJU83!NF><.1SC@Y9Z7R]HD+A.+
MWV%O8 @.5(=EGJ9#]2;9$.ZTE J,9&9QU%,8J+"JB?M[F(_@</3T4AZ7.R2<
MM2PD1!BR5TGPA!^E DG,^$]B":.*@D _:B%U^:=U;P0P.O -0^' 1GS OP*C
M I]#7YK^X2O3]1-7:(6Y=_C!O"K?@PJU!"V,NO>69I1Z@\8J_B@M%C>X-'L"
M"GJK&^+,;^#NI$F*[Z1/4_X O)U 1@F[3)PNQE9-A1)9/3&U,$-[G>A1E.M9
MM3S@,G/=[AI&Q'J//]$99N**#A\W$QJF ->>9KX=F2%WK%A+@*$_0XIP[9A?
M5Q?2"#DUE#?_)NN7C4D@[-$8.$;H&/#8\54,6 V&^B7SHOL6S%]/L1<'.ZG$
MV$8^XDML&,Q/&UXA.<Q!)Z8R9IAC*_D<&@II+"=WI)"9]](<N<*[TLJ]AI&U
MN%&.)*23I@0:+CQ&7LP=%7I2!<3]Z_F$F&G_N4W4KX8U?E0&QT8R9O[=*MZ5
M<0'2VK7M/9-UR.'UZKO7T-4VDZ-C4L@ICS %:FF^<ET6Q$_+<\)" FF'SF+-
M\Q\'N/(!BYW4HB=V^0R&8%24JL4J.0^9*67PS[Z]I&JVLI+)$N>1VGI*LE!@
M$EYWBEC^M/=<O]H+WZJ/IN:TA?Q]5#UO7S^7]M_8Q$2#E+XM)%R=%@^1E>C2
M@6/C!J-NL*3;JM3HVU548X"B(JRY6E:BP>%+.NY=#@3MW%CV7IA>I;5/10DO
MC=H%:*[2:3>RW"K5F2T#/#JV*<);![;?>VICH*&LSF@#!B4[STW2^!X_P7O)
MVDSC0@C"1O4 ^,8D!L0NTC;:&A+QC2TP)<(ULYC89M'V&S_2FMJVLWI>E 7H
M@S D*RI45-5HX5/J8F(<$O5MI[G#!C\08RD)<&1TI>&,*:C:+=NBTBL7!UK<
MH+K#WX 8!/I.3';!V-)0?&;K.>;G.&M_E!Q]G(7<.Y2AV[D=I*]\A4DAKN4V
MXA\ETJW.<1O.&?'1D'!ZV,WCVC2<ZD6'ZB&DCF:W*3T8GQH:7 *T'@/#8P@O
M8&B\]**1-5]'#V>/4*#4;4(.O)3 _1RFO%F)6(??1 \/'\&NYEC%N0666"L2
M_3((9=D6/ P!!D\><0]T3+<2&'QF[IKLW&ZY)I8[Z)CXG+=V'QX_BK2+Y-PA
M<9I$++1%JY3X--^;*SR\F#+!GF_!-$D_TL5;SU&S:' '<3[NN\I\EQDX3)@C
MM>4F_7F#2/')@E *.-X&W&#>HOACU8B&M.P3$Y7*FMB6M7E@;PZ 3U4NGH:%
M?41M]GV5TWCXTH3I:LYO(-L60J+B\T#5N3B_;_'#%7D7C.=3"R^OJ[+=J.S@
MXH3KI!#_)V<8???Z!VG5&:[G&H&<"N8J57E=)6M)+;.K:!"+@#H%^,[2M#^H
MT";,8!&DE,V<FIUGKH8$7\/E=6"IE&O@&I)\X4G(B )GF]VZ<%E@ ]O.%N2J
M8L4$NS>@)2Z#.J:\:?/\0*M#B"'X0)PP&?0[MBMT7N,N6+#6CZBST;TBGH3.
M%E(@'-6ZBD)M>I_"?[3)!Q#;=8J]&Q@IHT^HU)L@$:;D6FXS4QBBZ[Y(4<U!
MW>R=7U@AR:<G<>Q:-]Z<LG0CM+%[$U0>D&G#BS*MPQU]\N_%$2MQ8^1M!,/
M08;*99OAZ54EI6G2J]6O,O:X\P[^]2__X;C'&SD(SA^A6M2F2]2E')>_[%Q.
M)=A<2TXR%%&-4+A5559]"$)&9 )93HJ+81QSI0<T>%QDNLX^*IK@1E52DK4"
M]7^;HDM(?N%%@(X+-)E5XF_Z(0#@H,0KWVR:UP]G1$_XF=4&E(/[Z& ,M0S
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M;X!WJ"1.K.H#^M^"VO1>2!"1\J-%XWCGHC49,GB$.BIFVSQK.X*Y90HMHFW
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M;VYT96YT7U1Y<&5S72YX;6Q02P$"% ,4    "  L@6=)2'4%[L4    K @
M"P              @ $) @  7W)E;',O+G)E;'-02P$"% ,4    "  L@6=)
M>AY=XL4!  !G'   &@              @ 'W @  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  L@6=)PG?#"]X"  "F#   $
M        @ 'T!   9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "R!9TE*
M],5=/@$  &D#   1              "  0 (  !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( "R!9TF97)PC$ 8  )PG   3              "  6T)
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ +(%G2<_)OMMM @
MH P   T              ( !K@\  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  L@6=)(SC(1 4$  #0#P  #P              @ %&$@  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ +(%G25Z6\PA/ @  ]0<  !@
M ( !>!8  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "R!
M9TE;FIQ&]@,  *02   8              "  ?T8  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    "  L@6=)N99-YR$"  !_!P  &
M        @ $I'0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ +(%G2=^4A-PJ!   VA(  !@              ( !@!\  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "R!9TG>LIXH4 (  %\'   8
M              "  > C  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    "  L@6=)P\(]$?\#   I$@  &               @ %F)@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ +(%G2=>F![*= 0
ML0,  !@              ( !FRH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( "R!9TE?T:1]GP$  +$#   8              "  6XL
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  L@6=)>06B
M,*$!  "Q P  &               @ %#+@  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ +(%G209N0)2B 0  L0,  !D
M ( !&C   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  L
M@6=)R\5NV:$!  "Q P  &0              @ 'S,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "R!9TE0^LV>HP$  +$#   9
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M970Q-BYX;6Q02P$"% ,4    "  L@6=)=N,]+J$!  "Q P  &0
M    @ ')/0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M "R!9TEJ7ZCBH0$  +$#   9              "  :$_  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ +(%G26R![C7> 0  @P4  !D
M             ( !>4$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    "  L@6=)!:_Z0>8!  "J!0  &0              @ &.0P  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "R!9TF,8/B1R@$
M . $   9              "  :M%  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ +(%G2313_8&& 0  .@,  !D              ( !
MK$<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  L@6=)
MMN;/I9D!  "N P  &0              @ %I20  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( "R!9TD(*C(:0@,  *@0   9
M      "  3E+  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ +(%G27=XG<GG 0  S 4  !D              ( !LDX  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  L@6=)\-]J0/4!   N!@
M&0              @ '04   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( "R!9TFX;@1% @(  .T%   9              "  ?Q2  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ +(%G27(%4&/R
M 0  <04  !D              ( !-54  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    "  L@6=)BRNK\Z4!  "Q P  &0
M@ %>5P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "R!
M9TF^L;FDX0(  .8,   9              "  3I9  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ +(%G28M>?=S+ 0  ? 0  !D
M         ( !4EP  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    "  L@6=)_@PHI94$   "&P  &0              @ %47@  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "R!9TEGS,MBX@(   ,.
M   9              "  2!C  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ +(%G20SCED@7 @  ;@8  !D              ( !.68
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  L@6=)C<>H
M:>4!  !1!0  &0              @ &':   >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( "R!9TF]"X9L$ (  &@&   9
M  "  :-J  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M+(%G21N^A](A @  ]08  !D              ( !ZFP  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    "  L@6=)"WA((O<!  !N!0  &0
M            @ %";P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( "R!9TF/\3(9*@(  /0&   9              "  7!Q  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ +(%G2;5'2&]J @
M&0D  !D              ( !T7,  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    "  L@6=)(QZ@M/$%  "-)   &0              @ %R
M=@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "R!9TGF
M%$O1Q0(  .H*   9              "  9I\  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ +(%G28GQ/&P) @  ] 4  !D
M     ( !EG\  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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52P4&     #< -P#S#@  I1H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Marketable Securities (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/MarketableSecuritiesNotes</Role>
      <ShortName>Marketable Securities (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Collaborative Agreements (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/CollaborativeAgreementsNotes</Role>
      <ShortName>Collaborative Agreements (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Certain Balance Sheet Items (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsNotes</Role>
      <ShortName>Certain Balance Sheet Items (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Long-Term Debt, Net (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetNotes</Role>
      <ShortName>Long-Term Debt, Net (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Share-based Compensation (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationNotes</Role>
      <ShortName>Share-based Compensation (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersDeficitEquity</Role>
      <ShortName>Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/MarketableSecuritiesNotes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Collaborative Agreements Collaborative Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables</Role>
      <ShortName>Collaborative Agreements Collaborative Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CertainBalanceSheetItemsNotes</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/ShareBasedCompensationNotes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesCashEquivalentsAndMarketableSecuritiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Revenue recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies Income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Summary of Significant Accounting Policies Net (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossIncomePerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Net (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402410 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Marketable Securities Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/MarketableSecuritiesTextualsDetails</Role>
      <ShortName>Marketable Securities Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Collaborative Agreements Collaborative Agreements Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails</Role>
      <ShortName>Collaborative Agreements Collaborative Agreements Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Collaborative Agreements Collaborative Agreements tables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails</Role>
      <ShortName>Collaborative Agreements Collaborative Agreements tables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid expenses and other assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails</Role>
      <ShortName>Certain Balance Sheet Items - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails</Role>
      <ShortName>Long-Term Debt, Net Long-Term Debt Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails</Role>
      <ShortName>Share-based Compensation Share-based compensation textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails</Role>
      <ShortName>Share-based Compensation Share-based compensation, valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails</Role>
      <ShortName>Share-based Compensation Share-based compensation, unrecognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="halo-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Stockholders' (Deficit) Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersDeficitEquityDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/StockholdersDeficitEquity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>halo-20160930.xml</File>
    <File>halo-20160930.xsd</File>
    <File>halo-20160930_cal.xml</File>
    <File>halo-20160930_def.xml</File>
    <File>halo-20160930_lab.xml</File>
    <File>halo-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001159036-16-000133-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001159036-16-000133-xbrl.zip
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MT"^='J U2$]+7__;H L!<:-,-1*@OJ)(29(WUPN+KQ<'#EU]KBJAUT8I7+L
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M']]JY&>(-,%R<$"7JP\6"IDT%PP;HY4SPG)K27TO#%XJ T#I$0'=O9# 2Q$
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M-OI)*[O"D*,V0C2&K4*8FI29JM2<1G3%KE8/20O#$,(+Q[L9L ?CT1J!$$\
M#X]!2V.2UA%.<DBS#EHB\='QF+PV,G?CS\,RA2L[COB0B4,@T!?18(@C-,A5
M5;7HL&D:YT,00BMQ9@LX>T/=NE0B>LLT"JG/0C!AK=.54T;@ .1QH7X]&MWM
M2F=+7& <!ZQ\5-I+AI6MG1P160/$F"B\4JVS!I2]H&VC+X(0!L20,>&"3\L2
ME*EN_9S@OHF^.-E0]6!HWX 1'W<&7=!R.Q+8..VU$*#DN-?@HTM<N4U,$X/V
M)/ "//O#W5H2136/+@3#,=A#ZPVK,UA(*T'W)/5FN/<(;FFPSF!)P$,-$9@8
MV)C5U4S@<.23(-9"F<=_&R%K;9/V*# 5HPZ2 1\@96(]?@I"UJ89%;M MKJG
MI'E_RA;[+D!9.7 " $P()CVQ:0/)G$M9YL^\(HR13&NM ^<A4+=.(B7$3=;V
M."=9X)9*4\?  MNL%.D5%1QE1W]PJ#<,DL;(0+BN.2>2$> )(NO:.Q2QR9(8
MKX G9,86QX"ZC=8RR50*AJFW@0M-8[V:1J7;ZPQJR=G* .RMH1[!#_\R''9'
M[X?][LZ\#" &8C"EP8'PTS03L%I/K:0TV=69F.RX6H)S"8!=86NCHI5!(%!1
M'CDB)$&"UIMH'6,-0QB1PJL,NS]PFR:<2Q$\1N!V"02!J'>JOG/4VIC\V@A3
M=DC8V@C'L0A.@(="'"7&,2%$/;O.^ES4"1C0G8!+84PUOW1GEG.1,$IB1$8#
ME)SJ:*I,M_9,YEM<&<(R@VX1A)W!:^4ZJR4F&"QC8$9: (J:.FT*<7B^ZXQ+
M=DCX-C">)!89YJ*&9YI((,KB5::-.P"Z86N4%H<%K]7,>-!D$.=;QRC$4H(B
M40NMI#(?=RP4!-G;PS?M)4SS<Z^OBRM@TK\5?\Z6H(*;]+;L05A]VP>-.<T.
MO+DVW>%D3/-N]W8>4Q\LLMQJ!=%^2M_5^4P+BKVI(W()A[WA7,1V>:&U[8QZ
MH_=@%3K=-X._=\I>NO5Z!R$FWCBO>.<%U_/YSFEY_7+NK_.U=W-WLVD1MK7@
MM1D;!(@T5A1B:U05'8"SO-2H.]\C#M(YI^&VV)\_Q7J#;2@FG+8"48\A (Y,
M:HY\/7K*\J5]< L40_*0%'/#+\6@DWZ_N>WW.H.KS;.P]UB>/E=F&+ ,BE#.
M,#C2GIJ:29AW*+S\L9<$MX)E':8YU,?'L'KQ?3'H#<N$W2A#SRH*$@#.'T\=
M/D8BQ^O2/(=E/ )ZOAA=E;W;Z439Q4.?<,-1#Y,S$U*G-=8I3<*=P'7Z&GN?
ML+WMWXU>C#\7\%]9%*\@6AM_?O'S:_OFW8M4U+0._W:<UM,"H&H<_[MZW[$'
MT@MF0RR:C;00E6(:<! 2"1M2QFCF3E-+<^>!9PFM=2@<"<TY&U_=E6DYZ\?Q
M!ARC$T(A&I0P5/N@N*J[ZDEP^?37,T(QD]0UUM]$[J,VFD%@#X&R%YC6DU"B
M#]E%C#P$BL4)>'41289 *QG+(5AAE@L7J"%U8:SS^5!4WHYCL1'%ZJIFMO7Y
M-:!9%JLE@(=12FMPIH >9\S8*!!VS''DJB0(A)HQ2R?(5I37X+.9 -5=51R6
M4_</0OLE*B0BT%_9^ZUMT-;"&V+P04LI+4E+N:RR]7T2\2A?2+F!L]LP:J/#
ME%))AT\O2>!#5_!"Y].&J^D'L<)*V5DR4RRH-,V:)%Z(=>&G!.]CC;NEY%H/
MM0VKD]%B*Y98)@38;4 [""N"!;,=)*7UQ'%I3%/]'1!"\J="B!:MOTP(J9TE
MFA.7 I3(B7*L3NPJ3^,:CB"')L1H=)></'^<0&7Q"@Y;,.)<4,:($%QJ4@]3
M4AS"MB3_6+Q"^!41:W%<A/:H2+6P]ER_"<.YL)HPZ;RE&O&9@D\.F,)N@A%]
MA<DKLC9N>@R,UL<0!'QI8KB)((G61<V<F1>&1HZJ,X)?#\5H5DM\G]YV5+Z+
M7+-(E*(L[0QWR'A5N9#P,Z<23ARE4Z)X'4Z+P!X3I6VXCD6G,?4\4!D1!8?1
MF;K'*%W+3\Y()3E"9X3/>IY#SA$3*<A2M(BHF.Q#%;=2:B9Z@>!#X[,0YAV5
M^X0EP&=.<F4-V'SAM:RJ/;2EC+S\\;HWZ/1?W,Q@>]%-Q!Y>3R+7V=>_FG[_
MB_2 %W_V^OT7'XO)ZT6G[/>*,KW]_^O]C__^W[! _S/]?/(=?WXN!B]NI[D_
M>$!GT'W1JYQ@",YO.[WT@Q?7=_W^O\#'%S^?D 6H)L2![_X)4/WG_4T-SW__
M;XI@^3]'+\K>I\_C%^/AB[*X*GI?BA?EY VIU.ANT 7 TI>Y8;_?^9@:B=+7
MF4\0C$^JD_YE A(\N'HRN'43ZDW_1O&_O$B"N<V1+QSF^M-_V[E/OWT W/9,
M36PCG01)ZR85:-8%.._(61V4.]"B+W^<G\)PT+^'<YB E5(5Y?#NT^<7?^T,
M[CKE_8L$U#KD%W$Y#<;KY5=SI1W!1BD?I+ &HKFJ@%T%$FC*.S4B?#V<,LAU
MKX37L'HQ2=&,'HCS)"#H7<W>O1'MY4_/)=O 6^6O<!  >O]^EH:>?>E*#O9A
M$>-B':!78'*%\\0%ZYBV6(=JVDT:P) 7+U+)VP*F%6*<AFKJU%3#W&'O)(3;
M4=D 4A;KJUMDD<Y+.=094DV?FFJ1$<6#))B(P,!#DK8N0V2$Y]D),BW_/2NJ
M$70*JBTEZ[B304,0@Y 6CD0.IKT>/L=)5FPQW6MS>*I-M*#M]/O#X:#ZT= 6
M;Y-1/U9>=I%[5!#286(5A I6::8EK6_]A:79S2O;B7E:L%M/H=\&G:H#-I73
MGS*[&44:BZ"0U=3(0*)3KNY$HUYF+;%X=7G?1DR.C?9V'+"(LT0B&N(@D'<2
M7%J-4;T("!''\YX(=DB<[T9%UP[+<OAG6G3:N>U<@2MXPJ2]MRZ5YJ8R;L6<
MC-370R@9MCKKN:GN7M:CWX+1SH1X<'"SE=\7+%&.&Z:I(Q 0>%?G<Q@)'.*V
MJUF#-@0A$#RD2[<7'0@:BELXZ&(2?'P ]^\?(.<OWH\A+!B_^.OPKDS1T.3N
MCGTG^?^[(\%:(H%_%"E:*;KF2U%V/A6+Z;*3I8%QC-P2P[V@- J#D%1UG8+2
M2P-;%Y)^6JP$OBVH+&-]7< )=*<;@8M)J<MD+/:I]*(QBBGDJ6$D=8%R9&TU
M1DV;(#,=D:N(-0@T8?FN^%(,=BU0UMB3--I=$^% ?=M :PB)HGE)(J=DI8!H
MY?&[0K;@YBR]V91E*NV8F+ZE,["=KW &G0V45PI[CQ7X*$JXP(R*N"XLTS%?
M0*=S]71:M%X/^KVK5($U+JX^#X;]X:<M!AY&#RP5X<R<]P)CQDT=:P.VV?T2
M4ZLC:DZ-Y;OAU>=-B^I9%!;00!Q^9T02R7Q=U&:CRFKFJ494G2562Y>AGA +
M.DZ:@$U0RJ3!P[.S2OW1#5@]'D=6;UU(77U9?..F*5 Q0IS@M??:I=7NE**Z
MMLJ$O.M!2\(>&]5WQ:A(';-F ,[?EZ(_O)U$6UOCG K(O**2I_$$4:)ZC$'*
M>PF4!P1,X(/AW-;H00T($K";$1#V:^;3W(MZW83,+Z$YDNR@D!U)PS/0?(99
M%#SS/NETA.K+)Q)T%HFJ=<;U5&CMH^&YLYIX&Q&1PD5#:=IL6.E"%S))8DRS
MPVGX?;#<2L-;QQC6QH+C+(2TQN#ZZ)"B6<D\%?Q,L5H*@BTS:?,[53RH0)VP
M9*[UK,^G,H@\-7(RK!ZHX2U*:^:D )5'6"3&&$YJ7'4^EOPQA>]0&AX)D"Z/
MC=:4<NJ1B1;5VP5=OEV0RY6U9=OCO-=<,A>P$&GAJ746XY28J[=.$["P61)&
M4]1J=1N&>6T+9GOC(8081B/P"D0:#&BBKONG10B9W@:?J57V-X/YM^'@:B^"
M@G)B%GQFJJC6#@(?7V6(04F)/'JC&K>>^!R0/:%MIZME(J8BX "<*I3C]5H9
M)HC/.WV08@^'MO[M:OAID))7#<49TQ:E6@Z38+ZY7I"[G2U_0)C!OQ;^041(
M9D-E%(%7:*9\2+ONR5$X&;[;F!6.TQYG#EYEX!8"(62H]$PP EZ=)SZ+T/7I
ML?W]D*>;5I8&Y<%B8(H-J-; JB9)ISG+]$.>2CX7?+<Y76=,FLHBG298$6<@
M* 2'5G! &I1AOC6MX3KEN.B* PLO!G%EQJ7%QZ!:J9(RU/,G!<XG!)]:>+?'
M=YOC%8(;38@DEJ?Y<)8P78^%2Z.3FK9\GAC;@PHO,NE"S%F2QOEP#^=)ZMV&
MA.;;6TXMO-OCN\WI8N11C%)*:CE'R@;G*D/$? A9N<)AA/=#Y^MD4-CHYU[G
M8Z\_F;ZY6M*^>5X)>#78$2TX<0 Z1)5U7PFE.+<J#4"O@6,9Y-L2GC^I? *W
M>S:AM]-\+]/0R;Q(; MZ X/;916#F!'4)K+US3-5(A.E/.)8"\M#0%YMSUV2
M?A<Q9]A R(#!%Q,*JSH)G7*<^8R-$\#<T/&\"#-XN9')*(2Q1DN(Y9R=7^RA
M/$^9-VT<!>0V,BL="3%<2L]1T*!"F:W2"0Q,:A:8X5S+[@PS_+E?[,LCRV..
MD)UL+[32* CAN*ZG5W#P]#)[B E>379OANKA6&R<.D>U$8%18H4!E1+!LE?M
M'<KGUTA8"O$@+$*G'/0&GT;5J*_4G'BUC4XAB[07&JL0.(!M,% [S9*H CRM
MY$I3UGP2V2OT'=9SV!MAV0_8W]<#ZY0SX#)(PVCBZX@HKM,/'#/6 BPY K"Y
M&ED$%O0<A)\F^3W "@B,BJJ[7")9O9E:!I8>!=@6RF(F>5*]QLBH(:Q"6E2C
MD!28=]$"+-^)LC>W_>%] ?9]LJ!YP6SNE^]AF@>DK:$8:\HLL:SN52 V9BV%
M2M!EF=L(SP.!;_4_B/5@6P0* 0R[1%Z@>K-X^E,&/'S?PX%_7Y1?>E=%=3QI
M5<!-&GLQ42]_&PZ^%*-45?!GI^R./@S'G?[BZ^GV_6_#\>_%>.Z@M2<G)U^4
MY2%K8-+LK#>34HU-^?*T<8.F;F^E"(,8V))8.VN!9]H5'"3>3*V#$^!LJ?P.
M'E+VKN!!$SIOW%OC&/7:$B.X"QYT%JZ7ET>3CU('PN,+A9<H_!L0:/3N_6\;
M-PM:1X0!&P!^/(X0+]JJ;(Y(JS.MI=G*).&G3>AIH6<<EK,?I?=MCE-W5B3S
M$"0$C70P%J$($6JZHJZS:3(8\?+'M^1WC'\Y 7T;47]R1%^C5Q9*OK (Q+L@
M>20<XA MYX- 6903@LL+O?>D]ZJ667 HP),07@:BHM#<$VWJV7II0/Z$[OHL
MZ%Y//9^E3R83V#\,IXM9/Y2=P>BZ*$?KBGG;7$+%L/$0_&KE>"!::<NK.FS"
MK,@24@MJ=1>@#H=,ZYQ7SQDG1&BB&3=.I\"A0H9&= QDIJ,?T_J:6 YOIK/#
M[\"G?W-;3-OW1K:X'I:S$9$?.E^+4?@Z+CO#LML;=,K[U^/B9I3NS>"3Y;#?
MAX^NG[NQ87(?TQH8FG,K)<$4:[<P_UCR? %=&GPJEO,:1T3G,:G6EHCPT;@T
M!!1+![^DTM3.AZ3+U2AY.GAUY1KT.5)MPYA#9I$-AG,,ZH*DY)^7]:06XE1.
M-2+%2B7I,Z5:&Z\YX\#62S O6N. '6(^SB\[2%:<]4HRQ.GC40T^/IOR:(M!
M<=W;72>ET?W!4>$9A*,T@(P)4J?YM,EJ"3-,,Q#VA;)ULX=26G EP>^E$6/F
M%:Z+YA1EIX)RTTQ;Y:/GSCOE)0N(8(2K11U86-&0^%6L@7<.!FL;12%P2 OA
MF:!22\0EEK)VKHQ7#=.K]H)U:;C1Z\%L@N?H;><^S:!+V>#I[*>%9,_.S&&X
MMHKQ&*D-TD>J@Q U"S.2%?4(M!+H[P?G,3#=<&@>?$&026*9<UY0C(6LLD;@
M)S0X$)BATZ'Z;C(Q(7W)SD>8&IPY)=R"%<)*&4OJAGMA+<F2-:\DEUOB-8?J
MX5AL.!X@M<1IH8M$1AK'!0^5_+/ \KUW*4U-,YO[0#Q::RVW<;? -:>1B(C!
MW=*@P=)MRNPHX >YX\!6;_PWPO1 !#8-CS="1YF:,L#)5FDH'ZV3Z$*1!L\'
M7CTD J\AP!R,A^4^NBSXX((*@@6L*.)<8U%OTK&BH?]'K*R!:P7G 7!O&EN-
MM1;.<XP)8E(1CN:WA6 (L\B.4I&Y3?O"_6;\N2AG[M7@TT,LB0**L]2A%% P
M"MP-.(AZ@5A@6;WMJ]7;_1V .QA.F\0A)C>.3@8@&!$]"O7$0FFTR[I87I$\
MY#P,3F_+(DWHJ61IYC> P9E\WS2NW_VR'449>; !<Z.1LQ(BGGJ/G<H%!J_V
M8.T'YS$PW61=!-B50) F1!!-'':N7@.G.,^78J0A= ='=1J)3-I67>>V-YZN
M!S[A"%(,OH\6EGBCO?+"<T:K)(HF5&>E(3J7T68<FO"<$63GJ IAE6X](W-(
M>4LT9?7NV#1%*8\$:.:G+0&P*VRM$J-I=-@P+6A$5$H:ZRP4QC%?J4V57LVF
M[ _;A@A*J<A%3+M*'(1\)E+NZQHV)F46?W.21=\/@JW51Q4L!F] ?3JBC')X
M(3>@0PX;!K]#[0E<$I.-5>@'FGH!ND1H*K0)(2*DM45^WN;H=+X^?G570P/L
M^Z#VD%EEZT9:>"W@D ()7(!3J"$<KY+GP%TY:G2UTOX0J(DM3FTO32@D#M&D
MK2I.&H)%6D)3>^J4Y#LV5HOD3H7=[@<'"$6* SB)F.,8N#6VREZB&!I6GJZ6
MX1X(M>.8,&F,2I5>B'FP$T0S4,%UGDBH'#NTSH8=&[W=3RXR[RCQ1)@T"U(+
M(6.5C,%,^ZP1E.V,VC0JN(^]06_TN>A.EBQ-5GNE;L#RR]K5M.OB76FL0I(+
M8\ P>P<*L!['STA>WT[IJJ7>"-"#X6\MNXI*6BXQ=LB I"#J>+T[T?&8:0$L
M^&HB;S\$&@O4VRB-TU@2H:VS041*0Z"R,C0N$)^Q/7BWJX['_-$[@53S\=N[
MC_W>U6_C6;Q2?W"A*>*N_T?YT]W;GPC:- D&@0?E1202C RAJ1X2(^MYM,%Q
M'C-'5.&,TX^/SD_W_6)0?$WWUC<?T\B93?*KK. ^6FP=F90B:EYK7A$BSN=^
MK1;E[X=5&X<'9PF6'-@:$4\QB=34VP!%M U[+15?3>CL"=-1&$=XH9$4SEN+
MG3!I5$_M<#&P=+D<'(K$1V4<&AC(@$/1&AHL#?-3 E^$9"%/-CQM(U;O.G_^
MT@'CT(.'/T#A W<P@!3\)IN6DP&PNFJJYL[%+&,@Y&JJ>1,\#X6^31BX@""7
M.X72Y8WG8%W)/-\1\_LZ/+D*?SCX_QB6?Z1\P?"J&#V$^F!=O5-I<R$&YQPC
MZ6.]T@E\O5QK,K7&WJZ'Z,$(M!U RKT@%0GV*G@=@.BR7KFEP,7.)^&@U2AP
M9P1&X\EXX;H&)HT3[ ]'=VL6SM=B7G_ WM=__*E7E&EFPOVD=&;)RZO?\WIP
M>S>KL:$;%J)PSH4"_U0Z!-I8I:QI/=HI^+S.8(40ZS%[" T65=V1:+#$$N (
M&&,T>+@.S).G7M4:13>,D=B+!@MI5C.85LY]'O:[13D*_WF7IJSOI@2UII8'
M+$VZ;<-6S?<\. 3A5MY@A>6*-[8)H(<!WR:"A@@G X2!VDI"L=.&5IE0S1J6
M&A-%F%:' 'ZOKHY(1!#8,*-QY$Q0H4,U)\QYD8=$@K"5V\WV5HB'-FZ$B"SU
M:9D5$<#!"BM179@I+_)>!$[$RA7!)OBN9EGE66'FJ.UNLG7;<I0!S(=0$HC'
M**:ZWA.OM,]3<"1-VU\&= TH^\/;6K9"K,1!^8@M08X1S$6U$,=9E ]&(:G,
MY:@ ;\B_6H&UE-30* *X_B(X6FDRE<;AY\MQU='A;<UE@[612"HPPRC0$+E6
MU= BH#;."$Q3H>D>  \'GS[,<B,[EN]RT+3.)>ABL)*"H:C"*1F9SWQ]"";E
MLK^S^.SM86J/IR3\ ^32Q 3F:;1UDATK@O,>9@W*D^X,U%ZZ4FH?.>4!(@9P
M<L&3X*J.C:(4^>IM4%9D+6A-RF@;"-NH!QH2K W$"3$)M&/(S)LV-<V'U&'P
MU]DN$((GZ#JCS^ 7?NEUBZZ]_VV4=N--!\;V!I_,U;CW9:IK&XH+=Z_W@&@4
MA!ZG@D=O39#,SW=8L8:%TYB*9>OT,("/B?H&[:%%,,HJQ2T8O1AM&NQ;^6TV
ML*8L,UV96G=TW*<.XN&/7:*THDU%SQPH>@YF7]67!Y(T#6T1C&V#^I8 'Q/U
M#<<N(.;':5<= F4'[(Z)(C7J)H_@7FFI5BH&CXY[75UQX&-75CJ%P J!,C64
M@&G2JD[O!9;52KX"!;MBXA\&\3%QWU2C%"%8#3%2XM/^*F=CO1Y$>))/[GE%
MF<!'Q'U>*;ZS(RR83G4]E-NT%UD8(WUUAT^4,-MTDBP!L!MDK>8$; .1UFMK
M0:E@;7BL] J2-.;"E7=K[ O9!M^66Q5-&@?!N33$"T;JS!FG-I^F]XHHS;+C
MWQ>RULH"Z4BJ#P5F\P* ]!"75SDQ@50NE)(+FMG@-9!-9NZ_N:Y9]'WQ:;JK
M:@LH5R;])].O;5*='C0GDVJ^[3+5Y2^ .7L(F,P%$-=!L@AN_>(#A(,80EW4
M)"BITQ13Y5T5%$ 0UE H12A9(6<#&/M V5[I"8Y'6C("8*66!NWJQ!F$6J%!
M&Q&-#P_E!J&)0E ?G*+&2@8X:5,7G1&J8MX00XAD]!A0MBH=[A .:2(;5Y81
M9BVKRZVX8EDS [@ @O*=H)S4PV6%\7O%.)8:SY7V5"G&A99:UV,]N=,NB[\8
M7ID/U [,0\!NS;H%!.X"TU9'&2277M)ZH (5*KL9I&KEYN'!8&^8^GKH4@:0
MS( 8B<3" :2]:U;7IBP-^\H07BUEV(C& W$^P@HDPC67V#B3VGV"4C;:.A=(
MP6/>-))M#Y0;JF$W21"3WM@ P"'-?!I0R'&5IA(XALQ@3HH$,RBSZM96>%KO
MA%*-&>AG1<#V&.NBDY57#2&CSH(IMFIN6N!)O>EE\;D8C'I?9DV#OPW*8EJS
M^M.PWP6=]9=.;Y TUIO!Y*2G:>VR-X*7//QU\*G>*?_F^D/GZ\X6U4CAI:3<
M,.I1< 9\SZJHAX,GT+ST9@6](^#Q:+1J+=-F$F&CB5 44:0\Q;JZ'\3.X9P7
M\#.FU0;O0F,,D1=C/%JN*-A"<#/JE3Z8YOT6F-+G3:W6=!5C+E6M2JW *P-A
M= +-D]VYUL,K;4TG(];V)KLE5H\$48M8V@02N:685W8(7#S2L'MEU>M<"\B^
MX+89 *^PI@I+D@;Z<4N$Y_607$9I7D.-98-+MQVX\-)PV5G=MTN!AR"B5RAU
M?F/#'<1+U60%Q37)W.8FF-="\T"X6Q-X@:8F,QTD.,8Q#;VO5\Y1[5T^85LT
MF-NC +XI!:%3X4BP-FAXLW)>FSKAS$+("@4H9:<#O(WB$. ;#]X-U<AYC -C
MJ"[=]#B?BZ!%@P>P/>"SMJ39RWL%60J9J$P47E"(6A3\JK?@407:)9=(W<#=
MC8#L"VZ; M%11Z\#UQZ!:@A825>!RPC/!QS@:37I7N!^^-P9?"AN;H=E&C=Q
M Y\H4QXF:?QI*>"L(,5\Z?3ZJ>'X>EB..OUB;@QVGN<K/:)RT@.-=0 ,K8_U
M6%8:=&;H5Q%[.,B+5$A+=U\/_KTWZ.X]E(9.7&)*4D[12G#TF*NJ':4B^;:<
M!83RI^\*VR8_02/+O$FZ@X*S@+U0%;$E0S3C)8U7RF4W03A==C\;T_EA""[
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M,/F3G<%5,9G#M7.V@*3YUNGZF/G C4]M/77)!26V;=OA9F@>"ONF G2"M +
M!7";-)PSC6T-N\MO4TCJOEF5[7UQJ-[TYGKJ;_XVZ!;E:_C!8+(O?M!MSM>E
ME,,(WM:_2Y[IPGZ2W8].2TL(X0H"$;#J%N)84>D,@8W:HN/DJ/@\(N$V=;M9
M[;FGDQ'XDVU0)-1IBP@TRDT"6?4I'H%N*9GXYOJ *5TF4\\YIC'B$'PT5M7C
MDY1V>362D)*NVISMP3L<6IO:$V24E!J)D;6@IK&SH9[$;K3(KI2X)&HUPC@
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M$.2YD:GAMGVI:%M[\%F8%4SX8)&T8"\\37OE">++/6C/F9DV#3P"3P]C\$R
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MG%5Z2WA(E,ABCWE_Y"P!RL$L8.)QDGGP,DCPPFNW3O[9]"9$ IA0N&K@ %:
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MB%/0)![E*%!-.'IJ: '5DR@5]86Q#VPEL;[0-LB/2VRFK,J@G*TH8F'VM$_
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M[V<X$%AA> AF#B/'I_7J$EYXBSC@H6*DC0VKH6 77P%@ !$!2A%?-KR5X&&
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MMBDJ%D]*V<25#_B,Y6%FA%_B(6*,*;\*;> K3 D"ZLZ8"'/IZ0*->(:1<&L
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M:'KOZ4K&%+9;O,J1CGR!F&KFA$SS?($G4!'23Q>)#C-=S.<;S,;G89ACC @
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MR.(Z,&7TH'20DA3A^34H21Z>&>,<(U2^&^JP36(/71>KX%05V.Z\+"/5UDF
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M+^O(Y,LB\(XD4?K9R-L0%T6);M^LZ^O6!YC[A0*:#)0#T'H04+7&>P,J5-1
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M%5&X#>8./CO@8Y;;_>%V6"G&J2#17G[W2$GS_J-%_SL$++? ;U/,E9 8/0R
MHYU]SG=<.H/#3T!-Q3++?_Z0I(GXX1_X^-;+:!QF.LRL'S.W7T-U"V)N7D^U
M _#WDS/8703O%;ZB5DRH5:79N_^83@58?<^ P^LZ7)TX_%7WP#>Z?5VTWB
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MZFT;G!LM!W&LL6L&4$UO$,A3&!H6&E#WW(7(WWEOVF_+D,!29+((R!TJKB,
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M"WO+)BN]7%]%4& XYNEI@>6^BXBIE/+6/$7XQX8.5916#&OE(Y=#Z!&;P]S
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M(I^G !_FE5=%Q+_#^+R\DPD=MPV?4[KPE<I@@#N*Q3).5\(4M2"WGPH8C*Z
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MR$67)E<I?DF6*W ?6-,U=1=A!W9U@7\4(3G6I'8;(_\P-O4<&%2:8=A,&6F
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M!$8=@FG^NGG4?Q7QZ@'\25DW .>V?TLY:CW,ZG.">FX*YZB\VUT*R%W"^<4
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MJ%F1%PBS((;QI^EB"7L+/1CKWP4^EJMIY_">3RM<PC@H66%S2S'-\=%TD@?
MA6CO61H64V!7\!F>!OF5"8G/1=?ZZDQK&F1?]N+HF'"%.%$F%C J[DW.13SS
MXFA& +E*T]"LJ1[J? ZL_0)8DR'T,N!?T37ND^&#?P5+ "2@@#?+T@5!@]KP
M7<#6"3X?L^+*.PL!<P%X69!' (XW.L&\TWI_\?',?&J_?XNHQT"G>TL9@P#H
M*R^X$B!J!)T7G!_ )_$(AQ#??#H0"<_'A"NPV&4!2D@@!0F:21'_Z64_%E]^
M[+1H65EP YL D@+DE^8@%T%2(#*RXJ)T&X4H@/!)&"%]:*J:HC8?(M8"Y@C4
M>6B@$$5<ND192)B72''JG<6Q%T89HF%U$EYWE$R+#/$LF,&:;@<T3CX-EL0L
M_^+Y->6MJL1?2/@9P#4%E"*LS=5V,Z%71LP'=YE'"Z;K:(U[+(/IGP#[D(B&
M"+\ZVNG>E\LV#K'/G!)2NQ+B5Q!HFB; ^DFDU 3HOW5/>QX\%0,C:1AD_]:N
M>VDU &U3O:*A?X0O$O&]GF4B*UQ,T!;(2U;D>XG(?4NHQO!5?; >-Q<-1J?M
M6I>V#L1U>8:,&5B]4F0L^4)*R(<@_A[$>6"*NH;O6>!]3:=S4?EVFL9Q,$F5
ME-8*TLLV*[Z"M$Y ?_T*.'R51/FV0SL6>08J.BA)@FZARWA?DO4RK<.P\HRG
MOPQ6;*VSK@$<NH!5938.@!X<7&5"T'-HB6S]I1QI$:Q0D8F+4'A)FF1B!D.2
M&C<3.&NN](LIR$I$,*5?E7/XH#E/42NA%WPD(@$:=R)HQ;BA_ 1L"6&M'G$?
M:2.:15,P*N81/,6_A$("X$D;5(2Q:VM(7]%B4F12O0H+VZG129%=PR(9B+)8
M+L&46B-(8G/_@(5EZ0HH3]DE#'IXU!@>,$<1DVY'9[2VO"P+DBL%^V/&R(P)
MZR\+)>$\T/[+PB!! PU-*T*$(I^#VI S *Z*B'_'(U:OZL$0?<@BW1C<NYD+
M&!VT;>V9!*BF-Z1IP]"H[Y-6NQ#Y.^]-^VVI!8%Q+ LP5*_1SHT '%-BGT%B
M'P6HS:#.R/?>FX[U:BAB> ULE#FZM:9*E4?,U,@R#V#8"3I1,_1<PL\P1-<:
M I<J11QKO4QQ9#9AP9K!WR?%"@@T J2/OO/XVBF 1,82[$W/&A0Q"L7&)(JC
M?(5O8G/T%!\'>TI*D!!/:):VGIZY?U%L[Q)ISZ]%E=J8XP :VO:)?A'Y@93!
M)[/@>J.:<6 #2#7IM?N>23V'OT4I,0KU,9*G9OW(T([0@"F]6,!X;^8I\ [@
M']YR'F2+8"H*"NQZ(?JSHDF!GDL?'^/MVAXC>'V>2O+4L+Z0PJ\9QJY.0%\'
M70O.(5V W#EE#E69+T/NGZ(D8B4'!D<I1A)!Q5A0D"E9P(M&[Q0*+7P?M) 8
MY&EQ-4<7:#J;P82P9G*9T4Q3D9$S%(M'E]I=1GZO["H F4I6@*PXZ_[SRZ_2
M]M;Y:_N[PH2.A+7"++W*@@5L[=M<5':5!W^BNRF/C6!3\/)!0@;L8\HB^2=N
M)$XEZ4SI#:BU<AXM:1J2IG!D2;H K4\6$YF3IJ"&L[QA%T6&(/<1!/16 L<$
M)(#J(AYV.@&"4!M%*"L?,^@"\&FA!S5*];*(XY-\GA%42:$[2O&IZ9,@HI1;
M@=KL#, 2X>E9GFYT%&81J4.D"P=YP+Y@HTF CAZA+U5#+Q/PGX0Q G JNQ)8
MHUR+K^V)F<&I=R8ICH&*.B%1J7 >V5:VF(#:6<XAI]GZ$[9?F*G59 0H0K.H
M^GCIX+=EFMAV!5M_;$QLL9V/#XD-WF:AX?F\%S1RLVN%#0':2<CQ* Z'2(^[
M1H @!\R0$2NP$$N78N?KR@?P[E:4H*P@6$\<*P3XYP^M'^BS7 93_5EM>QU'
M;#!\ P25WB_BQON: L=^[^U"CFW- VZB,)^_&^Z5<U;-\]K_X?OU+X MWB<)
M;(.<UG9?24DD];L^F\M*LP1U8/#X/$O8^[TRX#8VOX5W',SBK!B87UGDU9/&
M@8X-(J=U)LMR%V<J54S4 S$](%A0D"[-2H<>T+G(LC3#H*"'>(#43-P@F*(/
MSBL2BA!:ZNI$2V_X>B*NHH2BVK5L2T;?5?)6/1QNJ:/2Y!M,PMH6FM^(^%K4
MNM;2":5A#5I5Q'[V4^_7(C,Z%*NAG+ @0J-*@=2A-\K3XN"L\H9F\&X6H2<R
M08=5FERE%#).@G@E(WK=TN@T"@5Y#MKZ':)[GZ1.Q\N/C)<[SOW^HS;?4<.Y
M$%N2RA[&N]':#>VQ.93!A)IBRDH">O0T+R@)R\KJ0@,3'@0ZED('!,RC5K3"
MF++D-]<*G2TED(-4EF#<T"!/5L:K0.^KR"+RT2-3:[46RK&E3(>^$*J!\HJ
MX3H%D(%@+'-YHJE83^S1F4(@\E8;=LWMOE'''1UW?(G<$?3:!2B(7SC,ZGW4
M?L/Z%%QV2$X#.=_NE;09&MJC"06.$PH-PF,+(7+SK(H&>\A+5::J=DDM>2/Z
MB7*J;0R9!_!M70D8:*Q<H89#PVJN@RA&LN:,EK30*IMR)6;B*LA((U4NL8UA
M3JWRM-O_>E;VLU:;Y3B2XTC/Q)%^I=")841$=S6J;;\+HQ=5V)&)U2PH:9),
M*<UV,!IB9<VHU'$KD*)92UE"592YQOBV,O5ENGUR/9$)LG"<B?,7S'+T8#YK
M=#?S:$HAGS#UDC1G7=&LA!74C5UI%:BT+DTZ=X41YZ!;Z;& ?>K5L@TZ5>QP
MPVN!*1D<"/ P$H!;*R0'K"(4 Q1<T""B3!W,H(!C!$L5&*W2VO30*B?"V@:L
M/XC*!&6UAQ*XE%V-,/("*Q']6FC%F'5(];I4CNZ G)]RTWFBCVH)UGBIOI<'
MIS!"1]>VA<1LB]^:UPZ6X&YI61@NDUPT0=FTH5#Y><\EN!XKD)H<##@KO=A6
MC<C.B%;I@D''RX+//[UA/QR[TZ9Q $+21&AUS(6#AXBA$Q%CTAI[\E(+,<*-
MZ7%)1V:EP=__+J(,333 SBM0]@1:LLBW_BC"*Z(+A&HD,8[[AS)% <;)E05:
MC:=6'%+3ERK^44ES\ -\$>O/JK"(:)A*KW%P%?"$!2U$/D_#-$ZO5NQ:C:,[
M YJ:^@.N:E+9:1P41+K1H2.3\5?)(5A+&A#LHON+DG97>KF^BJ# <,S3L;8K
MCA814RGEK7F*\(\-':HHK1C6:GMMV*:O%*//Y-BT8I.8[C"/*#G3Q[0\&/J$
MSQHY^+6J"YMMRC+TI,0Q_I?+OTPV!B?2==]Z,6**M$O;5CH]I#Q2Q-5$Q*I
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M1A &MR$"Q==8V]:!7%-CBQM$^0#SDO:Q3).J]"?O(J<(8"]49C<9):F1LD
M*=5F6\C"N/RB2LVH+JRLY:B@ZB)5^D6%Y:]CHB%_(/-HJCQDFWI/I2\&/<M@
M(!0T4+?G.?7.J^$BM32+:EB'YD/23NJ2N>+*;&:K[2;LL>=%BV5 7N?-I4Z
M8ZNT%A4B)MLJS2G*5GG^+]/1!B.KAHB/TK7![1_N-.;679*$IS:.VKH74/ N
MX1Q&F ^B,A+L=U!9L+0!UAN,N-@I/<O$;*T1[M==9TLSJVJ;G7PW#]W$2+-Q
MZ8E_4\Y,ZE&IS52(4.G>FT#UO?OTA?&5D\)JVE+1IW;U;C'^DSN[M7B_[3KX
M4"A'[T-.UO!Q<O&LG[%6_RL*F8(J1;!,1KT*MEP;?P_9)#-1=O"I)GI4<D 4
MJR?O$2X]2$SD1_$$Q7=+YKZ%Z+&YD'<%QZ7C:<=+\K]3XES%/40 4?XQY-&(
M,;;L42XK11O\'/%UL/2D5&XMS$@1)).H(*2TJRL6WDZ%R%;9/R=J:&7Q2F%+
M2GL\$NTFQF\M0!FH*.%T+P<BZ'1IVCR9U[0UR[E5VYY']*<,!J(E:]4;,,(9
M27614C5!5B0+3';*CRHE'+^L.OB,X+-8 *4QS2BI!Q7LK$"RS4U4IMSI1""P
MQ'=T2TJDZ<^S*APL16_W1@F>,^YO<0=<B2&%G+UI!Y-IQ<DTH_5S2Q/V_!!_
MD'/MBE0ZA0I,<3:^]@5M18J9.:A]=Z.3P/! [KM<'\2-?C<'GIDSF@=5_7G[
M@2D%"U^V9<8>N&\0 S8:)=27=X=ZJ91]#0]R4E5!RDW+&']X+R5V'&U,]UQE
MZ"G7_4XWD=WEINSX9[RZI,6L>:#7G?Q6X)>Z!$KMURUU;E9(K].X6+#];0<&
M[++:+5YBSE&RO*);EKFCIQUM3E)T%^8\N_S-^R4]Q9!>ZZ0]] ^5N+*EJ:5W
MXOUL5OTS.T)K"7/:%N;&#+AG8Y#8MN=:][ZJU:.+VK?97&N8$%AG 4> 1A R
M\TQ@GEB9&5)-!J'R(M).4,,LWY=Z=+3?45V=;3YALZZU"=%%5WG6\L[9KQ&U
M YFC>2AO[U5X/#TT!JW74<?3'3RVCJ>]=PK],9;OT'N;C@RB!F"X"9@Q%-Y!
M!JD\1:2N81+WJMK[LMJ$2Y'F&D6F^O4Y/F?+97,MQ:8O^(U\J[,4,:['?*3T
MHA4Y+%6L!_T>L<IG+.(;.$I_/DKOO$9*YSQ>$)1I+&*..00RM^F$.M4ZDGB5
M)-%]C21AN_(LCZ6*)U5%E/*]E!W:5>J0E3]AV]J/)J,F6Y!KZG0H9N1%4 X(
M-/36<PL"NJ:'M?>)*-5Y#LKIM@*H-5#;@(Q<BONK(1P2)ZN?NWQK9W -VL-Z
MS@/[!925DFW8'D6B*N#RE?96A/IJ+ML3$<EJQIYQ_3+\=+J^@=26/ >^SX^<
M04IABA+;GU8FC)%C*RR3"3A >;PNC*\/N1=@(R]<&Z'6?9C;#-'*" HQ>( 8
MPWV<3\"(L%=,@GW ,R'V"SM4LC=4)0[ZQG3T>5LPXNMZ4O(MX9IJ0<^=Z?%W
MIL;ORKIY9'K\NMM'A1OY[B[8.^4)I;%VV:VJ 1XB)Y7WLP>N[$Q8?,]GC94+
M[#</$O:,"@SAF'(>-=VV"Q9@G8DZ5MWHZ<$76ASQ%5^75$EY([2C5V5Z4M C
MS8"F!RW@FRNI+E[[=P$R@5MT^]:C%I:;Y- =^?63U98<YRKJ*S&NYYI5ZC#T
MMQ76,$TS;-25<I=#M01US\3Q<M=OMR0)>_EJJ2ZJU/[AC?PO*\B!U*N"DT*E
M7YFT'5OJ4T*;.JN3R>I$EST@4Z&H$'[)?ZED-XQ" )53M1TY(6MQFG8W2[4>
M5&)20]LV&FC,5%#/HK@SYPW\G@.; KZEPN$%I[AD0B755+6?*?XGC@..;55"
MS1@]QLP'VYL>,?>]*[C *J%*TM>BQKJW&!5U*CQ3Q</%$5^V\Y4"[;")7U*@
M@M[!H@N'*IFAP7W5AY_CFACB*Z14&:"WG73=MY0]XY5DYZH?>^7VFEJV]QSW
MVY]O[2ZO+H:4=N_:6?565K^2.;CEUE2\^CCF]@4S[.HS-U]GM'_]$:M,LD1=
MVLMZSMI%KV!WST6 NK9,IQ$IOW8$SRIE/Q!)';32?%>-*Q=UBO7*+7/OG[?]
MZ,IF#3(O.VM@P.HDQ-1JZE5LWR9-U>[Z.NG*];*Z612]G,YFZ[=($_=6&GBU
MXY]>4<5*\#%B!U+A!?&"K[;:_M%2VS_Q_;W'>Q?ZUSON3"[K1P#M H,O$Z"3
M6414'DQU.GUYMXXA93T*5KAI\J]<7&P]86PC;?E6V4-93&.ZC52,)C5SD:/+
MSPR+UO%=.Z2KG*DU"!F@Z5)Y#"5?ZJPNDM.FLE2#AQ':U_JR:U-%LW.VV8PL
M'7-S#J6Z$$RX29+J]"6W%?[N?[*C:I_"K;TK'^0$7+L1N\Y& )S/5-X_=,LE
MXENDQI;2:S(]3#>>6R_J_C9?OV^<9]]1T;V#2?N5VGO?5-AC\3DNF4O*_?4+
MQO-JQ?^V0O];5W^T7.=W-CY4:9M57:MS?ZMY1^*[F!9:]FOALY/2[$K0L_":
M?%!ZO-UUN:K<@!7?JS0-9>7J2/:^*C<MU;&2/<2W2-J75NU>5MD'RTX4/O4N
MR5!6U0Z;?DO%ILI*)B8+7B*/I*/J:59Y9(<K4Q,(&=/:AZ7$.[<AY%HFFH!S
M!2M3E#"AW\S QXN./V\FDO%Y"\;*+8Z\*#E16=NA53&I.5F H3+@?;?( R!P
M3K_&B>X0"-X;4]M^UWB$M?3H323%6ZW<L1.3[EW3-23FYC9.T4 <4:BFW.4[
M)E+JNWTO%?%%J;!7\SA.&>8&8?'*;'$KX(R6R9GF.Z!P&]%OW?X+TD#/M=;T
MC;2FH]<[OU@9F^NT10Z&BI;(F)7.T).U"$)A^OWJSK[TGJZ0+Q5$@R[5RQ2U
M.XKU U8I\'J"]4F5LV,BYD$\8UVA]%GM["5!:[6J*Q)QE>9165%QC6TS*E=+
M>%S#RG_S>E96D*](!-51J$CT+$YO0+3]IZ[G\3=7( 5ER"K;64Y!I<65WJ39
MG^M<FQ.\.3!%E394MFP*$<E52U3.Z])1(G++8JHE^N^59$9850OAB7N6LCQ1
M/1.EU0H9J!B5:0+VMLI=^!NMV%D!ID*2@?;%V649YYCK5+,E3,G!0:VF+0 1
MS,(X.[]J>)1=,XXXL*+Y@*TM;R.=8#K-"A.!U[U<S6U'NO^&+D'1=W%2J$5U
M9U8!@,QN3TP(95#)5JY4\SKJ6VD=D'6&_MHAZ2=D#B/HY OLU2QD6:E=W=JI
MQ_W(85HJ!S;.)=MVV)BXBCPV=$@9LB*L2M4TI2%:2;O9HKX"EMO=&*JXML8<
M%FG(Z?!O9I0#P85A_GHVY%HWT+4Q 39Y"N8(J62W4?A;;G%+??=H<;1=P@Q*
ME8?C4G=6X9AT$0U*7D7A7X7V]2L+UVYXK5F2?8'KFC6MU==;<K^Y3HZ8\A4%
M!R-I<A<R-3WL2"5T;)[.CZ93*3)#8A[9QJJW>AU*4"CU!#60D+H]J!A%6?*F
M]B[3. I58)X[,2*#*5T&: D8&;%,):5GO"!%Y!*.5IQPR]9S(&  (^W\R5CH
M@=JI9M2DRFS',KNJSFA M>F?JER*G5: 4=2&GW\);H W5N]K_GIYMG9?\\9;
M7#A>?>FWM9>0(>*WO([MU>N5(;ZLC[&K/"8H\CD0D&K7?55$_#NY4G!Y)RPV
M;/CH,GEV30M@Y.E*6-DSE>L/OZLR<;*.$@:1RI3!A!(LLP4>F!4Z56H!1%YD
M93>(JPR=Z$AU?K7M2=D@>19$6379G&;Q=47;=IM:=5;) D3'$T1-%6^FVEGF
M/[! (.+RE@*K]ZN>!6QXHHI-,)F9*ELGP ?;CW!7@LYZ]R]R<>T:8*/8#QC[
MA-LR*%&F$^3N'(K2;G8-YW$U-0<&0*(GZ?;=KQT 7E2;8$H!<.FTD/'*_G7W
M ' F5*AYD68SH;ROF_Z2M:['\JZ3"=2%;)3)\8(8]>>$#OA;\!W =,S<V:Y,
MC'A3.6VJT.7.'MX8P/7ZW%SLU/M-V1K$3? KWRK--X-PZRW6-?48I8/.('V%
MYY27I<C*;2FEU)=8W<^^DB#+J*>1N95BQCT*Z+L=<^?<\V,%EBMF0&D7#G6Q
M,=H9+GYB7.)\%XUBF@P6D?#E,/@@-<\B3LRMF[4SFZ:HJ&+VYK1':*H;LO#+
M,* JY44H NNS:H--(X'(RA6<K)1]K=OWE$V<5#-)I>*M'S#W<3#'MON\RAY+
MW+>.+&W=TUJU,D8!'UP%*&AHV$3DVX;VK=9DUN5D:*A\5ZWQTI@B( 18CG H
MIT*6%E?4SHJBJ=A'\]3[N&/U;)+2*:I0FF%E6:CY/A<A+]!S%T=_4AT'"%*N
ML-8)Q%K%-,YI"63)K3RY9A>LJ?S4^]<F8)322VUH09#"H49R+E1#?>"@XC8X
MU9;S])?(TII25N@NB>I-+G=!4'D::$<$0/R%VGYRO,6Z(.X;5:*C6; @.)1X
MBU5U08S^WMR07U4[8;K3=,ON5XNR)I7N0)HZ9P6L!TD4L*C,608T$^R,J05J
M"6!*/?D.?%,S<BQ1T]HNQ3*GF['*0^BV?"S;'M2$,3<5Y:&60?_6/NVB;RG>
M9A,]"+"UG34L;5#KTGQ+(J'I'26V;%4*%OMYP*9'#/[M]/+4FXF0NN39?GZ\
M$&Q1$&4=2@>K^PZ /72P7X!Y_H2)[E^ V9.-<+2>1K#XHRE) \K<7Y+[?;'
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M!#C7OO(R@:+RGLJ?Q>9QR55L#Z=0Y(ZJ>?7W__E'(4^N@F#YSG(TE=VLOJ0
M.#BP;T#_'V*0"__W__U__H]Y P7%'%B2R.0G"C1@30[>7AW3=83F)0IJPH>O
M8O;/'RX^HG;RW]W_^?;Q!R\*X0O JY./%Q\^=OO=BU'K4_^\.^IU!N.+WJCS
ML==NC3_U6A<__-\U+F:?T7ISBUW,Z5ZBHTY;9I-]6Z"S.[R_^2C@"*+\K<<
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M1.(TXTV*DLG]4?(3ZS4RL78T04ZCVH]<:"'1H<T>1L "AVZS5/?O?A?%@VG
M-& :M4SC,]<"TZ@+)/L9+T;94@2#WS= \W!59$EB5.$3780(>N[QQ)+/F@R.
MRE-TP8?J2 :(Z#4B7)NLUM871*!T<WCI9AFF]3R,JKH0F["HUVA(2OV9\K&9
M1SB@U_?$ > "N(ZPD]L$QW1R/'T'U]"S\C_7AP7_U*"%G*,%!E*P:]OR*N\'
M9'JCO[*.+GA"%@]$*9R#M,XW&]\71*$*0#;]_E5,)2D+%C0R>X<YKS=YS'C"
M/,=!(@-T 5T*T.6QB8<:',H$A]GOAI>ED63B\7FQ? X!VNC]!%\-. .RR+;]
MAY+^ $Z TTYS>3Y=@#T0/*&<H+B<P(RH+@H<5]U^"[<2 2SM4X7S*6/UH@E<
ME&GL\VEF:>\^J.. S31R1[#9<6SF,B\8MV\S7=R',%JFD 8\\<&.5T0ZHS#@
MS9NJ:W%IQ&F4U$)4*TZ-3+;S?"_4)7$XC9.XBKFX3DHM19EX@5).XJ0R1Y-'
M>4S#)$PC;I0+SJM2E;(4O9KBG#?)@C#0 T]K#F6IS350EH*R%-W'0UD*9524
MF:'?L[4$E*7@F0/Q3"A+G3WI_"P"Q:G4F7[@1GA?<"YR'30::D4%:HVX81J9
MZ>S?2^R"5>&.<$==K'IB*YO5^>7E)H[D&1MSSLOU.6X/S>KR81J*FE@>KN1:
ML[\\A/!2"8C/$SYJ9Q_X#_SGC'1^V%+I.%WG^=LL6KP\NP1!FO[\I?VV*'0@
M_S?H[;*)0[=IKON7OZOV ZH!U8!J%%--P$R;;@1>]R__5*HY,=?O?@PHY6V0
MBM&G8H,;E?&98T+-!L-G0!25N0+FC3%^IG1%1T:!5*Q]XNJ-:(;CL "%#J +
MZ%*"+I]Y+M!UIMR^^_OXMSQ>3NNBE,UA\M3[G5,R)2\>X@@:-,A;",PU85X0
M(&]!)0"(HEKYF>-"V$D7(1J_ZX'!6E=F]M-H*+(6G2B,TH@G->>J#15,YCET
MS+;+:(<;H,-\!UP"EV2XM-EX3"=:-&A<0AJW++>2=4:>%>)<6V1%R(H(]D=]
M55)$_64C( J(VH,HVT3' >H,BL2GF)'R2NA.*8H&D.% ^K&5SO%!2#\Z)O,=
M1?LZ0Y1^!)N!S<!FK;&9S0(+;*8B"MXM9/O:SU>CNOQP'X;YY5V=YXEL5@F3
M3VNUU3LAMOHE+J,D*^N"EU\;"WQ*LNC;];O?KI(X_78YS[(JS2I^T_S!>))_
M563BQ1=5E5^.1H^/CQ=/TR*YR(K[T=@T[9'XYY&X\/WF^FJ5-]<W=^;IC,_>
MBUN/7MS[^MW52-PGOA2_7_\'4$L#!!0    ( "R!9TD@2)>_-@X  $>9   1
M    :&%L;RTR,#$V,#DS,"YX<V3M75MSVS86?N^OP.IEDYG*DFRGB3UQ.K(=
MM]ZQ8Z\O;=\Z$'DD84P"*@#:5G_] N!=XEU2S:R4R8-,XMSPG0.< X+@YY]?
M70<] Q>$T9/.8*_?04 M9A,Z.>D\WG>']V>7EYV?O_SP^5_=[A^G=U?HG%F>
M"U2B,PY8@HU>B)RBWVT03VC,F8M^9_R)/.-NUR="YL>KL(^%-047(RPE)R-/
MP@7C[CF,L>?(DXY'__*P0\8$;*6" UI$JD'BML1\ O(;=D',L 4GG:F4L^->
M[^7E96^*'?;WW(4]B[F]_?[@I_[1@3)*F4G%L;Y9O;5#Z%.J]>N(.WN,3U3+
M_D%/WQYA 6%SRBCUW&P"6_*>G,^@IQIU52O@Q(KHRHG2!+H!*5",4"$QM2+%
M7I<,>3DPK0='1T<]<S=J*NRLAHKMH/?']=6]0;#SY0>$#*+$G3$N$5U"8HS%
MR%!ZHCO!>&;ZMML?= \&'>3[P16SL#1>%] 8(S()>^!($5[IQJSVE X=U*NG
M#F<.B#7I8WBMJI"&>%T*&5Y-%"KRHAQUEDGT7]V0KJLO=0?[JVD1!UD]+4*Z
M=6AQU,/<TE KV"S9A=>9@RF6C,\OU-_5-',X3W'Y&C/1*AYI%0<_K:"BX4QA
MHH?DZBHEJ=:J1XUN"2E6EI\]R%91(TGYS2=<HS;--&FN1A*0#^8ONR(<"0(M
M^$,]D0*LO0E[[EG,HY+/*P]I673A'TW&LC13CW.5T330)DD8_;6R/C80S?&P
MCBHAC?[1C8F;*0"OUK1V9T1$YM?*G4#H,PBI&1[4T2)!%OSNQBR::4(QL<SD
M.ZBC2$SE_^S&#)JI(8A56XF01O]870$YX_4U"(G,KP(=,*5,&D;Z4GAQ-B-T
MS/PKZIJ>LH_#>?L.QLADIL?!K%F<O_9FG,V 2Z(RJ41>;AA,.8P5M<KTNV&&
M_Z>%G3V5\89-E@2D,PHS0RD2RW.,$5>QDB$'/6:?=(3J; <"R_]QHVP8US5*
MD1!*6FR3@T=U;5(DX+34G!F'NN8H$J%JX4:.IQD\J :(J++N3.F)"3W%CD[/
M[Z< \E*"*X:6F6O%'5B@ZO:1 ^>@&CJB@S3]X]UE?LEL-*S/.-0RU#-VPR_[
MA_V/A_U]U$7G1%@.$QX']4<@ P5"D)&"C!AU-Y2$>"0*O0N$O?_<6Y2Q(-T3
M8-_0+^;W8F\'Q$&3 L*%X:$R73H",\F"BR&8S2#F'MBJZ  J0*P/WRRNI>!^
MK VN%H-".3MD$QB<PQA49FK?P3-0;UV1F\.U%-E/]9 -Q:! S@[9! :7*L&E
MDG&RMGC-X%B*Z$$]1!,B=F FNOX;D[ R?CZ3(L@&_8^#?K\.9.\,TQU$KKCE
M,,,DFLV&U+Z14^!#(4"N*P(KR2B-R<-Z,1D(11#.GYC:B&FY"!O!NTA-0602
M^KG"YNM?'IGIYU!K0S^?=2GH'^J"[LLR8$?2=DB7P/$-Y .\2@\[ZPOY2E)*
M\?]I'?C_B)1H]"X4_G[G#PFD'G39N#+> 9<B/ _Z'P_Z@UJSM,]UJU!BCH-'
MC"LUGF$XX6!V!(B<RS6Q:\*[&-'#+$23_%#,,/_&#N=*6-0=FE<043PN'V85
M2+51ET;B=H[%]:!I.#6O)*34 Y;7*FM[0"ASYP-QI]0KF8MX%%?,AUD5<^X
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M9R&/ MSZT<P;O7V3^&F6> T[E."W1=!<,3IY /VNT$BOK2?_;+AD4(-C\?K
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MFO_<W< /KKDYC0U.7T [-57]W$SB")?7 -/S*=QT9\XULWK:O04'B+.=P$O
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M26RU8VF[ 4HP7@J5X4N@,F0YSPM2,.<)!%!%[KAWME]*5#T=V1@)J 12\O"
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MQ-+,IIZ#L'$Q^9NFI2_R7"F0A#OTIC@(3P1HQ,D(H 91LK+?>5)I<@"CRL$
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M2&X]YE!Q;"HCVIE&1?*=149Z$65+4/5RE**)21M#*#H0]&OK_F8U<A)7*ZN
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M/L\6V")^C1SP(A]EV7CA QP?TF(YSXKWU]N--FR\QRTDC09+$&!>4A;6R+"
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M6OR:+6/9]3JDNT;CC(\D?!K=9N/5-'M_K;X&&B)=/B\^I8_)>U/CZ82CQDD
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M# UVN1*6<(<UP%Y2)9TEP!'#I='\4.#VC\J@+.$4H&#8$><XI%8Q!"0H(21
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MSC/M$^Z8=D(:Y1$E85V-$=:2+1T,A4&E>@>G+VU@VJ<UWO%EWX9K0X64DMA
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M-8%GI?NNW+#'G3W'W/7Q*_[!_O/((\FM0/&6D]4 6: DQ3G -$,H3;(@3Z(
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MA),@PP1E08YC%J0P"0@ _88P#2)5Q=.T,HD"WGG=5"ZV@AI\RD-?ET9I<9R
M01VQ/$>>OH#JLJ@LJ!.P:2*P>JRJB.YY L9%V)"TV8BRJ1\O1=H*,^;5A:(
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M<$V8YNT,9WN8J>"><_:2TAH1,P.)-<-?VNHB-DY$?#\<E]N^[#:DD'\_#_*
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M'.,$DLXN3/)\\:VH/I>R2P9S>RKC:PA->IA]/#X\+*L?]=M-#=IN3U)Q)K;
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M/GC*PEB@H4?7/)1!%_SS(,.$ UDU:-\LQ;OUQZ+ZQO^E4Z$%2E"6(41CFH?
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MEF2'VL?5UV)]W!;O[B_8SWZ((ZGEKKY\K+EI%P _Q(#')C$?\7[.EWT@ZI!
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MY&3!#2>**S09.IRH0._]R.A79V@>HUX#=VG:-S1&>:LC! ,0\D\"2%D8ASB
M,>LLP"!56D:H?'>:D:Z5!5:B1V&T.V!&:[S?),$[8.#:F%?D:4:C7A7YN7&O
MY;WT]1F;W>;A^-"O/1 /''",(/9CS!*:!WVJ(@L5+\Q0^K+CT=^"T5P**)(D
MIP#N^%'3 &EJW-QT,61A1 ?TV)J'$FAB?WY_A0$#\I?I?!_:@( E8BLZ8Q2C
M./2YZG0V@HS%:M?GJ'S9M1HT8'350(TD235PQH^B&LA2X^C>F^]R:J#%UDS4
M0 _[B]ML]!G0*XNMEQ\!Q8SAR ?\JQ%&@(9A+SO ATI) (W/.]:%9Y6;6GD!
M'=+D),(Q7VHZH4C5!"6N5Y('!NS-0S=,'!BM;]7@0D]!WBX?^@H4$!$*(,D9
M8W$4QIBR/HV!@A#JZXB"D6G5Y,X3T#0S$/I$ZFB+(PZ-%$:6O@F4YD2/M-YH
M,#I'U=%Q8U1[M'F1*DK#HCF[*@R"_31@:0I3%@>(^CGUN\^G82I?B*;R4<<*
M(Y#H5% I\3(N($XI41.,2=A0J"%SQ8I>W9@<.W*%8@//SBB@MO,S* C3@ET:
M-KJBHL'NTE*4TBB'B9\'XJ<,$-!_GOA8_AYYE8^Z5S2H.X:E>9%4-!>4*"N:
M>S84%<T%*]J*)L&.O*+!ZXJFZOQ,%$T9]G-%T_-;6M'0<K<^?"VJ8GG/-:-3
M3TJ2)(S#+/<CBD  4';*:2&0*\F;E@7W6H?JVSY.P'0'NQZ!DCKHG#ME4;PM
M;8J"Z9P^;?54IU%>3,]Y/::L1BS-1&;-?'BNN188D0\I_^_CLN)6MC_:?87W
MRQ^#Z_%Q&,$8Q3!'*8Q)Q@#,2&<U#'-?+=(TLS5% -HC]+KML!:C=C!FR*]L
MQ#H=M1J![.Q858U\IV/7(" V8%DA5!ZE8C2"MD/B3!3?EC<OXFV;+,F'X>-6
M*0YXR)]DD1^D(6%A3$A?@,8X9K6 W,S6%*&Y=;TRY5<V7I^.6HW(?7:LJH;S
MT[%K$-A/,@N,4S$:[=LA<2:S@"UO7JP ;+(D/0NDXU:3#"1A&/D)8AAD,(@P
M[H\9I1D!2K. H2WWLT!J7Z],^96<!2:D5GD6F"&KBK/ A.QJSP)&+,O/ N-4
MC,T"EDB<R2Q@RYOGLX!5EF1G@= ?MTJBB'$C##,&\Y!&*$_[C0 6(J8R"YC:
M<CX+A+YUO3+F5VX6F)):U5E@CJRJS0)3LJL["YBQ+#T+7*%B9!:P1>(\9@%K
MWI1NNII)^>Z;_F4Y&M' 9T$:08Q\[&>(T-,AY"PW. 4@;\.QZK^H;W^C^WJD
M-HGC$C\E?VK2KD7=!&6[;R2>E#1E<XY%NQI>C-;LZK*BISJO]_OCDGM-EX<B
M6  _3M,X%D_X1 2G009S-HAVI78B;=AQK#X=&&_-T9C(C2)[.I+CCC@CV;GS
M>A+I&(D3",\3AJ3%1X_7.0J0IB>C(F3"CIX0Y<M5@1_*X^ZP #3,?)BD-/4)
MHSE(&>T/2[$D,CB]I&#$L01]$J^!>5MQO>CGY590;:)#*N3IB) CW@P52*#R
M&EBWU)\3.=+BH\'G')5'QXU1V='F13/XV?&16^P/'[C*U2]\K]\7O._M#LLO
MQ2+)?8 !]&'@)US] H+\_BVDW(=*US-8-.LZ-&JQ>17'=>?M:WC>8X_/*%HR
MHELK>)J*:=-8JF/]0\UZ ]5[?YWU*<*K$0[EHRT;#3%'";3CV'@L9H\[/9FD
MQ7Y5;1Y%:O3=_7\LJXUXL4F@R9;[S7X1(8:B*$QAGF4H3?TH)_TRU2<F0FEH
M>-H<EGC5N8<KGBSK ->#VJLAFZBG:2OHZ.>$#6"HH ;<3Z"AXSQ*JZBEYIBC
MCMIR;51)K?*GIZ6UI8^/5;%<O]L-(00+A&',8!:E,:6,D#A.</],%2,^T==1
M Z-3:V@-U6NP>GPL/QG()O)I0KR.=$[$N:%LZM$]@6)>ID]:+2VTP!R5TH9;
MHRIIC3<5A?Q[L?GRE8>V^%M1\;AV&/,N0O%<=YBQ,,UR%G%S,>AU.2!AHBJ,
M)K8FT,-GRT%UT3/B4E[KIJ)17>+NO Z;UX*3I-29L(UP=47/;+ \'QFSXLT9
M];+'DLIS?(]-D<C^4'XNEH^/VTVQ/I1K#F?3B^DB &$:(Y"G%*=)EC!"_=.]
MTB24BNILVW0L8BU2KX/J'4KO<^&U:,6_";S>";#ZZW16F!^7NEN2KB9Y?Q:^
MU1\(G)IWHS<#+?"O])"@!#F7"@,=T#N# D$77IUY@= ^:WJIA/=%M2G7FU5;
MJKA@+&6)#RE!>9)G>>ZCH'_9#$?08-M<U=+428,.7U=Y:Y(G4&95)SG@DE##
MC( TEQ,D 9[1)+WRUZ5W/G&R!5]&U_AF#.GIU:_+P[':''Z(FJ)!)G8!(Q)&
M&4Y2$*=)&F3,C_OC]CY#2J^BV+$XM7YU..M2NB=[&29*ILVWCJ)-0;6ALFFP
M/('&72!.6NM,B9^CYAG[-*I]=AB3RA,\$]VJ:&/'O"C:/?P%)E \)QDG "0Q
M8B0!@Y=F@-RNCRU;CG7OA,F[+_@(;*N*%%:C-OB46/5/3*5IQ':B-1>TOK\)
MK0J+^XGIU5O47Z/Y&LMR2_GK5%Q:PELD<09+=YO>E&ZZFDGH2\IOQ6XI_OGP
MN-V(:N]%@A#%>88@@"SS,^JSK"_<BL,XTH]Z-8Q-$?!N!F-IU4+D/^1_[F":
M!+LZ#.O$N8[)-9P*.G0>N4[J!+'M2[*DPUH#GN<8T9JX,QK,&O,D*VC=EAHI
M]X<]63YN#LOMYK^*]2+S@SA'*(R '_HDX.J9P;X"E0&INRJ,C3@6L'[WN ;F
M#9"I:98^B7):-0E_:AJE09T39;I$S8@B&;,Y#R4R=Z.TW,O,SNRLJF*Y+_!J
M51V+=8=E$:0 9 G(81K &$84YG':'Y:&L<&E";H6'6M2"Z>O;#$[F:-)JDX(
M-06?AG%4!_'.DV9YDI,X9XF3CJE,B9^'G%GVZ<K1&QN,:1Z(+KJCD.*(=9Y@
MX,<@QHQE*3C=2D_#+# X#RUMP[&8O2EVO-N(Q(K1,6AYRG2$RPU;AE+%0<WA
M#'2A? 1:F<PYRH^&%^,'H#59D9>8^Z*JBG6^V8FU8AW!_:TJ]_L%"F" @C"@
M+"=9BN($M[L?F"5Q"!2K1W2M3++SVEU<(G"IRHTV?;*",P5S.I(S)&U_Y]6@
MIE:<"]R,:HXIGW-1'6,_7NB.'694\T?L^V.QVQ>B4RT"GW\.,S\+01['*0D2
MUE?)A8':12\ZWY\J:]1BNJOK0/4R1DJTJ26+7#&FF2?JR:)C9#G-$0T8D4@/
MZ? W#U4Q\N!"4DB?#5DE^5BLCERX:@LXR/,@12R%) YXI!2!K#^0%N:A4O)9
MY;N.E>/=\; _+'?KS>Z+P1U12D3):88KCM2THD5Q X48^#^B##HLS4,1M)"7
MYGW$)%'RVV[Y4%8'D8&FF_VJ7CTQEE $$A(GN<^B.$>)?WK(C\92CS?;LS;)
MJF:0$QA@]#J0)GD5+89U,BRNR37,M2CQ.D'6Y0Q=TOD7$ZKGH546_1G-R9@S
M9;;318OFGWE9-67[;XO#@OH^CE&>QS[%&0@RF*1]!AI#:"!P1F8=*]VGHGJH
M Z([;]/"M+'MI<>PR=Z7<W(M;8!Y/W5(?[[S.,8Y;'^=XTYY#\RH >:H?W8<
MD]H-L\"=^0FB!8(YBG** @*2)(5I&B?]L7Z2$JD'["V8<:QX_:$5TZO*U;C3
MT39GM!EJV9-S/W,YZB,M6%JLSE&@]!R1/LFCR(WFD>NF>ER$(?L%A2"(PLA'
M!&5Q$I,D@/W38#$E2KDG S-3+RXW7:*VW&U_B#,\? (P.G"MQ*F.,#FCTU"8
MNG>B:F W/6<]($A:F+18G:,PZ3DR?KQ:GQO='-AQ7ZRSLJK*/S:[+V3YN%QQ
M86QK"7!(<S]E61+[*5?)(.?+UOYD(V4&S[J8V9T^+R;0>CU<K\-[=ZV$QGT3
MZ*7+IF+?.'&F2_PD6;01%A7R:3;:8H[Z:,FS*SDV>^Q95=#A 7$? Q#Y89YF
M& 51$J8L[K<S"<=F7495C,](2RW=7V&C12RJJJO&<">M,[GAXCJ?IB*KTS1_
M(J75<D]';O5YM'*#61TN9\OMMBQWW8_*K'B_W*P7*$PP(N+R-)]&P =9&/<O
ML$*6VKO<S 2$8PT6I7K;[I9!BW><&?&NM2"_#>6FR_5G-Z,UZW9QAWJ-O/]Q
M<_NC0#^CN]-&.)9?\=MOMCFJL LW52YCL\>KU!U%M:JTHK+<MW?RE/=EM?E2
M_TVUV:TVC\OM(DYS4;:7(!CG 0V#. QHO\/#4JEW?NQ:G%)OO>6^N[!(/##3
M@?5ZM KW[=BC?%Q];\>VFM3^"8A6N-[H)H3K77)DB7BYNXYD>3DS'[GA=0;W
M'MGWJ739$\VGE>5ZO1%==+E=5\L_%C$C 488^:GOPPR#F.$^L\,R)'_[G1US
M-YQ03D@] =5<Y%29UI]*'))L;QZY.;_F,XA#GNU/'[)\&\T=3QE1G#@TZ9SO
MK*'KD,248<25;'+HW>%K4;57+;S9+#]OMMQFL7_+&3E6%<>Q"#%%.9^D("51
MAE**(M0GI8(4()4LD+DUQ[-%=_5(5W!QY^UZ;&K9'PO$RJ5YIN54;7*HL?7W
MN0S0W7EOK_/J)&-SE:Z1U(P]JN>1@['H3^FJ4RJ>4_RZK,3+HL5:7,Y7[/;U
MY(H_[P_5<G589-2/LRSB 7:"\C2,?!#1&(44ICXC,9)]L-?0BKOQ5@-[]5D@
M\X;0O']TX/[7Q&?W1ID:&6J6*)['.+/ES/-#?S8YDMY-VNQ7VW)_K(IW]T.S
M'XJM>":]OM/@!*S-I>X_%=\/&:?D]T6<9PC[.02(X"B-4)[0I$,5@Q K;2HY
MQN)Z?[^'+X+W)^.U]:"[^6,XKCLWO'\(1[S:D\NC^C9M*+E!-:/F4]RGFJ#E
MW.Q7F5$^MFTU46/.0]$G\_;Y)M:D+,O."3S0$S5CF]V7]^5VL^*!7C\))4'@
MITF8@C '.228A&E<&T0$40QEB\L-++A3@1,HKT-ULT#K,D$C8]8"J_,8CC8<
M*:WW.+5!1(X/1SZ(-]\*=G]?K [O[M\6?PQ0-!L'V^+UKMF[?G>/UV53-T1$
MC3L*"8_R8IPP/TA8W@&"/I':)9X AN-PZH3<:Z"+N9F#]X;CM(,O7D%H'!"_
MU;F@%D:Y;#$Y69Q)8ZG)ILMV<J*M^BR/:.\$33</;9["T7+R8:&F[>P_CZ*R
MOI] 0H H) '-?.)3/^&V AKS"(S %,;PVKZ@YE?=C>@&R,UBGZ<\C(PY3<+F
M,8YTP9=6.HUB&O; %QM?RRVG9-\8?%L>BM/BY;0@B7R&0SZX_" /21JPR ^R
MSKX/$K;X5E2?2^GKY*S951DL0XCRJ=H!U/]37/EQSX/,P\]> UOQTCE[=$LF
MP&_"LV(N_ G!K40)F-X@>W.[3(PTA6-)<NO-, ^I<^#7\]2Y(^:DM]VK+\O=
MYK_JW TI=WN^Q%PWV?O=^CWOU%U9R+O[YJ[@S7+[D?^DJ-,YO7@C\7Q>CN,D
M"4A"8,3"(&JS.4 4ELGN($\"QN$N\P"_>(]MX(&WW*V]H0]B%=%[X9W<N%GP
M8H7\L3WK21MW'OHQL<_/][YOP+BL[KP5M[<4[^[?/195#6*_(# ,,289BJB?
MA7RQ0Q/6&2))GJM%8!H&G(=:PP:I!2$[[C>[8N0N?6O<R0FP8]+4U+0!(W3R
M!.>&<=)+;D;$SH#(>2B7B0.EM4ZEN-C;?-EM^.IEN3N\3)J? JDT2U$6)1!A
M -(\)8 0O\FLH#0#$5)<Z=DQZGZ9=WQX6%8_Q' :0/;.;!TI+ODLD2ZYWIN>
M;<7%WCBWMUSG25$WMLBSR_T\=,ZV4\^7=RXXDS]O_U@5/*IK0S[<7&3\M#8K
MQQ0'- L"$OIA$#.*_*Q+,_O43]7$T(9%YTHX!%E'8<L!3-63]188EJQ1FIA:
MQ3JD 3IQ]\CCMNCI'4*]V>I6@KZQFB*+Y,]#]ZQZ].* NVVV+"C>@L(,X!3X
M$".8)3! B-'.(LMRI=H$$SNN:SG'U,TKF@=ZK*G<=5:-U<TJH6Y4K3Y$\EB5
MZ^/J%O<M7:1.3]&D"9^]DLE[(J]@BNQ(KUU77XOU<<N7R1>*Z:N*]\PF-9?]
M>%%9B?]85NM/R\_;8@$3/P04QXS!(*$8A'[J=_L$L9\F2J]B38;*L2IVCM3+
MWTMG4X;>>)]_G"N9]FJ7^"I..*58[#YA$TLNIF?9NHKK[6D;ULW*W%8[C"W>
M)V_K><P.-_#[>0K@1LQ+U\S7!OA_@K]O]HL(X #FN9]&(8A2E(5YB#H;!*D]
MK*'V9<<S0#.^!1J^!N5X%,5;D24Y 79'D)J(RG/CYLC D(81#=.C:QXZI(G]
M^5D  P8,3RY+J-0)W6[]GG>PM\N'@I8/R\UND1. ,QS3"*681G& <\8ZJ%D4
M *6@]!8 ':M36Q76!B$-)M7P\B;M)AEISKW)U/12K;6F/,]NQ.A8^'C+!IR'
M@M^6 KD3]U.VA_21@X?';?FC*.I*QW?UX89?BX?/1<7MA3Z&&>6?SC!-0)2E
M:6</X4"QY%K?SC0EUEYSL$-Q>]V /3EIGH8V17UM,7D-<0TJ[Q\-KJG/=%SB
M9T0MS3F=A^19\./YH0]+S,B*SX=B?Z@VJT.QKBW^MML<]A\^_M;:C A) 0!^
MP*(P]0%F&<6]X/&86B4J-;/D.+P\@?/V]9 Z"GAJ2F1(I9P:3<>BFB(-"&PT
MJ4;F_<2Q[7^^D3*-<C6B3G8XGH="6?*E=-$+C92JM06R-".$!IB2D(=E "99
MV-FB4:IT29&>A:F5:2GB4S-IDN5.2Y(<T&8H1;-0'U754:1QEFJCZL.XRF@Q
M8BVI=VFY^&:S*UX?BH?](DDHP8C&D$69'^5I@M-^=4@RJ+:O[!Z.ZPUEB;W&
M*UN-PA>O=L9VIL]"8UK*ZTW;CHI;Q],TX6W2?U>)-TGVV6O5>>CZE ZK)O)L
M<ZU_<T)?NXE]OD#/@C",_#"+D8\ST@? A&"EIS -S+A6^*?W(JR[>Q&*)OG_
MTZ'X?C@NMS^;WI @3ZND)D_#J*+6GKL# 1]X_//Y>!#%#>+AM/=+<2'S[:X(
MODC<F%::LST3#;3@R-6[#32Y4=*LU_O]L5C38R5.VM2W*M4"NA^D'/?L>U&M
M-EQ1%^+X(<Q@A$@<D83Y)$I(!R0/ -2X]L4N .>;$V^/8MTAZN?V-4SQIU7Y
M\, #H69%OJG]$2]\+#W^]\=M?4_:?K"GX16M.ZIG!QVTEX)(WJZA)@Y4[]HM
ME/V=U_FS/]UG=P.556+^FOJZ:<89J;(C!\^IM4LNW1<@/0.X[Z[5^WNQ^?+U
M4*PQ%\CEEZ+[^_?59E4LLC0 .0"Q[Z>0P\X0PWW")<2)XK43,P,_[=:V]T>+
MU5LV8/N)0;PCN%(\=C0S*IV7.MV\ ]B?E<:K[<>GI3NO<]QK/>]_RWL_VIMF
M5G"ETZY.2K&<=K"9S)<S)<=:^=8$;2@[3[^ORE51K/<Y;X7S\0'-,T##G,(X
MH"P!?H93V-_IF>2)VM1J;L_]6JHX\)FN@>F)WOEDF;3OI\/+,;<KIN4FKVDI
M5IMOWC_A=5@9MN\GAHG7,E?I&I%Q>U3/0WDM^E.ZZI06LTG/-F]K;>:C_]U]
M7E;WQ4;<>+5?4!C1&/L^83'&01YG@$0=KBC-(XO))2MX)EHMM FE=>V$>#:V
MCO::[-.=2#&=J0BY\W9%G7>Z/_EC,=EDISDMY)XF;T>-/+[7@/<:]'VX_K%M
MP!<%*FVP_[9IP%RB :?//,GPKIN(LMJF\U#["?U525,Y8%HI:[5_O]RLN:U/
MR^]_WQR^BKT/CI#_X'S O\@QMP[XK 5@ +,8ACGJ+[W/$Z@8(#N!,.'^@RBF
M]?;ULZR\^W+Y.)3B?7$A^=[#9K=Y.#YX?YQ\\@[+[\J3@)-64L@,W;)Y-/([
M>T_@K5N (_8&D.N?U;_C92]R0#=(S2@2>RW!XJJ=9B+?3ET\E^QPRZ=TRJ)]
MA[!]I?!3*0N'P,0/4)"D09B!+,Z",.DS*'&<*5V+X R$XX*8_M50,?*Y]C[1
M8O&S%Y%[?<K$^\9_7#0!O&+:PUEK269#YM!0BDF2KHVZUU_Y%'I1N,\D[R?.
MGV@2/)96<=UF\Q!P]VX^3\),PZOS>O8V=_3N>-@?ECL!O8D_%UF"0\PB'$0I
M HD/:(Y AQ.3C%K>!K:.SWF</H#T+*LMKD,\K_T3U;7K-ZJE/=V;MN;MBHD&
M?MUYC6<SVY15;1@75?'&G6 >4\X-_;=5,V^I):1O5ONVW&Q%<;.8'9?;XF.Q
M.E:;P_ %9YPAEM X#2F$?H1CG":HN4PT0Y1AV3.*%BRY4YP>W"L>>;[:<WC>
M"=_MWBF_2MF(%ECD>QZ#VZ9#S^\LL\V5^I6ZER$T%RLB&C',J"]R#CF .6-Q
MW-D/(Z!T-;@]JZ[/MPQN3KTR1,UNNS5F7S)(NPGQBL&7-<X=7T1[A<*Q,,EZ
M,\Q#(1WX=?&B6+O,R>KEK\O_75;B9K#]NWM:?#[@W;HYM3-0;''M)#>;HA0D
M$8IX-Z)IF 1!9SU*H5(NU)9-QUI9PZPO2*V/QPBD]:JW/<CV))Q1OUO6&O%R
M0GD+SM5DTAK=3E12DK\1C;3= O-02.M>E6[[K75U;*]1!""-(A:!W(]0@'%
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MZI))*Z+9,_OA"K,3B>,SPI1T4)?LN4J>MC]7U<V,*8/-:Q':]CM!0RF-XA"
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M+G5O4S>@=!IYMT/H=#KT^L2'7JZ4EBW/GL$\TUG?(_P=3"_$.,U $@4))2V
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MUW^FCT_;XCG/[_+RVV:57[Y6/-Y6Q+*O/CSPF="7W>:_\G5]=V+U]$^]E9?
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M>K[GNPAX('!!DH#6>(@ID@E+FDP:CC8=RJM5?^T"G5S8T$6X6#28@6LYD==
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M#PCU0M*:P*$G=8FXU <;3O;?O<CL%8ZIR[$DG]=K)6A,0C]?\BZ8M0LS98=
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M<&O' -7C2F&@[^DJ4Z+Y_>&WY:'Y?_^Y.7S=[#[L\G_DR]--J8O,]S$%-,L
M@5&0NIA@MP4%42BUFV 8RO3%3:>*)N>Q0W_C['B0/OR5;[_ESF.Q.WS55O"D
MI\G&UD)-WEH:RZ1N'([>^:W77.]Y<WVNF^NWJKGZ9;6V%%&)D*Y47Z6U->W0
M[JF<%:[*,L#Q>/V_W?'T;[GER1]_E.YCL:^>!-W_QY%]D]_)_BVGF_UJ6_"K
M=]\?^2/?'QZZGWJ7[_>?ORY;/Q9!G)$T020  +#>'?D$Q2U\'&6NGD@Q,6C#
M,:7&QR>$R\'HLMDYQ\YMA[_WZ3PU+MTX6^:3<V!..<4N=YZ96[K"S=0]9&Q@
MLKASC UA-_U9 >L.)T<=[JG3.7'C])QU3MZR.-=UMMX/O^LZ#_/:^<=0YYDX
MX.EM3*70.%-_LCV(SD6+<+B=M=U$ W/U/BPW\SE_?"K*9?E\^_C$D@&^FL]!
M<S?X DR],=WZRO1@_\+7!?9#WX^B(/9 YB8 QPB'+;J,32EEXNY4F R'U?K!
MYDK5.D><DR=.[0H_7GYAS44N>$[6BF*QT<8&E M]HFW7\^/&&9SR31O0-+7
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MQ,3/CH;1N2KJ_,$Q.A7(B952F<P!)37?0'8H[01^%E-W?:4]Z-,IPL"%%&0
MTY! %&&4Q!YIS0",I5[8D/[P:3:MYCL6>T[(VYO,\MS9,;+4X5_>4%;EX:UQ
M\'6Y+1;U2MVA6*ZX:V5^.):[?'W<'??Y^JE.G189&WAIC&@0 1H1"I,X[,QZ
M+A6:0FDS9GHF5:]<'@JG!NFT*)T:IM/@%$L[]%$\G%W,PJ[D#,M28M?%ZL@S
MS"H:V47P"VC3$7TN_\SU2M0!]D$EZ:)D7)!X[3S.*_GZW2D,]3>YU.A=L?O"
MWP?GAV]/I8 L 8LQ#D(O@)Z7D<A+0-;8H@%RI2:H:A8,BS\']0N?:%8GW>5F
MEHJ4B<T:S;,E)^8OB7+^F*W"^"(Q ZGE."+MR"]'^E#H[%IRLG(Z./CR?ME/
M^79YR.N;Y:OK^>Y[U_.=TE\7LED?2" ,_-#''B0$N91]AT:1AQ,@>@C:, IS
MH^X$_-7-UPWV^K[JFTM7<\XW\QO']\!@GJ@A[1CU4SE;S#)89%=NV,=O^&-U
MU;6=3=T"$R<<>ID?(N('R/>BP L;6S .75>NHD;-AO'*FD]W\<2G,B\2,;AZ
M,X8X.P;;2!]>K>.,9T1Q:/R^VQSVG^Y^;TM[PBQ,:$0S%Z>0X!0@#[4V<0C\
M44-$TM8$0^7W>8?*2T+$AXPBD58.'55?AH?0*(:$=W)%7DHZO^JS."RWKZ\#
M/?PC/YS>45I0$@<Q]=(XH( R'0A<D#9X,?2 U$;#?"B-[P2?O^S"$#K/^:'W
MY)KDYN]\#2JX.?Q#M*7<I$7B8;WSFYMO+KSN(]$'S&PYFVJBH2WIV;N%':'%
M A[.M[3G1V1'2*N7JK.B[)U^=1<L^!("O=A+$LC26P*SF+9.^&$B57MI&70+
M@M]-^^ H?_&L!]Z2H*C8)6:.E.9[@V7A4[H7_5AA]6)[SA%KQW6L_^8!>"0Y
M4T5E'6TH?/GP:E4<=VR6FZ_RS3=^+O=]?B#'LN0O%K7+JZD;!E&4>22#"4RP
M1^.L/:J59 03T6MA==@RIX$M/.>$CU\]?F "5V.<;6M#A+@!L='*NQT2H=>E
M\VM+]?,E5"37VBT[N]SQI@2#7U*W/Q2KKG"]*/>+V$T\EQ" TS  %(<@=N,6
M!"&AT"M<ADP;SER[P7I"7!>.-YB="C0O3WH!6Z+LRT!K"%37S=L0BH+Y([6!
M1"'>O&VA5I:GNTW$JO2DF;I6LV>.<@LJ^ PZ5TS2;;7&L@7( DJCD/W/#:#O
M0ABA]OH+$K*_- :O-VW-%:V*ZB[E%V-3JSR^3;*6F*257Q-!:&)2M089K>2:
MC"K&@XAZU!#F\(<($^+>R,4%299&!(*7\8<&B4]B'Z84T3"C_*K*]K(&$B<A
M&1D)Y(S-%0K*]NC<<<=Z5R\]>WE">;2225*O'!_,L:XI0.B=E$C2.CI"F*-7
M,40\UBROCY?HO7'^JIY4ZQ[ XJ7%+/=Q[I?L4U:YL_^:YP=GO3SDSD_\-COV
M3SM^>'?K%$\Y'P2[+\[J><67Y/[ZNEE]98.E=#9[9UOLON3ES]6VPI>B6.^9
M.#O[]F:-GS:[U?:XYK]\*)?KO-<']C_S)RP.SM<E&U[W>;YSUOF6#;7JCG/V
M$<5VS5]QZ@%AK<!&.P=^?]QO=OE^_R]&(MZ(B9):I[ VYBFZ\W;0&\.3^LKZ
MW\IBOV_6$1=1AE.0 (J2,"(HC5TO *W1# 12SSN,-#5]Q+MQOG" DJ_@C214
M=9/"&)<:MB<J;-T&Q=R[$GVFI/8CE"BV=2="S9DW]R!&<"26J&^WQ5\\%K-0
M2C>\#O;^R#. +,_WR]V:G]"H$"VRS M01N+4=ST(<( B7C)4VTY2!!:[_ L_
MM/%9-&G795AH[.%Z[+W"*#X.6[A5SK'N 78>&.+J:J]UBUDFK=3&OTC*/BGG
M:GKW@N<^2"=K>::S\BR3P\_!MV(B?\Y[A:RE^V4CC,U_!5FYF@3K9M6&3%B[
M3X7)?JBOVF3!#% W\3$./(B &R=1TJ7A, 7AXL"+9U0S8@E#4OEPATEX@%4U
M0/S6C-=9\2Z?/8<[\:1842),KZWYFXHK$A4DDOR(#JWJ/:T/#Q]9QVLEG]]%
MN?FRJ^XPW!T:3)O=EX_%=K/:Y+W7MPB.:9;Y;.8;^&'JLH'ON0TD&)$LE#NP
M9Q2*S.!4.L]7OVG'W^#NX9>;J9IM"[%YK#6-()?U762_OB[W!-TY87=:\#/>
M#C*&Z@&1G:0%[1#A:5PM9A@A<B+^/O^K9[0L=NS+5;WO4T%XKO][@I&F+O#\
MV(M"F&&,_01G[88=A""F<L*MW;QQL8[7Q5.G$!_S7;74WWV3R0B/P&>"\<(O
M.6'7WSYB8CYKP\@).(-ZG>V;6JZ?G3^:OV?3;%E&!W3:6./8H<WFW"LFZN1R
M&DR6^Z\L#O"_TO]W9-G[]H2@=W-5$O@I\-,,>BB%&? A1IUM',4RVS=Z+!K>
MQ>'HG!X\.>'41*J86D[/IYQ$5E3R@'7.J3WR*$3A@";J;0([A%"S3X7)3BO[
M9%SY9W[@RQ1W_'GNS8&ENO&WY6;+OY45Y=VR_R\UI@4@U(T2'Z<84=\+PBB(
MV]O2(0Y=J=M%C  P+(@GS,X)FIPJFN%=3"1GIUQ.,R^R?>-TB']Y*,I?>!'C
MBW^V14Y5R!Y05Z-M9X?8FG7QU<.$QOD<EWV>[J4:"A,+D*&84"\,X@R'('5]
M+_6Z10D6-,8GI9J &);F$\HJQ=*1JNIJ@3$9[ SD:TMLSYKDATQ_Q?B7SHHU
M-ZL=^CV-JT(YM!%^1?4\6V[*OR^WQ_S#0[;9+7>KS7)[NV. CKV%C4408(^$
M,'&SD*:8N#A(N]7D($TD[Y358]/XVBV'Z50X^4)MA]3I0953;DU<BTGT]"3+
M:;$ N_;HK1"9 \*JMS'L4%#-/A4FNZ^<)M[NOC$;1?EJ09<D/DWCF,89#-S(
M)21+N@7=#.!$3@:5S1A7OA:9](*!.G-BHC8)97(ZUD&R1ZVNL30@4*.)M4.3
MQKM1:.YP2F\Q]N[5.K<+?3=$ <7\KO34I_RIWK2S&T%/]NKRL?:,:U'[ZJKR
MS8X:.!43IVG)E%.I"RS:HU=O$C<@7/I(MT/!-/IS^1E-;4P)KQ@6^\.'![Y$
M^6JW*(L\"#WL><Q4YE+7I7'4+5$& 903LQ&&C*M8=>MH5358WT=Q)W[IAPX>
M!5?UIB%0<LVN8:Z"98]F7>=J:'UM/,%VJ)0.1\[7QG1Q(_%$3,Y^EB^X42:-
MV^*)SRS3[_SJT[R97Z(PB@!"B-E-D(?#S$=M*7P <(:D'XH9;7&"?*L&61^H
M.L%T&IR2JJ6%9='\:UIZ93.P85[MD38!'@<3,GVM8(?8:?7H]8,^FMD2.DO=
M?\[NK(K\.2M*PGYOLUIN/Y>;Y;8=]^>JG/A1@@(88^*Z08"HZP?M?D20$2"H
MC9/!,9_B-2B="J:D7$[7*L-::F5SR GMR^=!ST_B/%>GAJ^TE93VSM1^$H>Z
M;6M'M?/>+]MS>6K/IU-[KMKV/%3MF3?.C+W_2 .!%R+EY&UCP:GQ2=TM9AH#
M<O./R^\Q?'AJSGG=[OC!H,VW_",;#>U^%P&)CPE*4!AC-Z'8I=3MD"1(\CB5
M"03&PVS]\$ORZN$7N6F)$?+%IBESLRX73:^_L_/A=+"MP^Q4H*V9R2A0/3"S
M,=EP=LQTC'I83#<,9+?[5\5C_GGY_5SW,<!,\+T@#DB8X#0*V=RK-4<HE"I7
M539BN!2UQN4P8/)[_:JTB>[U3\"8[%Y_2Y8]JS77:!K<[!_)K!UJ-=Z-5YO]
M6G@1?H5R6>Y8+KK_F)>5&)Y;]1/(K/H)4SE",A11ZK5WZ 4!3:3D9ZPMPRKT
M/C\X/[TK]ON?G6:,,:#U&W^2SSB.Y51,FZ:D4TZB6F0G NV1JC=8&U L77S;
M(5S:O#E_\$\K2\+SV/P+7]3YE#\5Y6EN_>I@:.QC%&7(@Q!$D/I9B-O:@B B
M62HC9GHL&I:T!B33LP=^/;?"%%4/KX*3TLDIE9R&-FQV .U1-2'JAJ:56JFW
M0^$T^W0^=33 V$GM^KWG'?OJW_^I_0[[#U\(^?=_^O]02P,$%     @ +(%G
M27.H@&&=5@  FB<$ !4   !H86QO+3(P,38P.3,P7W!R92YX;6SLO6N7&S>2
M)OQ]?X7?WL]NXWZ9,[-[<.W1KFQI);EGYU,>BI4E<<UBUO BJ_K7OP#)S+J2
M3(*98!;5/6=LN91 (9YX $0$ H%__9_?;Z8_?2OGBTDU^[>_P+^"O_Q4SL;5
MU63VY=_^\OO'G]5'\^;-7_[G__AO__K__?SS_]4?WOYDJ_'JIIPM?S+S<K0L
MKW[Z<[+\^M-_7)6+/WZZGE<W/_U'-?]C\FWT\\^;1C^M_S"=S/[X/%J4/WU?
M3/YE,?Y:WHS>5N/1<OUKORZ7M__RRR]__OGG7[]_GD__6LV__(( P+\TK79^
M$?_KY_JSG^./?H;H9PS_^GUQ]9>?@G"S18O^MU_^R_?X@T??_XG77T,IY2_K
MOVT^74Q>^C!T"W_YO[^^_;@6\>?);+$<S<;E7_['?_OIIW^=5]/R0WG]4_SW
M[Q_>/&K_=32M_G%W4_YU7-W\$C_XQ93SY6@RTZ-I[.'CU[)<OEF6-PLU'E>K
MV7+QH1R7 >?/T]*6X</I(@PMCO!?OL[+Z]!WZ#   AF0&$0X_GMRA\N[V_+?
M_K*8W-Q. U2_="O+?%5>N>^WY6Q1+DX79$]O_4EAR^MR/B^O/I3?RMGJ5'7L
M[ZT_*=[,PN];5O/)R7K8W5-_H_^M6I;) W[4N+\QOI^7MZ-)PT\UNWJW_%K.
MU6)1+D_%_)B^^Y2PN@U_=1=^O?NOU>0V;A0G"W:PR[SR_%8N/Y7?EZO1]'2=
M'=-[?U)^BFM^LA2/6W<PRFHZ'7VNYL$X^%:J+_.RC+@L=ORXY=A/Z/,\$K6E
MUNE=9Y?OR,G31>>]R=ANVVG1MHL1WMQ,ENN>PX)BJMDR&/'!F)^T&>#!IEV,
M;W85]Z;8_Z*:3JZB]_!P-5F\'\W#$+Z6R\EX-#T\YJ3N<LCQ^VRTNIJ$GYXN
MP[.N>AK_QV7XYYH [Z[-:/'53ZL_3Y2C79<YY*EN;N?EU_!-F'YOJT67<AWL
M.H-\[X(1L?:D.Q1L3Y^G2U2'$*+=$Y::Y=V;V74UOUG_OD,C;]/V]!&^K69?
M/I7S&UM^CA;9P_\\<OLZOJ?.1]]JC]K7YO01_3J:_Q&D#-;'QW*\FD^6[9W,
M%DW[&5\KV XV[&=L[:S>PRU[&MUQ4^2(+DX?[[OYE]%L\H_U>A'6$+U:3&;E
MXN 8#S0[?5P?OP9K18_62_)-].'7OZHE@JT:]S7&5O.D1=.^QO?R3X_D: ==
MYY7O]]F\'%=? F?+JQYDW--]7CG_/IJN3I\JQ_7=EX3M5O4V;3L8X;(:__&U
MFEZ5\QB1GHPGRQBC6MX='-ZAACV.K2T'6K;O8*2KFYO1_.[=]<=)F"OA-XV"
MY;HY;@D>]OM@>;=QSX_K)=>HU55U&YGW[CH>'#WZ8E[-PA_'&V>BK5+Z_*6Y
M,(E^;J32M]%T&TQYR;CYM1PM5O/R2BW]:#*/JTSY;O8A_O4\]!6F]J1;T/H:
M52Y4W\Q"@_+3Z'NGJ.SJ-9]4QYZWG=IO+LG6?NYB"_#[<K[>L3J5L<UOR"5M
MMZOXN5;S#^5B.9^,E\&J"*M%I\K:VW4^^=:GZ1\V5NLQ!F,WW>>2\V/Y)6Z
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M<M*J,YU6?T:S\KJ:VTF,#GU>19WXLER,9E?A1YL![EQZ6K8OO$=4>*,<AH@
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MA2?/ZD9G0#[#5A7SH\(6>S_0 YGV+WY?$& X8XP3[SBD'BOI:"V6PS@Q5W&
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M?G&Y^<6CYAI'65_CV'YP:$5IVT]!(' 60^.)A!9(SQ6D]S"AU_\>6Z;5I"?
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M/3J+]K)XUCWP>;EVA-FUIU5A./><:>FA"*NUP #Z1D1J7&+P[^C<VXOEUHF
MGX-3!ZVM'2V*L,%S)8300 OGE./,X5HT;U+O*AZ=R'OA7$H"^QP\:F=D[6L6
MA.1*>NE0,"DE1@(3TQB3&.!$CU#\DU$=(7[6J./OL]'J:O+@VNRE11RM1(8
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M8WV.\@"#5LO-[D:%L]9#SK!4@@L"G?2!\EL!'<.)59J&;<OTPYO.0,YTO>Y
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MOUR5DSAO2?Q#%)$\F*[A1\TX'PSOTX[7R?9]7@C ( )<!'*P8/\22J6K1<&
M)2;9#.A620]:K3K'M?7:?@(]&@R^3UZR%5NT*EA8F81$VGD$K+(<&(FV0C%-
MF7CU9.E&I?OY<0*BO='$5C>CR4MON#__J&"Q;BO4Q@L!P[ZEL$"Z'K(4-C$
M-WP2I.GM!2XDX9ACA0C;>+F.E;1?'IHF!3*& ,,%P3I 0; AB-3B(,H3UX8!
M97GG6!M2X>R<'9M=\D/Y99TT,5O^-KK995J\]&DA*:%26@8MPA@ @X5NYH?
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M*23#QC)NO'..8$24=<WN*6#J<V(#W#).4>Q>CB2#F1)F4O%'^T-+#SXIJ%%
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M 8I(XP!'I)@&HZ1A8.T@^:5:T8$;P.M !_:[W7VVW^NJ&"Q/- ]'/ADYQ9$
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M2P$"% ,4    "  L@6=)($B7OS8.  !'F0  $0              @ $F-@$
M:&%L;RTR,#$V,#DS,"YX<V102P$"% ,4    "  L@6=)?6X,K[P6  #X]
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E,#$V,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  +UX @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
